https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e139524a 2026-08-07 https://biopharmsignal.com/news/SRRK/scholar-rock-announces-fda-review-of-apitegromab-biologics-license-application-b-ba9f6662 2026-08-07 https://biopharmsignal.com/news/AMWL/amwell-makes-grant-to-new-employees-under-inducement-plan-8fec64da 2026-08-07 https://biopharmsignal.com/news/ENTX/entera-announces-second-quarter-2026-financial-results-and-business-updates-986e7094 2026-08-07 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-733c2ae4 2026-08-07 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-648c6f73 2026-08-07 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-canaccord-genuity-46th-annual-growth-confe-e6022b66 2026-08-07 https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-second-quarter-2026-results-program-prioritization-and-cor-fd0d7566 2026-08-07 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-220d5920 2026-08-07 https://biopharmsignal.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-662493df 2026-08-07 https://biopharmsignal.com/news/PGNY/progyny-inc-to-present-at-the-canaccord-genuity-annual-growth-conference-b39cf730 2026-08-07 https://biopharmsignal.com/news/FEMY/femasys-secures-30-million-private-placement-with-potential-proceeds-of-up-to-90-9edc7de9 2026-08-07 https://biopharmsignal.com/news/RCEL/avita-medical-announces-participation-at-canaccord-genuity-growth-conference-d565c588 2026-08-07 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-reports-second-quarter-2026-financial-results-and-highlights-1142fce8 2026-08-07 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-to-announce-corporate-update-and-second-quarter-2026-finan-b30abd1a 2026-08-07 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-590bdb3d 2026-08-07 https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dcb742e9 2026-08-07 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635--1abe04ba 2026-08-07 https://biopharmsignal.com/news/HUMA/humacyte-to-announce-2026-second-quarter-financial-results-and-provide-business--20c7f207 2026-08-07 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-second-quarter-2026-results-and-continued-stron-0f0ca732 2026-08-07 https://biopharmsignal.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-31057b4b 2026-08-07 https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-updates-and-second-quarter-2026-financial-results-6b343331 2026-08-07 https://biopharmsignal.com/news/TMCI/treace-medical-concepts-reports-second-quarter-2026-financial-results-7a569b1c 2026-08-07 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-reports-second-quarter-2026-financial-results-96221a52 2026-08-07 https://biopharmsignal.com/news/NERV/minerva-neurosciences-provides-second-quarter-2026-financial-results-and-busines-c01af06c 2026-08-07 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-reports-second-quarter-2026-and-year-to-date-financial-results-4aa1bb4b 2026-08-07 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-second-quarter-2026-and-year-to-date-financial-results-1f32e996 2026-08-07 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-7b61887b 2026-08-07 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-245c2e4a 2026-08-07 https://biopharmsignal.com/news/PPBT/purple-biotech-reports-second-quarter-2026-financial-results-bf7cc915 2026-08-07 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-reports-record-second-quarter-2026-financial-results-68f15c4b 2026-08-07 https://biopharmsignal.com/news/EMBC/embecta-corp-reports-third-quarter-fiscal-2026-financial-results-99a5ad0e 2026-08-07 https://biopharmsignal.com/news/EMBC/embecta-announces-quarterly-cash-dividend-971e0322 2026-08-07 https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-executive-chair-transition-f7c96c55 2026-08-06 https://biopharmsignal.com/news/BIIB/biogen-completes-acquisition-of-raythera-inc-bef275f3 2026-08-06 https://biopharmsignal.com/news/BSEM/biostem-technologies-announces-nasdaq-uplisting-1112648d 2026-08-06 https://biopharmsignal.com/news/LMAT/lemaitre-to-participate-in-the-11th-annual-needham-virtual-medtech-diagnostics-1-1522d9d5 2026-08-06 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-receives-fast-track-designation-for-modzatinib-ati-2138-for-9a314e80 2026-08-06 https://biopharmsignal.com/news/MGTX/meiragtx-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-3ee9d0a1 2026-08-06 https://biopharmsignal.com/news/CLLS/cellectis-reports-financial-results-for-the-second-quarter-2026-b233bf32 2026-08-06 https://biopharmsignal.com/news/VTAK/flyte-achieves-record-revenues-in-july-65ffa3f3 2026-08-06 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-reports-financial-results-for-the-second-quarter-2026-and-dd1f3bfc 2026-08-06 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-q2-2026-financial-results-and-provides-business-up-f66d0912 2026-08-06 https://biopharmsignal.com/news/GMED/globus-medical-reports-second-quarter-2026-results-558d9243 2026-08-06 https://biopharmsignal.com/news/YOU/clear-launches-corporate-memberships-bringing-seamless-travel-benefits-to-busine-2d9b963b 2026-08-06 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-co-879da21b 2026-08-06 https://biopharmsignal.com/news/NEPH/nephros-announces-strong-financial-results-for-quarter-ended-june-30-2026-e71fa082 2026-08-06 https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-second-quarter-2026-financial-results-and-provides-bus-f3dbe474 2026-08-06 https://biopharmsignal.com/news/IRTC/irhythm-to-acquire-vitalconnect-expanding-its-cardiac-monitoring-platform-across-364d9af8 2026-08-06 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-sec-9330d763 2026-08-06 https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-second-quarter-2026-financial-results-and-recent--f516f2ee 2026-08-06 https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-2026-financial-results-9a026aba 2026-08-06 https://biopharmsignal.com/news/CVRX/cvrx-reports-second-quarter-2026-financial-and-operating-results-01c03331 2026-08-06 https://biopharmsignal.com/news/OCS/oculis-reports-q2-2026-financial-results-and-provides-company-update-e5367096 2026-08-06 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-reports-second-quarter-2026-financial-results-10f4a960 2026-08-06 https://biopharmsignal.com/news/INGN/inogen-announces-second-quarter-2026-financial-results-83867f19 2026-08-06 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-reports-second-quarter-2026-financial-results-and-busin-c4940e1e 2026-08-06 https://biopharmsignal.com/news/ECOR/electrocore-announces-second-quarter-2026-financial-results-08dfc7f0 2026-08-06 https://biopharmsignal.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-june-30-2-53516e1a 2026-08-06 https://biopharmsignal.com/news/VXRT/vaxart-provides-business-update-and-reports-second-quarter-2026-financial-result-f6dfcbb4 2026-08-06 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-reports-second-quarter-2026-financial-results-41096692 2026-08-06 https://biopharmsignal.com/news/AORT/artivion-reports-second-quarter-2026-financial-results-66273319 2026-08-06 https://biopharmsignal.com/news/ALEC/alector-reports-second-quarter-2026-financial-results-and-provides-business-upda-d57d0201 2026-08-06 https://biopharmsignal.com/news/ARDX/ardelyx-reports-second-quarter-2026-financial-results-and-provides-business-upda-6ff72f66 2026-08-06 https://biopharmsignal.com/news/IRTC/irhythm-holdings-announces-second-quarter-2026-financial-results-e4b2e270 2026-08-06 https://biopharmsignal.com/news/RLAY/relay-therapeutics-reports-second-quarter-2026-financial-results-and-corporate-u-f325a004 2026-08-06 https://biopharmsignal.com/news/ICUI/icu-medical-announces-second-quarter-2026-results-and-updates-its-fiscal-year-20-82f8d7f2 2026-08-06 https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-52cfb9fa 2026-08-06 https://biopharmsignal.com/news/PLSE/pulse-biosciences-reports-business-updates-and-second-quarter-2026-financial-res-4e89618c 2026-08-06 https://biopharmsignal.com/news/HYPR/hyperfine-inc-reports-second-quarter-2026-financial-results-9a8e863d 2026-08-06 https://biopharmsignal.com/news/HCAT/health-catalyst-reports-second-quarter-2026-results-bff66ad3 2026-08-06 https://biopharmsignal.com/news/RCEL/avita-medical-reports-second-quarter-results-raises-2026-revenue-guidance-and-ex-2f35a8f6 2026-08-06 https://biopharmsignal.com/news/INAB/in8bio-reports-second-quarter-2026-financial-results-and-recent-business-highlig-81c5698f 2026-08-06 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-closes-credit-facility-for-up-to-27-5-million-in-non-dil-81cf3a45 2026-08-06 https://biopharmsignal.com/news/PGNY/progyny-inc-announces-second-quarter-2026-results-ca463ac9 2026-08-06 https://biopharmsignal.com/news/XENE/xenon-reports-q2-2026-financial-results-and-provides-business-update-5005aa04 2026-08-06 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-39377bb8 2026-08-06 https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-second-quarter-2026-financial-results-and-prov-164fe544 2026-08-06 https://biopharmsignal.com/news/ASND/ascendis-to-report-second-quarter-2026-financial-results-and-provide-business-up-f021ee6b 2026-08-06 https://biopharmsignal.com/news/DNLI/denali-therapeutics-reports-second-quarter-2026-financial-results-and-business-h-04a0e77e 2026-08-06 https://biopharmsignal.com/news/CLDX/celldex-reports-second-quarter-financial-results-and-provides-corporate-update-6d3ad2e0 2026-08-06 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2026--e0de761b 2026-08-06 https://biopharmsignal.com/news/OM/outset-medical-reports-second-quarter-2026-results-9a4d1cac 2026-08-06 https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-reports-second-quarter-2026-financial-results-1a8e70d3 2026-08-06 https://biopharmsignal.com/news/VYGR/voyager-reports-second-quarter-2026-financial-and-operating-results-b3aecbfa 2026-08-06 https://biopharmsignal.com/news/XRAY/dentsply-sirona-reports-second-quarter-2026-results-61d81bd6 2026-08-06 https://biopharmsignal.com/news/NXTC/nextcure-provides-business-update-and-reports-second-quarter-2026-financial-resu-b8c0c9e3 2026-08-06 https://biopharmsignal.com/news/REPL/replimune-announces-fda-accelerated-approval-of-tudriqevtm-in-combination-with-n-9ad39372 2026-08-06 https://biopharmsignal.com/news/INMB/inmune-bio-inc-announces-second-quarter-2026-results-and-highlights-regulatory-m-fcee152b 2026-08-06 https://biopharmsignal.com/news/CYTK/cytokinetics-reports-second-quarter-2026-financial-results-and-provides-business-f82f53a5 2026-08-06 https://biopharmsignal.com/news/INKT/mink-therapeutics-presents-early-observations-from-ongoing-phase-2-trial-at-the--34378519 2026-08-06 https://biopharmsignal.com/news/NRSN/neurosense-completes-primec-pre-nds-process-and-advances-toward-december-2026-fi-0cca2aac 2026-08-06 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-delivers-141-u-s-revenue-growth-in-fy-q1-60-total-revenue-637c5159 2026-08-06 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-to-report-third-quarter-fiscal-year-2026-financial-results--3c6af746 2026-08-06 https://biopharmsignal.com/news/ICU/seastar-medical-to-report-second-quarter-financial-results-on-august-12-2026-23d1e391 2026-08-06 https://biopharmsignal.com/news/CELC/celcuity-schedules-release-of-second-quarter-2026-financial-results-and-webcast--d136ece1 2026-08-06 https://biopharmsignal.com/news/RNXT/renovorx-announces-first-commercial-clinical-use-of-renovocath-in-sarcoma-patien-e5885230 2026-08-06 https://biopharmsignal.com/news/AQB/aquabounty-technologies-announces-expansion-of-strategic-alternatives-review-to--127fa408 2026-08-06 https://biopharmsignal.com/news/VTGN/vistagen-announces-topline-results-for-repeat-dose-study-of-fasedienol-for-acute-d6fe0efe 2026-08-06 https://biopharmsignal.com/news/INKT/mink-therapeutics-to-report-second-quarter-2026-financial-results-provide-clinic-55e96291 2026-08-06 https://biopharmsignal.com/news/CGON/cg-oncology-reports-second-quarter-2026-financial-results-and-provides-business--af164da3 2026-08-06 https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-participate-in-piper-sandler-virtual-cns-symposium-cef5c361 2026-08-06 https://biopharmsignal.com/news/ICCM/icecure-medical-adds-adventist-health-as-u-s-clinical-site-for-its-post-marketin-442281ef 2026-08-06 https://biopharmsignal.com/news/DCTH/delcath-systems-reports-second-quarter-2026-results-and-business-highlights-a6c7e160 2026-08-06 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-second-quarter-2026-fin-563b3b45 2026-08-06 https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-second-quarter-2026-financial-results-and-updates-on-corpo-502ead8a 2026-08-06 https://biopharmsignal.com/news/PRME/prime-medicine-reports-second-quarter-2026-financial-results-and-provides-busine-1fa9eea6 2026-08-06 https://biopharmsignal.com/news/ALXO/alx-oncology-reports-second-quarter-2026-financial-results-and-provides-corporat-d99f8edc 2026-08-06 https://biopharmsignal.com/news/ANNX/annexon-reports-first-u-s-and-european-patient-cohort-of-gbs-forward-study-demon-55ea85ca 2026-08-06 https://biopharmsignal.com/news/PCRX/pacira-biosciences-announces-publication-of-positive-two-year-phase-1-data-for-p-f056da45 2026-08-06 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-reports-q2-2026-financial-results-and-provides-a-corporat-cb7ad5a0 2026-08-06 https://biopharmsignal.com/news/VANI/vivani-medical-announces-successful-dosing-of-all-participants-in-slim-1-a-phase-af1ac68e 2026-08-06 https://biopharmsignal.com/news/XTNT/xtant-medical-to-announce-second-quarter-2026-financial-results-on-august-11-202-47535cc5 2026-08-06 https://biopharmsignal.com/news/ASND/ascendis-announces-coach-week-78-results-and-provides-update-on-achondroplasia-p-13eabecd 2026-08-06 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-announces-acquisition-of-cy-biopharma-and-up-to-77-million-p-9ff78eef 2026-08-06 https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-gro-04739d27 2026-08-06 https://biopharmsignal.com/news/LNSR/lensar-to-report-second-quarter-2026-results-on-august-13th-2026-3534c420 2026-08-06 https://biopharmsignal.com/news/BLTE/belite-bio-to-host-webcast-on-august-13-2026-to-discuss-second-quarter-2026-fina-8562d274 2026-08-06 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter--02c621cf 2026-08-06 https://biopharmsignal.com/news/ARGX/argenx-announces-commencement-of-tender-offer-to-acquire-forte-biosciences-inc-ff1c7665 2026-08-06 https://biopharmsignal.com/news/PEPG/pepgen-reports-second-quarter-2026-financial-results-and-recent-corporate-highli-a03bb5f3 2026-08-06 https://biopharmsignal.com/news/SABS/sab-bio-reports-q2-2026-financial-results-and-provides-business-highlights-596e64d5 2026-08-06 https://biopharmsignal.com/news/ABEO/abeona-therapeutics-to-host-second-quarter-2026-financial-results-conference-cal-9a5111ba 2026-08-06 https://biopharmsignal.com/news/PEPG/pepgen-to-advance-pgn-edodm1-into-highest-dose-cohort-in-phase-2-freedom2-dm1-st-70f43b50 2026-08-06 https://biopharmsignal.com/news/IFRX/inflarx-reports-second-quarter-2026-results-and-highlights-key-achievements-and--0d4f5d46 2026-08-06 https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-2026-second-quarter-financial-results-and-provides--7f8ce8b7 2026-08-06 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provid-3ddbf00d 2026-08-06 https://biopharmsignal.com/news/BIVI/biovie-announces-topline-results-of-phase-2-sunrise-pd-trial-of-bezisterim-in-ea-e54e169b 2026-08-06 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-to-present-at-the-46th-annual-canaccord-genuity-growth-con-320e768e 2026-08-06 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-raises-2026-full-year-financial-guidance-building-on-st-2d099289 2026-08-06 https://biopharmsignal.com/news/TARS/tarsus-reports-second-quarter-2026-financial-results-advances-next-phase-of-grow-d06452ef 2026-08-06 https://biopharmsignal.com/news/TARS/tarsus-pharmaceuticals-announces-oversubscribed-125-0-million-private-placement--5cb3be14 2026-08-06 https://biopharmsignal.com/news/OCGN/ocugen-provides-business-update-with-second-quarter-2026-financial-results-5feb3ea6 2026-08-06 https://biopharmsignal.com/news/TARS/tarsus-pharmaceuticals-to-acquire-alkeus-pharmaceuticals-and-advance-eye-care-le-1386fc44 2026-08-06 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-reports-record-second-quarter-2026-revenue-of-99m-busine-a6998a52 2026-08-06 https://biopharmsignal.com/news/GHRS/gh-research-reports-second-quarter-2026-financial-results-and-provides-business--14c0e67c 2026-08-06 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-second-quarter-2026-financial-and-corporate-update-7fd78e1f 2026-08-06 https://biopharmsignal.com/news/ROIV/roivant-reports-financial-results-for-the-first-quarter-ended-june-30-2026-and-p-456d14ce 2026-08-06 https://biopharmsignal.com/news/ROIV/priovant-announces-first-patients-enrolled-in-phase-3-study-beacon-of-brepocitin-65eb89c6 2026-08-06 https://biopharmsignal.com/news/SHC/sotera-health-delivers-strong-second-quarter-and-first-half-2026-results-and-rai-0dfdcd0f 2026-08-06 https://biopharmsignal.com/news/XERS/xeris-biopharma-reports-second-quarter-2026-financial-results-d07d833f 2026-08-06 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-second-quarter-2026-financial-results-and-busi-1240d177 2026-08-06 https://biopharmsignal.com/news/MGRX/mangoceuticals-merger-partner-nuclea-energy-inc-signs-mou-with-new-mining-co-to--e01e8771 2026-08-06 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-reports-second-quarter-2026-financial-results-and-recent-busi-284a6cbe 2026-08-06 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2026-financial-results-and-busine-65d22ddf 2026-08-06 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-shares-by-chief-executive-officer-6d7d9380 2026-08-06 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-second-quarter-2026-financial-result-3d0c39d8 2026-08-06 https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-quar-73b76638 2026-08-06 https://biopharmsignal.com/news/INSM/insmed-reports-second-quarter-2026-financial-results-and-provides-business-updat-e68db27f 2026-08-06 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-second-quarter-2026--3ee8752a 2026-08-06 https://biopharmsignal.com/news/HROW/harrow-acquires-global-rights-to-tyrvaya-the-first-and-only-fda-approved-nasal-s-6685d2e8 2026-08-06 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-reports-second-quarter-2026-financial-results-and-provide-f8a1aff0 2026-08-06 https://biopharmsignal.com/news/SRRK/scholar-rock-reports-second-quarter-2026-financial-results-and-recent-business-h-6dbccec0 2026-08-06 https://biopharmsignal.com/news/IMCR/immunocore-reports-second-quarter-financial-results-and-provides-a-business-upda-ab8c4319 2026-08-06 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2026-financial-results-and-provides--7e16687a 2026-08-06 https://biopharmsignal.com/news/PHVS/assessment-of-aae-c1inh-disease-burden-and-validation-of-clinical-trial-endpoint-6809dac5 2026-08-06 https://biopharmsignal.com/news/BDX/bd-reports-third-quarter-fiscal-2026-financial-results-eb2d4405 2026-08-06 https://biopharmsignal.com/news/LFST/lifestance-reports-strong-second-quarter-2026-financial-results-and-raises-full--a96b052a 2026-08-06 https://biopharmsignal.com/news/PRVA/privia-health-reports-strong-second-quarter-and-year-to-date-2026-results-70aa0ee0 2026-08-06 https://biopharmsignal.com/news/TARS/tarsus-to-report-second-quarter-2026-financial-results-on-thursday-august-6-2026-95cc2351 2026-08-06 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-516a82db 2026-08-05 https://biopharmsignal.com/news/CHRS/coherus-oncology-reports-second-quarter-2026-financial-results-and-provides-busi-6d46d16c 2026-08-05 https://biopharmsignal.com/news/EHC/encompass-health-reports-results-for-second-quarter-2026-6620c58b 2026-08-05 https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-second-quarter-2026-operating-and-pipeline-progress-4ea9f57f 2026-08-05 https://biopharmsignal.com/news/PRI/primerica-reports-second-quarter-2026-results-2d9c0d67 2026-08-05 https://biopharmsignal.com/news/BFRI/biofrontera-inc-to-report-second-quarter-2026-financial-results-on-august-13-202-51ded09a 2026-08-05 https://biopharmsignal.com/news/PNTG/pennant-reports-second-quarter-2026-results-d9d53579 2026-08-05 https://biopharmsignal.com/news/HLF/herbalife-reports-second-quarter-net-sales-growth-marks-fourth-consecutive-quart-cfee54b5 2026-08-05 https://biopharmsignal.com/news/PACB/pacbio-appoints-mark-van-oene-as-president-and-chief-executive-officer-71597294 2026-08-05 https://biopharmsignal.com/news/CLOV/clover-health-reports-second-quarter-2026-results-0e38ca76 2026-08-05 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-reports-second-quarter-2026-financial-results-and-provides-b-fdaeeca5 2026-08-05 https://biopharmsignal.com/news/PCVX/vaxcyte-reports-second-quarter-2026-financial-results-and-provides-business-upda-042c4801 2026-08-05 https://biopharmsignal.com/news/ADMA/adma-biologics-reports-second-quarter-2026-financial-results-and-provides-busine-af0e70d6 2026-08-05 https://biopharmsignal.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-7e98165f 2026-08-05 https://biopharmsignal.com/news/RXST/rxsight-inc-reports-second-quarter-2026-results-and-provides-update-on-2026-outl-7fbe81a1 2026-08-05 https://biopharmsignal.com/news/SGHT/sight-sciences-reports-second-quarter-2026-financial-results-6e097262 2026-08-05 https://biopharmsignal.com/news/BMEA/biomea-fusion-reports-second-quarter-2026-financial-results-and-corporate-highli-c0417574 2026-08-05 https://biopharmsignal.com/news/OSUR/orasure-announces-second-quarter-2026-financial-results-c79a749f 2026-08-05 https://biopharmsignal.com/news/BTMD/biote-reports-second-quarter-2026-financial-results-93f58511 2026-08-05 https://biopharmsignal.com/news/GDRX/goodrx-reports-second-quarter-2026-results-7441e3c7 2026-08-05 https://biopharmsignal.com/news/EXEL/exelixis-announces-second-quarter-2026-financial-results-and-provides-corporate--778a8828 2026-08-05 https://biopharmsignal.com/news/INVA/innoviva-reports-second-quarter-2026-financial-results-highlights-recent-company-2006edc4 2026-08-05 https://biopharmsignal.com/news/HLF/herbalife-announces-planned-cfo-transition-de6a0a61 2026-08-05 https://biopharmsignal.com/news/MGRX/mangoceuticals-merger-partner-nuclea-energy-nuclea-executes-mou-with-utah-office-57201b51 2026-08-05 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-second-quarter-financial-results-and-provides-a-bus-6fd7af1f 2026-08-05 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-second-quarter-2026-financial-results-and-business-h-372d5580 2026-08-05 https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-expected-completion-date-for-redomiciliation-to-del-79de9580 2026-08-05 https://biopharmsignal.com/news/PACB/pacbio-announces-second-quarter-2026-financial-results-d741855e 2026-08-05 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2026-financial-results-and-recent--2e896069 2026-08-05 https://biopharmsignal.com/news/ZVRA/zevra-reports-second-quarter-2026-financial-results-and-corporate-update-6cc97616 2026-08-05 https://biopharmsignal.com/news/SGHT/sight-sciences-announces-aetna-coverage-for-omni-and-sion-surgical-systems-52d81027 2026-08-05 https://biopharmsignal.com/news/RVMD/revolution-medicines-reports-second-quarter-2026-financial-results-and-update-on-fd8742ee 2026-08-05 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-second-quarter-2026-financial-results-and-pro-1f4c0ee2 2026-08-05 https://biopharmsignal.com/news/MNKD/mannkind-reports-second-quarter-2026-financial-results-and-provides-business-upd-f2b608a1 2026-08-05 https://biopharmsignal.com/news/BDSX/biodesix-announces-second-quarter-2026-results-and-highlights-45941193 2026-08-05 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-second-quarter-2026-results-and-business-updates-733cacb7 2026-08-05 https://biopharmsignal.com/news/AXON/axon-reports-q2-2026-revenue-of-904-million-up-35-year-over-year-cb48f7cd 2026-08-05 https://biopharmsignal.com/news/ARQT/arcutis-announces-second-quarter-2026-financial-results-and-provides-business-up-b7ecdf90 2026-08-05 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-report-second-quarter-financial-results-on-august-12-2-464ebfdf 2026-08-05 https://biopharmsignal.com/news/NEPH/nephros-schedules-second-quarter-2026-financial-results-conference-call-bb447b75 2026-08-05 https://biopharmsignal.com/news/BCDA/biocardia-to-host-q2-2026-financial-results-and-corporate-update-conference-call-896613d1 2026-08-05 https://biopharmsignal.com/news/MMSI/merit-medical-to-participate-in-upcoming-investors-conferences-in-august-59f5c518 2026-08-05 https://biopharmsignal.com/news/SYK/stryker-declares-an-0-88-per-share-quarterly-dividend-a54358d7 2026-08-05 https://biopharmsignal.com/news/PACB/pacbio-announces-faster-runs-up-to-50-more-hifi-data-and-new-compliance-controls-9380483d 2026-08-05 https://biopharmsignal.com/news/JAGX/jaguar-health-satisfies-conditions-for-receipt-of-non-dilutive-2-million-holdbac-5b74dd1d 2026-08-05 https://biopharmsignal.com/news/PAVM/lucid-diagnostics-secures-commercial-coverage-policy-spanning-multiple-health-pl-b63d71ae 2026-08-05 https://biopharmsignal.com/news/LUCD/lucid-diagnostics-secures-commercial-coverage-policy-spanning-multiple-health-pl-9b974f96 2026-08-05 https://biopharmsignal.com/news/ACRV/acrivon-advances-acr-2316-a-potential-first-in-class-wee1-pkmyt1-inhibitor-into--fc7c1501 2026-08-05 https://biopharmsignal.com/news/FBIO/journey-medical-corporation-to-announce-second-quarter-2026-financial-results-on-03da3eb2 2026-08-05 https://biopharmsignal.com/news/DRMA/dermata-therapeutics-announces-commercial-launch-date-for-tome-tm-foundational-t-11e4aa47 2026-08-05 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-issuance-of-new-us-patent-broadening-protection-for-2866528c 2026-08-05 https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-second-quarter-2026-financial-results-on-2458bb4f 2026-08-05 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-completes-usability-study-supporting-fda-510-k-submiss-11859358 2026-08-05 https://biopharmsignal.com/news/ICCM/icecure-medical-to-report-first-half-2026-financial-and-operating-results-on-aug-a71aaf99 2026-08-05 https://biopharmsignal.com/news/AEMD/aethlon-medical-to-release-first-quarter-financial-results-and-host-conference-c-9569497a 2026-08-05 https://biopharmsignal.com/news/URGN/urogen-reports-50-4-million-of-zusduri-revenue-and-provides-second-quarter-2026--d8903f44 2026-08-05 https://biopharmsignal.com/news/ALT/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-u-2d1960ad 2026-08-05 https://biopharmsignal.com/news/IMRX/immuneering-reports-second-quarter-2026-financial-results-and-provides-business--b3909a5b 2026-08-05 https://biopharmsignal.com/news/KURA/kura-oncology-to-report-second-quarter-financial-results-074e0252 2026-08-05 https://biopharmsignal.com/news/BCTX/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cde0a86e 2026-08-05 https://biopharmsignal.com/news/USNA/usana-chairman-ceo-kevin-guest-shares-5-ways-to-make-happiness-happen-at-work-an-1c11c072 2026-08-05 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-august-e5b49ee5 2026-08-05 https://biopharmsignal.com/news/BCRX/biocryst-reports-second-quarter-2026-financial-results-00d7eb2b 2026-08-05 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-financi-71d32549 2026-08-05 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-host-second-quarter-2026-financial-results-and-business--3cfcfb78 2026-08-05 https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-second-quarter-2026-financial-results-and-provides-bu-592fe156 2026-08-05 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-upcoming-investor-conferences-47f5fb2d 2026-08-05 https://biopharmsignal.com/news/CRL/charles-river-laboratories-announces-second-quarter-2026-results-9fc8eef8 2026-08-05 https://biopharmsignal.com/news/ACIU/ac-immune-first-half-2026-financial-and-corporate-update-148e97d7 2026-08-05 https://biopharmsignal.com/news/EYPT/eyepoint-reports-second-quarter-2026-financial-results-and-highlights-recent-cor-6ef36797 2026-08-05 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-reports-second-quarter-2026-financial-results-41f75d4e 2026-08-05 https://biopharmsignal.com/news/GERN/geron-corporation-reports-second-quarter-2026-financial-results-and-recent-busin-c583ce9f 2026-08-05 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-second-quarter-2026-financial-results-and-provides-26a4f5e5 2026-08-05 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-expands-infantile-hemangioma-franchise-with-acquisition-of--8893e69c 2026-08-05 https://biopharmsignal.com/news/PRGO/perrigo-reports-second-quarter-2026-financial-results-from-continuing-operations-0a57cffb 2026-08-05 https://biopharmsignal.com/news/RXRX/recursion-reports-second-quarter-financial-results-genentech-options-first-neuro-2ed0e822 2026-08-05 https://biopharmsignal.com/news/YOU/clear-announces-second-quarter-2026-financial-results-538bfe04 2026-08-05 https://biopharmsignal.com/news/TWST/twist-bioscience-announces-pricing-of-upsized-300-0-million-public-offering-of-c-0c189948 2026-08-05 https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-10-million-private-placement-f65d0314 2026-08-05 https://biopharmsignal.com/news/SGHT/sight-sciences-receives-fda-510-k-clearance-of-the-omni-ultra-surgical-system-8bb2f7b4 2026-08-04 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-second-quarter-2026-financial-results-and-provide-b-6790c424 2026-08-04 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-announces-inducement-grants-under-nasdaq-listing-rule-563-3e8d99d7 2026-08-04 https://biopharmsignal.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-0d4c3b30 2026-08-04 https://biopharmsignal.com/news/AZTA/azenta-reports-third-quarter-results-for-fiscal-2026-ended-june-30-2026-a074df8d 2026-08-04 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-report-second-quarter-2026-financial-results-and-provi-e1e2e66c 2026-08-04 https://biopharmsignal.com/news/EDIT/editas-medicine-strengthens-board-of-directors-with-appointment-of-patrick-t-ell-517ace14 2026-08-04 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-to-participate-in-the-canaccord-genuity-46th-annual-growth-c-f242d4ed 2026-08-04 https://biopharmsignal.com/news/XTNT/xtant-medical-to-participate-in-the-canaccord-genuity-46th-annual-growth-confere-79f8e392 2026-08-04 https://biopharmsignal.com/news/USNA/usana-health-sciences-reports-second-quarter-2026-results-4131b1e9 2026-08-04 https://biopharmsignal.com/news/MGRX/mangoceuticals-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-min-8398ceee 2026-08-04 https://biopharmsignal.com/news/IRIX/iridex-to-report-second-quarter-2026-financial-results-on-august-18-2026-99ba9bdd 2026-08-04 https://biopharmsignal.com/news/AMWL/amwell-announces-results-for-the-second-quarter-2026-00e6efb6 2026-08-04 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-to-report-second-quarter-2026-financial-results-and-recent-cor-62eb13db 2026-08-04 https://biopharmsignal.com/news/PRCT/procept-biorobotics-reports-second-quarter-2026-financial-results-325eefde 2026-08-04 https://biopharmsignal.com/news/LMAT/lemaitre-q2-2026-financial-results-9fa7f47c 2026-08-04 https://biopharmsignal.com/news/RARE/ultragenyx-reports-second-quarter-2026-financial-results-and-corporate-update-629023e6 2026-08-04 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-reports-second-quarter-2026-financial-results-and-provides-co-a2566614 2026-08-04 https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-second-quarter-2026-financial-results-fc63b776 2026-08-04 https://biopharmsignal.com/news/PSNL/personalis-reports-second-quarter-results-and-recent-highlights-faf41eee 2026-08-04 https://biopharmsignal.com/news/TWST/twist-bioscience-announces-proposed-public-offering-of-250-0-million-of-common-s-242d974e 2026-08-04 https://biopharmsignal.com/news/SNDX/syndax-reports-second-quarter-2026-financial-results-and-provides-business-updat-f0b01267 2026-08-04 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing--e04d211e 2026-08-04 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-fiscal-2026-third-quarter-results-04a63b64 2026-08-04 https://biopharmsignal.com/news/RIGL/rigel-reports-second-quarter-2026-financial-results-abcb40e5 2026-08-04 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-26fad73b 2026-08-04 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-announce-second-quarter-2026-financial-results-on-a-bb22d826 2026-08-04 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-release-second-quarter-2026-financial-results-and-host--45ec0663 2026-08-04 https://biopharmsignal.com/news/PNTG/pennant-acquires-river-centre-assisted-living-in-tucson-arizona-301ad6cd 2026-08-04 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-acquires-fda-priority-review-voucher-4a0417b4 2026-08-04 https://biopharmsignal.com/news/IMMX/immix-biopharma-to-participate-in-the-morgan-stanley-24th-annual-global-healthca-f710644e 2026-08-04 https://biopharmsignal.com/news/VTAK/flyte-partners-with-volato-ai-to-become-first-enterprise-customer-accelerating-t-191d4780 2026-08-04 https://biopharmsignal.com/news/RNXT/renovorx-to-highlight-tamp-platform-at-jonestrading-virtual-key-opinion-leader-w-6e36fcef 2026-08-04 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-announces-last-patient-last-visit-in-canyon-1-study-of-cr-9d359b65 2026-08-04 https://biopharmsignal.com/news/PAVM/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-8e5e0f6c 2026-08-04 https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-9b811364 2026-08-04 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-to-report-second-quarter-2026-financial-results-and-provid-8d513331 2026-08-04 https://biopharmsignal.com/news/ENTX/entera-bio-phase-2-data-supporting-eb613-s-oral-pth-1-34-anabolic-effect-on-post-5a471747 2026-08-04 https://biopharmsignal.com/news/VERU/veru-announces-notice-of-allowance-for-key-methods-of-use-u-s-patent-for-enobosa-a0328556 2026-08-04 https://biopharmsignal.com/news/RANI/rani-therapeutics-appoints-michelle-gilson-to-board-of-directors-33169018 2026-08-04 https://biopharmsignal.com/news/ALZN/alzamend-neuro-announces-initial-closing-of-securities-purchase-agreement-with-a-65090ea0 2026-08-04 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-announce-second-quarter-2026-financial-results-and-hos-3e424d6c 2026-08-04 https://biopharmsignal.com/news/XAIR/beyond-air-schedules-conference-call-to-discuss-financial-results-for-the-quarte-a4714eb0 2026-08-04 https://biopharmsignal.com/news/IMNN/imunon-to-hold-second-quarter-2026-financial-results-and-business-update-confere-0d2bdadc 2026-08-04 https://biopharmsignal.com/news/GALT/galectin-therapeutics-announces-conversion-of-105-8-million-in-debt-to-equity-si-ce202c56 2026-08-04 https://biopharmsignal.com/news/XGN/exagen-inc-reports-second-quarter-2026-financial-results-51c0ee9c 2026-08-04 https://biopharmsignal.com/news/TWST/twist-bioscience-corporation-announces-inducement-grants-under-nasdaq-listing-ru-6b7d2061 2026-08-04 https://biopharmsignal.com/news/LPCN/lipocine-announces-financial-results-for-the-second-quarter-ended-june-30-2026-2511d375 2026-08-04 https://biopharmsignal.com/news/INTS/intensity-therapeutics-to-announce-second-quarter-2026-financial-results-on-augu-543d453f 2026-08-04 https://biopharmsignal.com/news/ABEO/cms-grants-new-technology-add-on-payment-ntap-status-for-zevaskyn-300aae33 2026-08-04 https://biopharmsignal.com/news/HRMY/harmony-biosciences-announces-record-q2-2026-revenue-and-shares-initial-clinical-92065642 2026-08-04 https://biopharmsignal.com/news/IBRX/immunitybio-reports-record-q2-2026-net-product-revenue-of-50-7-million-up-92-yea-a886a63e 2026-08-04 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-to-present-at-the-canaccord-genuity-annual-growth-conference-549d8be6 2026-08-04 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-reports-second-quarter-2026-financial-results-and-busines-bf05205a 2026-08-04 https://biopharmsignal.com/news/NRIX/nurix-announces-10-million-milestone-payment-associated-with-initiation-of-a-pha-7c23128a 2026-08-04 https://biopharmsignal.com/news/CERT/certara-reports-second-quarter-2026-financial-results-d58e07eb 2026-08-04 https://biopharmsignal.com/news/TELA/tela-bio-announces-appointment-of-heather-getz-as-chief-executive-officer-and-di-172ffd1d 2026-08-04 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-provides-update-following-termination-of-merger-agreement-b0ae6a2c 2026-08-04 https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-second-quarter-2026-financial-results-and-announces-fi-f3a9cb51 2026-08-04 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-to-participate-in-the-canaccord-genuity-46th-annual-growth-c-d57562ef 2026-08-04 https://biopharmsignal.com/news/BRKR/bruker-reports-second-quarter-2026-financial-results-4f25580a 2026-08-04 https://biopharmsignal.com/news/ACON/aclarion-announces-nociscan-now-available-at-goodman-campbell-brain-spine-at-asc-6d220f84 2026-08-04 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-second-quarter-2026-financial-and-business-update-a986353a 2026-08-04 https://biopharmsignal.com/news/IBIO/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-c-9c0b0cd2 2026-08-04 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-preliminary-data-from-phase-2-trial-that-showed-a30ab64d 2026-08-04 https://biopharmsignal.com/news/BNTX/biontech-ver-ffentlicht-ergebnisse-f-r-das-zweite-quartal-2026-sowie-information-2f0be20d 2026-08-04 https://biopharmsignal.com/news/BNTX/biontech-announces-second-quarter-2026-financial-results-and-corporate-update-20d0ffe1 2026-08-04 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-reports-second-quarter-2026-financial-results-and-provides-bu-9a262261 2026-08-04 https://biopharmsignal.com/news/MD/pediatrix-medical-group-reports-second-quarter-results-c25210f0 2026-08-04 https://biopharmsignal.com/news/BDSX/biodesix-to-participate-in-canaccord-genuity-s-46th-annual-growth-conference-9a24f4ae 2026-08-04 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-first-patient-enrolled-in-registrational-phase-3-da-2b8297cd 2026-08-04 https://biopharmsignal.com/news/HSTM/healthstream-announces-second-quarter-2026-results-378943b2 2026-08-03 https://biopharmsignal.com/news/TDOC/teladoc-health-appoints-financial-executive-mark-anquillare-to-its-board-of-dire-60022d8f 2026-08-03 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-56-a75d3369 2026-08-03 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-announces-earnings-release-date-conference-call-and-webca-85bbcf60 2026-08-03 https://biopharmsignal.com/news/SEER/seer-to-participate-in-the-canaccord-genuity-46th-annual-growth-conference-1f16ca9b 2026-08-03 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2026-fin-cbce5bc0 2026-08-03 https://biopharmsignal.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-second-quarter-2026-and-raises-202-cc17b0e9 2026-08-03 https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operation-3a2b7016 2026-08-03 https://biopharmsignal.com/news/SEER/seer-to-report-second-quarter-2026-financial-results-on-august-11-2026-2c903d64 2026-08-03 https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-7440e985 2026-08-03 https://biopharmsignal.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-ru-852a06cf 2026-08-03 https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635--8e9e1f10 2026-08-03 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2026-financial-results-and-prov-88f72dc1 2026-08-03 https://biopharmsignal.com/news/LGVN/longeveron-to-report-2026-second-quarter-financial-results-and-host-conference-c-7defe4de 2026-08-03 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-reports-second-quarter-2026-results-fa22032b 2026-08-03 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-report-second-quarter-2026-financial-results-and-host-co-312b2ce2 2026-08-03 https://biopharmsignal.com/news/KROS/keros-therapeutics-reports-second-quarter-2026-financial-results-ba3903e0 2026-08-03 https://biopharmsignal.com/news/ARGX/argenx-announces-extraordinary-general-meeting-of-shareholders-on-september-17-2-afc05e25 2026-08-03 https://biopharmsignal.com/news/PMN/promis-neurosciences-to-report-second-quarter-2026-financial-results-and-busines-ddaf05d1 2026-08-03 https://biopharmsignal.com/news/GNFT/genfit-answers-its-investors-episode-3-august-3-2026-17ab91a1 2026-08-03 https://biopharmsignal.com/news/XCUR/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-is-1a1431d7 2026-08-03 https://biopharmsignal.com/news/AIM/aim-immunotech-ahead-of-schedule-on-last-dose-duripanc-critical-clinical-inflect-24b1fcf5 2026-08-03 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-appoints-ronald-dadino-and-gloria-cosgrove-to-lead-cmc-sup-fde99cb7 2026-08-03 https://biopharmsignal.com/news/VERU/veru-to-report-fiscal-2026-third-quarter-financial-results-on-august-10th-3c5f1e88 2026-08-03 https://biopharmsignal.com/news/CUE/cue-biopharma-announces-appointment-of-james-m-ahlers-as-chief-financial-officer-3c179293 2026-08-03 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-completes-interference-study-examining-the-impact-of-e-e1495685 2026-08-03 https://biopharmsignal.com/news/CADL/candel-therapeutics-to-present-extended-data-from-phase-3-results-of-aglatimagen-3ca43971 2026-08-03 https://biopharmsignal.com/news/DSGN/design-therapeutics-provides-restore-fa-clinical-development-update-and-reports--ceffa181 2026-08-03 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-futur-b3e4fc14 2026-08-03 https://biopharmsignal.com/news/STIM/neuronetics-and-jorey-chernett-announce-shared-vision-df32000a 2026-08-03 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-appoints-alejandra-carvajal-as-chief-legal-officer-fcf0cd34 2026-08-03 https://biopharmsignal.com/news/ECOR/electrocore-to-participate-in-upcoming-investor-conferences-3d1a9bbe 2026-08-03 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-announces-initiation-of-a-phase-2-basket-trial-to-study-ebri-eb84a9e4 2026-08-03 https://biopharmsignal.com/news/ALT/altimmune-initiates-performa-phase-3-trial-of-pemvidutide-in-patients-with-mash-e85d90c3 2026-08-03 https://biopharmsignal.com/news/LPCN/lipocine-appoints-michael-j-grissinger-to-board-of-directors-28b9afc6 2026-08-03 https://biopharmsignal.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listin-bd27d591 2026-08-03 https://biopharmsignal.com/news/BBIO/bridgebio-to-report-second-quarter-2026-financial-results-and-commercial-updates-0b329680 2026-08-03 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcast-on-august-13-outlining-0390283c 2026-08-03 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-announces-publication-of-four-year-real-world-data-from-u-s-e-c8254a50 2026-08-03 https://biopharmsignal.com/news/TWST/twist-bioscience-announces-fiscal-2026-third-quarter-financial-results-a79ae39a 2026-08-03 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-reports-preliminary-second-quarter-2026-net-product-revenue-9b30030a 2026-08-03 https://biopharmsignal.com/news/TGTX/tg-therapeutics-reports-second-quarter-2026-financial-results-and-raises-briumvi-ccdc59b0 2026-08-03 https://biopharmsignal.com/news/ANL/adlai-nortye-announces-clinical-trial-notification-submission-and-hrec-approval--6427309b 2026-08-03 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-positive-minutes-from-type-c-fda-meeting-to-disc-cea2cde0 2026-08-03 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-positive-clinical-safety-update-from-initial-th-979c2d7f 2026-08-03 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2026-financial-results-and-business-hi-0807f056 2026-08-03 https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-second-quarter-2026-financial-and-operating-results-6dbba7e1 2026-08-03 https://biopharmsignal.com/news/COCP/cocrystal-pharma-announces-5-million-private-placement-with-opko-health-1279403a 2026-08-03 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-thursday-e5252f95 2026-08-03 https://biopharmsignal.com/news/SUPN/supernus-announces-second-quarter-2026-financial-results-5dc034a4 2026-08-03 https://biopharmsignal.com/news/INDV/indivior-reports-second-quarter-2026-financial-results-and-raises-full-year-2026-aea080a0 2026-08-03 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-and-indivior-pharmaceuticals-to-merge-creating-a-divers-3b4a29fd 2026-08-03 https://biopharmsignal.com/news/BNTX/biontech-ernennt-dr-guido-oelkers-zum-neuen-vorstandsvorsitzenden-ee848391 2026-08-03 https://biopharmsignal.com/news/BNTX/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-exe-ec8ad74b 2026-08-03 https://biopharmsignal.com/news/OCS/oculis-announces-positive-fda-pre-ind-feedback-supporting-privosegtor-developmen-e07fbd26 2026-08-03 https://biopharmsignal.com/news/FMS/fresenius-medical-care-accelerates-income-growth-to-23-in-the-second-quarter-of--52863b21 2026-08-03 https://biopharmsignal.com/news/FMS/fresenius-medical-care-appoints-cassie-mclean-as-new-management-board-member-for-7c1c70ef 2026-08-03 https://biopharmsignal.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-a098f270 2026-07-31 https://biopharmsignal.com/news/ENTX/entera-bio-to-participate-in-the-canaccord-genuity-46th-annual-growth-conference-8f6abc7d 2026-07-31 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-congratulates-partner-aspen-neuroscience-on-fda-regenerative-me-2a2fb6d2 2026-07-31 https://biopharmsignal.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-f69791eb 2026-07-31 https://biopharmsignal.com/news/PRPO/precipio-announces-q2-2026-shareholder-update-call-e822ad89 2026-07-31 https://biopharmsignal.com/news/MBRX/moleculin-announces-pricing-of-9-3-million-public-offering-7e9f0e5b 2026-07-31 https://biopharmsignal.com/news/VTGN/vistagen-appoints-douglas-j-williamson-to-its-board-of-directors-542dad50 2026-07-31 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-announced-granting-of-new-hire-inducement-awards-925196f6 2026-07-31 https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-options-trading-begins-on-cboe-options-exchange-a661a6f0 2026-07-31 https://biopharmsignal.com/news/PAVM/pavmed-to-hold-second-quarter-2026-business-update-conference-call-and-webcast-o-9ee0d410 2026-07-31 https://biopharmsignal.com/news/IRMD/iradimed-corporation-reports-second-quarter-2026-financial-results-9c473d3d 2026-07-31 https://biopharmsignal.com/news/MBRX/moleculin-s-miracle-r-r-aml-trial-reports-positive-interim-data-with-37-blinded--0b92f426 2026-07-31 https://biopharmsignal.com/news/AZYO/elutia-to-report-second-quarter-2026-financial-results-on-thursday-august-13-202-125af4ad 2026-07-31 https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-august-investor-conferences-2ecb8549 2026-07-31 https://biopharmsignal.com/news/DTIL/precision-biosciences-to-report-second-quarter-2026-financial-results-on-august--ad1b9fdb 2026-07-31 https://biopharmsignal.com/news/REGN/regeneron-awards-150-000-to-winners-of-the-2026-regeneron-prize-for-creative-inn-b562f013 2026-07-31 https://biopharmsignal.com/news/TLSA/tiziana-reports-reduction-in-brain-inflammation-in-third-multiple-system-atrophy-626b4f51 2026-07-31 https://biopharmsignal.com/news/TENX/tenax-therapeutics-reports-second-quarter-2026-financial-results-and-provides-co-e8377bbc 2026-07-31 https://biopharmsignal.com/news/INMB/inmune-bio-receives-r-d-rebates-of-approximately-4-6-million-b9fb7430 2026-07-31 https://biopharmsignal.com/news/INMB/inmune-bio-inc-to-report-second-quarter-2026-financial-results-and-provide-corpo-908a49f8 2026-07-31 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-reports-second-quarter-2026-financial-results-and-recent-c-88be86cf 2026-07-31 https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-provide-business-highlights-and-report-second-quarte-9488302c 2026-07-31 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--cf0f42bb 2026-07-31 https://biopharmsignal.com/news/PRI/primerica-household-budget-index-hbi-purchasing-power-for-middle-income-american-887f4410 2026-07-31 https://biopharmsignal.com/news/REPL/replimune-announces-favorable-outcome-of-fda-s-cellular-tissue-and-gene-therapie-4ca65fc6 2026-07-30 https://biopharmsignal.com/news/SEER/seer-confirms-receipt-of-further-revised-unsolicited-acquisition-proposals-from--cb8f763a 2026-07-30 https://biopharmsignal.com/news/CLLS/cellectis-to-report-second-quarter-financial-results-on-august-6-2026-9a15aa1c 2026-07-30 https://biopharmsignal.com/news/COO/coopercompanies-announces-release-date-for-third-quarter-2026-92c94495 2026-07-30 https://biopharmsignal.com/news/KPTI/karyopharm-plans-to-submit-snda-for-selinexor-plus-ruxolitinib-in-myelofibrosis--3856c192 2026-07-30 https://biopharmsignal.com/news/FLGT/fulgent-reports-second-quarter-2026-financial-results-eedcdc21 2026-07-30 https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-canaccord-genuity-s-46th-annual-growth-conferenc-33705951 2026-07-30 https://biopharmsignal.com/news/MMSI/merit-medical-reports-second-quarter-2026-results-and-updates-full-year-2026-gui-fefcae97 2026-07-30 https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-announce-second-quarter-2026-financial-results-and-corpora-957fff80 2026-07-30 https://biopharmsignal.com/news/KPTI/karyopharm-announces-topline-results-from-phase-3-xport-ec-042-trial-in-endometr-a31032de 2026-07-30 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-host-second-quarter-2026-investor-update-call-fd41929b 2026-07-30 https://biopharmsignal.com/news/SYK/stryker-reports-second-quarter-2026-operating-results-2db5f238 2026-07-30 https://biopharmsignal.com/news/ANNX/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-fina-e092eb12 2026-07-30 https://biopharmsignal.com/news/ALHC/alignment-healthcare-reports-second-quarter-2026-results-surpassing-high-end-of--71256e53 2026-07-30 https://biopharmsignal.com/news/XENE/xenon-to-report-q2-2026-financial-results-on-august-6-2026-3b8e2d4f 2026-07-30 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-second-quarter-2026-financ-46f83caa 2026-07-30 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-to-report-second-quarter-2026-financial-results-on-th-16ae1983 2026-07-30 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-second-quarter-2026-finan-be6289f0 2026-07-30 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2026-financial-results-6237f8ed 2026-07-30 https://biopharmsignal.com/news/KROS/keros-therapeutics-to-receive-development-milestone-payment-from-partner-takeda-a7403395 2026-07-30 https://biopharmsignal.com/news/MDXH/mdxhealth-to-release-second-quarter-2026-financial-results-on-august-13-3e04359c 2026-07-30 https://biopharmsignal.com/news/IVA/correction-inventiva-annonce-ses-r-sultats-financiers-pr-liminaires-pour-le-prem-fc78c7dc 2026-07-30 https://biopharmsignal.com/news/IVA/correction-inventiva-announces-preliminary-financial-results-for-the-first-half--b27594e7 2026-07-30 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-provides-update-on-fda-advisory-committee-meeting-for-dera-ef1c36a3 2026-07-30 https://biopharmsignal.com/news/IMNN/imunon-reports-strong-enrollment-momentum-in-phase-3-ovation-3-trial-of-imnn-001-36e425e2 2026-07-30 https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-trading-volume-reaches-860mm-622-month-ov-4a0e06d2 2026-07-30 https://biopharmsignal.com/news/SABS/sab-bio-to-host-second-quarter-2026-financial-results-conference-call-and-webcas-99a1b001 2026-07-30 https://biopharmsignal.com/news/IRON/disc-medicine-reports-second-quarter-2026-financial-results-and-provides-busines-ab5a4d9e 2026-07-30 https://biopharmsignal.com/news/CELC/newly-fda-approved-revtorpyk-gedatolisib-included-in-the-national-comprehensive--9760bfe7 2026-07-30 https://biopharmsignal.com/news/CING/cingulate-announces-publication-of-phase-3-adhd-trial-results-in-journal-of-chil-db095e97 2026-07-30 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-augus-436992c6 2026-07-30 https://biopharmsignal.com/news/PRGO/perrigo-announces-quarterly-dividend-a2e51c0e 2026-07-30 https://biopharmsignal.com/news/VERU/veru-to-participate-in-fireside-chat-at-the-canaccord-genuity-s-46th-annual-grow-ba050a79 2026-07-30 https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-hold-second-quarter-2026-business-update-conference-call-an-fdcc99f1 2026-07-30 https://biopharmsignal.com/news/PAVM/lucid-diagnostics-to-hold-second-quarter-2026-business-update-conference-call-an-6832ca29 2026-07-30 https://biopharmsignal.com/news/HYPR/hyperfine-announces-the-release-of-multiple-peer-reviewed-publications-expanding-30a31af5 2026-07-30 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-report-second-quarter-2026-financial-results-and-prov-94ad361d 2026-07-30 https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-report-second-quarter-financial-results-and-host-a-conf-1d91f28e 2026-07-30 https://biopharmsignal.com/news/APRE/aprea-therapeutics-provides-acesot-1051-program-update-for-wee1-inhibitor-apr-10-f8182df4 2026-07-30 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-to-announce-2nd-quarter-2026-financial-results-on-august-6-2-0808d448 2026-07-30 https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-report-second-quarter-2026-financial-results-and-pr-8da697b1 2026-07-30 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-to-report-second-quarter-2026-financial-results-and-corp-17e76401 2026-07-30 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-report-second-quarter-2026-financial-results-on-august-6--97882886 2026-07-30 https://biopharmsignal.com/news/PYPD/polypid-to-report-second-quarter-2026-financial-results-and-operational-highligh-77e27a6e 2026-07-30 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-on-august-6-to-discuss-second-quar-4c11a227 2026-07-30 https://biopharmsignal.com/news/IMMP/immutep-quarterly-activities-report-q4-fy26-813a9fec 2026-07-30 https://biopharmsignal.com/news/ECOR/electrocore-to-announce-second-quarter-june-30-2026-financial-results-on-thursda-1b5a79de 2026-07-30 https://biopharmsignal.com/news/VXRT/vaxart-to-host-stockholder-fireside-chat-on-august-7-at-4-30-p-m-et-1f079317 2026-07-30 https://biopharmsignal.com/news/CRIS/curis-doses-first-five-patients-in-takeaim-cll-study-2fe4da53 2026-07-30 https://biopharmsignal.com/news/VCEL/vericel-reports-second-quarter-2026-financial-results-raises-full-year-financial-6a014b54 2026-07-30 https://biopharmsignal.com/news/IFRX/inflarx-to-report-second-quarter-2026-results-on-august-6-2026-2e4e70f5 2026-07-30 https://biopharmsignal.com/news/WVE/wave-life-sciences-reports-second-quarter-2026-financial-results-and-provides-bu-ce5af4f7 2026-07-30 https://biopharmsignal.com/news/DGX/bacterial-vaginosis-linked-to-increased-sti-co-infection-finds-national-study-of-e9bf30a4 2026-07-30 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-releases-appendix-4c-q4-fy26-quarterly-cash-flow-report-co-536052cb 2026-07-30 https://biopharmsignal.com/news/USNA/new-12-week-consumer-study-highlights-visible-skin-benefits-with-usana-glow-47082bfd 2026-07-30 https://biopharmsignal.com/news/XAIR/beyond-air-announces-up-to-30-1-million-private-placement-offering-priced-at-the-9860617a 2026-07-30 https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provi-4eca043e 2026-07-30 https://biopharmsignal.com/news/HCM/hutchmed-reports-2026-interim-results-1642187b 2026-07-30 https://biopharmsignal.com/news/MGRX/mangoceuticals-announces-business-combination-agreement-with-nuclea-energy-inc-t-cef06d33 2026-07-30 https://biopharmsignal.com/news/INMB/inmune-bio-establishes-scientific-advisory-board-to-support-late-stage-developme-c0e6866f 2026-07-30 https://biopharmsignal.com/news/EYPT/eyepoint-completes-enrollment-of-both-pivotal-phase-3-trials-of-duravyu-for-trea-38a1e114 2026-07-30 https://biopharmsignal.com/news/BEAT/heartbeam-to-host-second-quarter-2026-results-conference-call-on-thursday-august-4cfd76dd 2026-07-30 https://biopharmsignal.com/news/IMCR/immunocore-to-report-second-quarter-2026-financial-results-and-host-call-on-augu-527188fc 2026-07-30 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provid-09026018 2026-07-30 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-second-quarter-financial-results-for-2026-87f265f8 2026-07-30 https://biopharmsignal.com/news/REGN/regeneron-reports-second-quarter-2026-financial-and-operating-results-39145cc1 2026-07-30 https://biopharmsignal.com/news/AGIO/agios-reports-second-quarter-2026-financial-results-and-provides-business-update-2482094f 2026-07-30 https://biopharmsignal.com/news/CYTK/cytokinetics-announces-mhra-marketing-authorisation-for-myqorzo-aficamten-and-po-73c9effe 2026-07-30 https://biopharmsignal.com/news/AMRX/amneal-reports-second-quarter-2026-financial-results-43ee7ea0 2026-07-30 https://biopharmsignal.com/news/IBRX/immunitybio-receives-united-arab-emirates-uae-marketing-authorization-for-anktiv-9a6a04b3 2026-07-29 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--bf21b718 2026-07-29 https://biopharmsignal.com/news/DYN/dyne-therapeutics-reports-second-quarter-2026-financial-results-and-recent-busin-f9e05f26 2026-07-29 https://biopharmsignal.com/news/BNTX/europ-ische-kommission-genehmigt-marktzulassung-des-an-xfg-angepassten-covid-19--ca9e72a1 2026-07-29 https://biopharmsignal.com/news/BNTX/european-commission-authorizes-pfizer-and-biontech-xfg-adapted-covid-19-vaccine--2746d430 2026-07-29 https://biopharmsignal.com/news/BDRX/result-of-general-meeting-4c1bd30b 2026-07-29 https://biopharmsignal.com/news/MDXG/mimedx-announces-second-quarter-2026-operating-financial-results-2c1638cf 2026-07-29 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-reports-second-quarter-2026-financial-results-98b81673 2026-07-29 https://biopharmsignal.com/news/TELA/tela-bio-to-participate-in-the-canaccord-genuity-46th-annual-growth-conference-0473c6fd 2026-07-29 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-report-financial-results-for-second-quarter-2026-after-m-4ad84d96 2026-07-29 https://biopharmsignal.com/news/LUNG/pulmonx-reports-second-quarter-2026-financial-results-2544a60b 2026-07-29 https://biopharmsignal.com/news/CORT/corcept-therapeutics-announces-second-quarter-financial-results-and-provides-cor-8ea3b293 2026-07-29 https://biopharmsignal.com/news/TDOC/teladoc-health-reports-second-quarter-2026-results-45e56fd1 2026-07-29 https://biopharmsignal.com/news/BSEM/biostem-technologies-to-host-second-quarter-2026-financial-results-conference-ca-f263b00d 2026-07-29 https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a 2026-07-29 https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce 2026-07-29 https://biopharmsignal.com/news/MDXG/mimedx-to-acquire-sanara-medtech-f0a3d419 2026-07-29 https://biopharmsignal.com/news/IVA/inventiva-annonce-ses-r-sultats-financiers-pr-liminaires-pour-le-premier-semestr-7be242c7 2026-07-29 https://biopharmsignal.com/news/IVA/inventiva-announces-preliminary-financial-results-for-the-first-half-of-2026-21bb435e 2026-07-29 https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9 2026-07-29 https://biopharmsignal.com/news/ALVO/alvotech-tilkynnir-a-matv-la-og-lyfjaeftirlit-bandar-kjanna-fda-hefur-loki-ttekt-ebe2b467 2026-07-29 https://biopharmsignal.com/news/ALVO/alvotech-announces-successful-closure-of-fda-inspection-of-manufacturing-facilit-f9dda4fa 2026-07-29 https://biopharmsignal.com/news/VTAK/flyte-partners-with-ldv-at-the-maidstone-to-elevate-luxury-travel-to-the-hampton-d6f57df9 2026-07-29 https://biopharmsignal.com/news/HCWB/hcw-biologics-inc-announces-pricing-of-1-6-million-private-placement-offering-ea86202c 2026-07-29 https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-a54edc06 2026-07-29 https://biopharmsignal.com/news/HSCS/heartsciences-files-preliminary-proxy-statement-for-business-combination-with-fo-565e47a4 2026-07-29 https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-report-second-quarter-2026-financial-results-on-august-1-13c2e2e8 2026-07-29 https://biopharmsignal.com/news/PYPD/polypid-announces-fda-acceptance-of-nda-with-priority-review-for-d-plex-d8b950d0 2026-07-29 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-d-70ba2236 2026-07-29 https://biopharmsignal.com/news/BDRX/biodexa-initiates-support-activities-for-fap-patients-and-treatment-centers-in-f-386d63a6 2026-07-29 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-to-report-second-quarter-2026-financial-results-and-provid-d049bf35 2026-07-29 https://biopharmsignal.com/news/CLNN/clene-to-present-at-the-canaccord-46th-annual-growth-conference-2a84d8af 2026-07-29 https://biopharmsignal.com/news/RXRX/recursion-to-report-second-quarter-2026-business-updates-and-financial-results-o-9a849d6b 2026-07-29 https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922 2026-07-29 https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c 2026-07-29 https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec 2026-07-29 https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3 2026-07-29 https://biopharmsignal.com/news/CADL/candel-therapeutics-to-present-at-canaccord-genuity-s-46th-annual-growth-confere-98365fa6 2026-07-29 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-host-investor-day-on-august-5-2026-00cdef02 2026-07-29 https://biopharmsignal.com/news/URGN/urogen-pharma-to-report-second-quarter-2026-financial-results-on-wednesday-augus-bbf2c6c0 2026-07-29 https://biopharmsignal.com/news/SRRK/scholar-rock-to-present-at-the-canaccord-genuity-46th-annual-growth-conference-9ad1248c 2026-07-29 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-report-second-quarter-2026-financial-results-and-discuss--2657d229 2026-07-29 https://biopharmsignal.com/news/MDWD/mediwound-to-report-second-quarter-2026-financial-results-11b5e0a5 2026-07-29 https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-host-conference-call-on-second-quarter-2026-financial-results-190cd0b2 2026-07-29 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-inc-announces-acquisition-of-vidya-therapeutics-inc-and-589446e2 2026-07-29 https://biopharmsignal.com/news/BDRX/biodexa-lance-des-activit-s-de-soutien-aux-patients-atteints-de-polypose-ad-noma-9041aded 2026-07-29 https://biopharmsignal.com/news/AXGN/axogen-inc-reports-second-quarter-2026-financial-results-4cea3351 2026-07-29 https://biopharmsignal.com/news/OCGN/ocugen-announces-that-the-u-s-food-and-drug-administration-has-granted-ocu410-re-ce6aa687 2026-07-29 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-report-second-quarter-2026-financial-results-and-recen-04e9cd49 2026-07-29 https://biopharmsignal.com/news/ADMA/adma-biologics-to-report-second-quarter-2026-financial-results-on-august-5-2026-2950865d 2026-07-29 https://biopharmsignal.com/news/SYBX/synlogic-and-caldera-therapeutics-announce-merger-agreement-and-concurrent-priva-11695f09 2026-07-29 https://biopharmsignal.com/news/PLSE/pulse-biosciences-surpasses-enrollment-midpoint-in-nanopulse-af-ide-pivotal-stud-f32400cf 2026-07-29 https://biopharmsignal.com/news/OPCH/option-care-health-announces-financial-results-for-the-second-quarter-ended-june-f4ffab93 2026-07-29 https://biopharmsignal.com/news/HUM/humana-elects-paul-smith-and-frederick-crawford-to-board-of-directors-3fd96960 2026-07-29 https://biopharmsignal.com/news/AMRN/amarin-reports-2026-second-quarter-financial-results-demonstrating-early-success-f75796f5 2026-07-29 https://biopharmsignal.com/news/TEVA/teva-delivers-strong-q2-results-and-raises-outlook-for-all-three-key-innovative--d2dd028b 2026-07-29 https://biopharmsignal.com/news/ACON/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-o-e20bb5ae 2026-07-29 https://biopharmsignal.com/news/BDX/ems-and-bd-expand-access-to-glp-1-therapies-in-brazil-with-semaglutide-launch-ecbaad65 2026-07-29 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-announces-submission-of-prior-approval-supplement-to-expand-954a1f41 2026-07-29 https://biopharmsignal.com/news/MNKD/mannkind-reports-positive-phase-1b-inflo-1-results-demonstrating-safety-and-tole-a3fa2397 2026-07-29 https://biopharmsignal.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2026-cbac35ee 2026-07-29 https://biopharmsignal.com/news/IART/integra-lifesciences-reports-second-quarter-2026-financial-results-034ed2c1 2026-07-29 https://biopharmsignal.com/news/HUM/humana-reports-second-quarter-2026-financial-results-affirms-full-year-2026-adju-a3dc91c3 2026-07-29 https://biopharmsignal.com/news/GSK/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-living-wi-f233257f 2026-07-29 https://biopharmsignal.com/news/FMS/fresenius-medical-care-announces-beacon-us-generating-real-world-evidence-suppor-8547f5f8 2026-07-29 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-to-announce-financial-results-for-the-second-quarter-on-thur-0e8d09be 2026-07-28 https://biopharmsignal.com/news/SEER/seer-stockholders-vote-to-re-elect-all-seven-of-seer-s-director-nominees-at-2026-57216236 2026-07-28 https://biopharmsignal.com/news/HCAT/health-catalyst-to-announce-second-quarter-2026-operating-results-and-host-confe-038ea875 2026-07-28 https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a 2026-07-28 https://biopharmsignal.com/news/AORT/artivion-to-participate-in-upcoming-investor-conferences-5ff1d4ef 2026-07-28 https://biopharmsignal.com/news/LUNG/pulmonx-to-present-at-the-canaccord-genuity-46th-annual-growth-conference-ff07eee2 2026-07-28 https://biopharmsignal.com/news/ACHC/acadia-healthcare-announces-second-quarter-2026-results-and-updates-full-year-20-6faf7a06 2026-07-28 https://biopharmsignal.com/news/PACB/pacbio-to-participate-in-the-canaccord-genuity-46th-annual-growth-conference-4761c1ba 2026-07-28 https://biopharmsignal.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2026-financial-results-and-b9eb5649 2026-07-28 https://biopharmsignal.com/news/DCTH/delcath-systems-to-participate-at-the-canaccord-genuity-46th-annual-growth-confe-67f1478e 2026-07-28 https://biopharmsignal.com/news/MNKD/mannkind-to-report-second-quarter-financial-results-and-host-conference-call-on--73ad1212 2026-07-28 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-to-report-second-quarter-2026-financial-results-on-august-5--5364bc95 2026-07-28 https://biopharmsignal.com/news/OCGN/ocugen-to-host-conference-call-on-thursday-august-6-at-8-30-a-m-et-to-discuss-bu-9cbdb920 2026-07-28 https://biopharmsignal.com/news/PNTG/pennant-announces-second-quarter-2026-earnings-release-and-call-03474342 2026-07-28 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-appoints-medical-device-commercial-leader-erica-jordan-as-c-0c0f0fbe 2026-07-28 https://biopharmsignal.com/news/JAGX/jaguar-health-reports-positive-consumer-and-veterinary-market-research-findings--7b92e347 2026-07-28 https://biopharmsignal.com/news/XGN/exagen-inc-to-participate-in-upcoming-investor-conference-36ea91ca 2026-07-28 https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-296daf37 2026-07-28 https://biopharmsignal.com/news/STIM/greenbrook-opens-national-center-of-excellence-for-advanced-interventional-psych-02bd5807 2026-07-28 https://biopharmsignal.com/news/CVRX/cvrx-to-present-at-canaccord-genuity-s-46th-annual-growth-conference-3209525f 2026-07-28 https://biopharmsignal.com/news/STIM/neuronetics-to-report-second-quarter-2026-financial-and-operating-results-and-ho-e0688305 2026-07-28 https://biopharmsignal.com/news/ANGO/angiodynamics-to-participate-in-upcoming-investor-conferences-da9e7851 2026-07-28 https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2 2026-07-28 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11 2026-07-28 https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a 2026-07-28 https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859 2026-07-28 https://biopharmsignal.com/news/PCRX/pacira-biosciences-announces-new-national-survey-revealing-the-hidden-toll-of-pa-32ad8384 2026-07-28 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-participate-in-the-canaccord-genuity-46th-annual-gro-94590452 2026-07-28 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-reports-second-quarter-2026-financial-results-6bb2d24b 2026-07-28 https://biopharmsignal.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-second-quarter-2026-results-3744bba0 2026-07-28 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-announces-fda-clearance-to-initiate-tempo-1-registrationa-5499960d 2026-07-28 https://biopharmsignal.com/news/BCLI/brainstorm-appoints-former-fda-associate-commissioner-peter-j-pitts-as-executive-0d7242f8 2026-07-28 https://biopharmsignal.com/news/GSK/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum-plans-ann-1d427d5e 2026-07-28 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-u-s-fda-clearance-of-investigational-new-drug-ind-ap-634d2404 2026-07-28 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-reports-second-quarter-2026-financial-results-and-recent-826865f9 2026-07-28 https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-results-from-a-second-phase-iii--07f96324 2026-07-28 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-meets-both-its-primary-and-secondary-endpoints-in-the-phase-d04e8293 2026-07-28 https://biopharmsignal.com/news/ALKS/alkermes-plc-reports-second-quarter-2026-financial-results-c2d63966 2026-07-28 https://biopharmsignal.com/news/SNDX/syndax-to-announce-second-quarter-2026-financial-results-and-host-conference-cal-ea131128 2026-07-28 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-chief-scientific-officer-63ff975a 2026-07-28 https://biopharmsignal.com/news/ALT/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvi-1fc61fa7 2026-07-28 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-announces-positive-end-of-phase-1-meeting-with-fda-for-cln-68006175 2026-07-28 https://biopharmsignal.com/news/RGEN/repligen-reports-second-quarter-2026-financial-results-and-updates-full-year-202-465808e8 2026-07-28 https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-receipt-of-type-a-meeting-minutes-from-u-s-food-and-5b4963b2 2026-07-28 https://biopharmsignal.com/news/CATX/perspective-therapeutics-receives-european-orphan-medicinal-product-designation--6620bea5 2026-07-28 https://biopharmsignal.com/news/PMN/promis-neurosciences-reports-positive-blinded-six-month-interim-safety-and-bioma-90dad1c6 2026-07-28 https://biopharmsignal.com/news/CGON/cg-oncology-announces-publication-of-pivotal-phase-3-bond-003-cohort-c-study-res-236fb0f5 2026-07-27 https://biopharmsignal.com/news/ORGO/organogenesis-announces-publication-of-peer-reviewed-clinical-trial-results-demo-4f52441f 2026-07-27 https://biopharmsignal.com/news/BNGO/bionano-to-report-second-quarter-2026-financial-results-and-host-a-conference-ca-b586998e 2026-07-27 https://biopharmsignal.com/news/BRLI/opko-health-reports-second-quarter-2026-business-highlights-and-financial-result-2ac27e11 2026-07-27 https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-report-second-quarter-2026-financial-results-and-business-55ac999b 2026-07-27 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-terence-rooney-md-as-chief-medical-officer-93d7b265 2026-07-27 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-reports-inducement-awards-under-nasdaq-listing-rule-5635--a1d96146 2026-07-27 https://biopharmsignal.com/news/PMN/promis-neurosciences-to-host-webinar-to-discuss-upcoming-6-month-blinded-interim-36c2d083 2026-07-27 https://biopharmsignal.com/news/CAPR/capricor-comments-on-briefing-materials-ahead-of-july-29-fda-advisory-committee--3a3054d7 2026-07-27 https://biopharmsignal.com/news/GSK/viiv-healthcare-s-2-drug-regimen-dovato-is-as-effective-as-3-drug-regimen-biktar-781cde81 2026-07-27 https://biopharmsignal.com/news/ISRG/intuitive-collaborates-with-deion-coach-prime-sanders-to-raise-patient-awareness-6b900bbc 2026-07-27 https://biopharmsignal.com/news/SPRO/spero-therapeutics-appoints-debra-jeske-zack-m-d-ph-d-as-chief-medical-officer-9dc7a3d5 2026-07-27 https://biopharmsignal.com/news/ICCM/icecure-medical-kicks-off-its-post-marketing-choice-study-for-the-low-risk-breas-9de814e1 2026-07-27 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-appoints-michael-severino-m-d-chief-executive-officer-5e7c3ca8 2026-07-27 https://biopharmsignal.com/news/ENTX/entera-bio-announces-pricing-of-oversubscribed-275-million-private-placement-6af48bd5 2026-07-27 https://biopharmsignal.com/news/HRTX/heron-therapeutics-to-report-second-quarter-2026-financial-results-on-monday-aug-c850c6e7 2026-07-27 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-completes-enrollment-of-pivotal-phase-3-sonata-hcm-study-684930b3 2026-07-27 https://biopharmsignal.com/news/VERU/veru-announces-full-enrollment-for-phase-2b-plateau-clinical-trial-of-enobosarm--ce89119d 2026-07-27 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-publishes-new-clinical-framework-addressing-growing-mar-0496e8ef 2026-07-27 https://biopharmsignal.com/news/APVO/aptevo-strengthens-solid-tumor-strategy-with-patent-filing-for-nectin-4-x-pd-l1--2cdf8d86 2026-07-27 https://biopharmsignal.com/news/PCRX/pacira-biosciences-advances-pcrx-201-development-program-with-successful-transit-5e500af3 2026-07-27 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-appointment-of-charles-fuchs-m-d-m-p-h-to-the-boar-83ccd537 2026-07-27 https://biopharmsignal.com/news/HUMA/humacyte-announces-fda-acceptance-of-ind-for-first-in-human-clinical-study-of-ct-0d8bc87b 2026-07-27 https://biopharmsignal.com/news/ATRC/atricure-to-participate-at-upcoming-investor-conferences-6f05f34e 2026-07-27 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-and-elevatebio-enter-into-commercial-manufacturing-and-supp-297d17c6 2026-07-27 https://biopharmsignal.com/news/VTAK/flyte-partners-with-319-golf-society-and-named-exclusive-private-aviation-partne-c5cad797 2026-07-27 https://biopharmsignal.com/news/FBIO/fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys-therapeuti-bb9478e3 2026-07-27 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-completes-enrollment-in-global-phase-3-yosemite-study--adc124af 2026-07-27 https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-changes-to-senior-leadership-team-to-support-adv-b4289bd9 2026-07-27 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-reports-favorable-nmra-215-toxicology-results-with-planned--bb103196 2026-07-27 https://biopharmsignal.com/news/OKYO/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026-75cdfd34 2026-07-27 https://biopharmsignal.com/news/HROW/harrow-to-report-second-quarter-2026-financial-results-after-market-close-on-aug-38f34b84 2026-07-27 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-august--7e18d9ce 2026-07-27 https://biopharmsignal.com/news/KURA/kura-oncology-reports-durable-clinical-activity-of-darlifarnib-plus-cabozantinib-3697cd98 2026-07-27 https://biopharmsignal.com/news/ENSG/the-ensign-group-reports-second-quarter-2026-results-74822708 2026-07-27 https://biopharmsignal.com/news/LEGN/legend-biotech-announces-ceo-transition-6f26346e 2026-07-27 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-ide892-a-potential-best-in-class-mta-cooperative-pr-d6c184c3 2026-07-27 https://biopharmsignal.com/news/ARGX/argenx-to-acquire-forte-biosciences-inc-adding-first-in-class-anti-cd122-antibod-fae8b638 2026-07-27 https://biopharmsignal.com/news/RXST/rxsight-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-54fac423 2026-07-26 https://biopharmsignal.com/news/MDXH/mdxhealth-announces-receipt-of-nasdaq-notification-regarding-minimum-market-valu-cf439d90 2026-07-24 https://biopharmsignal.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-65f2b9fb 2026-07-24 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-2337a088 2026-07-24 https://biopharmsignal.com/news/IRMD/iradimed-corporation-to-hold-second-quarter-2026-financial-results-conference-ca-de1ca3b1 2026-07-24 https://biopharmsignal.com/news/DYN/dyne-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-b364d778 2026-07-24 https://biopharmsignal.com/news/BRKR/bruker-announces-date-and-time-of-second-quarter-2026-earnings-release-and-webca-29470a21 2026-07-24 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-lytenava-fda-approval-as-the-first-and-only-fda-a-01fa2fea 2026-07-24 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-and-menarini-group-receive-positive-chmp-opinion-recommendin-6e39bfc3 2026-07-24 https://biopharmsignal.com/news/IMMP/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-e824d073 2026-07-24 https://biopharmsignal.com/news/AMWL/amwell-to-report-second-quarter-2026-operating-results-05b3d1ab 2026-07-24 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-provides-update-on-regulatory-submission-for-arimoclomol-for--1d67bc55 2026-07-24 https://biopharmsignal.com/news/TMCI/treace-to-report-second-quarter-2026-financial-results-on-august-7-2026-8e2b6ab2 2026-07-24 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-discuss-second-quarter-2026-financial-results-on-august-7-f8a7cc57 2026-07-24 https://biopharmsignal.com/news/MNKD/mannkind-announces-50-million-private-placement-acb8f8d7 2026-07-24 https://biopharmsignal.com/news/MNKD/mannkind-announces-fda-approval-of-furoscix-readyflow-the-first-and-only-autoinj-fc4f89fc 2026-07-24 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-announce-second-quarter-2026-financial-results-on-augu-0f27c9ca 2026-07-23 https://biopharmsignal.com/news/HSCS/heartsciences-files-its-fiscal-2026-annual-report-on-form-10-k-51b4983b 2026-07-23 https://biopharmsignal.com/news/EMBC/embecta-to-report-fiscal-third-quarter-financial-results-7cbbc9ad 2026-07-23 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-report-second-quarter-2026-financial-results-on-august-3-2026-2f96b902 2026-07-23 https://biopharmsignal.com/news/CVRX/cvrx-to-report-second-quarter-2026-financial-and-operating-results-and-host-conf-cb424df0 2026-07-23 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-provides-update-regarding-cash-dividend-reverse-stock-split-an-5aa0e568 2026-07-23 https://biopharmsignal.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-second-quart-b684f865 2026-07-23 https://biopharmsignal.com/news/PRME/prime-medicine-announces-u-s-fda-clearance-of-investigational-new-drug-applicati-fad1ff80 2026-07-23 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-a-3a9bfff6 2026-07-23 https://biopharmsignal.com/news/ROIV/roivant-to-report-financial-results-for-the-first-quarter-ended-june-30-2026-and-f72f7838 2026-07-23 https://biopharmsignal.com/news/HYPR/hyperfine-inc-to-announce-second-quarter-2026-financial-results-on-august-6-2026-4c953895 2026-07-23 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-key-leadership-hiring-promotions-40b9699b 2026-07-23 https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-first-quarter-ended-june-30-2026--73653d45 2026-07-23 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-july--a55706ea 2026-07-23 https://biopharmsignal.com/news/DCTH/delcath-systems-to-host-second-quarter-2026-earnings-call-3175cc66 2026-07-23 https://biopharmsignal.com/news/MGNX/macrogenics-provides-clinical-update-on-ongoing-phase-1-study-for-mgc026-66fcf182 2026-07-23 https://biopharmsignal.com/news/ATRC/atricure-reports-second-quarter-2026-financial-results-e6a18a2f 2026-07-23 https://biopharmsignal.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-august-6-2026-18350192 2026-07-23 https://biopharmsignal.com/news/PGNY/progyny-inc-announces-details-for-its-second-quarter-2026-results-report-c59a2781 2026-07-23 https://biopharmsignal.com/news/BRLI/opko-health-to-report-second-quarter-2026-financial-results-on-july-27-2026-4b38e04c 2026-07-23 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-director-aba58ba0 2026-07-23 https://biopharmsignal.com/news/INDV/indivior-to-report-second-quarter-2026-financial-results-and-host-webcast-e230b5ef 2026-07-23 https://biopharmsignal.com/news/HSTM/healthstream-to-host-second-quarter-2026-earnings-conference-call-ef3a27e5 2026-07-23 https://biopharmsignal.com/news/IMNN/imunon-to-present-imnn-001-data-at-inaugural-aacr-conference-on-drug-discovery-a-a82143f6 2026-07-23 https://biopharmsignal.com/news/LGVN/deborah-d-ascheim-m-d-elected-to-longeveron-board-of-directors-86a5bee6 2026-07-23 https://biopharmsignal.com/news/ISRG/intuitive-shares-vision-for-an-ai-enabled-future-of-healthcare-d04e70a8 2026-07-23 https://biopharmsignal.com/news/OM/outset-medical-to-report-second-quarter-2026-financial-results-on-thursday-augus-628adf55 2026-07-23 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-achieves-key-milestone-ahead-of-planned-fda-510-k-subm-d70bf174 2026-07-23 https://biopharmsignal.com/news/WVE/wave-life-sciences-second-quarter-2026-financial-results-scheduled-for-july-30-2-a9974bb9 2026-07-23 https://biopharmsignal.com/news/ICUI/icu-medical-announces-time-of-second-quarter-2026-earnings-conference-call-20153c86 2026-07-23 https://biopharmsignal.com/news/ARDX/ardelyx-to-report-second-quarter-2026-financial-results-on-august-6-2026-cf11d40a 2026-07-23 https://biopharmsignal.com/news/IXHL/incannex-commences-participant-screening-in-dreamzz-phase-2-study-of-ihl-42x-for-752babf4 2026-07-23 https://biopharmsignal.com/news/BBLG/bone-biologics-issues-mid-year-shareholder-update-highlighting-progress-across-2-9130fb80 2026-07-23 https://biopharmsignal.com/news/HCWB/hcw-biologics-reaches-milestones-for-its-proprietary-tetravalent-second-generati-fd18e4a2 2026-07-23 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-release-second-quarter-of-fiscal-year-2026-financial-0275b558 2026-07-23 https://biopharmsignal.com/news/EHC/encompass-health-increases-and-declares-dividend-on-common-stock-0b0608a6 2026-07-23 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-fda-orphan-drug-designation-granted-to-ikt-001-b6d23765 2026-07-23 https://biopharmsignal.com/news/XERS/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026-2634780e 2026-07-23 https://biopharmsignal.com/news/VKTX/viking-therapeutics-appoints-dorothy-gemmell-to-board-of-directors-d154bd33 2026-07-23 https://biopharmsignal.com/news/SHC/sotera-health-announces-second-quarter-2026-earnings-release-date-978177a2 2026-07-23 https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-updated-data-from-phase-1-2-trial-of-beam-302-in-al-9a5bdf4f 2026-07-23 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-chief-executive-officer-c26c1c2c 2026-07-23 https://biopharmsignal.com/news/INSM/insmed-to-host-second-quarter-2026-financial-results-conference-call-on-thursday-b4396c01 2026-07-23 https://biopharmsignal.com/news/DGX/quest-diagnostics-reports-second-quarter-2026-financial-results-raises-revenue-a-c3c6c528 2026-07-23 https://biopharmsignal.com/news/AVAH/aveanna-announces-second-quarter-2026-earnings-release-date-and-conference-call-bc2c9faa 2026-07-23 https://biopharmsignal.com/news/TDOC/teladoc-health-introduces-a-virtual-care-practice-built-around-the-person-shapin-9116dbc9 2026-07-23 https://biopharmsignal.com/news/GNTA/genenta-backed-s-phia-high-tech-brings-aerospace-precision-inside-a-nuclear-fusi-b9c88834 2026-07-23 https://biopharmsignal.com/news/ARGX/argenx-reports-half-year-2026-financial-results-and-provides-second-quarter-busi-a7cfe76d 2026-07-23 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2026-financial-results-and-h-58b4f63d 2026-07-22 https://biopharmsignal.com/news/EXEL/exelixis-to-release-second-quarter-2026-financial-results-on-wednesday-august-5--57b00d9c 2026-07-22 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-reports-second-quarter-2026-results-b91c0014 2026-07-22 https://biopharmsignal.com/news/MOH/molina-healthcare-reports-second-quarter-2026-financial-results-343e2d32 2026-07-22 https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e 2026-07-22 https://biopharmsignal.com/news/OSUR/orasure-to-announce-second-quarter-2026-financial-results-and-host-earnings-call-6dc566e7 2026-07-22 https://biopharmsignal.com/news/RVMD/revolution-medicines-new-drug-application-for-daraxonrasib-accepted-for-review-b-f594345f 2026-07-22 https://biopharmsignal.com/news/CLOV/clover-health-to-participate-in-upcoming-canaccord-genuity-46th-annual-growth-co-ed8fb164 2026-07-22 https://biopharmsignal.com/news/SGHT/sight-sciences-to-report-second-quarter-2026-financial-results-on-august-5-2026-ec2572f5 2026-07-22 https://biopharmsignal.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corpor-1db34366 2026-07-22 https://biopharmsignal.com/news/BTMD/biote-schedules-second-quarter-2026-financial-results-release-and-conference-cal-3e266bdc 2026-07-22 https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff 2026-07-22 https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f 2026-07-22 https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-31c72267 2026-07-22 https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902 2026-07-22 https://biopharmsignal.com/news/CHRS/coherus-oncology-to-report-second-quarter-2026-financial-results-on-august-5-202-7a426d67 2026-07-22 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-chairman-991103cf 2026-07-22 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-direct-408569cd 2026-07-22 https://biopharmsignal.com/news/JAGX/additional-infant-patient-to-receive-jaguar-health-s-crofelemer-for-compassionat-1d69ef0c 2026-07-22 https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432 2026-07-22 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-announce-second-quarter-2026-financial-results-f4a4e3da 2026-07-22 https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c 2026-07-22 https://biopharmsignal.com/news/PRGO/perrigo-to-release-second-quarter-2026-financial-results-on-august-5-2026-ff2ea2a5 2026-07-22 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-and-pictor-inc-partner-to-develop-and-commercialize-bio-7ee819d4 2026-07-22 https://biopharmsignal.com/news/PCRX/pacira-to-report-second-quarter-2026-financial-results-on-tuesday-august-4-2026-0cbb1687 2026-07-22 https://biopharmsignal.com/news/MNPR/monopar-initiates-rolling-nda-submission-for-alxn1840-in-wilson-disease-e671ddcf 2026-07-22 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-announces-details-for-q2-2026-financial-results-call-13766b2b 2026-07-22 https://biopharmsignal.com/news/BBIO/bridgebio-announces-fda-acceptance-of-nda-for-encaleret-for-adh1-c90bb02f 2026-07-22 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-topline-results-from-phase-3-shasta-3-and-shas-fca7dc05 2026-07-22 https://biopharmsignal.com/news/GSK/jideytro-zidesamtinib-approved-in-the-us-for-previously-treated-ros1-positive-no-a284b13c 2026-07-22 https://biopharmsignal.com/news/IPHA/innate-pharma-to-participate-in-a-bladder-cancer-panel-at-the-btig-virtual-biote-960627c0 2026-07-22 https://biopharmsignal.com/news/BCRX/biocryst-to-report-second-quarter-2026-financial-results-on-august-5-9520c4fa 2026-07-22 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-shares-by-executive-chairman-7921398d 2026-07-22 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-chief-medical-officer-dff9c1eb 2026-07-22 https://biopharmsignal.com/news/GERN/geron-plans-to-announce-second-quarter-2026-financial-results-on-august-5-2026-cc0edc91 2026-07-22 https://biopharmsignal.com/news/CRIS/curis-announces-positive-emavusertib-update-0e0fa8ea 2026-07-22 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-the-btig-biotechnology-conference-399b4284 2026-07-22 https://biopharmsignal.com/news/BDX/mike-garrison-to-retire-from-bd-a251fa3e 2026-07-22 https://biopharmsignal.com/news/PHVS/publication-in-clinical-reviews-in-allergy-immunology-summarizes-decades-of-evid-a202e0d7 2026-07-22 https://biopharmsignal.com/news/BDSX/biodesix-to-report-second-quarter-2026-financial-results-on-august-5-2026-cf36c056 2026-07-22 https://biopharmsignal.com/news/RGEN/repligen-to-acquire-biolife-solutions-expanding-its-cell-therapy-capabilities-wi-b25607c1 2026-07-22 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-approval-to-expand-flamingo-01-into-the-united--ec05cb97 2026-07-22 https://biopharmsignal.com/news/YOU/clear-to-announce-second-quarter-2026-financial-results-on-august-5-2026-ad41d7b4 2026-07-22 https://biopharmsignal.com/news/GNTA/genenta-backed-s-phia-high-tech-reports-fiscal-year-2025-results-ab0d6779 2026-07-22 https://biopharmsignal.com/news/PRI/national-survey-middle-income-americans-are-adjusting-not-giving-up-as-rising-co-5af838bd 2026-07-22 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-pricing-of-upsized-375-million-public-offering-of-co-689996ee 2026-07-22 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-proposed-public-offering-of-common-stock-263bfe83 2026-07-21 https://biopharmsignal.com/news/ACRV/acrivon-to-highlight-the-power-of-its-ap3-platform-for-streamlined-pathway-based-9df593ea 2026-07-21 https://biopharmsignal.com/news/OSUR/orasure-receives-emergency-use-authorization-for-second-generation-ebola-test-aff25f4f 2026-07-21 https://biopharmsignal.com/news/VTAK/flyte-partners-with-blade-to-expand-vision-jet-distribution-aaf3caf3 2026-07-21 https://biopharmsignal.com/news/XRAY/dentsply-sirona-to-host-second-quarter-conference-call-on-august-6th-21fd2675 2026-07-21 https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8 2026-07-21 https://biopharmsignal.com/news/GOCO/gohealth-successfully-completes-financial-restructuring-and-emerges-well-positio-242faf08 2026-07-21 https://biopharmsignal.com/news/IMRX/publication-in-cancer-research-details-atebimetinib-s-broad-durable-preclinical--0e49c6eb 2026-07-21 https://biopharmsignal.com/news/PLSE/pulse-biosciences-schedules-second-quarter-2026-financial-results-conference-cal-40c79816 2026-07-21 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-appoints-samir-siddhanti-chief-business-officer-c85190fc 2026-07-21 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05 2026-07-21 https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004 2026-07-21 https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7 2026-07-21 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-hsr-clearance-of-global-collaboration-with-roche-to-2860a8c3 2026-07-21 https://biopharmsignal.com/news/CLDX/celldex-reports-results-from-phase-2-study-of-barzolvolimab-in-prurigo-nodularis-3b2fe3ca 2026-07-21 https://biopharmsignal.com/news/XGN/exagen-to-announce-second-quarter-financial-results-on-august-4-2026-2e4ac1ee 2026-07-21 https://biopharmsignal.com/news/IMNN/imunon-reports-positive-phase-2-mrd-clinical-data-for-imnn-001-demonstrating-the-33641008 2026-07-21 https://biopharmsignal.com/news/OKYO/okyo-pharma-to-present-at-the-h-c-wainwright-6th-annual-ophthalmology-virtual-co-7754810b 2026-07-21 https://biopharmsignal.com/news/STXS/stereotaxis-to-report-second-quarter-2026-financial-results-on-august-11-2026-40f8033c 2026-07-21 https://biopharmsignal.com/news/DRTS/alpha-tau-reports-positive-data-demonstrating-100-objective-response-rate-and-18-ca86b4f0 2026-07-21 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-completes-precision-testing-strengthening-fda-510-k-su-5345c744 2026-07-21 https://biopharmsignal.com/news/MXCT/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-t-3ff788d8 2026-07-21 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522 2026-07-21 https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-report-second-quarter-2026-financial-results-on-august-4--140a8f01 2026-07-21 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-announces-1-for-50-reverse-stock-split-and-provides-update-reg-ea42613d 2026-07-21 https://biopharmsignal.com/news/VXRT/vaxart-to-participate-in-btig-biotechnology-conference-2026-f2702b19 2026-07-21 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-tuesda-7e7002e7 2026-07-21 https://biopharmsignal.com/news/PYPD/polypid-announces-exclusive-partnership-with-azurity-pharmaceuticals-for-the-com-acf32640 2026-07-21 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-webcast-fiscal-2026-third-quarter-results-94b47bc2 2026-07-21 https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043 2026-07-21 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-to-participate-in-the-virtual-btig-biotechnology-conferenc-5aaa51f2 2026-07-21 https://biopharmsignal.com/news/TPST/tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst--73d502e9 2026-07-21 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-announces-start-of-phase-3-zenith-ad-program-evaluating-nove-f2b52f43 2026-07-21 https://biopharmsignal.com/news/AGIO/agios-provides-update-on-phase-2-trial-of-tebapivat-in-sickle-cell-disease-847f0155 2026-07-21 https://biopharmsignal.com/news/ACON/aclarion-announces-presentation-of-two-abstracts-highlighting-nociscan-s-growing-2363a199 2026-07-21 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-presentation-of-pas-004-data-to-european-society-99db076a 2026-07-21 https://biopharmsignal.com/news/BNTX/biontech-ver-ffentlicht-am-4-august-2026-ergebnisse-f-r-das-zweite-quartal-2026--87f9447b 2026-07-21 https://biopharmsignal.com/news/BNTX/biontech-to-report-second-quarter-2026-financial-results-and-corporate-update-on-aeeb45ba 2026-07-21 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-successful-completion-of-enrollment-in-the-symon-i-f7cec8c0 2026-07-21 https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640 2026-07-21 https://biopharmsignal.com/news/SIBN/si-bone-to-report-second-quarter-2026-financial-results-on-august-3-2026-5bb93a97 2026-07-20 https://biopharmsignal.com/news/TELA/tela-bio-to-announce-second-quarter-2026-financial-results-d696973e 2026-07-20 https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0 2026-07-20 https://biopharmsignal.com/news/STIM/neuronetics-appoints-nir-naor-chief-financial-officer-announces-additional-manag-6e471c15 2026-07-20 https://biopharmsignal.com/news/MTLS/materialise-aandeleninkoopprogramma-dfec872e 2026-07-20 https://biopharmsignal.com/news/MTLS/materialise-share-buy-back-program-7a2516b1 2026-07-20 https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f 2026-07-20 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-receives-fast-track-designation-for-pelareorep-in-second-line-a2a9c705 2026-07-20 https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9 2026-07-20 https://biopharmsignal.com/news/STXS/university-of-szeged-pioneers-first-robotic-cardiology-program-in-hungary-f69bf77d 2026-07-20 https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-m-f80acd25 2026-07-20 https://biopharmsignal.com/news/PSNL/tempus-to-acquire-personalis-more-tightly-integrating-molecular-residual-disease-403131a5 2026-07-20 https://biopharmsignal.com/news/VIRI/dogwood-enrolls-first-200-patients-in-ongoing-halneuron-phase-2b-chemotherapy-in-dd9f404d 2026-07-20 https://biopharmsignal.com/news/MDXG/mimedx-to-host-second-quarter-2026-operating-and-financial-results-conference-ca-b62fe7a7 2026-07-20 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-report-second-quarter-2026-financial-results-and-prov-7a7f699d 2026-07-20 https://biopharmsignal.com/news/BLTE/belite-bio-announces-oral-presentation-at-the-asrs-annual-meeting-featuring-addi-54caf9d6 2026-07-20 https://biopharmsignal.com/news/HROW/samsung-bioepis-and-harrow-present-interim-data-from-a-large-scale-post-marketin-f2b635bb 2026-07-20 https://biopharmsignal.com/news/SRRK/scholar-rock-provides-update-on-timing-of-committee-for-medicinal-products-for-h-018ed6e6 2026-07-20 https://biopharmsignal.com/news/MNPR/monopar-advances-launch-readiness-with-addition-of-veteran-commercial-executive--6af36ead 2026-07-20 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-u-s-fda-acceptance-of-biologics-license-application--1a190c38 2026-07-20 https://biopharmsignal.com/news/USNA/usana-health-sciences-renews-four-year-partnership-with-nordiq-canada-deepening--7aaacadb 2026-07-20 https://biopharmsignal.com/news/HLF/herbalife-cfo-to-participate-in-maxim-group-health-wellness-longevity-virtual-co-145c5335 2026-07-20 https://biopharmsignal.com/news/SEER/seer-urges-stockholders-to-vote-for-seer-s-highly-qualified-director-nominees-on-6787833a 2026-07-20 https://biopharmsignal.com/news/IRIX/iridex-adds-endoprobe-handpieces-to-eyeprogpo-product-offering-deb0efd9 2026-07-20 https://biopharmsignal.com/news/NEPH/nephros-to-participate-in-the-health-wellness-longevity-virtual-conference-prese-04bc108f 2026-07-20 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-filing-of-annual-report-with-strengthened-cash-position-an-b4946b7f 2026-07-20 https://biopharmsignal.com/news/INMB/inmune-bio-completes-commercial-manufacturing-milestone-supporting-planned-globa-65214648 2026-07-20 https://biopharmsignal.com/news/HROW/harrow-highlights-growing-clinical-evidence-supporting-iheezo-and-byooviz-at-asr-8b380ee4 2026-07-20 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda 2026-07-20 https://biopharmsignal.com/news/SEER/special-committee-of-seer-s-board-of-directors-unanimously-rejects-unsolicited-a-61f31e25 2026-07-20 https://biopharmsignal.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-at-kalkine-media-webinar-ebc4e4b7 2026-07-20 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-clinical-updates-on-flamingo-01-99f074c4 2026-07-20 https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096 2026-07-20 https://biopharmsignal.com/news/FMS/fresenius-medical-care-introduces-therapywise-analytics-for-kidney-replacement-t-6fa82f2a 2026-07-20 https://biopharmsignal.com/news/FDMT/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broa-89439f1c 2026-07-18 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c105f1fc 2026-07-17 https://biopharmsignal.com/news/DMAC/diamedica-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-58a5078e 2026-07-17 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-present-at-the-european-society-for-medical-oncology-7b982012 2026-07-17 https://biopharmsignal.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-under-nasdaq-listing-rule-56-f0ff2185 2026-07-17 https://biopharmsignal.com/news/IMRX/immuneering-corporation-announces-grants-of-inducement-awards-64768f57 2026-07-17 https://biopharmsignal.com/news/VXRT/vaxart-announces-results-of-annual-meeting-of-stockholders-25ca999f 2026-07-17 https://biopharmsignal.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-681bf23e 2026-07-17 https://biopharmsignal.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1e80a7fe 2026-07-17 https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-acceptance-of-vmt-net-data-for-oral-presentat-0e2c17aa 2026-07-17 https://biopharmsignal.com/news/CMPX/compass-therapeutics-announces-tovecimig-data-accepted-for-an-oral-presentation--350ddb60 2026-07-17 https://biopharmsignal.com/news/IMTX/immatics-announces-upcoming-presentations-across-its-prame-franchise-at-esmo-con-da7395b0 2026-07-17 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-esmo-2026-presentations-for-darovasertib-and-ide849-3e0620d8 2026-07-17 https://biopharmsignal.com/news/AMRX/amneal-expands-iohexol-injection-portfolio-with-u-s-fda-approval-of-additional-s-5f3ad56b 2026-07-17 https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206 2026-07-17 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-merger-with-kira-pharmaceuticals-a3889d24 2026-07-16 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-intent-to-appeal-rulings-in-cg-oncology-matter-62a30dad 2026-07-16 https://biopharmsignal.com/news/GMED/globus-medical-schedules-second-quarter-earnings-release-and-conference-call-ff53d98d 2026-07-16 https://biopharmsignal.com/news/LFST/lifestance-to-host-second-quarter-2026-earnings-conference-call-on-august-6-2026-bb81c31c 2026-07-16 https://biopharmsignal.com/news/AZYO/elutia-signs-definitive-agreement-to-sell-simpliderm-in-transaction-valued-at-up-fa42185e 2026-07-16 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-appoints-three-new-members-to-its-board-of-directors-88d118b2 2026-07-16 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-appoints-three-new-members-to-its-board-of-directors-baf9de29 2026-07-16 https://biopharmsignal.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-563-3c4d65f4 2026-07-16 https://biopharmsignal.com/news/ISRG/intuitive-announces-second-quarter-earnings-822e0df5 2026-07-16 https://biopharmsignal.com/news/IRTC/irhythm-holdings-to-report-second-quarter-2026-financial-results-on-august-6-202-c95df473 2026-07-16 https://biopharmsignal.com/news/DCTH/delcath-systems-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-15301d33 2026-07-16 https://biopharmsignal.com/news/ARQT/arcutis-expands-board-of-directors-with-appointment-of-chris-peetz-301b4fb5 2026-07-16 https://biopharmsignal.com/news/INBX/inhibrx-announces-amended-loan-agreement-with-oxford-finance-expanding-total-fac-d29cd85b 2026-07-16 https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-results-from-a-nonclinical-osteoarthritis-study-sup-fa16911f 2026-07-16 https://biopharmsignal.com/news/HRMY/harmony-biosciences-preannounces-record-quarterly-revenue-for-q2-2026-reaffirms--db1c81b5 2026-07-16 https://biopharmsignal.com/news/VCEL/vericel-to-report-second-quarter-2026-financial-results-on-july-30-2026-99cb171e 2026-07-16 https://biopharmsignal.com/news/INGN/inogen-to-report-second-quarter-2026-financial-results-on-august-6-2026-29d58db2 2026-07-16 https://biopharmsignal.com/news/IART/integra-lifesciences-to-host-second-quarter-2026-financial-results-conference-ca-8ae1bf89 2026-07-16 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-jul-5e0dd98e 2026-07-16 https://biopharmsignal.com/news/ECOR/new-review-examines-anatomical-and-methodological-differences-between-auricular--75858401 2026-07-16 https://biopharmsignal.com/news/GRFS/grifols-doses-first-patients-in-two-phase-3-trials-to-expand-indications-of-its--100c71fa 2026-07-16 https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-release-second-quarter-2026-financial-results-and-ho-8492a4a5 2026-07-16 https://biopharmsignal.com/news/SRRK/scholar-rock-to-report-second-quarter-2026-financial-results-on-august-6-2026-4387875b 2026-07-16 https://biopharmsignal.com/news/ABUS/arbutus-initiates-international-patent-infringement-enforcement-actions-against--c6198417 2026-07-16 https://biopharmsignal.com/news/BCTX/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metas-16e6cb45 2026-07-16 https://biopharmsignal.com/news/VRAX/virax-biolabs-ceo-james-foster-provides-shareholder-update-following-fiscal-2026-e1b97d68 2026-07-16 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-european-approval-for-combining-both-hla-popula-adf83f60 2026-07-16 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-a5332b5c 2026-07-16 https://biopharmsignal.com/news/ANL/adlai-nortye-announces-first-patient-dosed-in-intermittent-weekly-dosing-arm-of--5ee3e1aa 2026-07-16 https://biopharmsignal.com/news/GANX/gain-therapeutics-ceo-gene-mack-issues-letter-to-shareholders-and-provides-opera-8b796693 2026-07-16 https://biopharmsignal.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-daeb0fac 2026-07-16 https://biopharmsignal.com/news/INSM/insmed-announces-positive-12-month-data-from-the-ongoing-open-label-extension-st-7880862e 2026-07-16 https://biopharmsignal.com/news/IMRN/immuron-fy26-sales-four-consecutive-quarters-of-growth-over-prior-year-6f03cdb9 2026-07-16 https://biopharmsignal.com/news/MOLN/molecular-partners-announces-clinical-progress-in-phase-2-tactic-combination-tri-1a550eb2 2026-07-16 https://biopharmsignal.com/news/ARGX/argenx-to-report-half-year-2026-financial-results-and-second-quarter-business-up-391e9c59 2026-07-16 https://biopharmsignal.com/news/CCEL/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2026-financial-7072363c 2026-07-15 https://biopharmsignal.com/news/RXST/rxsight-announces-appointments-of-aziz-mottiwala-as-chief-executive-officer-and--e8d69a0c 2026-07-15 https://biopharmsignal.com/news/CERT/certara-to-report-second-quarter-2026-financial-results-on-august-4th-2026-0693daa9 2026-07-15 https://biopharmsignal.com/news/PRI/primerica-schedules-second-quarter-2026-financial-results-webcast-8557ad05 2026-07-15 https://biopharmsignal.com/news/MXCT/maxcyte-to-report-second-quarter-2026-financial-results-on-august-12-2026-1e03d6dc 2026-07-15 https://biopharmsignal.com/news/LUNG/pulmonx-to-report-second-quarter-2026-financial-results-on-july-29-2026-aba8edf7 2026-07-15 https://biopharmsignal.com/news/PLSE/pulse-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-5413df0c 2026-07-15 https://biopharmsignal.com/news/PACB/pacbio-to-report-second-quarter-2026-financial-results-on-august-5-2026-ad299ae5 2026-07-15 https://biopharmsignal.com/news/TDOC/teladoc-health-to-announce-second-quarter-2026-financial-results-afe8ecc8 2026-07-15 https://biopharmsignal.com/news/ERAS/erasca-announces-closing-of-upsized-public-offering-of-common-stock-including-fu-dbcc43e8 2026-07-15 https://biopharmsignal.com/news/CLDX/celldex-announces-planned-transition-of-chief-financial-officer-26ce0227 2026-07-15 https://biopharmsignal.com/news/ARQT/arcutis-to-report-second-quarter-2026-financial-results-and-host-conference-call-00bbf84b 2026-07-15 https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-nuvalent-inc-c44954f4 2026-07-15 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-publication-in-the-peer-reviewed-journal-of-viro-14c8c277 2026-07-15 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-journal-of-clinical-oncology-publication-of-phas-905efc2b 2026-07-15 https://biopharmsignal.com/news/DRTS/alpha-tau-successfully-treats-first-immunocompromised-patient-with-recurrent-cut-6fd4ea97 2026-07-15 https://biopharmsignal.com/news/LIXT/nomad-power-solutions-strengthens-subsidiary-executive-leadership-694eafe1 2026-07-15 https://biopharmsignal.com/news/BIIB/biogen-appoints-michael-j-parini-as-chief-legal-officer-883bb2ac 2026-07-15 https://biopharmsignal.com/news/RANI/rani-therapeutics-announces-positive-initial-phase-1a-data-for-rt-114-for-the-tr-e7d21ddc 2026-07-15 https://biopharmsignal.com/news/ATYR/atyr-pharma-to-present-subgroup-analysis-of-phase-3-efzo-fit-study-of-efzofitimo-127c1891 2026-07-15 https://biopharmsignal.com/news/URGN/urogen-receives-new-u-s-patent-allowance-expected-to-provide-protection-into-jul-c474cf91 2026-07-15 https://biopharmsignal.com/news/TWST/twist-bioscience-to-report-fiscal-2026-third-quarter-financial-results-on-monday-a700171a 2026-07-15 https://biopharmsignal.com/news/MNOV/medicinova-announces-patient-enrollment-milestone-achieved-in-seanobi-study-expa-14636d8a 2026-07-15 https://biopharmsignal.com/news/CRL/charles-river-laboratories-schedules-second-quarter-2026-earnings-release-and-co-1ac856d9 2026-07-15 https://biopharmsignal.com/news/VTAK/vtak-announces-preliminary-second-quarter-record-revenue-in-excess-of-1-million-02ab1666 2026-07-15 https://biopharmsignal.com/news/AMRN/amarin-to-report-second-quarter-2026-financial-results-and-host-conference-call--e5f8b443 2026-07-15 https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-the-h-c-wainwright-6th-annual-ophthalmology-virtual-ac101a6e 2026-07-15 https://biopharmsignal.com/news/INTS/intensity-therapeutics-inc-restarts-patient-treatment-in-the-randomized-presurgi-51761e30 2026-07-15 https://biopharmsignal.com/news/SNTI/senti-biosciences-holdings-inc-announces-a-strategic-transaction-to-unlock-value-e313e317 2026-07-15 https://biopharmsignal.com/news/BCTX/briacell-arranges-scalable-manufacturing-with-fujifilm-biotechnologies-for-bria--afc58e51 2026-07-15 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-e-12dd8779 2026-07-15 https://biopharmsignal.com/news/RGEN/repligen-to-report-second-quarter-2026-financial-results-f6af0b9d 2026-07-15 https://biopharmsignal.com/news/CLRB/cellectar-biosciences-announces-publication-of-phase-1-study-of-iopofosine-i-131-1d5d4326 2026-07-15 https://biopharmsignal.com/news/TPST/tempest-unveils-next-generation-in-vivo-car-t-pipeline-with-first-clinical-study-0c9efd5e 2026-07-15 https://biopharmsignal.com/news/BCRX/biocryst-appoints-david-w-jenkins-as-chief-scientific-officer-a24b8329 2026-07-15 https://biopharmsignal.com/news/INMB/inmune-bio-s-xpro1595-prevents-brain-injury-induced-alzheimer-s-pathology-memory-b4b1b19b 2026-07-15 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-announces-fda-acceptance-of-new-drug-application-for-axs-12--867574ca 2026-07-15 https://biopharmsignal.com/news/AXGN/axogen-inc-to-report-second-quarter-2026-financial-results-on-july-29-2026-56aa71ab 2026-07-15 https://biopharmsignal.com/news/BRKR/bruker-expands-infection-detection-portfolio-with-acquisition-of-metagenomic-mng-36c3ebd1 2026-07-15 https://biopharmsignal.com/news/MD/pediatrix-medical-group-provides-second-quarter-update-c9e66696 2026-07-15 https://biopharmsignal.com/news/MOLN/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-confere-65fa2d1b 2026-07-15 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-6852bd7a 2026-07-15 https://biopharmsignal.com/news/LMAT/lemaitre-will-announce-second-quarter-2026-earnings-results-on-august-4-2026-269755ae 2026-07-14 https://biopharmsignal.com/news/CELC/celcuity-announces-fda-approval-of-revtorpyk-gedatolisib-for-the-treatment-of-hr-371190ee 2026-07-14 https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-dee5e3ab 2026-07-14 https://biopharmsignal.com/news/USNA/usana-schedules-second-quarter-2026-earnings-release-and-conference-call-d0dc753b 2026-07-14 https://biopharmsignal.com/news/ANNX/annexon-to-present-phase-2-archer-baseline-characteristics-associated-with-confi-9bc8b0ef 2026-07-14 https://biopharmsignal.com/news/SEER/seer-board-of-directors-issues-letter-to-shareholders-setting-the-record-straigh-cbf9fae4 2026-07-14 https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc--dcb62dc5 2026-07-14 https://biopharmsignal.com/news/ABSI/absci-to-report-business-updates-and-second-quarter-2026-financial-and-operating-a4348c21 2026-07-14 https://biopharmsignal.com/news/RCEL/avita-medical-to-announce-second-quarter-2026-financial-results-8e67c186 2026-07-14 https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2026-financial-results-on-august-4t-255b7bdd 2026-07-14 https://biopharmsignal.com/news/VANI/vivani-medical-to-present-at-the-emerging-growth-conference-on-july-15-2026-793033b6 2026-07-14 https://biopharmsignal.com/news/ALKS/alkermes-to-report-second-quarter-financial-results-on-july-28-2026-457faa19 2026-07-14 https://biopharmsignal.com/news/BIIB/leqembi-real-world-leader-study-presented-at-aaic-2026-finds-over-75-of-early-al-7237927c 2026-07-14 https://biopharmsignal.com/news/BIIB/biogen-presents-phase-2-celia-data-at-aaic-demonstrating-meaningful-clinical-out-e25ca134 2026-07-14 https://biopharmsignal.com/news/XOMA/xoma-royalty-announces-closing-of-its-acquisition-by-ligand-6ca7a63d 2026-07-14 https://biopharmsignal.com/news/ARTL/artelo-biosciences-issues-reminder-to-shareholders-to-vote-in-advance-of-annual--371c2cf4 2026-07-14 https://biopharmsignal.com/news/ICU/seastar-medical-supports-advances-in-critical-care-of-pediatric-patients-with-ac-66530222 2026-07-14 https://biopharmsignal.com/news/ICCM/icecure-expands-u-s-commercial-team-to-meet-surging-demand-for-prosense-cryoabla-7980c317 2026-07-14 https://biopharmsignal.com/news/SUPN/supernus-celebrates-five-year-anniversary-of-qelbree-fda-approval-continuing-to--ca53fc4f 2026-07-14 https://biopharmsignal.com/news/HUMA/humacyte-appoints-key-nephrologists-as-advisors-to-prepare-for-planned-commercia-5778fa4b 2026-07-14 https://biopharmsignal.com/news/SNDX/syndax-to-highlight-late-stage-programs-and-unveil-new-pipeline-assets-at-r-d-ev-34c76450 2026-07-14 https://biopharmsignal.com/news/IMMP/immutep-secures-fourth-united-states-patent-for-eftilagimod-alfa-in-combination--eee3de23 2026-07-14 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-awarded-5-3-million-installment-in-nida-funding-completing-m-ee1ecc0e 2026-07-14 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-sale-of-50-million-of-shares-through-its-at-th-30edf4cb 2026-07-14 https://biopharmsignal.com/news/IRWD/ironwood-appoints-dr-jeffrey-silber-chief-medical-officer-and-head-of-research-a-b6d13a27 2026-07-14 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-105-million-non-recourse-non-dilutive-financing-bac-78ef9a05 2026-07-14 https://biopharmsignal.com/news/KURA/kura-oncology-to-present-first-long-term-follow-up-data-further-supporting-darli-448fa88f 2026-07-14 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-initiates-first-in-human-phase-1-clinical-trial-of-at-587-f-8ed8b55f 2026-07-14 https://biopharmsignal.com/news/SPRO/spero-therapeutics-and-innovent-biologics-announce-exclusive-license-for-sp001-i-90969442 2026-07-14 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-to-report-second-quarter-2026-financial-results-on-august-10-d05e9c7e 2026-07-14 https://biopharmsignal.com/news/BEAT/heartbeam-awarded-new-u-s-patent-expanding-acoustic-sensing-and-fluid-monitoring-e0c78764 2026-07-14 https://biopharmsignal.com/news/PSNL/personalis-accelerates-global-expansion-with-ukca-marking-for-next-personal-expa-dbe31487 2026-07-14 https://biopharmsignal.com/news/ANGO/angiodynamics-reports-record-fiscal-year-2026-fourth-quarter-and-full-year-finan-44aa8657 2026-07-14 https://biopharmsignal.com/news/NXTC/nextcure-and-avere-therapeutics-announce-merger-to-advance-once-weekly-oral-il-2-9774b133 2026-07-14 https://biopharmsignal.com/news/PMN/promis-neurosciences-reports-first-human-evidence-of-amyloid-beta-oligomer-targe-9106127e 2026-07-14 https://biopharmsignal.com/news/ERAS/erasca-announces-pricing-of-upsized-public-offering-of-common-stock-fbb7f193 2026-07-14 https://biopharmsignal.com/news/BIIB/fda-approves-leqembi-iqlik-lecanemab-irmb-subcutaneous-injection-as-an-initiatio-d8834a4b 2026-07-13 https://biopharmsignal.com/news/ERAS/erasca-announces-proposed-public-offering-of-500-million-of-common-stock-f66f583d 2026-07-13 https://biopharmsignal.com/news/TARS/tarsus-pharmaceuticals-announces-executive-leadership-transition-as-company-adva-ed9d7cf8 2026-07-13 https://biopharmsignal.com/news/ERAS/erasca-announces-updated-preliminary-phase-1-data-and-registration-enabling-plan-3c4d65b6 2026-07-13 https://biopharmsignal.com/news/HLF/herbalife-named-to-time-s-list-of-america-s-best-companies-2026-14afe60c 2026-07-13 https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-positive-results-with-art27-13-in-a-nonclinical-mod-86480dfe 2026-07-13 https://biopharmsignal.com/news/ENLV/enlivex-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-266c9b7b 2026-07-13 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-reports-fda-regulatory-milestone-and-strong-clinical-progress-ed86b993 2026-07-13 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-names-flavia-borellini-ph-d-and-robert-iannone-m-d-m-s-c-e-t-22eb831f 2026-07-13 https://biopharmsignal.com/news/CUE/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head--f7d28689 2026-07-13 https://biopharmsignal.com/news/VYGR/voyager-demonstrates-single-iv-dose-of-vy1706-well-tolerated-reduced-tau-in-6-mo-d6b19d18 2026-07-13 https://biopharmsignal.com/news/AEMD/aethlon-medical-continues-to-observe-directional-changes-in-second-cohort-of-aus-9cc3f8f7 2026-07-13 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-announces-the-completion-of-enrollment-in-the-phase-2-b-supr-4b435b0f 2026-07-13 https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-follow-on-publication-in-the-new-england-journal-of-c0fc934b 2026-07-13 https://biopharmsignal.com/news/LCTX/lineage-provides-update-on-cor1-cell-therapy-program-for-corneal-endothelial-dis-fe72f64a 2026-07-13 https://biopharmsignal.com/news/CRL/charles-river-provides-ngs-services-to-arovella-therapeutics-accelerating-progre-ea8e3539 2026-07-13 https://biopharmsignal.com/news/IMMP/immutep-provides-clinical-update-in-1st-line-nsclc-positive-mature-overall-survi-62ccc2c6 2026-07-13 https://biopharmsignal.com/news/GERN/geron-announces-appointment-of-chinmaya-rath-as-chief-business-officer-bb96f9cb 2026-07-13 https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-three-new-resmetirom-patents-strengthening-ip-f27ea704 2026-07-13 https://biopharmsignal.com/news/TCMD/tactile-medical-enters-exclusive-u-s-distribution-agreement-with-elastimed-for-i-116aea64 2026-07-13 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-participating-in-fireside-chat-at-b-riley-securities-mind-4d2d423c 2026-07-13 https://biopharmsignal.com/news/LGVN/longeveron-announces-presentation-of-clinical-data-at-the-2026-alzheimer-s-assoc-50c3353b 2026-07-13 https://biopharmsignal.com/news/OCGN/ocugen-inc-announces-binding-term-sheet-with-roots-pharmaceutical-to-license-ocu-2ac6b744 2026-07-13 https://biopharmsignal.com/news/ANL/adlai-nortye-expands-scientific-advisory-board-with-appointment-of-two-leading-m-704804d4 2026-07-13 https://biopharmsignal.com/news/ALKS/alkermes-alixorexton-demonstrated-sustained-improvement-in-wakefulness-in-adults-fc6e6d53 2026-07-13 https://biopharmsignal.com/news/EYPT/eyepoint-appoints-tarek-s-hassan-m-d-as-chief-strategic-science-officer-4900131f 2026-07-13 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-major-managed-medicare-payer-agreement-for-tonmy-bb25eccc 2026-07-13 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-drug-applica-b21b9788 2026-07-13 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-positive-six-month-topline-data-from-the-phase-4-o-658a24f6 2026-07-13 https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-achieves-sustained-clinical-complete-responses-in-dmmr-msi--18610cf7 2026-07-13 https://biopharmsignal.com/news/PRTC/puretech-founded-entity-celea-therapeutics-doses-first-patient-in-global-phase-3-ca178bb0 2026-07-13 https://biopharmsignal.com/news/BIIB/leqembi-subcutaneous-autoinjector-clinical-data-supports-similar-efficacy-and-sa-4f61441c 2026-07-12 https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-844649bd 2026-07-10 https://biopharmsignal.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-81ab24dd 2026-07-10 https://biopharmsignal.com/news/VRAX/virax-biolabs-group-limited-announces-closing-of-exercise-of-preferred-investmen-cc034f76 2026-07-10 https://biopharmsignal.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-02809453 2026-07-10 https://biopharmsignal.com/news/DGX/one-in-five-american-workers-tested-had-a-positive-hair-drug-test-in-2025-signal-cb4ae34e 2026-07-10 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-declares-special-cash-dividend-in-connection-with-the-proposed-971ae5b2 2026-07-10 https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing--b7458b7e 2026-07-10 https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-b379a2b1 2026-07-10 https://biopharmsignal.com/news/BSEM/biostem-technologies-publicly-files-form-10-registration-statement-with-the-secu-edc93c54 2026-07-10 https://biopharmsignal.com/news/CUE/cue-biopharma-announces-50-0-million-private-placement-de7af494 2026-07-10 https://biopharmsignal.com/news/EHC/encompass-health-announces-date-of-2026-second-quarter-earnings-call-6ef36947 2026-07-09 https://biopharmsignal.com/news/IVA/inventiva-annonce-la-finalisation-de-la-restructuration-des-bsa-bei-la-suite-de--60ee4494 2026-07-09 https://biopharmsignal.com/news/IVA/inventiva-announces-completion-of-the-eib-warrant-restructuring-with-the-issuanc-ea832ac9 2026-07-09 https://biopharmsignal.com/news/ACHC/acadia-healthcare-announces-date-for-second-quarter-2026-earnings-release-3581e462 2026-07-09 https://biopharmsignal.com/news/BDX/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2026-fae7aaa2 2026-07-09 https://biopharmsignal.com/news/CLOV/clover-health-to-report-second-quarter-2026-financial-results-on-august-5-2026-53f0271f 2026-07-09 https://biopharmsignal.com/news/RANI/rani-therapeutics-announces-research-and-development-collaboration-with-pegbio-t-5a7630da 2026-07-09 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-2026-financial-results-on-july-1166d6b4 2026-07-09 https://biopharmsignal.com/news/FLGT/fulgent-to-announce-second-quarter-2026-financial-results-on-thursday-july-30-20-db6ce056 2026-07-09 https://biopharmsignal.com/news/GDRX/goodrx-announces-date-for-second-quarter-2026-earnings-release-and-conference-ca-172941f0 2026-07-09 https://biopharmsignal.com/news/OPCH/option-care-health-to-announce-second-quarter-2026-financial-results-and-host-co-a16fbd12 2026-07-09 https://biopharmsignal.com/news/ICCC/immucell-announces-a-12-increase-in-product-sales-in-q2-of-2026-and-a-21-increas-9613a4a9 2026-07-09 https://biopharmsignal.com/news/AMRX/amneal-to-report-second-quarter-2026-results-on-july-30-2026-e7677e7f 2026-07-09 https://biopharmsignal.com/news/SERA/prime-subgroup-analysis-demonstrates-22-reduction-in-nicu-admissions-in-first-ti-1eec527c 2026-07-09 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-reports-second-quarter-2026-financial-results-and-provides-co-84944bef 2026-07-09 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2-bb26c15c 2026-07-09 https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-give-opening-plenary-address-at-alzheimer-s-association-i-4deb6898 2026-07-09 https://biopharmsignal.com/news/VRAX/virax-biolabs-group-limited-announces-exercise-of-preferred-investment-options-f-60095931 2026-07-09 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-receives-fda-ind-clearance-to-initiate-phase-2-study-of-qr-16d52698 2026-07-09 https://biopharmsignal.com/news/TEVA/teva-and-polpharma-biologics-announce-global-licensing-agreement-for-a-biosimila-995296b2 2026-07-09 https://biopharmsignal.com/news/FATE/fate-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-5f43a8db 2026-07-09 https://biopharmsignal.com/news/STXS/stereotaxis-completes-acquisition-of-robocath-cf0c62e9 2026-07-09 https://biopharmsignal.com/news/ALHC/alignment-healthcare-to-announce-second-quarter-2026-financial-results-and-host--bc4225f6 2026-07-09 https://biopharmsignal.com/news/INAB/in8bio-announces-publication-in-the-journal-of-clinical-oncology-demonstrating-d-4c0f417a 2026-07-09 https://biopharmsignal.com/news/DCTH/delcath-systems-announces-first-patient-dosed-in-phase-2-clinical-trial-of-hepza-10c88413 2026-07-09 https://biopharmsignal.com/news/VERA/vera-therapeutics-announces-appointment-of-nancy-boman-as-chief-regulatory-offic-3bddef92 2026-07-09 https://biopharmsignal.com/news/IPSC/century-therapeutics-selected-for-oral-presentations-of-cnty-813-preclinical-dat-b81a8a73 2026-07-09 https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-to-report-second-quarter-of-fiscal-year-2026-financia-0a1983ce 2026-07-09 https://biopharmsignal.com/news/VRAX/virax-biolabs-signs-multi-country-commercial-supply-agreement-with-fosun-diagnos-d54171ee 2026-07-09 https://biopharmsignal.com/news/INMB/inmune-bio-to-present-positive-phase-2-imaging-data-for-xpro-in-early-alzheimer--4c03457b 2026-07-09 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-european-approval-for-use-of-commercially-manuf-3adb0b48 2026-07-09 https://biopharmsignal.com/news/GSK/roy-jakobs-to-join-gsk-board-as-non-executive-director-560f2019 2026-07-09 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-the-new-england-journal-of-medicine-publication-d9ff91a2 2026-07-08 https://biopharmsignal.com/news/AMRX/amneal-and-adalvo-announce-fda-acceptance-for-review-of-two-u-s-andas-for-generi-0a6b37df 2026-07-08 https://biopharmsignal.com/news/TARS/tarsus-advances-eye-care-leadership-strategy-with-acquisition-of-irenix-medical--7b08b92f 2026-07-08 https://biopharmsignal.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-092e425c 2026-07-08 https://biopharmsignal.com/news/PCVX/vaxcyte-to-participate-in-upcoming-investor-conferences-dc75a6b6 2026-07-08 https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c--18613580 2026-07-08 https://biopharmsignal.com/news/GNFT/genfit-half-year-report-of-liquidity-contract-with-cr-dit-industriel-et-commerci-c386698c 2026-07-08 https://biopharmsignal.com/news/MKT/maia-biotechnology-reports-strong-initial-efficacy-data-in-third-line-non-small--1bd9a96f 2026-07-08 https://biopharmsignal.com/news/RARE/ultragenyx-releases-2025-impact-report-emphasizing-commitment-to-rare-disease-pa-6c0c6160 2026-07-08 https://biopharmsignal.com/news/DGX/quest-diagnostics-now-the-largest-clinical-reference-lab-to-extend-oncology-test-e734c702 2026-07-08 https://biopharmsignal.com/news/LIXT/nomad-increases-voyager-fleet-energy-storage-by-up-to-56-bringing-eagle-and-falc-4f686804 2026-07-08 https://biopharmsignal.com/news/PRME/prime-medicine-announces-positive-resolution-to-arbitration-with-beam-therapeuti-975e6962 2026-07-08 https://biopharmsignal.com/news/ARQT/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast-cre-09abb4cc 2026-07-08 https://biopharmsignal.com/news/URGN/urogen-announces-fda-clearance-of-the-ind-for-ugn-501-an-investigational-next-ge-1733c603 2026-07-08 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-2026-financial-results-on-july-ffc9b6aa 2026-07-08 https://biopharmsignal.com/news/AZTA/azenta-completes-sale-of-b-medical-systems-869ef834 2026-07-08 https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-and-precision-medicine-pioneer-scipher-medicine-announce-m-14c02ebe 2026-07-08 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-participation-in-b-riley-securities-mind-muscle--c2ef8757 2026-07-08 https://biopharmsignal.com/news/SEER/seer-board-of-directors-issues-letter-to-shareholders-demonstrating-the-strength-2fe1284b 2026-07-08 https://biopharmsignal.com/news/OVID/ovid-therapeutics-strengthens-executive-leadership-team-to-support-continued-pip-258bfecb 2026-07-08 https://biopharmsignal.com/news/OKYO/okyo-pharma-reports-positive-feedback-from-fda-type-d-meeting-and-accelerates-ur-846c4e6f 2026-07-08 https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-early-clinical-data-showing-potential-for-ser-155-i-55053722 2026-07-08 https://biopharmsignal.com/news/CATX/perspective-therapeutics-appoints-paul-lyne-ph-d-as-chief-science-officer-co-fou-463c2453 2026-07-08 https://biopharmsignal.com/news/TECH/bio-techne-launches-expanded-r-d-systems-ai-engineered-designer-protein-portfoli-21b908e1 2026-07-08 https://biopharmsignal.com/news/ADXN/addex-announces-publication-of-research-highlighting-therapeutic-potential-of-mg-565b76c5 2026-07-08 https://biopharmsignal.com/news/BBLG/bone-biologics-announces-up-to-9-0-million-private-placement-priced-at-the-marke-7231c29e 2026-07-08 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-announces-ceo-succession-533f8792 2026-07-07 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--477fc08a 2026-07-07 https://biopharmsignal.com/news/VTAK/flyte-partners-with-lifevac-to-equip-every-vision-jet-with-life-saving-equipment-c5bba138 2026-07-07 https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-singapore-court-hearing-to-be-held-on-july-14-2026--d94f52e6 2026-07-07 https://biopharmsignal.com/news/VOR/vor-bio-appoints-david-zaccardelli-to-board-of-directors-7c744ed5 2026-07-07 https://biopharmsignal.com/news/VERA/vera-therapeutics-receives-fda-accelerated-approval-for-trutakna-for-adult-patie-79e89de4 2026-07-07 https://biopharmsignal.com/news/RVMD/european-medicines-agency-expedites-assessment-of-revolution-medicines-daraxonra-a47b14e8 2026-07-07 https://biopharmsignal.com/news/AIM/aim-immunotech-announces-release-of-new-ceo-corner-segment-highlighting-growing--e216a6e4 2026-07-07 https://biopharmsignal.com/news/PRVA/privia-health-to-report-second-quarter-2026-results-on-thursday-august-6-8393f062 2026-07-07 https://biopharmsignal.com/news/ENLV/enlivex-announces-1-for-15-reverse-stock-split-effective-july-9-2026-ba251da0 2026-07-07 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-quarterly-cypath-lung-sales-double-to-new-record-as-com-fee483fe 2026-07-07 https://biopharmsignal.com/news/CLOV/clinical-excellence-in-continuity-of-care-counterpart-assistant-ca-use-associate-c70791e1 2026-07-07 https://biopharmsignal.com/news/VERU/veru-to-present-at-2026-obesity-weight-loss-drug-development-summit-and-pre-conf-f5d70201 2026-07-07 https://biopharmsignal.com/news/OGEN/oragenics-achieves-full-activation-of-australian-phase-iia-trial-network-all-thr-ec4ff0b0 2026-07-07 https://biopharmsignal.com/news/CERT/certara-accelerates-drug-discovery-and-development-with-nvidia-bionemo-agent-too-9f8b9eee 2026-07-07 https://biopharmsignal.com/news/SABS/breakthrough-t1d-awards-grant-to-support-prise-hatg-study-of-sab-142-in-stage-3--2892a9e2 2026-07-07 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-and-remagine-labs-announce-strategic-collaboration-to-0ffd9b54 2026-07-07 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-announces-clia-certification-clearing-the-path-for-advanci-1691650e 2026-07-07 https://biopharmsignal.com/news/VANI/vivani-medical-enters-into-agreement-with-novo-nordisk-to-evaluate-npm-139-a-min-9e9275ac 2026-07-07 https://biopharmsignal.com/news/MGTX/meiragtx-announces-400-million-strategic-investment-by-oberland-capital-to-suppo-b21561a1 2026-07-07 https://biopharmsignal.com/news/BCTX/briacell-engages-consulting-and-branding-firms-to-support-commercial-and-market--1c9ffd2a 2026-07-07 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-present-data-on-enhanced-brain-delivery-ebd-technology-95eca401 2026-07-07 https://biopharmsignal.com/news/CYTK/cytokinetics-announces-three-late-breaking-science-abstracts-at-the-european-soc-852ccfe1 2026-07-07 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-reg-0d480791 2026-07-07 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-participate-in-leerink-partners-therapeutics-forum-i-i-e3aab3f7 2026-07-07 https://biopharmsignal.com/news/AGIO/u-s-fda-grants-priority-review-to-agios-snda-for-mitapivat-in-sickle-cell-diseas-ca03247b 2026-07-07 https://biopharmsignal.com/news/ACON/aclarion-announces-texas-spine-care-center-as-new-clarity-site-e1c30414 2026-07-07 https://biopharmsignal.com/news/OKYO/okyo-pharma-to-participate-in-a-fireside-chat-at-piper-sandler-2026-virtual-opht-a2f767e0 2026-07-07 https://biopharmsignal.com/news/ANVS/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-35d9e2ee 2026-07-07 https://biopharmsignal.com/news/ACIU/ac-immune-to-showcase-neurodegenerative-disease-pipeline-with-three-presentation-edc83995 2026-07-07 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-initiates-focus-2-phase-3-trial-of-solriamfetol-in-children--f3b8fe5b 2026-07-07 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-elizabeth-laws-ph-d-as-senior-vice-president-global-f322a3cc 2026-07-07 https://biopharmsignal.com/news/TEVA/teva-to-advance-its-anti-il-15-antibody-designed-for-quarterly-dosing-into-phase-03b70cd6 2026-07-07 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-the-leerink-partners-therapeutics-forum-ef62dbcf 2026-07-07 https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--f70a7f47 2026-07-06 https://biopharmsignal.com/news/RXST/alcon-and-rxsight-announce-collaboration-to-develop-adjustable-pciols-d11bd105 2026-07-06 https://biopharmsignal.com/news/RXST/rxsight-inc-announces-preliminary-second-quarter-financial-results-and-product-p-644e5a5e 2026-07-06 https://biopharmsignal.com/news/CNTX/context-therapeutics-added-to-russell-2000-and-russell-3000-indexes-71f8f968 2026-07-06 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-receives-upfront-payment-of-25m-usd-from-the-exclusive-licen-d14ff076 2026-07-06 https://biopharmsignal.com/news/ORGO/organogenesis-announces-fda-acceptance-of-biologics-license-application-for-renu-dd638fde 2026-07-06 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-announces-closing-of-15-million-registered-direct-offering-a94b4898 2026-07-06 https://biopharmsignal.com/news/LGVN/longeveron-appoints-marie-washburn-as-chief-financial-officer-510c9ad9 2026-07-06 https://biopharmsignal.com/news/VXRT/vaxart-reports-topline-12-month-safety-data-from-the-400-participant-sentinel-sa-ad993e0f 2026-07-06 https://biopharmsignal.com/news/CRIS/curis-consents-first-six-patients-in-takeaim-cll-study-45969449 2026-07-06 https://biopharmsignal.com/news/AEMD/aethlon-medical-announces-pricing-of-4-0-million-follow-on-offering-priced-at-th-e3315678 2026-07-06 https://biopharmsignal.com/news/PCRX/pacira-biosciences-joins-life-science-cares-as-national-corporate-partner-bfd68c2a 2026-07-06 https://biopharmsignal.com/news/NRSN/neurosense-to-participate-in-roth-hosted-kol-webinar-on-the-future-of-als-treatm-467c5922 2026-07-06 https://biopharmsignal.com/news/MBRX/moleculin-ceo-walter-klemp-highlights-positive-preliminary-miracle-trial-results-5d91d9cd 2026-07-06 https://biopharmsignal.com/news/STIM/neuronetics-to-participate-in-a-panel-discussion-at-b-riley-securities-mind-musc-e3db286d 2026-07-06 https://biopharmsignal.com/news/FATE/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-the-shelf-ca-2ca1e01e 2026-07-06 https://biopharmsignal.com/news/LIXT/lixte-completes-corporate-name-change-to-nomad-power-solutions-inc-to-begin-trad-1e7a1571 2026-07-06 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-announces-launch-of-new-telehealth-prescribing-option-to-accel-e7f681dd 2026-07-06 https://biopharmsignal.com/news/ICCM/icecure-highlights-expanding-commercial-adoption-of-prosense-cryoablation-in-bra-814ddba1 2026-07-06 https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-present-at-b-riley-securities-2026-mind-muscle-visi-93d042e3 2026-07-06 https://biopharmsignal.com/news/VTAK/catheter-precision-inc-announces-issuance-of-two-key-patents-119649de 2026-07-06 https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-sy-df1f51d3 2026-07-06 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-appoints-leonardo-viana-nicacio-m-d-as-chief-medical-offi-7e9400c6 2026-07-06 https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-initiation-of-phase-2-trial-evaluating-briumvi-in-pati-4f9159d1 2026-07-06 https://biopharmsignal.com/news/SEER/seer-files-investor-presentation-highlighting-strong-momentum-commercial-opportu-e67fff29 2026-07-06 https://biopharmsignal.com/news/NEPH/nephros-announces-inclusion-in-the-russell-microcap-index-8f384e42 2026-07-06 https://biopharmsignal.com/news/BLTE/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-59165567 2026-07-06 https://biopharmsignal.com/news/PHVS/pharvaris-announces-fda-acceptance-of-new-drug-application-for-deucrictibant-ir--11e9782b 2026-07-06 https://biopharmsignal.com/news/IMRN/immuron-advances-imm-529-clostridioides-difficile-infection-partnering-strategy-00549010 2026-07-06 https://biopharmsignal.com/news/MOLN/molecular-partners-updates-on-clinical-progress-across-expanding-pipeline-of-dar-8013e88f 2026-07-06 https://biopharmsignal.com/news/TDOC/teladoc-health-announces-employee-inducement-award-under-nyse-rule-303a-08-0f589387 2026-07-03 https://biopharmsignal.com/news/ALVO/vi-skipti-stj-rnenda-og-tengdra-a-ila-53408632 2026-07-03 https://biopharmsignal.com/news/ALVO/transactions-of-managers-and-closely-associated-persons-9140a9e4 2026-07-03 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-56-74d5744c 2026-07-03 https://biopharmsignal.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ef99a3b3 2026-07-02 https://biopharmsignal.com/news/SEER/seer-announces-receipt-of-unsolicited-acquisition-proposal-from-omid-farokhzad-m-c91bb35c 2026-07-02 https://biopharmsignal.com/news/OM/outset-medical-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-21643aa5 2026-07-02 https://biopharmsignal.com/news/XERS/xeris-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-713b1411 2026-07-02 https://biopharmsignal.com/news/XERS/correcting-and-replacing-xeris-announces-inducement-grants-under-nasdaq-listing--0c3e5deb 2026-07-02 https://biopharmsignal.com/news/TENX/tenax-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--795d95d7 2026-07-02 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc8c2359 2026-07-02 https://biopharmsignal.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-2026-results-on-july-30-2026-f3864c0a 2026-07-02 https://biopharmsignal.com/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc49cd8f 2026-07-02 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-56-d71ac313 2026-07-02 https://biopharmsignal.com/news/MDXH/mdxhealth-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price-d-bdf178d6 2026-07-02 https://biopharmsignal.com/news/IVA/r-sultats-des-votes-de-l-assembl-e-g-n-rale-mixte-des-actionnaires-r-unie-le-30--623fc98c 2026-07-02 https://biopharmsignal.com/news/IVA/results-of-the-votes-of-the-combined-shareholders-general-meeting-of-june-30-202-4542eebe 2026-07-02 https://biopharmsignal.com/news/GNFT/genfit-announces-u-s-medicare-coverage-and-future-reimbursement-for-nashnext-a-n-2769741e 2026-07-02 https://biopharmsignal.com/news/MGNX/macrogenics-completes-sale-of-gmp-manufacturing-operations-to-bora-pharmaceutica-b2889ad8 2026-07-02 https://biopharmsignal.com/news/IART/integra-lifesciences-appoints-topaz-kirlew-chief-regulatory-officer-89ac0b20 2026-07-02 https://biopharmsignal.com/news/CING/cingulate-inc-nasdaq-cing-added-to-russell-3000e-1ee91267 2026-07-02 https://biopharmsignal.com/news/LIXT/lixte-completes-merger-with-nomad-transportable-power-systems-3aa02eed 2026-07-02 https://biopharmsignal.com/news/RVMD/revolution-medicines-presents-phase-1-2-clinical-data-for-zoldonrasib-combinatio-b6abe879 2026-07-02 https://biopharmsignal.com/news/ATRC/atricure-to-announce-second-quarter-2026-financial-results-ccf9a74f 2026-07-02 https://biopharmsignal.com/news/VTAK/flyte-announces-successful-launch-of-new-direct-to-consumer-booking-platform-75c8ddff 2026-07-02 https://biopharmsignal.com/news/VANI/vivani-announces-entry-into-merger-agreement-between-wholly-owned-subsidiary-cor-743c93e1 2026-07-02 https://biopharmsignal.com/news/BBIO/acoramidis-associated-with-first-ever-early-and-sustained-direct-kidney-protecti-a72e923d 2026-07-02 https://biopharmsignal.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-afb4cc8d 2026-07-02 https://biopharmsignal.com/news/TENX/tenax-therapeutics-announces-late-breaking-presentation-of-level-clinical-trial--99fd99ae 2026-07-02 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-to-participate-in-piper-sandler-virtual-ophthalmology-symp-a9cd7ac0 2026-07-02 https://biopharmsignal.com/news/ENSG/the-ensign-group-purchases-real-estate-and-operations-in-texas-fafd93f0 2026-07-02 https://biopharmsignal.com/news/HCM/hutchmed-announces-nmpa-approval-for-orpathys-for-the-treatment-of-gastric-cance-e8d2b97e 2026-07-02 https://biopharmsignal.com/news/OCS/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference-17f42704 2026-07-02 https://biopharmsignal.com/news/PRTC/puretech-founded-entity-celea-therapeutics-completes-180-million-financing-to-ad-3954c132 2026-07-02 https://biopharmsignal.com/news/PRTC/puretech-announces-completion-of-180-million-financing-for-founded-entity-celea--b2099580 2026-07-02 https://biopharmsignal.com/news/MOLN/molecular-partners-and-orano-med-announce-first-patients-dosed-in-phase-1-2a-tri-d6e48cfa 2026-07-02 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-announces-pricing-of-15-million-registered-direct-offering-c7de05c2 2026-07-02 https://biopharmsignal.com/news/XRAY/pds-health-surpasses-five-million-cerec-chairside-restorations-with-dentsply-sir-7db929d4 2026-07-01 https://biopharmsignal.com/news/MTLS/annual-general-meeting-of-materialise-nv-held-at-the-registered-office-of-the-co-5541f657 2026-07-01 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-initiates-phase-2-study-of-crinecerfont-in-pediatric-pati-8fe2e2b9 2026-07-01 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--c43a8fbe 2026-07-01 https://biopharmsignal.com/news/FATE/fate-therapeutics-to-participate-in-upcoming-third-quarter-2026-conferences-457e2808 2026-07-01 https://biopharmsignal.com/news/INGN/inogen-announces-the-appointment-of-andy-reding-as-chief-operating-officer-4f2d5fcf 2026-07-01 https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-cc27221e 2026-07-01 https://biopharmsignal.com/news/VXRT/vaxart-enters-cooperation-agreement-with-stockholder-group-and-announces-board-a-2ed5b0dd 2026-07-01 https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-symposium-presentation-at-the-european-association--26e086a1 2026-07-01 https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-new-data-supporting-art26-12-as-a-potential-first-i-d595235b 2026-07-01 https://biopharmsignal.com/news/AMRX/amneal-s-new-u-s-sterile-manufacturing-facility-selected-for-fda-precheck-pilot--2719d102 2026-07-01 https://biopharmsignal.com/news/HYPR/hyperfine-announces-european-launch-of-next-generation-swoop-system-eb9cfb69 2026-07-01 https://biopharmsignal.com/news/RIGL/rigel-appoints-board-member-alison-l-hannah-m-d-as-chief-medical-officer-c2f47409 2026-07-01 https://biopharmsignal.com/news/PCRX/pacira-biosciences-announces-unitedhealthcare-now-provides-separate-reimbursemen-87b0c6a8 2026-07-01 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-upcoming-presentations-at-the-alzheimer-s-associat-5f8e7eb9 2026-07-01 https://biopharmsignal.com/news/ANVS/annovis-appoints-cheng-fang-ph-d-as-chief-scientific-officer-56e8ee3d 2026-07-01 https://biopharmsignal.com/news/INTS/intensity-therapeutics-provides-mid-year-update-highlighting-late-stage-developm-93ef635a 2026-07-01 https://biopharmsignal.com/news/SYK/stryker-to-announce-second-quarter-2026-financial-results-94b73874 2026-07-01 https://biopharmsignal.com/news/BBIO/bridgebio-raises-1-billion-in-preferred-equity-to-accelerate-present-and-upcomin-7cd369f3 2026-07-01 https://biopharmsignal.com/news/HLF/herbalife-to-announce-second-quarter-2026-results-on-august-5-b85d8156 2026-07-01 https://biopharmsignal.com/news/USNA/kevin-guest-world-cup-determination-shows-the-power-of-grit-preparation-persiste-ce0b681d 2026-07-01 https://biopharmsignal.com/news/SEER/seer-prevails-in-european-patent-opposition-as-u-s-itc-opens-investigation-into--47d79284 2026-07-01 https://biopharmsignal.com/news/INMB/inmune-bio-advances-cordstrom-platform-patent-application-in-the-u-s-following-f-4ac73a4a 2026-07-01 https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-july-industry-conferences-c2e70176 2026-07-01 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-appoints-kelly-gold-experienced-chief-financial-officer-to-it-316d9f27 2026-07-01 https://biopharmsignal.com/news/HROW/harrow-announces-commercial-launch-of-byooviz-in-the-united-states-234ff9de 2026-07-01 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-participate-in-july-scientific-and-investor-conferences-339a542b 2026-07-01 https://biopharmsignal.com/news/IBIO/ibio-reports-single-dose-of-ibio-610-achieved-near-complete-active-activin-e-inh-15c14063 2026-07-01 https://biopharmsignal.com/news/ALVO/alvotech-styrkir-lausafj-rst-u-s-na-enn-frekar-me-a-gengi-a-75-millj-na-dala-l-n-5c600a72 2026-07-01 https://biopharmsignal.com/news/ALVO/alvotech-further-strengthens-liquidity-by-securing-term-loan-facility-of-75-mill-80932cf9 2026-07-01 https://biopharmsignal.com/news/APTO/aptose-biosciences-announces-completion-of-acquisition-by-hanmi-pharmaceutical-de9f8903 2026-06-30 https://biopharmsignal.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules-b37a2f05 2026-06-30 https://biopharmsignal.com/news/BDRX/result-of-annual-general-meeting-3325d1d7 2026-06-30 https://biopharmsignal.com/news/PRGO/perrigo-announces-appointment-of-two-new-independent-directors-to-board-47cee7b5 2026-06-30 https://biopharmsignal.com/news/AMRN/amarin-reaffirms-the-proven-guideline-recommended-role-of-vascepa-icosapent-ethy-d4f2d021 2026-06-30 https://biopharmsignal.com/news/COO/coopercompanies-releases-2025-corporate-sustainability-report-with-scope-3-emiss-7902aa71 2026-06-30 https://biopharmsignal.com/news/FDMT/4dmt-announces-presentation-at-44th-annual-scientific-meeting-of-the-american-so-2d1eff08 2026-06-30 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-aug-4b8a9657 2026-06-30 https://biopharmsignal.com/news/SERA/sera-prognostics-announces-appointment-of-mark-capone-to-its-board-of-directors-8cc61214 2026-06-30 https://biopharmsignal.com/news/ARQT/arcutis-launches-new-virtual-health-platform-supporting-access-to-care-for-indiv-1503fca8 2026-06-30 https://biopharmsignal.com/news/JAGX/presentation-at-espghan-2026-describes-additional-groundbreaking-results-of-eval-34e0fbe8 2026-06-30 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-receives-fda-510-k-clearance-expanding-indications-and-pa-421ff719 2026-06-30 https://biopharmsignal.com/news/ARTL/artelo-biosciences-presents-evidence-for-a-common-lipid-signaling-link-across-mu-3e4320d0 2026-06-30 https://biopharmsignal.com/news/VVOS/vivos-vida-appliance-shows-statistically-significant-improvement-in-insomnia-sev-76ccf0ec 2026-06-30 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-appoints-iain-dukes-venture-partner-at-orbimed-as-chair-of--8101d663 2026-06-30 https://biopharmsignal.com/news/XCUR/exicure-announces-board-and-committee-changes-3e7d491d 2026-06-30 https://biopharmsignal.com/news/ADPT/imviva-biotech-receives-fda-ide-authorization-for-clonoseq-assay-in-tenacity-01--1f1babe9 2026-06-30 https://biopharmsignal.com/news/SRPT/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-40aea7f9 2026-06-30 https://biopharmsignal.com/news/MBRX/moleculin-reports-positive-phase-2-3-miracle-interim-results-with-annamycin-comp-cd51c7b9 2026-06-30 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-receives-u-s-notice-of-allowance-for-patent-covering-combi-9c801c3f 2026-06-30 https://biopharmsignal.com/news/ASND/children-with-achondroplasia-treated-with-transcon-cnp-showed-continued-improvem-93d02f62 2026-06-30 https://biopharmsignal.com/news/HCWB/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-lett-e27131c5 2026-06-30 https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-initiation-of-global-pivotal-phase-3-aurora-trial--bd75a6e3 2026-06-30 https://biopharmsignal.com/news/APVO/aptevo-secures-1-5-million-non-dilutive-research-grant-from-the-andy-hill-care-f-0120aa19 2026-06-30 https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-multiple-a-1d18e89a 2026-06-30 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-submission-of-new-drug-application-nda-for-bezuclas-2951df92 2026-06-30 https://biopharmsignal.com/news/ALXO/alx-oncology-appoints-scott-garland-as-chairman-of-the-board-and-michael-listgar-e952538a 2026-06-30 https://biopharmsignal.com/news/ANGO/angiodynamics-to-report-fiscal-2026-fourth-quarter-and-full-year-financial-resul-d0a55e66 2026-06-30 https://biopharmsignal.com/news/MNOV/medicinova-ceo-provides-shareholder-update-9776ffac 2026-06-30 https://biopharmsignal.com/news/BDRX/biodexa-announces-pricing-of-3-5-million-registered-direct-offering-concurrent-p-6a51a733 2026-06-30 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-announces-the-grant-of-essential-u-s-patent-for-its-stenop-de7abd3e 2026-06-30 https://biopharmsignal.com/news/AKBA/u-s-renal-care-and-akebia-announce-interim-analysis-of-voice-trial-demonstrated--7cc9c9bc 2026-06-30 https://biopharmsignal.com/news/GNLX/genelux-announces-publication-of-translational-analysis-supporting-immune-activa-f94dc658 2026-06-30 https://biopharmsignal.com/news/MNPR/monopar-therapeutics-receives-fda-rare-pediatric-disease-designation-for-alxn184-4666946b 2026-06-30 https://biopharmsignal.com/news/SCYX/scynexis-initiates-phase-1-study-of-scy-770-a-novel-ampk-activator-for-the-treat-9e4687ee 2026-06-30 https://biopharmsignal.com/news/PCRX/pacira-biosciences-announces-agreement-to-divest-its-iovera-business-to-zimmer-b-e7793cda 2026-06-30 https://biopharmsignal.com/news/PYXS/pyxis-oncology-announces-up-to-114-million-private-placement-financing-to-advanc-a7414ffd 2026-06-30 https://biopharmsignal.com/news/IFRX/inflarx-assessing-feasibility-of-broadened-strategy-for-anca-associated-vasculit-7f39d900 2026-06-30 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-receives-complete-response-letter-from-fda-regarding-resu-2c152ab0 2026-06-30 https://biopharmsignal.com/news/XERS/xeris-announces-updates-to-its-board-of-directors-f32772e5 2026-06-30 https://biopharmsignal.com/news/ACIU/ac-immune-reports-interim-12-month-data-from-phase-1b-2-abate-trial-of-aci-24-in-aa4acde5 2026-06-30 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-positive-interim-phase-1-advanced-cancer-study-d-e066723c 2026-06-30 https://biopharmsignal.com/news/BEAT/heartbeam-completes-enrollment-in-heart-attack-detection-pilot-study-ahead-of-sc-c3aedd75 2026-06-30 https://biopharmsignal.com/news/HCM/hutchmed-to-announce-2026-half-year-financial-results-cae79711 2026-06-30 https://biopharmsignal.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-94ea959e 2026-06-30 https://biopharmsignal.com/news/PRI/primerica-household-budget-index-hbi-gas-prices-continued-to-weigh-on-purchasing-cd4ad354 2026-06-30 https://biopharmsignal.com/news/ARQT/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-ps-597a9084 2026-06-29 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-announces-extension-period-for-relutrigine-for-treatm-f28fc662 2026-06-29 https://biopharmsignal.com/news/YOU/your-travel-day-super-hero-has-arrived-clear-teams-up-with-marvel-animation-s-x--1b04f659 2026-06-29 https://biopharmsignal.com/news/GANX/gain-therapeutics-receives-fda-clearance-of-ind-to-advance-gt-02287-into-phase-2-11cfdeaf 2026-06-29 https://biopharmsignal.com/news/NRSN/neurosense-achieves-primary-endpoint-in-phase-2b-als-study-with-statistically-si-6471ada3 2026-06-29 https://biopharmsignal.com/news/ARTL/artelo-biosciences-presents-clinical-and-biomarker-data-supportive-of-the-develo-0285995c 2026-06-29 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer-bc693f44 2026-06-29 https://biopharmsignal.com/news/BDRX/approval-from-health-canada-to-expand-serenta-registrational-phase-3-trial-in-fa-8f66fbbf 2026-06-29 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-joins-russell-2000-index-26eba5ff 2026-06-29 https://biopharmsignal.com/news/DGX/quest-diagnostics-foundation-commits-nearly-5-million-to-improving-health-outcom-a6539690 2026-06-29 https://biopharmsignal.com/news/VYGR/voyager-s-tau-targeted-gene-therapy-vy1706-for-alzheimer-s-disease-to-be-feature-7e183bb9 2026-06-29 https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-h-c-wainwright-4th-annual-cell-therapy-faa61d70 2026-06-29 https://biopharmsignal.com/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-end-2026-financial-results-and--829c51fd 2026-06-29 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-added-to-russell-2000-and-russell-3000-indexes-6dfc9229 2026-06-29 https://biopharmsignal.com/news/MDXH/mdxhealth-announces-peer-reviewed-publication-of-oxford-gps-prompt-study-in-euro-d931d4ac 2026-06-29 https://biopharmsignal.com/news/FDMT/4dmt-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-of-4d-150-i-9bfd89ef 2026-06-29 https://biopharmsignal.com/news/FDMT/4dmt-secures-strategic-credit-facility-for-up-to-200-million-from-hercules-capit-904f292b 2026-06-29 https://biopharmsignal.com/news/RANI/rani-therapeutics-appoints-nicholas-maestas-as-chief-financial-officer-5b23c7dd 2026-06-29 https://biopharmsignal.com/news/XLO/xilio-therapeutics-appoints-ben-harshbarger-as-chief-legal-officer-d248a423 2026-06-29 https://biopharmsignal.com/news/ZURA/zura-bio-exceeds-enrollment-target-in-both-hidradenitis-suppurativa-hs-systemic--cfd7a19d 2026-06-29 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-horizon-study--041b721f 2026-06-29 https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-inclusion-in-the-russell-2000-index-expanding-ma-949bcb8c 2026-06-29 https://biopharmsignal.com/news/BCRX/biocryst-sharpens-scientific-focus-on-external-innovation-with-wind-down-of-inte-83b84c41 2026-06-29 https://biopharmsignal.com/news/AORT/artivion-announces-u-s-fda-approval-of-the-amds-hybrid-prosthesis-15da88f3 2026-06-29 https://biopharmsignal.com/news/AGIO/agios-to-host-second-quarter-2026-financial-results-conference-call-and-webcast--fc5d305e 2026-06-29 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes-d9416ec4 2026-06-29 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-joins-russell-2000-and-russell-3000-indexes-f3211c84 2026-06-29 https://biopharmsignal.com/news/BIIB/biogen-to-highlight-breadth-of-alzheimer-s-disease-portfolio-at-aaic-2026-includ-923651d3 2026-06-29 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-positive-open-label-data-and-submission-of-first-mo-5e1889f2 2026-06-29 https://biopharmsignal.com/news/TBPH/theravance-biopharma-enters-into-definitive-agreement-to-be-acquired-by-zymework-7bcac832 2026-06-29 https://biopharmsignal.com/news/YOU/clear-to-strengthen-caller-verification-in-contact-centers-with-aws-a6b19977 2026-06-29 https://biopharmsignal.com/news/AMRX/zambon-and-amneal-announce-positive-chmp-opinion-for-hopledo-ipx203-for-adults-w-6b0e1405 2026-06-29 https://biopharmsignal.com/news/BBIO/bridgebio-announces-publication-in-the-new-england-journal-of-medicine-of-phase--239e7199 2026-06-28 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-fri-42a5b003 2026-06-26 https://biopharmsignal.com/news/MNPR/monopar-presents-new-analyses-of-phase-3-focus-data-at-ean-2026-showing-greater--6b830c10 2026-06-26 https://biopharmsignal.com/news/ASND/ascendis-joins-multiple-russell-u-s-indexes-including-the-russell-3000-russell-1-d1ad8aa7 2026-06-26 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-fda-advisory-committee-meeting-to-review-bla-for-4de22ae1 2026-06-26 https://biopharmsignal.com/news/CRIS/curis-announces-eleven-active-clinical-sites-in-takeaim-cll-study-reaffirms-pati-978d906e 2026-06-26 https://biopharmsignal.com/news/CAPR/capricor-to-present-positive-five-year-hope-2-ole-data-and-hope-3-phase-3-result-4fe04208 2026-06-26 https://biopharmsignal.com/news/HCWB/hcw-biologics-announces-1-for-6-reverse-stock-split-effective-on-june-30-2026-31a4d4f1 2026-06-26 https://biopharmsignal.com/news/MDNA/medicenna-therapeutics-reports-fiscal-year-2026-financial-results-and-operationa-270c22c3 2026-06-26 https://biopharmsignal.com/news/LIXT/lixte-joins-russell-microcap-index-2eee8aca 2026-06-26 https://biopharmsignal.com/news/AEMD/aethlon-medical-announces-publication-demonstrating-novel-long-covid-biomarker-a-2129c0c1 2026-06-26 https://biopharmsignal.com/news/REPL/replimune-announces-fda-acceptance-of-rp1-biologics-license-application-resubmis-9ba52bee 2026-06-26 https://biopharmsignal.com/news/VXRT/vaxart-publishes-presentation-urging-shareholders-to-vote-for-all-six-of-the-com-2bf27563 2026-06-26 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-enrolls-first-patient-in-final-phase-of-pf614-mpar-102-clini-3e521199 2026-06-26 https://biopharmsignal.com/news/VANI/vivani-medical-announces-appointment-of-august-j-moretti-to-board-of-directors-a-38ca0d85 2026-06-26 https://biopharmsignal.com/news/XAIR/beyond-air-reports-fourth-quarter-and-full-year-2026-financial-results-and-provi-8c4a9c6f 2026-06-26 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-initiates-focus-3-phase-3-trial-of-solriamfetol-in-adolescen-328278bb 2026-06-26 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes-3ee6d18b 2026-06-26 https://biopharmsignal.com/news/CLLS/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026-28c487bb 2026-06-25 https://biopharmsignal.com/news/REGN/regeneron-to-report-second-quarter-2026-financial-and-operating-results-and-host-c2e371f6 2026-06-25 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-multiple-presentations-highlighting-its-tsha-102-4055adda 2026-06-25 https://biopharmsignal.com/news/KROS/keros-therapeutics-appoints-anne-prener-to-its-board-of-directors-7c27ad3b 2026-06-25 https://biopharmsignal.com/news/ASND/ascendis-to-showcase-advances-in-treatment-of-achondroplasia-at-iccbh-2026-cf687b9b 2026-06-25 https://biopharmsignal.com/news/NRSN/neurosense-reports-positive-biomarker-findings-from-phase-2-road-proof-of-concep-8751aee3 2026-06-25 https://biopharmsignal.com/news/JAGX/jaguar-health-announces-conversion-of-series-o-convertible-preferred-stock-issue-a3daf981 2026-06-25 https://biopharmsignal.com/news/LGMK/survey-exposes-a-crisis-of-avoidance-in-family-caregiving-d8e5b6c5 2026-06-25 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-announces-completion-of-brtx-100-phase-2-manufacturing--27587c89 2026-06-25 https://biopharmsignal.com/news/ICCM/icecure-regains-compliance-with-nasdaq-minimum-bid-price-requirement-7340e049 2026-06-25 https://biopharmsignal.com/news/MKT/maia-biotechnology-completes-international-enrollment-in-part-c-of-phase-2-thio--0735c98e 2026-06-25 https://biopharmsignal.com/news/CADL/candel-therapeutics-appoints-mark-sims-as-chief-commercial-officer-81ff1e69 2026-06-25 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-h-c-wainwright-4th-annual-cell-the-25f96787 2026-06-25 https://biopharmsignal.com/news/IXHL/incannex-secures-u-s-patent-grant-for-ihl-42x-in-obstructive-sleep-apnea-e23ab89e 2026-06-25 https://biopharmsignal.com/news/VXRT/vaxart-announces-update-to-barda-funding-award-to-reflect-current-scope-of-covid-7ad6f011 2026-06-25 https://biopharmsignal.com/news/BCTX/briacell-partners-with-uneedle-for-scalable-microneedle-administration-of-bria-i-cc0d128d 2026-06-25 https://biopharmsignal.com/news/VANI/vivani-medical-receives-regulatory-approval-for-the-initiation-of-slim-1-a-phase-040f1891 2026-06-25 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-completes-patient-enrollment-in-phase-3-c-forward-trial-eva-825c5ef5 2026-06-25 https://biopharmsignal.com/news/TLSA/tiziana-announces-last-patient-successfully-dosed-in-its-phase-2-inform-ms-trial-bc955226 2026-06-25 https://biopharmsignal.com/news/INMB/inmune-bio-inc-achieves-mhra-approval-of-pip-for-cordstrom-b84bc01e 2026-06-25 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-participate-in-upcoming-investor-conference-ec70e012 2026-06-25 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-completes-enrollment-in-the-phase-2b-broaden2-trial-of-kt-62-eddcfec5 2026-06-25 https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-host-webcast-on-july-8-2026-to-discuss-results-of-investig-6fc7afb2 2026-06-25 https://biopharmsignal.com/news/PRQR/proqr-prices-50-0-million-underwritten-registered-direct-offering-and-concurrent-67a09dc9 2026-06-25 https://biopharmsignal.com/news/PRQR/proqr-announces-positive-phase-1-target-engagement-data-for-ax-0810-establishing-ceb340ef 2026-06-25 https://biopharmsignal.com/news/TECH/merck-kgaa-darmstadt-germany-agrees-to-acquire-bio-techne-strengthening-leadersh-50e2ac1c 2026-06-25 https://biopharmsignal.com/news/ADXN/addex-therapeutics-reports-first-quarter-2026-financial-results-and-provides-cor-7b0b3a95 2026-06-25 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-pricing-of-public-offering-of-common-stock-and-p-2e78d875 2026-06-25 https://biopharmsignal.com/news/HCM/hutchmed-highlights-pivotal-phase-ii-data-for-fanregratinib-in-intrahepatic-chol-bda8536d 2026-06-25 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-present-clinical-data-from-ras-on-inhibitor-combination--4a11ac0f 2026-06-24 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-provides-commercial-and-financial-updates-8c04d85d 2026-06-24 https://biopharmsignal.com/news/BEAT/heartbeam-announces-strategic-shift-to-accelerate-global-adoption-of-its-ambulat-2e1e9ad3 2026-06-24 https://biopharmsignal.com/news/PASG/passage-bio-and-remix-therapeutics-announce-merger-agreement-8fb9a1f7 2026-06-24 https://biopharmsignal.com/news/SERA/sera-prognostics-collaborates-on-arpa-h-award-to-advance-point-of-care-diagnosti-7f391c59 2026-06-24 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-proposed-public-offering-of-common-stock-and-pre-4e5395e4 2026-06-24 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-felix-j-baker-ph-d-as-chairman-of-the-board-of-dire-f3d892d4 2026-06-24 https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-listing-of-the-rain-token-on-gate-one-of-the-w-5d152041 2026-06-24 https://biopharmsignal.com/news/FEMY/femasys-regains-compliance-with-nasdaq-listing-requirements-6f7badb3 2026-06-24 https://biopharmsignal.com/news/VRAX/virax-biolabs-group-limited-announces-1-for-25-share-consolidation-aa5a26d6 2026-06-24 https://biopharmsignal.com/news/DGX/quest-diagnostics-receives-new-york-state-approval-for-haystack-mrd-broadening-p-b4f0a6c5 2026-06-24 https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-initiation-of-phase-2a-portion-of-inlight-trial-of--2b38bb83 2026-06-24 https://biopharmsignal.com/news/BNGO/bionano-announces-hiring-of-chief-scientific-officer-8e8bfe70 2026-06-24 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-and-arrotex-pharmaceuticals-announce-exclusive-license-and-com-069a15c4 2026-06-24 https://biopharmsignal.com/news/AIM/aim-immunotech-accelerates-toward-potential-pivotal-pancreatic-cancer-program-as-798127a2 2026-06-24 https://biopharmsignal.com/news/GSK/gsk-announces-commencement-of-tender-offer-to-acquire-nuvalent-inc-67201c53 2026-06-24 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-aligns-on-key-aspects-of-pivotal-study-for-zervimesine-ct-28fb1908 2026-06-24 https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-1-study-to-evaluate-novel-amyl-743d8a79 2026-06-24 https://biopharmsignal.com/news/ABSI/absci-announces-pricing-of-100-million-underwritten-offering-with-leading-strate-23f03cff 2026-06-24 https://biopharmsignal.com/news/ABSI/absci-announces-positive-interim-phase-1-data-from-the-headline-trial-of-abs-201-efe7a211 2026-06-24 https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-announces-pricing-of-upsized-200-million-public-offe-ee7b4228 2026-06-24 https://biopharmsignal.com/news/SERA/sera-applauds-illinois-initiative-to-expand-medicaid-coverage-for-proteomic-bloo-969662d4 2026-06-23 https://biopharmsignal.com/news/CHRS/coherus-and-zumutor-biologics-announce-clinical-collaboration-to-evaluate-zm008--1faecd28 2026-06-23 https://biopharmsignal.com/news/GNFT/genfit-positive-phase-1b-data-with-gns561-in-combination-therapy-in-heavily-pret-b018e66c 2026-06-23 https://biopharmsignal.com/news/JAGX/jaguar-health-completes-submission-of-new-animal-drug-application-for-full-fda-a-3e34cfd7 2026-06-23 https://biopharmsignal.com/news/MXCT/vectorbuilder-partners-with-maxcyte-to-advance-clinical-grade-cell-engineering-00dc0502 2026-06-23 https://biopharmsignal.com/news/MNKD/mannkind-awarded-breakthrough-t1d-grant-to-support-advancement-of-inhale-1st-ped-53177c79 2026-06-23 https://biopharmsignal.com/news/DRTS/alpha-tau-successfully-treats-first-recurrent-glioblastoma-patient-outside-of-th-72be30a9 2026-06-23 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-receives-fda-conditional-approval-of-qyleki-as-the-propose-52762b71 2026-06-23 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-first-patients-dosed-in-phase-2-trial-of-dm199--97b3dc71 2026-06-23 https://biopharmsignal.com/news/ICU/seastar-medical-announces-new-icd-10-pcs-codes-for-its-scd-therapy-for-acute-kid-ac132d55 2026-06-23 https://biopharmsignal.com/news/ICCM/icecure-highlights-new-peer-reviewed-journal-article-in-leading-surgery-journal--2af39cdd 2026-06-23 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-enters-into-asset-sale-agreements-with-lilly-and-astellas-bbbd2927 2026-06-23 https://biopharmsignal.com/news/IART/integra-lifesciences-announces-key-executive-appointments-f7e1cda6 2026-06-23 https://biopharmsignal.com/news/RVMD/revolution-medicines-begins-treating-patients-in-rasolute-305-a-phase-3-clinical-82b446eb 2026-06-23 https://biopharmsignal.com/news/IMNN/imunon-announces-data-monitoring-committee-recommends-continuation-of-phase-3-ov-dc87870c 2026-06-23 https://biopharmsignal.com/news/GALT/galectin-therapeutics-announces-positive-type-c-meeting-with-the-fda-for-belapec-a0feb2ff 2026-06-23 https://biopharmsignal.com/news/INMB/inmune-bio-receives-mhra-written-alignment-supporting-planned-2026-uk-conditiona-fec66d18 2026-06-23 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-completes-patient-enrollment-ahead-of-schedule-in-phase--929df80d 2026-06-23 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-announces-publication-of-positive-miplyffa-data-from-pediatri-1b3061b9 2026-06-23 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-appoints-ron-philip-to-board-of-directors-7373732c 2026-06-23 https://biopharmsignal.com/news/INSM/insmed-appoints-samuele-butera-as-senior-vice-president-general-manager-global-r-5bfb9a1f 2026-06-23 https://biopharmsignal.com/news/BDX/bd-awarded-vizient-innovative-technology-contract-for-centrovena-one-insertion-s-a27e1c7c 2026-06-23 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-partner-abbvie-receives-european-commission-approval-of-m-5130ab2a 2026-06-23 https://biopharmsignal.com/news/ARGX/argenx-to-host-autoimmune-myositis-r-d-webinar-30608012 2026-06-23 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-participation-in-upcoming-investor-conference-and--e1573657 2026-06-23 https://biopharmsignal.com/news/MGNX/macrogenics-to-receive-milestone-payment-from-sanofi-for-recent-tzield-approval-201de8b5 2026-06-22 https://biopharmsignal.com/news/HUM/humana-inc-to-release-second-quarter-2026-results-on-july-29-2026-10d8b923 2026-06-22 https://biopharmsignal.com/news/VTAK/flyte-partners-with-gse-worldwide-and-pga-tour-professional-emiliano-grillo-debu-c329a37a 2026-06-22 https://biopharmsignal.com/news/IMNN/imunon-to-present-at-the-life-sciences-investor-forum-on-june-25th-0e776a96 2026-06-22 https://biopharmsignal.com/news/DYN/dyne-therapeutics-appoints-barry-greene-to-board-of-directors-2945a376 2026-06-22 https://biopharmsignal.com/news/TNGX/tango-therapeutics-appoints-robert-azelby-to-board-of-directors-5950b38e 2026-06-22 https://biopharmsignal.com/news/VANI/vivani-medical-ceo-adam-mendelsohn-to-present-at-the-2026-bio-international-conv-1c65f673 2026-06-22 https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-announces-proposed-public-offering-9f72be6d 2026-06-22 https://biopharmsignal.com/news/XAIR/beyond-air-schedules-fiscal-year-end-2026-financial-results-conference-call-and--03178c17 2026-06-22 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-receives-marketing-authorization-in-the-european-union-84b496ff 2026-06-22 https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-holdings-valued-at-approximately-1-14-bil-d4fb3d5a 2026-06-22 https://biopharmsignal.com/news/JAGX/jaguar-health-announces-plan-to-explore-strategic-alternatives-aligned-with-targ-61f860e8 2026-06-22 https://biopharmsignal.com/news/NRSN/everythingals-to-host-neurosense-in-a-community-event-named-primec-connecting-th-d3cba239 2026-06-22 https://biopharmsignal.com/news/AIM/aim-immunotech-to-present-in-the-webull-corporate-connect-webinar-series-f9839594 2026-06-22 https://biopharmsignal.com/news/ICU/seastar-medical-to-present-at-upcoming-investor-summit-conference-599d1254 2026-06-22 https://biopharmsignal.com/news/ENTX/entera-bio-receives-positive-fda-feedback-on-12-month-registrational-phase-3-stu-2dde7917 2026-06-22 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-and-streeterville-extend-timeframe-of-strategic-financing-agr-76425cab 2026-06-22 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-receives-complete-response-letter-from-fda-for-cytisinicli-673c44de 2026-06-22 https://biopharmsignal.com/news/HYPR/hyperfine-forms-global-neurosurgery-advisory-council-to-support-expansion-of-por-cc32f725 2026-06-22 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-in-the-second-pivotal--f2e2423b 2026-06-22 https://biopharmsignal.com/news/PRME/prime-medicine-receives-u-s-fda-regenerative-medicine-advanced-therapy-rmat-desi-fca769a6 2026-06-22 https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-planned-leadership-transition-for-steve-kelsey-m--1540cbdf 2026-06-22 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-completion-of-dosing-in-reveal-pivotal-trial-and-251737f9 2026-06-22 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-receives-fda-breakthrough-therapy-designation-for-els-3a72d004 2026-06-22 https://biopharmsignal.com/news/EXEL/exelixis-provides-update-on-the-phase-3-stellar-303-trial-evaluating-zanzalintin-de926b13 2026-06-22 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-appoints-ritesh-srivastava-as-chief-legal-and-compliance-of-eb83a070 2026-06-22 https://biopharmsignal.com/news/VTAK/catheter-precision-inc-announces-allowance-of-key-intellectual-property-016e7009 2026-06-22 https://biopharmsignal.com/news/SRRK/scholar-rock-to-showcase-neuromuscular-research-portfolio-at-2026-annual-cure-sm-c0fc71a6 2026-06-22 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-positive-preclinical-findings-showing-proprieta-c62b401e 2026-06-22 https://biopharmsignal.com/news/BBIO/bridgebio-to-present-primary-results-from-phase-3-propel-3-trial-of-oral-infigra-69b73c11 2026-06-22 https://biopharmsignal.com/news/SEER/seer-and-korea-university-present-preliminary-data-at-asms-2026-demonstrating-po-c0fb0439 2026-06-22 https://biopharmsignal.com/news/REGN/cemdisiran-regulatory-submissions-accepted-for-review-by-fda-and-ema-for-the-tre-c71f8f44 2026-06-22 https://biopharmsignal.com/news/ELDN/eledon-presents-long-term-extension-phase-2-bestow-results-at-american-transplan-761f9216 2026-06-22 https://biopharmsignal.com/news/ADXN/addex-therapeutics-to-report-2026-first-quarter-financial-results-and-host-confe-561a3fbc 2026-06-22 https://biopharmsignal.com/news/MLTX/moonlake-announces-week-52-results-of-sonelokimab-from-its-phase-3-vela-program--404e4fd3 2026-06-21 https://biopharmsignal.com/news/ENSG/the-ensign-group-inc-declares-quarterly-dividend-of-0-0650-per-share-0f946fe9 2026-06-19 https://biopharmsignal.com/news/TEVA/teva-releases-q2-2026-aide-memoire-6629f681 2026-06-18 https://biopharmsignal.com/news/TEVA/teva-submits-nda-for-ecopipam-a-first-in-class-investigational-therapy-for-pedia-c6b1f13a 2026-06-18 https://biopharmsignal.com/news/TEVA/teva-to-host-conference-call-to-discuss-second-quarter-2026-financial-results-on-1d81af9d 2026-06-18 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-announces-closing-of-3-2-million-offering-d0a98ce9 2026-06-18 https://biopharmsignal.com/news/GRI/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathi-36c7f058 2026-06-18 https://biopharmsignal.com/news/LGVN/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-a-7acdaf6c 2026-06-18 https://biopharmsignal.com/news/AIM/aim-immunotech-achieves-clinical-milestone-as-final-subject-receives-first-dose--531a8f40 2026-06-18 https://biopharmsignal.com/news/JAGX/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health--92e11b1e 2026-06-18 https://biopharmsignal.com/news/DGX/uti-causing-bacteria-resistant-to-current-drugs-finds-national-study-by-hackensa-7470e6b9 2026-06-18 https://biopharmsignal.com/news/RCEL/avita-medical-highlights-first-u-k-clinical-experience-with-recell-go-at-british-188835be 2026-06-18 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-completes-establishment-of-japanese-subsidiary-to-advance--cbcbe641 2026-06-18 https://biopharmsignal.com/news/MKT/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomer-d8f512f9 2026-06-18 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-provides-update-on-nomad-acquisition-transaction-expected-to-6b4749f0 2026-06-18 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-strengthens-leadership-with-appointment-of-healthcare-e-e42cdec1 2026-06-18 https://biopharmsignal.com/news/HYPR/hyperfine-swoop-system-scan-volume-in-the-united-states-hits-record-milestones-a-388aa4d6 2026-06-18 https://biopharmsignal.com/news/PRME/prime-medicine-announces-new-zealand-clearance-of-clinical-trial-application-for-1ccaaa92 2026-06-18 https://biopharmsignal.com/news/INVA/nortiva-bio-launches-to-develop-long-acting-oral-medicines-fa8b8b55 2026-06-18 https://biopharmsignal.com/news/CRL/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-f5af9c6a 2026-06-18 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-to-present-trial-in-progress-poster-on-phase-2-stenoparib--3d7c3404 2026-06-18 https://biopharmsignal.com/news/BCDA/biocardia-letter-to-stockholders-on-2026-priorities-and-strategic-opportunities-187b0df4 2026-06-18 https://biopharmsignal.com/news/DNLI/denali-therapeutics-enters-agreement-to-sell-rare-pediatric-disease-priority-rev-0e62f7af 2026-06-18 https://biopharmsignal.com/news/BNGO/bionano-announces-67-year-over-year-growth-in-studies-featuring-optical-genome-m-7d9e22b4 2026-06-18 https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-2026-fiscal-year-end-financial-results-provides-bus-86a698f4 2026-06-18 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-host-a-webinar-on-its-cardiometabolic-pipeline-as-p-23e46e93 2026-06-18 https://biopharmsignal.com/news/TMCI/treace-announces-first-surgical-case-with-the-hyperplate-xm-dynamic-compression--59d08381 2026-06-18 https://biopharmsignal.com/news/BEAM/beam-therapeutics-announces-clearance-of-investigational-new-drug-application-fo-e796a8e2 2026-06-18 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-announces-advancement-of-its-zelicapavir-clinical-develop-bcf5354e 2026-06-18 https://biopharmsignal.com/news/NEPH/nephros-to-host-virtual-investor-event-beyond-filtration-the-nephros-model-in-ac-6be1cdda 2026-06-18 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-highlights-the-importance-of-brain-health-during-alzheimer-s-bc410f7e 2026-06-18 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-its-ion-channel-modulator-kio-300-suppressed-seizu-6aa93b6c 2026-06-18 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-second-quarter-2026-on-july-30-2026-e7e58681 2026-06-18 https://biopharmsignal.com/news/ALVO/alvotech-announces-closing-of-public-offering-and-full-exercise-by-underwriters--e62559dc 2026-06-18 https://biopharmsignal.com/news/ALVO/hlutafj-r-tbo-i-alvotech-bandar-kjunum-loki-og-umsj-nara-ilar-n-ttu-s-r-a-fullu--e06378af 2026-06-18 https://biopharmsignal.com/news/LEGN/legend-biotech-corporation-announces-pricing-of-public-offering-c0ab1d0b 2026-06-18 https://biopharmsignal.com/news/BIIB/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inc-83b60b54 2026-06-17 https://biopharmsignal.com/news/CERT/certara-announces-cfo-transition-efe8507b 2026-06-17 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-2099927f 2026-06-17 https://biopharmsignal.com/news/BDRX/postponement-and-re-scheduling-of-annual-general-meeting-deab90e5 2026-06-17 https://biopharmsignal.com/news/LEGN/legend-biotech-corporation-announces-proposed-public-offering-3615b70e 2026-06-17 https://biopharmsignal.com/news/CORT/corcept-resubmits-new-drug-application-for-relacorilant-as-a-treatment-for-patie-aa5e76db 2026-06-17 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-dividend-f5175d84 2026-06-17 https://biopharmsignal.com/news/ALKS/alkermes-presents-detailed-positive-results-from-vibrance-2-phase-2-study-of-ali-2543cd92 2026-06-17 https://biopharmsignal.com/news/SPRO/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary--f04b5246 2026-06-17 https://biopharmsignal.com/news/ICCM/icecure-announces-pricing-of-5-5-million-private-placement-priced-at-a-premium-t-b922b2c5 2026-06-17 https://biopharmsignal.com/news/GSK/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary--23a9b29e 2026-06-17 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-announces-pricing-of-3-2-million-offering-1649014b 2026-06-17 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-investor-day-to-highlight-u-s-fda-alignment-on-axpaxli-nda-wi-72a30a89 2026-06-17 https://biopharmsignal.com/news/ANGO/angiodynamics-receives-fda-ide-approval-for-relief-feasibility-study-evaluating--d19f649d 2026-06-17 https://biopharmsignal.com/news/ICCM/icecure-reports-70-growth-in-active-u-s-commercial-install-base-for-breast-cance-66477381 2026-06-17 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-reports-multiple-complete-responses-after-eli-002-7p-treatme-921744fd 2026-06-17 https://biopharmsignal.com/news/ECOR/electrocore-to-participate-in-iaccess-alpha-virtual-best-ideas-summer-investment-07437969 2026-06-17 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-expanded-debt-facility-of-up-to-400-million-with-her-da75d1fb 2026-06-17 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-corporation-prices-upsized-300-million-convertible-seni-92356ee8 2026-06-17 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-yujiro-s-hata-elected-chairman-of-its-board-of-dire-49a534d1 2026-06-17 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-to-report-second-quarter-2026-financial-results-on-july-22--c41eebc2 2026-06-16 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2026-financial-res-04e8ed16 2026-06-16 https://biopharmsignal.com/news/HCAT/health-catalyst-to-participate-in-upcoming-investor-conference-70ce0f58 2026-06-16 https://biopharmsignal.com/news/RIGL/rigel-announces-closing-of-licensing-agreement-for-veppanu-vepdegestrant-31709183 2026-06-16 https://biopharmsignal.com/news/YOU/clear-launches-at-indianapolis-international-airport-e04b0732 2026-06-16 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-secures-new-u-s-patent-protecting-commercial-manufacturing-of-006020e4 2026-06-16 https://biopharmsignal.com/news/ENTX/entera-reports-robust-preclinical-data-for-eb612-oral-la-pth-1-34-for-hypoparath-8299fc88 2026-06-16 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-initiates-clinical-study-supporting-fda-clearance-and--36ea2bdd 2026-06-16 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-announces-positive-clinical-update-from-ongoing-pediatric--1dca0871 2026-06-16 https://biopharmsignal.com/news/DMAC/diamedica-receives-fda-feedback-on-dm199-preeclampsia-nonclinical-program-34bd4bf5 2026-06-16 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-announces-program-to-advance-veteran-lung-health-philip-eac5a36d 2026-06-16 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-fda-acceptance-of-resubmitted-biologics-license-a-5b01e9f0 2026-06-16 https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-announces-distribution-and-licensing-agreement-w-72aeec01 2026-06-16 https://biopharmsignal.com/news/CING/cingulate-issued-first-u-s-patent-for-lead-adhd-asset-ctx-1301-15332cda 2026-06-16 https://biopharmsignal.com/news/VXRT/vaxart-s-two-newest-independent-directors-james-breitmeyer-m-d-ph-d-and-kevin-fi-c15307a2 2026-06-16 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-announces-new-composition-of-matter-patent-extending-pate-502b8861 2026-06-16 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-announces-nomination-of-two-enhanced-brain-delivery-ebd-d-d74b8122 2026-06-16 https://biopharmsignal.com/news/USNA/usana-celebrates-10-years-of-making-the-world-a-better-place-during-world-servic-f04545e5 2026-06-16 https://biopharmsignal.com/news/NEPH/nephros-positions-ultrafiltration-technology-as-a-solution-to-emerging-microplas-60dc48d7 2026-06-16 https://biopharmsignal.com/news/HCWB/hcw-biologics-announces-positive-results-for-preliminary-human-data-readout-for--d173c93d 2026-06-16 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-amendments-to-clinical-study-protocol-for-phase--66feaf01 2026-06-16 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-expands-pipeline-with-avtx-010-a-long-acting-next-generation--527ab39d 2026-06-16 https://biopharmsignal.com/news/EMBC/embecta-appoints-nimish-muzumdar-as-svp-and-president-north-america-07ce387f 2026-06-16 https://biopharmsignal.com/news/ALVO/alvotech-announces-pricing-of-152-million-public-offering-of-ordinary-shares-and-93e13d1e 2026-06-16 https://biopharmsignal.com/news/ALVO/alvotech-tilkynnir-um-ver-og-thlutun-hlutabr-fa-a-andvir-i-um-152-millj-nir-doll-617f05a3 2026-06-16 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-announces-pricing-of-convertible-notes-offering-to-refinance-20-5fd25e00 2026-06-16 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-closing-of-upsized-public-offering-of-common-stoc-18f4fdad 2026-06-15 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-announces-plan-to-separate-its-mrd-and-immune-medicine--ef270574 2026-06-15 https://biopharmsignal.com/news/NBIX/soleno-therapeutics-presents-new-vykat-xr-diazoxide-choline-data-at-endo-2026-de-957f2080 2026-06-15 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-corporation-announces-proposed-convertible-senior-notes-783f611f 2026-06-15 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-first-retrospective-case-series-of-crenessity-cr-43411fd1 2026-06-15 https://biopharmsignal.com/news/ENSG/the-ensign-group-inc-announces-increased-stock-repurchase-authorization-63cb7613 2026-06-15 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-multiple-new-data-presentations-from-mc4r-agoni-35805771 2026-06-15 https://biopharmsignal.com/news/ALVO/alvotech-efnir-til-tbo-s-hlutabr-fum-bandar-kjunum-a-andvir-i-125-millj-nir-doll-43ee2f81 2026-06-15 https://biopharmsignal.com/news/ALVO/alvotech-announces-proposed-125-million-public-offering-and-concurrent-private-p-2b3eb96f 2026-06-15 https://biopharmsignal.com/news/GNFT/genfit-june-15-2026-combined-shareholders-meeting-results-d07ad996 2026-06-15 https://biopharmsignal.com/news/INBX/inhibrx-announces-u-s-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conve-d0380d86 2026-06-15 https://biopharmsignal.com/news/ENLV/enlivex-announces-issuance-of-australian-patent-covering-the-use-of-allocetra-84-ef9a7b08 2026-06-15 https://biopharmsignal.com/news/ENTX/endo-2026-oral-presentation-highlights-comparative-clinical-data-for-entera-s-br-849d555e 2026-06-15 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demons-7b58b0b2 2026-06-15 https://biopharmsignal.com/news/IART/integra-lifesciences-to-present-at-the-2026-truist-securities-medtech-conference-aaefd7ef 2026-06-15 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demons-7a58af1f 2026-06-15 https://biopharmsignal.com/news/FATE/fate-therapeutics-appoints-laura-hamill-to-board-of-directors-d47c62a6 2026-06-15 https://biopharmsignal.com/news/AIM/aim-immunotech-regains-nyse-american-compliance-company-resolves-stockholder-equ-179f9283 2026-06-15 https://biopharmsignal.com/news/HUMA/humacyte-s-bioengineered-blood-vessel-outperforms-the-standard-of-care-for-women-b5163c36 2026-06-15 https://biopharmsignal.com/news/SYRE/spyre-announces-potential-best-in-class-spy002-anti-tl1a-part-a-induction-result-8bf3759a 2026-06-15 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-reports-data-from-phase-3-koastal-program-and-provides-busi-ef08b010 2026-06-15 https://biopharmsignal.com/news/VXRT/vaxart-to-showcase-oral-vaccine-platform-and-strategic-vision-at-bio-2026-and-ta-50053d80 2026-06-15 https://biopharmsignal.com/news/GRFS/grifols-launches-fesilty-fibrinogen-human-chmt-in-the-u-s-90d9c01c 2026-06-15 https://biopharmsignal.com/news/LEGN/legend-biotech-establishes-clinical-proof-of-concept-for-lb2501-a-potential-firs-fb89efa6 2026-06-15 https://biopharmsignal.com/news/BRLI/preclinical-data-for-opko-biologics-opk8801001-in-acromegaly-presented-at-endo-2-5e19f000 2026-06-15 https://biopharmsignal.com/news/IMRX/immuneering-appoints-andrew-gengos-as-chief-financial-officer-715e6b21 2026-06-15 https://biopharmsignal.com/news/APTO/aptose-presents-safety-response-and-mrd-clinical-data-from-tuscany-phase-1-2-cli-65fa124b 2026-06-15 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-exhibit-at-children-s-tumor-foundation-2026-nf-c-c12a7718 2026-06-15 https://biopharmsignal.com/news/SEER/seer-board-of-directors-issues-letter-to-shareholders-highlighting-the-company-s-7fdebe86 2026-06-15 https://biopharmsignal.com/news/ALKS/alkermes-announces-orphan-drug-designations-for-alixorexton-in-the-u-s-and-europ-2489558f 2026-06-15 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-announces-proposed-convertible-notes-offering-to-refinance-2026-14ae6d2e 2026-06-15 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-reports-results-from-phase-2-amplify-7p-study-and-outlines-r-fe5d45e1 2026-06-15 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-presents-new-data-highlighting-its-innovative-sleep-medicine-f9bcb2c7 2026-06-15 https://biopharmsignal.com/news/PHVS/data-supporting-differentiated-profile-of-deucrictibant-in-hae-management-presen-1a36672e 2026-06-15 https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-positive-interim-efficacy-and-safety-results-from-c45e8d77 2026-06-15 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-563-91e85c01 2026-06-15 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-ide892-a-potential-best-in-class-mta-cooperative-pr-8351a4df 2026-06-15 https://biopharmsignal.com/news/CRNX/crinetics-presents-full-results-from-phase-2-trial-of-atumelnant-in-congenital-a-c1c2be50 2026-06-14 https://biopharmsignal.com/news/CRNX/crinetics-presents-long-term-data-at-endo-2026-confirming-palsonify-paltusotine--eaa37cc2 2026-06-14 https://biopharmsignal.com/news/CLDX/celldex-presents-long-term-barzolvolimab-results-demonstrating-sustained-off-tre-61dd564d 2026-06-14 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-presents-late-breaking-data-on-lorundrostat-and-heart-fai-35eaa6f1 2026-06-14 https://biopharmsignal.com/news/CLDX/celldex-presents-positive-first-in-human-results-from-phase-1-study-of-novel-bis-b70274b7 2026-06-14 https://biopharmsignal.com/news/ASND/phase-3-data-show-transcon-pth-replicated-systemic-actions-of-endogenous-pth-thr-c45e7bfc 2026-06-13 https://biopharmsignal.com/news/AGIO/agios-showcases-rise-up-phase-3-results-at-eha-2026-plenary-session-reinforcing--2ee47a9d 2026-06-13 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-presents-positive-interim-six-month-data-from-phase-2-tri-76fc9023 2026-06-13 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-additional-positive-phase-3-results-for-lonvoguran-d89fa3fd 2026-06-13 https://biopharmsignal.com/news/BLTE/belite-bio-completes-rolling-submission-of-new-drug-application-to-u-s-food-and--156ed1a0 2026-06-13 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grant-db6e062d 2026-06-12 https://biopharmsignal.com/news/XOMA/xoma-royalty-corporation-declares-quarterly-preferred-stock-dividend-and-announc-b8285e5a 2026-06-12 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-to-announce-interim-six-month-phase-2-results-evaluating--d85fc623 2026-06-12 https://biopharmsignal.com/news/IVA/inventiva-annonce-le-remboursement-des-pr-ts-bei-le-rachat-d-une-partie-des-bsa--76c5faf3 2026-06-12 https://biopharmsignal.com/news/IVA/inventiva-announces-repayment-of-eib-loans-repurchase-of-a-portion-of-eib-warran-20fe087f 2026-06-12 https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-changes-to-its-board-of-directors-7faed22a 2026-06-12 https://biopharmsignal.com/news/PRPO/precipio-is-requesting-shareholders-brokers-vote-today-to-avoid-costly-adjournme-a1496f3a 2026-06-12 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-presents-updated-safety-data-and-translational-insights-for-r-248fa339 2026-06-12 https://biopharmsignal.com/news/JAGX/jaguar-health-presenting-june-24-2026-at-the-life-sciences-virtual-investor-foru-11b80baf 2026-06-12 https://biopharmsignal.com/news/IRON/disc-medicine-presents-positive-clinical-updates-at-the-2026-european-hematology-3a623f7d 2026-06-12 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-to-acquire-nomad-transportable-power-systems-the-market-lead-137709e4 2026-06-12 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-preclinical-data-from-novel-jak2-v617f-inhibitor-at-915c4be5 2026-06-12 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-detailed-data-from-apex-pivotal-trial-of-bezuclasti-cffdc7b4 2026-06-12 https://biopharmsignal.com/news/GSK/gsk-s-momelotinib-granted-orphan-drug-designations-in-the-us-and-eu-for-vexas-sy-c6603aa7 2026-06-12 https://biopharmsignal.com/news/BCRX/biocryst-presents-new-clinical-data-and-real-world-evidence-demonstrating-impact-0fbfa230 2026-06-12 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-closing-of-sale-of-rare-pediatric-disease-prior-34401501 2026-06-12 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-presents-phase-1-data-in-healthy-japanese-adults-for-kt-621--a0403465 2026-06-12 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-receives-prix-galien-uk-award-395b0660 2026-06-12 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stoc-f72b0424 2026-06-12 https://biopharmsignal.com/news/HCM/hutchmed-highlights-sovleplenib-eslim-02-phase-iii-data-in-warm-antibody-autoimm-110d8144 2026-06-12 https://biopharmsignal.com/news/PRPO/precipio-to-present-at-the-planet-microcap-las-vegas-03ee4335 2026-06-11 https://biopharmsignal.com/news/XERS/xeris-biopharma-announces-notice-of-allowance-from-u-s-patent-and-trademark-offi-deb8c436 2026-06-11 https://biopharmsignal.com/news/TMCI/treace-to-present-at-the-sidoti-small-cap-conference-885cf5b0 2026-06-11 https://biopharmsignal.com/news/AZYO/elutia-to-present-at-planet-microcap-showcase-2026-on-june-17th-52191312 2026-06-11 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre--4c0b4cdc 2026-06-11 https://biopharmsignal.com/news/VYGR/voyager-to-present-at-h-c-wainwright-7th-annual-neuro-perspectives-hybrid-confer-3d59c3bb 2026-06-11 https://biopharmsignal.com/news/ASND/5-year-phase-2-data-show-transcon-pth-replicated-systemic-actions-of-endogenous--57728427 2026-06-11 https://biopharmsignal.com/news/PRI/survey-reveals-85-of-canadians-trust-professional-financial-advice-over-social-m-49637e88 2026-06-11 https://biopharmsignal.com/news/NRSN/neurosense-granted-south-korean-patent-covering-primec-composition-for-als-9f9ebf0f 2026-06-11 https://biopharmsignal.com/news/KALV/chiesi-group-completes-acquisition-of-kalvista-pharmaceuticals-e7f7e66b 2026-06-11 https://biopharmsignal.com/news/LQDA/liquidia-announces-poster-presentations-at-the-pha-2026-international-ph-confere-bceb1ac6 2026-06-11 https://biopharmsignal.com/news/DRTS/alpha-tau-receives-fda-clearance-to-complete-enrollment-in-regain-recurrent-glio-3c500481 2026-06-11 https://biopharmsignal.com/news/ZVRA/zevra-s-chief-medical-officer-to-step-down-for-personal-reasons-as-part-of-plann-23754929 2026-06-11 https://biopharmsignal.com/news/HSCS/european-patent-granted-for-ecg-based-assessment-of-diastolic-function-expands-h-e7b16789 2026-06-11 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-intent-to-file-a-registration-statement-for-a-propo-e20065b2 2026-06-11 https://biopharmsignal.com/news/XRAY/dentsply-sirona-appoints-john-fortson-as-chief-financial-officer-fc7266be 2026-06-11 https://biopharmsignal.com/news/RNXT/renovorx-highlights-peer-reviewed-publication-supporting-intra-arterial-gemcitab-165aa510 2026-06-11 https://biopharmsignal.com/news/HRMY/harmony-biosciences-announces-poster-presentations-at-2026-sleep-annual-meeting-fe33047a 2026-06-11 https://biopharmsignal.com/news/KURA/kura-oncology-and-kyowa-kirin-report-encouraging-long-term-results-for-ziftomeni-e78c0c0a 2026-06-11 https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-long-term-vispa-cel-data-in-second-line-large-b-cell-167f9970 2026-06-11 https://biopharmsignal.com/news/OSUR/orasure-technologies-inc-announces-fda-clearance-that-expands-patient-friendly-a-af042dfa 2026-06-11 https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-dose-escalation-durability-data-for-cb-011-at-the-20-12c09675 2026-06-11 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-updated-positive-phase-1-clinical-data-and-alignm-72798101 2026-06-11 https://biopharmsignal.com/news/VTAK/flyte-expands-strategic-relationship-with-volato-by-joining-vaunt-platform-037e2889 2026-06-11 https://biopharmsignal.com/news/BNGO/bionano-announces-multiple-publications-in-2026-describing-unique-utility-of-ogm-3d3adb94 2026-06-11 https://biopharmsignal.com/news/IMRX/immuneering-announces-first-patient-dosed-in-pivotal-phase-3-mapkeeper-301-trial-6d0c3831 2026-06-11 https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-appointment-of-hubert-c-chen-m-d-as-chief-medical--ca51f016 2026-06-11 https://biopharmsignal.com/news/SNDX/syndax-showcases-revuforj-revumenib-clinical-activity-in-multiple-acute-leukemia-f498202f 2026-06-11 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-report-updated-phase-1a-b-results-for-btk-degrader-bexobru-e82ed85b 2026-06-11 https://biopharmsignal.com/news/MDNA/medicenna-strengthens-u-s-patent-estate-with-newly-issued-and-allowed-patents-ac-c3f9e8a7 2026-06-11 https://biopharmsignal.com/news/XERS/xeris-biopharma-announces-private-exchange-of-convertible-notes-6f62b17c 2026-06-11 https://biopharmsignal.com/news/SNDX/syndax-announces-publication-of-save-data-on-revuforj-revumenib-in-combination-w-271b6070 2026-06-11 https://biopharmsignal.com/news/PPBT/purple-biotech-presents-new-preclinical-data-at-eacr-2026-highlighting-im1240-s--ae5734d7 2026-06-11 https://biopharmsignal.com/news/CCCC/c4-therapeutics-presents-phase-1-data-at-european-hematology-association-eha-202-2551b658 2026-06-11 https://biopharmsignal.com/news/ACIU/ac-immune-to-receive-research-grant-from-goradia-family-for-development-of-aci-7-f87fb9a8 2026-06-11 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-cns-drug-development-veteran-michael-quirk-as-seni-41648713 2026-06-11 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-to-attend-btig-infectious-disease-day-2026-f9bab1aa 2026-06-11 https://biopharmsignal.com/news/PHVS/pharvaris-announces-annual-general-meeting-of-shareholders-d8f6d597 2026-06-11 https://biopharmsignal.com/news/OCS/oculis-to-present-privosegtor-at-upcoming-clinical-trials-at-the-summit-2026-9d523d72 2026-06-11 https://biopharmsignal.com/news/CLLS/cellectis-presents-final-phase-1-results-of-lasme-cel-and-preliminary-results-on-ea9f9ebc 2026-06-11 https://biopharmsignal.com/news/HUMA/humacyte-inc-announces-pricing-of-public-offering-of-common-stock-9cecd8f3 2026-06-11 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-announces-inducement-grant-under-nasdaq-listing-rule-5635-326cd74a 2026-06-10 https://biopharmsignal.com/news/FENC/fennec-announces-results-of-annual-meeting-1c0b3630 2026-06-10 https://biopharmsignal.com/news/HUM/humana-announces-agreement-to-divest-minority-interest-in-gentiva-8c639230 2026-06-10 https://biopharmsignal.com/news/MOH/molina-healthcare-wins-illinois-medicaid-contract-f1325608 2026-06-10 https://biopharmsignal.com/news/AEMD/aethlon-medical-announces-fiscal-year-end-march-31-2026-financial-results-and-co-7600574b 2026-06-10 https://biopharmsignal.com/news/AORT/artivion-to-participate-in-the-2026-truist-securities-medtech-conference-e00c2184 2026-06-10 https://biopharmsignal.com/news/BSEM/biostem-technologies-to-present-at-the-planet-microcap-las-vegas-2026-conference-c4d6e13c 2026-06-10 https://biopharmsignal.com/news/IDYA/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwrit-b9bc3239 2026-06-10 https://biopharmsignal.com/news/HUMA/humacyte-inc-announces-proposed-public-offering-of-common-stock-1947e97c 2026-06-10 https://biopharmsignal.com/news/HUMA/humacyte-atev-met-superiority-primary-endpoint-compared-to-standard-of-care-av-f-65b1d338 2026-06-10 https://biopharmsignal.com/news/XCUR/exicure-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-7d2e1517 2026-06-10 https://biopharmsignal.com/news/CLDX/celldex-announces-multiple-upcoming-presentations-from-leading-mast-cell-targeti-2a9c11f3 2026-06-10 https://biopharmsignal.com/news/PRTC/results-of-annual-general-meeting-3242a586 2026-06-10 https://biopharmsignal.com/news/TEVA/teva-closes-acquisition-of-emalex-biosciences-strengthening-late-stage-neuroscie-725672fb 2026-06-10 https://biopharmsignal.com/news/MKT/maia-biotechnology-activates-and-opens-enrollment-at-second-u-s-clinical-site-fo-6dac7639 2026-06-10 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-key-collaboration-agreement-with-multi-location-flo-8a573b10 2026-06-10 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-announces-commencement-of-tender-offer-by-kuva-labs-inc-8ed38f12 2026-06-10 https://biopharmsignal.com/news/IXHL/incannex-receives-a-6-0-million-r-d-tax-incentive-refund-for-fy25-further-streng-c634fd54 2026-06-10 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-strengthens-vafseo-vadadustat-patent-portfolio-17cb62c9 2026-06-10 https://biopharmsignal.com/news/SENS/senseonics-and-welldoc-partner-to-develop-next-generation-app-for-eversense-365-6acf0328 2026-06-10 https://biopharmsignal.com/news/XAIR/beyond-air-inc-urges-stockholders-to-vote-for-all-proposals-ahead-of-the-upcomin-31020f6e 2026-06-10 https://biopharmsignal.com/news/ARTL/artelo-biosciences-presents-art26-12-human-metabolite-data-demonstrating-favorab-8e442b13 2026-06-10 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-shares-new-clinical-data-across-its-portfolio-of-t-cell-en-1824446e 2026-06-10 https://biopharmsignal.com/news/PLSE/pulse-biosciences-inc-announces-planned-redemption-of-warrants-85138b2e 2026-06-10 https://biopharmsignal.com/news/ACON/aclarion-to-present-at-the-planet-microcap-las-vegas-powered-by-microcapclub-87cbf66e 2026-06-10 https://biopharmsignal.com/news/GANX/gain-therapeutics-to-present-at-h-c-wainwright-7th-annual-neuro-perspectives-exp-b322982c 2026-06-10 https://biopharmsignal.com/news/HROW/harrow-re-launches-verkazia-cyclosporine-ophthalmic-emulsion-0-1-for-vernal-kera-d7c7e3c9 2026-06-10 https://biopharmsignal.com/news/FMS/interwell-health-delivers-strong-quality-scores-and-shared-savings-in-cms-value--e2c55e86 2026-06-10 https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-pricing-of-75-million-public-offering-1147ed04 2026-06-10 https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-pricing-of-600-million-upsized-public-offering-2335552e 2026-06-10 https://biopharmsignal.com/news/PCRX/pacira-biosciences-announces-stockholders-have-elected-all-three-of-the-company--5de48c68 2026-06-09 https://biopharmsignal.com/news/CLLS/cellectis-receives-fda-rmat-designation-for-lasme-cel-the-first-allogeneic-car-t-629c5c17 2026-06-09 https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-proposed-public-offering-81c3c0e1 2026-06-09 https://biopharmsignal.com/news/IRIX/iridex-to-present-at-the-planet-microcap-las-vegas-2026-conference-3221318c 2026-06-09 https://biopharmsignal.com/news/IVA/assembl-e-g-n-rale-mixte-du-30-juin-2026-modalit-s-de-mise-disposition-des-docum-4fc94ffc 2026-06-09 https://biopharmsignal.com/news/IVA/combined-general-meeting-of-june-30-2026-availability-of-the-preparatory-documen-4c686402 2026-06-09 https://biopharmsignal.com/news/IVA/information-relative-au-nombre-total-de-droits-de-vote-et-d-actions-composant-le-0a72cf85 2026-06-09 https://biopharmsignal.com/news/IVA/statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital--1d9ce97c 2026-06-09 https://biopharmsignal.com/news/EHC/eastside-rehabilitation-hospital-now-open-in-georgia-cc955c09 2026-06-09 https://biopharmsignal.com/news/AIM/aim-immunotech-announces-2-65-million-financing-priced-at-market-under-nyse-amer-d6db12ff 2026-06-09 https://biopharmsignal.com/news/LGVN/longeveron-granted-small-or-medium-sized-enterprise-sme-status-by-the-european-m-25b20fb2 2026-06-09 https://biopharmsignal.com/news/AMN/amn-healthcare-acquires-jaide-health-to-expand-language-access-across-the-patien-ca9f1e96 2026-06-09 https://biopharmsignal.com/news/IRON/disc-medicine-provides-update-from-fda-type-a-meeting-for-bitopertin-in-erythrop-f5d339d3 2026-06-09 https://biopharmsignal.com/news/VCEL/vericel-to-present-at-the-2026-truist-securities-medtech-conference-on-tuesday-j-4259fa3f 2026-06-09 https://biopharmsignal.com/news/IXHL/incannex-announces-initiation-of-research-coverage-by-alliance-global-partners-cb80ca26 2026-06-09 https://biopharmsignal.com/news/VTAK/flyte-announces-world-cup-activation-strategy-targeting-global-travel-demand-sur-01636dd5 2026-06-09 https://biopharmsignal.com/news/ECOR/frontiers-in-neuroscience-accepts-review-article-synthesizing-evidence-that-cerv-90a5568d 2026-06-09 https://biopharmsignal.com/news/STTK/shattuck-labs-announces-exercise-of-outstanding-common-stock-warrants-and-provid-5897ec16 2026-06-09 https://biopharmsignal.com/news/VXRT/vaxart-to-participate-in-btig-infectious-disease-day-2026-65d0d8a3 2026-06-09 https://biopharmsignal.com/news/GSK/gsk-enters-agreement-to-acquire-nuvalent-inc-11ce8091 2026-06-09 https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-topline-phase-1-data-for-subcutaneous-briumvi-60f03f06 2026-06-09 https://biopharmsignal.com/news/CVRX/cvrx-announces-chief-financial-officer-transition-aaf1cf0d 2026-06-09 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-announces-additional-investment-in-angel-pharmaceuticals--ebda81bd 2026-06-09 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-achieves-alignment-with-u-s-fda-on-pivotal-phase-3-program-1ea42631 2026-06-09 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-announces-strategic-licensing-agreement-with-westgene-bio-c264bca3 2026-06-09 https://biopharmsignal.com/news/BSEM/biostem-technologies-announces-appointment-of-three-new-members-to-its-board-of--a0bd4547 2026-06-09 https://biopharmsignal.com/news/ACON/aclarion-partners-with-pria-healthcare-to-advance-reimbursement-and-commercial-a-730b08c0 2026-06-09 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-first-participant-dosed-in-phase-1-trial-of-oral-i-dfe3d7d4 2026-06-09 https://biopharmsignal.com/news/PSNL/personalis-enables-global-biopharma-support-with-ce-ivd-marked-specimen-collecti-076f8412 2026-06-09 https://biopharmsignal.com/news/OCS/oculis-announces-first-patient-randomized-in-predict-1-registrational-trial-of-l-559f59f1 2026-06-09 https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-reports-positive-multiple-ascending-7098585c 2026-06-09 https://biopharmsignal.com/news/ASND/ascendis-to-showcase-advances-in-treatment-of-rare-endocrine-diseases-at-endo-20-57c79a1c 2026-06-08 https://biopharmsignal.com/news/PRGO/perrigo-announces-leadership-transition-fef2604a 2026-06-08 https://biopharmsignal.com/news/JAGX/jaguar-health-reports-approval-of-all-proposals-at-2026-annual-meeting-of-stockh-15b299fa 2026-06-08 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-clinically-meaningful-response-data-on-treat-f17ae208 2026-06-08 https://biopharmsignal.com/news/IPSC/new-cnty-813-preclinical-data-demonstrate-durable-glucose-control-immune-evasion-e65eb4fc 2026-06-08 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-he-6027ff68 2026-06-08 https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-proposed-500-million-public-offering-e7a83d9c 2026-06-08 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-penny-carlson-as-senior-vice-president-development--ec9a44a3 2026-06-08 https://biopharmsignal.com/news/OCS/oculis-to-present-at-the-47th-annual-goldman-sachs-global-healthcare-conference-96a2cecb 2026-06-08 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-to-participate-in-the-small-cap-showcase-wtr-insights-on-june-ea30ba7e 2026-06-08 https://biopharmsignal.com/news/GNFT/genfit-nashnext-powered-by-genfit-s-non-invasive-diagnostic-technology-nis4-laun-bff6954d 2026-06-08 https://biopharmsignal.com/news/VTAK/flyte-vtak-makes-strategic-investment-in-volato-soar-3dcb84bc 2026-06-08 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-to-present-at-upcoming-investor-conferences-17e93e26 2026-06-08 https://biopharmsignal.com/news/AIM/aim-immunotech-reports-positive-mid-year-interim-clinical-progress-from-phase-2--75e762b5 2026-06-08 https://biopharmsignal.com/news/VOR/telitacicept-receives-nmpa-approval-for-the-treatment-of-sj-gren-s-disease-in-ch-185b18e7 2026-06-08 https://biopharmsignal.com/news/LQDA/liquidia-corporation-announces-inclusion-in-the-s-p-smallcap-600-index-9947f2fe 2026-06-08 https://biopharmsignal.com/news/CRMD/u-s-court-of-appeals-for-the-federal-circuit-affirms-victory-for-cormedix-therap-ae49f299 2026-06-08 https://biopharmsignal.com/news/VOR/telitacicept-receives-nmpa-conditional-approval-for-the-treatment-of-iga-nephrop-59acfea5 2026-06-08 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-announces-exploration-of-strategic-alternatives-to-maximize-5109c181 2026-06-08 https://biopharmsignal.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-use-of-mn-166-in-761464fe 2026-06-08 https://biopharmsignal.com/news/BCDA/biocardia-announces-4-4-million-financing-0937a2f3 2026-06-08 https://biopharmsignal.com/news/VXRT/vaxart-urges-shareholders-to-vote-for-all-six-of-the-company-s-highly-qualified--577eccb1 2026-06-08 https://biopharmsignal.com/news/TEVA/teva-s-data-on-austedo-deutetrabenazine-tablets-and-austedo-xr-deutetrabenazine--60e874b5 2026-06-08 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-announces-orange-book-listing-of-u-s-patent-strengthening-exc-8b37df19 2026-06-08 https://biopharmsignal.com/news/CYTK/cytokinetics-announces-call-for-proposals-for-annual-corporate-giving-program-d243df03 2026-06-08 https://biopharmsignal.com/news/SNGX/soligenix-applying-for-vaccine-development-funding-for-bundibugyo-ebola-vaccine-a724aab6 2026-06-08 https://biopharmsignal.com/news/ACON/aclarion-rejects-echo-lake-capital-s-unsolicited-acquisition-proposal-fc44ebdb 2026-06-08 https://biopharmsignal.com/news/ELDN/eledon-announces-updated-data-from-investigator-initiated-islet-transplant-trial-f9e63a60 2026-06-08 https://biopharmsignal.com/news/ACON/aclarion-stockholders-approve-all-proposals-at-2026-annual-meeting-8bdd67ee 2026-06-08 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-presents-new-preclinical-lupus-data-for-kt-579-first-in-clas-b973b897 2026-06-08 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-secures-second-commercial-payer-agreement-for-tonmya-expan-e1b63cc6 2026-06-08 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-present-late-breaking-data-on-lorundrostat-at-the-endo-03fb3c48 2026-06-08 https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-combination-of-vopimetostat-and-daraxonrasib-demons-4a741d4c 2026-06-08 https://biopharmsignal.com/news/BMY/mariska-hargitay-partners-with-bristol-myers-squibb-for-investigating-myeloma-aw-222e93ab 2026-06-08 https://biopharmsignal.com/news/USNA/usana-s-celavive-contouring-face-neck-cr-me-named-among-canada-s-top-skincare-pr-f27928e1 2026-06-08 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-re-56a2333e 2026-06-08 https://biopharmsignal.com/news/STTK/shattuck-labs-announces-phase-1-results-for-sl-325-e7f7caf7 2026-06-08 https://biopharmsignal.com/news/ALVO/alvotech-announces-fda-acceptance-of-biologics-license-application-for-avt16-a-p-a3f5f59c 2026-06-08 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-global-collaboration-with-roche-to-co-develop-and-c-adfb8149 2026-06-08 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-announces-everest-medicines-acquired-rights-to-develop-and-com-434c4009 2026-06-07 https://biopharmsignal.com/news/GOCO/gohealth-inc-to-strengthen-its-position-ahead-of-aep-2026-through-restructuring--56003736 2026-06-07 https://biopharmsignal.com/news/SENS/real-world-evidence-of-eversense-365-presented-at-ada-demonstrating-strong-perfo-37d528e7 2026-06-06 https://biopharmsignal.com/news/CORT/corcept-presents-new-data-at-ada-improved-outcomes-in-patients-receiving-a-glp-1-72aa9a5b 2026-06-06 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-t-ce-5c413068 2026-06-06 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-closing-of-up-to-23-7-million-private-placement-pr-08b77eb3 2026-06-06 https://biopharmsignal.com/news/MNKD/data-at-ada-2026-highlights-key-findings-from-clinical-and-real-world-studies-of-9a37ea00 2026-06-05 https://biopharmsignal.com/news/BMEA/biomea-fusion-presents-new-clinical-and-translational-data-for-icovamenib-at-the-82402558 2026-06-05 https://biopharmsignal.com/news/NBTX/information-mensuelle-relative-au-nombre-total-de-droits-de-vote-et-d-actions-co-7ae99676 2026-06-05 https://biopharmsignal.com/news/NBTX/voting-rights-and-shares-capital-of-the-company-e4d12ebe 2026-06-05 https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-publication-in-nature-medicine-highlighting-pha-725abfa4 2026-06-05 https://biopharmsignal.com/news/STTK/shattuck-labs-to-host-investor-call-and-webcast-on-phase-1-clinical-data-of-sl-3-d25fd1ba 2026-06-05 https://biopharmsignal.com/news/TEVA/teva-presents-new-data-on-austedo-deutetrabenazine-tablets-and-austedo-xr-deutet-781c95a4 2026-06-05 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-binding-agreement-for-senior-debt-to-equity-exchang-90f29f14 2026-06-05 https://biopharmsignal.com/news/MBRX/independent-market-research-finds-strong-physician-intent-to-prescribe-moleculin-e1baa7b5 2026-06-05 https://biopharmsignal.com/news/URGN/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-c57d219f 2026-06-05 https://biopharmsignal.com/news/BCDA/fda-confirms-cardiamp-hf-ii-may-support-premarket-approval-of-cardiamp-cell-ther-336b7f77 2026-06-05 https://biopharmsignal.com/news/AMRX/amneal-announces-full-study-population-interim-phase-4-elevate-pd-results-reinfo-5b3b907f 2026-06-05 https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--1bc9926f 2026-06-05 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-heal-33b89134 2026-06-05 https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-two-transactions-to-strengthen-balance-sheet-reduce-c0cf0416 2026-06-05 https://biopharmsignal.com/news/ADXN/addex-convenes-annual-general-meeting-2026-d5a3fe38 2026-06-05 https://biopharmsignal.com/news/TPST/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph-to-board-of-direc-c635ea3d 2026-06-04 https://biopharmsignal.com/news/ELDN/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet--7d835714 2026-06-04 https://biopharmsignal.com/news/PCRX/pacira-biosciences-reminds-stockholders-to-vote-the-blue-proxy-card-for-the-elec-0beb752f 2026-06-04 https://biopharmsignal.com/news/COO/coopercompanies-announces-second-quarter-2026-results-b3a604de 2026-06-04 https://biopharmsignal.com/news/SIBN/si-bone-to-present-at-truist-securities-2026-medtech-conference-on-june-16-2026-78a98d1b 2026-06-04 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-to-present-phase-1-2-safety-and-translational-data-for-ronde--049c6b7a 2026-06-04 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-to-participate-in-goldmans-sachs-47th-annual-global-h-5d9e3d11 2026-06-04 https://biopharmsignal.com/news/PNTG/the-pennant-group-and-hartford-healthcare-expand-collaboration-to-advance-home-b-1e5098c7 2026-06-04 https://biopharmsignal.com/news/MKT/maia-biotechnology-reports-strong-enrollment-and-dosing-momentum-in-pivotal-phas-00bc65f1 2026-06-04 https://biopharmsignal.com/news/LGVN/longeveron-to-present-at-bio-international-convention-2026-d62abe73 2026-06-04 https://biopharmsignal.com/news/HCAT/health-catalyst-to-divest-vitalware-for-147-million-accelerating-strategic-trans-3fdcad3f 2026-06-04 https://biopharmsignal.com/news/LGMK/america-s-caregiving-dilemma-90-burnout-a-gen-z-reckoning-and-the-ai-lifeline-fa-92af446d 2026-06-04 https://biopharmsignal.com/news/NXGL/nexgel-to-present-at-planet-microcap-conference-las-vegas-on-june-16th-18th 2026-06-04 https://biopharmsignal.com/news/AIM/aim-immunotech-releases-virtual-investor-what-this-means-video-segment-discussin-f392f33f 2026-06-04 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-that-its-collaboration-partner-received-approval-from-the-israeli-ministry-of-health-to-conduct-exploratory-investigator-initiated-study-of-dnase-i-in-combination-with-anti-cd19-car-t-cells-in-large-b-cell-lymphoma 2026-06-04 https://biopharmsignal.com/news/MBRX/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent--3b671f86 2026-06-04 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-to-participate-in-planet-microcap-las-vegas-conference-8043a445 2026-06-04 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-announces-japan-s-mhlw-grants-orphan-drug-designation-for--87d20011 2026-06-04 https://biopharmsignal.com/news/TEVA/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-bd87cf56 2026-06-04 https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-data-from-ft819-and-ft839-programs-at-the-european-c-c6edd4ee 2026-06-04 https://biopharmsignal.com/news/RNXT/renovorx-ceo-shaun-bagai-to-present-at-the-iaccess-alpha-virtual-best-ideas-summer-investment-conference-2026-on-june-23rd 2026-06-04 https://biopharmsignal.com/news/ARVN/arvinas-joins-the-michael-j-fox-foundation-s-lite-and-ppmi-programs-to-advance-new-therapies-targeting-lrrk2-for-parkinson-s-disease 2026-06-04 https://biopharmsignal.com/news/SPRY/drew-brees-collaborates-with-ars-pharmaceuticals-to-raise-awareness-about-living-61e393ec 2026-06-04 https://biopharmsignal.com/news/IMMP/immutep-to-present-positive-interim-phase-i-data-for-imp761-a-first-in-class-lag-b9b47442 2026-06-04 https://biopharmsignal.com/news/IMNN/imunon-announces-up-to-10-million-cash-financing-259340f1 2026-06-04 https://biopharmsignal.com/news/NXTC/nxtc-announces-replay-available-for-virtual-kol-event-discussing-asco-2026-dose--a8660fb2 2026-06-04 https://biopharmsignal.com/news/AMRX/amneal-announces-u-s-fda-approval-of-romidepsin-injection-solution 2026-06-04 https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-announces-presentation-of-two-clinical-program-abstracts-at-the-american-headache-society-s-68th-annual-scientific-meeting 2026-06-04 https://biopharmsignal.com/news/AVCO/avalon-globocare-appoints-seasoned-ai-and-finance-executive-as-chief-financial-officer 2026-06-04 https://biopharmsignal.com/news/LPCN/lipocine-inc-to-host-virtual-kol-event-highlighting-unmet-needs-in-postpartum-depression-and-the-clinical-profile-of-lpcn-1154 2026-06-04 https://biopharmsignal.com/news/PSTV/plus-therapeutics-announces-cap-accreditation-of-cnsider-diagnostics-clinical-laboratory 2026-06-04 https://biopharmsignal.com/news/BIIB/biogen-s-salanersen-receives-fda-breakthrough-therapy-designation-for-spinal-mus-cb2731fd 2026-06-04 https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2a-postpartum-depression-results 2026-06-04 https://biopharmsignal.com/news/OVID/ovid-therapeutics-to-participate-in-upcoming-investor-conferences-4a42f3fa 2026-06-04 https://biopharmsignal.com/news/BYSI/beyondspring-announces-leadership-transition-to-deliver-focused-execution-on-its-7cdf7bc8 2026-06-04 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-2026-160a01c1 2026-06-04 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-presents-new-symbravo-data-at-the-americal-headache-society--867a4010 2026-06-04 https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-positive-enabling-data-supporting-advancement-of-oral-an2-502998-to-phase-2-study-for-chronic-chagas-disease 2026-06-04 https://biopharmsignal.com/news/SNDX/syndax-announces-private-placement-of-250-0-million-of-convertible-senior-notes 2026-06-04 https://biopharmsignal.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-06-04 https://biopharmsignal.com/news/OPCH/option-care-health-appoints-robert-okunski-as-vice-president-investor-relations 2026-06-04 https://biopharmsignal.com/news/BRKR/bruker-showcases-expanding-microbiology-and-infection-diagnostics-portfolio-at-asm-microbe-2026 2026-06-04 https://biopharmsignal.com/news/REGN/regeneron-to-highlight-progress-across-its-metabolic-disease-ophthalmology-and-rare-disease-pipelines-at-ada-and-endo 2026-06-04 https://biopharmsignal.com/news/ALKS/alkermes-to-present-new-data-on-alixorexton-and-lumryzr-sodium-oxybate-at-sleep-2026-highlighting-breadth-of-sleep-medicine-research 2026-06-04 https://biopharmsignal.com/news/USNA/usana-earns-dual-best-of-state-honors-for-product-innovation-and-development 2026-06-04 https://biopharmsignal.com/news/TECH/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization 2026-06-04 https://biopharmsignal.com/news/BIIB/eular-2026-dapirolizumab-pegol-shows-potential-to-reduce-flare-rates-and-maintai-adcfb6f4 2026-06-04 https://biopharmsignal.com/news/CELC/celcuity-inc-announces-pricing-of-upsized-public-offering-of-0-250-convertible-s-34cde08e 2026-06-04 https://biopharmsignal.com/news/SEER/seer-files-definitive-proxy-materials-and-mails-letter-to-stockholders 2026-06-03 https://biopharmsignal.com/news/RARE/ultragenyx-to-participate-at-goldman-sachs-47th-annual-global-healthcare-confere-aa3364c0 2026-06-03 https://biopharmsignal.com/news/INKT/mink-therapeutics-announces-its-virtual-2026-annual-shareholders-meeting-57694aec 2026-06-03 https://biopharmsignal.com/news/MD/pediatrix-medical-group-announces-publication-of-new-research-addressing-urgent-questions-in-neonatology 2026-06-03 https://biopharmsignal.com/news/HLF/herbalife-named-to-three-2026-usa-today-most-trusted-brands-lists 2026-06-03 https://biopharmsignal.com/news/KPTI/karyopharm-to-participate-in-webcast-featuring-endometrial-cancer-key-opinion-leader-on-june-8-2026 2026-06-03 https://biopharmsignal.com/news/ALKS/alkermes-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference 2026-06-03 https://biopharmsignal.com/news/IOVA/iovance-s-amtagvir-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia 2026-06-03 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-to-host-webcast-conference-call-to-discuss-phase-1-elvn-001-clinical-data-being-presented-at-eha-2026-congress 2026-06-03 https://biopharmsignal.com/news/ALHC/alignment-healthcare-named-to-the-fortune-1000-2026-list-for-second-consecutive-year 2026-06-03 https://biopharmsignal.com/news/MKT/maia-biotechnology-receives-fda-clearance-to-open-u-s-enrollment-in-ongoing-phase-2-thio-101-trial-expansion 2026-06-03 https://biopharmsignal.com/news/INAB/in8bio-announces-publication-in-nature-communications-highlighting-advances-in-gamma-delta-t-cell-engineering-and-combination-therapies 2026-06-03 https://biopharmsignal.com/news/DRTS/alpha-tau-and-tolmar-announce-strategic-collaboration-to-bring-alpha-dart-therap-82e0cf6e 2026-06-03 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-announces-16-566-027-registered-direct-offering-priced-at-th-ca30162b 2026-06-03 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-new-two-year-crenessityr-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026 2026-06-03 https://biopharmsignal.com/news/ARQT/new-expert-consensus-provides-age-specific-guidance-for-improving-care-for-individuals-with-genital-psoriasis-published-in-the-american-journal-of-clinical-dermatology 2026-06-03 https://biopharmsignal.com/news/PRME/prime-medicine-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference 2026-06-03 https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-research-collaboration-with-university-of-leicester-to-evaluate-icovamenib-in-combination-with-semaglutide-in-obesity 2026-06-03 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-upcoming-presentations-at-the-national-lipid-association-nla-2026-scientific-sessions 2026-06-03 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-announces-completion-of-enrollment-in-skyway-basket-trial-eva-ce4b09e5 2026-06-03 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-highlights-updated-miv-cel-data-at-eular-demonstrating-subs-5e700d3e 2026-06-03 https://biopharmsignal.com/news/LXRX/lexicon-to-present-data-at-the-american-diabetes-association-ada-2026-scientific-60360dc3 2026-06-03 https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-47th-annual-global-goldman-sachs--472ea0f3 2026-06-03 https://biopharmsignal.com/news/CTMX/cytomx-announces-expansion-of-strategic-research-collaboration-with-regeneron-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer 2026-06-03 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-completion-of-enrollment-in-registrational-expansion-cohort-of-achieve-trial-of-z-basivarsen-for-myotonic-dystrophy-type-1-dm1 2026-06-03 https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-results-from-phase-1-trial-evaluating-subcutaneous-briumvir-ublituximab-xiiy 2026-06-03 https://biopharmsignal.com/news/BIIB/biogen-announces-upcoming-kidney-presentations-at-european-renal-association-and-6e16e21e 2026-06-03 https://biopharmsignal.com/news/CELC/celcuity-inc-announces-public-offering-of-convertible-senior-notes-due-2032-1a75ce4c 2026-06-03 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-announces-interim-data-from-mypeaktm-1-showing-treatment-of-mybpc3-associated-hcm-with-tn-201-gene-therapy-resulted-in-consistent-signs-of-cardiac-remodeling-and-reductions-in-symptoms 2026-06-03 https://biopharmsignal.com/news/OVID/ovid-therapeutics-appoints-leading-physician-scientist-and-biotech-innovator-ann-fa44e719 2026-06-03 https://biopharmsignal.com/news/COCP/cocrystal-pharma-appoints-james-sapirstein-biopharma-industry-leader-with-extens-347ef789 2026-06-03 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-announces-settlement-resolving-all-sunosi-solriamfetol-paten-ed5bbf97 2026-06-03 https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-new-rese-cel-data-and-development-updates-across-autoimmune-portfolio-including-encouraging-early-pc-free-lupus-findings-at-eular-2026-congress 2026-06-03 https://biopharmsignal.com/news/PNTG/pennant-expands-senior-living-presence-with-pleasant-hill-california-community 2026-06-03 https://biopharmsignal.com/news/MDNA/medicenna-s-mdna11-potential-in-earlier-line-melanoma-setting-highlighted-in-presentation-of-the-neo-cyt-trial-at-asco-2026 2026-06-03 https://biopharmsignal.com/news/KURA/kura-oncology-highlights-darlifarnib-s-potential-as-a-foundational-combination-platform-for-kras-mutant-cancers-and-outlines-development-strategy 2026-06-03 https://biopharmsignal.com/news/CATX/perspective-therapeutics-expands-therapeutic-focus-areas-first-patient-dosed-wit-a2195748 2026-06-03 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-pricing-of-150-million-underwritten-offering-of-common-stock 2026-06-03 https://biopharmsignal.com/news/MNKD/mannkind-enters-data-rich-development-period-with-completion-of-randomization-in-phase-1b-inflo-1-study-and-enrollment-of-first-patient-in-phase-2-inflo-2-trial-for-nintedanib-dpi-in-patients-with-ipf 2026-06-03 https://biopharmsignal.com/news/ACON/aclarion-adds-institute-of-neuro-innovation-to-support-nociscan-growth-and-real--1ec7d9b9 2026-06-03 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-repurchase-of-royalty-obligations-in-tanabe-license-agreement-and-concurrent-financing 2026-06-03 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-clinical-collaboration-with-roche-in-mtap-deleted-ras-mutant-pancreatic-cancer 2026-06-03 https://biopharmsignal.com/news/FMS/fresenius-medical-care-launches-kinexus-worldwide-a-unified-digital-platform-to-support-home-dialysis 2026-06-03 https://biopharmsignal.com/news/ARGX/argenx-presents-new-efgartigimod-data-showing-long-term-sustained-patient-benefi-e5897167 2026-06-03 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-to-announce-new-interim-data-from-mypeaktm-1-phase-1b-2-trial-of-tn-201-for-adults-with-mybpc3-associated-hcm-on-wednesday-june-3-2026 2026-06-02 https://biopharmsignal.com/news/NBTX/nanobiotix-fait-le-point-sur-sa-tresorerie-et-son-activite-operationnelle-pour-l-bd477f84 2026-06-02 https://biopharmsignal.com/news/NBTX/nanobiotix-provides-first-quarter-2026-operational-and-financial-update-9771bec3 2026-06-02 https://biopharmsignal.com/news/STIM/neuronetics-appoints-robert-greene-as-senior-vice-president-sales 2026-06-02 https://biopharmsignal.com/news/PCVX/vaxcyte-doses-first-participant-in-phase-1-study-evaluating-vax-a1-for-the-prevention-of-disease-caused-by-group-a-streptococcus-in-healthy-adults 2026-06-02 https://biopharmsignal.com/news/EQ/equillium-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-790eaafb 2026-06-02 https://biopharmsignal.com/news/CUE/cue-biopharma-announces-board-transition-and-addition-of-new-directors-with-cont-a9391e4e 2026-06-02 https://biopharmsignal.com/news/BCTX/briacell-therapeutics-announces-closing-of-offering-6518e981 2026-06-02 https://biopharmsignal.com/news/CRNX/crinetics-and-leading-patient-groups-launch-everyday-advocacy-initiative-to-empo-3a497246 2026-06-02 https://biopharmsignal.com/news/IBIO/ibio-to-participate-in-upcoming-healthcare-investor-conferences 2026-06-02 https://biopharmsignal.com/news/SNDX/syndax-highlights-revuforjr-revumenib-data-presented-at-asco-2026-including-an-oral-presentation-of-post-transplant-data 2026-06-02 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-up-to-23-6-million-private-placement-priced-at-the-market-under-nasdaq-rules 2026-06-02 https://biopharmsignal.com/news/BRKR/bruker-launches-new-timsmrms-mass-spectrometry-platform-for-unique-ultra-complex-mixture-applications-in-the-energy-industry 2026-06-02 https://biopharmsignal.com/news/KPTI/karyopharm-s-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-selected-for-late-breaking-oral-presentation-at-eha-2026 2026-06-02 https://biopharmsignal.com/news/MKT/maia-biotechnology-announces-open-market-purchases-by-ceo-and-director 2026-06-02 https://biopharmsignal.com/news/LEGN/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing--075d2e3b 2026-06-02 https://biopharmsignal.com/news/ENLV/enlivex-to-present-quality-longevity-model-powered-by-prediction-markets-treasur-916d457f 2026-06-02 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-appointment-of-steve-glover-to-board-of-directors-a-23493926 2026-06-02 https://biopharmsignal.com/news/MOH/molina-healthcare-announces-second-quarter-2026-earnings-release-and-conference-call-dates 2026-06-02 https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-publication-calling-for-updated-fda-approaches-to-als-rare-diseases-and-regenerative-medicine 2026-06-02 https://biopharmsignal.com/news/KPTI/karyopharm-to-present-results-from-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-in-late-breaking-oral-presentation-at-asco-2026-with-simultaneous-publication-in-the-journal-of-clinical-oncology 2026-06-02 https://biopharmsignal.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-publication-in-blood-of-ziftomenib-plus-venetoclax-azacitidine-combination-in-patients-with-r-r-npm1-m-aml 2026-06-02 https://biopharmsignal.com/news/STIM/neuronetics-highlights-continued-advancements-in-tms-research-at-ctmss-2026 2026-06-02 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-commences-multi-site-method-comparison-study-for-fda-5-81a340fc 2026-06-02 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-submits-ind-application-for-qrx003-in-peeling-skin-syndrom-57517fe1 2026-06-02 https://biopharmsignal.com/news/HSCS/heartsciences-launches-myovista-insights-version-1-3-with-ai-ecg-algorithm-marke-e814d01c 2026-06-02 https://biopharmsignal.com/news/IVA/inventiva-annonce-la-reprise-des-n-gociations-de-ses-actions-ordinaires-sur-euro-fe66b104 2026-06-02 https://biopharmsignal.com/news/IVA/inventiva-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris-dbf15b12 2026-06-02 https://biopharmsignal.com/news/ICCM/icecure-medical-announces-1-for-30-reverse-share-split-to-support-nasdaq-compliance 2026-06-02 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-appoints-jeffrey-farrow-and-reid-waldman-md-to-board-of-directors 2026-06-02 https://biopharmsignal.com/news/IVA/inventiva-annonce-une-optimisation-globale-de-sa-structure-financi-re-comprenant-8d349aa5 2026-06-02 https://biopharmsignal.com/news/IVA/inventiva-announces-a-comprehensive-capital-structure-optimization-including-deb-a83cac35 2026-06-02 https://biopharmsignal.com/news/CELC/celcuity-s-gedatolisib-combination-regimens-doubled-the-likelihood-of-survival-w-bafa8e71 2026-06-02 https://biopharmsignal.com/news/HRTX/u-s-district-court-issues-decision-regarding-cinvanti-patents-21c1ecf3 2026-06-02 https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-publication-in-the-lancet-oncology-of-pivotal-phase-3-data-demonstrating-significant-improvement-in-disease-free-survival-with-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer 2026-06-02 https://biopharmsignal.com/news/AEMD/aethlon-medical-to-release-fiscal-year-end-financial-results-and-host-conference-call-on-june-10-2026 2026-06-02 https://biopharmsignal.com/news/IRON/disc-medicine-presents-updated-positive-data-from-rally-mf-phase-2-trial-in-patients-with-myelofibrosis-mf-and-anemia-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting 2026-06-02 https://biopharmsignal.com/news/PROK/prokidney-appoints-kenneth-locke-as-chief-technical-officer 2026-06-02 https://biopharmsignal.com/news/ALHC/alignment-healthcare-shows-how-earlier-coordinated-care-leads-to-better-health-and-fewer-emergencies-in-2025-impact-report 2026-06-02 https://biopharmsignal.com/news/VTAK/flyte-activates-high-frequency-belmont-stakes-flight-program-deploying-fleet-to--643469ed 2026-06-02 https://biopharmsignal.com/news/CING/cingulate-receives-complete-response-letter-from-fda-for-ctx-1301-ef9797e1 2026-06-02 https://biopharmsignal.com/news/ECOR/electrocore-to-present-at-the-planet-microcap-las-vegas-2026-powered-by-microcap-9774a6c0 2026-06-02 https://biopharmsignal.com/news/INMB/inmune-bio-reports-statistically-significant-treatment-effect-on-advanced-white--deb7e05e 2026-06-02 https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-con-22b3475f 2026-06-02 https://biopharmsignal.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-f4e26896 2026-06-02 https://biopharmsignal.com/news/URGN/urogen-announces-agreement-resolving-patent-litigation-relating-to-jelmytor-mitomycin-for-pyelocalyceal-solution 2026-06-02 https://biopharmsignal.com/news/TCMD/tactile-medical-launches-next-generation-afflovestr-airway-clearance-therapy 2026-06-02 https://biopharmsignal.com/news/BMY/izalontamab-brengitecan-iza-bren-demonstrates-statistically-significant-and-clinically-meaningful-improvements-in-overall-survival-and-progression-free-survival-in-patients-with-triple-negative-breast-cancer-and-esophageal-squamous-cell-carcinoma 2026-06-02 https://biopharmsignal.com/news/BIAF/multidisciplinary-physician-panel-to-share-real-world-benefits-of-bioaffinity-technologies-noninvasive-cypath-lung-cancer-test-in-upcoming-society-for-advanced-bronchoscopy-webinar 2026-06-02 https://biopharmsignal.com/news/BFRG/bullfrog-ai-announces-new-commercial-leadership-team-to-execute-growth-strategy-for-its-integrated-pharma-ai-platform 2026-06-02 https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-healthcare-conference 2026-06-02 https://biopharmsignal.com/news/IART/integra-lifesciences-to-present-at-the-2026-jefferies-global-healthcare-conference 2026-06-02 https://biopharmsignal.com/news/AVAH/aveanna-healthcare-holdings-completes-acquisition-of-family-first-homecare-and-updates-full-year-2026-guidance 2026-06-02 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-participate-in-upcoming-june-2026-events 2026-06-02 https://biopharmsignal.com/news/HLF/herbalife-chief-financial-officer-to-present-at-east-coast-ideas-conference-on-june-11 2026-06-02 https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-june-investor-and-industry-conferences-694d1d48 2026-06-02 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-orphan-drug-designation-by-fda-of-pas-004-for-treatment-of-amyotrophic-lateral-sclerosis-als 2026-06-02 https://biopharmsignal.com/news/VERA/vera-therapeutics-announces-alignment-with-u-s-fda-on-earlier-origin-phase-3-ana-53ed5fb6 2026-06-02 https://biopharmsignal.com/news/BYSI/beyondspring-presents-the-latest-update-of-a-phase-2-study-demonstrating-durable-b6c4b5ec 2026-06-02 https://biopharmsignal.com/news/TRDA/independent-safety-data-monitoring-committee-recommends-initiation-of-cohort-2-a-2a48ec2d 2026-06-02 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-host-investor-day-on-june-17-2026-640541ba 2026-06-02 https://biopharmsignal.com/news/IBIO/ibio-becomes-a-clinical-stage-company-with-first-participant-dosed-in-phase-1-clinical-trial-of-ibio-600-in-adults-with-obesity 2026-06-02 https://biopharmsignal.com/news/BEAT/heartbeam-announces-new-peer-reviewed-article-demonstrating-potential-to-help-identify-heart-attack-risk-at-home 2026-06-02 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-and-argonaut-manufacturing-services-announce-strategic-partnership 2026-06-02 https://biopharmsignal.com/news/ENSG/the-ensign-group-purchases-memory-care-facility-in-california-644602e8 2026-06-02 https://biopharmsignal.com/news/ENSG/the-ensign-group-acquires-real-estate-and-operations-in-iowa-6c5670c6 2026-06-02 https://biopharmsignal.com/news/PSNL/personalis-highlights-early-colorectal-cancer-recurrence-detection-and-ultrasensitive-mrd-performance-across-a-broad-set-of-tumor-types-at-asco-2026 2026-06-02 https://biopharmsignal.com/news/CRNX/crinetics-paradigm-shifting-portfolio-and-pipeline-on-display-at-endo-2026-with--b53db9a2 2026-06-02 https://biopharmsignal.com/news/NBTX/nanobiotix-rejoint-l-indice-euronext-tech-leaders-a0f42fda 2026-06-02 https://biopharmsignal.com/news/NBTX/nanobiotix-joins-the-euronext-tech-leaders-index-54eebd12 2026-06-02 https://biopharmsignal.com/news/IVA/inventiva-annonce-la-suspension-temporaire-du-cours-de-ses-actions-ordinaires-su-fe8a7c2c 2026-06-02 https://biopharmsignal.com/news/IVA/inventiva-announces-temporary-trading-halt-of-its-ordinary-shares-on-euronext-pa-7f45a99e 2026-06-02 https://biopharmsignal.com/news/MESO/asx-ceo-connect-presentation 2026-06-02 https://biopharmsignal.com/news/FLGT/fulgent-presents-updated-fid-007-data-at-asco-2026 2026-06-01 https://biopharmsignal.com/news/EMBC/embecta-to-participate-in-investor-events 2026-06-01 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5-1f326240 2026-06-01 https://biopharmsignal.com/news/PCRX/pacira-biosciences-highlights-leading-independent-proxy-advisory-firm-iss-recommendation-to-vote-for-all-of-pacira-s-director-nominees 2026-06-01 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--4f6f3117 2026-06-01 https://biopharmsignal.com/news/TEVA/teva-to-present-at-the-goldman-sachs-global-healthcare-conference-c0b58a99 2026-06-01 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-participate-in-upcoming-investor-conferences 2026-06-01 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-provides-vormatrigine-program-update 2026-06-01 https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference 2026-06-01 https://biopharmsignal.com/news/LUNG/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-06-01 https://biopharmsignal.com/news/NERV/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs 2026-06-01 https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-8b813e20 2026-06-01 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-discontinuation-of-pociredir-program-in-sickle-ce-a4687a0d 2026-06-01 https://biopharmsignal.com/news/SERA/sera-prognostics-announces-board-transition 2026-06-01 https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-participation-at-goldman-sachs-47th-annual-global-h-1adfec22 2026-06-01 https://biopharmsignal.com/news/XCUR/exicure-announces-receipt-of-nasdaq-delinquency-notice-and-filing-of-form-10-q-47e8448d 2026-06-01 https://biopharmsignal.com/news/IBRX/immunitybio-presents-new-clinical-and-comparative-data-across-lung-and-bladder-cancer-at-asco-2026 2026-06-01 https://biopharmsignal.com/news/INVA/innoviva-to-participate-in-upcoming-investor-conferences-24a49e78 2026-06-01 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-and-servier-provide-complete-data-from-phase-2-3-registrational-optimum-02-trial-of-the-darovasertib-combination-in-first-line-hla-a2-01-negative-metastatic-uveal-melanoma-in-a-late-breaking-oral-presentation-at-asco 2026-06-01 https://biopharmsignal.com/news/LEGN/legend-biotech-presents-first-in-human-lb2102-results-in-solid-tumors-and-new-ca-f6f84458 2026-06-01 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-showcases-compelling-asco-2026-data-demonstrating-dnase-i-significantly-enhances-car-t-cell-persistence-tumor-control-and-survival 2026-06-01 https://biopharmsignal.com/news/ENLV/allocetra-shows-durable-6-month-efficacy-in-knee-osteoarthritis-phase-iia-trial--60e1246b 2026-06-01 https://biopharmsignal.com/news/DRTS/alpha-tau-announces-strong-overall-survival-results-from-alpha-dart-pancreatic-c-53d95f95 2026-06-01 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-positive-initial-preclinical-findings-supporting-fu-5be55556 2026-06-01 https://biopharmsignal.com/news/XGN/exagen-announces-publication-of-systematic-review-confirming-robust-real-world-performance-of-avise-lupus 2026-06-01 https://biopharmsignal.com/news/AIM/aim-immunotech-completes-phase-2-duripanc-enrollment-milestone-ahead-of-schedule-465b5d8f 2026-06-01 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-announces-strategic-transformation-into-ai-energy-infrastruc-7b029b1c 2026-06-01 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-resubmission-of-biologics-license-application-to-u-s-fda-for-ons-5010-lytenavatm-bevacizumab-vikg 2026-06-01 https://biopharmsignal.com/news/INAB/in8bio-presents-updated-overall-survival-data-surpassing-19-5-months-for-deltex-dri-in-newly-diagnosed-glioblastoma-at-asco-2026 2026-06-01 https://biopharmsignal.com/news/IRON/disc-medicine-launches-expanded-access-program-for-bitopertin-for-epp-patients 2026-06-01 https://biopharmsignal.com/news/CELC/celcuity-to-hold-conference-call-to-discuss-results-for-the-pik3ca-mutant-cohort-9ce6c49d 2026-06-01 https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-c00fcf01 2026-06-01 https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-clinical-data-for-ft836-at-the-american-society-of-cancer-oncology-annual-meeting 2026-06-01 https://biopharmsignal.com/news/PYPD/polypid-completes-new-drug-application-submission-to-fda-for-d-plex 2026-06-01 https://biopharmsignal.com/news/VXRT/vaxart-files-definitive-proxy-statement-and-mails-letter-to-shareholders-b7b0e0a9 2026-06-01 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-presents-flamingo-01-phase-iii-trial-open-label-data-published-at-asco-meeting-2026 2026-06-01 https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-highlight-compelling-new-efficacy-data-from-phase-2b-clover-wam-study-of-iopofosine-i-131-in-r-r-waldenstroem-macroglobulinemia-at-the-american-society-of-clinical-oncology-annual-meeting 2026-06-01 https://biopharmsignal.com/news/ALXO/alx-oncology-to-present-at-the-2026-jefferies-global-healthcare-conference-in-new-york 2026-06-01 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-goldman-sachs-47th-annual-global-healthcare-conference-2026 2026-06-01 https://biopharmsignal.com/news/APRE/aprea-therapeutics-presents-updated-phase-1-data-on-wee1-inhibitor-apr-1051-at-asco-2026-demonstrating-early-monotherapy-activity-and-manageable-tolerability-in-advanced-solid-tumors 2026-06-01 https://biopharmsignal.com/news/NCNA/nucana-appoints-ian-webster-as-chief-financial-officer 2026-06-01 https://biopharmsignal.com/news/IMTX/immatics-presents-clinical-activity-and-response-dynamics-of-anzu-cel-prame-cell-therapy-at-2026-asco-annual-meeting 2026-06-01 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-announces-publication-in-peer-reviewed-journal-science-advan-b349682a 2026-06-01 https://biopharmsignal.com/news/NXTC/nextcure-presents-positive-sim0505-phase-1-dose-escalation-data-in-patients-with-fb481c8c 2026-06-01 https://biopharmsignal.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-2a3e1bc2 2026-06-01 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-exploration-of-strategic-alternatives-to-maximize--09867656 2026-06-01 https://biopharmsignal.com/news/SENS/senseonics-highlights-analyst-event-and-oral-presentation-of-eversense-365-real--5826a5ba 2026-06-01 https://biopharmsignal.com/news/VYGR/voyager-receives-fda-ind-clearance-for-vy1706-first-gene-therapy-approach-to-red-9cffdbcc 2026-06-01 https://biopharmsignal.com/news/XAIR/beyond-air-receives-nasdaq-hearing-panel-decision-granting-continued-listing-fe2e861e 2026-06-01 https://biopharmsignal.com/news/GERN/geron-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conferen-924410f0 2026-06-01 https://biopharmsignal.com/news/CRL/charles-river-laboratories-to-present-at-william-blair-and-jefferies-conferences 2026-06-01 https://biopharmsignal.com/news/AMRX/amneal-to-participate-in-goldman-sachs-47th-annual-global-healthcare-conference-2026 2026-06-01 https://biopharmsignal.com/news/RLYB/rallybio-corporation-and-avenzo-therapeutics-announce-merger-agreement-to-advance-next-generation-oncology-therapies-and-215-million-concurrent-private-placement 2026-06-01 https://biopharmsignal.com/news/BTMD/biote-appoints-komal-bajaj-md-ms-as-chief-medical-officer 2026-06-01 https://biopharmsignal.com/news/MKT/maia-biotechnology-presents-trial-in-progress-poster-for-pivotal-phase-3-clinical-trial-of-novel-telomere-targeting-agent-at-2026-annual-meeting-of-american-society-of-clinical-oncology 2026-06-01 https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-publication-of-post-hoc-data-from-the-phase-3-ultimate-i-and-ii-trials-in-treatment-naive-patients-with-relapsing-forms-of-ms-published-in-frontiers-in-immunology 2026-06-01 https://biopharmsignal.com/news/IMRX/immuneering-presents-compelling-17-3-month-median-overall-survival-and-favorable-tolerability-with-atebimetinib-chemotherapy-in-first-line-pancreatic-cancer-patients-at-asco 2026-06-01 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-participating-in-upcoming-investor-conferences-24f55c3d 2026-06-01 https://biopharmsignal.com/news/BCTX/briacell-presents-positive-clinical-data-at-asco-2026-62b22cc1 2026-06-01 https://biopharmsignal.com/news/CYTK/cytokinetics-bringt-myqorzo-aficamten-in-der-europ-ischen-union-auf-den-markt-de-9cd940d2 2026-06-01 https://biopharmsignal.com/news/CYTK/cytokinetics-launches-myqorzo-aficamten-in-european-union-with-first-commercial--764f10aa 2026-06-01 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-report-additional-phase-3-haelo-data-for-lonvoguran-ziclumeran-lonvo-z-in-late-breaking-oral-presentation-at-eaaci-2026 2026-06-01 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-announces-clearance-of-investigational-new-drug-ind-application-for-il-12-tethered-til-therapy-iov-5001 2026-06-01 https://biopharmsignal.com/news/KPTI/karyopharm-to-host-investor-conference-call-featuring-expert-perspectives-on-the-phase-3-sentry-trial-in-myelofibrosis-following-2026-asco-presentation 2026-06-01 https://biopharmsignal.com/news/USNA/kevin-guest-encourages-professionals-to-prioritize-wellness-during-professional-wellness-month 2026-06-01 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-partners-with-the-headache-alliance-to-highlight-the-impact--034f4716 2026-06-01 https://biopharmsignal.com/news/SNDX/syndax-to-host-randd-day-highlighting-its-late-stage-programs-and-early-stage-assets-on-july-14-2026 2026-06-01 https://biopharmsignal.com/news/OPCH/option-care-health-awarded-time-s-world-s-most-impactful-companies-2026-ranking 2026-06-01 https://biopharmsignal.com/news/BRKR/bruker-announces-major-strides-in-4d-proteomics-performance-further-advances-in-intact-and-top-down-functional-proteoform-analysis-and-innovations-in-hybrid-qual-quant-4d-metabolomics-all-to-enable-deeper-insights-into-disease-biology 2026-06-01 https://biopharmsignal.com/news/MNPR/monopar-presents-phase-2-alxn1840-data-demonstrating-liver-disease-stabilization-and-neurologic-improvement-in-treatment-experienced-wilson-disease-patients-at-easl-2026 2026-06-01 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibb-s-supplemental-new-drug-application-for-camzyos-mavacamten-to-treat-adolescents-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-ohcm 2026-06-01 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-opdivor-nivolumab-in-combination-with-avd-receives-expanded-eu-label-with-approval-in-frontline-advanced-classical-hodgkin-lymphoma 2026-06-01 https://biopharmsignal.com/news/ACON/aclarion-technology-demonstrates-potential-beyond-surgical-planning-in-new-immun-8f22a702 2026-06-01 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-regarding-form-10-k-filing-5fb4f975 2026-06-01 https://biopharmsignal.com/news/YOU/concierge-powered-by-clear-launched-at-mia-to-elevate-travel-experiences-at-florida-s-busiest-airport-for-international-passengers 2026-06-01 https://biopharmsignal.com/news/AGIO/agios-enters-exclusive-global-license-agreement-with-oscotec-to-develop-and-comm-5081deb9 2026-06-01 https://biopharmsignal.com/news/BIIB/ucb-and-biogen-announce-publication-in-the-lancet-of-positive-dapirolizumab-pego-f2f17cd8 2026-06-01 https://biopharmsignal.com/news/BCTX/briacell-therapeutics-announces-pricing-of-offering-942dc9e2 2026-05-31 https://biopharmsignal.com/news/IMTX/immatics-presents-data-on-ima401-magea4-8-bispecific-at-2026-asco-annual-meeting-with-simultaneous-publication-in-nature-medicine-supporting-development-of-ima401-ima402-combination-in-lung-cancer 2026-05-31 https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-asco-plenary-presentation-highlighting-unprecedented-results-from-pivotal-phase-3-rasolute-302-clinical-trial-of-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer 2026-05-31 https://biopharmsignal.com/news/REPL/replimune-presents-final-first-in-human-data-for-rp2-in-advanced-solid-tumors-during-oral-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting 2026-05-31 https://biopharmsignal.com/news/IMCR/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma 2026-05-31 https://biopharmsignal.com/news/BNTX/globale-daten-der-rosetta-lung-02-studie-ermutigende-wirksamkeit-f-r-biontechs-u-1ddd9391 2026-05-30 https://biopharmsignal.com/news/BNTX/global-data-for-biontech-and-bristol-myers-squibb-s-pd-l1xvegf-a-bispecific-pumi-a3a4e1af 2026-05-30 https://biopharmsignal.com/news/BMY/global-data-for-biontech-and-bristol-myers-squibb-s-pd-l1xvegf-a-bispecific-pumitamig-shows-encouraging-efficacy-in-patients-with-non-small-cell-lung-cancer-in-rosetta-lung-02-trial 2026-05-30 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-presents-new-data-from-the-phase-3-launch-htn-trial-of-lorundrostat-in-participants-with-hypertension-and-chronic-kidney-disease-at-european-meeting-on-hypertension-and-cardiovascular-protection-esh-2026 2026-05-30 https://biopharmsignal.com/news/EXEL/exelixis-announces-results-from-subgroup-analysis-of-phase-3-cabinet-pivotal-trial-evaluating-cabometyxr-cabozantinib-in-non-functional-and-functional-neuroendocrine-tumors-at-asco-2026 2026-05-30 https://biopharmsignal.com/news/IMTX/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynecologic-cancers-at-2026-asco-annual-meeting 2026-05-30 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-detailed-clinical-data-from-peak-phase-3-trial-with-bezuclastinib-in-combination-with-sunitinib-in-gastrointestinal-stromal-tumors-gist-at-2026-american-society-of-clinical-oncology-asco-annual-meeting 2026-05-30 https://biopharmsignal.com/news/MOLN/molecular-partners-holds-presentations-at-asco-and-snmmi-2026-on-dll3-targeting--e5a66348 2026-05-30 https://biopharmsignal.com/news/REPL/replimune-presents-3-year-landmark-overall-survival-analysis-from-ignyte-clinical-trial-during-oral-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting 2026-05-30 https://biopharmsignal.com/news/CORT/corcept-presents-new-data-at-asco-2026-lifyorlitm-overall-survival-across-all-subgroups-of-patients-with-platinum-resistant-ovarian-cancer-including-those-with-recent-taxane-exposure 2026-05-29 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--ba1c82e1 2026-05-29 https://biopharmsignal.com/news/RXRX/recursion-reports-grant-of-inducement-awards-as-permitted-by-the-nasdaq-listing--92e9e803 2026-05-29 https://biopharmsignal.com/news/ARVN/arvinas-to-present-at-jefferies-global-healthcare-conference 2026-05-29 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-upcoming-investor-conferences 2026-05-29 https://biopharmsignal.com/news/OCS/oculis-announces-topline-results-from-diamond-phase-3-trials-with-ocs-01-in-diabetic-macular-edema 2026-05-29 https://biopharmsignal.com/news/MNKD/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval 2026-05-29 https://biopharmsignal.com/news/MNKD/mannkind-announces-fda-approval-of-afrezzar-the-first-and-only-inhaled-mealtime-insulin-for-use-in-children-and-adolescents-aged-6-and-older-living-with-diabetes 2026-05-29 https://biopharmsignal.com/news/MBRX/moleculin-presents-asco-2026-data-demonstrating-no-detectable-cardiotoxicity-wit-852249ee 2026-05-29 https://biopharmsignal.com/news/TPST/tempest-therapeutics-announces-warrant-exercise-for-approximately-2-million-in-gross-proceeds 2026-05-29 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-2026 2026-05-29 https://biopharmsignal.com/news/SABS/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-association-s-2026-scientific-sessions-and-focis-2026-annual-meeting 2026-05-29 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-seven-abstracts-accepted-for-presentation-at-en-52c36d21 2026-05-29 https://biopharmsignal.com/news/EHC/encompass-health-to-build-36-bed-inpatient-rehabilitation-hospital-in-bridgeport-west-virginia 2026-05-29 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-celmod-mezigdomide-reduces-risk-of-disease-progression-or-death-by-more-than-50-vs-standard-of-care-in-relapsed-or-refractory-multiple-myeloma 2026-05-29 https://biopharmsignal.com/news/REPL/replimune-announces-planned-rp1-bla-resubmission-following-productive-discussion-with-fda 2026-05-29 https://biopharmsignal.com/news/ADPT/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseqr-mrd-testing-across-hematology-clinical-practice-and-research 2026-05-29 https://biopharmsignal.com/news/APTO/aptose-biosciences-announces-update-on-anticipated-timing-of-closing-of-the-plan-17e05f74 2026-05-29 https://biopharmsignal.com/news/SEER/seer-files-itc-complaint-against-nanomics 2026-05-29 https://biopharmsignal.com/news/AGIO/agios-provides-update-on-phase-2b-trial-of-tebapivat-in-lower-risk-myelodysplast-8ebf0825 2026-05-29 https://biopharmsignal.com/news/PHVS/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026-f5146f6d 2026-05-29 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-expands-commercial-leadership-team 2026-05-29 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-planned-ceo-succession 2026-05-28 https://biopharmsignal.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conferences-156042fe 2026-05-28 https://biopharmsignal.com/news/ISRG/intuitive-announces-new-chief-commercial-and-marketing-officer-taylor-patton 2026-05-28 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-presented-retrospective-u-s-real-world-claims-analysis-of-opioid-use-in-patients-with-fibromyalgia-at-the-2026-american-society-of-clinical-psychopharmacology-ascp-annual-meeting 2026-05-28 https://biopharmsignal.com/news/PCRX/leading-independent-proxy-advisory-firm-glass-lewis-recommends-stockholders-vote-for-all-of-pacira-s-director-nominees 2026-05-28 https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-upcoming-investor-conference-presentations 2026-05-28 https://biopharmsignal.com/news/CGON/cg-oncology-to-present-at-upcoming-investor-conferences-in-june-3c0d37b0 2026-05-28 https://biopharmsignal.com/news/EQ/equillium-to-participate-in-the-2026-jefferies-global-healthcare-conference-52c2761f 2026-05-28 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-confe-b815d20d 2026-05-28 https://biopharmsignal.com/news/APGE/apogee-therapeutics-to-participate-in-upcoming-june-conferences-d1984190 2026-05-28 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-updated-presentation-time-for-upcoming-investor-confer-ef3968d7 2026-05-28 https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-64-5-million-contract-modification-for-batr-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy 2026-05-28 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-pricing-of-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2026-05-28 https://biopharmsignal.com/news/REGN/regeneron-s-ebola-antibody-recommended-by-world-health-organization-for-investigational-use-in-response-to-current-bundibugyo-ebolavirus-outbreak 2026-05-28 https://biopharmsignal.com/news/ACON/aclarion-inc-comments-on-echo-lake-capital-s-letter-and-unsolicited-proposal-98d7da4b 2026-05-28 https://biopharmsignal.com/news/ANGO/angiodynamics-expands-patient-access-to-nanoknife-ire-for-prostate-and-liver-cancer-as-medicare-coverage-framework-takes-effect 2026-05-28 https://biopharmsignal.com/news/ALT/pemvidutide-demonstrates-significant-metabolic-improvements-in-patients-with-mas-a943260b 2026-05-28 https://biopharmsignal.com/news/PMN/promis-neurosciences-to-participate-in-upcoming-conferences-in-june-00cd700a 2026-05-28 https://biopharmsignal.com/news/JAGX/jaguar-health-research-in-ethnobotanical-medicine-helps-advance-crofelemer-development-for-genetically-defined-rare-congenital-gastrointestinal-disorders 2026-05-28 https://biopharmsignal.com/news/MDNA/medicenna-announces-closing-of-public-offering-of-units-raising-cdn-4-44-million-to-support-lead-programs 2026-05-28 https://biopharmsignal.com/news/PGNY/new-progyny-study-shows-growing-demand-for-human-guidance-in-an-increasingly-digital-healthcare-system 2026-05-28 https://biopharmsignal.com/news/INKT/mink-therapeutics-announces-first-patient-dosed-in-randomized-phase-2-trial-of-a-116222e3 2026-05-28 https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-holdings-valued-at-approximately-1-16-bil-23336240 2026-05-28 https://biopharmsignal.com/news/TDOC/teladoc-health-expands-access-to-care-through-walmart-s-better-care-services-3bb2d2ac 2026-05-28 https://biopharmsignal.com/news/BTMD/biote-names-bob-peterson-current-chief-financial-and-chief-business-officer-as-interim-ceo 2026-05-28 https://biopharmsignal.com/news/ENTX/entera-s-eb613-first-in-class-oral-pth-1-34-anabolic-for-osteoporosis-single-tab-ad3e3a0f 2026-05-28 https://biopharmsignal.com/news/CELC/celcuity-to-participate-in-upcoming-investor-conferences-b840e74b 2026-05-28 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conf-a0a234d5 2026-05-28 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-confe-9895b44d 2026-05-28 https://biopharmsignal.com/news/VOR/vor-bio-to-participate-in-the-2026-jefferies-global-healthcare-conference-045fc6d4 2026-05-28 https://biopharmsignal.com/news/VANI/vivani-medical-ceo-adam-mendelsohn-to-present-at-the-jefferies-global-healthcare-conference-on-june-4-2026 2026-05-28 https://biopharmsignal.com/news/RNXT/renovorx-announces-fda-orphan-drug-designation-granted-oxaliplatin-for-the-treatment-of-pancreatic-cancer 2026-05-28 https://biopharmsignal.com/news/VRCA/verrica-to-participate-in-the-jefferies-global-healthcare-conference 2026-05-28 https://biopharmsignal.com/news/APVO/aptevo-therapeutics-appoints-mary-j-janatpour-ph-d-as-senior-vice-president-and-chief-scientific-officer 2026-05-28 https://biopharmsignal.com/news/AVAH/aveanna-healthcare-announces-successful-debt-repricing 2026-05-28 https://biopharmsignal.com/news/DSGN/design-therapeutics-to-participate-in-2026-jefferies-global-healthcare-conference 2026-05-28 https://biopharmsignal.com/news/PRME/prime-medicine-to-present-at-jefferies-global-healthcare-conference-053549bc 2026-05-28 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-nda-with-priority-review-for-bezuclastinib-in-combination-with-sunitinib-for-patients-with-gist 2026-05-28 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june 2026-05-28 https://biopharmsignal.com/news/IMMP/systemic-immune-activation-with-eftilagimod-alfa-associated-with-statistically-s-e144089b 2026-05-28 https://biopharmsignal.com/news/BCDA/biocardia-announces-japan-pmda-record-of-advice-supports-regulatory-submission-f-6bb5419d 2026-05-28 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-present-at-the-2026-jefferies-global-healthcare-conferenc-a2e97fe3 2026-05-28 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-publication-of-new-bardet-biedl-syndrome-diagno-6e9a9095 2026-05-28 https://biopharmsignal.com/news/PRCT/procept-biorobotics-advances-prostate-cancer-program-with-water-iv-study-enrollm-de942ff2 2026-05-28 https://biopharmsignal.com/news/BNGO/bionano-announces-full-retirement-of-outstanding-senior-secured-convertible-debentures 2026-05-28 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences 2026-05-28 https://biopharmsignal.com/news/GSK/bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b 2026-05-28 https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-appoints-former-fda-associate-commissioner-peter-j-pitts-to-board-of-directors 2026-05-28 https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference 2026-05-28 https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-june-investor-events-1eb21840 2026-05-28 https://biopharmsignal.com/news/KPTI/karyopharm-to-participate-at-the-2026-jefferies-global-healthcare-conference 2026-05-28 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-presents-new-data-from-serenity-at-home-phase-3-trial-for-agitation-associated-with-bipolar-disorders-or-schizophrenia-at-2026-ascp-annual-meeting 2026-05-28 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-to-participate-in-upcoming-investor-conferences-bcefd6c5 2026-05-28 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-to-present-at-the-jefferies-global-healthcare-conference-i-0a5525cb 2026-05-28 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference 2026-05-28 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-present-at-the-jefferies-global-healthcare-conference 2026-05-28 https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-presents-new-data-highlighting-the-burden-of-injectable-on-demand-treatment-in-young-children-with-hereditary-angioedema 2026-05-28 https://biopharmsignal.com/news/FMS/fresenius-medical-care-launches-first-tranche-of-its-share-buyback-program-of-up-to-eur-600-million 2026-05-28 https://biopharmsignal.com/news/ARGX/argenx-to-host-myositis-r-d-webinar-on-june-23-2026-5b497566 2026-05-28 https://biopharmsignal.com/news/PRI/primerica-household-budget-indextm-hbitm-rising-gas-prices-limit-purchasing-power-of-middle-income-americans-in-april 2026-05-28 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference-in-new-york 2026-05-27 https://biopharmsignal.com/news/CVRX/cvrx-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-2026 2026-05-27 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-june-investor-conferences 2026-05-27 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-enters-into-10-year-focused-ultrasound-development-partnership-with-sungkyunkwan-university-south-korea-further-expanding-our-drug-delivery-ecosystem-and-global-footprint 2026-05-27 https://biopharmsignal.com/news/PCRX/pacira-biosciences-mails-letter-to-stockholders-reiterating-confidence-in-the-company-s-strategic-direction-and-highly-qualified-nominees 2026-05-27 https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-to-participate-in-upcoming-investor-conferences 2026-05-27 https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-june-2026-investor-conferences 2026-05-27 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-announces-participation-in-upcoming-investor-conferences-2cfd961d 2026-05-27 https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-june-9d492b03 2026-05-27 https://biopharmsignal.com/news/ZNTL/zentalis-strengthens-commercial-leadership-with-appointments-of-shannon-campbell-34c7acfb 2026-05-27 https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference-2026 2026-05-27 https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-june 2026-05-27 https://biopharmsignal.com/news/CYTK/cytokinetics-to-participate-in-june-investor-conferences-4c0c88f2 2026-05-27 https://biopharmsignal.com/news/MNKD/mannkind-to-present-at-jefferies-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/IRWD/fda-approves-use-of-linzessr-linaclotide-in-pediatric-patients-two-years-of-age-and-older-with-functional-constipation-fc 2026-05-27 https://biopharmsignal.com/news/MNKD/mannkind-to-showcase-new-data-at-ada-2026-advancing-understanding-of-inhaled-insulin-afrezzar-in-pediatric-care-pregnancy-and-use-with-automated-insulin-delivery-aid-systems 2026-05-27 https://biopharmsignal.com/news/PRVA/privia-health-enters-new-jersey 2026-05-27 https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-protocol-jumps-into-top-three-global-pred-bd3bdf1e 2026-05-27 https://biopharmsignal.com/news/FMS/fresenius-medical-care-highlights-new-renal-research-and-innovation-at-era-congress-2026 2026-05-27 https://biopharmsignal.com/news/JAGX/jaguar-health-compliant-with-nasdaq-bid-price-rule 2026-05-27 https://biopharmsignal.com/news/GDRX/goodrx-launches-goodrx-companion-a-new-subscription-designed-to-lower-everyday-healthcare-costs 2026-05-27 https://biopharmsignal.com/news/AIM/aim-immunotech-announces-emerging-ebola-opportunity-for-ampligen-amid-escalating-56540075 2026-05-27 https://biopharmsignal.com/news/ALT/altimmune-to-participate-in-upcoming-investor-conferences-90ad12d9 2026-05-27 https://biopharmsignal.com/news/ANGO/angiodynamics-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-present-at-2026-jefferies-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-participate-in-upcoming-investor-conferences-c2b1d291 2026-05-27 https://biopharmsignal.com/news/RIGL/rigel-to-present-at-the-jefferies-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/APVO/aptevo-and-niowave-launch-strategic-collaboration-for-radiopharmaceutical-therapeutic-development-includes-strategic-equity-investment-by-niowave-at-closing 2026-05-27 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-participation-in-the-2026-jefferies-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-real-world-study-showing-exparelr-use-was-associated-with-reduced-opioid-use-and-healthcare-costs-in-patients-undergoing-total-shoulder-arthroplasty 2026-05-27 https://biopharmsignal.com/news/ANNX/annexon-to-participate-in-upcoming-june-investor-conferences 2026-05-27 https://biopharmsignal.com/news/BIVI/join-biovie-s-exclusive-live-investor-webinar-and-q-and-a-session-on-june-2-972b03ed 2026-05-27 https://biopharmsignal.com/news/GALT/galectin-therapeutics-presents-new-easl-2026-oral-and-poster-analyses-demonstrat-c8e53529 2026-05-27 https://biopharmsignal.com/news/ALT/new-impact-phase-2b-data-highlight-concurrent-improvements-across-multiple-non-i-c3ed7d9e 2026-05-27 https://biopharmsignal.com/news/AMRN/new-reduce-it-analysis-presented-at-the-european-atherosclerosis-society-eas-con-932ee205 2026-05-27 https://biopharmsignal.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-8671d2af 2026-05-27 https://biopharmsignal.com/news/MDGL/madrigal-presents-data-demonstrating-rezdiffra-reduced-markers-of-cardiovascular-511077cf 2026-05-27 https://biopharmsignal.com/news/ATRC/atricure-to-participate-in-the-goldman-sachs-47th-annual-global-health-care-conference 2026-05-27 https://biopharmsignal.com/news/CORT/corcept-to-resubmit-its-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-cushing-s-syndrome 2026-05-27 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-announces-notification-of-mexico-patent-allowance-covering-novel-lung-cancer-detection-methods-using-cypathr-lung-technology 2026-05-27 https://biopharmsignal.com/news/ERAS/erasca-to-present-at-the-jefferies-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/TWST/twist-bioscience-to-present-at-william-blair-46th-annual-growth-stock-conference 2026-05-27 https://biopharmsignal.com/news/HCWB/hcw-biologics-exercised-option-to-regain-full-rights-for-two-commercial-ready-re-06b1f3a5 2026-05-27 https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-topline-results-from-phase-3-enhance-trial 2026-05-27 https://biopharmsignal.com/news/CNTX/context-therapeutics-to-present-at-the-jefferies-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/BBIO/bridgebio-announces-fda-acceptance-and-priority-review-of-nda-for-bbp-418-for-lg-4630be72 2026-05-27 https://biopharmsignal.com/news/BCRX/biocryst-to-present-new-hae-data-from-orladeyor-berotralstat-and-navenibart-at-the-2026-european-academy-of-allergy-and-clinical-immunology-annual-meeting 2026-05-27 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-presents-new-drug-drug-interaction-results-supporting-potential-best-in-class-profile-of-the-regimen-of-bemnifosbuvir-and-ruzasvir-for-the-treatment-of-hepatitis-c-virus-at-easl-congress-2026 2026-05-27 https://biopharmsignal.com/news/MDWD/mediwound-reports-first-quarter-2026-financial-results-and-provides-corporate-up-d4323a9b 2026-05-27 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-presents-two-posters-at-easl-2026-on-denifanstat-resmetirom--397d6e07 2026-05-27 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-7aa62ad2 2026-05-27 https://biopharmsignal.com/news/HROW/harrow-to-present-at-william-blair-s-46th-annual-growth-stock-conference-683e18e0 2026-05-27 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-participate-in-upcoming-investor-conferences-1fafa41c 2026-05-27 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-to-participate-in-upcoming-investor-conferences-b472b879 2026-05-27 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-to-participate-in-fireside-chat-at-the-jefferies-global-heal-ae919645 2026-05-27 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-phase-1-clinical-data-of-tnx-1500-an-fc-modified-anti-cd40l-cd154-monoclonal-antibody-in-the-peer-reviewed-journal-of-clinical-immunology 2026-05-27 https://biopharmsignal.com/news/INSM/insmed-to-present-at-the-2026-goldman-sachs-annual-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-clinical-data-on-rnai-based-obesity-and-mash-candidate-aro-inhbe-at-easl-2026 2026-05-27 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference 2026-05-27 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conferenc-f9d25fa3 2026-05-27 https://biopharmsignal.com/news/APGE/apogee-therapeutics-announces-1-3-billion-strategic-financing-collaboration-with-d3051363 2026-05-27 https://biopharmsignal.com/news/APGE/apogee-therapeutics-announces-positive-16-week-part-b-induction-dose-optimizatio-77f20dd2 2026-05-27 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-presents-positive-data-at-the-easl-congress-2026 2026-05-27 https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-new-and-late-breaking-pbgene-hbv-clinical-data-from-the-eliminate-b-study-at-european-association-for-the-study-of-the-liver-congress-2026 2026-05-27 https://biopharmsignal.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-467a8d4f 2026-05-27 https://biopharmsignal.com/news/MNOV/medicinova-announces-completion-of-last-patient-last-visit-in-the-mn-001-natg-202-clinical-trial-of-mn-001-tipelukast 2026-05-26 https://biopharmsignal.com/news/NBTX/nanobiotix-annonce-le-r-glement-livraison-de-son-offre-globale-5ca7f4bc 2026-05-26 https://biopharmsignal.com/news/NBTX/nanobiotix-announces-closing-of-global-offering-db0d1bbf 2026-05-26 https://biopharmsignal.com/news/XRAY/dentsply-sirona-continues-to-expand-u-s-distribution-network-to-strengthen-acces-23141708 2026-05-26 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-to-participate-in-upcoming-june-investor-conferences-70aa562d 2026-05-26 https://biopharmsignal.com/news/MDRX/veradigm-files-2023-and-2024-form-10-k 2026-05-26 https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-the-closing-of-its-offering-of-common-stock-and-pre-funded-warrants-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares 2026-05-26 https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-participation-in-upcoming-investor-conferences 2026-05-26 https://biopharmsignal.com/news/SEER/seer-to-showcase-ai-driven-multi-cancer-screening-approach-and-next-generation-proteomics-capabilities-at-asms-2026 2026-05-26 https://biopharmsignal.com/news/APGE/apogee-therapeutics-to-host-conference-call-to-report-part-b-16-week-data-from-t-16f5e4cf 2026-05-26 https://biopharmsignal.com/news/DCTH/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts 2026-05-26 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-june 2026-05-26 https://biopharmsignal.com/news/ARQT/arcutis-management-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference 2026-05-26 https://biopharmsignal.com/news/IVA/inventiva-publie-ses-informations-financi-res-du-premier-trimestre-2026-b3f1b808 2026-05-26 https://biopharmsignal.com/news/IVA/inventiva-reports-2026-first-quarter-financial-information-758b8751 2026-05-26 https://biopharmsignal.com/news/MOLN/molecular-partners-to-present-at-td-cowen-s-7th-annual-oncology-innovation-summi-394e5deb 2026-05-26 https://biopharmsignal.com/news/BRTX/biorestorative-completes-phase-2-dosing-of-brtx-100-advancing-lead-regenerative--8f9156be 2026-05-26 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-positive-clinical-cardiometabolic-data-at-the-94th-european-atherosclerosis-society-eas-congress 2026-05-26 https://biopharmsignal.com/news/SRRK/scholar-rock-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference 2026-05-26 https://biopharmsignal.com/news/PACB/pacbio-sprq-nx-chemistry-now-shipping-worldwide-enabling-sub-300-hifi-genomes-fo-ef99fc7e 2026-05-26 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-pricing-of-up-to-319-4-million-public-offering-127eec22 2026-05-26 https://biopharmsignal.com/news/RNXT/renovorx-announces-promising-pharmacokinetic-data-using-the-tamptm-platform-presented-at-the-2026-asco-annual-meeting 2026-05-26 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-participation-in-upcoming-investor-conferences 2026-05-26 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences 2026-05-26 https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-oppenheimer-26th-annual-consumer-growth-and-e-commerce-conference 2026-05-26 https://biopharmsignal.com/news/HYPR/hyperfine-to-join-russell-2000r-and-russell-3000r-indexes 2026-05-26 https://biopharmsignal.com/news/MDRX/veradigm-to-release-business-update-may-26th-and-host-investor-call-may-27th 2026-05-26 https://biopharmsignal.com/news/PGNY/progyny-inc-announces-share-repurchase-program 2026-05-26 https://biopharmsignal.com/news/PCRX/pacira-biosciences-sets-the-record-straight-regarding-doma-s-misleading-statements-about-pacira-s-intellectual-property-strategy 2026-05-26 https://biopharmsignal.com/news/RANI/rani-therapeutics-holdings-inc-announces-pricing-of-20-0-million-registered-direct-offering-of-class-a-common-stock-priced-at-the-market-under-nasdaq-rules 2026-05-26 https://biopharmsignal.com/news/ESPR/esperion-presents-new-data-from-clear-outcomes-and-the-clear-path-phase-2-pediatric-study-at-the-european-atherosclerosis-society-congress-2026 2026-05-26 https://biopharmsignal.com/news/BIVI/biovie-announces-full-enrollment-of-the-address-lc-trial-of-bezisterim-for-the-t-bacc426e 2026-05-26 https://biopharmsignal.com/news/COCP/cocrystal-pharma-announces-discovery-of-pan-viral-inhibitors-targeting-hantaviru-6c5d714e 2026-05-26 https://biopharmsignal.com/news/GANX/gain-therapeutics-presents-positive-interim-data-from-phase-1b-clinical-study-of-7715a5b9 2026-05-26 https://biopharmsignal.com/news/ANVS/annovis-bio-regains-nyse-listing-compliance-d6911038 2026-05-26 https://biopharmsignal.com/news/GSK/gsk-to-showcase-long-term-outcomes-and-pipeline-expansion-with-latest-oncology-research-at-asco-and-eha 2026-05-26 https://biopharmsignal.com/news/HUMA/humacyte-announces-presentation-at-vasa-meeting-of-research-highlighting-self-repair-of-atev-after-cannulation-for-dialysis-access 2026-05-26 https://biopharmsignal.com/news/YOU/clear-partners-with-samsung-bringing-clear-id-to-samsung-wallet 2026-05-26 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-to-participate-in-upcoming-investor-conferences 2026-05-26 https://biopharmsignal.com/news/BNGO/bionano-announces-largest-ogm-study-of-t-cell-acute-lymphoblastic-leukemia 2026-05-26 https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-data-presentations-for-briumvir-at-the-2026-consortium-of-multiple-sclerosis-centers-annual-meeting 2026-05-26 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-submission-of-biologics-license-application-bla-to-u-s-fda-for-z-rostudirsen-in-exon-51-duchenne-muscular-dystrophy-dmd 2026-05-26 https://biopharmsignal.com/news/PSTV/plus-cnside-diagnostic-platform-demonstrates-substantial-healthcare-cost-reduction-in-patients-with-leptomeningeal-metastases 2026-05-26 https://biopharmsignal.com/news/BCTX/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-6e482276 2026-05-26 https://biopharmsignal.com/news/SNGX/suitability-of-vaccine-platform-for-bundibugyo-virus-cause-of-the-ebola-outbreak-in-congo 2026-05-26 https://biopharmsignal.com/news/VRAX/virax-biolabs-reports-positive-early-clinical-data-for-viraximmunetm-in-long-covid-and-related-post-acute-infection-syndromes 2026-05-26 https://biopharmsignal.com/news/NGEN/nervgen-announces-positive-independent-blinded-biomechanical-gait-analyses-demon-0bf3b1bf 2026-05-26 https://biopharmsignal.com/news/OLMA/olema-oncology-announces-clinical-trial-collaboration-and-supply-agreement-with-bayer-to-evaluate-op-3136-in-combination-with-nubeqar-darolutamide-in-metastatic-castration-resistant-prostate-cancer 2026-05-26 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-secures-up-to-150-million-of-non-dilutive-financing-from--8424c4cb 2026-05-26 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-host-immunology-day-to-showcase-promising-initial-clini-cc2e30f1 2026-05-26 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-presents-new-auvelity-data-in-major-depressive-disorder-at-t-53aaeb28 2026-05-26 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-presented-retrospective-u-s-real-world-claims-analysis-characterizing-patients-with-fibromyalgia-at-the-professional-society-for-health-economics-and-outcomes-research-ispor-2026-annual-meeting 2026-05-26 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-wins-appeal-following-formal-dispute-resolution-process-for-ons-5010-lytenavatm-bevacizumab-vikg 2026-05-26 https://biopharmsignal.com/news/BRKR/champalimaud-foundation-s-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri 2026-05-26 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-reports-updated-crb-701-phase-1-2-clinical-data-demonstrating-robust-activity-in-2l-oropharyngeal-and-cervical-cancers 2026-05-26 https://biopharmsignal.com/news/ALKS/alkermes-to-showcase-leadership-in-psychiatry-and-orexin-biology-with-new-data-at-the-american-society-of-clinical-psychopharmacology-annual-meeting 2026-05-26 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-proposed-public-offering-1685aa73 2026-05-26 https://biopharmsignal.com/news/KURA/kura-oncology-reports-strong-clinical-activity-and-safety-with-darlifarnib-adagrasib-in-kras-g12c-mutated-solid-tumors 2026-05-26 https://biopharmsignal.com/news/EDIT/editas-medicine-presents-edit-401-preclinical-data-demonstrating-robust-reductio-8f1aef48 2026-05-26 https://biopharmsignal.com/news/PSNL/personalis-to-highlight-breadth-of-next-personalr-ultra-sensitive-ctdna-data-at-asco-2026-annual-meeting-including-podium-presentation-from-tracerx-consortium 2026-05-26 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-participation-at-the-2026-jefferies-global-healthcare-conference 2026-05-26 https://biopharmsignal.com/news/FMS/fresenius-medical-care-announces-new-share-buyback-program-with-a-total-volume-of-around-eur-1-billion-with-phased-execution-over-12-months 2026-05-25 https://biopharmsignal.com/news/GNFT/genfit-highlights-broad-scientific-and-strategic-presence-at-easl-congress-2026 2026-05-25 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-closing-of-150-million-underwritten-offering-of-common-fbf30fd8 2026-05-22 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-q-filing 2026-05-22 https://biopharmsignal.com/news/NBTX/nanobiotix-annonce-l-exercice-integral-de-l-option-de-surallocation-portant-le-p-c77e1d84 2026-05-22 https://biopharmsignal.com/news/NBTX/nanobiotix-announces-full-exercise-of-underwriters-over-allotment-option-bringin-2fa7ab33 2026-05-22 https://biopharmsignal.com/news/SCYX/scynexis-announces-one-for-eight-reverse-stock-split 2026-05-22 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-jefferies-global-healthcare-conferen-eacfb4e3 2026-05-22 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4 2026-05-22 https://biopharmsignal.com/news/AGIO/agios-pyrukynd-mitapivat-approved-in-the-european-union-for-adults-with-thalasse-7a0583c1 2026-05-22 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-to-present-data-at-asco-2026-reinforcing-pelareorep-s-potenti-ae06f28b 2026-05-22 https://biopharmsignal.com/news/HYPR/hyperfine-announces-presentation-of-results-from-the-prime-study-showing-portable-mri-substantially-reduces-time-to-imaging-in-emergency-departments 2026-05-22 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-09df65d6 2026-05-22 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-participate-in-jefferies-global-healthcare-confere-9abd2552 2026-05-22 https://biopharmsignal.com/news/BCTX/briacell-presentations-highlight-positive-clinical-data-for-bria-imt-at-asco-202-da635715 2026-05-22 https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-william-blair-46th-annual-growth-stock-confer-369a40b0 2026-05-22 https://biopharmsignal.com/news/IBRX/immunitybio-highlights-patient-survey-data-at-ispor-2026-showing-majority-of-uk-adults-living-with-nmibc-favor-bladder-preservation 2026-05-22 https://biopharmsignal.com/news/IBRX/immunitybio-presents-health-economic-analysis-at-ispor-2026-showing-anktivar-plus-bcg-delivers-lower-cost-per-sustained-complete-response-versus-tar-200-in-bcg-unresponsive-nmibc-cis 2026-05-22 https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-pricing-of-100-million-offering-of-common-stock-and-pre-funded-warrants 2026-05-22 https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-expansion-of-abi-6250-clinical-development-into-cholestatic-liver-diseases 2026-05-22 https://biopharmsignal.com/news/BSEM/biostem-technologies-announces-2-5-million-private-placement-financing-with-its--2f24dae1 2026-05-22 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-annual-shareholder-meeting-to-be-hel-653bf181 2026-05-22 https://biopharmsignal.com/news/ACIU/ac-immune-presents-new-phase-1-data-indicating-higher-uptake-of-tdp-43-pet-trace-219b543b 2026-05-22 https://biopharmsignal.com/news/REGN/otarmenitm-lunsotogene-parvec-receives-ema-filing-acceptance-for-genetic-hearing-loss 2026-05-22 https://biopharmsignal.com/news/MDNA/medicenna-announces-the-filing-of-its-prospectus-supplement-and-investment-term-sheet 2026-05-22 https://biopharmsignal.com/news/BNTX/biontech-pr-sentiert-auf-der-asco-jahrestagung-2026-fortschritte-aus-pipelinepro-a9b7e13a 2026-05-22 https://biopharmsignal.com/news/BNTX/biontech-to-showcase-progress-across-late-stage-oncology-pipeline-at-the-2026-as-f9c981b1 2026-05-22 https://biopharmsignal.com/news/NGEN/nervgen-announces-pricing-of-us-60-0-million-public-offering-of-securities-c0024b9c 2026-05-22 https://biopharmsignal.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meetin-65dc1574 2026-05-22 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-new-research-supporting-integration-and-use-of-pedmarkr-at-the-2026-asco-annual-meeting 2026-05-21 https://biopharmsignal.com/news/BIIB/biogen-and-denali-therapeutics-provide-update-on-phase-2b-luma-study-of-biib122--b39e0122 2026-05-21 https://biopharmsignal.com/news/DNLI/biogen-and-denali-therapeutics-provide-update-on-phase-2b-luma-study-of-biib122--cfdf22fe 2026-05-21 https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-present-data-from-all-clinical-programs-at-the-2026--e41c812b 2026-05-21 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-present-phase-1b-muir-trial-data-showing-encouraging-6d0f0eb0 2026-05-21 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting 2026-05-21 https://biopharmsignal.com/news/RIGL/rigel-announces-oral-and-poster-presentations-at-the-2026-asco-annual-meeting-and-eha2026-congress 2026-05-21 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-positive-phase-2-results-for-silevertinib-in-frontline-nsclc-patients-with-egfr-non-classical-mutations 2026-05-21 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of--55624eac 2026-05-21 https://biopharmsignal.com/news/FLGT/fulgent-announces-rapid-oral-full-abstract-publication-for-fid-007-within-the-head-and-neck-cancer-track-session-at-the-asco-2026-annual-meeting 2026-05-21 https://biopharmsignal.com/news/MBRX/moleculin-highlights-abstract-accepted-for-poster-presentation-at-the-2026-asco--ab112469 2026-05-21 https://biopharmsignal.com/news/SNDX/syndax-announces-four-revuforjr-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data 2026-05-21 https://biopharmsignal.com/news/REGN/lynozyficr-linvoseltamab-monotherapy-demonstrates-deep-and-rapid-responses-in-all-treated-patients-with-second-line-plus-systemic-amyloid-light-chain-amyloidosis 2026-05-21 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-unveil-new-data-at-ascor-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline 2026-05-21 https://biopharmsignal.com/news/IMRX/immuneering-reports-17-3-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus-chemotherapy 2026-05-21 https://biopharmsignal.com/news/OLMA/olema-oncology-announces-encouraging-initial-clinical-data-from-the-phase-1-study-of-op-3136-a-kat6-inhibitor-at-2026-asco-annual-meeting 2026-05-21 https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-present-promising-phase-1-clinical-data-for-ctx-8371-in--211bb911 2026-05-21 https://biopharmsignal.com/news/LEGN/legend-biotech-announces-presentations-at-asco-2026-b3367a52 2026-05-21 https://biopharmsignal.com/news/EXEL/exelixis-announces-presentations-at-asco-2026-highlighting-ongoing-studies-in-diverse-tumor-types 2026-05-21 https://biopharmsignal.com/news/SEER/seer-board-of-directors-unanimously-rejects-further-revised-unsolicited-proposal-from-radoff-jec-group 2026-05-21 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-to-participate-in-upcoming-investor-conferences-e86987e6 2026-05-21 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-host-investor-conference-call-on-positive-rasolute-302-results-following-2026-asco-presentation 2026-05-21 https://biopharmsignal.com/news/CUE/cue-biopharma-to-present-at-the-2026-jefferies-global-healthcare-conference-d45e24ff 2026-05-21 https://biopharmsignal.com/news/PACB/pacbio-to-participate-in-the-jefferies-global-healthcare-conference-c27c5d94 2026-05-21 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-to-present-at-upcoming-investor-conferences 2026-05-21 https://biopharmsignal.com/news/AZTA/azenta-publishes-2025-environmental-social-and-governance-esg-report 2026-05-21 https://biopharmsignal.com/news/NGEN/nervgen-announces-proposed-public-offering-of-securities-fc0d7421 2026-05-21 https://biopharmsignal.com/news/IVA/inventiva-pr-sentera-lors-de-la-2026-jefferies-global-healthcare-conference-9a46baee 2026-05-21 https://biopharmsignal.com/news/IVA/inventiva-to-present-at-2026-jefferies-global-healthcare-conference-80e957e9 2026-05-21 https://biopharmsignal.com/news/IPHA/outcome-of-innate-pharma-s-2026-annual-general-meeting 2026-05-21 https://biopharmsignal.com/news/TEVA/the-european-medicines-agency-accepts-teva-s-marketing-authorization-application-df277552 2026-05-21 https://biopharmsignal.com/news/GNFT/genfit-reports-first-quarter-2026-financial-information-and-provides-a-corporate-update 2026-05-21 https://biopharmsignal.com/news/NBTX/nanobiotix-annonce-les-modalites-definitives-de-son-offre-globale-sursouscrite-a-9174d539 2026-05-21 https://biopharmsignal.com/news/TLSA/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial-7d59e347 2026-05-21 https://biopharmsignal.com/news/NBTX/nanobiotix-announces-pricing-of-oversubscribed-85m-global-offering-0a62d5e9 2026-05-21 https://biopharmsignal.com/news/HCWB/hcw-biologics-inc-announces-pricing-of-approximately-4-0-million-private-placeme-215b14c3 2026-05-21 https://biopharmsignal.com/news/NBTX/nanobiotix-annonce-la-reprise-des-n-gociations-de-ses-actions-ordinaires-sur-eur-132d679e 2026-05-21 https://biopharmsignal.com/news/NBTX/nanobiotix-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris-a76bc986 2026-05-21 https://biopharmsignal.com/news/BFRI/biofrontera-inc-to-participate-in-the-lytham-partners-spring-2026-investor-confe-5a188e40 2026-05-21 https://biopharmsignal.com/news/ISRG/intuitive-announces-innovations-to-advance-quintuple-aim 2026-05-21 https://biopharmsignal.com/news/MDXG/mimedx-to-participate-in-craig-hallum-23rd-annual-institutional-investor-conference 2026-05-21 https://biopharmsignal.com/news/FATE/fate-therapeutics-announces-presentations-at-2026-asco-and-eular-annual-meetings-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and-autoimmune-diseases 2026-05-21 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conference 2026-05-21 https://biopharmsignal.com/news/AEMD/aethlon-medical-monitoring-current-ebola-outbreak-and-reaffirms-outbreak-pandemic-preparedness 2026-05-21 https://biopharmsignal.com/news/VTAK/flyte-activates-high-frequency-memorial-day-weekend-flight-network-to-capture-su-081616db 2026-05-21 https://biopharmsignal.com/news/BCDA/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-fd6856cf 2026-05-21 https://biopharmsignal.com/news/APYX/new-study-shows-significant-improvement-in-cellulite-and-skin-laxity-with-advanc-d19ed0bc 2026-05-21 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-june-investor-conferences 2026-05-21 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-announces-the-appointment-of-nishant-saxena-as-chief-business-officer-and-schedules-a-pre-2026-asco-crb-701-data-conference-call 2026-05-21 https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-to-present-at-td-cowen-s-7th-annual-oncology-innovation-summit 2026-05-21 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-pricing-of-150-million-underwritten-offering-of-common-15fc60bd 2026-05-21 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-completes-meeting-with-fda-for-zervimesine-ct1812-in-deme-d47aaed7 2026-05-21 https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-239640de 2026-05-21 https://biopharmsignal.com/news/DTIL/precision-biosciences-to-host-investor-webcast-to-discuss-late-breaking-pbgene-hbv-data-from-eliminate-b-trial-presented-at-european-association-for-the-study-of-the-liver-congress-2026 2026-05-21 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-95-complete-response-rate-in-interim-update-from-relap-603927c0 2026-05-21 https://biopharmsignal.com/news/ALKS/alkermes-showcases-data-from-psychiatry-portfolio-and-sleep-research-into-real-world-patient-experience-at-spring-2026-scientific-conferences 2026-05-21 https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-present-at-2026-jefferies-global-healthcare-conference 2026-05-21 https://biopharmsignal.com/news/PEPG/pepgen-announces-presentations-at-the-15th-international-myotonic-dystrophy-consortium-highlighting-clinical-data-from-the-pgn-edodm1-program 2026-05-21 https://biopharmsignal.com/news/BDX/bd-delivers-kidney-stone-care-for-urology-teams-with-the-elyratm-thulium-fiber-laser-system 2026-05-21 https://biopharmsignal.com/news/HCM/hutchmed-and-innovent-jointly-announce-nmpa-approval-for-elunate-fruquintinib-in-63bef51f 2026-05-21 https://biopharmsignal.com/news/BDSX/biodesix-to-participate-in-upcoming-investor-conferences-ab591711 2026-05-21 https://biopharmsignal.com/news/NBTX/nanobiotix-annonce-la-suspension-temporaire-du-cours-de-ses-actions-ordinaires-s-24eae800 2026-05-21 https://biopharmsignal.com/news/NBTX/nanobiotix-announces-temporary-trading-halt-of-its-ordinary-shares-on-euronext-p-6479b7f4 2026-05-21 https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-pricing-of-public-offering-of-common-stock-00372d13 2026-05-21 https://biopharmsignal.com/news/NBTX/nanobiotix-annonce-le-lancement-d-une-offre-globale-fedeb5f0 2026-05-20 https://biopharmsignal.com/news/NBTX/nanobiotix-announces-launch-of-global-follow-on-offering-8ca5d3dc 2026-05-20 https://biopharmsignal.com/news/FMS/fresenius-medical-care-annual-general-meeting-strengthening-performance-and-advancing-innovation-in-kidney-care 2026-05-20 https://biopharmsignal.com/news/JAGX/jaguar-health-reports-first-quarter-2026-financials 2026-05-20 https://biopharmsignal.com/news/CVRX/cvrx-to-present-at-the-william-blair-46th-annual-growth-stock-conference 2026-05-20 https://biopharmsignal.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-25-2026 2026-05-20 https://biopharmsignal.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-june-a4d71e69 2026-05-20 https://biopharmsignal.com/news/XRAY/dentsply-sirona-to-participate-in-the-2026-stifel-jaws-paws-conference-30feaf7d 2026-05-20 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-reports-first-quarter-2026-financial-results-and-provides-ope-cb53f29b 2026-05-20 https://biopharmsignal.com/news/EQ/equillium-to-host-virtual-investor-event-to-share-new-insights-into-the-aryl-hyd-aa0abe04 2026-05-20 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-o-fd6070d7 2026-05-20 https://biopharmsignal.com/news/LGVN/longeveron-issues-letter-to-stockholders-highlighting-corporate-strategy-strateg-3307c1ca 2026-05-20 https://biopharmsignal.com/news/TCMD/tactile-medical-to-present-at-the-william-blair-46th-annual-growth-stock-conference 2026-05-20 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-and-goldman-sachs-47th-annual-global-healthcare-conference 2026-05-20 https://biopharmsignal.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-fa6a315d 2026-05-20 https://biopharmsignal.com/news/AIM/aim-immunotech-announces-2-4-million-financing-including-concurrent-registered-d-04c67dc4 2026-05-20 https://biopharmsignal.com/news/INKT/mink-therapeutics-reports-new-data-on-agent-797-an-allo-inkt-cell-therapy-at-ats-9f528b72 2026-05-20 https://biopharmsignal.com/news/INDV/new-studies-show-adherence-to-monthly-injectable-buprenorphine-is-associated-wit-df904f86 2026-05-20 https://biopharmsignal.com/news/JAGX/jaguar-health-to-hold-investor-webcast-may-26-regarding-q1-2026-financials-and-corporate-updates-jaguar-ceo-lisa-conte-presenting-may-28-at-lytham-partners-spring-2026-investor-conference 2026-05-20 https://biopharmsignal.com/news/IRMD/iradimed-corporation-to-present-at-the-goldman-sachs-47th-annual-global-healthca-01c6b756 2026-05-20 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-75-enrollment-milestone-in-remedy2-phase-2-3-acute-ischemic-stroke-trial 2026-05-20 https://biopharmsignal.com/news/PYPD/polypid-to-participate-in-the-craig-hallum-23rd-annual-institutional-investor-conference 2026-05-20 https://biopharmsignal.com/news/ABSI/absci-to-participate-in-upcoming-investor-conferences-51fc7c18 2026-05-20 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-highlights-breadth-of-independent-vonoprazan-research-at-digestive-disease-week-2026-annual-meeting 2026-05-20 https://biopharmsignal.com/news/ANVS/annovis-announces-pricing-of-15-0-million-public-offering-of-common-stock-and-ac-b755aa8d 2026-05-20 https://biopharmsignal.com/news/MDGL/madrigal-to-present-new-data-from-the-company-s-mash-program-at-easl-2026-demons-fce26674 2026-05-20 https://biopharmsignal.com/news/TARA/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-and-eha 2026-05-20 https://biopharmsignal.com/news/SRRK/scholar-rock-to-present-at-the-2026-jefferies-global-healthcare-conference 2026-05-20 https://biopharmsignal.com/news/HUMA/humacyte-announces-symvessr-is-now-under-contract-with-the-strategic-acquisition-center-sac-of-the-u-s-department-of-veterans-affairs 2026-05-20 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-initiation-of-phase-3-forzetto-trial-of-z-rostudirsen-in-duchenne-muscular-dystrophy-dmd-ahead-of-planned-bla-submission-for-u-s-accelerated-approval 2026-05-20 https://biopharmsignal.com/news/RGEN/repligen-announces-publication-of-the-company-s-2025-corporate-sustainability-re-9ff9ce31 2026-05-20 https://biopharmsignal.com/news/EBS/emergent-biosolutions-to-participate-in-upcoming-investor-conferences 2026-05-20 https://biopharmsignal.com/news/ROIV/roivant-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provides-business-update 2026-05-20 https://biopharmsignal.com/news/CCCC/c4-therapeutics-to-participate-in-upcoming-conferences-10ae0b56 2026-05-20 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-620dbf2c 2026-05-20 https://biopharmsignal.com/news/SNDX/syndax-announces-participation-in-upcoming-investor-conferences 2026-05-20 https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026 2026-05-20 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-strategic-agreement-with-anthropic-to-position-claude-enterprise-as-the-shared-intelligence-platform-across-its-global-operations 2026-05-20 https://biopharmsignal.com/news/PCRX/pacira-biosciences-files-investor-presentation-highlighting-successful-execution-of-its-long-term-strategy-to-drive-value-for-all-stockholders 2026-05-20 https://biopharmsignal.com/news/BLTE/belite-bio-reports-unaudited-first-quarter-2026-financial-results-and-provides-a-49952858 2026-05-20 https://biopharmsignal.com/news/PSNL/personalis-secures-fourth-medicare-coverage-decision-for-next-personalr-expanding-breast-cancer-coverage-to-pre-surgical-treatment-monitoring 2026-05-20 https://biopharmsignal.com/news/YOU/clear-and-gdit-announce-strategic-collaboration-agreement 2026-05-20 https://biopharmsignal.com/news/IBRX/immunitybio-announces-fda-acceptance-of-supplemental-bla-for-anktivar-plus-bcg-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-with-papillary-disease-pdufa-date-set-for-january-6-2027 2026-05-20 https://biopharmsignal.com/news/FMS/fresenius-medical-care-reappoints-chief-financial-officer-martin-fischer 2026-05-19 https://biopharmsignal.com/news/MNPR/monopar-announces-publication-of-phase-2-study-demonstrating-alxn1840-significantly-improves-copper-balance-in-patients-with-wilson-disease 2026-05-19 https://biopharmsignal.com/news/YOU/clear-partners-with-expedia-to-bring-a-more-seamless-airport-experience-to-travelers 2026-05-19 https://biopharmsignal.com/news/FBIO/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-healthcare--cca64eaf 2026-05-19 https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference 2026-05-19 https://biopharmsignal.com/news/DGX/quest-diagnostics-declares-quarterly-cash-dividend 2026-05-19 https://biopharmsignal.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-8b939a2f 2026-05-19 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-expands-rare-disease-portfolio-through-agreement-for-u-s-co-fc60e8c8 2026-05-19 https://biopharmsignal.com/news/RXST/rxsight-inc-to-present-at-the-stifel-2026-virtual-ophthalmology-forum 2026-05-19 https://biopharmsignal.com/news/ANVS/annovis-announces-launch-of-proposed-public-offering-of-common-stock-and-accompa-8ec0d147 2026-05-19 https://biopharmsignal.com/news/IRTC/irhythm-holdings-to-participate-in-upcoming-investor-conferences-46a8c364 2026-05-19 https://biopharmsignal.com/news/IRIX/iridex-reports-first-quarter-2026-financial-results 2026-05-19 https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-proposed-public-offering-of-common-stock-858217e7 2026-05-19 https://biopharmsignal.com/news/KURA/kura-oncology-to-present-at-td-cowen-7th-annual-oncology-innovation-summit 2026-05-19 https://biopharmsignal.com/news/VXRT/vaxart-files-preliminary-proxy-statement-and-issues-open-letter-to-shareholders-7ff9930b 2026-05-19 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-presents-safety-data-from-52-weeks-of-continuous-cytisinicline-treatment 2026-05-19 https://biopharmsignal.com/news/MMSI/merit-medical-shareholders-elect-scott-r-ward-to-board-of-directors-b8f2f33a 2026-05-19 https://biopharmsignal.com/news/NXGL/nexgel-reports-positive-data-from-randomized-single-center-irb-study-to-evaluate-the-effectiveness-and-safety-of-a-hydrogel-laser-treatment-patch-in-laser-hair-removal-with-a-95-6-reduction-in-plume-concentration 2026-05-19 https://biopharmsignal.com/news/JAGX/jaguar-health-announces-active-treatment-only-continuation-of-pivotal-multicenter-clinical-trial-in-pediatric-patients-with-microvillus-inclusion-disease-mvid-to-support-a-new-drug-application-nda-for-liquid-oral-crofelemer 2026-05-19 https://biopharmsignal.com/news/OGEN/oragenics-to-present-at-sidoti-s-micro-cap-virtual-investor-conference-may-20-21 2026-05-19 https://biopharmsignal.com/news/HSCS/heartsciences-signs-commercial-agreement-with-north-shore-health-the-first-hospi-a0d1b489 2026-05-19 https://biopharmsignal.com/news/RNXT/renovorx-to-present-at-the-alliance-global-partners-virtual-annual-healthcare-company-showcase-on-may-20th 2026-05-19 https://biopharmsignal.com/news/ICCM/icecure-s-prosenser-reports-nearly-90-recurrence-free-rate-for-cryoablation-of-kidney-cancer-data-presented-at-ecio-2026-and-first-ever-breast-cryoablation-master-class-overbooked 2026-05-19 https://biopharmsignal.com/news/AIM/aim-immunotech-announces-significant-increase-in-stockholder-equity-and-extensio-7b977acc 2026-05-19 https://biopharmsignal.com/news/ARDX/ardelyx-to-participate-at-the-jefferies-global-healthcare-conference-2026-a45950e8 2026-05-19 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-host-webcast-for-investors-highlighting-updated-results-from-phase-2-trial-of-silevertinib-in-1l-egfrm-nsclc 2026-05-19 https://biopharmsignal.com/news/CGON/suo-ctc-and-cg-oncology-announce-award-recipients-of-the-second-annual-non-muscl-f95ea5a8 2026-05-19 https://biopharmsignal.com/news/BBLG/bone-biologics-achieves-29-month-validated-shelf-life-for-rhnell-1-287ecf34 2026-05-19 https://biopharmsignal.com/news/BCDA/biocardia-to-participate-in-a-fireside-chat-at-the-alliance-global-partners-a-g--7891d68a 2026-05-19 https://biopharmsignal.com/news/EXEL/exelixis-announces-clinical-development-collaboration-with-merck-for-phase-3-stellar-316-pivotal-trial-for-patients-with-colorectal-cancer 2026-05-19 https://biopharmsignal.com/news/LPCN/lipocine-announces-lpcn-1154-phase-3-data-accepted-for-oral-presentation-at-2026-ascp-annual-meeting 2026-05-19 https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-aggregate-of-400-000-in-private-placements-priced-at-premium-to-market 2026-05-19 https://biopharmsignal.com/news/PSTV/plus-therapeutics-partners-with-ephemeral-technologies-to-deploy-ai-execution-platform-for-cns-oncology 2026-05-19 https://biopharmsignal.com/news/IBRX/immunitybio-presents-favorable-comparative-effectiveness-data-in-complete-response-rates-of-nai-bcg-versus-nadofaragene-and-tar-200-at-aua-2026 2026-05-19 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-data-presentations-support-advancement-of-ath434-into-phas-4753e92a 2026-05-19 https://biopharmsignal.com/news/TLSA/tiziana-announces-new-positive-clinical-data-for-intranasal-foralumab-in-non-act-3c192d58 2026-05-19 https://biopharmsignal.com/news/OKYO/okyo-expands-scientific-advisory-board-with-the-appointment-of-international-exp-87078f1a 2026-05-19 https://biopharmsignal.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-cef7e0be 2026-05-19 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-receives-fda-orphan-drug-designation-for-cln-049-a-novel-f-c84381bb 2026-05-19 https://biopharmsignal.com/news/MDNA/medicenna-announces-the-finalization-of-the-terms-of-its-public-offering-of-securities 2026-05-19 https://biopharmsignal.com/news/BSX/fracture-ide-trial-of-the-boston-scientific-seismiqtm-4ce-coronary-intravascular-lithotripsy-catheter-meets-primary-safety-and-effectiveness-endpoints 2026-05-19 https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-initial-clinical-data-demonstrating-that-zovegalisi-7d0d964f 2026-05-19 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-engages-floyd-regulatory-strategic-consulting-as-regulatory-affairs-advisor-and-danforth-health-as-strategic-operations-partner 2026-05-19 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-announces-pricing-of-up-to-approximately-32-million-underwritten-offering 2026-05-19 https://biopharmsignal.com/news/PNTG/pennant-group-to-participate-in-the-2026-rbc-global-healthcare-conference 2026-05-18 https://biopharmsignal.com/news/PNTG/pennant-announces-an-acquisition-of-senior-living-community-in-arizona 2026-05-18 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-present-initial-clinical-data-for-cln-978-in-treatment--e39e8b02 2026-05-18 https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-positive-update-on-restoraation-2-trial-wve-006-gal-3518234b 2026-05-18 https://biopharmsignal.com/news/CERT/certara-to-participate-in-upcoming-investor-conferences-0602d00a 2026-05-18 https://biopharmsignal.com/news/AZYO/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-c5c3be7a 2026-05-18 https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference 2026-05-18 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-presentation-of-new-data-from-the-phase-3-launch-htn-trial-of-lorundrostat-at-the-35th-european-meeting-on-hypertension-and-cardiovascular-protection-esh-2026 2026-05-18 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-real-world-data-highlighting-functional-impact-of-mild-tardive-dyskinesia-severity-and-improvement-with-ingrezzar-valbenazine-capsules 2026-05-18 https://biopharmsignal.com/news/DRTS/alpha-tau-announces-first-quarter-2026-financial-results-and-provides-corporate--7d96f3ed 2026-05-18 https://biopharmsignal.com/news/CCCC/c4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-70d8c55a 2026-05-18 https://biopharmsignal.com/news/BEAM/beam-therapeutics-presents-recently-reported-topline-clinical-data-for-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-american-thoracic-society-ats-2026-international-conference 2026-05-18 https://biopharmsignal.com/news/BLTE/belite-bio-receives-orphan-drug-status-for-tinlarebant-in-stargardt-disease-in-s-68b33b80 2026-05-18 https://biopharmsignal.com/news/ARVN/arvinas-employees-give-back-during-company-wide-impact-day 2026-05-18 https://biopharmsignal.com/news/ENLV/enlivex-announces-dosing-of-first-patient-in-the-united-states-as-part-of-its-ph-67ad5378 2026-05-18 https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-saudi-food-and-drug-authority-approval-for-acam2000r-smallpox-and-mpox-vaccinia-vaccine-live 2026-05-18 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-completes-acquisition-of-soleno-therapeutics 2026-05-18 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-commencement-of-halneuronr-chemotherapy-induced-neuropathic-pain-phase-2b-long-term-extension-study 2026-05-18 https://biopharmsignal.com/news/DRTS/alpha-tau-to-participate-in-may-investor-conferences-c95a86c8 2026-05-18 https://biopharmsignal.com/news/SSKN/new-peer-reviewed-publication-confirms-unprecedented-response-rates-for-strata-s-afe4339a 2026-05-18 https://biopharmsignal.com/news/TEVA/fitch-upgrades-teva-to-investment-grade-amid-pivot-to-growth-execution-9f1c7e65 2026-05-18 https://biopharmsignal.com/news/OGEN/oragenics-provides-investor-update 2026-05-18 https://biopharmsignal.com/news/FBIO/fortress-biotech-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference 2026-05-18 https://biopharmsignal.com/news/ALHC/alignment-healthcare-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference-2026 2026-05-18 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-names-greg-martini-as-chief-financial-officer-526628e6 2026-05-18 https://biopharmsignal.com/news/BIVI/biovie-announces-completion-of-phase-2-sunrise-pd-trial-in-early-stage-parkinson-5865bdf4 2026-05-18 https://biopharmsignal.com/news/VTAK/catheter-precision-reports-200-revenue-growth-and-completes-transformative-flyte-7478746b 2026-05-18 https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-fireside-chat-at-a-g-p-s-annual-healthcare-company-show-840282ca 2026-05-18 https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-united-kingdom-mhra-approval-of-vyjuvek-for-the-treatm-23d2eafe 2026-05-18 https://biopharmsignal.com/news/TEVA/teva-study-finds-only-23-of-younger-adults-with-mood-disorders-and-tardive-dyski-a603c03d 2026-05-18 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-appoints-mamata-gokhale-ph-d-rac-as-senior-vice-president-of-regulatory-affairs 2026-05-18 https://biopharmsignal.com/news/LPCN/lipocine-to-present-at-a-g-p-s-annual-virtual-healthcare-company-showcase 2026-05-18 https://biopharmsignal.com/news/TARA/protara-therapeutics-to-host-virtual-investor-webinar-to-discuss-tara-002-for-lymphatic-malformations-on-tuesday-may-19-2026 2026-05-18 https://biopharmsignal.com/news/IBRX/immunitybio-announces-comprehensive-u-s-patents-covering-combination-of-anktiva-with-bcg-for-cancer-treatment-with-terms-through-2035 2026-05-18 https://biopharmsignal.com/news/IPHA/innate-pharma-to-participate-in-the-jefferies-global-healthcare-conference 2026-05-18 https://biopharmsignal.com/news/NGEN/nervgen-reports-first-quarter-2026-financial-results-and-provides-business-updat-d7cfb0d6 2026-05-18 https://biopharmsignal.com/news/AMWL/nature-human-behaviour-study-finds-silvercloud-by-amwell-reduced-prevalence-of-m-dd7dd711 2026-05-18 https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-four-week-iv-data-from-the-restore-fa-trial-of-dt-216p2-demonstrating-clinical-improvements-and-comprehensive-biomarker-activity-in-friedreich-ataxia 2026-05-18 https://biopharmsignal.com/news/BYSI/beyondspring-announces-poster-presentation-at-2026-asco-annual-meeting-121bfb8e 2026-05-18 https://biopharmsignal.com/news/AORT/artivion-completes-acquisition-of-endospan-ltd 2026-05-18 https://biopharmsignal.com/news/BSX/boston-scientific-enters-into-2-billion-accelerated-share-repurchase-agreement 2026-05-18 https://biopharmsignal.com/news/REGN/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicontm-conjugates-across-multiple-therapeutic-areas 2026-05-18 https://biopharmsignal.com/news/BDX/peter-menziuso-named-evp-and-president-bd-interventional 2026-05-18 https://biopharmsignal.com/news/CNTX/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202 2026-05-18 https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-first-patients-dosed-in-new-cohorts-of-two-on-f86856dd 2026-05-18 https://biopharmsignal.com/news/BSX/boston-scientific-announces-strategic-investment-in-mirus-llc 2026-05-18 https://biopharmsignal.com/news/GSK/gsk-s-rsv-vaccine-arexvy-receives-expanded-approval-in-japan-for-adults-aged-18-59-at-increased-risk 2026-05-18 https://biopharmsignal.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-fc878ee8 2026-05-17 https://biopharmsignal.com/news/DSGN/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreich-s-ataxia-on-monday-may-18-2026 2026-05-17 https://biopharmsignal.com/news/IBRX/immunitybio-signs-exclusive-u-s-agreement-with-japan-bcg-laboratory-for-the-tokyo-strain-of-bcg-to-enhance-bcg-supply-in-the-united-states 2026-05-16 https://biopharmsignal.com/news/MTLS/materialise-houdt-jaarlijkse-aandeelhoudersvergadering-op-16-juni-2026 2026-05-16 https://biopharmsignal.com/news/REGN/regeneron-provides-update-on-phase-3-trial-of-fianlimab-lag-3-inhibitor-combination-in-first-line-unresectable-or-metastatic-melanoma 2026-05-16 https://biopharmsignal.com/news/ENLV/enlivex-announces-receipt-of-nasdaq-minimum-bid-price-notification-135abfe7 2026-05-15 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-reports-first-quarter-2026-results-and-continued-stenopari-9dd3e261 2026-05-15 https://biopharmsignal.com/news/BNTX/aktion-rinnen-und-aktion-re-der-biontech-se-stimmen-auf-der-ordentlichen-hauptve-30a4382a 2026-05-15 https://biopharmsignal.com/news/BNTX/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting--3dc40ce1 2026-05-15 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-reports-first-quarter-2026-financial-results 2026-05-15 https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-first-quarter-2026-financial-results-provides-corporate-update-announces-cfo-transition 2026-05-15 https://biopharmsignal.com/news/PSTV/plus-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update-on-reyobiqtm-clinical-program-and-cnsider-commercial-rollout 2026-05-15 https://biopharmsignal.com/news/CADL/candel-therapeutics-reports-extended-clinical-benefit-over-multiple-clinical-endpoints-in-patients-from-phase-3-trial-of-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer-under-prolonged-follow-up-at-aua-2026-annual-meeting 2026-05-15 https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-15 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update 2026-05-15 https://biopharmsignal.com/news/MTLS/materialise-to-hold-annual-shareholders-meeting-on-june-16-2026 2026-05-15 https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-9a263134 2026-05-15 https://biopharmsignal.com/news/REGN/next-generation-of-scientific-leaders-awarded-more-than-7-million-at-the-2026-regeneron-international-science-and-engineering-fair 2026-05-15 https://biopharmsignal.com/news/PROK/prokidney-reports-first-quarter-2026-financial-results-and-business-highlights 2026-05-15 https://biopharmsignal.com/news/EMBC/embecta-completes-acquisition-of-owen-mumford-holdings-limited 2026-05-15 https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-sale-of-approximately-69-million-of-shares-through-its-at-the-market-atm-facility 2026-05-15 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-to-participate-in-two-upcoming-investor-conferences-ec428c77 2026-05-15 https://biopharmsignal.com/news/MBRX/moleculin-reports-first-quarter-2026-financial-results-and-provides-clinical-upd-415315ab 2026-05-15 https://biopharmsignal.com/news/PULM/pulmatrix-announces-first-quarter-2026-financial-results 2026-05-15 https://biopharmsignal.com/news/CGON/cg-oncology-reports-positive-first-results-from-core-008-cohort-cx-phase-2-trial-68aac602 2026-05-15 https://biopharmsignal.com/news/COCP/cocrystal-pharma-provides-business-update-and-reports-first-quarter-2026-financi-f400071b 2026-05-15 https://biopharmsignal.com/news/BCDA/biocardia-reports-first-quarter-2026-business-highlights-and-financial-results-95035218 2026-05-15 https://biopharmsignal.com/news/GALT/galectin-therapeutics-reports-march-31-2026-financial-results-and-provides-busin-a4c2539c 2026-05-15 https://biopharmsignal.com/news/INMB/inmune-bio-publishes-phase-2-mindful-trial-results-in-npj-dementia-advancing-the-08acd595 2026-05-15 https://biopharmsignal.com/news/BLTE/belite-bio-announces-oral-presentation-at-the-27th-fundus-disease-forum-and-inte-5a8574c4 2026-05-15 https://biopharmsignal.com/news/URGN/urogen-reports-94-5-six-month-duration-of-response-in-phase-3-utopia-trial-advancing-ugn-103-toward-potential-approval-in-recurrent-low-grade-intermediate-risk-nmibc 2026-05-15 https://biopharmsignal.com/news/PAVM/pavmed-provides-business-update-and-reports-first-quarter-2026-financial-results 2026-05-15 https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-first-quarter-2026-results-and-provides-corporate-update 2026-05-15 https://biopharmsignal.com/news/IMRX/immuneering-reports-first-quarter-2026-financial-results-and-provides-business-updates 2026-05-15 https://biopharmsignal.com/news/INKT/mink-therapeutics-reports-first-quarter-2026-financial-results-and-advances-inkt-5c1b4fad 2026-05-15 https://biopharmsignal.com/news/BCTX/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-b-d5b4bb5f 2026-05-15 https://biopharmsignal.com/news/ANVS/annovis-provides-corporate-updates-and-reports-first-quarter-2026-financial-resu-76bda777 2026-05-15 https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-15 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results 2026-05-15 https://biopharmsignal.com/news/TIL/instil-bio-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-15 https://biopharmsignal.com/news/PPBT/purple-biotech-reports-first-quarter-2026-financial-results-and-business-highlig-940a55fe 2026-05-15 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-reports-first-quarter-2026-financial-results-and-provides--f6dfe577 2026-05-15 https://biopharmsignal.com/news/NTRB/nutriband-inc-to-showcase-expanding-ai-wellness-product-portfolio-and-new-june-p-84b69db9 2026-05-15 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-presentations-on-kt-621-a-first-in-class-oral-stat-d9ed67f1 2026-05-15 https://biopharmsignal.com/news/TARA/protara-therapeutics-announces-positive-updated-12-month-data-demonstrating-durable-responses-in-the-fully-enrolled-bcg-naive-cohort-of-the-ongoing-phase-2-advanced-2-trial-of-tara-002-in-nmibc 2026-05-15 https://biopharmsignal.com/news/TNYA/positive-interim-data-from-cohorts-1-and-2-of-tenaya-s-ridgetm-1-phase-1b-2-clinical-trial-of-tn-401-demonstrated-consistent-reductions-in-arrhythmia-burden-for-adults-with-pkp2-associated-arvc 2026-05-15 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-reports-first-quarter-2026-financial-results-and-corporate-u-eb055120 2026-05-15 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-files-first-quarter-2026-quarterly-report-on-form-10-q-provi-bac03f9c 2026-05-14 https://biopharmsignal.com/news/PRPO/precipio-announces-q1-2026-financial-results-8999c84d 2026-05-14 https://biopharmsignal.com/news/EHC/encompass-health-issues-notice-for-partial-redemption-of-its-4-500-senior-notes-due-2028 2026-05-14 https://biopharmsignal.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-05-14 https://biopharmsignal.com/news/OCGN/ocugen-inc-announces-closing-for-130-0-million-of-6-75-convertible-senior-notes-c2674be1 2026-05-14 https://biopharmsignal.com/news/HCWB/hcw-biologics-reports-first-quarter-2026-business-highlights-and-financial-resul-709d9da9 2026-05-14 https://biopharmsignal.com/news/TPST/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-14 https://biopharmsignal.com/news/EHC/encompass-health-announces-pricing-of-500-million-of-senior-notes-due-2034-in-a-private-offering 2026-05-14 https://biopharmsignal.com/news/FBIO/fortress-biotech-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights 2026-05-14 https://biopharmsignal.com/news/CUE/cue-biopharma-reports-first-quarter-2026-financial-results-and-recent-strategic--cd21408e 2026-05-14 https://biopharmsignal.com/news/AZYO/elutia-reports-first-quarter-2026-results-and-highlights-nxt-41x-progress-toward-1-5-billion-u-s-plastic-and-reconstructive-surgery-market 2026-05-14 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexobrutideg-nx-5948-in-chronic-spontaneous-urticaria-at-the-2026-society-for-investigative-dermatology-annual-meeting 2026-05-14 https://biopharmsignal.com/news/OCS/oculis-publishes-results-of-2026-annual-general-meeting-and-announces-election-of-gregory-d-perry-to-its-board-of-directors 2026-05-14 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-reports-first-quarter-2026-financial-results-9b096001 2026-05-14 https://biopharmsignal.com/news/BSEM/biostem-technologies-reports-first-quarter-2026-financial-results-9e5b1f5d 2026-05-14 https://biopharmsignal.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-march-31-20-d73ca2ba 2026-05-14 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-first-quarter-2026-financial-results-and-provides-co-31f86d47 2026-05-14 https://biopharmsignal.com/news/RCEL/avita-medical-reports-first-quarter-2026-financial-results-fc8fc795 2026-05-14 https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-first-quarter-2026-financial-results-and-business-highli-43d18eb3 2026-05-14 https://biopharmsignal.com/news/RNXT/renovorx-reports-record-first-quarter-2026-increasing-revenue-by-136-quarter-over-quarter 2026-05-14 https://biopharmsignal.com/news/PIII/p3-health-partners-announces-first-quarter-2026-results 2026-05-14 https://biopharmsignal.com/news/ARTL/artelo-biosciences-provides-business-update-outlining-upcoming-milestones-and-reports-2026-first-quarter-financial-results 2026-05-14 https://biopharmsignal.com/news/INBX/inhibrx-reports-first-quarter-2026-financial-results 2026-05-14 https://biopharmsignal.com/news/ALHC/alignment-health-plan-recognized-as-one-of-four-medicare-advantage-prescription-drug-plans-in-the-u-s-for-2026-excellence-in-quality 2026-05-14 https://biopharmsignal.com/news/NCNA/nucana-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-14 https://biopharmsignal.com/news/AZYO/elutia-to-present-at-the-16th-annual-ld-micro-invitational-on-may-18th 2026-05-14 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-reports-recent-business-highlights-and-first-quarter-2026-f-f0b80f3a 2026-05-14 https://biopharmsignal.com/news/CELC/celcuity-inc-reports-release-of-first-quarter-2026-financial-results-and-provide-9a4dd9aa 2026-05-14 https://biopharmsignal.com/news/PSNL/personalis-to-participate-in-upcoming-investor-events 2026-05-14 https://biopharmsignal.com/news/MGNX/macrogenics-to-participate-in-the-stifel-2026-virtual-targeted-oncology-forum 2026-05-14 https://biopharmsignal.com/news/MNPR/monopar-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates 2026-05-14 https://biopharmsignal.com/news/IXHL/incannex-healthcare-officially-commences-dreamzz-clinical-study-for-ihl-42x-in-o-51fb3eb4 2026-05-14 https://biopharmsignal.com/news/GRI/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differ-75cdc254 2026-05-14 https://biopharmsignal.com/news/EHC/encompass-health-announces-private-offering-of-senior-notes 2026-05-14 https://biopharmsignal.com/news/SNTI/senti-biosciences-holdings-reports-first-quarter-2026-financial-results-and-high-bc8c22b2 2026-05-14 https://biopharmsignal.com/news/AIM/aim-immunotech-posts-virtual-investor-key-opinion-leader-segment-spotlighting-am-841a83f1 2026-05-14 https://biopharmsignal.com/news/SNTI/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-b2d7e183 2026-05-14 https://biopharmsignal.com/news/BIIB/biogen-completes-acquisition-of-apellis-pharmaceuticals-ff8d8bbe 2026-05-14 https://biopharmsignal.com/news/STIM/neuronetics-and-ant-neuro-announce-strategic-collaboration-to-integrate-neuronavigation-with-neurostar-tms-treatment 2026-05-14 https://biopharmsignal.com/news/TARS/tarsus-and-john-cena-partner-to-raise-awareness-of-demodex-blepharitis-a-common-eyelid-disease-affecting-approximately-25-million-americans 2026-05-14 https://biopharmsignal.com/news/BDRX/biodexa-issues-letter-to-shareholders-aaad91d4 2026-05-14 https://biopharmsignal.com/news/VOR/vor-bio-announces-publication-of-interim-analysis-of-teligan-a-china-phase-3-tri-0cb4e360 2026-05-14 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-first-quarter-2026-financial-results 2026-05-14 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-present-at-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq 2026-05-14 https://biopharmsignal.com/news/CADL/candel-therapeutics-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights 2026-05-14 https://biopharmsignal.com/news/RIGL/rigel-to-present-at-the-2026-rbc-capital-markets-global-healthcare-conference 2026-05-14 https://biopharmsignal.com/news/INAB/in8bio-presents-new-translational-data-demonstrating-deltex-dri-reshapes-the-immune-landscape-in-glioblastoma 2026-05-14 https://biopharmsignal.com/news/MGTX/meiragtx-reports-first-quarter-2026-financial-and-operational-results 2026-05-14 https://biopharmsignal.com/news/CVRX/cvrx-announces-humana-medicare-advantage-coverage-policy-for-barostim-therapy 2026-05-14 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-to-present-at-upcoming-investor-conferences-7918ca0f 2026-05-14 https://biopharmsignal.com/news/CING/cingulate-inc-reports-first-quarter-2026-financial-results-and-provides-an-updat-d516ef82 2026-05-14 https://biopharmsignal.com/news/CLNN/clene-reports-first-quarter-2026-financial-results-and-recent-operating-highligh-05f09938 2026-05-14 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-announces-retrospective-clinical-publication-evaluating-065196d3 2026-05-14 https://biopharmsignal.com/news/INMB/inmune-bio-receives-fda-fast-track-designation-for-xpro1595-in-early-alzheimer-s-4e05f375 2026-05-14 https://biopharmsignal.com/news/PRCT/aua-guidelines-strengthen-recommendation-for-aquablation-therapy-b17aee34 2026-05-14 https://biopharmsignal.com/news/KROS/keros-therapeutics-reports-recent-first-quarter-2026-financial-results-632f1ff6 2026-05-14 https://biopharmsignal.com/news/PAVM/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financ-e9046b9f 2026-05-14 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-appoints-pharma-industry-veteran-brent-pfeiffenberger-to-board-of-directors 2026-05-14 https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-14 https://biopharmsignal.com/news/SLS/sellas-life-sciences-to-participate-in-upcoming-investor-conferences 2026-05-14 https://biopharmsignal.com/news/INTS/intensity-therapeutics-recognized-with-ghp-magazine-s-2026-healthcare-and-pharmaceutical-award 2026-05-14 https://biopharmsignal.com/news/BNTC/benitec-biopharma-releases-third-quarter-2026-financial-results-and-provides-operational-update 2026-05-14 https://biopharmsignal.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results 2026-05-14 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-reports-first-quarter-2026-financial-results-and-provides--fa8848c2 2026-05-14 https://biopharmsignal.com/news/INKT/mink-therapeutics-and-first-lviv-territorial-medical-union-initiate-randomized-p-e4ff7dca 2026-05-14 https://biopharmsignal.com/news/BFRI/biofrontera-inc-reports-first-quarter-2026-financial-results-and-provides-a-busi-fcdfd44e 2026-05-14 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-receives-second-philanthropic-donation-to-extend-ongoing--75478377 2026-05-14 https://biopharmsignal.com/news/HCWB/hcw-biologics-discovers-that-hcw11-040-prevents-bronchopulmonary-dysplasia-bpd-d-4dacf791 2026-05-14 https://biopharmsignal.com/news/BCTX/briacell-completes-manufacturing-of-clinical-supplies-of-bria-pros-for-prostate--900f9141 2026-05-14 https://biopharmsignal.com/news/CELC/celcuity-s-phase-3-viktoria-2-trial-of-gedatolisib-as-a-first-line-treatment-for-a1d031c2 2026-05-14 https://biopharmsignal.com/news/CYTK/cytokinetics-to-host-annual-symposium-on-contemporary-landscapes-in-muscle-biolo-18c414fa 2026-05-14 https://biopharmsignal.com/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-6d81197f 2026-05-14 https://biopharmsignal.com/news/KPTI/karyopharm-reports-first-quarter-2026-financial-results-and-completion-of-phase-3-endometrial-cancer-trial-enrollment 2026-05-14 https://biopharmsignal.com/news/CCRN/cross-country-expands-ai-powered-workforce-intelligence-for-health-systems-through-exclusive-optime-solution 2026-05-14 https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2026-financial-results-and-provides-corporate-updates 2026-05-14 https://biopharmsignal.com/news/CABA/cabaletta-bio-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-14 https://biopharmsignal.com/news/DTIL/precision-biosciences-presents-new-preclinical-data-supporting-the-advancement-of-pbgene-dmd-into-clinic-at-the-american-society-of-gene-and-cell-therapy-2026-annual-meeting 2026-05-14 https://biopharmsignal.com/news/GHRS/gh-research-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-14 https://biopharmsignal.com/news/AVAH/aveanna-healthcare-holdings-announces-first-quarter-financial-results-and-revised-2026-guidance 2026-05-14 https://biopharmsignal.com/news/INDV/indivior-to-participate-in-upcoming-investor-conferences-1728ace0 2026-05-14 https://biopharmsignal.com/news/TLSA/tiziana-reports-reduced-brain-inflammation-in-multiple-system-atrophy-patients-t-a298154b 2026-05-14 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-reports-first-quarter-2026-financial-results-ac741558 2026-05-14 https://biopharmsignal.com/news/PYXS/pyxis-oncology-reports-first-quarter-2026-financial-results-and-advances-micvo-t-3b0d67d9 2026-05-14 https://biopharmsignal.com/news/EYPT/eyepoint-announces-third-consecutive-positive-dsmc-recommendation-for-phase-3-we-f438c63c 2026-05-14 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-reports-first-quarter-2026-financial-results-and-business-u-4607ce54 2026-05-14 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-to-present-retrospective-u-s-real-world-claims-analysis-characterizing-patients-with-fibromyalgia-at-ispor-2026 2026-05-14 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-presents-soquelitinib-phase-1-atopic-dermatitis-data-at-the-society-for-investigative-dermatology-sid-annual-meeting 2026-05-14 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2026-financial-and-business-update 2026-05-14 https://biopharmsignal.com/news/CABA/cabaletta-bio-presents-preconditioning-free-clinical-data-and-automated-manufacturing-translational-data-for-rese-cel-at-asgct-2026-annual-meeting 2026-05-14 https://biopharmsignal.com/news/BIIB/topline-results-from-phase-2-celia-study-of-diranersen-biib080-first-study-to-sh-09b48a11 2026-05-14 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-14 https://biopharmsignal.com/news/EDIT/editas-medicine-reports-new-preclinical-data-demonstrating-progress-of-edit-401--a6308965 2026-05-14 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-first-quarter-2026-operating-results-and-provides-b-3244fd98 2026-05-13 https://biopharmsignal.com/news/PRPO/management-team-s-2025-market-based-options-have-vested-466b0d25 2026-05-13 https://biopharmsignal.com/news/APTO/aptose-reports-first-quarter-2026-results 2026-05-13 https://biopharmsignal.com/news/RVPH/reviva-reports-first-quarter-2026-financial-results-and-recent-business-highligh-95d102d4 2026-05-13 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference 2026-05-13 https://biopharmsignal.com/news/ICCM/icecure-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-requirement 2026-05-13 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-reports-first-quarter-2026-financial-results 2026-05-13 https://biopharmsignal.com/news/ACRV/acrivon-reports-first-quarter-2026-financial-results-and-highlights-progress-towards-key-2026-clinical-catalysts 2026-05-13 https://biopharmsignal.com/news/TNGX/tango-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-highlights 2026-05-13 https://biopharmsignal.com/news/SEER/seer-reports-first-quarter-2026-financial-results-and-reaffirms-full-year-2026-outlook 2026-05-13 https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference 2026-05-13 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-reports-first-quarter-2026-financial-results-and-recent-b-f0853ca4 2026-05-13 https://biopharmsignal.com/news/LGMK/logicmark-inc-announces-strong-first-quarter-2026-results-f4dfa115 2026-05-13 https://biopharmsignal.com/news/ICU/seastar-medical-reports-first-quarter-financial-results-and-provides-business-up-cbbf2b30 2026-05-13 https://biopharmsignal.com/news/LGVN/longeveron-announces-2026-first-quarter-financial-results-and-provides-business--e31f4e3d 2026-05-13 https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-2026-rbc-capital-markets-global-healthcare-conf-303e3f76 2026-05-13 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences-39ba28ab 2026-05-13 https://biopharmsignal.com/news/VANI/vivani-medical-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-13 https://biopharmsignal.com/news/BNGO/bionano-reports-first-quarter-2026-results-and-provides-a-business-update 2026-05-13 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-reports-first-quarter-2026-results 2026-05-13 https://biopharmsignal.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-financial-results-for-the-first-quarter-2026 2026-05-13 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2026-financial-results-and-business-update 2026-05-13 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-13 https://biopharmsignal.com/news/EQ/equillium-reports-first-quarter-2026-financial-results-and-corporate-highlights-d16ab101 2026-05-13 https://biopharmsignal.com/news/DERM/journey-medical-corporation-reports-first-quarter-2026-financial-results-and-rec-ed65bf9d 2026-05-13 https://biopharmsignal.com/news/MGNX/macrogenics-reports-first-quarter-2026-financial-results-and-highlights-business-transformation 2026-05-13 https://biopharmsignal.com/news/MDNA/medicenna-announces-the-launch-of-a-marketed-public-offering-of-securities 2026-05-13 https://biopharmsignal.com/news/BEAT/heartbeam-reports-first-quarter-2026-results 2026-05-13 https://biopharmsignal.com/news/FBIO/journey-medical-corporation-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights 2026-05-13 https://biopharmsignal.com/news/ATYR/atyr-pharma-to-participate-in-upcoming-investor-conferences 2026-05-13 https://biopharmsignal.com/news/MDXH/mdxhealth-reports-q1-2026-results-52a85fa2 2026-05-13 https://biopharmsignal.com/news/BLTE/belite-bio-to-host-webcast-on-may-20-2026-to-discuss-first-quarter-2026-financia-468f3947 2026-05-13 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-announces-ce-marking-of-velocity-alpha-mr-high-speed-surgical-drill-system-further-expanding-drug-delivery-ecosystem-and-global-footprint 2026-05-13 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-presents-new-preclinical-data-at-isct-2026-highlighting-9821fc30 2026-05-13 https://biopharmsignal.com/news/AMN/eric-palmer-joins-amn-healthcare-board-of-directors-b98bda3c 2026-05-13 https://biopharmsignal.com/news/RBOT/vicarious-surgical-demonstrates-sustained-system-performance-and-complex-hernia--7110f26f 2026-05-13 https://biopharmsignal.com/news/BFRI/biofrontera-launches-second-annual-hats-on-campaign-to-raise-awareness-of-actini-d33f19a2 2026-05-13 https://biopharmsignal.com/news/FEMY/femasys-expands-fertility-care-portfolio-in-europe-with-ce-mark-approval-for-fem-65944702 2026-05-13 https://biopharmsignal.com/news/ANGO/angiodynamics-announces-two-year-preserve-trial-data-demonstrating-durable-nanoknife-ire-system-outcomes-in-intermediate-risk-prostate-cancer 2026-05-13 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-reports-fiscal-third-quarter-revenue-growth-of-46-year-6f090164 2026-05-13 https://biopharmsignal.com/news/VOR/vor-bio-reports-first-quarter-2026-financial-results-and-provides-corporate-upda-1d7edace 2026-05-13 https://biopharmsignal.com/news/FATE/fate-therapeutics-reports-first-quarter-2026-financial-results-and-business-updates 2026-05-13 https://biopharmsignal.com/news/NXGL/nexgel-appoints-dave-hazard-as-vice-president-of-sales-for-bionx-surgical 2026-05-13 https://biopharmsignal.com/news/CADL/candel-therapeutics-to-present-at-upcoming-investor-conferences 2026-05-13 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-reports-first-quarter-2026-financial-results-and-highlights-continued-advancement-of-dnase-oncology-platform 2026-05-13 https://biopharmsignal.com/news/APVO/aptevo-therapeutics-provides-a-1q26-business-update-rainier-on-track-for-2026-completion-and-phase-2-dose-selection 2026-05-13 https://biopharmsignal.com/news/ESPR/esperion-announces-two-new-analyses-supporting-bempedoic-acid-to-reduce-ldl-c-levels-to-be-presented-at-the-european-atherosclerosis-society-eas-congress-2026 2026-05-13 https://biopharmsignal.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chats-at-three-upcoming-healthcare-conferences 2026-05-13 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq 2026-05-13 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-strengthens-leadership-team-with-appointment-of-industry-vet-5701fbe1 2026-05-13 https://biopharmsignal.com/news/MBRX/moleculin-announces-imminent-miracle-trial-unblinding-as-blinded-data-continue-t-8f7f16c8 2026-05-13 https://biopharmsignal.com/news/ECOR/electrocore-announces-publication-in-jama-highlighting-the-benefits-of-adding-qu-c4813dca 2026-05-13 https://biopharmsignal.com/news/INMB/inmune-bio-named-founding-member-of-the-american-biotech-innovation-alliance-abi-98afa80d 2026-05-13 https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-first-quarter-financial-results-and-business-update-c4d76676 2026-05-13 https://biopharmsignal.com/news/TARA/protara-therapeutics-announces-first-quarter-2026-financial-results-and-provides-a-business-update 2026-05-13 https://biopharmsignal.com/news/URGN/zusduri-median-duration-of-response-still-not-reached-with-64-5-36-month-duration-of-response-in-the-pivotal-envision-trial 2026-05-13 https://biopharmsignal.com/news/CRL/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions 2026-05-13 https://biopharmsignal.com/news/ABUS/arbutus-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-13 https://biopharmsignal.com/news/BCTX/briacell-adds-penn-medicine-s-abramson-cancer-center-as-clinical-site-in-pivotal-3a4bbb14 2026-05-13 https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-participate-in-upcoming-investor-conferences-c593dd86 2026-05-13 https://biopharmsignal.com/news/ALT/altimmune-announces-first-quarter-2026-financial-results-and-business-update-8b5f5558 2026-05-13 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-reports-first-quarter-2026-results-and-provides-pipeline-update 2026-05-13 https://biopharmsignal.com/news/ZURA/zura-bio-expands-leadership-team-with-appointment-of-muzammil-mustufa-as-chief-business-officer 2026-05-13 https://biopharmsignal.com/news/PYPD/polypid-provides-corporate-update-and-reports-first-quarter-2026-financial-results 2026-05-13 https://biopharmsignal.com/news/ALT/altimmune-to-present-results-of-pemvidutide-in-mash-in-an-oral-presentation-and--05c23ca1 2026-05-13 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-announces-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-13 https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-may-scientific-and-investor-conferences-19c82528 2026-05-13 https://biopharmsignal.com/news/SEER/seer-files-patent-infringement-lawsuit-against-nanomics 2026-05-13 https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-at-2026-rbc-capital-markets-global-healthcare-conference 2026-05-13 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-present-three-abstracts-at-easl-2026-congress-highlighting-progress-across-viral-hepatitis-pipeline 2026-05-13 https://biopharmsignal.com/news/BCRX/biocryst-to-present-new-real-world-evidence-underscoring-the-ongoing-burden-of-pediatric-hereditary-angioedema-at-ispor-2026 2026-05-13 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences 2026-05-13 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-i-4a601333 2026-05-13 https://biopharmsignal.com/news/BYSI/beyondspring-reports-first-quarter-2026-financial-results-and-provides-corporate-7bef7d23 2026-05-13 https://biopharmsignal.com/news/PDSB/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-p-0e7c9dd2 2026-05-13 https://biopharmsignal.com/news/HUMA/humacyte-announces-first-quarter-2026-financial-results-and-provides-business-update 2026-05-13 https://biopharmsignal.com/news/PRTC/puretech-to-showcase-deupirfenidone-program-at-the-american-thoracic-society-international-conference 2026-05-13 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-to-participate-in-upcoming-investor-conferences 2026-05-13 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-updates 2026-05-13 https://biopharmsignal.com/news/XTNT/xtant-medical-reports-first-quarter-2026-financial-results 2026-05-13 https://biopharmsignal.com/news/APRE/aprea-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update 2026-05-13 https://biopharmsignal.com/news/VERU/veru-reports-fiscal-2026-second-quarter-financial-results-and-phase-2b-plateau-clinical-trial-progress 2026-05-13 https://biopharmsignal.com/news/VYGR/voyager-asgct-late-breaker-single-iv-dose-of-vy1706-well-tolerated-reduced-tau-i-daac488a 2026-05-13 https://biopharmsignal.com/news/PSNL/personalis-receives-medicare-coverage-for-next-personalr-for-immunotherapy-monitoring-across-late-stage-solid-tumors 2026-05-13 https://biopharmsignal.com/news/YOU/clear-expands-to-northwest-arkansas-national-airport 2026-05-13 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-announces-ten-abstracts-accepted-for-presentation-at-the-easl-congress-2026 2026-05-13 https://biopharmsignal.com/news/ASMB/assembly-biosciences-to-present-topline-phase-1a-data-on-hepatitis-delta-virus-entry-inhibitor-abi-6250-at-the-easl-congress-2026 2026-05-13 https://biopharmsignal.com/news/ALHC/alignment-healthcare-strengthens-leadership-team-to-support-long-term-growth-and-shareholder-value-creation 2026-05-12 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-participate-in-upcoming-investor-conferences-c41e4ae7 2026-05-12 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may 2026-05-12 https://biopharmsignal.com/news/ANAB/anaptys-announces-first-quarter-2026-financial-results-and-provides-business-update 2026-05-12 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-participate-in-the-2026-rbc-capital-markets-global-healthcare-conference 2026-05-12 https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-first-quarter-2026-financial-results-and-provides-busi-5df78103 2026-05-12 https://biopharmsignal.com/news/MXCT/maxcyte-reports-first-quarter-2026-financial-results-and-reiterates-full-year-2026-guidance 2026-05-12 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-announces-nmpa-acceptance-of-new-drug-application-for-f351-hyd-21816a90 2026-05-12 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-nmpa-acceptance-of-new-drug-application-for-f351-hydronidone-for-chb-induced-liver-fibrosis-treatment 2026-05-12 https://biopharmsignal.com/news/RANI/rani-therapeutics-to-participate-in-the-h-c-wainwright-annual-bioconnect-investor-conference 2026-05-12 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-12 https://biopharmsignal.com/news/STXS/stereotaxis-reports-2026-first-quarter-financial-results-business-updates-369195bc 2026-05-12 https://biopharmsignal.com/news/BMEA/biomea-fusion-to-participate-at-upcoming-investor-conferences-90b3eaa9 2026-05-12 https://biopharmsignal.com/news/SANA/sana-biotechnology-presents-preclinical-data-for-in-vivo-car-t-cell-therapy-sg293-surrogate-demonstrating-cell-specific-delivery-potent-car-t-cell-generation-and-deep-b-cell-depletion-in-nhps 2026-05-12 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-bexobrutideg-oral-presentation-at-the-2026-european-hematology-association-congress 2026-05-12 https://biopharmsignal.com/news/TELA/tela-bio-reports-first-quarter-2026-financial-results 2026-05-12 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-to-participate-in-2026-rbc-capital-markets-global-healthcar-1ddcb108 2026-05-12 https://biopharmsignal.com/news/BSEM/biostem-technologies-to-present-at-the-16th-annual-ld-micro-invitational-c907d1bc 2026-05-12 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-b-b5fec9e5 2026-05-12 https://biopharmsignal.com/news/PHVS/pharvaris-reports-first-quarter-2026-financial-results-and-provides-business-upd-ee6740ac 2026-05-12 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-reports-first-quarter-2026-financial-results-and-clinic-88f6acf7 2026-05-12 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-12 https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2026-financial-results-and-operational-progress 2026-05-12 https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-12 https://biopharmsignal.com/news/IBIO/ibio-reports-q3-fiscal-year-2026-financial-results-and-provides-corporate-update 2026-05-12 https://biopharmsignal.com/news/TXMD/therapeuticsmd-announces-first-quarter-2026-financial-results 2026-05-12 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-12 https://biopharmsignal.com/news/HYPR/hyperfine-inc-reports-first-quarter-2026-financial-results 2026-05-12 https://biopharmsignal.com/news/PEPG/pepgen-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights 2026-05-12 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-announces-initiation-of-rolling-sps-bla-submission-and-repo-4005961c 2026-05-12 https://biopharmsignal.com/news/KURA/kura-oncology-reports-first-quarter-2026-financial-results 2026-05-12 https://biopharmsignal.com/news/NKTX/nkarta-reports-first-quarter-2026-financial-results-and-corporate-highlights 2026-05-12 https://biopharmsignal.com/news/PCRX/pacira-biosciences-sends-letter-to-stockholders-reiterating-superior-qualifications-of-its-board-nominees 2026-05-12 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-reports-first-quarter-2026-financial-results 2026-05-12 https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-12 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-first-quarter-2026-financial-results-and-highlights-recent-activity 2026-05-12 https://biopharmsignal.com/news/MOLN/molecular-partners-reports-financial-results-and-highlights-for-q1-2026-with-cli-19038c50 2026-05-12 https://biopharmsignal.com/news/CYTK/cytokinetics-to-participate-in-the-2026-rbc-capital-markets-global-healthcare-co-7508bc93 2026-05-12 https://biopharmsignal.com/news/CRIS/curis-provides-first-quarter-2026-business-update 2026-05-12 https://biopharmsignal.com/news/SNDX/syndax-highlights-12-revuforjr-revumenib-abstracts-accepted-for-eha-2026-advancing-leadership-in-menin-inhibition 2026-05-12 https://biopharmsignal.com/news/NXGL/nexgel-to-report-first-quarter-2026-financial-results-on-may-15th 2026-05-12 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-oral-presentation-at-the-eha-2026-congress-featuring-additional-positive-phase-1-clinical-trial-data-for-elvn-001-in-cml 2026-05-12 https://biopharmsignal.com/news/IPHA/innate-pharma-reports-first-quarter-2026-business-update-and-financial-results 2026-05-12 https://biopharmsignal.com/news/KURA/kura-oncology-and-kyowa-kirin-to-present-updated-frontline-ziftomenib-7-3-combination-data-at-eha-2026-congress 2026-05-12 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-completes-150-million-debt-refinancing-with-oaktree 2026-05-12 https://biopharmsignal.com/news/AGIO/agios-submits-snda-to-fda-for-u-s-accelerated-approval-of-mitapivat-in-sickle-ce-1b980507 2026-05-12 https://biopharmsignal.com/news/GERN/first-real-world-evidence-study-of-rytelo-imetelstat-in-lower-risk-myelodysplast-1c7afe38 2026-05-12 https://biopharmsignal.com/news/IRON/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-european-hematology-association-eha-2026-congress 2026-05-12 https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-highlight-vispa-cel-and-cb-011-programs-during-oral-presentations-at-the-2026-european-hematology-association-eha-annual-meeting 2026-05-12 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-multiple-presentations-at-the-european-hematology-association-eha-2026-congress 2026-05-12 https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-updated-biomarker-data-from-phase-1-2-beacon-trial-further-underscoring-risto-cel-s-ability-to-restore-red-blood-cell-health-and-function-in-sickle-cell-disease-at-eha2026 2026-05-12 https://biopharmsignal.com/news/AGIO/agios-to-present-new-data-at-eha-2026-reinforcing-the-significant-therapeutic-im-95b46b73 2026-05-12 https://biopharmsignal.com/news/MBRX/independent-cleveland-clinic-review-finds-no-clinically-significant-cardiotoxici-44ff26db 2026-05-12 https://biopharmsignal.com/news/CLLS/cellectis-to-present-clinical-data-on-lasme-cel-and-eti-cel-at-eha-2026-annual-congress 2026-05-12 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-record-monthly-cypath-lung-unit-sales-and-signi-5eb2e7cc 2026-05-12 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-4th-annual-h-c-wainwright-bioconnect-i-e7889bc9 2026-05-12 https://biopharmsignal.com/news/ICCM/icecure-reports-first-quarter-2026-financial-results-prosenser-sales-increase-substantially-in-the-u-s-and-north-america 2026-05-12 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2026-financial-results-and-corporate-highlights 2026-05-12 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-may-investor-conferences 2026-05-12 https://biopharmsignal.com/news/IXHL/incannex-healthcare-wins-medtech-breakthrough-award-for-ihl-42x-underscoring-lea-e117bc59 2026-05-12 https://biopharmsignal.com/news/VTAK/flyte-activates-high-frequency-preakness-flight-program-deploying-fleet-to-serve-1de4d0a7 2026-05-12 https://biopharmsignal.com/news/IMNN/imunon-reports-first-quarter-2026-financial-results-and-provides-business-update-fbed5541 2026-05-12 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-new-data-presentations-at-the-2026-european-con-3f1e5eb3 2026-05-12 https://biopharmsignal.com/news/HUMA/humacyte-appoints-dr-todd-e-rasmussen-as-chief-surgical-officer 2026-05-12 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-reports-q1-2026-financial-results-and-provides-a-corporate-update 2026-05-12 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-announces-expansion-of-patent-protection-for-groundbreaking-mpar-r-overdose-protection-technology 2026-05-12 https://biopharmsignal.com/news/DCTH/delcath-systems-to-participate-at-the-h-c-wainwright-4th-annual-bioconnect-investor-conference 2026-05-12 https://biopharmsignal.com/news/OPKO/opko-health-s-modex-therapeutics-will-present-data-demonstrating-in-vivo-car-t-cell-generation-and-deep-b-cell-depletion-in-preclinical-studies 2026-05-12 https://biopharmsignal.com/news/INKT/mink-therapeutics-presents-clinical-evidence-that-a-single-off-the-shelf-inkt-ce-1765f3c2 2026-05-12 https://biopharmsignal.com/news/SABS/sab-bio-reports-q1-2026-financial-results-and-recent-business-highlights 2026-05-12 https://biopharmsignal.com/news/AVAH/aveanna-to-participate-at-the-william-blair-46th-annual-growth-stock-conference 2026-05-12 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-investor-conferen-298ae515 2026-05-12 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-reports-first-quarter-2026-financial-results-and-provides-co-a6a72aae 2026-05-12 https://biopharmsignal.com/news/XLO/xilio-therapeutics-reports-first-quarter-2026-financial-results-and-provides-pip-859a3b0c 2026-05-12 https://biopharmsignal.com/news/BCTX/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients-899022b0 2026-05-12 https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-first-quarter-2026-financial-results-and-provides-corpor-18bef22d 2026-05-12 https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-may-investor-events-a79d8121 2026-05-12 https://biopharmsignal.com/news/BBIO/bridgebio-submits-nda-to-fda-for-encaleret-for-individuals-living-with-adh1-6c4a2bce 2026-05-12 https://biopharmsignal.com/news/KPTI/karyopharm-to-participate-at-upcoming-investor-conferences 2026-05-12 https://biopharmsignal.com/news/ARVN/arvinas-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-12 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-strengthens-board-and-commercial-leadership-with-three-senior-appointments-from-team-previously-at-verona-pharma 2026-05-12 https://biopharmsignal.com/news/VKTX/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026 2026-05-12 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-announces-first-quarter-2026-financial-results-and-provides-business-update 2026-05-12 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-12 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may 2026-05-12 https://biopharmsignal.com/news/ARVN/arvinas-and-pfizer-enter-into-a-transaction-with-rigel-pharmaceuticals-for-the-exclusive-global-rights-of-veppanu-vepdegestrant 2026-05-12 https://biopharmsignal.com/news/IMTX/immatics-announces-first-quarter-2026-financial-results-and-business-update 2026-05-12 https://biopharmsignal.com/news/OLMA/olema-oncology-reports-first-quarter-2026-financial-and-operating-results 2026-05-12 https://biopharmsignal.com/news/OVID/ovid-therapeutics-reports-business-updates-and-first-quarter-2026-financial-resu-976aff4a 2026-05-12 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnec-c9eedb96 2026-05-12 https://biopharmsignal.com/news/TENX/tenax-therapeutics-reports-first-quarter-2026-financial-results-and-provides-cor-c6147cfe 2026-05-12 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-first-quarter-2026-financial-results-bc86f115 2026-05-12 https://biopharmsignal.com/news/CCCC/c4-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-dc6ffcc8 2026-05-12 https://biopharmsignal.com/news/PRQR/proqr-announces-first-quarter-2026-operating-and-financial-results-dda57c8a 2026-05-12 https://biopharmsignal.com/news/ACIU/ac-immune-announces-retirement-of-ceo-dr-andrea-pfeifer-at-upcoming-agm-b1180180 2026-05-12 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-ba885971 2026-05-12 https://biopharmsignal.com/news/LEGN/legend-biotech-reports-first-quarter-2026-results-and-recent-highlights-a43caca4 2026-05-12 https://biopharmsignal.com/news/RIGL/rigel-enters-exclusive-global-licensing-agreement-for-veppanutm-vepdegestrant-an-oral-protac-for-the-treatment-of-2l-er-her2-esr1m-advanced-or-metastatic-breast-cancer 2026-05-12 https://biopharmsignal.com/news/PLSE/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million 2026-05-12 https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-participate-in-h-c-wainwright-4th-annual-bioconnect-investor-conference 2026-05-12 https://biopharmsignal.com/news/MDNA/medicenna-and-fondazione-melanoma-onlus-announce-first-patient-dosed-in-the-neo-cyt-study-of-mdna11-in-neoadjuvant-melanoma 2026-05-12 https://biopharmsignal.com/news/ALKS/alkermes-announces-positive-topline-results-from-revitalyz-phase-3-study-evaluating-lumryzr-sodium-oxybate-extended-release-in-adults-with-idiopathic-hypersomnia 2026-05-12 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-reports-first-quarter-2026-financial-results-and-provides-business-updates 2026-05-12 https://biopharmsignal.com/news/PMN/promis-neurosciences-announces-first-quarter-2026-financial-results-and-provides-eb827d9e 2026-05-12 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-and-hengrui-pharma-announce-strategic-agreements-to-advance-innovative-medicines-across-oncology-hematology-and-immunology 2026-05-12 https://biopharmsignal.com/news/MGNX/macrogenics-to-sell-gmp-manufacturing-operations-to-bora-pharmaceuticals 2026-05-11 https://biopharmsignal.com/news/BCDA/biocardia-to-host-q1-2026-financial-results-and-corporate-update-conference-call-c6729cf7 2026-05-11 https://biopharmsignal.com/news/BMEA/biomea-fusion-reports-first-quarter-2026-financial-results-and-corporate-highlights 2026-05-11 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-reports-first-quarter-2026-financial-results-unaudited-60a52bab 2026-05-11 https://biopharmsignal.com/news/SHC/sotera-health-announces-secondary-offering-of-common-stock-f691dd2e 2026-05-11 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-highlights 2026-05-11 https://biopharmsignal.com/news/CLLS/cellectis-reports-financial-results-for-the-first-quarter-2026 2026-05-11 https://biopharmsignal.com/news/EHC/encompass-health-announces-plans-to-build-a-50-bed-inpatient-rehabilitation-hospital-in-post-falls-idaho 2026-05-11 https://biopharmsignal.com/news/SCYX/scynexis-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-11 https://biopharmsignal.com/news/CGON/cg-oncology-s-presence-at-american-urological-association-aua-annual-meeting-und-d2cbaaa3 2026-05-11 https://biopharmsignal.com/news/PHVS/pharvaris-announces-closing-of-132-3-million-underwritten-offering-of-ordinary-s-aebfbb42 2026-05-11 https://biopharmsignal.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-first-quarter-2026-and-raises-2026-guidance 2026-05-11 https://biopharmsignal.com/news/OCS/oculis-reports-q1-2026-financial-results-and-provides-company-update 2026-05-11 https://biopharmsignal.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-1q-2026-51d96ebf 2026-05-11 https://biopharmsignal.com/news/ROIV/roivant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provide-business-update-on-wednesday-may-20-2026 2026-05-11 https://biopharmsignal.com/news/CVRX/cvrx-reports-first-quarter-2026-financial-and-operating-results 2026-05-11 https://biopharmsignal.com/news/SANA/sana-biotechnology-reports-first-quarter-2026-financial-results-and-business-updates 2026-05-11 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-results 2026-05-11 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-announces-first-quarter-2026-earnings-call-fce096a8 2026-05-11 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-reports-first-quarter-2026-financial-results-and-provides-co-36874087 2026-05-11 https://biopharmsignal.com/news/AMWL/amwell-to-participate-in-upcoming-investor-conference-c285d2c6 2026-05-11 https://biopharmsignal.com/news/HCAT/health-catalyst-reports-first-quarter-2026-results-bc27d6b4 2026-05-11 https://biopharmsignal.com/news/HROW/harrow-announces-first-quarter-2026-financial-results-ab5b91bc 2026-05-11 https://biopharmsignal.com/news/CHRS/coherus-oncology-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-11 https://biopharmsignal.com/news/OM/outset-medical-to-present-at-rbc-global-healthcare-conference 2026-05-11 https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provide-business-update-on-wednesday-may-20-2026 2026-05-11 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights 2026-05-11 https://biopharmsignal.com/news/ERAS/erasca-reports-first-quarter-2026-business-updates-and-financial-results 2026-05-11 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-march-31-2026 2026-05-11 https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-and-scientific-highlights 2026-05-11 https://biopharmsignal.com/news/ATYR/atyr-pharma-provides-regulatory-and-clinical-update-for-efzofitimod-in-pulmonary-sarcoidosis-following-fda-type-c-meeting 2026-05-11 https://biopharmsignal.com/news/GNFT/genfit-annual-combined-general-meeting-of-june-15-2026-availability-of-preparatory-documents 2026-05-11 https://biopharmsignal.com/news/PGNY/progyny-inc-to-present-at-bofa-securities-2026-health-care-conference 2026-05-11 https://biopharmsignal.com/news/CYTK/cytokinetics-announces-new-data-related-to-myqorzo-aficamten-at-esc-heart-failur-236af792 2026-05-11 https://biopharmsignal.com/news/BBIO/acoramidis-continues-to-demonstrate-disease-modifying-effects-in-attr-cm-reducin-fbbba509 2026-05-11 https://biopharmsignal.com/news/BDSX/biodesix-announces-ats-2026-presentations-providing-real-world-clinical-evidence-45441597 2026-05-11 https://biopharmsignal.com/news/ANAB/anaptys-appoints-chris-murphy-as-chief-financial-officer-and-owen-hughes-to-board-of-directors 2026-05-11 https://biopharmsignal.com/news/LGVN/longeveron-announces-independent-data-monitoring-committee-positive-review-and-r-e11ae1ed 2026-05-11 https://biopharmsignal.com/news/PACB/hifi-solves-sub-fertility-consortium-in-asia-pacific-reports-first-major-study-u-7eafc311 2026-05-11 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-may 2026-05-11 https://biopharmsignal.com/news/BEAT/heartbeam-initiates-pilot-study-of-first-on-demand-12-lead-ecg-patch-to-detect-ischemia-outside-the-clinic 2026-05-11 https://biopharmsignal.com/news/IRON/disc-medicine-to-participate-in-upcoming-investor-conferences-cfac8d98 2026-05-11 https://biopharmsignal.com/news/ABEO/abeona-therapeutics-announces-activation-of-children-s-hospital-of-philadelphia--5d698078 2026-05-11 https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-ft819-clinical-activity-in-sle-without-the-use-of-conditioning-chemotherapy-at-the-2026-asgct-annual-meeting 2026-05-11 https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-report-first-quarter-financial-results-and-host-a-conference-call-on-thursday-may-14-2026 2026-05-11 https://biopharmsignal.com/news/ASMB/assembly-biosciences-to-present-at-the-bofa-securities-2026-global-health-care-conference 2026-05-11 https://biopharmsignal.com/news/GALT/galectin-therapeutics-announces-publication-of-navigate-phase-2b-trial-results-f-81825c4e 2026-05-11 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-receives-expanded-fda-510-k-clearance-adding-power-lipo-c64ec7c1 2026-05-11 https://biopharmsignal.com/news/PRQR/proqr-announces-multiple-upcoming-scientific-conference-presentations-highlighti-883b5faf 2026-05-11 https://biopharmsignal.com/news/HRTX/heron-therapeutics-announces-first-quarter-2026-financial-results-and-reaffirms--bde6d661 2026-05-11 https://biopharmsignal.com/news/INBX/inhibrx-reports-interim-phase-2-data-for-inbrx-106-in-first-line-hnscc-initial-results-demonstrate-potential-costimulatory-benefit-over-pd-1-monotherapy 2026-05-11 https://biopharmsignal.com/news/CRL/charles-river-accelerates-digital-pathology-with-ai-powered-end-to-end-workflow 2026-05-11 https://biopharmsignal.com/news/XGN/exagen-inc-reports-first-quarter-2026-results 2026-05-11 https://biopharmsignal.com/news/GSK/gsk-enters-exclusive-collaboration-with-sbp-group-a-market-leader-in-hepatology-in-china-to-accelerate-bepirovirsen-at-launch 2026-05-11 https://biopharmsignal.com/news/DYN/dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights 2026-05-11 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2026-financial-results-and-business-updates 2026-05-11 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-announces-publication-demonstrating-the-utility-of-quantit-6333aeeb 2026-05-11 https://biopharmsignal.com/news/DRTS/alpha-tau-announces-groundbreaking-interim-results-from-its-u-s-alpha-dart-recur-807d0d83 2026-05-11 https://biopharmsignal.com/news/APGE/apogee-therapeutics-provides-pipeline-progress-and-reports-first-quarter-2026-fi-92ff7d07 2026-05-11 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-to-present-mechanism-of-action-data-for-its-fasn-inhibitors--e43ecc88 2026-05-11 https://biopharmsignal.com/news/GANX/gain-therapeutics-reports-financial-results-for-first-quarter-2026-and-provides--070df9ff 2026-05-11 https://biopharmsignal.com/news/ERAS/erasca-announces-clinical-trial-collaboration-and-supply-agreement-with-merck-to-evaluate-eras-0015-in-combination-with-keytrudar-pembrolizumab 2026-05-11 https://biopharmsignal.com/news/LQDA/liquidia-corporation-reports-first-quarter-2026-financial-results 2026-05-11 https://biopharmsignal.com/news/CERT/certara-reports-first-quarter-2026-financial-results 2026-05-11 https://biopharmsignal.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-16-2026 2026-05-11 https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-announces-positive-outcome-from-its-final-pre-bla-meeting-with-the-u-s-fda-and-reports-first-quarter-2026-financial-results 2026-05-10 https://biopharmsignal.com/news/ECOR/electrocore-to-present-at-the-ld-micro-invitational-xvi-conference-on-may-18-202-96c7400c 2026-05-09 https://biopharmsignal.com/news/ARGX/argenx-announces-u-s-fda-approval-expanding-vyvgart-and-vyvgart-hytrulo-for-use--b08c9b1e 2026-05-08 https://biopharmsignal.com/news/INKT/mink-therapeutics-to-report-first-quarter-2026-financial-results-and-highlight-p-97ad3328 2026-05-08 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--af9b71b6 2026-05-08 https://biopharmsignal.com/news/ENTX/entera-announces-first-quarter-2026-financial-results-and-updates-across-its-ora-338e17bb 2026-05-08 https://biopharmsignal.com/news/FEMY/femasys-announces-financial-results-for-quarter-ended-march-31-2026-and-provides-b1152e28 2026-05-08 https://biopharmsignal.com/news/LGVN/longeveron-announces-constructive-type-c-meeting-with-u-s-fda-ahead-of-data-read-71976773 2026-05-08 https://biopharmsignal.com/news/BFRI/biofrontera-inc-to-report-first-quarter-2026-financial-results-and-host-a-confer-c92fce36 2026-05-08 https://biopharmsignal.com/news/CCEL/cryo-cell-receives-acceptance-of-compliance-plan-from-nyse-american 2026-05-08 https://biopharmsignal.com/news/INBX/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-inbrx-106-hexagon-study-in-first-line-hnscc 2026-05-08 https://biopharmsignal.com/news/CYTK/cytokinetics-announces-closing-of-public-offering-of-common-stock-and-full-exerc-450af331 2026-05-08 https://biopharmsignal.com/news/MMSI/merit-medical-to-participate-in-the-bank-of-america-healthcare-conference-20d54d66 2026-05-08 https://biopharmsignal.com/news/DRTS/alpha-tau-to-host-conference-call-to-discuss-interim-results-from-first-three-pa-06ecfd00 2026-05-08 https://biopharmsignal.com/news/EMBC/embecta-to-participate-at-the-2026-bofa-securities-global-health-care-conference 2026-05-08 https://biopharmsignal.com/news/DRTS/alpha-tau-completes-patient-enrollment-in-its-u-s-pivotal-skin-cancer-study-adva-3fbbb340 2026-05-08 https://biopharmsignal.com/news/JAGX/jaguar-health-regains-compliance-with-nasdaq-s-publicly-held-shares-requirement-and-receives-additional-extension-until-may-18-2026-to-demonstrate-compliance-with-nasdaq-s-bid-price-rule 2026-05-08 https://biopharmsignal.com/news/MBRX/moleculin-biotech-secures-strategic-additional-patent-strengthening-global-posit-b3a8c08f 2026-05-08 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-ceo-to-present-at-precision-medicine-forum-europe-2026-in--031409fc 2026-05-08 https://biopharmsignal.com/news/AIM/aim-immunotech-inc-announces-exercise-of-warrants-for-approx-4-2-million-in-gros-a81a4e71 2026-05-08 https://biopharmsignal.com/news/CGON/cg-oncology-reports-first-quarter-2026-financial-results-and-provides-business-u-248365cc 2026-05-08 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-bank-of-america-healthcare-confe-33f392b6 2026-05-08 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-first-quarter-2026-results-and-expanding-adopti-dc401622 2026-05-08 https://biopharmsignal.com/news/IFRX/inflarx-announces-closing-of-150-million-underwritten-offering-of-ordinary-share-085761a8 2026-05-08 https://biopharmsignal.com/news/IART/integra-lifesciences-to-present-at-the-bofa-securities-2026-health-care-conference 2026-05-08 https://biopharmsignal.com/news/ALXO/alx-oncology-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-08 https://biopharmsignal.com/news/BCDA/biocardia-and-fda-align-on-helix-transendocardial-delivery-catheter-clearance-pa-cf945662 2026-05-08 https://biopharmsignal.com/news/MDXG/mimedx-announces-launch-of-g4dermr-plus 2026-05-08 https://biopharmsignal.com/news/HUMA/humacyte-to-announce-2026-first-quarter-financial-results-and-provide-business-update-on-may-13-2026 2026-05-08 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-ceo-presents-at-inaugural-clinical-pain-symposium-in-amsterdam 2026-05-08 https://biopharmsignal.com/news/PSTV/plus-therapeutics-announces-oral-presentation-highlighting-reyobiqtm-clinical-and-translational-data-demonstrating-favorable-safety-survival-and-emerging-immunomodulation-in-leptomeningeal-metastases 2026-05-08 https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-updates-and-first-quarter-2026-financial-results 2026-05-08 https://biopharmsignal.com/news/IBIO/ibio-appoints-distinguished-biotech-leader-elizabeth-stoner-to-its-board-of-directors 2026-05-08 https://biopharmsignal.com/news/TMCI/treace-medical-concepts-reports-first-quarter-2026-financial-results 2026-05-08 https://biopharmsignal.com/news/LNSR/lensar-reports-first-quarter-2026-results-and-provides-business-update-4b47a128 2026-05-08 https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-the-bofa-securities-2026-healthcare-conference 2026-05-08 https://biopharmsignal.com/news/HLF/herbalife-and-cristiano-ronaldo-bring-performance-nutrition-to-everyday-routines-with-fuel-like-ronaldo-campaign 2026-05-08 https://biopharmsignal.com/news/REGN/regeneron-named-to-dow-jones-best-in-class-world-index-for-global-responsibility-leadership-for-seven-consecutive-years 2026-05-08 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-08 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-deucravacitinib-for-the-treatment-of-active-psoriatic-arthritis-in-adults 2026-05-08 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-reports-first-quarter-2026-financial-results-and-raises-2026-8805534e 2026-05-08 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-reports-first-quarter-fiscal-2026-results-64ae47f1 2026-05-08 https://biopharmsignal.com/news/PHVS/pharvaris-announces-pricing-of-115-million-underwritten-offering-of-ordinary-sha-af563f9c 2026-05-08 https://biopharmsignal.com/news/BIIB/update-on-fda-priority-review-of-leqembi-iqlik-lecanemab-irmb-subcutaneous-injec-9720c80b 2026-05-08 https://biopharmsignal.com/news/MTLS/materialise-rapporteert-resultaten-eerste-kwartaal-2026 2026-05-08 https://biopharmsignal.com/news/LFST/lifestance-health-group-announces-pricing-of-secondary-public-offering 2026-05-08 https://biopharmsignal.com/news/CUE/cue-biopharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-04c81002 2026-05-07 https://biopharmsignal.com/news/LMAT/lemaitre-to-present-at-the-bank-of-america-healthcare-conference-3f9a75f1 2026-05-07 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-takes-legal-action-to-protect-patient-access-to-deramiocel-for-duchenne-muscular-dystrophy 2026-05-07 https://biopharmsignal.com/news/LFST/lifestance-health-group-announces-launch-of-secondary-public-offering-508d0ff5 2026-05-07 https://biopharmsignal.com/news/INAB/in8bio-reports-first-quarter-2026-financial-results-and-recent-business-highlights 2026-05-07 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-reports-financial-results-for-the-first-quarter-2026-and--a5b00920 2026-05-07 https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-first-quarter-financial-results-and-provides-busines-4da315c4 2026-05-07 https://biopharmsignal.com/news/AMN/amn-healthcare-announces-first-quarter-2026-results-69e52158 2026-05-07 https://biopharmsignal.com/news/GMED/globus-medical-reports-first-quarter-2026-results-93928c0b 2026-05-07 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-q1-2026-financial-results-and-provides-business-update 2026-05-07 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-07 https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights 2026-05-07 https://biopharmsignal.com/news/ABSI/absci-reports-business-updates-and-first-quarter-2026-financial-and-operating-results 2026-05-07 https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/INTS/intensity-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-07 https://biopharmsignal.com/news/NEPH/nephros-announces-financial-results-for-quarter-ended-march-31-2026-6679efc9 2026-05-07 https://biopharmsignal.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-march-31--4b91433e 2026-05-07 https://biopharmsignal.com/news/NXTC/nextcure-provides-business-update-and-reports-first-quarter-2026-financial-resul-833f438a 2026-05-07 https://biopharmsignal.com/news/PYXS/pyxis-oncology-appoints-nelson-azoulay-as-chief-business-officer-ac9a049b 2026-05-07 https://biopharmsignal.com/news/VXRT/vaxart-provides-business-update-and-reports-first-quarter-2026-financial-results-2dde7a08 2026-05-07 https://biopharmsignal.com/news/ALEC/alector-reports-first-quarter-2026-financial-results-and-provides-business-updat-145e9f5a 2026-05-07 https://biopharmsignal.com/news/PACB/pacbio-announces-first-quarter-2026-financial-results-bc752f40 2026-05-07 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-reports-first-quarter-2026-financial-results-and-recent-co-f32809b0 2026-05-07 https://biopharmsignal.com/news/FDMT/4dmt-reports-first-quarter-2026-financial-results-operational-highlights-and-exp-06362a4b 2026-05-07 https://biopharmsignal.com/news/ICUI/icu-medical-announces-first-quarter-2026-results-5829e642 2026-05-07 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provi-b5dbce2c 2026-05-07 https://biopharmsignal.com/news/AORT/artivion-reports-first-quarter-2026-financial-results-and-announces-exercise-of-option-to-acquire-endospan 2026-05-07 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-first-quarter-financial-results-and-provides-a-business-update 2026-05-07 https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-may 2026-05-07 https://biopharmsignal.com/news/SYK/stryker-completes-acquisition-of-amplitude-vascular-systems-to-add-next-generation-ivl-technology-to-peripheral-vascular-portfolio 2026-05-07 https://biopharmsignal.com/news/LPCN/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2026 2026-05-07 https://biopharmsignal.com/news/INGN/inogen-announces-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/OM/outset-medical-reports-first-quarter-results 2026-05-07 https://biopharmsignal.com/news/PGNY/progyny-inc-announces-first-quarter-2026-results 2026-05-07 https://biopharmsignal.com/news/ANNX/annexon-reports-first-quarter-2026-financial-results-portfolio-progress-and-key-anticipated-milestones 2026-05-07 https://biopharmsignal.com/news/XENE/xenon-reports-q1-2026-financial-results-and-provides-business-update 2026-05-07 https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-reports-first-quarter-2026-financial-results-a7b4bee3 2026-05-07 https://biopharmsignal.com/news/VYGR/voyager-reports-first-quarter-2026-financial-and-operating-results-96486bc3 2026-05-07 https://biopharmsignal.com/news/CLDX/celldex-reports-first-quarter-financial-results-and-provides-corporate-update-986faf26 2026-05-07 https://biopharmsignal.com/news/BBIO/bridgebio-reports-first-quarter-2026-financial-results-and-corporate-updates-a8539e05 2026-05-07 https://biopharmsignal.com/news/DNLI/denali-therapeutics-reports-first-quarter-2026-financial-results-and-business-hi-b2e6c27c 2026-05-07 https://biopharmsignal.com/news/AMRX/amneal-reports-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-provides-first-quarter-2026-corporate-update 2026-05-07 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/PSNL/personalis-reports-first-quarter-results-and-recent-highlights 2026-05-07 https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum 2026-05-07 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-fiscal-2026-second-quarter-results 2026-05-07 https://biopharmsignal.com/news/ASMB/assembly-biosciences-reports-first-quarter-2026-financial-results-and-recent-highlights 2026-05-07 https://biopharmsignal.com/news/INMB/inmune-bio-inc-announces-first-quarter-2026-results-and-provides-business-update-316c5dba 2026-05-07 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-bank-of-america-securities-2026-hea-e907fb55 2026-05-07 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-first-quarter-2026-financial-results-and-highlights-recent-progress 2026-05-07 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-reports-expanded-phase-2-blinded-dataset-for-brtx-100-s-3dd6ee17 2026-05-07 https://biopharmsignal.com/news/DRTS/alpha-tau-successfully-treats-first-pancreatic-cancer-patient-in-italy-with-alph-b57cbcca 2026-05-07 https://biopharmsignal.com/news/EHC/encompass-health-declares-dividend-on-common-stock 2026-05-07 https://biopharmsignal.com/news/BEAT/heartbeam-expands-commercial-presence-across-four-key-u-s-markets-with-addition-of-premier-concierge-practice 2026-05-07 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-reports-first-quarter-2026-f-2e9330e9 2026-05-07 https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-07 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026 2026-05-07 https://biopharmsignal.com/news/OGEN/oragenics-signs-letter-of-intent-to-license-cardiodialysistm-technology-from-sigyn-therapeutics-to-target-tbi-induced-systemic-inflammation 2026-05-07 https://biopharmsignal.com/news/AIM/aim-immunotech-announces-50-objective-response-rate-orr-in-upmc-recurrent-ovaria-2f39fa52 2026-05-07 https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-provides-regulatory-update-on-tabelecleucel-36f03b9d 2026-05-07 https://biopharmsignal.com/news/ARDX/ardelyx-presents-analysis-supporting-long-term-safety-of-xphozah-at-nkf-s-spring-06ad1b71 2026-05-07 https://biopharmsignal.com/news/PRME/prime-medicine-reports-first-quarter-2026-financial-results-and-provides-business-updates 2026-05-07 https://biopharmsignal.com/news/ALXO/alx-oncology-s-evorpacept-in-combination-with-zanidatamab-generates-promising-durable-response-in-patients-with-advanced-her2-positive-breast-cancer-and-high-cd47-expression 2026-05-07 https://biopharmsignal.com/news/MDWD/mediwound-to-report-first-quarter-2026-financial-results-6c090220 2026-05-07 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcast-for-its-first-quarter--ec9dabd2 2026-05-07 https://biopharmsignal.com/news/SLDB/solid-biosciences-doses-first-participant-in-phase-3-impact-duchenne-clinical-tr-0b3eb7cf 2026-05-07 https://biopharmsignal.com/news/CELC/celcuity-schedules-release-of-first-quarter-2026-financial-results-and-webcast-c-05212a3d 2026-05-07 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-bofa-securities-2026-health-care-conference-f4e6ec6b 2026-05-07 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/DCTH/delcath-systems-reports-first-quarter-2026-results-and-business-highlights 2026-05-07 https://biopharmsignal.com/news/XTNT/xtant-medical-to-announce-first-quarter-2026-financial-results-on-may-13-2026 2026-05-07 https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-upcoming-investor-conferences 2026-05-07 https://biopharmsignal.com/news/VCEL/vericel-reports-first-quarter-2026-financial-results-and-raises-full-year-financ-80a8b132 2026-05-07 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-07 https://biopharmsignal.com/news/PSTV/plus-therapeutics-receives-medicare-enrollment-approval-for-cnside-diagnostic 2026-05-07 https://biopharmsignal.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-first-quarter-2026-financ-6cce7130 2026-05-07 https://biopharmsignal.com/news/BCTX/briacell-adds-nyu-langone-health-s-perlmutter-cancer-center-as-clinical-site-in--118f1137 2026-05-07 https://biopharmsignal.com/news/ANVS/annovis-ceo-to-present-on-multi-protein-model-of-alzheimer-s-disease-at-fierce-b-d7fc4395 2026-05-07 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provide-4b7317fd 2026-05-07 https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-bank-of-america-securities-2026-global-health-1f7f2206 2026-05-07 https://biopharmsignal.com/news/HRMY/harmony-biosciences-reports-q1-financial-results-and-confirms-2026-net-revenue-guidance-of-over-1-billion-reinforces-2026-strategic-priorities 2026-05-07 https://biopharmsignal.com/news/ASND/ascendis-pharma-reports-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/IBRX/immunitybio-reports-record-q1-2026-results-net-product-revenue-increased-nearly-2-7x-year-over-year-to-44-million-in-q1-2026-expanding-on-the-2025-full-year-700-year-over-year-revenue-growth-cash-and-marketable-securities-total-381-million 2026-05-07 https://biopharmsignal.com/news/ZURA/zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates 2026-05-07 https://biopharmsignal.com/news/KPTI/karyopharm-to-report-first-quarter-2026-financial-results-on-may-14-2026 2026-05-07 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-i-925ace19 2026-05-07 https://biopharmsignal.com/news/USNA/usana-s-people-first-culture-earns-spot-on-usa-today-top-workplaces-list 2026-05-07 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-reports-first-quarter-2026-financial-results-4b45cf5b 2026-05-07 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-strong-first-quarter-2026-results-with-97-year-over-year-linzess-u-s-net-sales-growth-maintains-full-year-2026-financial-guidance 2026-05-07 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-highlights-positive-first-quarter-2026-results-business-achievements-and-corporate-updates 2026-05-07 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update 2026-05-07 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-first-quarter-financial-results 2026-05-07 https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-updates 2026-05-07 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-reports-first-quarter-2026-financial-results-and-provides-b-d6958b61 2026-05-07 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-reports-first-quarter-2026-financial-results-29696195 2026-05-07 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-first-quarter-2026-financial-results-and-commercial--7f76a4c0 2026-05-07 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-f-48bdb09d 2026-05-07 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-announces-positive-topline-results-from-cohort-1-of-partici-8bfbed27 2026-05-07 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-first-quarter-2026-financial-results-and-busin-705bfd4d 2026-05-07 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-recognizes-mental-health-month-7efeb9fe 2026-05-07 https://biopharmsignal.com/news/DCTH/delcath-systems-announces-presentation-of-new-data-on-percutaneous-hepatic-perfusion-with-melphalan-in-liver-dominant-metastatic-breast-cancer-at-esmo-breast-cancer-2026 2026-05-07 https://biopharmsignal.com/news/XERS/xeris-biopharma-reports-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/SRRK/scholar-rock-reports-first-quarter-2026-financial-results-and-recent-business-highlights 2026-05-07 https://biopharmsignal.com/news/INSM/insmed-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-07 https://biopharmsignal.com/news/CRL/charles-river-laboratories-announces-first-quarter-2026-results 2026-05-07 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2026-financial-results-and-provides-c-c157b37c 2026-05-07 https://biopharmsignal.com/news/BNTX/biontech-k-ndigt-neues-r-ckkaufprogramm-f-r-american-depositary-shares-an-2fe8880c 2026-05-07 https://biopharmsignal.com/news/BNTX/biontech-announces-new-ads-repurchase-program-283cdf90 2026-05-07 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-may-14-2026 2026-05-07 https://biopharmsignal.com/news/BDX/bd-appoints-vitor-roque-chief-financial-officer 2026-05-07 https://biopharmsignal.com/news/BDX/bd-reports-second-quarter-fiscal-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/STTK/shattuck-labs-reports-first-quarter-2026-financial-results-and-recent-business-h-6437ab70 2026-05-07 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-updat-f2e6dffb 2026-05-07 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-update 2026-05-07 https://biopharmsignal.com/news/LFST/lifestance-reports-first-quarter-2026-results 2026-05-07 https://biopharmsignal.com/news/PRVA/privia-health-reports-first-quarter-2026-financial-results 2026-05-07 https://biopharmsignal.com/news/ACON/aclarion-announces-addition-of-first-private-practice-site-in-los-angeles-into-c-eaf542ac 2026-05-07 https://biopharmsignal.com/news/OCS/oculis-announces-agreement-with-fda-on-a-special-protocol-assessment-spa-for-optic-neuritis-registrational-trial 2026-05-07 https://biopharmsignal.com/news/ARGX/argenx-reports-first-quarter-2026-financial-results-and-provides-business-update-88c0fcd8 2026-05-07 https://biopharmsignal.com/news/MTLS/materialise-reports-first-quarter-2026-results 2026-05-07 https://biopharmsignal.com/news/USNA/usana-hosts-inspiring-spa-and-wellness-retreat-to-empower-women-across-asia-pacific 2026-05-07 https://biopharmsignal.com/news/CYTK/cytokinetics-announces-pricing-of-upsized-public-offering-of-common-stock-225092df 2026-05-07 https://biopharmsignal.com/news/SCYX/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635-c-4 2026-05-07 https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-publication-in-new-england-journal-of-medicine-of-phase-1-2-clinical-data-on-daraxonrasib-in-pancreatic-cancer 2026-05-06 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-to-be-acquired-by-knox-lane-in-all-cash-transaction-valued-at-437-million 2026-05-06 https://biopharmsignal.com/news/PRPO/precipio-announces-q1-2026-shareholder-update-call-bc40e49f 2026-05-06 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-the-bank-of-america-2026-health-care-conference 2026-05-06 https://biopharmsignal.com/news/RARE/ultragenyx-to-participate-at-bank-of-america-s-2026-healthcare-conference-7eaf7ec3 2026-05-06 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-w-c8a2a4f7 2026-05-06 https://biopharmsignal.com/news/ARGX/argenx-to-present-at-bofa-securities-2026-health-care-conference-6aca0aae 2026-05-06 https://biopharmsignal.com/news/BNGO/bionano-announces-leadership-transition 2026-05-06 https://biopharmsignal.com/news/INSM/insmed-and-ty-pennington-team-up-to-drive-awareness-and-proper-diagnosis-of-bronchiectasis 2026-05-06 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-highlights 2026-05-06 https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-first-quarter-2026-operating-and-financial-results 2026-05-06 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-announce-first-quarter-2026-financial-results-on-may-13-2026 2026-05-06 https://biopharmsignal.com/news/PRI/primerica-reports-first-quarter-2026-results 2026-05-06 https://biopharmsignal.com/news/HLF/herbalife-reports-first-quarter-2026-net-sales-growth-and-adjusted-ebitda-above-guidance-raises-full-year-2026-constant-currency-net-sales-and-adjusted-ebitda-guidance-midpoints 2026-05-06 https://biopharmsignal.com/news/LFVN/lifevantage-declares-quarterly-dividend-50b7e2de 2026-05-06 https://biopharmsignal.com/news/OSUR/orasure-announces-first-quarter-2026-financial-results 2026-05-06 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-06 https://biopharmsignal.com/news/ADMA/adma-biologics-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-06 https://biopharmsignal.com/news/TARS/tarsus-reports-first-quarter-2026-financial-results-and-recent-business-achievements 2026-05-06 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-2026 2026-05-06 https://biopharmsignal.com/news/CLOV/clover-health-reports-first-quarter-2026-results 2026-05-06 https://biopharmsignal.com/news/RXST/rxsight-inc-reports-first-quarter-2026-results-and-reiterates-full-year-sales-outlook 2026-05-06 https://biopharmsignal.com/news/SGHT/sight-sciences-reports-first-quarter-2026-financial-results-and-raises-full-year-2026-revenue-guidance 2026-05-06 https://biopharmsignal.com/news/PCVX/vaxcyte-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-06 https://biopharmsignal.com/news/ZVRA/zevra-reports-first-quarter-2026-financial-results-and-corporate-update-12c01b45 2026-05-06 https://biopharmsignal.com/news/ECOR/electrocore-announces-first-quarter-2026-financial-results-489578e0 2026-05-06 https://biopharmsignal.com/news/PNTG/pennant-reports-first-quarter-2026-results 2026-05-06 https://biopharmsignal.com/news/BTMD/biote-reports-first-quarter-2026-financial-results 2026-05-06 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-06 https://biopharmsignal.com/news/INVA/innoviva-reports-first-quarter-2026-financial-results-highlights-recent-company-progress 2026-05-06 https://biopharmsignal.com/news/GDRX/goodrx-reports-first-quarter-2026-results 2026-05-06 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2026-financial-results-and-recent-corporate-developments 2026-05-06 https://biopharmsignal.com/news/LFVN/lifevantage-announces-financial-results-for-the-third-quarter-of-fiscal-2026 2026-05-06 https://biopharmsignal.com/news/HYPR/hyperfine-inc-to-participate-in-upcoming-2026-jefferies-global-healthcare-conference 2026-05-06 https://biopharmsignal.com/news/SERA/sera-prognostics-reports-first-quarter-2026-financial-results 2026-05-06 https://biopharmsignal.com/news/RVMD/revolution-medicines-reports-first-quarter-2026-financial-results-and-update-on-corporate-progress 2026-05-06 https://biopharmsignal.com/news/BBIO/bridgebio-to-participate-in-may-and-june-investor-conferences-5ca0eac5 2026-05-06 https://biopharmsignal.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-and-board-of-directors-appoin-3abcc261 2026-05-06 https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-first-quarter-2026-financial-results-on--4fe55408 2026-05-06 https://biopharmsignal.com/news/ASND/new-2-year-data-from-pivotal-approach-trial-of-transconr-cnp-navepegritide-show-pronounced-gains-in-growth-outcomes-in-children-with-achondroplasia-aged-5-years 2026-05-06 https://biopharmsignal.com/news/AXON/axon-reports-q1-2026-revenue-of-807-million-up-34-year-over-year 2026-05-06 https://biopharmsignal.com/news/FBIO/journey-medical-corporation-to-announce-first-quarter-2026-financial-results-on-may-13-2026 2026-05-06 https://biopharmsignal.com/news/MNKD/mannkind-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-06 https://biopharmsignal.com/news/MDRX/veradigm-launches-health-network-architecture-to-level-the-playing-field-for-independent-practices 2026-05-06 https://biopharmsignal.com/news/ARQT/arcutis-announces-first-quarter-2026-financial-results-and-provides-business-update 2026-05-06 https://biopharmsignal.com/news/NXGL/nexgel-appoints-brian-kieser-and-kevin-harris-from-new-strategic-partner-sequence-lifesciencetm-to-board-of-directors 2026-05-06 https://biopharmsignal.com/news/JAGX/jaguar-health-announces-preliminary-discussion-with-fda-to-evaluate-breakthrough-therapy-designation-for-crofelemer-for-treatment-of-microvillus-inclusion-disease-mvid 2026-05-06 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-to-participate-in-the-rbc-capital-markets-global-healthcare-conference 2026-05-06 https://biopharmsignal.com/news/IFRX/inflarx-announces-pricing-of-150-million-underwritten-offering-of-ordinary-share-36e34ae6 2026-05-06 https://biopharmsignal.com/news/ICCM/icecure-medical-to-report-first-quarter-2026-financial-and-operating-results-on-may-12-2026 2026-05-06 https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-participate-in-upcoming-investor-conferences 2026-05-06 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-to-report-first-quarter-financial-results-and-provide-business-update 2026-05-06 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-to-present-at-the-bank-of-america-securities-2026-global-healthcare-conference 2026-05-06 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-publication-of-expert-recommendations-for-glucocorticoid-dose-reduction-after-initiating-crenessityr-crinecerfont-for-the-treatment-of-classic-congenital-adrenal-hyperplasia 2026-05-06 https://biopharmsignal.com/news/VERU/veru-to-report-fiscal-2026-second-quarter-financial-results-on-may-13th 2026-05-06 https://biopharmsignal.com/news/IFRX/inflarx-announces-advancement-of-izicopan-in-anca-associated-vasculitis-and-sele-3cdb784a 2026-05-06 https://biopharmsignal.com/news/ICU/seastar-medical-to-report-first-quarter-financial-results-on-may-13-2026-b078aadd 2026-05-06 https://biopharmsignal.com/news/APVO/aptevo-reports-87-clinical-benefit-and-81-remission-in-31-evaluable-frontline-aml-patients-through-cohort-5-substantially-outperforming-benchmark-rainier-on-track-for-2026-completion-and-phase-2-dose-selection 2026-05-06 https://biopharmsignal.com/news/MDRX/veradigm-survey-independent-practices-rely-on-technology-to-stay-independent 2026-05-06 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-06 https://biopharmsignal.com/news/INAB/in8bio-to-showcase-next-generation-t-cell-engager-platform-and-new-clinical-data-at-upcoming-randd-day-and-medical-conferences 2026-05-06 https://biopharmsignal.com/news/ANNX/annexon-to-present-at-the-bank-of-america-securities-health-care-conference-2026 2026-05-06 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-participation-in-upcoming-bank-of-america-globa-1a117766 2026-05-06 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-conference-call-and-webcast-for-2026-first-quarter-financi-02129dba 2026-05-06 https://biopharmsignal.com/news/GSK/gsk-presents-latest-respiratory-research-to-advance-patient-care-at-ats-2026 2026-05-06 https://biopharmsignal.com/news/XTNT/xtant-medical-expands-triviumtm-portfolio-with-the-commercial-launch-of-triviumtm-shaped 2026-05-06 https://biopharmsignal.com/news/URGN/urogen-reports-zusduritm-revenue-more-than-doubled-quarter-over-quarter-and-provides-first-quarter-2026-financial-results-and-highlights 2026-05-06 https://biopharmsignal.com/news/ERAS/erasca-to-present-at-the-bank-of-america-securities-health-care-conference 2026-05-06 https://biopharmsignal.com/news/PYPD/polypid-to-report-first-quarter-2026-financial-results-and-operational-highlights-on-may-13-2026 2026-05-06 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-announce-first-quarter-2026-financial-results-on-may-13-2026 2026-05-06 https://biopharmsignal.com/news/BCTX/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-c-2d9c26c2 2026-05-06 https://biopharmsignal.com/news/ALT/altimmune-to-report-first-quarter-2026-financial-results-and-provide-business-up-e4890a75 2026-05-06 https://biopharmsignal.com/news/BBIO/beyonttra-acoramidis-the-first-near-complete-ttr-stabilizer-90-approved-by-anvis-4d91d740 2026-05-06 https://biopharmsignal.com/news/KURA/kura-oncology-to-participate-in-bank-of-america-securities-healthcare-conference 2026-05-06 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-cor-86158817 2026-05-06 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-business-highlights-on-may-13-and-host-conference-call-on-may-14-at-8-00-a-m-et 2026-05-06 https://biopharmsignal.com/news/TGTX/tg-therapeutics-reports-first-quarter-2026-financial-results-and-raises-briumvi-revenue-guidance 2026-05-06 https://biopharmsignal.com/news/TPST/tempest-presents-clinical-update-at-isct-2026-annual-meeting 2026-05-06 https://biopharmsignal.com/news/BCRX/biocryst-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-06 https://biopharmsignal.com/news/EYPT/eyepoint-reports-first-quarter-2026-financial-results-and-highlights-recent-corp-d107717e 2026-05-06 https://biopharmsignal.com/news/GERN/geron-corporation-reports-first-quarter-2026-financial-results-and-recent-busine-19a68e04 2026-05-06 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-may-investor-conferences-415068c4 2026-05-06 https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provid-3b9a7132 2026-05-06 https://biopharmsignal.com/news/IMCR/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update 2026-05-06 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-report-first-quarter-2026-financial-results-on-tuesday-may-12-2026 2026-05-06 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-secures-commercial-payer-coverage-for-tonmyar-providing-access-for-35-million-u-s-patients 2026-05-06 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-the-bank-of-america-securities-healthcare-conference-2026 2026-05-06 https://biopharmsignal.com/news/RXRX/recursion-reports-first-quarter-financial-results-and-provides-business-update-5395800d 2026-05-06 https://biopharmsignal.com/news/MNKD/mannkind-announces-ralinepag-dry-powder-inhalation-dpi-program-to-be-pursued-for-pulmonary-hypertension-and-fibrotic-lung-diseases 2026-05-06 https://biopharmsignal.com/news/PRGO/perrigo-reports-first-quarter-2026-financial-results-from-continuing-operations 2026-05-06 https://biopharmsignal.com/news/BRKR/bruker-reports-first-quarter-2026-financial-results 2026-05-06 https://biopharmsignal.com/news/TECH/bio-techne-declares-dividend 2026-05-06 https://biopharmsignal.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2026-results 2026-05-06 https://biopharmsignal.com/news/ACON/aclarion-announces-inducement-grant-to-new-commercial-director-western-u-s-12ab02a1 2026-05-06 https://biopharmsignal.com/news/YOU/clear-announces-first-quarter-2026-financial-results 2026-05-06 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-pricing-of-375-million-public-offering 2026-05-06 https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-poster-presentations-of-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions 2026-05-05 https://biopharmsignal.com/news/CRIS/curis-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-12-2026 2026-05-05 https://biopharmsignal.com/news/AZTA/azenta-reports-second-quarter-results-for-fiscal-2026-ended-march-31-2026-updates-full-year-fiscal-2026-guidance-and-extends-long-range-plan-to-2029 2026-05-05 https://biopharmsignal.com/news/EHC/encompass-health-rehabilitation-hospital-of-concordville-now-open-in-pennsylvania 2026-05-05 https://biopharmsignal.com/news/PCRX/pacira-biosciences-mails-letter-to-stockholders 2026-05-05 https://biopharmsignal.com/news/LGVN/longeveron-to-report-2026-first-quarter-financial-results-and-host-conference-ca-0ab4eac6 2026-05-05 https://biopharmsignal.com/news/CYTK/cytokinetics-announces-proposed-public-offering-of-common-stock-4f62bec4 2026-05-05 https://biopharmsignal.com/news/USNA/usana-health-sciences-reports-first-quarter-2026-results 2026-05-05 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-reports-first-quarter-2026-financial-results 2026-05-05 https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-bofa-securities-2026-health-care-conference 2026-05-05 https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-the-bofa-securities-2026-healthcare-conference 2026-05-05 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-announces-upcoming-presentation-of-phase-2-data-highlighting-the-potential-abscopal-effects-of-vp-315-in-the-treatment-of-basal-cell-carcinoma-at-the-2026-society-for-investigative-dermatology-sid-annual-meeting 2026-05-05 https://biopharmsignal.com/news/AMWL/amwell-announces-results-for-first-quarter-2026-1abdf658 2026-05-05 https://biopharmsignal.com/news/LMAT/lemaitre-q1-2026-financial-results-1a3119ae 2026-05-05 https://biopharmsignal.com/news/RLAY/relay-therapeutics-reports-first-quarter-2026-financial-results-and-corporate-up-9af87a5e 2026-05-05 https://biopharmsignal.com/news/CYTK/cytokinetics-reports-first-quarter-2026-financial-results-and-provides-business--882a567b 2026-05-05 https://biopharmsignal.com/news/EXEL/exelixis-announces-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-05 https://biopharmsignal.com/news/SUPN/supernus-announces-first-quarter-2026-financial-results 2026-05-05 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants 2026-05-05 https://biopharmsignal.com/news/IRIX/iridex-to-report-first-quarter-2026-financial-results-on-may-19-2026 2026-05-05 https://biopharmsignal.com/news/RARE/ultragenyx-reports-first-quarter-2026-financial-results-and-corporate-update-25d3e69f 2026-05-05 https://biopharmsignal.com/news/XRAY/dentsply-sirona-reports-first-quarter-2026-results-245a4ec7 2026-05-05 https://biopharmsignal.com/news/ATRC/atricure-reports-first-quarter-2026-financial-results 2026-05-05 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2026-financial-results 2026-05-05 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-achieves-positive-topline-results-in-phase-2-lotus-trial-of-abdakibart-avtx-009-in-moderate-to-severe-hidradenitis-suppurativa 2026-05-05 https://biopharmsignal.com/news/RIGL/rigel-reports-first-quarter-2026-financial-results 2026-05-05 https://biopharmsignal.com/news/INMB/inmune-bio-and-anthony-nolan-announce-strategic-expansion-of-cordstrom-msc-platf-ed8d867c 2026-05-05 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-12-2026-67e73e87 2026-05-05 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026 2026-05-05 https://biopharmsignal.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-q1-2026-business-update 2026-05-05 https://biopharmsignal.com/news/DRTS/alpha-tau-announces-upcoming-podium-presentation-at-the-ahns-12th-international--5c7129ce 2026-05-05 https://biopharmsignal.com/news/HSCS/heartsciences-signs-first-saas-revenues-agreement-following-full-launch-of-myovi-421f6f7f 2026-05-05 https://biopharmsignal.com/news/FEMY/femasys-enables-ob-gyns-to-deliver-first-line-fertility-treatment-with-initial-c-79383680 2026-05-05 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-health-care-conference-2026 2026-05-05 https://biopharmsignal.com/news/CLNN/clene-announces-7-million-underwritten-offering-of-common-stock-ea05bb73 2026-05-05 https://biopharmsignal.com/news/OCGN/ocugen-provides-business-update-with-first-quarter-2026-financial-results-655a18c1 2026-05-05 https://biopharmsignal.com/news/SABS/sab-bio-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-may-12-2026-08-30-am-et 2026-05-05 https://biopharmsignal.com/news/IRON/disc-medicine-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-05 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-158d8bc3 2026-05-05 https://biopharmsignal.com/news/IMNN/imunon-to-hold-first-quarter-2026-financial-results-and-business-update-conferen-a080c89a 2026-05-05 https://biopharmsignal.com/news/FATE/fate-therapeutics-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing-readiness-of-ft819 2026-05-05 https://biopharmsignal.com/news/OGEN/oragenics-activates-second-site-in-phase-iia-clinical-trial-of-onp-002-for-concussion-and-mild-traumatic-brain-injury 2026-05-05 https://biopharmsignal.com/news/ICCM/icecure-showcases-prosenser-cryoablation-at-american-society-of-breast-surgeons-2026-annual-meeting-as-commercial-momentum-accelerates-in-the-u-s-market 2026-05-05 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-to-announce-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-12-2026 2026-05-05 https://biopharmsignal.com/news/OCGN/ocugen-inc-announces-pricing-of-115-million-of-6-75-convertible-senior-notes-2f1e5939 2026-05-05 https://biopharmsignal.com/news/NERV/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates 2026-05-05 https://biopharmsignal.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-first-quarter-2026-financial-results 2026-05-05 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-12-2026 2026-05-05 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-reports-first-quarter-2026-financial-results-and-provides-cor-2307b20e 2026-05-05 https://biopharmsignal.com/news/CGON/cg-oncology-to-present-at-upcoming-investor-conferences-in-may-649589bb 2026-05-05 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-advances-stenoparib-toward-pivotal-development-with-phase--6f85ecf3 2026-05-05 https://biopharmsignal.com/news/CLNN/clene-to-present-at-upcoming-may-conferences-e4de6669 2026-05-05 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-first-patient-dosed-in-aspenova-phase-3-trial-37a459e0 2026-05-05 https://biopharmsignal.com/news/GERN/geron-plans-to-present-at-upcoming-investor-conferences-61147851 2026-05-05 https://biopharmsignal.com/news/MDGL/madrigal-adds-clinical-stage-sirna-asset-targeting-pnpla3-to-its-mash-pipeline-4bdcd377 2026-05-05 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-to-host-in-person-and-virtual-kol-event-at-asco-2026 2026-05-05 https://biopharmsignal.com/news/BNGO/bionano-announces-a-56-increase-in-publications-describing-the-utility-of-ogm-in-rare-diseases-in-q1-2026-vs-q1-2025 2026-05-05 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-bank-of-america-securities-health-care-conference 2026-05-05 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-licenses-clinical-mash-program-targeting-pnpla3-to-madrigal-pharmaceuticals 2026-05-05 https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026 2026-05-05 https://biopharmsignal.com/news/STIM/neuronetics-reports-first-quarter-2026-financial-and-operating-results 2026-05-05 https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-2026-first-quarter-financial-results-and-provides-c-7bfdf19a 2026-05-05 https://biopharmsignal.com/news/BBIO/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ec-d0f63540 2026-05-05 https://biopharmsignal.com/news/CYTK/cytokinetics-announces-positive-topline-results-from-acacia-hcm-the-pivotal-phas-7e221cd2 2026-05-05 https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-doses-first-patient-in-phase-1b-2-trial-of-piktor-in-hr-her2-advanced-breast-cancer 2026-05-05 https://biopharmsignal.com/news/KURA/kura-oncology-to-report-first-quarter-2026-financial-results 2026-05-05 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-participate-in-upcoming-investor-conferences 2026-05-05 https://biopharmsignal.com/news/IBRX/immunitybio-to-present-new-comparative-data-scientific-advances-in-non-muscle-invasive-bladder-cancer-cis-and-an-update-on-bcg-naive-registrational-trial-at-american-urological-association-annual-meeting 2026-05-05 https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of-iopofosine-i-131-in-r-r-waldenstroem-macroglobulinemia 2026-05-05 https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-two-poster-presentations-at-european-congress-on-obesity-eco-2026 2026-05-05 https://biopharmsignal.com/news/SHC/sotera-health-delivers-strong-first-quarter-2026-results-and-reaffirms-2026-outlook 2026-05-05 https://biopharmsignal.com/news/DTIL/precision-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-05 https://biopharmsignal.com/news/SHC/sotera-health-announces-leadership-transition 2026-05-05 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-host-first-quarter-2026-financial-results-and-business-update-conference-call-on-may-12-2026 2026-05-05 https://biopharmsignal.com/news/ARVN/arvinas-to-report-first-quarter-2026-financial-results-on-may-12-2026 2026-05-05 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-7a711ec7 2026-05-05 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-report-first-quarter-2026-financial-results-and-host-con-ca5b70a9 2026-05-05 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-first-quarter-2026-results-and-business-updates-a6d00413 2026-05-05 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-reports-first-quarter-2026-financial-results-and-business-hig-4dff1de3 2026-05-05 https://biopharmsignal.com/news/RGEN/repligen-reports-first-quarter-2026-financial-results-and-updates-full-year-2026-1626b6b5 2026-05-05 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-presents-new-preclinical-ibd-data-for-kt-579-a-first-in-clas-33c797f9 2026-05-05 https://biopharmsignal.com/news/REGN/dupixentr-dupilumab-demonstrates-improved-esophageal-function-in-eosinophilic-esophagitis-eoe-phase-4-trial 2026-05-05 https://biopharmsignal.com/news/CLRB/cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million 2026-05-05 https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates 2026-05-05 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-and-florida-atlantic-university-s-christine-e-lynn-college-of-nursing-release-purpose-under-pressure-the-state-of-nursing-in-2026 2026-05-05 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-present-ndv-01-abstracts-at-aua2026 2026-05-05 https://biopharmsignal.com/news/ALKS/alkermes-plc-reports-first-quarter-2026-financial-results 2026-05-05 https://biopharmsignal.com/news/BDX/bd-and-wellstar-advance-patient-care-and-safety-with-medication-management-powered-by-ai 2026-05-05 https://biopharmsignal.com/news/BNTX/biontech-ver-ffentlicht-ergebnisse-f-r-das-erste-quartal-2026-sowie-informatione-f97bd26e 2026-05-05 https://biopharmsignal.com/news/BNTX/biontech-announces-first-quarter-2026-financial-results-and-corporate-update-cf711753 2026-05-05 https://biopharmsignal.com/news/EMBC/embecta-corp-reports-second-quarter-fiscal-2026-financial-results 2026-05-05 https://biopharmsignal.com/news/IART/integra-lifesciences-reports-first-quarter-2026-financial-results 2026-05-05 https://biopharmsignal.com/news/ACON/aclarion-announces-second-commercial-agreement-with-weill-cornell-medicine-5a460780 2026-05-05 https://biopharmsignal.com/news/IART/integra-lifesciences-announces-leadership-transition 2026-05-05 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-05-05 https://biopharmsignal.com/news/MD/pediatrix-medical-group-reports-first-quarter-results 2026-05-05 https://biopharmsignal.com/news/OCS/latest-findings-from-dme-aware-delphi-study-presented-at-arvo-2026-annual-meeting 2026-05-05 https://biopharmsignal.com/news/FMS/fresenius-medical-care-delivers-strong-operating-income-growth-in-q1-2026-while-advancing-the-u-s-rollout-of-5008x-caresystems-at-speed 2026-05-05 https://biopharmsignal.com/news/ABSI/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 2026-05-05 https://biopharmsignal.com/news/PNTG/pennant-announces-first-quarter-2026-earnings-release-and-call 2026-05-04 https://biopharmsignal.com/news/XRAY/dentsply-sirona-expands-u-s-distribution-footprint-through-enhanced-agreement-wi-e8d1b3b1 2026-05-04 https://biopharmsignal.com/news/CVRX/cvrx-announces-first-patient-enrollment-in-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population 2026-05-04 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-thursday--2991431d 2026-05-04 https://biopharmsignal.com/news/TEVA/teva-to-present-at-the-bofa-securities-health-care-conference-445d1233 2026-05-04 https://biopharmsignal.com/news/CLLS/cellectis-to-report-first-quarter-financial-results-on-may-11-2026 2026-05-04 https://biopharmsignal.com/news/HSTM/healthstream-announces-first-quarter-2026-results 2026-05-04 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results 2026-05-04 https://biopharmsignal.com/news/COO/coopercompanies-appoints-paul-keel-to-its-board-of-directors-f12e0190 2026-05-04 https://biopharmsignal.com/news/ANAB/anaptys-to-participate-at-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference 2026-05-04 https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates 2026-05-04 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-announces-100-million-loan-facility-with-hercules-capita-f6f7746c 2026-05-04 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12 2026-05-04 https://biopharmsignal.com/news/TCMD/tactile-systems-technology-inc-reports-first-quarter-2026-financial-results 2026-05-04 https://biopharmsignal.com/news/OPCH/option-care-health-to-participate-in-the-bank-of-america-health-care-conference 2026-05-04 https://biopharmsignal.com/news/BDSX/biodesix-announces-first-quarter-2026-results-and-highlights-c1e0cb2b 2026-05-04 https://biopharmsignal.com/news/OCGN/ocugen-announces-private-offering-of-115-million-of-convertible-senior-notes-7be33294 2026-05-04 https://biopharmsignal.com/news/SENS/senseonics-announces-closing-of-92-million-public-offering-and-full-exercise-of--0e1d5fdd 2026-05-04 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026-and-participate-in-upcoming-investor-conference 2026-05-04 https://biopharmsignal.com/news/CYTK/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-cli-1715eb5b 2026-05-04 https://biopharmsignal.com/news/VTAK/flyte-increases-capacity-and-launches-hiring-initiative-as-spirit-airlines-shutd-8c2c1b61 2026-05-04 https://biopharmsignal.com/news/CHRS/coherus-oncology-to-report-first-quarter-2026-financial-results-on-may-11-2026 2026-05-04 https://biopharmsignal.com/news/DRTS/alpha-tau-announces-100-local-disease-control-rate-and-favorable-safety-profile--93d99483 2026-05-04 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-reports-durable-responses-in-second-line-ras-mutant-mss-color-de371576 2026-05-04 https://biopharmsignal.com/news/FATE/fate-therapeutics-announces-three-presentations-at-the-2026-asgct-annual-meeting-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and-autoimmune-diseases 2026-05-04 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-completes-acquisition-of-cullgen-to-create-u-s-and-china-based-07fefd40 2026-05-04 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-completes-acquisition-of-cullgen-to-create-u-s-and-china-based-fully-integrated-biopharmaceutical-company 2026-05-04 https://biopharmsignal.com/news/XRAY/dentsply-sirona-launches-smart-view-detect-world-s-first-fda-cleared-ai-enabled--3f962629 2026-05-04 https://biopharmsignal.com/news/ABEO/abeona-therapeutics-announces-date-of-first-quarter-financial-results-2a23133e 2026-05-04 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-new-survey-results-showing-significant-burden-of-tardive-dyskinesia-on-employment 2026-05-04 https://biopharmsignal.com/news/JAGX/jaguar-health-expands-neonorm-franchise-with-introduction-of-neonorm-dog-for-companion-animal-gut-health 2026-05-04 https://biopharmsignal.com/news/FBIO/fortress-biotech-to-participate-in-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference 2026-05-04 https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-report-first-quarter-2026-financial-results-on-may-11-2026 2026-05-04 https://biopharmsignal.com/news/CADL/candel-therapeutics-to-host-investor-conference-call-following-presentation-of-extended-data-from-phase-3-trial-of-aglatimagene-besadenovec-in-localized-prostate-cancer-at-the-american-urological-association-2026-annual-meeting 2026-05-04 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-appoints-nadia-dac-seasoned-commercial-leader-in-neurology--f1202d79 2026-05-04 https://biopharmsignal.com/news/CLNN/after-successful-fda-meeting-clene-filing-accelerated-approval-nda-for-als-ad6256ad 2026-05-04 https://biopharmsignal.com/news/PRQR/proqr-announces-annual-general-meeting-of-shareholders-to-be-held-june-2-2026-ed4cab08 2026-05-04 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-announces-vadadustat-post-hoc-win-statistics-analysis-demons-2bd9a600 2026-05-04 https://biopharmsignal.com/news/SENS/senseonics-enters-into-amended-loan-agreement-with-hercules-to-increase-borrowin-f17ffff6 2026-05-04 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-new-data-presentations-in-acquired-hypothalamic-6ce2deb1 2026-05-04 https://biopharmsignal.com/news/LEGN/legend-biotech-expands-scientific-advisory-expertise-to-inform-future-growth-806c85a2 2026-05-04 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference 2026-05-04 https://biopharmsignal.com/news/BSX/boston-scientific-announces-participation-in-bernstein-s-42nd-annual-strategic-decisions-conference-and-conference-call-discussing-second-quarter-2026-results 2026-05-04 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-participate-in-upcoming-investor-conferences 2026-05-04 https://biopharmsignal.com/news/LCTX/opregenr-3-year-results-in-patients-with-ga-presented-at-foundation-fighting-blindness-retinal-innovation-summit-2026 2026-05-04 https://biopharmsignal.com/news/VERA/vera-therapeutics-to-participate-in-the-bank-of-america-securities-2026-health-c-eb857e6e 2026-05-04 https://biopharmsignal.com/news/IFRX/inflarx-reports-favorable-reactive-metabolite-profile-for-izicopan-in-human-live-6c0b8eb5 2026-05-04 https://biopharmsignal.com/news/BBIO/bridgebio-to-present-new-acoramidis-data-on-disease-progression-biomarkers-and-c-ebb0b55a 2026-05-04 https://biopharmsignal.com/news/MGNX/macrogenics-and-sagard-healthcare-partners-enter-into-expanded-zynyzr-royalty-purchase-agreement 2026-05-04 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-participate-in-upcoming-may-2026-events 2026-05-04 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-nbip-2118-a-corticotropin-releasing-factor-type-2-receptor-agonist 2026-05-04 https://biopharmsignal.com/news/TWST/twist-bioscience-expands-clonal-genes-offering-to-include-long-and-complex-sequences 2026-05-04 https://biopharmsignal.com/news/TWST/twist-bioscience-announces-fiscal-2026-second-quarter-financial-results 2026-05-04 https://biopharmsignal.com/news/NXTC/nextcure-and-simcere-zaiming-initiate-dose-optimization-for-sim0505-cdh6-adc-in--e6572d0c 2026-05-04 https://biopharmsignal.com/news/IRWD/ironwood-survey-findings-at-ddw-2026-underscore-need-for-therapies-that-address-multiple-dimensions-of-total-parenteral-nutrition-tpn-burden-in-short-bowel-syndrome-sbs 2026-05-04 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-appointment-of-kartik-krishnan-m-d-ph-d-as-chief-medical-officer 2026-05-04 https://biopharmsignal.com/news/ADMA/adma-biologics-announces-fda-approval-to-expand-the-label-for-ascenivtm-to-include-pediatric-immune-compromised-patients-two-years-of-age-and-older 2026-05-04 https://biopharmsignal.com/news/SEER/seer-announces-appointment-of-anthony-bazarko-as-chief-commercial-officer 2026-05-04 https://biopharmsignal.com/news/BCRX/biocryst-announces-european-licensing-agreement-with-irish-affiliate-of-neopharmed-gentili-for-navenibart-in-hereditary-angioedema 2026-05-04 https://biopharmsignal.com/news/INDV/indivior-announces-175-million-accelerated-share-repurchase-b248ff09 2026-05-04 https://biopharmsignal.com/news/TENX/tenax-therapeutics-appoints-timothy-healey-mba-as-chief-commercial-officer-0ef7cf34 2026-05-04 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2026-financial-results-and-provides-bu-1ca95d81 2026-05-04 https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-first-quarter-2026-financial-and-operating-results-9aa0ae94 2026-05-04 https://biopharmsignal.com/news/MCRB/seres-therapeutics-presents-preclinical-data-at-digestive-disease-week-ddw-2026-supporting-ser-603-a-next-generation-cultivated-live-biotherapeutic-candidate-for-inflammatory-bowel-disease 2026-05-04 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-its-respiratory-syncytial-virus-and-stat6-inhibitor-programs-at-the-american-thoracic-society-international-conference-2026 2026-05-04 https://biopharmsignal.com/news/INSM/insmed-to-present-data-across-its-respiratory-portfolio-including-late-breaking-arikaycer-results-from-phase-3b-encore-study-at-the-american-thoracic-society-international-conference-2026 2026-05-04 https://biopharmsignal.com/news/TECH/bio-techne-to-present-at-the-bank-of-america-securities-2026-global-healthcare-conference 2026-05-04 https://biopharmsignal.com/news/PLSE/pulse-biosciences-reports-business-updates-and-first-quarter-2026-financial-results 2026-05-04 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-launches-won-t-lose-media-campaign-ahead-of-fifa-world-cup-2026tm 2026-05-04 https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-pricing-of-150-million-underwritten-offering 2026-05-04 https://biopharmsignal.com/news/MOLN/molecular-partners-to-hold-oral-presentations-on-dll3-targeting-radio-darpin-can-61a9ac5e 2026-05-04 https://biopharmsignal.com/news/PNTG/pennant-acquires-senior-living-communities-in-arizona-and-wisconsin 2026-05-01 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-inducement-grant-under-nasdaq-listing-rule-56-e4b38e90 2026-05-01 https://biopharmsignal.com/news/CELC/celcuity-s-phase-3-viktoria-1-trial-achieves-primary-endpoint-with-clinically-me-0f7cff3d 2026-05-01 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-demonstrating-durable-hormone-control-reduced-glucocorticoid-exposure-and-meaningful-clinical-improvements-in-pediatric-patients-with-classic-congenital-adrenal-hyperplasia 2026-05-01 https://biopharmsignal.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635-c-4 2026-05-01 https://biopharmsignal.com/news/ARVN/arvinas-announces-fda-approval-of-veppanu-vepdegestrant-for-the-treatment-of-esr1m-er-her2-advanced-breast-cancer 2026-05-01 https://biopharmsignal.com/news/RVMD/revolution-medicines-statement-on-fda-expanded-access-authorization-for-daraxonrasib-in-patients-with-previously-treated-metastatic-pancreatic-cancer 2026-05-01 https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-schedules-first-quarter-2026-earnings-release-and-confer-40b588f2 2026-05-01 https://biopharmsignal.com/news/PAVM/pavmed-to-hold-first-quarter-2026-business-update-conference-call-and-webcast-on-may-15-2026 2026-05-01 https://biopharmsignal.com/news/IRMD/iradimed-corporation-reports-first-quarter-2026-financial-results-2aefa164 2026-05-01 https://biopharmsignal.com/news/GDRX/goodrx-expands-offerings-to-now-include-ozempicr-pill-for-type-2-diabetes-patients 2026-05-01 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-highlight-voqueznar-vonoprazan-at-ddw-2026-annual-meeting 2026-05-01 https://biopharmsignal.com/news/VXRT/vaxart-to-host-stockholder-fireside-chat-on-may-8-at-4-30-p-m-et-61bd19ec 2026-05-01 https://biopharmsignal.com/news/HCAT/health-catalyst-to-announce-first-quarter-2026-operating-results-and-host-confer-a23ecc29 2026-05-01 https://biopharmsignal.com/news/SYK/stryker-to-participate-in-the-bank-of-america-securities-2026-global-healthcare-conference 2026-05-01 https://biopharmsignal.com/news/USNA/during-national-show-your-smile-month-kevin-guest-urges-leaders-to-lift-others-daily 2026-05-01 https://biopharmsignal.com/news/IFRX/inflarx-to-report-first-quarter-2026-results-on-may-7-2026-9f4af198 2026-05-01 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-receives-tga-approval-of-redemplor-plozasiran-in-australia-expanding-global-access-for-patients-with-familial-chylomicronemia-syndrome-fcs 2026-05-01 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-hosts-auvelity-fda-approval-investor-event-featuring-expert--f787f913 2026-05-01 https://biopharmsignal.com/news/ESPR/esperion-to-be-acquired-by-archimed 2026-05-01 https://biopharmsignal.com/news/MOLN/molecular-partners-publishes-phase-1-mp0317-data-in-nature-cancer-demonstrating--32955534 2026-05-01 https://biopharmsignal.com/news/FLGT/fulgent-reports-first-quarter-2026-financial-results 2026-05-01 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-granted-marketing-author-2aaf3706 2026-05-01 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-relaunches-hemangeol-propranolol-oral-solution-with-eton-ca-3e03425c 2026-05-01 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-announces-earnings-release-date-conference-call-and-webca-d61b9662 2026-05-01 https://biopharmsignal.com/news/OCS/oculis-to-present-at-upcoming-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting 2026-05-01 https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-announces-pricing-of-upsized-initial-public-offering 2026-05-01 https://biopharmsignal.com/news/SENS/senseonics-announces-pricing-of-80-million-public-offering-of-common-stock-and-p-30d1e0e6 2026-05-01 https://biopharmsignal.com/news/TELA/tela-bio-announces-strategic-board-refreshment-with-four-highly-experienced-commerical-leaders-to-accelerate-growth-and-drive-path-to-profitability-the-company-also-reports-preliminary-first-quarter-2026-revenues 2026-04-30 https://biopharmsignal.com/news/RXRX/recursion-announces-board-transition-f495c9f3 2026-04-30 https://biopharmsignal.com/news/EBS/emergent-biosolutions-reports-first-quarter-2026-financial-results 2026-04-30 https://biopharmsignal.com/news/PRGO/perrigo-completes-divestiture-of-dermacosmetics-business 2026-04-30 https://biopharmsignal.com/news/CUE/cue-biopharma-announces-30-million-private-placement-c8777404 2026-04-30 https://biopharmsignal.com/news/HCWB/hcw-biologics-announces-adjournment-of-special-meeting-of-stockholders-due-to-la-3cce136b 2026-04-30 https://biopharmsignal.com/news/EHC/encompass-health-reports-results-for-first-quarter-2026 2026-04-30 https://biopharmsignal.com/news/CUE/cue-biopharma-expands-pipeline-with-exclusive-license-from-ascendant-health-scie-d31a094f 2026-04-30 https://biopharmsignal.com/news/COO/coopercompanies-announces-release-date-for-second-quarter-2026-d53e901c 2026-04-30 https://biopharmsignal.com/news/ENSG/the-ensign-group-reports-first-quarter-2026-results-raises-2026-annual-earnings--f450c561 2026-04-30 https://biopharmsignal.com/news/SIBN/si-bone-to-present-at-bofa-securities-2026-healthcare-conference-on-may-12-2026 2026-04-30 https://biopharmsignal.com/news/AZYO/elutia-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026 2026-04-30 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-to-announce-1st-quarter-2026-financial-results-on-may-7-2026 2026-04-30 https://biopharmsignal.com/news/CUE/cue-biopharma-names-shao-lee-lin-m-d-ph-d-ceo-president-and-board-director-to-le-027b3f2d 2026-04-30 https://biopharmsignal.com/news/BSEM/biostem-technologies-to-host-first-quarter-2026-financial-results-conference-cal-c23bed48 2026-04-30 https://biopharmsignal.com/news/COCP/cocrystal-pharma-presentation-at-icar-2026-highlights-mechanism-of-action-and-cl-398ed2cd 2026-04-30 https://biopharmsignal.com/news/IPSC/century-therapeutics-selected-for-oral-presentation-of-cnty-813-preclinical-data-0932a2d5 2026-04-30 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-report-first-quarter-2026-financial-results-and-discuss-r-fb91dbfe 2026-04-30 https://biopharmsignal.com/news/IRTC/irhythm-holdings-announces-first-quarter-2026-financial-results-d2123e7c 2026-04-30 https://biopharmsignal.com/news/MMSI/merit-medical-reports-first-quarter-2026-results-and-updates-full-year-guidance-651680cc 2026-04-30 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-publishes-cross-species-findings-supporting-skin-as-a-surrogate-for-the-measurement-of-frataxin-in-tissues-clinically-relevant-to-friedreich-s-ataxia 2026-04-30 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-host-first-quarter-2026-investor-update-call 2026-04-30 https://biopharmsignal.com/news/SYK/stryker-reports-first-quarter-2026-operating-results 2026-04-30 https://biopharmsignal.com/news/CORT/corcept-phase-2-study-of-dazucorilant-demonstrates-two-year-overall-survival-benefit-in-patients-with-amyotrophic-lateral-sclerosis 2026-04-30 https://biopharmsignal.com/news/CORT/corcept-therapeutics-announces-first-quarter-financial-results-and-provides-corporate-update 2026-04-30 https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-attend-three-upcoming-investor-conferences-in-may-june-336852ab 2026-04-30 https://biopharmsignal.com/news/ALHC/alignment-healthcare-delivers-strong-first-quarter-2026-results-demonstrating-disciplined-growth-and-margin-expansion 2026-04-30 https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-first-quarter-2026-financial-results 2026-04-30 https://biopharmsignal.com/news/SENS/senseonics-announces-commencement-of-80-million-public-offering-of-common-stock--a0cb96fa 2026-04-30 https://biopharmsignal.com/news/ARDX/ardelyx-reports-first-quarter-2026-financial-results-and-provides-business-updat-8ab879af 2026-04-30 https://biopharmsignal.com/news/ENSG/the-ensign-group-purchases-facilities-in-wisconsin-a73e8514 2026-04-30 https://biopharmsignal.com/news/ENSG/the-ensign-group-acquires-real-estate-and-expands-operations-in-texas-841992a3 2026-04-30 https://biopharmsignal.com/news/XENE/xenon-to-report-q1-2026-financial-results-on-may-7-2026 2026-04-30 https://biopharmsignal.com/news/SNDX/syndax-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-04-30 https://biopharmsignal.com/news/ASND/ascendis-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-7-2026 2026-04-30 https://biopharmsignal.com/news/NEPH/nephros-schedules-first-quarter-2026-financial-results-conference-call-eb612ca2 2026-04-30 https://biopharmsignal.com/news/MDXH/mdxhealth-to-release-first-quarter-2026-financial-results-on-may-13-70772180 2026-04-30 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-announces-fda-approval-of-auvelity-dextromethorphan-hbr-and--3628711d 2026-04-30 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-to-present-new-data-at-isct-2026-highlighting-its-ongoi-184d1673 2026-04-30 https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-listing-of-the-rain-token-on-htx-a-leading-cry-c4872692 2026-04-30 https://biopharmsignal.com/news/HCAT/health-catalyst-appoints-steve-nelson-president-of-aetna-to-its-board-of-directo-59637695 2026-04-30 https://biopharmsignal.com/news/FATE/fate-therapeutics-announces-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-for-systemic-lupus-erythematosus-sle-at-the-ccr-east-2026-meeting 2026-04-30 https://biopharmsignal.com/news/RCEL/avita-medical-names-cary-vance-as-chief-executive-officer-9d7f5bda 2026-04-30 https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-hold-first-quarter-2026-business-update-conference-call-and-ef5e4a87 2026-04-30 https://biopharmsignal.com/news/BEAT/heartbeam-to-host-first-quarter-2026-results-conference-call-on-wednesday-may-13-2026-at-4-30-p-m-eastern-time 2026-04-30 https://biopharmsignal.com/news/PAVM/lucid-diagnostics-to-hold-first-quarter-2026-business-update-conference-call-and-webcast-on-may-14-2026 2026-04-30 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-first-patient-dosed-in-fortify-the-phase-1b-indication-expansion-trial-evaluating-pln-101095-in-patients-with-ici-refractory-solid-tumors 2026-04-30 https://biopharmsignal.com/news/RBOT/vicarious-surgical-reports-first-quarter-2026-financial-results-906caf78 2026-04-30 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-to-announce-corporate-update-and-first-quarter-2026-financ-1aa1cd9c 2026-04-30 https://biopharmsignal.com/news/TEVA/teva-s-2025-healthy-future-report-highlights-environmental-and-access-to-medicin-91ee2185 2026-04-30 https://biopharmsignal.com/news/BRLI/opko-health-expands-nicoya-agreement-to-support-rayaldeer-commercialization-in-greater-china 2026-04-30 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026 2026-04-30 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-to-present-pipeline-and-technology-advances-at-the-29th-ann-b357103b 2026-04-30 https://biopharmsignal.com/news/ALXO/alx-oncology-announces-that-cd47-biomarker-data-from-clinical-trial-evaluating-evorpacept-zanidatamab-combination-in-advanced-breast-cancer-will-be-presented-at-esmo-breast-cancer-2026 2026-04-30 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-to-present-at-the-bank-of-america-healthcare-conference-7cf1deff 2026-04-30 https://biopharmsignal.com/news/IMMP/immutep-receives-nasdaq-notice-of-bid-price-deficiency-97af9993 2026-04-30 https://biopharmsignal.com/news/IMMP/immutep-quarterly-activities-report-q3-fy26-497915eb 2026-04-30 https://biopharmsignal.com/news/ECOR/electrocore-tac-stim-named-national-semifinalist-in-national-safety-council-work-766a057b 2026-04-30 https://biopharmsignal.com/news/SLDB/solid-biosciences-to-showcase-a-large-presence-at-the-29th-annual-meeting-of-the-c4a8ff92 2026-04-30 https://biopharmsignal.com/news/INMB/inmune-bio-inc-to-report-first-quarter-2026-financial-results-and-provide-corpor-c72db2ca 2026-04-30 https://biopharmsignal.com/news/PRQR/proqr-announces-nomination-of-dr-lykke-hinsch-gylvin-to-its-board-of-directors-e6494607 2026-04-30 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-may-7--09daf4b7 2026-04-30 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-upcoming-scientific-conferences-5a0d2417 2026-04-30 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-report-first-quarter-2026-financial-results-on-may-7-2026 2026-04-30 https://biopharmsignal.com/news/OPKO/bioreferencer-launches-bioreference-directtm-expanding-access-to-consumer-initiated-diagnostic-testing-through-a-fully-integrated-digital-platform 2026-04-30 https://biopharmsignal.com/news/CRL/charles-river-launches-rat-in-vitro-fertility-services-demonstrating-embryology-capabilities 2026-04-30 https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-approval-from-singapore-health-sciences-authority-for-expanded-indication-of-acam2000r-smallpox-and-mpox-vaccinia-vaccine-live-to-include-mpox 2026-04-30 https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-host-conference-call-on-first-quarter-2026-financial-results-and-business-update 2026-04-30 https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-first-quarter-2026-financial-results-and-updates-on-corporate-developments 2026-04-30 https://biopharmsignal.com/news/BBIO/bridgebio-to-report-first-quarter-2026-financial-results-and-commercial-updates--b152d46d 2026-04-30 https://biopharmsignal.com/news/MDNA/medicenna-and-fondazione-melanoma-onlus-announce-presentation-on-neocyt-trial-at-asco-2026 2026-04-30 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-releases-appendix-4c-q3-fy26-quarterly-cash-flow-report-co-8a024ac6 2026-04-30 https://biopharmsignal.com/news/USNA/usana-celebrates-30-years-of-excellence-in-canada 2026-04-30 https://biopharmsignal.com/news/ACIU/ac-immune-first-quarter-2026-financial-and-corporate-updates-52496515 2026-04-30 https://biopharmsignal.com/news/OPCH/option-care-health-announces-financial-results-for-the-first-quarter-ended-march-31-2026 2026-04-30 https://biopharmsignal.com/news/DTIL/precision-biosciences-to-report-first-quarter-2026-financial-results-on-may-5-2026 2026-04-30 https://biopharmsignal.com/news/INDV/indivior-reports-first-quarter-2026-financial-results-and-raises-full-year-2026--0dbc826f 2026-04-30 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-reports-first-quarter-2026-financial-results-and-provides-b9938028 2026-04-30 https://biopharmsignal.com/news/BSEM/biostem-strengthens-leadership-team-with-appointment-of-katherine-gorrell-as-chi-3d9df331 2026-04-30 https://biopharmsignal.com/news/LNSR/lensar-to-report-first-quarter-2026-results-on-may-8-2026-05c060f4 2026-04-30 https://biopharmsignal.com/news/ACIU/ac-immune-initiates-final-cohort-in-ongoing-phase-1b-2-abate-trial-of-anti-abeta-971a228d 2026-04-30 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-first-quarter-2026-financial-results-and-provides--48367c85 2026-04-30 https://biopharmsignal.com/news/AXGN/axogen-inc-to-participate-in-the-2026-bank-of-america-global-healthcare-conference 2026-04-30 https://biopharmsignal.com/news/INSM/insmed-to-present-at-may-2026-investor-conferences 2026-04-30 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-04-30 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-first-quarter-financial-results-for-2026 2026-04-30 https://biopharmsignal.com/news/BDX/bd-achieves-excellence-in-employee-well-being-earning-top-industry-recognition 2026-04-30 https://biopharmsignal.com/news/ACON/aclarion-delivers-strong-q1-2026-results-with-196-annual-scan-volume-growth-refl-d5dcbffc 2026-04-30 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-to-initiate-new-drug-application-submission-from-the-darovasertib-optimum-02-trial-under-the-oncology-center-of-excellence-real-time-oncology-review-rtor-program 2026-04-30 https://biopharmsignal.com/news/ADXN/addex-reports-full-year-2025-financial-results-and-provides-corporate-update-9259fc1f 2026-04-30 https://biopharmsignal.com/news/ARGX/argenx-to-report-first-quarter-2026-financial-results-and-business-update-on-may-e657cac9 2026-04-30 https://biopharmsignal.com/news/VCNX/vaccinex-reports-2025-annual-financial-results 2026-04-30 https://biopharmsignal.com/news/MESO/quarterly-activities-appendix-4c-cash-flow-report 2026-04-29 https://biopharmsignal.com/news/LGMK/logicmark-inc-to-announce-first-quarter-2026-financial-results-on-may-13-2026-d1c71aeb 2026-04-29 https://biopharmsignal.com/news/TARS/tarsus-to-report-first-quarter-2026-financial-results-on-wednesday-may-6-2026 2026-04-29 https://biopharmsignal.com/news/HLF/herbalife-completes-1-45-billion-senior-secured-refinancing 2026-04-29 https://biopharmsignal.com/news/LFST/lifestance-to-present-at-upcoming-investor-conferences 2026-04-29 https://biopharmsignal.com/news/RXST/rxsight-inc-to-present-at-the-bank-of-america-healthcare-conference 2026-04-29 https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-second-quarter-conference-call-and-webcast 2026-04-29 https://biopharmsignal.com/news/SGHT/sight-sciences-to-present-at-two-upcoming-investor-conferences 2026-04-29 https://biopharmsignal.com/news/LUNG/pulmonx-reports-first-quarter-2026-financial-results 2026-04-29 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-report-financial-results-for-first-quarter-2026-after-market-close-on-may-6-2026 2026-04-29 https://biopharmsignal.com/news/MXCT/maxcyte-to-report-first-quarter-2026-financial-results-on-may-12-2026 2026-04-29 https://biopharmsignal.com/news/SEER/seer-to-report-first-quarter-2026-financial-results-on-may-13-2026 2026-04-29 https://biopharmsignal.com/news/RCEL/avita-medical-announces-tga-certification-in-australia-and-medsafe-wand-listing--30271fe0 2026-04-29 https://biopharmsignal.com/news/ALEC/alector-to-discontinue-phase-2-progress-ad-trial-of-nivisnebart-al101-gsk4527226-1b3ecd87 2026-04-29 https://biopharmsignal.com/news/TDOC/teladoc-health-reports-first-quarter-2026-results-775e25ab 2026-04-29 https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-announce-first-quarter-2026-financial-results-and-corporat-de8600bf 2026-04-29 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-announces-initiative-to-support-operational-efficiency-and--2ff6445e 2026-04-29 https://biopharmsignal.com/news/ACHC/acadia-healthcare-announces-first-quarter-2026-results 2026-04-29 https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-04-29 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-publication-establishing-clinically-meaningful-improvement-threshold-for-the-tardive-dyskinesia-impact-scale 2026-04-29 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-first-quarter-2026-results-may-13-2026 2026-04-29 https://biopharmsignal.com/news/BNGO/bionano-to-report-first-quarter-2026-financial-results-and-host-a-conference-call-webcast-on-may-13-2026 2026-04-29 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-wednesday-may-6-2026 2026-04-29 https://biopharmsignal.com/news/PRCT/procept-biorobotics-reports-first-quarter-2026-financial-results-c24cd67e 2026-04-29 https://biopharmsignal.com/news/MDXG/mimedx-announces-first-quarter-2026-operating-and-financial-results 2026-04-29 https://biopharmsignal.com/news/OLMA/olema-oncology-appoints-prakash-raman-ph-d-to-board-of-directors 2026-04-29 https://biopharmsignal.com/news/MNKD/mannkind-to-report-first-quarter-2026-financial-results-on-may-6-2026 2026-04-29 https://biopharmsignal.com/news/JAGX/jaguar-health-announces-statistically-significant-results-from-effectiveness-trial-of-crofelemer-fda-approved-canalevia-ca1-for-treatment-of-chemotherapy-induced-diarrhea-in-dogs 2026-04-29 https://biopharmsignal.com/news/RNXT/renovorx-to-host-first-quarter-2026-financial-results-and-business-highlights-conference-call-on-may-14th-at-4-30-pm-et 2026-04-29 https://biopharmsignal.com/news/HYPR/hyperfine-swoopr-system-introduced-as-india-s-first-portable-mri-for-bedside-brain-imaging-at-the-country-s-leading-medical-institution 2026-04-29 https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-commercialization-agreement-with-eversana-to-support-potential-u-s-launch-of-aglatimagene-besadenovec-in-localized-prostate-cancer 2026-04-29 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-announces-transition-to-trading-on-otcqb-venture-market-03ef95e7 2026-04-29 https://biopharmsignal.com/news/GHRS/gh-research-announces-pricing-of-117-5-million-underwritten-offering 2026-04-29 https://biopharmsignal.com/news/TPST/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting 2026-04-29 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6 2026-04-29 https://biopharmsignal.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2026-financial-results-and--6712f31a 2026-04-29 https://biopharmsignal.com/news/ECOR/electrocore-to-announce-first-quarter-march-31-2026-financial-results-on-wednesd-3b24458c 2026-04-29 https://biopharmsignal.com/news/URGN/urogen-pharma-to-report-first-quarter-2026-financial-results-on-wednesday-may-6th-2026 2026-04-29 https://biopharmsignal.com/news/SRRK/scholar-rock-to-present-at-the-bofa-securities-2026-health-care-conference 2026-04-29 https://biopharmsignal.com/news/RXRX/recursion-to-report-first-quarter-2026-business-updates-and-financial-results-on-371275ef 2026-04-29 https://biopharmsignal.com/news/EBS/emergent-biosolutions-secures-long-term-strategic-manufacturing-contract-with-sab-biotherapeutics-to-advance-type-1-diabetes-candidate-sab-142 2026-04-29 https://biopharmsignal.com/news/OCGN/ocugen-to-host-conference-call-on-tuesday-may-5-at-8-30-a-m-et-to-discuss-busine-6b6c1f44 2026-04-29 https://biopharmsignal.com/news/DTIL/precision-biosciences-activates-first-clinical-trial-site-and-begins-patient-enrollment-in-phase-1-2-function-dmd-study 2026-04-29 https://biopharmsignal.com/news/ADMA/adma-biologics-to-report-first-quarter-2026-financial-results-on-may-6-2026 2026-04-29 https://biopharmsignal.com/news/OKYO/okyo-ceo-and-cso-to-present-and-leadership-team-to-participate-at-upcoming-scien-899e0c00 2026-04-29 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-european-commission-approval-of-xolremdi-mavorixafo-d7025d6a 2026-04-29 https://biopharmsignal.com/news/EYPT/eyepoint-to-report-first-quarter-2026-financial-results-on-may-6-2026-09ed11b6 2026-04-29 https://biopharmsignal.com/news/AMRN/amarin-reports-2026-first-quarter-financial-results-56ba780b 2026-04-29 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-announces-first-patient-enrolled-in-sol-x-long-term-extension-665bc3e1 2026-04-29 https://biopharmsignal.com/news/TEVA/teva-delivers-strong-q1-2026-results-driven-by-innovative-portfolio-growth-and-d-5a77d620 2026-04-29 https://biopharmsignal.com/news/KALV/chiesi-group-to-acquire-kalvista-pharmaceuticals-expanding-its-global-rare-disease-portfolio 2026-04-29 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-of-phase-1-data-and-plans-for-an-adaptive-phase-2-field-study-of-tnx-4800-anti-borrelia-ospa-monoclonal-antibody-for-the-prevention-of-lyme-disease-at-the-4th-annual-ticks-and-tickborne-diseases-symposium-at-johns-hopkins-university 2026-04-29 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-announces-pricing-of-public-offering-of-common-stock 2026-04-29 https://biopharmsignal.com/news/EBS/emergent-biosolutions-partners-with-professional-baseball-player-davis-schneider-to-raise-awareness-of-narcanr-nasal-spray-among-canadians-and-help-save-lives 2026-04-29 https://biopharmsignal.com/news/BDX/bd-reimagines-central-line-insertion-advancing-leadership-in-patient-safety-through-breakthrough-vascular-access-technology 2026-04-29 https://biopharmsignal.com/news/AGIO/agios-reports-first-quarter-2026-financial-results-and-provides-business-update-bdeebcf5 2026-04-29 https://biopharmsignal.com/news/TEVA/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-ne-2cf86c96 2026-04-29 https://biopharmsignal.com/news/REGN/regeneron-reports-first-quarter-2026-financial-and-operating-results 2026-04-29 https://biopharmsignal.com/news/HCM/hutchmed-announces-nda-acceptance-in-china-with-priority-review-status-and-break-86e3b5fe 2026-04-29 https://biopharmsignal.com/news/HUM/humana-reports-first-quarter-2026-financial-results-affirms-full-year-2026-adjusted-financial-guidance 2026-04-29 https://biopharmsignal.com/news/PRTC/puretech-announces-annual-results-for-year-ended-december-31-2025 2026-04-29 https://biopharmsignal.com/news/PRTC/puretech-announces-intention-to-voluntarily-delist-american-depositary-shares-from-nasdaq-and-concentrate-trading-on-the-london-stock-exchange 2026-04-29 https://biopharmsignal.com/news/ADXN/addex-gabab-pam-candidate-demonstrates-solid-anti-tussive-activity-in-bleomycin--b4343672 2026-04-29 https://biopharmsignal.com/news/PRI/primerica-household-budget-indextm-hbitm-purchasing-power-for-middle-income-americans-held-steady-in-march-despite-continued-financial-pressures 2026-04-29 https://biopharmsignal.com/news/GSK/gsk-delivers-strong-q1-performance-and-start-to-2026 2026-04-29 https://biopharmsignal.com/news/MESO/patient-recruitment-target-achieved-in-clbp-pivotal-trial 2026-04-28 https://biopharmsignal.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-on-thursday-may-7-2026-after-close-of-u-s-based-financial-markets 2026-04-28 https://biopharmsignal.com/news/ORGO/organogenesis-completes-rolling-submission-of-biologics-license-application-for-renur 2026-04-28 https://biopharmsignal.com/news/PCRX/pacira-biosciences-files-definitive-proxy-materials-and-mails-letter-to-shareholders 2026-04-28 https://biopharmsignal.com/news/LUNG/pulmonx-to-present-at-the-bank-of-america-securities-2026-health-care-conference 2026-04-28 https://biopharmsignal.com/news/IRTC/irhythm-holdings-to-present-at-the-bank-of-america-securities-2026-health-care-c-301062b2 2026-04-28 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-reports-positive-topline-results-from-month-24-interim-analysis-of-pivot-hd-extension-study-of-votoplam 2026-04-28 https://biopharmsignal.com/news/BRLI/opko-health-reports-first-quarter-2026-business-highlights-and-financial-results 2026-04-28 https://biopharmsignal.com/news/HYPR/hyperfine-inc-to-announce-first-quarter-2026-financial-results-on-may-12-2026 2026-04-28 https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-first-quarter-2026-financial-results-and-recent-business-updates 2026-04-28 https://biopharmsignal.com/news/MDRX/veradigm-receives-klas-2026-points-of-light-award-for-embedding-sdoh-data-in-provider-ehr-workflows 2026-04-28 https://biopharmsignal.com/news/CCEL/cryo-cell-international-receives-fact-re-accreditation-setting-the-longest-independently-validated-quality-track-record-among-u-s-private-cord-blood-banks 2026-04-28 https://biopharmsignal.com/news/NRSN/neurosense-announces-pricing-of-insider-led-pipe-financing 2026-04-28 https://biopharmsignal.com/news/QNRX/correction-quoin-pharmaceuticals-provides-clinical-and-regulatory-update-for-qrx-39868fdf 2026-04-28 https://biopharmsignal.com/news/ENLV/enlivex-treasury-update-total-rain-holdings-rise-to-78-819-756-062-tokens-as-of--7c246002 2026-04-28 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-report-results-from-pivot-hd-long-term-extension-study 2026-04-28 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-launches-new-study-to-expand-use-of-cypath-lung-technol-a9a9c6dc 2026-04-28 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-provides-clinical-and-regulatory-update-for-qrx009-topical-c6f350bb 2026-04-28 https://biopharmsignal.com/news/PYPD/polypid-to-present-data-from-shield-ii-phase-3-trial-demonstrating-reduced-severity-of-surgical-site-infection-at-surgical-infection-society-2026-annual-meeting 2026-04-28 https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-strategic-collaboration-with-artificial-intelligence-ai-leader-sciencemachine-highlighting-new-expansion-opportunities-and-insights-for-fabp5-inhibitor-development 2026-04-28 https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2026-financial-results 2026-04-28 https://biopharmsignal.com/news/EBS/emergent-biosolutions-and-substipharm-biologics-announce-strategic-manufacturing-partnership-to-support-japanese-encephalitis-vaccine-in-the-united-states 2026-04-28 https://biopharmsignal.com/news/VTAK/flyte-deploys-additional-vision-jets-in-the-northeast-to-capture-surging-summer--25377793 2026-04-28 https://biopharmsignal.com/news/ECOR/electrocore-to-present-at-the-market-movers-investor-summit-on-may-5-2026-9c1ced3a 2026-04-28 https://biopharmsignal.com/news/BCDA/biocardia-announces-allowance-of-japanese-patent-on-proprietary-heart3d-fusion-i-723c77eb 2026-04-28 https://biopharmsignal.com/news/SLDB/solid-biosciences-announces-receipt-of-european-commission-orphan-drug-designati-a3572388 2026-04-28 https://biopharmsignal.com/news/ANVS/annovis-publishes-phase-2-3-alzheimer-s-trial-results-in-nature-portfolio-71f23bf5 2026-04-28 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-reports-first-quarter-2026-financial-results-be1ada7a 2026-04-28 https://biopharmsignal.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-first-quarter-2026-results-5d0924a1 2026-04-28 https://biopharmsignal.com/news/CABA/cabaletta-bio-and-cellares-announce-10-year-commercial-supply-agreement-for-rese-cel 2026-04-28 https://biopharmsignal.com/news/ATRC/atricure-to-participate-in-the-2026-bank-of-america-securities-health-care-conference 2026-04-28 https://biopharmsignal.com/news/GSK/bepirovirsen-accepted-for-priority-review-and-granted-breakthrough-therapy-designation-by-the-us-fda 2026-04-28 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-reports-first-quarter-2026-financial-results-and-recent-portfolio-execution 2026-04-28 https://biopharmsignal.com/news/PSTV/plus-therapeutics-secures-blue-shield-of-california-coverage-for-cnsider-cerebrospinal-fluid-assay-for-metastatic-cns-cancer 2026-04-28 https://biopharmsignal.com/news/AVAH/aveanna-to-participate-at-the-barclays-30th-annual-leveraged-finance-conference 2026-04-28 https://biopharmsignal.com/news/IFRX/inflarx-regains-compliance-with-nasdaq-minimum-bid-price-requirement-366f5d29 2026-04-28 https://biopharmsignal.com/news/WVE/wave-life-sciences-reports-first-quarter-2026-financial-results-and-provides-bus-1d4ffe20 2026-04-28 https://biopharmsignal.com/news/BBIO/bridgebio-launches-health-education-effort-on-often-overlooked-heart-condition-f-b13d730c 2026-04-28 https://biopharmsignal.com/news/CYTK/cytokinetics-announces-nine-upcoming-presentations-at-the-european-society-of-ca-435365bb 2026-04-28 https://biopharmsignal.com/news/SNGX/soligenix-announces-interim-results-from-the-phase-3-flash2-trial-evaluating-hybrytetm-in-treatment-of-cutaneous-t-cell-lymphoma 2026-04-28 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-marks-40-years-accelerates-next-generation-of-workforce-intelligence-and-orchestration 2026-04-28 https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-oral-presentation-at-the-american-society-of-gene-and-cell-therapy-asgct-2026-annual-meeting 2026-04-28 https://biopharmsignal.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences 2026-04-28 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026-c6339909 2026-04-28 https://biopharmsignal.com/news/AXGN/axogen-inc-reports-first-quarter-2026-financial-results 2026-04-28 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-180-million-sale-of-priority-review-voucher 2026-04-28 https://biopharmsignal.com/news/BNTC/benitec-biopharma-announces-oral-presentation-of-interim-phase-1b-2a-clinical-study-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting 2026-04-28 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-purchases-optional-milestone-buyout 2026-04-28 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-announces-positive-full-top-line-first-in-human-results-fro-968484cf 2026-04-28 https://biopharmsignal.com/news/ACON/aclarion-appoints-daniel-keefe-as-commercial-director-western-u-s-to-drive-conti-91536335 2026-04-28 https://biopharmsignal.com/news/ENSG/the-ensign-group-schedules-first-quarter-2026-earnings-call-for-friday-may-1-202-c1fff4a7 2026-04-28 https://biopharmsignal.com/news/MDRX/veradigm-doubles-india-based-employee-footprint-adds-new-managing-director 2026-04-28 https://biopharmsignal.com/news/MNOV/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation 2026-04-27 https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-positive-52-week-results-from-phase-2-covalent-112-trial-in-type-1-diabetes-showing-c-peptide-improvement-and-durability-following-12-weeks-of-icovamenib-treatment 2026-04-27 https://biopharmsignal.com/news/HRTX/heron-therapeutics-to-report-first-quarter-2026-financial-results-on-monday-may--8ba7e861 2026-04-27 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-present-new-preclinical-data-supporting-construct-design-of-tsha-102-for-rett-syndrome-at-the-asgct-2026-annual-meeting 2026-04-27 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-announces-the-european-commission-approval-of-palsonif-12a655a1 2026-04-27 https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-multiple-upcoming-presentations-including-data-on-rese-cel-without-preconditioning-and-rese-cel-with-automated-manufacturing-at-the-asgct-2026-annual-meeting 2026-04-27 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-provide-clinical-update-on-key-biologic-and-oral-inhibit-c67a7f91 2026-04-27 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-upcoming-presentation-highlighting-robust-cns-activity-in-nonhuman-primates-with-its-forcetm-platform-at-2026-asgct-annual-meeting 2026-04-27 https://biopharmsignal.com/news/VYGR/voyager-iv-delivered-cns-gene-therapies-featured-in-multiple-presentations-at-as-d9e79b58 2026-04-27 https://biopharmsignal.com/news/EDIT/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-4-b3498b67 2026-04-27 https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-oral-presentation-highlighting-preclinical-data-from-in-vivo-car-t-sg293-at-the-american-society-of-gene-and-cell-therapy-asgct-2026-annual-meeting 2026-04-27 https://biopharmsignal.com/news/CVRX/cvrx-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call-on-may-11-2026 2026-04-27 https://biopharmsignal.com/news/BDX/bd-to-present-at-bank-of-america-securities-health-care-conference 2026-04-27 https://biopharmsignal.com/news/DGX/quest-diagnostics-prices-500-million-of-senior-notes 2026-04-27 https://biopharmsignal.com/news/GPCR/structure-therapeutics-to-present-aleniglipron-amylin-and-combination-data-at-the-american-diabetes-association-86th-scientific-sessions 2026-04-27 https://biopharmsignal.com/news/OM/outset-medical-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026 2026-04-27 https://biopharmsignal.com/news/TARA/protara-therapeutics-to-present-updated-interim-12-month-data-from-the-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-american-urological-association-annual-meeting 2026-04-27 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-announces-proposed-public-offering-of-common-stock 2026-04-27 https://biopharmsignal.com/news/ERAS/erasca-announces-positive-preliminary-phase-1-dose-escalation-data-for-potentially-best-in-class-pan-ras-molecular-glue-eras-0015-in-kras-mutant-solid-tumors 2026-04-27 https://biopharmsignal.com/news/CLLS/cellectis-presents-epigenetic-editing-platform-to-turn-genes-off-without-altering-dna-at-the-asgct-annual-meeting 2026-04-27 https://biopharmsignal.com/news/DRTS/alpha-tau-announces-presentation-of-pancreatic-cancer-data-at-upcoming-asco-annu-47206d0a 2026-04-27 https://biopharmsignal.com/news/XGN/exagen-inc-to-announce-first-quarter-financial-results-on-may-11-2026 2026-04-27 https://biopharmsignal.com/news/NXGL/nexgel-appoints-ian-blackman-as-chief-financial-officer 2026-04-27 https://biopharmsignal.com/news/JAGX/jaguar-health-granted-extension-until-may-15-2026-to-demonstrate-compliance-with-nasdaq-s-bid-price-rule-company-announces-reverse-stock-split 2026-04-27 https://biopharmsignal.com/news/SLRX/decoy-therapeutics-to-present-at-two-peptide-therapeutics-conferences-in-boston 2026-04-27 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-announces-late-breaking-oral-presentation-of-new-clinical-data-from-ridgetm-1-phase-1b-2-clinical-trial-of-tn-401-gene-therapy-in-adults-with-pkp2-associated-arvc-at-asgct-2026 2026-04-27 https://biopharmsignal.com/news/IRMD/iradimed-corporation-to-hold-first-quarter-2026-financial-results-conference-cal-0f6dd0ae 2026-04-27 https://biopharmsignal.com/news/ERAS/erasca-to-host-conference-call-and-webcast-to-discuss-preliminary-phase-1-dose-escalation-data-for-potentially-best-in-class-pan-ras-molecular-glue-eras-0015 2026-04-27 https://biopharmsignal.com/news/ONCY/oncolytics-aligns-with-fda-on-planned-pivotal-anal-cancer-study-408d9262 2026-04-27 https://biopharmsignal.com/news/TERN/terns-pharmaceuticals-announces-fda-breakthrough-therapy-designation-granted-to-tern-701-for-certain-patients-with-chronic-myeloid-leukemia 2026-04-27 https://biopharmsignal.com/news/IRTC/new-data-presented-at-hrs-2026-show-short-term-holter-monitoring-misses-a-large--33898ed4 2026-04-27 https://biopharmsignal.com/news/ARDX/ardelyx-announces-abstract-accepted-for-poster-presentation-at-the-nkf-s-spring--6ee5c2f6 2026-04-27 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-to-report-first-quarter-2026-financial-results-and-corporate-updates-on-thursday-may-7-2026 2026-04-27 https://biopharmsignal.com/news/ARQT/arcutis-submits-supplemental-new-drug-application-to-the-fda-for-zoryver-roflumilast-cream-0-05-to-expand-indication-for-treatment-of-atopic-dermatitis-to-infants-down-to-3-months 2026-04-27 https://biopharmsignal.com/news/PCRX/real-world-data-on-exparelr-shows-reduced-opioid-use-and-lower-total-medical-costs-in-medicare-patients-undergoing-total-hip-arthroplasty 2026-04-27 https://biopharmsignal.com/news/BIVI/biovie-to-host-virtual-kol-event-to-discuss-the-phase-2-study-of-bezisterim-for--82dc0179 2026-04-27 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-noti-67c9525a 2026-04-27 https://biopharmsignal.com/news/BLTE/belite-bio-announces-oral-presentation-at-the-retinal-therapeutics-innovation-su-d48df09a 2026-04-27 https://biopharmsignal.com/news/HUMA/humacyte-to-host-virtual-kol-event-to-discuss-atev-for-arteriovenous-av-access-for-hemodialysis-patients-on-april-28-2026 2026-04-27 https://biopharmsignal.com/news/REPL/replimune-to-present-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting 2026-04-27 https://biopharmsignal.com/news/GSK/gsk-s-investigational-liver-therapy-efimosfermin-receives-us-fda-breakthrough-therapy-and-ema-priority-medicines-prime-designations-for-mash 2026-04-27 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-announces-positive-topline-results-from-phase-iii-respect--0fa0a7f3 2026-04-27 https://biopharmsignal.com/news/NGEN/nervgen-pharma-strengthens-leadership-team-with-appointment-of-keith-vendola-as--fd2a832c 2026-04-27 https://biopharmsignal.com/news/HCWB/hcw-biologics-delivers-a-major-update-for-its-t-cell-engager-program-revealing-m-d97ba35b 2026-04-27 https://biopharmsignal.com/news/BCTX/briacell-announces-six-clinical-data-presentations-at-asco-2026-efe536fc 2026-04-27 https://biopharmsignal.com/news/CMPX/tovecimig-demonstrates-statistically-significant-benefit-in-companion-002-random-132f7fbb 2026-04-27 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-receives-positive-fda-feedback-following-second-type-c-mee-1d6df9b0 2026-04-27 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-pricing-of-175-0-million-underwritten-offering-of--927d729b 2026-04-27 https://biopharmsignal.com/news/USNA/one-capsule-endless-glow-radiant-skin-starts-within 2026-04-27 https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-adds-intra-cellular-therapies-founder-and-ceo-dr-sharon-mates-to-its-board-of-directors 2026-04-27 https://biopharmsignal.com/news/SEER/seer-board-of-directors-unanimously-rejects-revised-unsolicited-proposal-from-radoff-jec-group 2026-04-27 https://biopharmsignal.com/news/PPBT/purple-biotech-announces-new-data-from-captn-3-platform-tri-specific-im1240-3225cecd 2026-04-27 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-provides-strategic-and-corporate-updates-84e1050f 2026-04-27 https://biopharmsignal.com/news/ALT/altimmune-announces-closing-of-225-million-oversubscribed-public-offering-of-sec-397d2df5 2026-04-27 https://biopharmsignal.com/news/HROW/harrow-to-report-first-quarter-2026-financial-results-after-market-close-on-may--a019caec 2026-04-27 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results--b3f1692d 2026-04-27 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences-8aa47cf7 2026-04-27 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-positive-phase-3-results-in-hereditary-angioedema-marking-a-global-first-for-in-vivo-gene-editing 2026-04-27 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-lonvoguran-ziclumeran-lonvo-z-as-a-one-time-treatment-for-hereditary-angioedema 2026-04-27 https://biopharmsignal.com/news/XOMA/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator 2026-04-27 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors-6c29e5a6 2026-04-27 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-announces-initiation-of-clinical-study-for-product-candidat-f5eb5327 2026-04-27 https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-clinical-data-for-zovegalisib-plus-atirmociclib-tri-0c625e9f 2026-04-27 https://biopharmsignal.com/news/GSK/tesaro-a-gsk-subsidiary-provides-update-on-anaptysbio-inc-litigation 2026-04-27 https://biopharmsignal.com/news/BSX/data-at-heart-rhythm-2026-highlight-key-boston-scientific-therapies 2026-04-26 https://biopharmsignal.com/news/PLSE/pulse-biosciences-presents-positive-outcomes-in-late-breaking-updated-data-from-npulsetm-cardiac-catheter-system-at-heart-rhythm-2026 2026-04-25 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026 2026-04-24 https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3--633662ff 2026-04-24 https://biopharmsignal.com/news/ANAB/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaro-s-anticipatory-breach-claim 2026-04-24 https://biopharmsignal.com/news/INDV/indivior-presents-new-real-world-data-at-asam-2026-annual-conference-supporting--1204991e 2026-04-24 https://biopharmsignal.com/news/PAVM/lucid-diagnostics-announces-closing-of-18-million-underwritten-offering-of-commo-146a4cff 2026-04-24 https://biopharmsignal.com/news/LUCD/lucid-diagnostics-announces-closing-of-18-million-underwritten-offering-of-common-stock 2026-04-24 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-announces-pricing-of-4-million-public-offering 2026-04-24 https://biopharmsignal.com/news/GANX/gain-therapeutics-announces-oral-presentation-at-3rd-international-gba1-meeting--0130f2fb 2026-04-24 https://biopharmsignal.com/news/JAGX/jaguar-health-announces-acceptance-of-two-late-breaking-abstracts-for-liquid-oral-crofelemer-treatment-of-intestinal-failure-in-pediatric-patients-at-the-european-society-for-pediatric-gastroenterology-hepatology-and-nutrition-espghan 2026-04-24 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-04-24 https://biopharmsignal.com/news/KURA/kyowa-kirin-and-kura-oncology-initiate-japanese-phase-2-registration-directed-trial-of-ziftomenib-in-r-r-npm1-m-aml 2026-04-24 https://biopharmsignal.com/news/HUMA/humacyte-expands-commercial-and-business-development-opportunities-through-realignment-of-ex-u-s-rights-to-symvessr 2026-04-24 https://biopharmsignal.com/news/TMCI/treace-to-report-first-quarter-2026-financial-results-on-may-8-2026 2026-04-24 https://biopharmsignal.com/news/SENS/senseonics-announces-european-launch-of-eversense-365-the-world-s-first-and-only-e704c2e4 2026-04-24 https://biopharmsignal.com/news/SNDX/syndax-to-announce-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-april-30-2026 2026-04-24 https://biopharmsignal.com/news/BRKR/bruker-announces-date-and-time-of-first-quarter-2026-earnings-release-and-webcast 2026-04-24 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-and-pfizer-to-make-eliquisr-apixaban-available-via-mark-cuban-cost-plus-drug-company 2026-04-24 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-discuss-first-quarter-2026-financial-results-on-may-8-202-4d2e48b6 2026-04-24 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-receives-positive-chmp-opinion-recommending-approval-of-redemplor-plozasiran-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome-fcs-in-europe 2026-04-24 https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-provide-several-upcoming-corporate-updates-8b1db0ef 2026-04-24 https://biopharmsignal.com/news/VXRT/vaxart-appoints-james-breitmeyer-m-d-ph-d-to-board-of-directors-6c833e2e 2026-04-23 https://biopharmsignal.com/news/EHC/encompass-health-to-participate-in-bofa-securities-2026-health-care-conference 2026-04-23 https://biopharmsignal.com/news/ACHC/acadia-healthcare-appoints-david-duckworth-as-interim-chief-financial-officer 2026-04-23 https://biopharmsignal.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-first-quarter-2026-financial-results 2026-04-23 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-announces-closing-of-373-8-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares 2026-04-23 https://biopharmsignal.com/news/RCEL/avita-medical-to-announce-first-quarter-2026-financial-results-090fd9b9 2026-04-23 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-closing-of-5-0-million-registered-direct-offering 2026-04-23 https://biopharmsignal.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update-and-host-conference-call 2026-04-23 https://biopharmsignal.com/news/ABSI/absci-to-report-business-updates-and-first-quarter-2026-financial-and-operating-results-on-may-7-2026 2026-04-23 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-april-28-2026 2026-04-23 https://biopharmsignal.com/news/PSNL/personalis-to-announce-first-quarter-2026-financial-results 2026-04-23 https://biopharmsignal.com/news/REGN/regeneron-announces-agreement-with-u-s-government-to-help-lower-drug-costs-for-american-patients-and-will-provide-innovative-new-gene-therapy-for-free-in-the-u-s 2026-04-23 https://biopharmsignal.com/news/PGNY/progyny-inc-announces-details-for-its-first-quarter-2026-results-report 2026-04-23 https://biopharmsignal.com/news/ACST/grace-therapeutics-provides-regulatory-update-on-new-drug-application-for-gtx-104 2026-04-23 https://biopharmsignal.com/news/REGN/otarmenitm-lunsotogene-parvec-cwha-approved-by-fda-as-first-and-only-gene-therapy-for-genetic-hearing-loss-regeneron-to-provide-otarmeni-for-free-in-the-u-s 2026-04-23 https://biopharmsignal.com/news/VTAK/catheter-precision-to-attend-and-share-new-clinical-data-at-the-47th-annual-hear-b323ecfb 2026-04-23 https://biopharmsignal.com/news/ENLV/enlivex-to-present-phase-iia-3-month-and-6-month-data-of-allocetra-at-oarsi-2026-3db38fd3 2026-04-23 https://biopharmsignal.com/news/DRTS/alpha-tau-announces-fda-approval-of-ide-supplement-to-expand-alpha-dart-impact-t-f98774e6 2026-04-23 https://biopharmsignal.com/news/DRTS/alpha-tau-successfully-treats-first-pancreatic-cancer-patient-in-europe-with-alp-392ddb2f 2026-04-23 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-worldwide-development-and-commercialization-partnership-for-anti-viral-assets-with-potential-value-up-to-100m 2026-04-23 https://biopharmsignal.com/news/VCEL/vericel-to-report-first-quarter-2026-financial-results-on-may-7-2026-fb241894 2026-04-23 https://biopharmsignal.com/news/ICUI/icu-medical-announces-time-of-first-quarter-2026-earnings-conference-call-6e434179 2026-04-23 https://biopharmsignal.com/news/RNXT/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamptm-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting 2026-04-23 https://biopharmsignal.com/news/DCTH/delcath-systems-to-host-first-quarter-2026-earnings-call 2026-04-23 https://biopharmsignal.com/news/LUCD/lucid-diagnostics-announces-18-million-underwritten-offering-of-common-stock 2026-04-23 https://biopharmsignal.com/news/INGN/inogen-to-report-first-quarter-2026-financial-results-on-may-7-2026 2026-04-23 https://biopharmsignal.com/news/MBRX/moleculin-s-annamycin-extends-survival-by-more-than-60-in-metastatic-pancreatic--badc760c 2026-04-23 https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-report-first-quarter-2026-financial-results-on-may-7-2026 2026-04-23 https://biopharmsignal.com/news/ARDX/ardelyx-announces-abstract-exploring-ibs-c-treatment-patterns-accepted-for-poste-a6113e73 2026-04-23 https://biopharmsignal.com/news/ESPR/esperion-to-report-first-quarter-2026-financial-results-on-may-7 2026-04-23 https://biopharmsignal.com/news/ECOR/electrocore-product-line-featured-in-documentary-underscoring-the-expanding-clin-3022ab7e 2026-04-23 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-release-first-quarter-of-fiscal-year-2026-financial--0b19da78 2026-04-23 https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazine-s-pote-52ff9238 2026-04-23 https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-four-upcoming-investor-conferences-cda76fe0 2026-04-23 https://biopharmsignal.com/news/PSTV/plus-therapeutics-initiates-manufacturing-activities-with-spectronrx-under-a-master-services-agreement-to-support-gmp-pivotal-trial-readiness-for-reyobiqtm 2026-04-23 https://biopharmsignal.com/news/CCRN/cross-country-appoints-darrick-sogabe-as-chief-product-officer-advancing-the-company-s-growing-technology-portfolio 2026-04-23 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors 2026-04-23 https://biopharmsignal.com/news/XERS/xeris-biopharma-to-report-first-quarter-2026-financial-results-on-may-7-2026 2026-04-23 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-share-real-world-hcp-perspectives-on-burden-of-total-parenteral-nutrition-in-short-bowel-syndrome-sbs-at-digestive-disease-weekr-2026 2026-04-23 https://biopharmsignal.com/news/OCGN/ocugen-to-present-at-april-2026-investor-and-industry-conferences-2c40aefc 2026-04-23 https://biopharmsignal.com/news/PPBT/purple-biotech-establishes-scientific-advisory-board-to-support-development-of-c-7f41f914 2026-04-23 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-to-report-first-quarter-2026-financial-results-on-april-30-2-163b9f34 2026-04-23 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-presents-updates-on-preclinical-immuno-oncology-programs-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026 2026-04-23 https://biopharmsignal.com/news/GNTA/genenta-signs-definitive-agreements-with-sophia-high-tech 2026-04-23 https://biopharmsignal.com/news/INSM/insmed-to-host-first-quarter-2026-financial-results-conference-call-on-thursday-may-7-2026 2026-04-23 https://biopharmsignal.com/news/AVAH/aveanna-announces-first-quarter-2026-earnings-release-date-and-conference-call 2026-04-23 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-acceptance-of-abstract-at-asco-2026 2026-04-23 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-appoints-industry-veteran-bill-nichols-jr-as-president-to-accelerate-advancement-of-first-in-class-tcap-pathway-therapy-pt00114 2026-04-23 https://biopharmsignal.com/news/ADXN/addex-spin-out-company-neurosterix-on-track-to-complete-phase-1-clinical-study-o-5bd5147e 2026-04-23 https://biopharmsignal.com/news/MTLS/materialise-nv-to-report-first-quarter-2026-earnings-on-thursday-may-7-2026 2026-04-23 https://biopharmsignal.com/news/ALT/altimmune-announces-pricing-of-225-million-oversubscribed-public-offering-of-sec-a28c523a 2026-04-23 https://biopharmsignal.com/news/XCUR/exicure-announces-co-development-agreement-with-adbiotech-for-burixafor-gpc-100-eafcfb43 2026-04-22 https://biopharmsignal.com/news/USNA/usana-malaysia-launches-new-vitamin-d-supplement-with-record-breaking-jogging-event-earning-malaysia-book-of-records-title 2026-04-22 https://biopharmsignal.com/news/REGN/dupixentr-dupilumab-approved-in-the-u-s-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria-csu 2026-04-22 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-k-filing 2026-04-22 https://biopharmsignal.com/news/SGHT/sight-sciences-announces-the-release-of-its-sustainability-report 2026-04-22 https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2026-on-april-29-2026 2026-04-22 https://biopharmsignal.com/news/PSTV/plus-therapeutics-reports-granting-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4 2026-04-22 https://biopharmsignal.com/news/EHC/encompass-health-and-cookeville-regional-medical-center-announce-plans-to-build-a-40-bed-inpatient-rehabilitation-hospital-in-cookeville-tennessee 2026-04-22 https://biopharmsignal.com/news/ALT/altimmune-announces-proposed-underwritten-public-offering-of-securities-5b987b91 2026-04-22 https://biopharmsignal.com/news/XRAY/dentsply-sirona-to-host-first-quarter-2026-conference-call-on-may-5-7e202f7f 2026-04-22 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-reports-first-quarter-2026-results 2026-04-22 https://biopharmsignal.com/news/MOH/molina-healthcare-reports-first-quarter-2026-financial-results 2026-04-22 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-may-5-2026 2026-04-22 https://biopharmsignal.com/news/OSUR/orasure-to-announce-first-quarter-2026-financial-results-and-host-earnings-call-on-may-6th 2026-04-22 https://biopharmsignal.com/news/RXST/rxsight-inc-to-report-first-quarter-2026-financial-results-on-may-6 2026-04-22 https://biopharmsignal.com/news/BTMD/biote-schedules-first-quarter-2026-financial-results-release-and-conference-call 2026-04-22 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-showing-sustained-glucocorticoid-dose-reductions-while-maintaining-androgen-control-in-adults-with-classic-congenital-adrenal-hyperplasia 2026-04-22 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-announces-fda-clearance-of-the-velocity-alpha-r-mr-high-speed-surgical-drill-system-and-first-clinical-use-further-expanding-our-drug-delivery-ecosystem-and-global-footprint 2026-04-22 https://biopharmsignal.com/news/FLGT/fulgent-selected-to-present-rapid-oral-abstract-within-the-head-and-neck-cancer-track-session-at-the-2026-asco-annual-meeting 2026-04-22 https://biopharmsignal.com/news/LFVN/lifevantage-to-announce-third-quarter-fiscal-year-2026-results-on-may-6-2026 2026-04-22 https://biopharmsignal.com/news/AXON/axon-to-release-first-quarter-2026-earnings-on-may-6-2026 2026-04-22 https://biopharmsignal.com/news/FEMY/femasys-launches-femaseed-complete-for-ob-gyns-at-acog-2026-df2f274c 2026-04-22 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-abstract-acceptance-for-presentation-at-the-2026-asco-annual-meeting 2026-04-22 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-late-breaking-presentation-of-hope-3-phase-3-results-at-the-american-academy-of-neurology-2026-annual-meeting 2026-04-22 https://biopharmsignal.com/news/IPHA/innate-pharma-to-participate-in-the-d-boral-capital-global-conference 2026-04-22 https://biopharmsignal.com/news/CUE/cue-biopharma-announces-1-for-30-reverse-stock-split-a02b207c 2026-04-22 https://biopharmsignal.com/news/ACON/aclarion-announces-2-5-million-stock-repurchase-plan-a9cb021c 2026-04-22 https://biopharmsignal.com/news/WVE/wave-life-sciences-first-quarter-2026-financial-results-scheduled-for-april-28-2-3e590da7 2026-04-22 https://biopharmsignal.com/news/PRGO/perrigo-to-release-first-quarter-2026-financial-results-on-may-6-2026 2026-04-22 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-announce-first-quarter-2026-financial-results 2026-04-22 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2026-04-22 https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-first-quarter-fiscal-year-2026-financial-results-on-may-6-2026 2026-04-22 https://biopharmsignal.com/news/TPST/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19-bcma-car-t 2026-04-22 https://biopharmsignal.com/news/ARQT/arcutis-zoryver-roflumilast-cream-receives-strong-recommendation-in-american-academy-of-dermatology-first-ever-pediatric-atopic-dermatitis-guidelines 2026-04-22 https://biopharmsignal.com/news/MDXG/mimedx-to-host-first-quarter-2026-operating-and-financial-results-conference-call-on-april-29 2026-04-22 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-announces-board-chair-transition 2026-04-22 https://biopharmsignal.com/news/IXHL/incannex-healthcare-psx-001-program-aligns-with-white-house-executive-order-acce-d0ded966 2026-04-22 https://biopharmsignal.com/news/IMMP/immutep-announces-abstract-accepted-for-presentation-at-the-american-society-of--0be09d39 2026-04-22 https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-release-first-quarter-2026-financial-results-and-hos-4c3ad4c1 2026-04-22 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-announces-abstracts-accepted-for-presentation-at-asco-2026-featuring-updated-clinical-data-for-crb-701 2026-04-22 https://biopharmsignal.com/news/HUMA/humacyte-appoints-jim-mercadante-as-chief-commercial-officer 2026-04-22 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026 2026-04-22 https://biopharmsignal.com/news/BRLI/opko-health-s-modex-therapeutics-begins-clinical-trial-of-tetraspecific-antibody-for-treatment-of-b-cell-lymphomas 2026-04-22 https://biopharmsignal.com/news/STXS/stereotaxis-announces-first-magic-procedures-in-the-united-states-ae393ae4 2026-04-22 https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-data-presentations-for-briumvi-in-multiple-sclerosis-at-the-american-academy-of-neurology-2026-annual-meeting 2026-04-22 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-announces-details-for-q1-2026-financial-results-call-42840f57 2026-04-22 https://biopharmsignal.com/news/CRVO/cervomed-announces-new-data-at-the-2026-aan-annual-meeting-that-demonstrated-nef-cd73de51 2026-04-22 https://biopharmsignal.com/news/RGEN/repligen-to-report-first-quarter-2026-financial-results-19fd11c7 2026-04-22 https://biopharmsignal.com/news/BFRG/bullfrog-ai-regains-compliance-with-nasdaq-shareholders-equity-requirement 2026-04-22 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-presents-new-analysis-of-ath434-phase-2-trial-data-in-late-ed52673d 2026-04-22 https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-late-breaking-poster-presentation-for-pbgene-hbv-at-european-association-for-the-study-of-the-liver-congress-2026 2026-04-22 https://biopharmsignal.com/news/SABS/sab-bio-presents-additional-clinical-and-mechanistic-data-from-sab-142-phase-1-trial-in-adult-patients-with-established-autoimmune-type-1-diabetes-at-ids-2026 2026-04-22 https://biopharmsignal.com/news/CERT/certara-enters-definitive-agreement-for-the-sale-of-its-regulatory-and-medical-writing-business-to-veristat 2026-04-22 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-new-preclinical-data-highlighting-breadth-of-targeted-protein-degradation-pipeline-at-aacr-2026 2026-04-22 https://biopharmsignal.com/news/TENX/tenax-therapeutics-appoints-thomas-r-staab-ii-as-chief-financial-officer-71975793 2026-04-22 https://biopharmsignal.com/news/NTRB/nutriband-ceo-gareth-sheridan-discusses-the-us-fentanyl-crisis-and-company-updat-88a89417 2026-04-22 https://biopharmsignal.com/news/BYSI/beyondspring-reports-compelling-new-data-plinabulin-advances-both-the-anticancer-ba2782eb 2026-04-22 https://biopharmsignal.com/news/GERN/geron-plans-to-announce-first-quarter-2026-financial-results-on-may-6-2026-7578b22f 2026-04-22 https://biopharmsignal.com/news/PRTC/puretech-reports-positive-topline-data-from-phase-1b-trial-of-lyt-200-in-relapsed-refractory-r-r-high-risk-hr-myelodysplastic-syndrome-mds-and-r-r-acute-myeloid-leukemia-aml 2026-04-22 https://biopharmsignal.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2026 2026-04-22 https://biopharmsignal.com/news/YOU/clear-to-announce-first-quarter-2026-financial-results-on-may-6-2026 2026-04-22 https://biopharmsignal.com/news/AMRX/amneal-agrees-to-acquire-kashiv-biosciences-to-create-global-biosimilar-leader-reports-strong-preliminary-first-quarter-2026-financial-results-and-raises-fy2026-standalone-guidance 2026-04-22 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-announces-pricing-of-upsized-325-million-public-offering 2026-04-22 https://biopharmsignal.com/news/KYTX/kyverna-presents-registrational-trial-primary-analysis-for-miv-cel-in-stiff-pers-8101e1d0 2026-04-21 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-present-updated-phase-1-2-clinical-data-for-daraxonrasib-in-first-line-metastatic-pancreatic-cancer-across-monotherapy-and-combination-cohorts-at-the-2026-aacr-annual-meeting 2026-04-21 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-present-preclinical-data-on-innovative-mutant-targeted-catalytic-ras-on-inhibitor-at-the-2026-aacr-annual-meeting 2026-04-21 https://biopharmsignal.com/news/EMBC/embecta-to-report-fiscal-second-quarter-financial-results 2026-04-21 https://biopharmsignal.com/news/ISRG/intuitive-announces-first-quarter-earnings 2026-04-21 https://biopharmsignal.com/news/ASND/ascendis-announces-redemption-of-all-575-million-of-outstanding-2-25-convertible-senior-notes-due-2028 2026-04-21 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-acceptance-of-abstracts-at-the-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/IMRX/immuneering-to-present-new-survival-data-from-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp-in-an-oral-presentation-at-the-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/SGHT/sight-sciences-to-report-first-quarter-2026-financial-results-on-may-6-2026 2026-04-21 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting 2026-04-21 https://biopharmsignal.com/news/TELA/tela-bio-to-announce-first-quarter-2026-financial-results 2026-04-21 https://biopharmsignal.com/news/OCS/oculis-publishes-invitation-to-the-annual-general-meeting 2026-04-21 https://biopharmsignal.com/news/INBX/inhibrx-provides-clinical-update-on-ozekibart-inbrx-109-in-late-line-colorectal-cancer 2026-04-21 https://biopharmsignal.com/news/EXEL/exelixis-to-release-first-quarter-2026-financial-results-on-tuesday-may-5-2026 2026-04-21 https://biopharmsignal.com/news/ALKS/alkermes-to-report-first-quarter-financial-results-on-may-5-2026 2026-04-21 https://biopharmsignal.com/news/BRLI/opko-health-to-report-first-quarter-2026-financial-results-on-april-28-2026 2026-04-21 https://biopharmsignal.com/news/OLMA/olema-oncology-to-present-initial-clinical-data-for-op-3136-at-the-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-hearing-on-proposed-redomiciliation-to-the-united-s-6d4b033f 2026-04-21 https://biopharmsignal.com/news/BLTE/belite-bio-initiates-rolling-submission-of-new-drug-application-to-the-u-s-food--3382f983 2026-04-21 https://biopharmsignal.com/news/CORT/corcept-to-present-new-data-from-pivotal-phase-3-rosella-trial-of-lifyorlitm-relacorilant-in-patients-with-platinum-resistant-ovarian-cancer-at-asco-2026 2026-04-21 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-present-pivotal-phase-3-rasolute-302-clinical-trial-results-for-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer-during-a-plenary-session-at-the-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/KPTI/karyopharm-s-phase-3-sentry-trial-in-myelofibrosis-selected-for-late-breaking-oral-presentation-at-asco-2026-annual-meeting 2026-04-21 https://biopharmsignal.com/news/REGN/cemdisiran-dosed-subcutaneously-every-12-weeks-demonstrates-rapid-deep-and-sustained-disease-control-in-generalized-myasthenia-gravis-gmg-phase-3-trial 2026-04-21 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-abstract-acceptance-at-asco-2026-featuring-az-3965d636 2026-04-21 https://biopharmsignal.com/news/IMTX/immatics-announces-four-upcoming-oral-presentations-across-its-clinical-cell-therapy-and-bispecific-portfolio-at-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/APRE/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting 2026-04-21 https://biopharmsignal.com/news/NXTC/nextcure-and-simcere-s-sim0505-cdh6-adc-phase-1-data-to-be-presented-at-asco-202-8c308b63 2026-04-21 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-2-3-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hla-a2-negative-metastatic-uveal-melanoma 2026-04-21 https://biopharmsignal.com/news/IRON/disc-medicine-announces-oral-presentation-of-data-from-rally-mf-phase-2-trial-of-disc-0974-in-patients-with-myelofibrosis-and-anemia-at-the-american-society-of-clinical-oncology-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/CLRB/cellectar-biosciences-announces-subset-of-clover-wam-clinical-trial-data-accepted-for-presentation-at-the-american-society-of-clinical-oncology-conference-2026 2026-04-21 https://biopharmsignal.com/news/ENLV/enlivex-announces-second-regulatory-approval-for-phase-2b-trial-of-allocetra-in--7c708fbe 2026-04-21 https://biopharmsignal.com/news/HSTM/healthstream-to-host-first-quarter-2026-earnings-conference-call 2026-04-21 https://biopharmsignal.com/news/PACB/pacbio-and-lucid-genomics-announce-compatibility-collaboration-to-advance-tertia-60c12d63 2026-04-21 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-completes-federal-dispute-resolution-fdr-meeting-with-fda-for-ons-5010-lytenavatm-bevacizumab-vikg 2026-04-21 https://biopharmsignal.com/news/STXS/stereotaxis-to-report-first-quarter-2026-financial-results-on-may-12-2026-3a325fa0 2026-04-21 https://biopharmsignal.com/news/NXGL/nexgel-new-strategic-partner-sequence-lifesciencetm-leads-financing-with-5-5-million-to-complete-acquisition-of-celularity-degenerative-disease-segment 2026-04-21 https://biopharmsignal.com/news/MBRX/moleculin-announces-abstract-accepted-for-poster-presentation-at-the-2026-asco-a-18c4c7e4 2026-04-21 https://biopharmsignal.com/news/FBIO/journey-medical-corporation-secures-contract-with-third-major-gpo-for-emrosi-d5055ce1 2026-04-21 https://biopharmsignal.com/news/AVCO/avalon-quantum-ai-teams-up-with-caylent-and-amazon-web-services-on-agentic-ai-platform-development 2026-04-21 https://biopharmsignal.com/news/ICCM/icecure-participates-in-society-of-breast-imaging-symposium-2026-as-u-s-prosenser-revenue-increases-by-30-in-first-quarter-of-2026-compared-to-first-quarter-of-2025 2026-04-21 https://biopharmsignal.com/news/STIM/neuronetics-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call 2026-04-21 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-expands-pivotal-phase-2-alpha3-trial-to-south-korea-and-australia 2026-04-21 https://biopharmsignal.com/news/DERM/journey-medical-corporation-secures-contract-with-third-major-gpo-for-emrositm 2026-04-21 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-oral-presentation-of-positive-phase-3-peak-trial-in-gastrointestinal-stromal-tumors-gist-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-presents-two-aacr-2026-posters-highlighting-stenoparib-s-p-da1d0165 2026-04-21 https://biopharmsignal.com/news/VTAK/catheter-precision-secures-u-s-patent-allowance-on-foundational-surgical-technol-f4d306e1 2026-04-21 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-announces-strategic-partnership-with-global-dermatology-30ec08d9 2026-04-21 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-report-first-quarter-2026-financial-results-on-may-4-2026-82c0212a 2026-04-21 https://biopharmsignal.com/news/HUMA/humacyte-announces-israeli-ministry-of-health-acceptance-of-marketing-authorization-application-for-symvessr-for-vascular-trauma-repair 2026-04-21 https://biopharmsignal.com/news/TWST/twist-bioscience-to-report-fiscal-2026-second-quarter-financial-results-on-monday-may-4-2026 2026-04-21 https://biopharmsignal.com/news/CRL/charles-river-highlights-effectiveness-of-vcgs-in-toxicology 2026-04-21 https://biopharmsignal.com/news/PULM/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-of-planned-merger 2026-04-21 https://biopharmsignal.com/news/LFVN/lifevantage-receives-u-s-patent-for-healthy-glow-essentials-stack 2026-04-21 https://biopharmsignal.com/news/SHC/sotera-health-announces-first-quarter-2026-earnings-release-date 2026-04-21 https://biopharmsignal.com/news/PSTV/plus-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement 2026-04-21 https://biopharmsignal.com/news/BCTX/briacell-presents-robust-anti-cancer-activity-of-bria-ots-in-preclinical-cancer--b188a313 2026-04-21 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-host-investor-and-analyst-meeting-on-may-14-2026-to-highlight-soquelitinib-data-being-presented-at-the-society-for-investigative-dermatology-sid-annual-meeting 2026-04-21 https://biopharmsignal.com/news/CCRN/cross-country-appoints-chris-tyrell-as-chief-information-officer-to-support-next-phase-of-enterprise-ai-and-platform-strategy 2026-04-21 https://biopharmsignal.com/news/IBRX/immunitybio-announces-anktivar-is-now-available-in-saudi-arabia-for-bladder-and-lung-cancer-patients-market-entry-achieved-within-two-months-of-mena-partnership 2026-04-21 https://biopharmsignal.com/news/MDNA/medicenna-presents-positive-data-demonstrating-superior-safety-and-efficacy-potential-of-its-first-in-class-anti-pd-1-x-il-2-bifunctional-superkine-mdna113-at-aacr-2026 2026-04-21 https://biopharmsignal.com/news/DGX/quest-diagnostics-reports-first-quarter-2026-financial-results-raises-revenue-and-eps-guidance-for-full-year-2026 2026-04-21 https://biopharmsignal.com/news/BNTX/biontech-ver-ffentlicht-am-5-mai-2026-ergebnisse-f-r-das-erste-quartal-2026-und--d4a90070 2026-04-21 https://biopharmsignal.com/news/BNTX/biontech-to-report-first-quarter-2026-financial-results-and-corporate-update-on--37ed499a 2026-04-21 https://biopharmsignal.com/news/PSNL/personalis-highlights-clinical-impact-of-ultrasensitive-ctdna-monitoring-and-new-therapy-resistance-tracking-at-aacr-2026 2026-04-21 https://biopharmsignal.com/news/ADXN/addex-gabab-pam-candidate-demonstrates-robust-anti-tussive-activity-in-non-human-f0602d38 2026-04-21 https://biopharmsignal.com/news/INBX/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-ozekibart-inbrx-109-in-late-line-colorectal-cancer 2026-04-20 https://biopharmsignal.com/news/CVRX/cvrx-announces-nomination-of-michael-dale-for-election-to-the-board-of-directors 2026-04-20 https://biopharmsignal.com/news/JAGX/jaguar-health-reports-approval-of-all-proposals-at-april-2026-special-meeting-of-stockholders 2026-04-20 https://biopharmsignal.com/news/SIBN/si-bone-to-report-first-quarter-2026-financial-results-on-may-11-2026 2026-04-20 https://biopharmsignal.com/news/EQ/equillium-to-participate-in-oppenheimer-s-2026-innovation-on-the-island-event-b78430fb 2026-04-20 https://biopharmsignal.com/news/AMWL/amwell-to-report-first-quarter-2026-operating-results-ae059d6a 2026-04-20 https://biopharmsignal.com/news/REGN/regeneron-announces-investor-conference-presentations 2026-04-20 https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-first-quarter-of-fiscal-year-2026-financial-results-on-may-4-2026 2026-04-20 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-announces-canadian-approval-for-its-navigation-system-further-expanding-our-drug-delivery-ecosystem-and-global-footprint 2026-04-20 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-webcast-fiscal-2026-second-quarter-results 2026-04-20 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-announces-proposed-public-offering 2026-04-20 https://biopharmsignal.com/news/VTAK/flyte-emerges-as-direct-beneficiary-as-rising-fuel-costs-drive-airline-retreat-f-8978301d 2026-04-20 https://biopharmsignal.com/news/GNFT/genfit-publication-of-the-2026-extra-financial-report-fiscal-year-2025 2026-04-20 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-initiates-validation-study-for-rapid-drug-screening-ca-823129b4 2026-04-20 https://biopharmsignal.com/news/ANAB/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations 2026-04-20 https://biopharmsignal.com/news/YOU/oracle-health-demonstrates-interoperability-leadership-achieves-cms-aligned-network-status 2026-04-20 https://biopharmsignal.com/news/IMRX/immuneering-presents-genetic-data-at-aacr-annual-meeting-demonstrating-mechanism-to-improve-durability-and-survival-supporting-use-of-atebimetinib-in-first-line-pancreatic-cancer-and-beyond 2026-04-20 https://biopharmsignal.com/news/GHRS/gh-research-welcomes-white-house-executive-order-to-accelerate-medical-treatments-for-serious-mental-illness 2026-04-20 https://biopharmsignal.com/news/OGEN/oragenics-reports-8-study-drug-doses-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury 2026-04-20 https://biopharmsignal.com/news/IART/integra-lifesciences-to-host-first-quarter-2026-financial-results-conference-call-on-may-5-2026 2026-04-20 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-showcases-momentum-with-clinical-and-platform-advancements-in-allogeneic-car-t-at-aacr-2026 2026-04-20 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-thursday-april-30-2026 2026-04-20 https://biopharmsignal.com/news/KYTX/kyverna-presents-longer-term-phase-2-data-for-miv-cel-in-generalized-myasthenia--d99b7e52 2026-04-20 https://biopharmsignal.com/news/BCDA/biocardia-and-japan-pmda-align-on-acceptability-of-cardiamp-clinical-data-to-sup-865ad52d 2026-04-20 https://biopharmsignal.com/news/ARDX/ardelyx-appoints-biopharmaceutical-veteran-felecia-w-ettenberg-as-chief-legal-of-2e4242f9 2026-04-20 https://biopharmsignal.com/news/XAIR/beyond-cancer-reports-updated-survival-and-safety-data-from-phase-1-uno-trial-pr-2ccd5ce5 2026-04-20 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2026-financial-results-conference-cal-42a5e6f1 2026-04-20 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-announces-submission-of-marketing-authorization-application-to-the-medicines-and-healthcare-products-regulatory-agency-for-vizzr-for-the-treatment-of-presbyopia-in-the-united-kingdom 2026-04-20 https://biopharmsignal.com/news/AMRX/amneal-announces-additional-positive-interim-phase-4-elevate-pd-results-with-crexontr-for-parkinson-s-disease-including-over-3-more-hours-of-daily-good-on-time-when-switching-from-rytaryr 2026-04-20 https://biopharmsignal.com/news/LFVN/lifevantage-inspires-with-breakthrough-announcements-at-2026-momentum-academy-in-las-vegas 2026-04-20 https://biopharmsignal.com/news/ASND/ascendis-pharma-announces-commencement-of-trading-of-its-ordinary-shares-on-nasdaq 2026-04-20 https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-approved-in-china-for-treatment-of-2l-relapsed-refractory-multiple-myeloma 2026-04-20 https://biopharmsignal.com/news/ARTL/artelo-announces-peer-reviewed-publication-supporting-its-fabp5-inhibitor-art26-12-as-a-novel-pain-treatment-with-a-potentially-first-in-class-profile 2026-04-20 https://biopharmsignal.com/news/BIIB/biogen-enters-into-agreement-with-tj-biopharma-for-felzartamab-assets-in-the-gre-ed02c876 2026-04-20 https://biopharmsignal.com/news/BCTX/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-cc496c99 2026-04-20 https://biopharmsignal.com/news/NKTR/52-week-topline-results-from-16-week-blinded-treatment-extension-of-rezolve-aa-demonstrate-deepening-of-responses-in-severe-to-very-severe-alopecia-areata-with-rezpegaldesleukin 2026-04-20 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-grant-of-rare-pediatric-disease-designation-rpdd-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1 2026-04-20 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-appointment-of-andreas-grauer-md-as-chief-medical--c954ba56 2026-04-20 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-american-association-for-ca-19a93152 2026-04-20 https://biopharmsignal.com/news/PASG/passage-bio-reports-updated-interim-data-from-uplift-d-trial-and-provides-regulatory-and-corporate-updates 2026-04-20 https://biopharmsignal.com/news/PLSE/pulse-biosciences-npulsetm-technology-to-be-featured-at-the-heart-rhythm-society-2026-annual-meeting 2026-04-20 https://biopharmsignal.com/news/MCRB/seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026 2026-04-20 https://biopharmsignal.com/news/PHVS/evidence-supporting-combined-use-of-deucrictibant-ir-with-deucrictibant-xr-prese-bedb4e34 2026-04-20 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-pimozide-tablets-wi-3a05a5d9 2026-04-20 https://biopharmsignal.com/news/MD/pediatrix-medical-group-2026-first-quarter-conference-call-webcast-scheduled-for-tuesday-may-5-2026 2026-04-20 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-pricing-of-90-0-million-underwritten-offering 2026-04-20 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-presents-preclinical-data-from-development-candidate-prt13722-a-first-in-class-orally-bioavailable-potent-and-highly-selective-kat6a-degrader-at-american-association-for-cancer-research-aacr-annual-meeting-2026 2026-04-20 https://biopharmsignal.com/news/CATX/perspective-therapeutics-presents-updated-interim-data-of-212pb-vmt-net-in-its-o-7075427d 2026-04-20 https://biopharmsignal.com/news/BDSX/biodesix-to-report-first-quarter-2026-financial-results-on-may-4-2026-16d481c4 2026-04-20 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-presents-flamingo-01-phase-iii-trial-open-label-data-published-at-aacr-meeting-2026 2026-04-20 https://biopharmsignal.com/news/OCS/oculis-announces-completion-of-last-patient-visit-in-phase-3-diamond-program-with-ocs-01-eye-drops-for-the-treatment-of-diabetic-macular-edema 2026-04-20 https://biopharmsignal.com/news/STRO/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next--bdf8f4ce 2026-04-19 https://biopharmsignal.com/news/MNPR/monopar-presents-phase-3-data-showing-greater-neurologic-benefit-with-alxn1840-vs-soc-in-wilson-disease-patients-with-neurologic-symptoms-at-aan-2026 2026-04-19 https://biopharmsignal.com/news/IMCR/kimmtrak-doubles-the-likelihood-of-being-alive-at-five-years-for-first-line-hla-a-02-01-patients-with-metastatic-uveal-melanoma 2026-04-19 https://biopharmsignal.com/news/XENE/results-from-the-phase-3-x-tole2-study-evaluating-azetukalner-a-novel-potent-kv7-channel-opener-in-adults-with-focal-onset-seizures-fos 2026-04-19 https://biopharmsignal.com/news/XENE/xenon-presents-azetukalner-phase-3-x-tole2-study-results-and-48-month-long-term-data-in-focal-onset-seizures-at-2026-aan-annual-meeting 2026-04-19 https://biopharmsignal.com/news/XENE/treatment-experiences-with-anti-seizure-medications-asms-patient-clinician-perspectives-on-titration-burden-quality-of-life-and-no-titration-options 2026-04-19 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-present-updated-phase-1-clinical-data-for-zoldonrasib-in-patients-with-previously-treated-kras-g12d-non-small-cell-lung-cancer-at-the-2026-aacr-annual-meeting 2026-04-19 https://biopharmsignal.com/news/MOLN/molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-16d9253c 2026-04-19 https://biopharmsignal.com/news/NKTR/nektar-to-hold-conference-call-to-discuss-52-week-topline-results-from-the-16-week-extension-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-april-20-2026 2026-04-19 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the-2026-aacr-annual-meeting 2026-04-18 https://biopharmsignal.com/news/ARGX/argenx-brings-neuromuscular-leadership-to-aan-2026-with-new-data-supporting-broa-fa3d3713 2026-04-18 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-to-hold-first-quarter-2026-earnings-conference-call-on-thursday-may-7-2026 2026-04-17 https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings-at-the-2026-american-association-for-cancer-research-aacr-annual-meeting 2026-04-17 https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-present-new-preclinical-data-showing-synergistic-anti-tumor-ac-5b636925 2026-04-17 https://biopharmsignal.com/news/GDRX/goodrx-announces-date-for-first-quarter-2026-earnings-release-and-conference-call 2026-04-17 https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-closing-of-concurrent-upsized-public-offerings-with-aggregate-gross-proceeds-of-approximately-2-2-billion-including-full-exercise-of-underwriters-option-to-purchase-additional-shares 2026-04-17 https://biopharmsignal.com/news/OLMA/olema-oncology-announces-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-annual-meeting 2026-04-17 https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-new-preclinical-data-at-aacr-annual-meeting-for-xtx-61e9b86b 2026-04-17 https://biopharmsignal.com/news/ACRV/acrivon-to-highlight-preclinical-data-with-three-posters-at-aacr-demonstrating-strong-acr-368-and-acr-2316-synergies-with-immune-checkpoint-inhibitors-and-adc-payloads-revealing-broad-clinical-development-opportunities 2026-04-17 https://biopharmsignal.com/news/NXGL/nexgel-moves-forward-shareholder-update-call-to-discuss-celularity-transaction-on-april-21st-at-4-30-p-m-et 2026-04-17 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-present-azenosertib-preclinical-data-in-triple-negat-50308417 2026-04-17 https://biopharmsignal.com/news/IMTX/prame-directed-cell-therapy-using-immatics-tcr-induces-deep-and-durable-remission-in-pediatric-patient-with-advanced-metastatic-nephroblastoma 2026-04-17 https://biopharmsignal.com/news/INKT/mink-therapeutics-reports-phase-ii-data-on-immune-reprogramming-and-durable-surv-b92e173f 2026-04-17 https://biopharmsignal.com/news/BRKR/bruker-spatial-biology-showcases-high-fidelity-spatial-data-and-integrated-multi-platform-workflows-for-unprecedented-multiomic-insights-at-aacr-2026 2026-04-17 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-advances-upcoming-fda-510-k-submission-successfully-co-02c9bbe7 2026-04-17 https://biopharmsignal.com/news/VXRT/vaxart-announces-share-purchase-agreement-for-up-to-25-million-with-lincoln-park-3ab5499c 2026-04-17 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-inc-announces-intention-to-voluntarily-file-form-25-for-delisting-from-nasdaq-and-subsequent-deregistration-with-the-sec 2026-04-17 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-poster-presentations-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026 2026-04-17 https://biopharmsignal.com/news/LXRX/lexicon-to-present-data-at-the-american-academy-of-neurology-aan-annual-meeting-87d3df03 2026-04-17 https://biopharmsignal.com/news/RGEN/repligen-opens-european-training-innovation-center-in-breda-expanding-global-cus-bacef301 2026-04-17 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-appoints-highly-experienced-biotech-executive-ann-cunningh-7d532621 2026-04-17 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-virtual-event-to-discuss-commercial-launch-plan-based-on-market-opportunity-assessment-for-igalmir-in-the-at-home-setting 2026-04-17 https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-host-analyst-event-on-april-25-2026 2026-04-17 https://biopharmsignal.com/news/IMRN/immuron-double-digit-3q-sales-growth-d78f60f6 2026-04-17 https://biopharmsignal.com/news/KURA/kura-oncology-reports-darlifarnib-plus-cabozantinib-demonstrates-robust-activity-in-patients-with-clear-cell-renal-cell-carcinoma-previously-treated-with-cabozantinib 2026-04-17 https://biopharmsignal.com/news/BRKR/bruker-expands-industry-leading-maldi-biotyperr-and-ir-biotyperr-workflows-for-microbial-identification-and-outbreak-management 2026-04-17 https://biopharmsignal.com/news/BRKR/bruker-launches-mygenius-pror-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026 2026-04-17 https://biopharmsignal.com/news/OSUR/orasure-technologies-appoints-john-d-bertrand-to-its-board-of-directors 2026-04-17 https://biopharmsignal.com/news/LFVN/lifevantage-appointing-terrence-moorehead-as-chief-executive-officer 2026-04-16 https://biopharmsignal.com/news/GMED/globus-medical-schedules-first-quarter-earnings-release-and-conference-call-f2d6394f 2026-04-16 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-inc-announces-closing-of-public-offering-and-full-exercise-of-3e1c4681 2026-04-16 https://biopharmsignal.com/news/LFST/lifestance-to-host-first-quarter-2026-earnings-conference-call-on-may-7-2026 2026-04-16 https://biopharmsignal.com/news/PACB/pacbio-to-report-first-quarter-2026-financial-results-on-may-7-2026-a1800a0b 2026-04-16 https://biopharmsignal.com/news/IRTC/irhythm-holdings-to-report-first-quarter-2026-financial-results-on-april-30-2026-423427e1 2026-04-16 https://biopharmsignal.com/news/BEAT/heartbeam-announces-closing-of-10-million-public-offering-of-common-stock 2026-04-16 https://biopharmsignal.com/news/EBS/emergent-biosolutions-successfully-refinances-term-loan-amends-asset-backed-loan-facility-and-increases-financial-flexibility 2026-04-16 https://biopharmsignal.com/news/EBS/emergent-biosolutions-to-report-first-quarter-2026-financial-results-on-april-30-2026 2026-04-16 https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-first-quarter-2026-earnings-release-and-conference-call 2026-04-16 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-closing-of-200-4-million-public-offering-of-common-stock 2026-04-16 https://biopharmsignal.com/news/INDV/survey-of-correctional-facility-staff-monthly-opioid-treatment-shot-may-help-red-c521928e 2026-04-16 https://biopharmsignal.com/news/NEPH/nephros-expands-strategic-focus-in-greater-new-york-market-with-dedicated-region-8d57692c 2026-04-16 https://biopharmsignal.com/news/IPHA/innate-pharma-to-present-matisse-phase-2-interim-results-of-iph5201-in-clinical-trials-plenary-session-at-aacr-2026 2026-04-16 https://biopharmsignal.com/news/MKT/maia-biotechnology-activates-first-u-s-site-for-ongoing-international-phase-2-expansion-trial-of-novel-telomere-targeting-treatment-targeting-advanced-non-small-cell-lung-cancer 2026-04-16 https://biopharmsignal.com/news/PGNY/progyny-expands-access-to-fertility-and-women-s-health-with-industry-s-first-fully-insured-supplemental-plan 2026-04-16 https://biopharmsignal.com/news/AIM/aim-immunotech-enters-pivotal-value-inflection-phase-with-planned-phase-3-study--e0428399 2026-04-16 https://biopharmsignal.com/news/FEMY/femasys-drives-international-growth-with-israeli-market-entry-for-fertility-port-bf45bbe7 2026-04-16 https://biopharmsignal.com/news/FATE/fate-therapeutics-announces-data-presentation-of-ft839-next-generation-off-the-shelf-car-t-cell-product-candidate-for-the-broad-treatment-of-hematological-malignancies-and-autoimmune-diseases-without-the-need-for-conditioning-chemotherapy-at-the-aacr-annual-meeting 2026-04-16 https://biopharmsignal.com/news/DGX/city-of-hope-to-evaluate-quest-diagnostics-haystack-mrdr-for-guiding-patient-management-in-multiple-cancers 2026-04-16 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-announces-appointment-of-andrew-d-goldberg-md-as-chief-executive-officer-and-to-the-board-of-directors 2026-04-16 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-announces-up-to-354-million-private-placement 2026-04-16 https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-present-open-label-extension-data-from-phase-3-argus-trial-at-the-2026-american-academy-of-neurology-annual-meeting 2026-04-16 https://biopharmsignal.com/news/ARDX/ardelyx-to-report-first-quarter-2026-financial-results-on-april-30-2026-9921f828 2026-04-16 https://biopharmsignal.com/news/PRME/prime-medicine-appoints-svetlana-makhni-as-chief-financial-officer 2026-04-16 https://biopharmsignal.com/news/PCRX/pacira-to-report-first-quarter-2026-financial-results-on-thursday-april-30-2026 2026-04-16 https://biopharmsignal.com/news/MDXG/mimedx-announces-restructuring-and-cost-reduction-initiative 2026-04-16 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-reports-inducement-grants-0c1f0148 2026-04-16 https://biopharmsignal.com/news/INMB/inmune-bio-inc-announces-new-preclinical-data-at-aacr-2026-demonstrating-inb03-x-326de20d 2026-04-16 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-secures-irb-approval-of-final-phase-of-pf614-mpar-102-clinical-study 2026-04-16 https://biopharmsignal.com/news/SRRK/scholar-rock-to-report-first-quarter-2026-financial-results-on-may-7-2026 2026-04-16 https://biopharmsignal.com/news/CRL/charles-river-laboratories-schedules-first-quarter-2026-earnings-release-and-conference-call 2026-04-16 https://biopharmsignal.com/news/TECH/bio-techne-introduces-streamlined-brand-architecture-to-help-customers-navigate-solutions-faster-and-with-greater-clarity 2026-04-16 https://biopharmsignal.com/news/MGTX/meiragtx-announces-pricing-of-100-million-offering-of-ordinary-shares 2026-04-16 https://biopharmsignal.com/news/XLO/xilio-therapeutics-appoints-cheryl-r-blanchard-ph-d-to-its-board-of-directors-4b7702b0 2026-04-16 https://biopharmsignal.com/news/FLGT/fulgent-to-announce-first-quarter-2026-financial-results-on-friday-may-1-2026 2026-04-16 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-announces-late-breaker-oral-presentation-at-the-american-a-65cf7b81 2026-04-16 https://biopharmsignal.com/news/MGTX/meiragtx-announces-the-acquisition-of-botaretigene-sparoparvovec-bota-vec-for-the-treatment-of-x-linked-retinitis-pigmentosa-xlrp 2026-04-16 https://biopharmsignal.com/news/MGTX/meiragtx-announces-positive-three-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-2-3-late-radiation-induced-xerostomia 2026-04-16 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-publication-of-positive-data-demonstrating-intra-fcd6f4a7 2026-04-16 https://biopharmsignal.com/news/HROW/harrow-announces-the-issuance-of-j-code-for-iopidine-1-f1b31e0e 2026-04-16 https://biopharmsignal.com/news/ALKS/alkermes-to-present-additional-data-from-vibrance-1-phase-2-study-of-alixorexton-in-patients-with-narcolepsy-type-1-at-the-american-academy-of-neurology-aan-2026-annual-meeting 2026-04-16 https://biopharmsignal.com/news/ANL/adlai-nortye-announces-150-0-million-private-placement-equity-financing 2026-04-16 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-announces-cfo-succession-plan-abc8069e 2026-04-16 https://biopharmsignal.com/news/BDX/bd-earns-industry-top-honors-for-transparency-resiliency-and-partnership 2026-04-16 https://biopharmsignal.com/news/ACON/aclarion-secures-u-s-patent-advancing-scalable-ai-driven-assessment-of-chronic-l-2cafb158 2026-04-16 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-enters-into-exclusive-license-deal-with-xiamen-amoytop-biotech-co-ltd-to-develop-and-commercialize-pevifoscorvir-sodium-in-greater-china-for-chronic-hepatitis-b-virus-infection 2026-04-16 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-present-new-data-on-nuzyrar-omadacycline-at-escmid-global-2026 2026-04-16 https://biopharmsignal.com/news/MESO/appendix-3y-for-gregory-george 2026-04-16 https://biopharmsignal.com/news/MESO/notification-of-cessation-of-securities-msb 2026-04-16 https://biopharmsignal.com/news/MESO/notification-regarding-unquoted-securities-msb 2026-04-16 https://biopharmsignal.com/news/MESO/application-for-quotation-of-securities-msb 2026-04-16 https://biopharmsignal.com/news/HLF/herbalife-announces-pricing-of-800-million-aggregate-principal-amount-of-senior-secured-notes-offering 2026-04-15 https://biopharmsignal.com/news/HUM/humana-board-declares-payment-of-quarterly-dividend-to-stockholders 2026-04-15 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-reports-full-year-2025-financial-results-9aebed39 2026-04-15 https://biopharmsignal.com/news/PRI/primerica-schedules-first-quarter-2026-financial-results-webcast 2026-04-15 https://biopharmsignal.com/news/NXGL/nexgel-reschedules-shareholder-update-conference-call-to-april-23rd-at-4-30-p-m-et-to-provide-update-on-celularity-transaction 2026-04-15 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-to-report-first-quarter-2026-financial-results-on-may-5-2026 2026-04-15 https://biopharmsignal.com/news/LUNG/pulmonx-to-report-first-quarter-2026-financial-results-on-april-29-2026 2026-04-15 https://biopharmsignal.com/news/TDOC/teladoc-health-to-announce-first-quarter-2026-financial-results-3cb09876 2026-04-15 https://biopharmsignal.com/news/NKTX/nkarta-announces-fda-agreement-on-outpatient-dosing-of-nkx019-in-autoimmune-disease-expanding-access-to-community-rheumatology-centers 2026-04-15 https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-proposed-redomiciliation-to-the-united-states-b54e335e 2026-04-15 https://biopharmsignal.com/news/ARQT/arcutis-to-report-first-quarter-2026-financial-results-and-host-conference-call-on-may-6-2026 2026-04-15 https://biopharmsignal.com/news/RCEL/avita-medical-founder-fiona-wood-honored-with-lifetime-achievement-award-by-amer-8084da1e 2026-04-15 https://biopharmsignal.com/news/INTS/intensity-therapeutics-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation 2026-04-15 https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-leadership-appointments-to-accelerate-late-stage-development-of-vopimetostat 2026-04-15 https://biopharmsignal.com/news/PACB/pacbio-and-covaris-announce-joint-workflow-enabling-hifi-long-read-sequencing-of-e38af568 2026-04-15 https://biopharmsignal.com/news/PRPH/prophase-labs-reports-year-end-2025-results-highlights-accelerating-settlement-activity-and-investment-ready-crown-medical-collections-platform 2026-04-15 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-fda-acceptance-of-sp16-investigational-new-drug-application-for-the-treatment-of-chemotherapy-induced-pain-and-neuropathy 2026-04-15 https://biopharmsignal.com/news/GDRX/goodrx-now-offers-access-to-wegovyr-hd-at-399-per-month-self-pay-price 2026-04-15 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-schedules-release-of-full-year-2025-financial-results-and-con-e003b303 2026-04-15 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-publication-of-positive-pds01adc-interim-phase-2-clinical--180f6097 2026-04-15 https://biopharmsignal.com/news/XENE/xenon-to-present-at-upcoming-investor-conferences 2026-04-15 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-nature-communications-publication-highlighting-pre-clinical-data-for-allo-329-a-next-generation-dual-targeted-cd19-cd70-allogeneic-car-t-for-autoimmune-diseases 2026-04-15 https://biopharmsignal.com/news/SABS/sab-bio-to-present-additional-data-supporting-the-unique-profile-of-sab-142-at-the-2026-immunology-of-diabetes-society-congress 2026-04-15 https://biopharmsignal.com/news/CUE/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammator-122a7c1e 2026-04-15 https://biopharmsignal.com/news/IMMP/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-be3939ed 2026-04-15 https://biopharmsignal.com/news/RVPH/reviva-announces-letter-to-shareholders-a6780413 2026-04-15 https://biopharmsignal.com/news/AMRN/amarin-to-report-first-quarter-2026-financial-results-and-host-conference-call-o-65f0bc9f 2026-04-15 https://biopharmsignal.com/news/XAIR/beyond-air-to-participate-in-the-d-boral-capital-global-conference-2026-cf820619 2026-04-15 https://biopharmsignal.com/news/TEVA/teva-launches-home-ground-schizophrenia-community-a-new-online-resource-hub-for--3d7f68cd 2026-04-15 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-announces-operational-progress-including-completion-of-technology-transfer-to-adare-pharma-solutions 2026-04-15 https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-35pharma-inc 2026-04-15 https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-completion-of-enrollment-for-the-phase-3-trial-evaluating-subcutaneous-briumvi 2026-04-15 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-the-appointment-of-charles-morris-m-d-as-chief-medical-officer 2026-04-15 https://biopharmsignal.com/news/ABUS/arbutus-receives-u-s-fda-fast-track-designation-for-imdusiran-for-the-treatment-of-chronic-hepatitis-b 2026-04-15 https://biopharmsignal.com/news/PSTV/plus-therapeutics-appoints-randy-h-goodman-phd-mha-as-vice-president-of-value-strategy-and-heor-to-advance-market-access-and-commercial-execution 2026-04-15 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-to-host-virtual-kol-event-to-share-new-insights-on-ath434--300ee020 2026-04-15 https://biopharmsignal.com/news/DTIL/precision-biosciences-expands-eliminate-b-trial-following-clinical-trial-application-approval-in-two-european-countries 2026-04-15 https://biopharmsignal.com/news/BCRX/biocryst-to-report-first-quarter-2026-financial-results-on-may-6 2026-04-15 https://biopharmsignal.com/news/STXS/stereotaxis-announces-definitive-agreement-to-acquire-robocath-37fd84a6 2026-04-15 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-steady-state-pharmacokinetics-of-tonmyar-after-20-days-of-daily-dosing-in-the-peer-reviewed-journal-clinical-pharmacology-in-drug-development 2026-04-15 https://biopharmsignal.com/news/USNA/usana-schedules-first-quarter-2026-earnings-release-and-conference-call 2026-04-15 https://biopharmsignal.com/news/SPRY/neffy-epinephrine-nasal-spray-approved-in-canada-as-the-first-and-only-needle-fr-17293ba4 2026-04-15 https://biopharmsignal.com/news/RVMD/revolution-medicines-inc-prices-2-0-billion-in-concurrent-upsized-offerings-of-common-stock-and-convertible-senior-notes 2026-04-15 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-announces-pricing-of-upsized-403-0-million-public-offering-of-d95abcb9 2026-04-15 https://biopharmsignal.com/news/BEAT/heartbeam-announces-pricing-of-10-million-public-offering-of-common-stock 2026-04-15 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-pricing-of-public-offering-of-common-stock 2026-04-15 https://biopharmsignal.com/news/MESO/acquires-car-platform-for-precision-enhanced-cell-products 2026-04-14 https://biopharmsignal.com/news/CCEL/cord-blood-banking-leader-cryo-cell-reports-fiscal-first-quarter-2026-financial-results 2026-04-14 https://biopharmsignal.com/news/LMAT/lemaitre-will-announce-first-quarter-2026-earnings-results-on-may-5-2026-b7240d53 2026-04-14 https://biopharmsignal.com/news/HSCS/heartsciences-reminds-its-shareholders-to-submit-their-vote-at-the-upcoming-apri-b33e7a56 2026-04-14 https://biopharmsignal.com/news/GPCR/structure-therapeutics-appoints-matthew-lang-j-d-as-chief-operating-officer-and-general-counsel 2026-04-14 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-announces-first-interim-analysis-results-from-the-phase-2-b-supreme-study-of-pevifoscorvir-sodium-in-participants-with-chronic-hepatitis-b-virus-infection-and-grant-of-fda-fast-track-designation 2026-04-14 https://biopharmsignal.com/news/BEAT/heartbeam-announces-proposed-public-offering-of-common-stock 2026-04-14 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2026-financial-results 2026-04-14 https://biopharmsignal.com/news/MOLN/molecular-partners-announces-all-board-proposals-approved-clare-fisher-elected-a-b63f2de0 2026-04-14 https://biopharmsignal.com/news/GRTX/galera-therapeutics-and-obsidian-therapeutics-announce-merger-agreement-and-350--61b32647 2026-04-14 https://biopharmsignal.com/news/ENTX/entera-bio-to-host-key-opinion-leader-webinar-highlighting-the-osteoporosis-trea-482758bb 2026-04-14 https://biopharmsignal.com/news/CLRB/cellectar-enrolls-first-patient-in-clr-125-auger-emitting-radioconjugate-phase-1b-clinical-trial-targeting-refractory-triple-negative-breast-cancer-tnbc 2026-04-14 https://biopharmsignal.com/news/MGTX/meiragtx-to-present-3-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-2-3-radiation-induced-xerostomia-on-thursday-april-16-2026 2026-04-14 https://biopharmsignal.com/news/RNXT/clinical-data-supporting-targeted-chemotherapeutic-delivery-via-renovorx-s-tamptm-therapy-platform-presented-at-2026-sir-annual-scientific-meeting 2026-04-14 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-first-real-world-head-to-head-claims-analysis-demonstrating-greater-treatment-persistence-with-ingrezzar-valbenazine-capsules-compared-to-austedo-xr 2026-04-14 https://biopharmsignal.com/news/HRMY/harmony-biosciences-appoints-glenn-reicin-as-chief-financial-officer 2026-04-14 https://biopharmsignal.com/news/TPST/tempest-appoints-andrew-fang-ph-d-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts 2026-04-14 https://biopharmsignal.com/news/HLF/herbalife-announces-proposed-offering-of-800-million-aggregate-principal-amount-of-senior-secured-notes 2026-04-14 https://biopharmsignal.com/news/BIVI/biovie-announces-abstract-accepted-for-presentation-at-the-2026-american-academy-270c1788 2026-04-14 https://biopharmsignal.com/news/ACON/aclarion-receives-pinnacle-award-for-ai-innovation-c0db7ac1 2026-04-14 https://biopharmsignal.com/news/TEVA/community-routes-access-to-mental-health-care-provides-continued-funding-for-men-132f04dc 2026-04-14 https://biopharmsignal.com/news/AMRX/amneal-launches-first-two-respiratory-metered-dose-inhalation-products-in-the-u-s 2026-04-14 https://biopharmsignal.com/news/BIAF/new-case-study-bioaffinity-technologies-cypathr-lung-diagnostic-supports-physician-s-assessment-prompts-follow-up-imaging-and-defers-unnecessary-biopsy 2026-04-14 https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-abstract-highlighting-strive-on-phase-3-trial-results-accepted-for-presentation-at-aan-2026 2026-04-14 https://biopharmsignal.com/news/HLF/herbalife-provides-preliminary-q1-2026-results-net-sales-above-guidance-adjusted-ebitda-expected-at-or-above-high-end-of-guidance-provides-update-on-senior-secured-debt-refinancing-plans 2026-04-14 https://biopharmsignal.com/news/ATRC/atricure-to-announce-first-quarter-2026-financial-results 2026-04-14 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-announces-last-patient-first-visit-in-canyon-1-study-of-crb-913-for-the-treatment-for-obesity 2026-04-14 https://biopharmsignal.com/news/RCEL/avita-medical-announces-positive-interim-results-from-cohealyx-study-demonstrati-622c172f 2026-04-14 https://biopharmsignal.com/news/VRAX/virax-biolabs-ceo-james-foster-outlines-strategic-priorities-and-near-term-milestones-in-letter-to-shareholders 2026-04-14 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-to-report-first-quarter-2026-financial-results-on-may-12-2026-6f13f45d 2026-04-14 https://biopharmsignal.com/news/MDNA/medicenna-to-present-at-the-2026-bloom-burton-and-co-healthcare-investor-conference 2026-04-14 https://biopharmsignal.com/news/BFRG/bullfrog-ai-announces-participation-at-aacr-annual-meeting 2026-04-14 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-announces-fda-acceptance-of-new-drug-application-for-ulixacaltamide-hcl-in-patients-with-essential-tremor 2026-04-14 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-late-breaking-poster-accepted-for-presentation-a-6ff235a9 2026-04-14 https://biopharmsignal.com/news/ALKS/findings-from-long-term-analysis-of-the-effects-of-lybalvir-olanzapine-and-samidorphan-on-negative-symptoms-of-schizophrenia-published-in-the-journal-of-clinical-psychiatry 2026-04-14 https://biopharmsignal.com/news/KPRX/kiora-s-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway 2026-04-14 https://biopharmsignal.com/news/AXGN/axogen-inc-to-report-first-quarter-2026-financial-results-on-april-28-2026 2026-04-14 https://biopharmsignal.com/news/TECH/bio-techne-to-host-conference-call-on-may-6-2026-to-announce-third-quarter-fiscal-2026-financial-results 2026-04-14 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-on-financing-strategy 2026-04-14 https://biopharmsignal.com/news/AIM/aim-immunotech-provides-routine-update-on-annual-filings-a6fbf4df 2026-04-13 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock-6759139a 2026-04-13 https://biopharmsignal.com/news/ICCC/immucell-bolsters-its-innovation-strategy-with-appointments-of-dr-gilles-guillem-0dff31ee 2026-04-13 https://biopharmsignal.com/news/SANA/sana-biotechnology-and-mayo-clinic-announce-strategic-collaboration-focused-on-improving-care-in-type-1-diabetes-and-accelerating-development-of-sc451 2026-04-13 https://biopharmsignal.com/news/RVMD/revolution-medicines-inc-announces-proposed-offerings-of-common-stock-and-convertible-senior-notes 2026-04-13 https://biopharmsignal.com/news/CLDX/celldex-to-present-at-upcoming-investor-conference-bcb9447f 2026-04-13 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-proposed-public-offering-of-175-million-of-common-stock 2026-04-13 https://biopharmsignal.com/news/SEER/seer-confirms-receipt-of-unsolicited-proposal-and-director-candidate-nominations-from-radoff-jec-group 2026-04-13 https://biopharmsignal.com/news/PYPD/polypid-to-present-new-phase-3-shield-ii-data-demonstrating-d-plex-sustained-local-release-at-escmid-global-2026 2026-04-13 https://biopharmsignal.com/news/XTNT/xtant-medical-and-dilon-technologies-announce-exclusive-u-s-distribution-agreement-for-dilon-s-hemoblastr-bellows-product 2026-04-13 https://biopharmsignal.com/news/SNTI/senti-biosciences-to-present-on-logic-gated-cell-therapies-in-educational-sessio-2566d28b 2026-04-13 https://biopharmsignal.com/news/STIM/optum-united-healthcare-united-behavioral-health-expands-neurostarr-tms-coverage-to-include-psychiatric-mental-health-nurse-practitioners 2026-04-13 https://biopharmsignal.com/news/ALXO/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer 2026-04-13 https://biopharmsignal.com/news/OGEN/oragenics-doses-first-patient-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury 2026-04-13 https://biopharmsignal.com/news/JAGX/artificial-intelligence-ai-platforms-could-enhance-jaguar-health-s-development-and-anticipated-commercialization-of-crofelemer-for-rare-disease-intestinal-failure-if-programs 2026-04-13 https://biopharmsignal.com/news/RVMD/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit-in-pivotal-phase-3-rasolute-302-clinical-trial-in-patients-with-metastatic-pancreatic-cancer 2026-04-13 https://biopharmsignal.com/news/CVRX/cvrx-reports-preliminary-first-quarter-2026-financial-results 2026-04-13 https://biopharmsignal.com/news/PCRX/pacira-presents-real-world-data-on-exparelr-showing-lower-total-healthcare-costs-in-outpatient-total-hip-and-knee-arthroplasty-procedures 2026-04-13 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-announces-first-participants-dosed-in-phase-1-clinical-trial-4f01b1a4 2026-04-13 https://biopharmsignal.com/news/GERN/geron-announces-appointment-of-timothy-williams-as-executive-vice-president-chie-59b2ffb6 2026-04-13 https://biopharmsignal.com/news/LCTX/lineage-announces-formation-of-scientific-advisory-board 2026-04-13 https://biopharmsignal.com/news/LIXT/favorable-results-of-ovarian-cancer-study-presented-at-annual-society-of-gynecological-care-conference 2026-04-13 https://biopharmsignal.com/news/PRAX/praxis-to-showcase-essential3-the-first-positive-phase-3-program-in-essential-tremor-at-aan-2026 2026-04-13 https://biopharmsignal.com/news/SYK/stryker-signs-definitive-agreement-to-acquire-amplitude-vascular-systems-to-add-next-generation-ivl-technology-to-peripheral-vascular-portfolio 2026-04-13 https://biopharmsignal.com/news/NGEN/nervgen-pharma-to-participate-in-the-h-c-wainwright-hcw-home-series-and-the-2026-7a53a187 2026-04-13 https://biopharmsignal.com/news/MDWD/newly-published-u-s-expert-consensus-aligns-with-mediwound-s-strategy-for-chroni-6111021e 2026-04-13 https://biopharmsignal.com/news/BFRG/bullfrog-ai-provides-business-update-strengthened-balance-sheet-supports-continued-execution-as-company-aims-to-ramp-commercial-activity-with-global-pharmaceutical-and-biotechnology-partners 2026-04-13 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-reports-interim-futility-analysis-from-pivotal-alpha3-trial-showing-58-3-mrd-clearance-with-cemacabtagene-ansegedleucel-cema-cel-vs-16-7-in-observation-arm-in-first-line-consolidation-lbcl 2026-04-13 https://biopharmsignal.com/news/SYRE/spyre-announces-potential-best-in-class-spy001-part-a-induction-results-from-sky-39ed4adc 2026-04-13 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-announces-additional-positive-week-52-data-from-landmark-sol--4f52fedf 2026-04-13 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-u-s-fda-fast-track-designation-for-kt-621-a-first--da13eb81 2026-04-13 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-announces-first-participant-dosed-in-phase-1-clinical-trial-of-edp-978-an-oral-once-daily-kit-inhibitor-in-development-for-the-treatment-of-urticaria 2026-04-13 https://biopharmsignal.com/news/BRKR/bruker-unveils-new-nmr-products-and-workflow-solutions-at-enc-2026 2026-04-13 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-the-launch-of-carbamazepine-extended-release-capsu-690cc3f9 2026-04-13 https://biopharmsignal.com/news/REGN/regeneron-and-telix-announce-strategic-radiopharma-collaboration 2026-04-13 https://biopharmsignal.com/news/PSNL/personalis-and-collaborators-to-highlight-ultrasensitive-ctdna-data-and-new-therapy-resistance-tracking-capabilities-at-aacr-2026 2026-04-13 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-and-servier-announce-positive-topline-results-from-phase-2-3-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-first-line-hla-a-02-01-negative-metastatic-uveal-melanoma 2026-04-13 https://biopharmsignal.com/news/YOU/clear-and-snappt-close-the-identity-gap-in-property-management 2026-04-13 https://biopharmsignal.com/news/CLLS/cema-cel-pivotal-trial-interim-data-highlight-strength-of-cellectis-allogeneic-car-t-platform 2026-04-13 https://biopharmsignal.com/news/PRTC/puretech-health-plc-notice-of-results 2026-04-13 https://biopharmsignal.com/news/PRTC/puretech-health-founded-entity-seaport-therapeutics-files-registration-statement-for-proposed-initial-public-offering 2026-04-13 https://biopharmsignal.com/news/REGN/dupixentr-dupilumab-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria-csu 2026-04-13 https://biopharmsignal.com/news/GSK/gsk-presents-positive-data-for-b7-h4-targeted-adc-in-gynaecological-cancers 2026-04-12 https://biopharmsignal.com/news/BNTX/biontechs-und-dualitybios-antik-rper-wirkstoff-konjugat-kandidat-trastuzumab-pam-2c316e37 2026-04-11 https://biopharmsignal.com/news/BNTX/biontech-and-dualitybio-s-antibody-drug-conjugate-trastuzumab-pamirtecan-demonst-936243cc 2026-04-11 https://biopharmsignal.com/news/REPL/replimune-receives-complete-response-letter-from-the-fda-for-rp1-biologics-license-application-for-the-treatment-of-advanced-melanoma 2026-04-10 https://biopharmsignal.com/news/CORT/corcept-presents-complete-data-from-pivotal-rosella-trial-in-sgo-late-breaker-with-simultaneous-publication-in-the-lancet-lifyorlitm-relacorilant-plus-nab-paclitaxel-improves-overall-survival-in-patients-with-platinum-resistant-ovarian-cancer 2026-04-10 https://biopharmsignal.com/news/HUM/humana-elects-robert-s-field-to-board-of-directors 2026-04-10 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-to-host-conference-call-to-report-spy001-part-a-induction-top-407f9400 2026-04-10 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13-2026 2026-04-10 https://biopharmsignal.com/news/IRMD/iradimed-corporation-to-participate-at-the-25th-annual-needham-virtual-healthcar-a4af6e99 2026-04-10 https://biopharmsignal.com/news/IPHA/innate-pharma-to-hold-its-annual-general-meeting-of-shareholders-on-may-21-2026 2026-04-10 https://biopharmsignal.com/news/ANVS/annovis-closes-10-million-offering-extending-cash-runway-through-phase-3-alzheim-06f76d2b 2026-04-10 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-announces-reset-psvt-registry-to-generate-real-world-evidence-on-cardamysttm-etripamil-nasal-spray-in-patients-with-psvt 2026-04-10 https://biopharmsignal.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026 2026-04-10 https://biopharmsignal.com/news/JAGX/reminder-jaguar-health-to-host-investor-webcast-at-8-30-am-eastern-on-friday-april-10-2026-regarding-q4-2025-financials-and-company-updates 2026-04-10 https://biopharmsignal.com/news/CRL/charles-river-advances-cardiovascular-health-awareness-through-support-of-the-american-heart-association 2026-04-09 https://biopharmsignal.com/news/EBS/emergent-biosolutions-partners-with-british-columbia-to-supply-narcanr-nasal-spray-for-the-launch-of-the-expanded-bc-take-home-naloxone-program 2026-04-09 https://biopharmsignal.com/news/CERT/certara-to-report-first-quarter-2026-financial-results-on-may-11th-2026 2026-04-09 https://biopharmsignal.com/news/BDX/bd-to-announce-financial-results-for-its-second-quarter-of-fiscal-2026 2026-04-09 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-announces-acceptance-of-late-breaking-abstract-highlighting-potential-abscopal-effect-of-vp-315-for-the-treatment-of-basal-cell-carcinoma-at-the-upcoming-2026-society-for-investigative-dermatology-annual-meeting 2026-04-09 https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-report-first-quarter-2026-financial-results-on-april-29-2-86748217 2026-04-09 https://biopharmsignal.com/news/BDX/rick-byrd-to-retire-from-bd 2026-04-09 https://biopharmsignal.com/news/LFVN/lifevantage-to-participate-in-water-tower-research-insights-conference-on-wednesday-april-15-2026 2026-04-09 https://biopharmsignal.com/news/BDSX/biodesix-recognized-as-a-top-workplace-for-third-consecutive-year-46402c81 2026-04-09 https://biopharmsignal.com/news/IMMX/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference-39e654b7 2026-04-09 https://biopharmsignal.com/news/FATE/fate-therapeutics-to-participate-in-upcoming-second-quarter-2026-conferences 2026-04-09 https://biopharmsignal.com/news/LFST/lifestance-publishes-outcomes-data-validating-the-benefit-of-mental-health-treatment-at-scale 2026-04-09 https://biopharmsignal.com/news/SLRX/decoy-therapeutics-builds-momentum-with-accelerating-execution-entering-a-highly-catalytic-phase-with-a-clearly-defined-path-to-clinical-development-of-its-antiviral-pipeline 2026-04-09 https://biopharmsignal.com/news/ANVS/annovis-announces-10-million-underwritten-offering-of-common-stock-and-accompany-124cee10 2026-04-09 https://biopharmsignal.com/news/HYPR/hyperfine-receives-ce-and-ukca-marks-for-next-generation-swoopr-system-and-latest-advancement-in-optive-aitm-software 2026-04-09 https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-09 https://biopharmsignal.com/news/ASMB/assembly-biosciences-highlights-presentations-on-positive-phase-1b-data-for-abi-5366-and-abi-1179-in-recurrent-genital-herpes-at-escmid-global-2026 2026-04-09 https://biopharmsignal.com/news/SEER/seer-and-precision-health-research-singapore-sign-collaboration-to-provide-deep-unbiased-proteomics-on-10-000-precise-sg100k-samples 2026-04-09 https://biopharmsignal.com/news/ALHC/alignment-healthcare-to-announce-first-quarter-2026-financial-results-and-host-conference-call-thursday-april-30-2026 2026-04-09 https://biopharmsignal.com/news/AIM/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event-b39514ee 2026-04-09 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-to-host-conference-call-on-new-data-across-neuroimmunology--6fd41335 2026-04-09 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-announce-first-quarter-2026-financial-results-on-april-a00320ac 2026-04-09 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-tuesday-79fca8ed 2026-04-09 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-400mg-qd-5-2-azenosertib-monotherapy-as-the-p-a29b6ece 2026-04-09 https://biopharmsignal.com/news/AMRX/amneal-launches-bimatoprost-ophthalmic-solution-0-01 2026-04-09 https://biopharmsignal.com/news/XTNT/xtant-medical-and-montana-governor-s-office-of-community-service-announce-support-for-threshold-of-life-memorial 2026-04-09 https://biopharmsignal.com/news/PSTV/plus-therapeutics-appoints-eric-j-daniels-m-d-mba-as-chief-development-officer-to-advance-clinical-pipeline 2026-04-09 https://biopharmsignal.com/news/IFRX/inflarx-reports-new-mechanistic-data-for-izicopan-supporting-its-potential-as-a--ebf7fd30 2026-04-09 https://biopharmsignal.com/news/AMN/amn-healthcare-to-hold-first-quarter-2026-earnings-conference-call-on-thursday-m-09f1e3de 2026-04-09 https://biopharmsignal.com/news/IBRX/immunitybio-reports-net-product-revenue-increased-nearly-2-7-times-year-over-year-to-record-44-million-in-q1-2026-and-381-million-in-cash-and-marketable-securities 2026-04-09 https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-09 https://biopharmsignal.com/news/KURA/kura-oncology-to-present-darlifarnib-plus-cabozantinib-data-in-patients-with-clear-cell-renal-cell-carcinoma-previously-treated-with-cabozantinib-at-ikcs-europe-2026 2026-04-09 https://biopharmsignal.com/news/GDRX/goodrx-expands-access-to-eli-lilly-and-company-s-new-oral-glp-1-foundayotm-and-zepboundr-kwikpenr-with-self-pay-pricing-at-more-than-70-000-pharmacies-nationwide 2026-04-09 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-09 https://biopharmsignal.com/news/NKTX/nkarta-to-participate-in-needham-virtual-healthcare-conference 2026-04-09 https://biopharmsignal.com/news/RANI/rani-therapeutics-appoints-dr-sara-kenkare-mitra-as-strategic-advisor-to-advance-platform-and-clinical-strategy 2026-04-09 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting 2026-04-09 https://biopharmsignal.com/news/INDV/indivior-to-report-first-quarter-2026-financial-results-and-host-webcast-on-apri-e8a593bb 2026-04-09 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-gilead-sciences-option-exercise-to-license-kt-200--919c065a 2026-04-09 https://biopharmsignal.com/news/MDNA/medicenna-therapeutics-appoints-dr-nageatte-ibrahim-as-chief-medical-officer 2026-04-09 https://biopharmsignal.com/news/PLSE/pulse-biosciences-strengthens-executive-leadership-team 2026-04-09 https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-present-at-carb-x-investor-day 2026-04-09 https://biopharmsignal.com/news/CCCC/c4-therapeutics-expands-long-term-partnership-with-roche-through-new-collaborati-b523cd96 2026-04-09 https://biopharmsignal.com/news/BDX/for-women-managing-nighttime-incontinence-better-sleep-and-comfort-start-with-bdr-purewickr-urine-collection-system 2026-04-09 https://biopharmsignal.com/news/PRI/national-survey-middle-income-americans-reprioritizing-spending-as-cost-pressures-persist 2026-04-09 https://biopharmsignal.com/news/HCM/hutchmed-highlights-data-to-be-presented-at-aacr-annual-meeting-2026-9600ae68 2026-04-09 https://biopharmsignal.com/news/MGNX/fda-removes-partial-clinical-hold-on-macrogenics-linnet-study 2026-04-08 https://biopharmsignal.com/news/RCEL/avita-medical-secures-10-year-barda-agreement-worth-up-to-25-5m-to-bolster-u-s-b-bf40be1e 2026-04-08 https://biopharmsignal.com/news/ANNX/annexon-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-08 https://biopharmsignal.com/news/RXST/rxsight-highlights-300-000-light-adjustable-lens-implant-milestone-and-strong-scientific-presence-at-ascrs-2026 2026-04-08 https://biopharmsignal.com/news/CLOV/clover-health-to-report-first-quarter-2026-financial-results-on-may-6-2026 2026-04-08 https://biopharmsignal.com/news/ICCC/immucell-announces-a-28-4-increase-in-product-sales-in-q1-of-2026-based-on-preli-34032873 2026-04-08 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-may--792398bd 2026-04-08 https://biopharmsignal.com/news/NXGL/nexgel-reschedules-shareholder-update-conference-call-to-april-15th-at-4-30-p-m-et-to-provide-update-on-celularity-transaction 2026-04-08 https://biopharmsignal.com/news/OPCH/option-care-health-to-announce-first-quarter-2026-financial-results-and-host-conference-call 2026-04-08 https://biopharmsignal.com/news/PRQR/proqr-highlights-pipeline-expansion-and-multiple-upcoming-clinical-catalysts-at--4995694c 2026-04-08 https://biopharmsignal.com/news/ASND/ascendis-pharma-to-list-ordinary-shares-directly-on-nasdaq 2026-04-08 https://biopharmsignal.com/news/ACHC/acadia-healthcare-announces-date-for-first-quarter-2026-earnings-release 2026-04-08 https://biopharmsignal.com/news/GRI/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-t-d98e1c0e 2026-04-08 https://biopharmsignal.com/news/ENLV/ondo-global-markets-tokenizes-enlivex-s-ordinary-shares-58c87824 2026-04-08 https://biopharmsignal.com/news/LGVN/longeveron-granted-chinese-patent-for-potency-assay-methods-for-assessing-human--f85b1776 2026-04-08 https://biopharmsignal.com/news/PRVA/privia-health-to-report-first-quarter-2026-results-on-thursday-may-7 2026-04-08 https://biopharmsignal.com/news/MKT/maia-biotechnology-expects-recent-33-million-capital-raise-to-fully-fund-ongoing-pivotal-phase-3-trial-of-novel-telomere-targeting-anticancer-therapy 2026-04-08 https://biopharmsignal.com/news/EQ/equillium-announces-poster-presentations-at-immunology2026-the-annual-meeting-of-d51c0a02 2026-04-08 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammator-7b227a02 2026-04-08 https://biopharmsignal.com/news/JAGX/jaguar-health-completes-effectiveness-trial-to-support-fda-approved-crofelemer-for-treatment-of-chemotherapy-induced-diarrhea-cid-in-dogs 2026-04-08 https://biopharmsignal.com/news/RNXT/renovorx-secures-first-notice-of-allowance-for-japanese-patent-covering-its-renovocathr-device-for-targeted-local-drug-delivery-via-the-vasa-vasorum 2026-04-08 https://biopharmsignal.com/news/ASND/new-data-from-week-52-of-the-ongoing-coach-trial-showed-that-transconr-hgh-accelerated-transconr-cnp-s-benefits-beyond-linear-growth-in-children-with-achondroplasia 2026-04-08 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-launches-targeted-direct-to-consumer-tv-campaign-for-arcalystr-rilonacept-in-recurrent-pericarditis 2026-04-08 https://biopharmsignal.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-08 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-08 https://biopharmsignal.com/news/ABSI/absci-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference 2026-04-08 https://biopharmsignal.com/news/OVID/ovid-therapeutics-to-host-potassium-chloride-co-transporter-2-kcc2-deep-dive-r-d-e19d6aec 2026-04-08 https://biopharmsignal.com/news/CUE/cue-biopharma-to-receive-7-5-million-preclinical-milestone-payment-from-boehring-1f227463 2026-04-08 https://biopharmsignal.com/news/ACON/aclarion-announces-agreement-with-weill-cornell-medicine-ef096e9c 2026-04-08 https://biopharmsignal.com/news/ECOR/electrocore-to-participate-in-the-25th-annual-needham-virtual-healthcare-confere-a7a39f35 2026-04-08 https://biopharmsignal.com/news/PRQR/proqr-announces-partnership-with-ginkgo-bioworks-and-formation-of-ai-advisory-bo-f225534c 2026-04-08 https://biopharmsignal.com/news/AMRN/american-college-of-cardiology-acc-scientific-sessions-2026-underscore-the-need--0f21aedf 2026-04-08 https://biopharmsignal.com/news/URGN/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer 2026-04-08 https://biopharmsignal.com/news/OPKO/opko-health-s-modex-therapeutics-initiates-clinical-trial-of-mdx2301-for-the-prevention-of-covid-19 2026-04-08 https://biopharmsignal.com/news/GSK/exdensur-depemokimab-approved-in-china-for-the-treatment-of-chronic-rhinosinusitis-with-nasal-polyps-crswnp 2026-04-08 https://biopharmsignal.com/news/EHC/encompass-health-announces-annual-stockholder-meeting-date 2026-04-08 https://biopharmsignal.com/news/PSTV/plus-therapeutics-granted-u-s-fda-orphan-drug-designation-to-reyobiqtm-in-pediatric-malignant-gliomas 2026-04-08 https://biopharmsignal.com/news/DTIL/precision-biosciences-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference 2026-04-08 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-enrollment-of-first-patients-in-u-s-department-of-war-funded-study-of-bxcl501-sublingual-dexmedetomidine-for-treatment-of-acute-stress-reactions 2026-04-08 https://biopharmsignal.com/news/BSEM/biostem-technologies-to-showcase-innovation-and-clinical-evidence-at-symposium-o-5d9e84f6 2026-04-08 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-to-report-first-quarter-2026-financial-results-on-may-4-b3d36cfc 2026-04-08 https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-08 https://biopharmsignal.com/news/IBIO/ibio-received-regulatory-clearance-to-initiate-its-phase-1-clinical-trial-of-ibio-600-in-australia 2026-04-08 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-fda-approval-and-launch-of-isosorbide-mononitrate--91815852 2026-04-08 https://biopharmsignal.com/news/BDX/bd-delivers-next-generation-tips-innovation-to-advance-portal-hypertension-care-across-the-european-union 2026-04-08 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update 2026-04-08 https://biopharmsignal.com/news/YOU/clear1-achieves-fedrampr-in-process-designation-to-support-public-sector-and-regulated-industries-advancing-secure-digital-identity-for-u-s-federal-agencies 2026-04-08 https://biopharmsignal.com/news/MESO/mesoblast-randd-day-presentation 2026-04-08 https://biopharmsignal.com/news/MESO/mesoblast-randd-day-features-commercial-and-blockbuster-programs 2026-04-08 https://biopharmsignal.com/news/EHC/encompass-health-announces-date-of-2026-first-quarter-earnings-call 2026-04-07 https://biopharmsignal.com/news/RCEL/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featurin-16176c61 2026-04-07 https://biopharmsignal.com/news/PCVX/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-07 https://biopharmsignal.com/news/IRIX/iridex-announces-new-partnership-with-eyeprogpo-to-expand-member-access-to-retina-laser-technology 2026-04-07 https://biopharmsignal.com/news/AMRX/amneal-to-report-first-quarter-2026-results-on-may-1-2026 2026-04-07 https://biopharmsignal.com/news/INSM/insmed-provides-clinical-update-on-phase-2b-cedar-study 2026-04-07 https://biopharmsignal.com/news/LMAT/lemaitre-to-present-at-the-25th-annual-needham-virtual-healthcare-conference-b000089f 2026-04-07 https://biopharmsignal.com/news/GNFT/genfit-announces-publication-of-the-2025-universal-registration-document 2026-04-07 https://biopharmsignal.com/news/AXON/axon-tackles-public-safety-s-data-overload-with-three-new-ai-tools 2026-04-07 https://biopharmsignal.com/news/IPHA/innate-pharma-to-present-at-the-aacr-2026-oncology-industry-partnering-event 2026-04-07 https://biopharmsignal.com/news/TMCI/treace-announces-first-surgical-cases-with-the-superbitetm-compression-screw-system 2026-04-07 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-formal-dispute-resolution-request-for-ons-5010-lytenavatm-bevacizumab-vikg-accepted-by-fda 2026-04-07 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-completes-private-placement-with-existing-private-equity-inve-0661c833 2026-04-07 https://biopharmsignal.com/news/MBRX/moleculin-releases-next-ceo-corner-segment-highlighting-annamycin-s-non-cardioto-8a419111 2026-04-07 https://biopharmsignal.com/news/IART/integra-lifesciences-unveils-new-real-world-evidence-highlighting-primatrixr-utilization 2026-04-07 https://biopharmsignal.com/news/CLOV/clover-health-empowers-members-to-take-charge-of-their-health-data-through-healthex-partnership 2026-04-07 https://biopharmsignal.com/news/CRMD/cormedix-to-participate-in-needham-virtual-healthcare-conference-1b7e4e75 2026-04-07 https://biopharmsignal.com/news/ABEO/abeona-therapeutics-announces-appointment-of-keith-a-goldan-to-its-board-of-dire-7742753a 2026-04-07 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-07 https://biopharmsignal.com/news/XENE/xenon-to-highlight-phase-3-x-tole2-and-long-term-data-for-azetukalner-in-focal-onset-seizures-at-2026-aan-annual-meeting 2026-04-07 https://biopharmsignal.com/news/JAGX/jaguar-health-reports-2025-financials 2026-04-07 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-announces-strategic-collaboration-with-203-creates-to-b-3759cc17 2026-04-07 https://biopharmsignal.com/news/AZTA/azenta-life-sciences-announces-leadership-transition-to-accelerate-gene-synthesis-strategy-and-multiomics-execution 2026-04-07 https://biopharmsignal.com/news/NXTC/nextcure-receives-fast-track-designation-for-sim0505-cdh6-adc-in-ovarian-cancer-f0bbc242 2026-04-07 https://biopharmsignal.com/news/EBS/emergent-biosolutions-launches-new-narcanr-nasal-spray-carrying-case-and-multipacks-alongside-college-campus-outreach-to-expand-opioid-overdose-preparedness 2026-04-07 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference 2026-04-07 https://biopharmsignal.com/news/ACON/aclarion-highlights-growing-adoption-of-nociscan-at-the-london-clinic-with-new-p-50a22f0c 2026-04-07 https://biopharmsignal.com/news/ECOR/electrocore-announces-first-patient-enrollment-in-investigator-led-study-of-gamm-11b16f33 2026-04-07 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biote-55016911 2026-04-07 https://biopharmsignal.com/news/AMRX/amneal-announces-2-million-donation-to-support-patient-access-to-essential-medicines-during-parkinson-s-awareness-month 2026-04-07 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-secures-second-financing-from-2025-agreement-to-advance-breakthrough-pain-programs 2026-04-07 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-cypathr-lung-to-be-featured-at-cleveland-clinic-annual-advances-in-early-lung-cancer-detection-symposium-april-16 2026-04-07 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension 2026-04-07 https://biopharmsignal.com/news/ALZN/alzamend-neuro-reports-encouraging-pharmacodynamic-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-a-trial-conducted-at-massachusetts-general-hospital 2026-04-07 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-07 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-in-second-line-hnscc-and-cervical-cancer 2026-04-07 https://biopharmsignal.com/news/ARTL/artelo-biosciences-regains-compliance-with-nasdaq-listing-requirements 2026-04-07 https://biopharmsignal.com/news/PSTV/plus-therapeutics-receives-ama-pla-code-for-cnsider-csf-tumor-cell-enumeration-test-advancing-reimbursement-and-u-s-commercial-adoption 2026-04-07 https://biopharmsignal.com/news/NGEN/nervgen-pharma-announces-successful-end-of-phase-2-meeting-and-fda-alignment-on--d3dbaa9e 2026-04-07 https://biopharmsignal.com/news/CRVO/cervomed-to-provide-neflamapimod-clinical-program-update-and-participate-in-a-pa-a8806faf 2026-04-07 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-to-present-at-needham-virtual-healthcare-conference-e21afa61 2026-04-07 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-investigator-sponsored-study-to-be-conducted-by-university-of-arizona-cancer-center 2026-04-07 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conference 2026-04-07 https://biopharmsignal.com/news/MDWD/mediwound-to-present-new-escharex-data-at-leading-wound-care-conferences-cb7e751c 2026-04-07 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-scientific-advisory-board-meeting-and-urcosimod-data-prese-b3d3a59e 2026-04-07 https://biopharmsignal.com/news/ACIU/ac-immune-announces-amendment-to-morphomer-tau-license-and-collaboration-agreeme-34a5cf21 2026-04-07 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-announces-private-placement-for-up-to-24-million-led-by-perceptive-advisors 2026-04-07 https://biopharmsignal.com/news/STIM/neuronetics-comments-on-letter-from-pointillist-family-office 2026-04-07 https://biopharmsignal.com/news/PLSE/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulsetm-cardiac-catheter-system-for-atrial-fibrillation 2026-04-07 https://biopharmsignal.com/news/AORT/artivion-announces-u-s-fda-approval-of-the-nexusr-aortic-arch-system 2026-04-07 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-zelicapavir-an-oral-once-daily-n-protein-inhibitor-in-development-for-the-treatment-of-respiratory-syncytial-virus-at-escmid-global-2026 2026-04-07 https://biopharmsignal.com/news/BRKR/bruker-invests-in-photothermal-afm-ir-to-advance-semiconductor-research 2026-04-07 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-publication-of-new-day-clinical-trial-results-in-o-3fc12e4b 2026-04-07 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-inc-announces-completion-of-624-patient-enrollments-in-symon-ii-pivotal-clinical-trial 2026-04-07 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-on-patent-claims-potentially-doubling-gp2-market-potential 2026-04-07 https://biopharmsignal.com/news/OCS/oculis-to-participate-in-upcoming-investor-conferences 2026-04-07 https://biopharmsignal.com/news/ORGO/organogenesis-achieves-primary-endpoint-in-randomized-controlled-trial-of-puraplyram 2026-04-06 https://biopharmsignal.com/news/STIM/neuronetics-announces-chief-financial-officer-transition 2026-04-06 https://biopharmsignal.com/news/IMRX/immuneering-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-06 https://biopharmsignal.com/news/OM/outset-medical-names-derick-elliott-as-executive-vice-president-of-commercial 2026-04-06 https://biopharmsignal.com/news/MDRX/veradigm-appoints-christian-greyenbuhl-as-chief-financial-officer 2026-04-06 https://biopharmsignal.com/news/ASND/ascendis-receives-orphan-drug-exclusivity-and-launches-yuviwelr-navepegritide-in-the-united-states 2026-04-06 https://biopharmsignal.com/news/INGN/inogen-announces-the-appointment-of-vafa-jamali-to-board-of-directors 2026-04-06 https://biopharmsignal.com/news/BDSX/biodesix-announces-aacr-2026-posters-and-presentations-highlighting-novel-diagno-f2d569d5 2026-04-06 https://biopharmsignal.com/news/CLDX/celldex-therapeutics-announces-closing-of-public-offering-of-common-stock-and-fu-cfb60edf 2026-04-06 https://biopharmsignal.com/news/NRSN/neurosense-granted-brazilian-patent-covering-primec-composition 2026-04-06 https://biopharmsignal.com/news/SLRX/decoy-therapeutics-to-participate-in-virtual-investor-closing-bell-event-highlighting-business-outlook-for-2026 2026-04-06 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-type-c-fda-meeting-to-discuss-single-arm-registrati-546e0240 2026-04-06 https://biopharmsignal.com/news/DCTH/delcath-systems-inc-announces-inclusion-of-chemosat-hepatic-delivery-system-for-melphalan-as-a-recommended-liver-directed-regional-therapy-option-in-the-esmo-euracan-clinical-practice-guidelines-for-uveal-melanoma 2026-04-06 https://biopharmsignal.com/news/STXS/stereotaxis-announces-fda-clearance-and-launch-of-synchrony-system-1b2706e5 2026-04-06 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference 2026-04-06 https://biopharmsignal.com/news/AVAH/aveanna-healthcare-announces-second-annual-aveanna-cares-month-of-service 2026-04-06 https://biopharmsignal.com/news/GERN/geron-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference-dfa04f68 2026-04-06 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-announces-positive-results-from-the-embrave-part-a-trial-of-elsunersen-in-patients-with-scn2a-early-onset-developmental-and-epileptic-encephalopathy 2026-04-06 https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2026-financial-results-on-may-7-2026 2026-04-06 https://biopharmsignal.com/news/IBRX/immunitybio-addresses-fda-correspondence-and-reaffirms-commitment-to-advertising-compliance 2026-04-06 https://biopharmsignal.com/news/BCRX/biocryst-appoints-sandeep-m-menon-chief-research-and-development-officer 2026-04-06 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-to-participate-in-25th-annual-needham-virtual-healthcare-co-d4665cb1 2026-04-06 https://biopharmsignal.com/news/AGIO/agios-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-o-4094bb2a 2026-04-06 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-poster-and-oral-presentations-at-the-fueling-mash--98a40efa 2026-04-06 https://biopharmsignal.com/news/IMCR/immunocore-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-06 https://biopharmsignal.com/news/AIRS/correction-airsculpt-technologies-reports-fourth-quarter-and-full-year-fiscal-20-805a94bd 2026-04-06 https://biopharmsignal.com/news/INAB/in8bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 2026-04-03 https://biopharmsignal.com/news/DNLI/denali-therapeutics-regains-full-rights-to-investigational-therapy-dnl593-ptv-pg-bc822ac2 2026-04-03 https://biopharmsignal.com/news/NRSN/neurosense-therapeutics-announces-receipt-of-nasdaq-notifications-regarding-minimum-bid-price-and-market-value-requirements 2026-04-03 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-changes-to-board-of-directors-dcef4596 2026-04-03 https://biopharmsignal.com/news/INKT/mink-therapeutics-and-memorial-sloan-kettering-to-present-phase-ii-study-of-agen-3001ab68 2026-04-03 https://biopharmsignal.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-2026-results-on-april-30-2026-1af622dd 2026-04-02 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-announces-management-team-changes 2026-04-02 https://biopharmsignal.com/news/REGN/regeneron-collaborates-with-trinetx-to-access-de-identified-electronic-health-records-of-300-million-patients-to-drive-research-and-product-development-in-life-sciences-and-digital-health-solutions 2026-04-02 https://biopharmsignal.com/news/RXST/rxsight-inc-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference 2026-04-02 https://biopharmsignal.com/news/NERV/minerva-announces-leadership-transition 2026-04-02 https://biopharmsignal.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4 2026-04-02 https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-present-initial-clinical-data-on-zovegalisib-in-vascular-a-5eb3b24e 2026-04-02 https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-04-02 https://biopharmsignal.com/news/XCUR/summary-notice-of-pendency-and-proposed-settlement-of-stockholder-derivative-act-c6597e3a 2026-04-02 https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-04-02 https://biopharmsignal.com/news/ESPR/esperion-therapeutics-closes-acquisition-of-corstasis-therapeutics-expanding-its-cardiovascular-franchise-with-enbumysttm-bumetanide-nasal-spray 2026-04-02 https://biopharmsignal.com/news/MDWD/mediwound-reports-barda-contract-award-to-vericel-for-nexobrid-valued-at-up-to-1-08d73638 2026-04-02 https://biopharmsignal.com/news/VCEL/vericel-announces-barda-award-valued-at-up-to-197-million-for-procurement-and-ad-adaf00c4 2026-04-02 https://biopharmsignal.com/news/PRTC/deupirfenidone-compared-with-pirfenidone-and-placebo-in-idiopathic-pulmonary-fibrosis-elevate-ipf-a-phase-2b-randomized-placebo-controlled-trial 2026-04-02 https://biopharmsignal.com/news/GNFT/genfit-reports-full-year-2025-financial-results-and-provides-corporate-update 2026-04-02 https://biopharmsignal.com/news/BCDA/biocardia-files-request-for-meeting-with-fda-to-discuss-accelerated-approval-pat-a1c49c28 2026-04-02 https://biopharmsignal.com/news/MDXG/mimedx-to-sponsor-leading-advanced-wound-care-conferences 2026-04-02 https://biopharmsignal.com/news/SLRX/decoy-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement 2026-04-02 https://biopharmsignal.com/news/ENTX/entera-bio-announces-pricing-of-10-0-million-direct-investment-by-bvf-partners-w-299951f5 2026-04-02 https://biopharmsignal.com/news/RARE/ultragenyx-announces-u-s-fda-acceptance-of-bla-resubmission-for-ux111-aav-gene-t-ff2a0690 2026-04-02 https://biopharmsignal.com/news/BDRX/biodexa-announces-partnership-with-syngene-to-manufacture-mtx240-gmp-clinical-tr-78ff98e8 2026-04-02 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-completes-clinical-cut-off-study-advances-fda-510-k-cl-f7b59300 2026-04-02 https://biopharmsignal.com/news/DRMA/dermata-receives-notice-of-acceptance-of-australian-patent-application-for-topical-application-of-dermal-fillers-with-its-bioneedle-delivery-system 2026-04-02 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-new-qualified-treatment-center-for-zevaskynr-in-new-york 2026-04-02 https://biopharmsignal.com/news/HRMY/harmony-biosciences-strengthens-executive-team-with-new-appointment-and-announces-additions-to-its-board 2026-04-02 https://biopharmsignal.com/news/COCP/cocrystal-pharma-receives-fda-fast-track-designation-for-cdi-988-for-norovirus-i-185fbcc5 2026-04-02 https://biopharmsignal.com/news/LPCN/lipocine-reports-topline-safety-and-efficacy-results-for-lpcn-1154-in-patients-with-postpartum-depression 2026-04-02 https://biopharmsignal.com/news/LFVN/lifevantage-announces-expansion-of-its-european-footprint-with-market-opening-in-portugal 2026-04-02 https://biopharmsignal.com/news/BNGO/bionano-announces-publication-from-johns-hopkins-and-md-anderson-showing-that-ogm-can-outperform-traditional-methods-in-analysis-of-multiple-myeloma 2026-04-02 https://biopharmsignal.com/news/EBS/emergent-biosolutions-participates-in-upcoming-international-preparedness-conferences 2026-04-02 https://biopharmsignal.com/news/PSTV/plus-therapeutics-secures-highmark-coverage-for-cnsider-csf-assay-expanding-reimbursement-to-75-million-covered-lives 2026-04-02 https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-ctim-76-receives-fda-fast-track-designation-for-the-treatment-of-platinum-resistant-ovarian-cancer 2026-04-02 https://biopharmsignal.com/news/ANVS/annovis-secures-u-s-patent-for-buntanetap-in-the-prevention-and-treatment-of-neu-40142f7e 2026-04-02 https://biopharmsignal.com/news/INKT/mink-therapeutics-to-present-new-data-at-asgct-2026-highlighting-context-depende-d71f9857 2026-04-02 https://biopharmsignal.com/news/SNGX/positive-clinical-results-from-hybrytetm-comparative-study-evaluating-hybrytetm-against-valchlorr-in-the-treatment-of-cutaneous-t-cell-lymphoma-published-in-oncology-and-therapy 2026-04-02 https://biopharmsignal.com/news/IPHA/innate-pharma-to-participate-in-the-kempen-life-sciences-conference 2026-04-02 https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-participate-in-upcoming-investor-conferences-64fada5b 2026-04-02 https://biopharmsignal.com/news/PRTC/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine 2026-04-02 https://biopharmsignal.com/news/PHVS/pharvaris-reports-fourth-quarter-and-full-year-2025-financial-results-and-provid-1c5c0c5a 2026-04-02 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-reports-fourth-quarter-and-full-year-fiscal-2025-results-7310ddce 2026-04-02 https://biopharmsignal.com/news/ANGO/angiodynamics-reports-fiscal-year-2026-third-quarter-financial-results-sustained-double-digit-med-tech-growth-drives-continued-profitability 2026-04-02 https://biopharmsignal.com/news/ROIV/priovant-expands-brepocitinib-development-program-with-new-phase-2b-3-trial-in-lichen-planopilaris-lpp 2026-04-02 https://biopharmsignal.com/news/ROIV/roivant-announces-expansion-of-brepocitinib-development-program-with-new-phase-2b-3-trial-in-lichen-planopilaris-lpp-and-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted 2026-04-02 https://biopharmsignal.com/news/IMVT/immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted 2026-04-02 https://biopharmsignal.com/news/IPHA/innate-pharma-files-its-2025-universal-registration-document-document-d-enregistrement-universel-and-2025-form-20-f-annual-report 2026-04-02 https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-announces-positive-proof-of-concept-topline-results-from-ongoing-phase-1-trial-of-glyphagotm-in-healthy-volunteers 2026-04-02 https://biopharmsignal.com/news/CLDX/celldex-announces-pricing-of-300-million-public-offering-of-common-stock-b1e77e27 2026-04-02 https://biopharmsignal.com/news/BEAM/beam-therapeutics-announces-publication-of-beacon-phase-1-2-data-for-risto-cel-in-patients-with-sickle-cell-disease-scd-in-the-new-england-journal-of-medicine 2026-04-01 https://biopharmsignal.com/news/PNTG/pennant-acquires-arbor-rose-senior-living-community-in-mesa-arizona 2026-04-01 https://biopharmsignal.com/news/SGHT/sight-sciences-interventional-technologies-for-glaucoma-and-dry-eye-disease-to-be-featured-in-multiple-clinical-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-ascrs-annual-meeting 2026-04-01 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-appoints-biopharmaceutical-leader-philip-vickers-ph-d-to-its-7834c1fd 2026-04-01 https://biopharmsignal.com/news/CLDX/celldex-announces-proposed-public-offering-of-common-stock-abaa02c1 2026-04-01 https://biopharmsignal.com/news/PSNL/personalis-to-participate-in-the-25th-annual-needham-virtual-conference 2026-04-01 https://biopharmsignal.com/news/RNXT/renovorx-named-to-fast-company-s-annual-list-of-the-world-s-most-innovative-companies-of-2026 2026-04-01 https://biopharmsignal.com/news/PGNY/progyny-commemorates-10-years-of-redefining-women-s-health-and-family-building-care 2026-04-01 https://biopharmsignal.com/news/MMSI/merit-medical-acquires-view-point-medical-inc-expanding-the-merit-therapeutic-on-b7f47047 2026-04-01 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-completes-domicile-change-to-the-united-states-ff8a9f89 2026-04-01 https://biopharmsignal.com/news/FEMY/femasys-appoints-john-canning-as-chief-operating-officer-to-drive-operational-ex-b153503b 2026-04-01 https://biopharmsignal.com/news/NEPH/nephros-expands-water-safety-capabilities-with-asse-12080-certified-water-manage-89c54891 2026-04-01 https://biopharmsignal.com/news/XAIR/beyond-air-expands-commercial-access-for-lungfit-ph-through-a-purchasing-agreeme-4896b511 2026-04-01 https://biopharmsignal.com/news/SNTI/senti-biosciences-announces-publication-in-cell-systems-demonstrating-advanced-l-1e4b43e3 2026-04-01 https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-closing-of-oversubscribed-30-million-private-placement 2026-04-01 https://biopharmsignal.com/news/CLOV/clover-health-announces-departure-of-chief-financial-officer-and-appointment-of-interim-chief-financial-officer-reiterates-most-recently-issued-financial-guidance-for-full-fiscal-year-2026 2026-04-01 https://biopharmsignal.com/news/DCTH/delcath-systems-to-participate-at-the-society-of-interventional-radiology-2026-meeting 2026-04-01 https://biopharmsignal.com/news/ARDX/rajani-dinavahi-md-appointed-chief-medical-officer-of-ardelyx-bdc09533 2026-04-01 https://biopharmsignal.com/news/ALHC/alignment-healthcare-to-present-at-the-bofa-securities-health-care-conference-2026 2026-04-01 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-submission-of-new-drug-application-for-bezuclastinib-in-gastrointestinal-stromal-tumors-gist 2026-04-01 https://biopharmsignal.com/news/ECOR/electrocore-announces-publication-in-frontiers-in-neuroscience-highlighting-bene-bbe6b428 2026-04-01 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-cypathr-lung-test-unit-sales-surged-146-year-over-year-in-q1-2026 2026-04-01 https://biopharmsignal.com/news/SYK/stryker-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2026 2026-04-01 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-participation-at-2026-academy-of-managed-care-pharmacy-amcp-conference-to-begin-shaping-access-in-us-for-potential-neuromuscular-medicines 2026-04-01 https://biopharmsignal.com/news/INKT/mink-therapeutics-announces-abstract-acceptance-for-presentation-at-the-american-52dec2b7 2026-04-01 https://biopharmsignal.com/news/CYCN/cyclerion-therapeutics-and-korsana-biosciences-announce-merger-agreement 2026-04-01 https://biopharmsignal.com/news/HLF/herbalife-to-announce-first-quarter-2026-results-on-may-6 2026-04-01 https://biopharmsignal.com/news/USNA/usana-ceo-kevin-guest-calls-for-daily-health-routines-on-world-health-day 2026-04-01 https://biopharmsignal.com/news/OCGN/ocugen-announces-early-completion-of-dosing-in-phase-2-3-pivotal-confirmatory-tr-691bb87b 2026-04-01 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-grant-of-fast-track-designation-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1-associated-plexiform-neurofibromas-pn-causing-significant-morbidity 2026-04-01 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-food-and-drug-administration-acceptance-of-supplemental-new-drug-application-for-use-of-igalmir-in-the-at-home-setting 2026-04-01 https://biopharmsignal.com/news/TLSA/tiziana-announces-data-showing-nasal-anti-cd3-improves-cognition-associated-with-f076e0e2 2026-04-01 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-present-additional-sol-1-data-and-analyses-at-upcoming-sci-fe14f158 2026-04-01 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-acquires-selective-pde10a-inhibitor-balipodect-for-the-treat-eff2a435 2026-04-01 https://biopharmsignal.com/news/ALKS/alkermes-announces-initiation-of-phase-3-brilliance-studies-evaluating-alixorexton-for-the-treatment-of-narcolepsy-type-1-and-type-2 2026-04-01 https://biopharmsignal.com/news/BRKR/bruker-announces-appointment-of-thierry-bernard-to-its-board-of-directors 2026-04-01 https://biopharmsignal.com/news/APTO/aptose-biosciences-announces-results-of-special-shareholders-meeting-announces-receipt-of-final-court-approval-of-plan-of-arrangement-reports-year-end-2025-results-and-corporate-highlights 2026-03-31 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-announces-fourth-quarter-and-fiscal-year-2025-earnings-re-4b72bffb 2026-03-31 https://biopharmsignal.com/news/HCWB/hcw-biologics-reports-fourth-quarter-2025-and-fiscal-year-2025-business-highligh-5b2d42fc 2026-03-31 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-ceo-issues-letter-to-shareholders-47afd97a 2026-03-31 https://biopharmsignal.com/news/GOCO/gohealth-prioritizes-consumer-fit-renewal-economics-and-cash-discipline-while-co-2b57e179 2026-03-31 https://biopharmsignal.com/news/NXGL/nexgel-reschedules-2025-financial-results-conference-call-to-april-8th-at-4-30-p-m-et-to-provide-shareholders-with-an-update-on-its-previously-announced-transaction-with-celularity 2026-03-31 https://biopharmsignal.com/news/BCAB/bioatla-announces-share-consolidation-87cc80c0 2026-03-31 https://biopharmsignal.com/news/MXCT/maxcyte-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-03-31 https://biopharmsignal.com/news/NERV/minerva-neurosciences-announces-first-patient-screened-in-global-phase-3-confirmatory-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia 2026-03-31 https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-disease-profile 2026-03-31 https://biopharmsignal.com/news/BSEM/biostem-technologies-to-present-at-the-25th-annual-needham-virtual-healthcare-co-c43558b0 2026-03-31 https://biopharmsignal.com/news/FEMY/femasys-announces-financial-results-for-year-ended-december-31-2025-and-provides-6bc5d9e1 2026-03-31 https://biopharmsignal.com/news/NXTC/nextcure-and-simcere-s-sim0505-cdh6-adc-abstract-accepted-for-asco-2026-4110bd75 2026-03-31 https://biopharmsignal.com/news/BCTX/briacell-and-briapro-announce-closing-of-asset-purchase-transaction-for-exclusiv-ecfa180f 2026-03-31 https://biopharmsignal.com/news/BCAB/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-12e923ba 2026-03-31 https://biopharmsignal.com/news/FBIO/fortress-biotech-reports-2025-financial-results-and-recent-corporate-highlights 2026-03-31 https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-full-year-2025-financial-results-and-provides-corporate-update 2026-03-31 https://biopharmsignal.com/news/ARQT/arcutis-management-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-03-31 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-files-2025-annual-report-on-form-10k-provides-operational-highlights-of-transformative-year 2026-03-31 https://biopharmsignal.com/news/BRKR/preomics-gmbh-and-biognosys-ag-prevail-in-u-s-patent-challenge 2026-03-31 https://biopharmsignal.com/news/NRSN/neurosense-therapeutics-reports-year-end-2025-financial-results-and-provides-business-update 2026-03-31 https://biopharmsignal.com/news/DRTS/alpha-tau-announces-first-ever-oral-presentation-of-alpha-dart-pancreatic-cancer-766eb303 2026-03-31 https://biopharmsignal.com/news/MKT/maia-biotechnology-reports-overall-survival-exceeding-two-years-for-eight-patients-in-ongoing-phase-2-clinical-trial-in-non-small-cell-lung-cancer 2026-03-31 https://biopharmsignal.com/news/INDV/new-cost-impact-model-highlights-potential-for-monthly-injectable-buprenorphine--7a0e3a57 2026-03-31 https://biopharmsignal.com/news/AVCO/avalon-quantum-ai-announces-strategic-collaboration-with-caylent-an-amazon-web-services-premier-tier-partner-to-advance-its-catch-up-product-into-a-fully-autonomous-agentic-ai-video-platform 2026-03-31 https://biopharmsignal.com/news/TARS/tarsus-doses-first-participant-in-calliope-a-phase-2-clinical-trial-of-tp-05-lotilaner-a-novel-investigational-oral-tablet-for-the-potential-prevention-of-lyme-disease 2026-03-31 https://biopharmsignal.com/news/PYPD/polypid-initiates-d-plex-nda-submission-to-the-fda 2026-03-31 https://biopharmsignal.com/news/INGN/inogen-announces-participation-in-the-25th-annual-needham-virtual-healthcare-conference 2026-03-31 https://biopharmsignal.com/news/RIGL/rigel-announces-publication-of-final-arrow-clinical-trial-data-on-gavretor-pralsetinib-in-patients-with-ret-nsclc-in-the-journal-of-clinical-oncology 2026-03-31 https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-participate-in-25th-annual-needham-virtual-healthcare-conference 2026-03-31 https://biopharmsignal.com/news/CRBU/caribou-biosciences-announces-the-fda-granted-regenerative-medicine-advanced-therapy-rmat-designation-to-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy 2026-03-31 https://biopharmsignal.com/news/ESPR/esperion-to-participate-in-25th-annual-needham-virtual-healthcare-conference 2026-03-31 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-reports-full-year-2025-financial-results-and-corporate-pro-ab60929e 2026-03-31 https://biopharmsignal.com/news/IMNN/imunon-reports-2025-financial-results-and-provides-business-update-highlighting--537950a1 2026-03-31 https://biopharmsignal.com/news/COCP/cocrystal-pharma-reports-2025-financial-results-and-provides-updates-on-its-anti-781ead2c 2026-03-31 https://biopharmsignal.com/news/ECOR/electrocore-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-9e1c60e4 2026-03-31 https://biopharmsignal.com/news/GALT/galectin-therapeutics-reports-2025-financial-results-and-provides-business-updat-21c93220 2026-03-31 https://biopharmsignal.com/news/ANVS/annovis-publishes-historical-review-of-buntanetap-in-the-scientist-2544bb35 2026-03-31 https://biopharmsignal.com/news/BLTE/belite-bio-announces-availability-of-annual-report-on-form-20-f-through-company--9dcb57e9 2026-03-31 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-announces-that-cardamysttm-etripamil-nasal-spray-is-available-on-express-scripts-commercial-national-formularies 2026-03-31 https://biopharmsignal.com/news/ANGO/angiodynamics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference 2026-03-31 https://biopharmsignal.com/news/SYK/stryker-names-nick-mead-vice-president-investor-relations 2026-03-31 https://biopharmsignal.com/news/NGEN/nervgen-pharma-reports-full-year-2025-financial-results-and-provides-business-up-0c8fb69d 2026-03-31 https://biopharmsignal.com/news/VRAX/virax-biolabs-achieves-iso-certifications-laying-foundation-for-regulated-ivd-development-and-u-s-clinical-validation 2026-03-31 https://biopharmsignal.com/news/INKT/mink-therapeutics-reports-q4-and-full-year-2025-results-phase-2-programs-advance-f81fd512 2026-03-31 https://biopharmsignal.com/news/IFRX/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-sym-6d37adbe 2026-03-31 https://biopharmsignal.com/news/IBRX/immunitybio-strengthens-balance-sheet-with-100-million-of-financing-transactions-including-75-million-of-non-dilutive-financing-to-support-global-expansion-and-advancement-of-broader-immunotherapy-pipeline 2026-03-31 https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2025-financial-results 2026-03-31 https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-first-patient-dosed-in-newly-initiated-phase-ii-programs-enrolling-type-2-diabetes-patients-failing-on-standard-of-care-therapies 2026-03-31 https://biopharmsignal.com/news/AGIO/agios-advances-mitapivat-toward-potential-u-s-accelerated-approval-in-sickle-cel-23b9b933 2026-03-31 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-full-year-2025-fina-403f36a2 2026-03-31 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-of-phase-1-data-and-outlines-planned-adaptive-phase-2-field-study-of-tnx-4800-for-the-prevention-of-lyme-disease-at-the-world-vaccine-congress-washington-2026 2026-03-31 https://biopharmsignal.com/news/XTNT/xtant-medical-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-31 https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-initiation-of-phase-2-investigator-initiated-clinical-trial-of-epetraborole-for-mycobacterium-abscessus-complex-lung-disease 2026-03-31 https://biopharmsignal.com/news/SRRK/scholar-rock-resubmits-biologics-license-application-bla-to-fda-for-apitegromab-for-treatment-of-children-and-adults-with-spinal-muscular-atrophy-sma 2026-03-31 https://biopharmsignal.com/news/APLS/biogen-to-acquire-apellis-enhancing-the-company-s-growth-portfolio-in-immunology-and-rare-disease-bolstering-growth-outlook-and-accelerating-expansion-into-nephrology 2026-03-31 https://biopharmsignal.com/news/BIIB/biogen-to-acquire-apellis-enhancing-the-company-s-growth-portfolio-in-immunology-cfb7001f 2026-03-31 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-evolves-and-expands-standing-in-the-gaap-to-advance-more-equitable-care-in-multiple-myeloma-as-program-marks-ten-years 2026-03-31 https://biopharmsignal.com/news/SCYX/scynexis-announces-40-0-million-private-placement 2026-03-31 https://biopharmsignal.com/news/CNTA/lilly-to-acquire-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders 2026-03-31 https://biopharmsignal.com/news/SCYX/scynexis-completes-transformative-acquisition-of-pxl-770-an-innovative-highly-selective-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd 2026-03-31 https://biopharmsignal.com/news/LNSR/lensar-reports-fourth-quarter-and-full-year-2025-results-and-provides-business-u-37104083 2026-03-31 https://biopharmsignal.com/news/OCS/oculis-announces-european-medicines-agency-prime-designation-for-privosegtor-advancing-a-potential-first-in-class-neuroprotective-candidate-for-optic-neuritis 2026-03-31 https://biopharmsignal.com/news/PRI/primerica-household-budget-indextm-data-purchasing-power-for-middle-income-americans-remained-flat-in-february 2026-03-31 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-30 https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-closing-of-11-0-million-private-placement-priced-at-the-market-under-nasdaq-rules 2026-03-30 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-reports-full-year-2025-financial-results-and-provides-business-highlights 2026-03-30 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-a-0ea21023 2026-03-30 https://biopharmsignal.com/news/TDOC/teladoc-health-appoints-susan-salka-experienced-healthcare-executive-to-its-boar-e7867935 2026-03-30 https://biopharmsignal.com/news/HUM/humana-inc-to-release-first-quarter-2026-results-on-april-29-2026 2026-03-30 https://biopharmsignal.com/news/RBOT/vicarious-surgical-completes-integrated-benchtop-testing-of-full-surgical-instru-72be302b 2026-03-30 https://biopharmsignal.com/news/SGHT/sight-sciences-to-present-at-the-25th-annual-needham-healthcare-conference-on-april-13th 2026-03-30 https://biopharmsignal.com/news/NTRB/nutriband-selects-commercial-brand-name-for-its-abuse-deterrent-fentanyl-patch-08ec44c0 2026-03-30 https://biopharmsignal.com/news/RNXT/renovorx-reports-full-year-2025-financial-results-and-provides-business-update 2026-03-30 https://biopharmsignal.com/news/TXMD/therapeuticsmd-announces-full-year-2025-financial-results 2026-03-30 https://biopharmsignal.com/news/FBIO/fortress-biotech-s-subsidiary-cyprium-therapeutics-closes-sale-of-rare-pediatric-disease-priority-review-voucher-for-205-million 2026-03-30 https://biopharmsignal.com/news/INGN/inogen-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-03-30 https://biopharmsignal.com/news/PEPG/pepgen-announces-topline-results-from-lowest-dose-5-mg-kg-mad-cohort-in-the-ongoing-phase-2-freedom2-study-demonstrating-favorable-safety-splicing-and-vhot-data 2026-03-30 https://biopharmsignal.com/news/ANNX/annexon-reports-fourth-quarter-and-year-end-2025-financial-results-portfolio-progress-and-key-anticipated-milestones 2026-03-30 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-f-f8a0a29d 2026-03-30 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-relutrigine-in-patients-with-scn2a-and-scn8a-dees 2026-03-30 https://biopharmsignal.com/news/INMB/inmune-bio-inc-announces-2025-results-and-provides-business-update-21d6c684 2026-03-30 https://biopharmsignal.com/news/INGN/inogen-announces-leadership-appointments-designed-to-accelerate-next-phase-of-growth 2026-03-30 https://biopharmsignal.com/news/BBIO/acoramidis-significantly-reduces-the-risk-of-all-cause-and-cardiovascular-mortal-91a32d32 2026-03-30 https://biopharmsignal.com/news/TPST/tempest-reports-year-end-2025-financial-results-and-provides-business-update 2026-03-30 https://biopharmsignal.com/news/RARE/ultragenyx-announces-fda-clearance-of-investigational-new-drug-ind-application-f-a65939f0 2026-03-30 https://biopharmsignal.com/news/ICU/seastar-medical-showcases-new-positive-data-from-the-quelimmune-save-registry-an-5bfbec98 2026-03-30 https://biopharmsignal.com/news/IRTC/data-presented-at-acc-26-further-demonstrate-the-benefits-of-irhythm-s-zio-ambul-d88b36ca 2026-03-30 https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-oversubscribed-30-million-private-placement 2026-03-30 https://biopharmsignal.com/news/VOR/vor-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-f61df8af 2026-03-30 https://biopharmsignal.com/news/ESPR/esperion-showcases-new-data-from-clear-outcomes-highlighting-value-of-nexletolr-bempedoic-acid-at-the-american-college-of-cardiology-s-annual-scientific-session-2026 2026-03-30 https://biopharmsignal.com/news/APRE/aprea-therapeutics-highlights-positive-emerging-clinical-activity-for-wee1-inhibitor-apr-1051-with-a-confirmed-partial-response-in-the-ongoing-phase-1-acesot-1051-trial 2026-03-30 https://biopharmsignal.com/news/PCRX/pacira-biosciences-to-present-real-world-data-on-exparelr-showing-reduced-cost-of-care-at-orthopaedic-research-society-2026-annual-meeting 2026-03-30 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-reports-positive-phase-2-blinded-data-for-brtx-100-demo-8ebc58b1 2026-03-30 https://biopharmsignal.com/news/ECOR/electrocore-expands-intellectual-property-portfolio-a5e42668 2026-03-30 https://biopharmsignal.com/news/VOR/vor-bio-doses-first-patient-in-global-phase-3-upstream-sjd-registrational-trial--449907d9 2026-03-30 https://biopharmsignal.com/news/TEVA/teva-gains-biosimilar-momentum-with-u-s-fda-approval-of-ponlimsi-denosumab-adet--2411c1a4 2026-03-30 https://biopharmsignal.com/news/URGN/journal-of-urology-publishes-envision-trial-results-showing-72-2-24-month-duration-of-response-with-zusduri 2026-03-30 https://biopharmsignal.com/news/GSK/exdensur-depemokimab-approved-in-china-for-the-treatment-of-severe-asthma 2026-03-30 https://biopharmsignal.com/news/BSX/boston-scientific-announces-conference-call-discussing-first-quarter-2026-results 2026-03-30 https://biopharmsignal.com/news/BIIB/fda-approves-new-high-dose-regimen-of-spinraza-nusinersen-for-spinal-muscular-at-07069757 2026-03-30 https://biopharmsignal.com/news/BYSI/beyondspring-announces-plinabulin-and-adc-combination-poster-presentation-at-aac-c9a32e06 2026-03-30 https://biopharmsignal.com/news/IFRX/inflarx-highlights-clinical-activity-of-vilobelimab-in-pyoderma-gangrenosum-in-l-ca16c294 2026-03-30 https://biopharmsignal.com/news/BFRG/bullfrog-ai-announces-commercial-agreement-with-top-5-global-pharmaceutical-company-to-identify-and-prioritize-therapeutic-target-in-major-depressive-disorder 2026-03-30 https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-full-year-2025-financial-results-and-provides-corporate-update 2026-03-30 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-receives-positive-fda-feedback-following-type-c-meeting-on-ba1aae76 2026-03-30 https://biopharmsignal.com/news/SGHT/sight-sciences-secures-order-on-post-trial-motions-that-preserves-the-jury-s-verdict-and-awards-monetary-damages-to-sight-sciences-against-alcon-and-its-hydrusr-microstent 2026-03-30 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-announces-full-year-2025-financial-results-and-provides-business-update 2026-03-30 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-completion-of-type-a-meeting-with-fda-for-anaphylmtm-dibutepinephrine-sublingual-film 2026-03-30 https://biopharmsignal.com/news/SEER/patent-board-upholds-seer-s-nano-and-micro-particle-protein-enrichment-patent-in-a-challenge-by-bruker-subsidiaries 2026-03-30 https://biopharmsignal.com/news/BSEM/biostem-technologies-announces-the-publication-of-its-audited-financial-statemen-3bfc8c86 2026-03-30 https://biopharmsignal.com/news/PDSB/pds-biotech-reports-full-year-2025-financial-results-and-provides-update-on-pds0-393b6df6 2026-03-30 https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-announces-positive-interim-phase-3-data-from-konfident-kid-trial-of-ekterlyr-sebetralstat-for-children-aged-2-11-years-at-the-2026-global-angioedema-leadership-conference 2026-03-30 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai 2026-03-30 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-4cc402b7 2026-03-30 https://biopharmsignal.com/news/BSX/boston-scientific-receives-fda-clearance-for-the-asurystm-fluid-management-system 2026-03-30 https://biopharmsignal.com/news/RVPH/reviva-reports-full-year-2025-financial-results-and-recent-business-highlights-e3bf9f95 2026-03-30 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-enrollment-completion-of-bla-enabling-relapsed-refractory-al-amyloidosis-trial-nexicart-2-and-upcoming-milestones 2026-03-30 https://biopharmsignal.com/news/GSK/bepirovirsen-accepted-for-regulatory-review-in-china-as-a-potential-first-in-class-functional-cure-for-chronic-hepatitis-b 2026-03-30 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-positive-results-from-phase-3-scout-hcm-trial-demonstrating-efficacy-and-safety-of-camzyos-mavacamten-in-adolescents-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-ohcm 2026-03-29 https://biopharmsignal.com/news/MLTX/moonlake-announces-week-40-results-from-its-phase-3-clinical-trials-of-sonelokimab-in-hidradenitis-suppurativa-at-the-2026-aad-annual-meeting 2026-03-28 https://biopharmsignal.com/news/ROIV/new-england-journal-of-medicine-publishes-positive-phase-3-valor-trial-results-of-brepocitinib-in-dermatomyositis 2026-03-28 https://biopharmsignal.com/news/BIIB/biogen-announces-second-positive-phase-2-litifilimab-trial-in-cutaneous-lupus-er-474154eb 2026-03-28 https://biopharmsignal.com/news/CORT/corcept-presents-data-from-momentum-trial-at-american-college-of-cardiology-annual-scientific-session 2026-03-28 https://biopharmsignal.com/news/NKTR/data-from-phase-2b-rezolve-ad-and-rezolve-aa-studies-of-rezpegaldesleukin-presented-at-2026-american-academy-of-dermatology-annual-meeting 2026-03-28 https://biopharmsignal.com/news/ARQT/arcutis-presents-new-phase-2-results-in-infants-with-atopic-dermatitis-in-late-breaking-session-today-at-the-2026-american-academy-of-dermatology-annual-meeting 2026-03-28 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-presents-kt-621-broaden-data-in-late-breaking-research-sessi-1171d406 2026-03-28 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-long-term-efficacy-and-safety-data-for-plozasiran-across-a-spectrum-of-hypertriglyceridemia-at-the-american-college-of-cardiology-s-75th-annual-scientific-session-and-expo 2026-03-28 https://biopharmsignal.com/news/BMY/open-label-outpatient-switch-study-demonstrates-symptom-stability-during-transition-from-oral-atypical-antipsychotics-to-cobenfytm-xanomeline-and-trospium-chloride 2026-03-28 https://biopharmsignal.com/news/BDRX/preliminary-results-for-the-year-ended-31-december-2025-78910bdd 2026-03-27 https://biopharmsignal.com/news/INTS/intensity-therapeutics-reports-2025-year-end-financial-results-and-highlights-and-provides-corporate-update 2026-03-27 https://biopharmsignal.com/news/CUE/cue-biopharma-announces-ceo-transition-95b92679 2026-03-27 https://biopharmsignal.com/news/MNPR/monopar-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-27 https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-11-0-million-private-placement-priced-at-the-market-under-nasdaq-rules 2026-03-27 https://biopharmsignal.com/news/CLDX/celldex-presents-positive-data-from-phase-2-chronic-spontaneous-urticaria-and-ph-1f183b60 2026-03-27 https://biopharmsignal.com/news/ACRS/results-presented-at-2026-american-academy-of-dermatology-aad-annual-meeting-pro-52ba78c0 2026-03-27 https://biopharmsignal.com/news/ANAB/first-tracks-biotherapeutics-the-planned-spin-off-of-anaptys-secures-commitments-of-145-million-in-private-placement 2026-03-27 https://biopharmsignal.com/news/ANAB/anaptys-board-of-directors-approves-spin-off-of-first-tracks-biotherapeutics 2026-03-27 https://biopharmsignal.com/news/ANAB/anaptys-announces-100-million-stock-repurchase-plan-and-provides-a-business-update 2026-03-27 https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-to-report-combination-dose-optimization-data-from-phase-1b-trial-of-rinzimetostat-in-patients-with-mcrpc 2026-03-27 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-receives-fda-approval-to-remove-age-requirement-from-neffy-1-dfc8802a 2026-03-27 https://biopharmsignal.com/news/IXHL/incannex-reactivates-share-repurchase-program-underscoring-confidence-in-valuati-90c33c16 2026-03-27 https://biopharmsignal.com/news/SNTI/senti-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provid-925a7185 2026-03-27 https://biopharmsignal.com/news/VOR/vor-bio-announces-75-million-private-placement-with-tcgx-b355062e 2026-03-27 https://biopharmsignal.com/news/GSK/bepirovirsen-accepted-for-review-by-the-european-medicines-agency-as-a-potential-first-in-class-treatment-for-chronic-hepatitis-b 2026-03-27 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-as-company-prepares-for-potential-igalmir-approval-in-outpatient-setting 2026-03-27 https://biopharmsignal.com/news/ADMA/adma-biologics-issues-statement-refuting-unsubstantiated-misleading-and-inaccurate-allegations-by-culper-research 2026-03-27 https://biopharmsignal.com/news/TIL/instil-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update 2026-03-27 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-result-3abf4980 2026-03-27 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-56772ec1 2026-03-27 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-de-87e56c4d 2026-03-27 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-fda-approval-of-kresladitm-for-pediatric-patients-with-severe-leukocyte-adhesion-deficiency-i-lad-i 2026-03-27 https://biopharmsignal.com/news/HUMA/humacyte-announces-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update 2026-03-27 https://biopharmsignal.com/news/GNTA/genenta-evolving-into-saentra-forge-has-signed-a-binding-offer-with-sophia-high-tech-an-italian-company-manufacturing-critical-parts-for-europe-s-space-and-defense-programs 2026-03-27 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-solicita-autoriza-o-de-comercializa-o-de-palsonify-pal-f9db26ae 2026-03-27 https://biopharmsignal.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-financial-results-for-the-year-ended-2025 2026-03-26 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2025-operating-results-4567c75f 2026-03-26 https://biopharmsignal.com/news/IRON/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria 2026-03-26 https://biopharmsignal.com/news/MD/pediatrix-expands-maternal-health-services-in-tennessee-in-partnership-with-tennessee-maternal-fetal-medicine 2026-03-26 https://biopharmsignal.com/news/VANI/vivani-medical-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-26 https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-provides-corporate-update 2026-03-26 https://biopharmsignal.com/news/XAIR/beyond-air-inc-announces-resignation-of-steve-lisi-ceo-and-appointment-of-robert-c0ba66db 2026-03-26 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-reports-full-year-2025-financial-results-and-operationa-aa87914d 2026-03-26 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-announces-submission-of-marketing-authorization-applic-307151b9 2026-03-26 https://biopharmsignal.com/news/IRIX/iridex-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-26 https://biopharmsignal.com/news/PIII/p3-health-partners-announces-fourth-quarter-and-full-year-2025-results 2026-03-26 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-provides-business-update-and-reports-fourth-quarter-and-ful-2061c4ed 2026-03-26 https://biopharmsignal.com/news/APGE/apogee-therapeutics-inc-announces-closing-of-public-offering-and-full-exercise-o-d67d8ba1 2026-03-26 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-full-year-2025-financial-results-and-highlights-recent-activity 2026-03-26 https://biopharmsignal.com/news/ENLV/enlivex-rain-update-rain-launches-an-openclaw-and-ai-agent-interface-allowing-an-db8373a7 2026-03-26 https://biopharmsignal.com/news/HSTM/virsys12r-named-a-leader-in-the-idc-marketscape-u-s-provider-data-management-for-payers-2025-2026-vendor-assessment 2026-03-26 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-receives-positive-chmp-opinion-for-imcivree-setmelanotide-e1f70cad 2026-03-26 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-reports-that-supported-professional-practices-have-achieved-i-aa4f68b4 2026-03-26 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-strengthens-european-ip-portfolio-with-eighth-patent-g-a18729f9 2026-03-26 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-reports-fourth-quarter-and-f-ff2df2d9 2026-03-26 https://biopharmsignal.com/news/RNXT/renovorx-announces-key-phase-iii-milestone-tiger-pac-trial-surpasses-100-randomized-patients-as-study-nears-completion-of-enrollment 2026-03-26 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-announces-publication-in-nicotine-and-tobacco-research-linking-cytisinicline-s-receptor-selectivity-to-low-nausea-rates-and-favorable-tolerability 2026-03-26 https://biopharmsignal.com/news/APVO/aptevo-provides-state-of-the-business-report-and-2025-financial-results 2026-03-26 https://biopharmsignal.com/news/MGTX/meiragtx-announces-fda-breakthrough-therapy-designation-for-aav2-haqp1-for-the-treatment-of-grade-2-and-grade-3-radiation-induced-xerostomia-rix-and-reports-fourth-quarter-and-full-year-2025-financial-and-operational-results 2026-03-26 https://biopharmsignal.com/news/CUE/cue-biopharma-to-host-virtual-r-d-day-event-on-april-7-2026-6693a4ed 2026-03-26 https://biopharmsignal.com/news/GERN/geron-announces-appointment-of-new-members-to-its-board-of-directors-4cb4fa7e 2026-03-26 https://biopharmsignal.com/news/PULM/pulmatrix-and-eos-senolytix-announce-merger-agreement-to-advance-novel-mitochondrial-therapies-to-improve-healthspan 2026-03-26 https://biopharmsignal.com/news/ALZN/alzamend-neuro-reports-positive-topline-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-al001-achieves-bioequivalence-and-demonstrates-superior-brain-delivery-across-all-measured-brain-regions 2026-03-26 https://biopharmsignal.com/news/ICCM/icecure-announces-pricing-of-4-0-million-registered-direct-offering-and-concurrent-private-placement 2026-03-26 https://biopharmsignal.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-26 https://biopharmsignal.com/news/HUMA/humacyte-appoints-rick-mcelheny-as-senior-vice-president-of-business-development 2026-03-26 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-reports-year-end-2025-financial-results-and-provides-clin-85443563 2026-03-26 https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-positive-interim-phase-1-data-from-inlight-further--8d9b1fdc 2026-03-26 https://biopharmsignal.com/news/IBRX/immunitybio-confirms-statistical-power-in-pivotal-randomized-bcg-naive-nmibc-trial-to-detect-clinically-meaningful-differences-between-anktivar-plus-bcg-versus-bcg-alone-supplemental-bla-submission-on-track-for-2026 2026-03-26 https://biopharmsignal.com/news/SNGX/soligenix-receives-orphan-drug-designation-from-the-european-commission-for-sgx945-for-the-treatment-of-behcet-s-disease 2026-03-26 https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-completion-of-enrollment-in-phase-3-vanquish-2-trial-of-vk2735 2026-03-26 https://biopharmsignal.com/news/GANX/gain-therapeutics-reports-financial-results-for-the-fourth-quarter-and-year-end--6366d091 2026-03-26 https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-completion-of-sale-of-oncology-assets-to-neotrail-thera-ff442692 2026-03-26 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-reports-financial-results-for-the-year-ended-december-31--36fef2e7 2026-03-26 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-first-participant-dosed-in-phase-1-investigator-initiated-pharmacodynamic-study-of-tnx-1900-intranasal-potentiated-oxytocin-to-assess-potential-for-treating-migraine-and-craniofacial-pain 2026-03-26 https://biopharmsignal.com/news/HLF/herbalife-to-expand-its-personalized-nutritional-supplement-capabilities-through-planned-acquisition-of-bioniq 2026-03-26 https://biopharmsignal.com/news/OGEN/oragenics-inc-receives-audit-opinion-with-going-concern-explanation 2026-03-25 https://biopharmsignal.com/news/RANI/rani-therapeutics-appoints-jesper-hoiland-as-head-of-strategy-to-advance-corporate-and-pipeline-prioritization 2026-03-25 https://biopharmsignal.com/news/BYSI/beyondspring-files-2025-annual-report-on-form-10-k-42bd97d0 2026-03-25 https://biopharmsignal.com/news/XCUR/exicure-inc-reports-full-year-2025-financial-results-04ba3dd4 2026-03-25 https://biopharmsignal.com/news/RBOT/vicarious-surgical-begins-quotation-on-the-otcqb-as-part-of-strategic-path-towar-43dfb064 2026-03-25 https://biopharmsignal.com/news/NERV/minerva-neurosciences-presents-data-from-its-open-label-safety-trial-evaluating-roluperidone-co-administered-with-olanzapine-at-sirs-2026 2026-03-25 https://biopharmsignal.com/news/EQ/equillium-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-7d8a6302 2026-03-25 https://biopharmsignal.com/news/LGMK/logicmark-inc-announces-strong-fourth-quarter-and-full-year-2025-results-044c1451 2026-03-25 https://biopharmsignal.com/news/ICU/seastar-medical-reports-fourth-quarter-and-full-year-2025-financial-results-and--bcc74b48 2026-03-25 https://biopharmsignal.com/news/ARTL/artelo-biosciences-expands-art27-13-development-as-a-potential-companion-therapy-to-glp-1-treatments 2026-03-25 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-closing-of-5-0-million-public-offering 2026-03-25 https://biopharmsignal.com/news/NKTX/nkarta-reports-fourth-quarter-and-full-year-2025-financial-results-and-corporate-highlights 2026-03-25 https://biopharmsignal.com/news/PROK/prokidney-expands-senior-leadership-team-with-appointment-of-greg-madison-as-chief-commercial-officer 2026-03-25 https://biopharmsignal.com/news/CELC/celcuity-inc-reports-release-of-fourth-quarter-and-full-year-2025-financial-resu-059cbcaa 2026-03-25 https://biopharmsignal.com/news/DERM/journey-medical-corporation-reports-full-year-2025-financial-results-and-recent--61ef9805 2026-03-25 https://biopharmsignal.com/news/FBIO/journey-medical-corporation-reports-full-year-2025-financial-results-and-recent-corporate-highlights 2026-03-25 https://biopharmsignal.com/news/CORT/fda-approves-corcept-s-selective-glucocorticoid-receptor-antagonist-lifyorlitm-relacorilant-plus-nab-paclitaxel-for-treatment-of-patients-with-platinum-resistant-ovarian-cancer 2026-03-25 https://biopharmsignal.com/news/CORT/espa-ol-fda-approves-corcept-s-selective-glucocorticoid-receptor-antagonist-lifyorlitm-relacorilant-plus-nab-paclitaxel-for-treatment-of-patients-with-platinum-resistant-ovarian-cancer 2026-03-25 https://biopharmsignal.com/news/DNLI/denali-therapeutics-announces-u-s-fda-approval-of-avlayah-tividenofusp-alfa-eknm-6c4b625b 2026-03-25 https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2b-results-for-mebufotenin-gh001-in-jama-psychiatry-and-reports-new-finding-of-severity-independent-efficacy-in-trd 2026-03-25 https://biopharmsignal.com/news/IPHA/innate-pharma-reports-full-year-2025-financial-results-and-business-update 2026-03-25 https://biopharmsignal.com/news/ENLV/enlivex-reports-full-year-2025-results-profit-net-income-of-1-23-billion-and-dil-0f5fe86e 2026-03-25 https://biopharmsignal.com/news/NXGL/nexgel-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-31st 2026-03-25 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-provides-clinical-and-regulatory-update-from-constructive--7f5e71b9 2026-03-25 https://biopharmsignal.com/news/HSCS/heartsciences-myovista-insights-receives-epic-toolbox-designation-for-ecg-manage-3c27b079 2026-03-25 https://biopharmsignal.com/news/BYSI/beyondspring-reports-2025-year-end-financial-results-99ab6e83 2026-03-25 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-appoints-biotech-banking-pioneer-jessica-chutter-to-board-of-directors 2026-03-25 https://biopharmsignal.com/news/ICCM/icecure-reports-positive-5-year-top-line-results-from-icesecret-kidney-cancer-cryoablation-study-89-4-and-83-9-recurrence-free-rates 2026-03-25 https://biopharmsignal.com/news/IMNN/imunon-reports-updated-phase-2-data-showing-continued-improvement-in-median-over-c16c9307 2026-03-25 https://biopharmsignal.com/news/SRPT/sarepta-announces-first-clinical-data-from-sirna-pipeline-targeting-fshd1-and-dm1 2026-03-25 https://biopharmsignal.com/news/PPBT/purple-biotech-announces-ai-collaboration-with-converge-bio-to-accelerate-develo-117007cb 2026-03-25 https://biopharmsignal.com/news/PMN/promis-neurosciences-announces-full-year-2025-financial-results-and-provides-cor-4e9c19b1 2026-03-25 https://biopharmsignal.com/news/IXHL/incannex-healthcare-announces-partnership-with-the-aasm-foundation-in-support-of-439ff4b6 2026-03-25 https://biopharmsignal.com/news/PRQR/proqr-to-host-virtual-investor-and-analyst-event-highlighting-pipeline-on-april--b6dc23ae 2026-03-25 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-to-host-live-virtual-physician-roundtable-on-integrating-cypathr-lung-into-pulmonary-practice 2026-03-25 https://biopharmsignal.com/news/BFRG/bullfrog-ai-unveils-bfarenastm-scenario-based-decision-engine 2026-03-25 https://biopharmsignal.com/news/XTNT/xtant-medical-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-31-2026 2026-03-25 https://biopharmsignal.com/news/RXRX/recursion-announces-vicki-goodman-m-d-as-incoming-chief-medical-officer-fcc4cb19 2026-03-25 https://biopharmsignal.com/news/VERA/vera-therapeutics-appoints-jane-wright-mitchell-as-chief-legal-officer-5222b449 2026-03-25 https://biopharmsignal.com/news/BEAM/beam-therapeutics-announces-compelling-updated-clinical-data-from-the-ongoing-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-to-support-advancement-to-pivotal-development 2026-03-25 https://biopharmsignal.com/news/CCCC/c4-therapeutics-announces-first-patient-dosed-in-phase-1b-trial-of-cemsidomide-i-e76719d4 2026-03-25 https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-reports-eight-months-fiscal-year-2025-financial-results-and-provides-corporate-update 2026-03-25 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-company-advances-retinal-disease-pipeline-with-two-active-phase-2-clinical-trials 2026-03-25 https://biopharmsignal.com/news/TERN/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml 2026-03-25 https://biopharmsignal.com/news/ADMA/adma-biologics-addresses-misleading-short-seller-report 2026-03-25 https://biopharmsignal.com/news/TECH/bio-techne-advances-spatial-biology-with-modular-expansion-of-comettm-suite 2026-03-25 https://biopharmsignal.com/news/APGE/apogee-therapeutics-inc-announces-pricing-of-350-million-underwritten-public-off-2f0efd8f 2026-03-25 https://biopharmsignal.com/news/MD/pediatrix-welcomes-two-nationally-renowned-physician-leaders 2026-03-24 https://biopharmsignal.com/news/HROW/harrow-announces-pricing-of-50-0-million-offering-of-senior-unsecured-notes-due--2d2ba740 2026-03-24 https://biopharmsignal.com/news/AMRX/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-of-magnesium-sulfate-in-water-for-injection-usp-4-g-100ml-ndc-70121-1720-3-due-to-a-product-mix-up-with-tranexamic-acid-in-0-7-sodium-chloride-injection-10-mg-ml 2026-03-24 https://biopharmsignal.com/news/TELA/tela-bio-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-24 https://biopharmsignal.com/news/MXCT/maxcyte-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-2026-guidance 2026-03-24 https://biopharmsignal.com/news/ABSI/absci-reports-business-updates-and-fourth-quarter-and-full-year-2025-financial-and-operating-results 2026-03-24 https://biopharmsignal.com/news/BMEA/biomea-fusion-reports-full-year-2025-financial-results-and-corporate-highlights 2026-03-24 https://biopharmsignal.com/news/BSEM/biostem-technologies-reports-fourth-quarter-and-full-year-2025-financial-results-158f9cbf 2026-03-24 https://biopharmsignal.com/news/BCDA/biocardia-reports-2025-business-highlights-and-financial-results-5763262b 2026-03-24 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-conference-call-and-webcast-for-2025-fourth-quarter-and-ye-3943f713 2026-03-24 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-to-report-first-quarter-2026-financial-results-on-april-22-2026 2026-03-24 https://biopharmsignal.com/news/SRPT/sarepta-to-share-first-clinical-data-from-sirna-pipeline-targeting-fshd1-and-dm1 2026-03-24 https://biopharmsignal.com/news/HSCS/heartsciences-to-present-at-investor-summit-group-virtual-conference-and-host-vi-9a888b5d 2026-03-24 https://biopharmsignal.com/news/ENLV/enlivex-announces-21-million-debt-financing-decentralized-prediction-markets-rai-4f086846 2026-03-24 https://biopharmsignal.com/news/PRVA/privia-health-earns-2026-hfma-map-award-for-revenue-cycle-excellence 2026-03-24 https://biopharmsignal.com/news/NRSN/neurosense-advances-toward-key-regulatory-milestones-with-strengthened-data-package-and-near-term-alzheimer-s-readout 2026-03-24 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-announces-u-s-retail-launch-of-advanced-burn-relief-hydrogel-in-cvs-and-walmart 2026-03-24 https://biopharmsignal.com/news/ICCM/icecure-appoints-meir-peleg-as-chief-financial-officer 2026-03-24 https://biopharmsignal.com/news/HROW/harrow-announces-add-on-offering-of-50-0-million-of-senior-unsecured-notes-to-su-642f58b8 2026-03-24 https://biopharmsignal.com/news/AEMD/aethlon-medical-inc-advances-to-final-cohort-in-oncology-clinical-trial-following-positive-dsmb-review 2026-03-24 https://biopharmsignal.com/news/ABSI/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic 2026-03-24 https://biopharmsignal.com/news/IMNN/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tue-4c801718 2026-03-24 https://biopharmsignal.com/news/INMB/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-u-9ae59a25 2026-03-24 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-investor-summit-group-virtual-confe-1d3fd49b 2026-03-24 https://biopharmsignal.com/news/LXRX/lexicon-announces-three-presentations-at-the-american-college-of-cardiology-acc--afef7d99 2026-03-24 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights 2026-03-24 https://biopharmsignal.com/news/LCTX/lineage-launches-new-cell-therapy-program-in-corneal-endothelial-disease 2026-03-24 https://biopharmsignal.com/news/INTS/intensity-therapeutics-strengthens-ip-portfolio-with-issuance-of-new-patent-in-the-us 2026-03-24 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-appoints-jeffrey-a-munsie-as-chief-legal-officer 2026-03-24 https://biopharmsignal.com/news/OCGN/ocugen-announces-topline-12-month-data-from-phase-2-armada-clinical-trial-evalua-5dd5770c 2026-03-24 https://biopharmsignal.com/news/USNA/tested-trusted-approved-usana-cellsentials-earns-consumerlab-com-seal-of-approval-for-purity-and-potency 2026-03-24 https://biopharmsignal.com/news/KPTI/karyopharm-announces-30-million-private-placement-with-ra-capital 2026-03-24 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-fourth-quarter-and-full-year-financi-50561737 2026-03-24 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-reports-fourth-quarter-unaudited-and-full-year-2025-financial-4054944c 2026-03-24 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates 2026-03-24 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-24 https://biopharmsignal.com/news/KPTI/karyopharm-s-phase-3-sentry-trial-in-myelofibrosis-met-first-co-primary-endpoint-demonstrating-statistically-significant-improvement-in-spleen-volume-reduction 2026-03-24 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-pricing-of-5-0-million-public-offering 2026-03-24 https://biopharmsignal.com/news/BNTX/biontech-auf-dem-elcc-kongress-2026-neue-klinische-daten-unterstreichen-das-pote-b434b79c 2026-03-24 https://biopharmsignal.com/news/BNTX/biontech-clinical-data-at-elcc-2026-highlight-potential-of-differentiated-late-s-bc9d5635 2026-03-24 https://biopharmsignal.com/news/GNTA/genenta-evolving-into-saentra-forge-continues-to-evaluate-strategic-options-for-its-original-biotechnology-platform-derived-from-the-research-of-professor-luigi-naldini 2026-03-24 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-proposed-public-offering 2026-03-23 https://biopharmsignal.com/news/GMED/globus-medical-announces-board-departure-514deb06 2026-03-23 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-presentations-at-world-vaccine-congress-washington-2026 2026-03-23 https://biopharmsignal.com/news/VOR/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-323a7c6f 2026-03-23 https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-full-year-2025-operating-and-financial-results 2026-03-23 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting 2026-03-23 https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-full-year-2025-financial-results-and-business-highlights-c81ab4c5 2026-03-23 https://biopharmsignal.com/news/BNGO/bionano-reports-fourth-quarter-and-full-year-2025-results-and-provides-revenue-outlook-for-2026 2026-03-23 https://biopharmsignal.com/news/APGE/apogee-therapeutics-inc-announces-proposed-300-million-underwritten-public-offer-86d6a4bb 2026-03-23 https://biopharmsignal.com/news/SYK/stryker-announces-annual-meeting-of-shareholders 2026-03-23 https://biopharmsignal.com/news/ENLV/quality-longevity-company-enlivex-receives-investigational-new-drug-ind-clearanc-58932461 2026-03-23 https://biopharmsignal.com/news/SNTI/senti-biosciences-to-present-clinical-and-translational-data-on-senti-202-at-the-ae237d4e 2026-03-23 https://biopharmsignal.com/news/MOLN/molecular-partners-publishes-invitation-to-annual-general-meeting-2026-and-propo-93239bc8 2026-03-23 https://biopharmsignal.com/news/MBRX/moleculin-hits-45-subject-enrollment-milestone-triggering-final-countdown-to-mid-fcfce269 2026-03-23 https://biopharmsignal.com/news/PCVX/vaxcyte-completes-enrollment-of-opus-1-and-opus-2-phase-3-trials-evaluating-vax-31-for-the-prevention-of-invasive-pneumococcal-disease-and-pneumonia-in-adults 2026-03-23 https://biopharmsignal.com/news/TARS/tp-03-lotilaner-ophthalmic-solution-0-25-now-approved-in-china-for-the-treatment-of-demodex-blepharitis-triggering-a-15m-milestone-payment-to-tarsus 2026-03-23 https://biopharmsignal.com/news/BDRX/biodexa-launches-global-early-access-program-for-erapa-for-fap-patients-through--e571f552 2026-03-23 https://biopharmsignal.com/news/RNXT/renovorx-announces-closing-of-oversubscribed-10-million-at-market-private-placement 2026-03-23 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-report-fourth-quarter-2025-financial-results-and-provide-a-business-update-march-31-2026 2026-03-23 https://biopharmsignal.com/news/MXCT/maxcyte-appoints-parmeet-ahuja-as-chief-financial-officer 2026-03-23 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-three-presentations-at-the-2026-american-college-of-cardiology-annual-scientific-session 2026-03-23 https://biopharmsignal.com/news/TPST/tempest-therapeutics-announces-up-to-6-million-private-placement 2026-03-23 https://biopharmsignal.com/news/MDXG/mimedx-announces-launch-of-choriofixtm 2026-03-23 https://biopharmsignal.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-announces-closing-of-10-million-public-offer-a2c629c7 2026-03-23 https://biopharmsignal.com/news/HUMA/humacyte-to-announce-2025-fourth-quarter-and-year-end-financial-results-and-provide-business-update-on-march-27-2026 2026-03-23 https://biopharmsignal.com/news/GSK/gsk-s-b7-h3-targeted-antibody-drug-conjugate-risvutatug-rezetecan-granted-orphan-drug-designation-for-small-cell-lung-cancer-in-japan 2026-03-23 https://biopharmsignal.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update 2026-03-23 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-to-report-fourth-quarter-and-year-end-2025-financial-resu-611693f3 2026-03-23 https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-fourth-quarter-an-411fb603 2026-03-23 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-and-novo-nordisk-announce-initiation-of-phase-1-study-wi-624565ca 2026-03-23 https://biopharmsignal.com/news/APTO/leading-independent-proxy-advisory-firm-glass-lewis-endorses-aptose-plan-of-arrangement 2026-03-23 https://biopharmsignal.com/news/SNGX/hybrytetm-treatment-results-to-be-presented-at-us-cutaneous-lymphoma-consortium-annual-workshop-2026 2026-03-23 https://biopharmsignal.com/news/CABA/cabaletta-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-23 https://biopharmsignal.com/news/OCGN/ocugen-to-host-webcast-on-tuesday-march-24-at-8-a-m-edt-to-discuss-phase-2-clini-058e7c56 2026-03-23 https://biopharmsignal.com/news/BSEM/biostem-appoints-jodi-ungrodt-to-board-of-directors-as-audit-committee-chair-766636c5 2026-03-23 https://biopharmsignal.com/news/PYXS/pyxis-oncology-provides-business-update-and-reports-fourth-quarter-and-full-year-a99df0d5 2026-03-23 https://biopharmsignal.com/news/PRCT/eau-guidelines-upgrade-aquablation-therapy-to-strong-surgical-recommendation-for-f3154503 2026-03-23 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-reports-2025-financial-results-and-recent-business-updates 2026-03-23 https://biopharmsignal.com/news/INSM/insmed-announces-positive-topline-results-from-phase-3b-encore-study-of-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-mac-lung-disease 2026-03-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reinforces-leadership-in-ohcm-with-new-camzyos-mavacamten-data-at-american-college-of-cardiology-annual-scientific-session-and-expo-2026-acc-26 2026-03-23 https://biopharmsignal.com/news/APGE/apogee-therapeutics-announces-positive-phase-2-part-a-52-week-data-of-zumilokiba-d8feb91b 2026-03-23 https://biopharmsignal.com/news/HCM/hutchmed-initiates-phase-iii-trial-of-hmpl-760-in-patients-with-relapsed-refract-8394c488 2026-03-23 https://biopharmsignal.com/news/APGE/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-t-0ba97deb 2026-03-22 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-transforms-the-classical-hodgkin-lymphoma-treatment-paradigm-with-expanded-u-s-and-ema-approvals-for-opdivor-nivolumab 2026-03-20 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-reports-inducement-grant-to-new-chief-financial-officer-under-6c1740e5 2026-03-20 https://biopharmsignal.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-may-6-2026-0d20a54c 2026-03-20 https://biopharmsignal.com/news/IBRX/immunitybio-announces-approval-in-macau-sar-china-for-anktivar-in-bcg-unresponsive-nmibc-with-cis-papillary-tumors 2026-03-20 https://biopharmsignal.com/news/BIIB/results-from-real-world-long-term-treatment-persistence-with-leqembi-lecanemab-i-354c8356 2026-03-20 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-announces-poster-on-results-from-phase-2a-trial-of-ati-2138-91f1db5b 2026-03-20 https://biopharmsignal.com/news/NKTR/data-from-phase-2b-studies-for-rezpegaldesleukin-accepted-for-two-oral-presentations-at-the-2026-american-academy-of-dermatology-annual-meeting 2026-03-20 https://biopharmsignal.com/news/RNXT/renovorx-to-host-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights-conference-call-on-march-30th-at-4-30-p-m-et 2026-03-20 https://biopharmsignal.com/news/BDSX/biodesix-announces-the-largest-lung-nodule-biomarker-clinical-validation-study-e-28bdb134 2026-03-20 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-update-on-the-commercial-launch-of-cardamysttm-etripamil-nasal-spray-for-the-treatment-of-psvt 2026-03-20 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-new-role-of-lori-j-braender-and-appointment-of-thomas-a-zalewski-as-chief-legal-officer-and-chief-compliance-officer 2026-03-20 https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-to-present-new-ekterlyr-sebetralstat-data-at-the-2026-global-angioedema-leadership-conference 2026-03-20 https://biopharmsignal.com/news/PHVS/evidence-of-efficacy-and-safety-of-deucrictibant-for-prophylaxis-and-on-demand-t-8ef1104d 2026-03-20 https://biopharmsignal.com/news/BCDA/biocardia-to-host-2025-financial-results-and-corporate-update-conference-call-on-35a2dfa4 2026-03-19 https://biopharmsignal.com/news/CLLS/cellectis-reports-full-year-2025-financial-results-and-provides-a-business-update 2026-03-19 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-setmelanotide-for-pati-77aa2484 2026-03-19 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-operating-and-f-c4c84843 2026-03-19 https://biopharmsignal.com/news/GANX/gain-therapeutics-to-present-at-the-38th-annual-roth-conference-01a05c6e 2026-03-19 https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-fourth-quarter-and-full-year-2025-financial-results--c85e79a0 2026-03-19 https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-an-3a2a2d8d 2026-03-19 https://biopharmsignal.com/news/RANI/rani-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results 2026-03-19 https://biopharmsignal.com/news/ASMB/assembly-biosciences-reports-year-end-2025-financial-results-and-recent-highlights 2026-03-19 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-8f6879be 2026-03-19 https://biopharmsignal.com/news/ECOR/electrocore-announces-full-year-2025-financial-results-and-organizational-change-75d8da35 2026-03-19 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-host-virtual-r-d-day-highlighting-robust-kidney-disease-p-cfb8b316 2026-03-19 https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-full-year-2025-financial-results-and-provides-corporate-update 2026-03-19 https://biopharmsignal.com/news/ZURA/zura-bio-reports-full-year-2025-financial-results-and-recent-corporate-updates 2026-03-19 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-announces-fourth-quarter-and-full-year-2025-earnings-call-9bb53d7f 2026-03-19 https://biopharmsignal.com/news/NCNA/nucana-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update 2026-03-19 https://biopharmsignal.com/news/SABS/sab-bio-announces-closing-of-85-million-public-offering-of-common-stock-and-pre-funded-warrants 2026-03-19 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-reports-fourth-quarter-and-full-year-2025-results-and-provides-business-update 2026-03-19 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2025-financial-resu-d112b464 2026-03-19 https://biopharmsignal.com/news/CRIS/curis-provides-fourth-quarter-2025-business-update 2026-03-19 https://biopharmsignal.com/news/INBX/inhibrx-reports-fourth-quarter-and-fiscal-year-2025-financial-results 2026-03-19 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-chairman-and-founder-acquires-shares-a71fe1cc 2026-03-19 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-director-acquires-shares-b98a1cdf 2026-03-19 https://biopharmsignal.com/news/DGX/quest-diagnostics-to-release-first-quarter-financial-results-on-april-21-2026 2026-03-19 https://biopharmsignal.com/news/BFRI/biofrontera-inc-reports-record-fourth-quarter-and-full-year-2025-financial-resul-5b263873 2026-03-19 https://biopharmsignal.com/news/ACON/aclarion-inc-adopts-limited-duration-stockholder-rights-plan-b61cad14 2026-03-19 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-to-present-new-mechanistic-and-translational-data-supporting--1f7a745b 2026-03-19 https://biopharmsignal.com/news/MBRX/moleculin-reports-full-year-2025-financial-results-and-confirms-highly-anticipat-c7dfe3bc 2026-03-19 https://biopharmsignal.com/news/HUMA/humacyte-receives-symvessr-purchase-commitment-for-clinical-evaluation-and-outreach-program-in-the-kingdom-of-saudi-arabia 2026-03-19 https://biopharmsignal.com/news/CLOV/primary-care-physician-use-of-counterpart-assistant-associated-with-18-22-fewer-flu-related-acute-care-events-among-copd-and-chf-patients 2026-03-19 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-to-announce-corporate-update-and-fourth-quarter-and-full-y-dfa2a4d4 2026-03-19 https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-full-year-2025-financial-results-and-provides-corporate--69bbe215 2026-03-19 https://biopharmsignal.com/news/HUMA/humacyte-inc-announces-pricing-of-20-million-registered-direct-offering-of-common-stock 2026-03-19 https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update 2026-03-19 https://biopharmsignal.com/news/SRPT/sarepta-provides-regulatory-update-on-amondys-45r-and-vyondys-53r 2026-03-19 https://biopharmsignal.com/news/APVO/aptevo-to-participate-in-march-2026-conferences 2026-03-19 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-reports-full-year-2025-financial-results-and-provides-corporate-update 2026-03-19 https://biopharmsignal.com/news/IMMP/immutep-reports-progress-from-phase-i-study-of-lag-3-agonist-for-autoimmune-dise-21dbf1a6 2026-03-19 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-to-present-positive-phase-2-blinded-data-for-brtx-100-d-a8c86e80 2026-03-19 https://biopharmsignal.com/news/INMB/inmune-bio-s-mindful-trial-featured-at-ad-pd-2026-plenary-as-successful-example--2a197106 2026-03-19 https://biopharmsignal.com/news/FULC/medicalert-foundation-sickle-cell-disease-association-of-america-inc-scdaa-and-f-f01205b1 2026-03-19 https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-year-end-and-fourth-quarter-2025-financial-results-and-provides-a-corporate-update 2026-03-19 https://biopharmsignal.com/news/ACST/grace-therapeutics-to-present-data-on-the-unmet-medical-needs-and-potential-benefits-of-gtx-104-in-the-treatment-of-asah-at-upcoming-medical-conferences 2026-03-19 https://biopharmsignal.com/news/ANGO/angiodynamics-to-report-fiscal-2026-third-quarter-results-on-april-2-2026 2026-03-19 https://biopharmsignal.com/news/GSK/lynavoy-linerixibat-approved-by-the-us-fda-for-cholestatic-pruritus-in-patients-with-primary-biliary-cholangitis-pbc 2026-03-19 https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-poster-presentation-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026 2026-03-19 https://biopharmsignal.com/news/TGTX/tg-therapeutics-secures-an-additional-500-million-in-non-dilutive-capital-from-blue-owl-and-expands-share-repurchase-program-to-300-million 2026-03-19 https://biopharmsignal.com/news/CRVO/cervomed-announces-new-data-at-the-ad-pd-2026-scientific-conference-that-reinfor-c5e9beb0 2026-03-19 https://biopharmsignal.com/news/ANVS/annovis-partners-with-neurorpm-to-deploy-ai-powered-digital-biomarker-technology-b4d42036 2026-03-19 https://biopharmsignal.com/news/IFRX/inflarx-reports-full-year-2025-results-and-highlights-key-achievements-and-expec-6ba38aa7 2026-03-19 https://biopharmsignal.com/news/APTO/leading-independent-proxy-advisory-firm-iss-recommends-aptose-biosciences-shareholders-vote-for-proposed-plan-of-arrangement-with-hanmi-pharmaceutical 2026-03-19 https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights 2026-03-19 https://biopharmsignal.com/news/AVAH/aveanna-healthcare-holdings-announces-fourth-quarter-and-full-year-2025-financial-results 2026-03-19 https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-chief-development-officer-and-director-acquires-shares-8c8fab0f 2026-03-19 https://biopharmsignal.com/news/ACIU/ac-immune-presents-first-in-vivo-images-of-brain-tdp-43-pathology-from-phase-1-t-5b4484d0 2026-03-19 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-19 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-first-quarter-2026-on-april-30-2026 2026-03-19 https://biopharmsignal.com/news/EMBC/embecta-announces-definitive-agreement-to-acquire-owen-mumford-holdings-limited 2026-03-19 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-addition-of-city-of-hope-to-flamingo-01 2026-03-19 https://biopharmsignal.com/news/MOLN/molecular-partners-presents-new-preclinical-data-highlighting-radio-darpins-amen-43024e59 2026-03-19 https://biopharmsignal.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-announces-pricing-of-10-million-public-offer-4f7255f6 2026-03-19 https://biopharmsignal.com/news/PCVX/positive-vax-31-phase-1-2-adult-data-published-in-the-lancet-infectious-diseases-highlight-best-in-class-potential-of-vaxcyte-s-31-valent-pneumococcal-conjugate-vaccine-pcv-candidate 2026-03-18 https://biopharmsignal.com/news/MRKR/marker-therapeutics-reports-year-end-2025-corporate-and-financial-results-5f613cab 2026-03-18 https://biopharmsignal.com/news/BDRX/adr-ratio-change-898caa2a 2026-03-18 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-to-present-at-bio-europe-spring-2026 2026-03-18 https://biopharmsignal.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends 2026-03-18 https://biopharmsignal.com/news/EHC/encompass-health-announces-plans-to-build-a-40-bed-inpatient-rehabilitation-hospital-in-bear-delaware 2026-03-18 https://biopharmsignal.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-announces-proposed-public-offering-b3a74e09 2026-03-18 https://biopharmsignal.com/news/ICU/seastar-medical-to-report-fourth-quarter-and-year-end-2025-financial-results-on--8d86ef90 2026-03-18 https://biopharmsignal.com/news/ICCC/immucell-appoints-former-elanco-animal-health-board-member-kathy-turner-to-board-5c7354ed 2026-03-18 https://biopharmsignal.com/news/FDMT/4dmt-reports-full-year-2025-financial-results-operational-highlights-and-expecte-fa021f5a 2026-03-18 https://biopharmsignal.com/news/HYPR/hyperfine-inc-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-18 https://biopharmsignal.com/news/SERA/sera-prognostics-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-18 https://biopharmsignal.com/news/PROK/prokidney-reports-full-year-2025-financial-results-and-business-highlights 2026-03-18 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-26-2026 2026-03-18 https://biopharmsignal.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-full-year-2025-financial-results 2026-03-18 https://biopharmsignal.com/news/PACB/basecamp-research-selects-pacbio-hifi-sequencing-to-power-trillion-gene-atlas-in-27570dd2 2026-03-18 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting 2026-03-18 https://biopharmsignal.com/news/FEMY/femasys-appoints-dr-kenneth-d-eichenbaum-to-board-of-directors-04936fcc 2026-03-18 https://biopharmsignal.com/news/AIM/aim-aa0e1860 2026-03-18 https://biopharmsignal.com/news/AIM/aim-immunotech-announces-final-approval-of-novel-cancer-therapy-patent-in-japan--0d1234ed 2026-03-18 https://biopharmsignal.com/news/RNXT/renovorx-announces-10-million-at-market-private-placement 2026-03-18 https://biopharmsignal.com/news/EQ/equillium-to-participate-in-the-38th-annual-roth-conference-6063a51d 2026-03-18 https://biopharmsignal.com/news/AMRN/amarin-highlights-guideline-recommended-role-of-icosapent-ethyl-in-managing-card-5908f432 2026-03-18 https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-year-end-2025-financial-results-on-march-60a53a64 2026-03-18 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-18 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-announces-launch-of-new-dermatology-product-line-under-person-and-covey-s-aquanil-brand-for-sensitive-skin 2026-03-18 https://biopharmsignal.com/news/FBIO/journey-medical-corporation-to-announce-year-end-2025-financial-results-on-march-25-2026 2026-03-18 https://biopharmsignal.com/news/GANX/gain-therapeutics-presents-additional-clinical-and-biomarker-data-from-phase-1b--34eec120 2026-03-18 https://biopharmsignal.com/news/ARQT/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting 2026-03-18 https://biopharmsignal.com/news/PMN/promis-neurosciences-to-present-data-on-als-parkinsons-disease-programs-at-alzhe-eab7f183 2026-03-18 https://biopharmsignal.com/news/IXHL/incannex-highlights-strong-balance-sheet-with-approximately-75-million-in-cash-a-37a54f68 2026-03-18 https://biopharmsignal.com/news/CING/cingulate-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-op-32d2026b 2026-03-18 https://biopharmsignal.com/news/CELC/celcuity-schedules-release-of-fourth-quarter-and-full-year-2025-financial-result-9938d799 2026-03-18 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-acces-179d0eb4 2026-03-18 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-to-participate-in-the-bmo-2026-metabolic-health-summit 2026-03-18 https://biopharmsignal.com/news/ARTL/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art27-13-in-glaucoma-patients 2026-03-18 https://biopharmsignal.com/news/BCTX/briacell-to-present-positive-clinical-data-for-bria-imt-and-preclinical-data-for-1676d9e5 2026-03-18 https://biopharmsignal.com/news/IFRX/inflarx-announces-late-breaker-oral-presentation-on-vilobelimab-phase-3-results--0a08c0de 2026-03-18 https://biopharmsignal.com/news/MDNA/medicenna-to-present-preclinical-data-from-its-first-in-class-tumor-anchored-and-conditionally-activated-anti-pd-1-il-2-bifunctional-superkine-at-the-aacr-annual-meeting-2026 2026-03-18 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026 2026-03-18 https://biopharmsignal.com/news/ARVN/arvinas-announces-positive-phase-1-data-for-arv-102-showing-greater-than-50-lrrk2-degradation-in-the-csf-of-patients-with-parkinson-s-disease-treated-for-28-days 2026-03-18 https://biopharmsignal.com/news/NTRB/nutriband-ai-kinesiology-tapes-approved-for-distribution-and-sale-in-costa-rica-550f57ba 2026-03-18 https://biopharmsignal.com/news/OKYO/okyo-pharma-reports-new-phase-2-data-demonstrating-meaningful-improvements-in-pa-6eae9683 2026-03-18 https://biopharmsignal.com/news/HROW/harrow-announces-three-abstracts-accepted-for-presentation-at-ascrs-2026-annual--fe751553 2026-03-18 https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026 2026-03-18 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-completes-enrollment-in-phase-2-trial-of-bosakitug-ati-045--b206a47b 2026-03-18 https://biopharmsignal.com/news/OVID/ovid-therapeutics-announces-new-ov329-data-and-indication-expansion-phase-1-clea-6db164f6 2026-03-18 https://biopharmsignal.com/news/OVID/ovid-therapeutics-announces-pricing-of-60-million-private-placement-95659686 2026-03-18 https://biopharmsignal.com/news/XOMA/xoma-royalty-reports-2025-financial-results-and-highlights-recent-business-achievements 2026-03-18 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-on-upcoming-aacr-meeting 2026-03-18 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-completes-combination-with-radius-health-expanding-its-multi-product-specialty-commercial-platform 2026-03-18 https://biopharmsignal.com/news/SABS/sab-bio-announces-pricing-of-85-million-public-offering-of-common-stock-and-pre-funded-warrants 2026-03-18 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-pricing-of-250-million-offering-of-common-stock-and-pre-funded-warrants 2026-03-18 https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-to-present-pre-clinical-ap3-data-at-the-2026-aacr-annual-meeting-revealing-strong-synergy-of-acr-368-with-adc-topo-1-inhibitor-payloads-and-of-both-acr-368-and-acr-2316-with-immune-checkpoint-inhibitors 2026-03-17 https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-announces-preclinical-rinzimetostat-oric-944-presentations-at-the-2026-american-association-for-cancer-research-aacr-annual-meeting 2026-03-17 https://biopharmsignal.com/news/OSUR/orasure-highlights-significant-operational-progress-and-value-creation-initiatives-following-letter-from-altai-capital 2026-03-17 https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-acceptance-of-vmt-net-data-for-presentation-a-48b35ba8 2026-03-17 https://biopharmsignal.com/news/XLO/xilio-therapeutics-to-present-new-preclinical-data-for-its-masked-t-cell-engager-4da12d37 2026-03-17 https://biopharmsignal.com/news/IMRX/immuneering-to-present-molecular-data-at-2026-aacr-annual-meeting-from-atebimetinib-treated-patients-highlighting-mechanism-designed-to-improve-durability-and-survival 2026-03-17 https://biopharmsignal.com/news/XAIR/beyond-cancer-reports-early-clinical-activity-and-favorable-safety-profile-with--584b2b68 2026-03-17 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentation-and-two-poster-presentations-on-preclinical-immuno-oncology-portfolio-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026 2026-03-17 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-acceptance-of-preclinical-abstract-for-prt13722-a-first-in-class-oral-kat6a-selective-degrader-at-the-2026-aacr-annual-meeting 2026-03-17 https://biopharmsignal.com/news/FLGT/fulgent-genetics-completes-acquisition-of-bako-diagnostics-and-stratadx 2026-03-17 https://biopharmsignal.com/news/OLMA/olema-oncology-to-present-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-annual-meeting 2026-03-17 https://biopharmsignal.com/news/MOLN/molecular-partners-to-hold-three-poster-presentations-at-aacr-2026-b6ff713f 2026-03-17 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-present-two-posters-at-the-american-association-for--34d23737 2026-03-17 https://biopharmsignal.com/news/SLS/sellas-life-sciences-to-present-preclinical-data-highlighting-potent-activity-of-sls009-in-aml-at-the-2026-aacr-conference 2026-03-17 https://biopharmsignal.com/news/IMCR/immunocore-will-present-five-year-overall-survival-data-for-kimmtrak-during-oral-presentation-at-the-2026-aacr-meeting 2026-03-17 https://biopharmsignal.com/news/LGVN/longeveron-announces-2025-full-year-financial-results-and-provides-business-upda-2785ab0c 2026-03-17 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-reports-fourth-quarter-and-full-year-2025-results 2026-03-17 https://biopharmsignal.com/news/SABS/sab-bio-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants 2026-03-17 https://biopharmsignal.com/news/MGRX/mangoceuticals-announces-lawsuit-seeking-damages-exceeding-73-million-against-fo-c81c07d4 2026-03-17 https://biopharmsignal.com/news/PSNL/personalis-appoints-dr-richard-chen-as-president-to-further-accelerate-mrd-adoption 2026-03-17 https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-and-scientific-highlights 2026-03-17 https://biopharmsignal.com/news/PNTG/update-pennant-group-to-participate-in-the-2026-oppenheimer-annual-healthcare-conference 2026-03-17 https://biopharmsignal.com/news/INDV/national-survey-finds-only-58-of-u-s-correctional-facilities-offer-medications-f-4647e9e8 2026-03-17 https://biopharmsignal.com/news/MBRX/moleculin-to-present-at-38th-annual-roth-conference-3eeb2391 2026-03-17 https://biopharmsignal.com/news/VVOS/recent-study-confirms-fundamental-correlation-between-severity-of-obstructive-sl-8d97e703 2026-03-17 https://biopharmsignal.com/news/PYPD/polypid-receives-pdufa-fee-waiver-from-fda-for-d-plex-s-new-drug-application 2026-03-17 https://biopharmsignal.com/news/OGEN/oragenics-files-annual-report-on-form-10-k 2026-03-17 https://biopharmsignal.com/news/ICCM/icecure-reports-2025-full-year-financial-and-operational-results 2026-03-17 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-and-webcast-on-march-24-2026 2026-03-17 https://biopharmsignal.com/news/ASND/new-insights-trial-of-transconr-hgh-lonapegsomatropin-in-turner-syndrome-demonstrated-comparable-efficacy-and-safety-to-daily-somatropin-at-week-52 2026-03-17 https://biopharmsignal.com/news/GRFS/grifols-shares-results-from-its-chronos-platform-identifying-early-molecular-cha-572db579 2026-03-17 https://biopharmsignal.com/news/CADL/candel-therapeutics-reports-extended-survival-tail-observed-in-trial-of-aglatimagene-besadenovec-can-2409-in-advanced-non-small-cell-lung-cancer-patients-with-inadequate-response-to-immune-checkpoint-inhibitors 2026-03-17 https://biopharmsignal.com/news/AZYO/elutia-to-present-at-sidoti-s-small-cap-virtual-investor-conference-march-18-19 2026-03-17 https://biopharmsignal.com/news/ESPR/esperion-to-present-two-new-analyses-from-clear-outcomes-clinical-trial-at-the-american-college-of-cardiology-2026-annual-scientific-session 2026-03-17 https://biopharmsignal.com/news/IXHL/incannex-regains-compliance-with-nasdaq-minimum-bid-price-requirement-9c4978f1 2026-03-17 https://biopharmsignal.com/news/GALT/galectin-therapeutics-strengthens-board-of-directors-with-appointment-of-henry-b-973b8a56 2026-03-17 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-res-e931cf70 2026-03-17 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights-on-march-24-2026 2026-03-17 https://biopharmsignal.com/news/PRPH/prophase-labs-provides-business-update-highlighting-advancing-crown-medical-collections-activity 2026-03-17 https://biopharmsignal.com/news/BNGO/bionano-announces-two-fold-increase-in-ogm-studies-presented-at-the-2026-american-college-of-medical-genetics-and-genomics-acmg-annual-clinical-genetics-meeting 2026-03-17 https://biopharmsignal.com/news/HUMA/humacyte-submits-marketing-authorization-application-for-symvessr-in-israel-for-vascular-trauma-repair 2026-03-17 https://biopharmsignal.com/news/HCWB/hcw-biologics-closes-exclusive-worldwide-license-for-hcw11-006-a-high-potential--88a37ca8 2026-03-17 https://biopharmsignal.com/news/STIM/neuronetics-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results 2026-03-17 https://biopharmsignal.com/news/BIAF/new-case-study-bioaffinity-technologies-cypathr-lung-provides-actionable-results-and-helps-patient-avoid-costly-invasive-procedures 2026-03-17 https://biopharmsignal.com/news/STIM/neuronetics-appoints-dan-reuvers-as-president-and-chief-executive-officer 2026-03-17 https://biopharmsignal.com/news/INKT/mink-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results--478730ac 2026-03-17 https://biopharmsignal.com/news/CRVO/cervomed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provide-bb15de98 2026-03-17 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-presents-evidence-of-zervimesine-s-impact-on-neuropsychia-4b864ae7 2026-03-17 https://biopharmsignal.com/news/IBRX/immunitybio-announces-nccnr-clinical-practice-guidelines-in-oncology-have-been-updated-to-include-anktivar-plus-bcg-for-patients-with-bcg-unresponsive-nmibc-with-papillary-only-disease 2026-03-17 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-reports-full-year-2025-financial-results-and-corporate-updates 2026-03-17 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-a-1a62814a 2026-03-17 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-announces-china-s-nmpa-grants-priority-review-to-the-nda-for-h-a7d61a40 2026-03-17 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-china-s-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment 2026-03-17 https://biopharmsignal.com/news/PPBT/purple-biotech-regains-compliance-with-nasdaq-922593b7 2026-03-17 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-re-c512e8eb 2026-03-17 https://biopharmsignal.com/news/PLSE/pulse-biosciences-announces-strategic-alignment-to-accelerate-cardiac-catheter-program-following-exceptional-long-term-afib-clinical-data 2026-03-17 https://biopharmsignal.com/news/BCDA/biocardia-announces-pre-submission-approval-package-for-helix-transendocardial-d-4b15f842 2026-03-17 https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-03-17 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-showing-continued-reduction-in-recurrence-rate-in-the-open-label-arm-of-flamingo-01 2026-03-17 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-completes-phytanix-separation-strengthens-balance-sheet-and-repositions-the-company-around-pt00114 2026-03-17 https://biopharmsignal.com/news/PNTG/pennant-group-to-participate-in-the-2026-oppenheimer-annual-healthcare-conference 2026-03-16 https://biopharmsignal.com/news/LNSR/lensar-announces-termination-of-merger-agreement-with-alcon-research-llc-329e1882 2026-03-16 https://biopharmsignal.com/news/IBIO/ibio-to-provide-an-update-on-cardiopulmonary-program-targeting-pulmonary-hypertension-associated-with-heart-failure-with-preserved-ejection-fraction-ph-hfpef 2026-03-16 https://biopharmsignal.com/news/HSCS/heartsciences-reports-fiscal-third-quarter-2026-financial-results-and-provides-b-401fac69 2026-03-16 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-resul-934c2336 2026-03-16 https://biopharmsignal.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-full-ye-0c9211ff 2026-03-16 https://biopharmsignal.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4 2026-03-16 https://biopharmsignal.com/news/CUE/cue-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-bu-e5bdfbb7 2026-03-16 https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-operational-progress 2026-03-16 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants 2026-03-16 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update 2026-03-16 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-topline-results-from-phase-3-emanate-trial-a7d1dc3b 2026-03-16 https://biopharmsignal.com/news/MDXH/mdxhealth-highlights-data-from-oxford-s-prompt-study-demonstrating-the-genomic-p-e654e848 2026-03-16 https://biopharmsignal.com/news/IRMD/iradimed-corporation-to-participate-at-the-38th-annual-roth-conference-19e358e6 2026-03-16 https://biopharmsignal.com/news/DRTS/alpha-tau-to-present-at-sidoti-march-virtual-small-cap-conference-bb83a5dd 2026-03-16 https://biopharmsignal.com/news/MMSI/merit-medical-launches-the-resilience-through-the-scope-esophageal-stent-0061b016 2026-03-16 https://biopharmsignal.com/news/SRPT/sarepta-announces-that-screening-and-enrollment-are-underway-in-endeavor-cohort-8-to-evaluate-enhanced-immunosuppression-regimen-as-part-of-elevidys-gene-therapy-for-non-ambulant-individuals-with-duchenne 2026-03-16 https://biopharmsignal.com/news/AMRN/new-reduce-it-data-in-patients-at-extreme-cardiovascular-risk-and-in-vitro-resea-281ecc49 2026-03-16 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-present-data-on-cardamysttm-etripamil-nasal-spray-at-the-2026-american-college-of-cardiology-annual-scientific-session 2026-03-16 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-settlement-agreement-resolving-pedmark-patent-litigation 2026-03-16 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-new-18-4-million-non-convertible-note-financing-and-amendment-to-existing-convertible-note 2026-03-16 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-for-bezuclastinib-in-patients-with-nonadvanced-systemic-mastocytosis-nonadvsm 2026-03-16 https://biopharmsignal.com/news/APRE/aprea-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update 2026-03-16 https://biopharmsignal.com/news/SYRE/spyre-announces-acceleration-of-expected-topline-readout-of-skyway-rheumatoid-ar-47e04c72 2026-03-16 https://biopharmsignal.com/news/HCWB/hcw-biologics-announces-positive-research-results-for-car-t-cell-therapy-manufac-ce86c830 2026-03-16 https://biopharmsignal.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-meetings-c11a3891 2026-03-16 https://biopharmsignal.com/news/LFVN/lifevantage-to-participate-in-the-sidoti-small-cap-conference 2026-03-16 https://biopharmsignal.com/news/ALZN/alzamend-neuro-initiates-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-patients-with-bipolar-disorder-in-collaboration-with-massachusetts-general-hospital 2026-03-16 https://biopharmsignal.com/news/ASND/new-two-year-data-from-pivotal-approach-trial-showing-durable-benefits-of-transconr-cnp-navepegritide-in-children-with-achondroplasia-shared-at-acmg-2026 2026-03-16 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-sells-sdx-portfolio-to-commave-therapeutics-for-50-million-d9212eef 2026-03-16 https://biopharmsignal.com/news/ANVS/annovis-provides-corporate-updates-and-reports-fiscal-year-2025-financial-result-41dbed59 2026-03-16 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-2025-financial-results-and-provides-business-update 2026-03-16 https://biopharmsignal.com/news/SHC/sotera-health-appoints-kenneth-d-krause-to-the-board-of-directors 2026-03-16 https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-positive-topline-data-from-phase-2-access-ii-trial-with-once-daily-oral-small-molecule-glp-1-receptor-agonist-aleniglipron 2026-03-16 https://biopharmsignal.com/news/OLMA/olema-oncology-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results 2026-03-16 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-resul-a42d54ef 2026-03-16 https://biopharmsignal.com/news/ELDN/eledon-announces-updated-data-from-investigator-initiated-islet-transplant-trial-2ffd5a00 2026-03-16 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-clinical-supply-agreement-to-support-phase-2-t-8d397d6e 2026-03-16 https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-data-from-zovegalisib-fulvestrant-at-the-phase-3-do-6b7f4178 2026-03-16 https://biopharmsignal.com/news/MNOV/medicinova-to-participate-at-the-38th-annual-roth-conference 2026-03-16 https://biopharmsignal.com/news/CTMX/cytomx-s-varsetatug-masetecan-epcam-probodyr-adc-continues-to-demonstrate-positive-data-supporting-potential-as-a-new-treatment-option-in-late-line-colorectal-cancer 2026-03-16 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-announces-its-intent-to-delay-the-filing-of-its-annual-re-54ae07b7 2026-03-16 https://biopharmsignal.com/news/ESPR/esperion-s-bempedoic-acid-receives-multiple-class-1-recommendations-in-2026-acc-aha-multisociety-guideline-for-management-of-dyslipidemia 2026-03-16 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-announces-35-75-million-private-placement-to-advance-pote-ee7fbe97 2026-03-16 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-use-of-commercially-manufactured-gp2-in-flamingo-01 2026-03-16 https://biopharmsignal.com/news/OCS/oculis-to-present-at-upcoming-north-american-neuro-ophthalmology-society-annual-meeting 2026-03-16 https://biopharmsignal.com/news/SENS/first-ever-real-world-evidence-of-eversense-365-presented-at-attd-demonstrates-s-5ee03257 2026-03-14 https://biopharmsignal.com/news/BMEA/biomea-fusion-presents-phase-ii-covalent-111-data-in-type-2-diabetes-at-the-19th-international-conference-on-advanced-technologies-and-treatments-for-diabetes-2026 2026-03-14 https://biopharmsignal.com/news/IFRX/inflarx-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-pric-ca687ea2 2026-03-13 https://biopharmsignal.com/news/HSTM/healthstream-announces-share-repurchase-program 2026-03-13 https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-continued-positive-clinical-results-through-14-months-from-type-1-diabetes-study-of-islet-cell-transplantation-without-immunosuppression 2026-03-13 https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-fourth-quarter-and-full-year-2025-earnings-release-and-conference-call 2026-03-13 https://biopharmsignal.com/news/PPBT/purple-biotech-announces-ceo-transition-c4b1459b 2026-03-13 https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments 2026-03-13 https://biopharmsignal.com/news/PPBT/purple-biotech-reports-fourth-quarter-and-full-year-2025-financial-results-eacefcc0 2026-03-13 https://biopharmsignal.com/news/EQ/equillium-announces-35-million-financing-with-ra-capital-management-813aea58 2026-03-13 https://biopharmsignal.com/news/IMMP/tacti-004-phase-iii-study-in-first-line-nsclc-to-be-discontinued-following-futil-2de38e30 2026-03-13 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-reports-full-year-2025-financial-results 2026-03-13 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-announces-record-2025-revenue-and-unit-sales-for-flagship-lung-cancer-diagnostic-cypathr-lung 2026-03-13 https://biopharmsignal.com/news/URGN/urogen-applauds-bcan-s-new-faces-of-bladder-cancer-report-highlighting-recurrence-burden-and-fear-of-recurrence 2026-03-13 https://biopharmsignal.com/news/IBRX/immunitybio-achieves-milestone-with-large-scale-nk-cell-production-and-cryopreservation-from-over-60-healthy-and-cancer-donors 2026-03-13 https://biopharmsignal.com/news/ACIU/ac-immune-reports-full-year-2025-financial-results-and-provides-a-corporate-upda-b7276343 2026-03-13 https://biopharmsignal.com/news/GSK/gsk-s-rsv-vaccine-arexvy-approved-in-us-for-expanded-age-indication-in-adults-aged-18-49-years-at-increased-risk 2026-03-13 https://biopharmsignal.com/news/GNTA/genenta-evolving-into-saentra-forge-announces-ceo-s-appointment-by-the-italian-government-to-the-board-of-guarantors-of-the-italian-academy-at-columbia-university 2026-03-13 https://biopharmsignal.com/news/INDV/indivior-prices-upsized-450-0-million-convertible-senior-notes-offering-fc4f1144 2026-03-13 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights 2026-03-12 https://biopharmsignal.com/news/PRPO/precipio-announces-q4-and-year-end-2025-shareholder-update-call-d3beba18 2026-03-12 https://biopharmsignal.com/news/CCEL/cryo-cell-receives-nyse-american-continued-listing-notice 2026-03-12 https://biopharmsignal.com/news/IRTC/irhythm-holdings-appoints-jason-patten-to-its-board-of-directors-b95ea829 2026-03-12 https://biopharmsignal.com/news/CLLS/cellectis-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026 2026-03-12 https://biopharmsignal.com/news/CRIS/curis-to-report-fourth-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-19-2026 2026-03-12 https://biopharmsignal.com/news/NGEN/nervgen-pharma-announces-voluntary-delisting-from-tsx-venture-exchange-c3927977 2026-03-12 https://biopharmsignal.com/news/ACHC/acadia-healthcare-appoints-daniel-cancelmi-to-board-of-directors 2026-03-12 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-12 https://biopharmsignal.com/news/NEPH/nephros-announces-fourth-quarter-and-record-fiscal-year-2025-financial-results-82c8e23c 2026-03-12 https://biopharmsignal.com/news/DGX/quest-diagnostics-elects-timothy-wentworth-former-ceo-of-walgreens-boots-alliance-evernorth-health-services-and-express-scripts-to-board-of-directors 2026-03-12 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-q4-and-full-year-2025-business-and-financial-results 2026-03-12 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-reports-full-year-2025-financial-results-and-provides-corpor-790852f6 2026-03-12 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-e284d9b8 2026-03-12 https://biopharmsignal.com/news/VXRT/vaxart-provides-business-update-and-reports-full-year-2025-financial-results-ec5da4ef 2026-03-12 https://biopharmsignal.com/news/HCAT/health-catalyst-reports-fourth-quarter-and-year-end-2025-results-e6b6fb2d 2026-03-12 https://biopharmsignal.com/news/ENSG/the-ensign-group-to-present-at-the-oppenheimer-36th-annual-healthcare-medtech-se-f9d44416 2026-03-12 https://biopharmsignal.com/news/IRIX/iridex-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-26-2026 2026-03-12 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-reports-fourth-quarter-2025-financial-results-and-provides-corporate-update 2026-03-12 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-update 2026-03-12 https://biopharmsignal.com/news/INAB/in8bio-reports-fourth-quarter-and-full-year-2025-financial-results-highlights-durable-survival-improvements-in-glioblastoma-advancing-pipeline-and-strengthened-financial-position-for-2026 2026-03-12 https://biopharmsignal.com/news/XENE/xenon-pharmaceuticals-announces-closing-of-747-5-million-upsized-public-offering-including-full-exercise-of-the-underwriters-option-to-purchase-additional-shares 2026-03-12 https://biopharmsignal.com/news/BEAT/heartbeam-reports-fourth-quarter-and-full-year-2025-results 2026-03-12 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-12 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update 2026-03-12 https://biopharmsignal.com/news/ERAS/erasca-reports-fourth-quarter-and-full-year-2025-business-updates-and-financial-results 2026-03-12 https://biopharmsignal.com/news/MOLN/molecular-partners-reports-highlights-and-financial-results-for-full-year-2025-a13d0cee 2026-03-12 https://biopharmsignal.com/news/PRI/primerica-household-budget-indextm-data-purchasing-power-for-middle-income-americans-remains-stable-in-january 2026-03-12 https://biopharmsignal.com/news/LGVN/longeveron-to-report-2025-full-year-financial-results-and-host-conference-call-o-17f05ec3 2026-03-12 https://biopharmsignal.com/news/PRCT/procept-biorobotics-announces-international-launch-of-the-hydros-robotic-system--ddb6e23e 2026-03-12 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-late-breaking-hope-3-data-at-the-2026-mda-conference-demonstrating-significant-functional-benefits-of-deramiocel-for-duchenne-muscular-dystrophy 2026-03-12 https://biopharmsignal.com/news/NXGL/nexgel-announces-consideration-terms-of-agreement-to-license-and-acquire-portfolio-of-commercial-stage-regenerative-biomaterial-products 2026-03-12 https://biopharmsignal.com/news/SLS/sellas-life-sciences-announces-enrollment-of-first-patient-in-newly-diagnosed-first-line-aml-trial-of-sls009 2026-03-12 https://biopharmsignal.com/news/RARE/ultragenyx-announces-positive-36-week-data-from-phase-3-study-of-dtx301-aav8-gen-cc3ecd9c 2026-03-12 https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-1-for-14-reverse-stock-split-56dd657c 2026-03-12 https://biopharmsignal.com/news/OGEN/oragenics-initiates-phase-iia-clinical-trial-site-activation 2026-03-12 https://biopharmsignal.com/news/CADL/candel-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights 2026-03-12 https://biopharmsignal.com/news/IXHL/incannex-healthcare-inc-announces-pricing-of-10-million-registered-direct-offeri-5ad32d13 2026-03-12 https://biopharmsignal.com/news/AEMD/aethlon-medical-engages-maxim-group-llc-to-evaluate-strategic-opportunities 2026-03-12 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-release-full-year-2025-financial-results-and-host-conference-call-and-webcast-on-march-19 2026-03-12 https://biopharmsignal.com/news/IXHL/incannex-strengthens-clinical-development-pathway-for-ihl-42x-following-positive-1b43bd05 2026-03-12 https://biopharmsignal.com/news/BIVI/biovie-announces-abstract-accepted-for-presentation-at-ad-pd-2026-b3e6adf3 2026-03-12 https://biopharmsignal.com/news/CLNN/clene-reports-full-year-2025-financial-results-and-recent-operating-highlights-b436e9a7 2026-03-12 https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-full-year-2025-financial-results-and-business-updat-7b62a847 2026-03-12 https://biopharmsignal.com/news/ARDX/ardelyx-announces-recipients-of-the-2026-derek-forfang-patient-advocate-award-ccc7fd8f 2026-03-12 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-20-2026 2026-03-12 https://biopharmsignal.com/news/AVAH/aveanna-healthcare-holdings-announces-agreement-to-acquire-family-first-homecare 2026-03-12 https://biopharmsignal.com/news/IFRX/inflarx-to-report-full-year-2025-results-on-march-19-2026-cc631b96 2026-03-12 https://biopharmsignal.com/news/INTS/intensity-therapeutics-inc-provides-update-on-the-phase-2-presurgical-triple-negative-breast-cancer-invincible-4-study 2026-03-12 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-guidance 2026-03-12 https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-participate-in-the-stifel-2026-virtual-cns-forum 2026-03-12 https://biopharmsignal.com/news/INDV/indivior-announces-proposed-convertible-senior-notes-offering-e75952f0 2026-03-12 https://biopharmsignal.com/news/CRVO/cervomed-announces-presentations-at-upcoming-ad-pd-2026-scientific-conference-fb00b88c 2026-03-12 https://biopharmsignal.com/news/GANX/gain-therapeutics-announces-presentations-at-ad-pdtm-2026-and-provides-u-s-fda-r-83a077e3 2026-03-12 https://biopharmsignal.com/news/PRQR/proqr-announces-year-end-2025-operating-and-financial-results-e00424a1 2026-03-12 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-report-fourth-quarter-2025-financial-results-on-thursday-march-19-2026 2026-03-12 https://biopharmsignal.com/news/ALKS/alkermes-announces-inaugural-alkermes-pathways-apn-research-awardstm-program 2026-03-12 https://biopharmsignal.com/news/DTIL/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides-business-update 2026-03-12 https://biopharmsignal.com/news/PLSE/pulse-biosciences-inc-announces-first-enrollments-in-feasibility-study-for-the-treatment-of-malignant-thyroid-tumors-with-npulsetm-technology 2026-03-12 https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates 2026-03-12 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-announces-follow-on-multi-system-order-from-samsung-biologics-to-expand-deployment-of-growth-directr-platform 2026-03-12 https://biopharmsignal.com/news/XOMA/xoma-royalty-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-18-2026 2026-03-12 https://biopharmsignal.com/news/BJDX/bluejay-announces-abstract-accepted-for-presentation-at-the-2026-society-of-academic-emergency-medicine-saem-annual-meeting 2026-03-12 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-an-764c2333 2026-03-12 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-12 https://biopharmsignal.com/news/PSNL/personalis-announces-new-publication-advancing-neoadjuvant-treatment-monitoring-in-breast-cancer-with-next-personalr 2026-03-12 https://biopharmsignal.com/news/FMS/fresenius-medical-care-publishes-its-annual-report-2025-the-power-of-care 2026-03-11 https://biopharmsignal.com/news/PCRX/pacira-biosciences-reaffirms-commitment-to-shareholder-value-creation 2026-03-11 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-closing-of-8-0-million-registered-direct-offering 2026-03-11 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-financial-update-for-2025-and-2026-strategic-outlook 2026-03-11 https://biopharmsignal.com/news/AZYO/elutia-reports-fourth-quarter-and-full-year-2025-financial-results-initiates-nxt-41-regulatory-process 2026-03-11 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-11 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-fourth-quarter-2025-financial-results 2026-03-11 https://biopharmsignal.com/news/BSEM/biostem-technologies-to-host-fourth-quarter-and-full-year-2025-financial-results-854415ae 2026-03-11 https://biopharmsignal.com/news/LGMK/logicmark-inc-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-dbe34635 2026-03-11 https://biopharmsignal.com/news/LGVN/longeveron-announces-closing-of-private-placement-of-up-to-30-million-04e8e009 2026-03-11 https://biopharmsignal.com/news/BTMD/biote-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-11 https://biopharmsignal.com/news/SLDB/solid-biosciences-provides-interim-positive-clinical-update-on-phase-1-2-inspire-11d715d3 2026-03-11 https://biopharmsignal.com/news/INDV/new-study-shows-adherence-to-monthly-injectable-buprenorphine-linked-to-lower-he-c4a4406e 2026-03-11 https://biopharmsignal.com/news/MBRX/moleculin-releases-next-ceo-corner-segment-highlighting-miracle-study-bca5edd3 2026-03-11 https://biopharmsignal.com/news/GDRX/goodrx-partners-with-viatris-to-offer-up-to-85-savings-on-established-brand-medications 2026-03-11 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-announces-fda-grants-fast-track-designation-for-qrx003-for-a93a073f 2026-03-11 https://biopharmsignal.com/news/SLRX/decoy-therapeutics-enters-strategic-partnership-with-quantori-to-deploy-google-cloud-native-integrated-ai-driven-peptide-design-and-molecular-simulation-platform 2026-03-11 https://biopharmsignal.com/news/OGEN/oragenics-explores-expansion-of-cns-platform-pursuing-acquistion-of-assets-in-brain-health-recovery-and-neuroprotection 2026-03-11 https://biopharmsignal.com/news/ICCM/u-s-fda-approves-icecure-s-post-marketing-choice-study-for-prosenser-cryoablation-in-the-local-treatment-of-low-risk-breast-cancer 2026-03-11 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-11 https://biopharmsignal.com/news/TPST/tempest-announces-partnership-for-tpst-2003-in-preparation-for-planned-u-s-registrational-study-in-2026 2026-03-11 https://biopharmsignal.com/news/LXRX/lexicon-to-present-data-on-effect-of-kidney-function-on-the-long-term-efficacy-a-9188aa43 2026-03-11 https://biopharmsignal.com/news/BFRG/bullfrog-to-host-webinar-on-new-precision-ai-capability 2026-03-11 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results--035d96f1 2026-03-11 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-announces-publication-of-peer-reviewed-study-evaluating-the-e-7ca921f2 2026-03-11 https://biopharmsignal.com/news/DTIL/precision-biosciences-receives-u-s-patent-allowances-covering-the-pbgene-hbv-program 2026-03-11 https://biopharmsignal.com/news/ARVN/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimer-s-and-parkinson-s-diseases-and-related-neurological-disorders 2026-03-11 https://biopharmsignal.com/news/NERV/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-business-updates 2026-03-11 https://biopharmsignal.com/news/XAIR/beyond-air-to-participate-in-the-38th-annual-roth-conference-in-march-0d42932a 2026-03-11 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-prices-upsized-convertible-senior-notes-offering 2026-03-11 https://biopharmsignal.com/news/PHVS/validation-of-patient-reported-outcomes-in-the-on-demand-treatment-of-hereditary-6bdeae9d 2026-03-11 https://biopharmsignal.com/news/XENE/xenon-pharmaceuticals-announces-pricing-of-upsized-650-0-million-public-offering 2026-03-11 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-keybanc-capital-markets-healthcare-forum 2026-03-10 https://biopharmsignal.com/news/TELA/tela-bio-to-announce-fourth-quarter-and-full-year-2025-financial-results 2026-03-10 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-stifel-2026-virtual-cns-forum-a57479a4 2026-03-10 https://biopharmsignal.com/news/ALKS/alkermes-to-present-at-the-stifel-2026-virtual-cns-forum 2026-03-10 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-approximately-8-0-million-registered-direct-offering 2026-03-10 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-establishment-of-new-pdufa-date-for-deramiocel-bla 2026-03-10 https://biopharmsignal.com/news/ARQT/arcutis-announces-publication-of-positive-long-term-safety-and-efficacy-data-with-zoryver-roflumilast-cream-0-05-for-treatment-of-mild-to-moderate-atopic-dermatitis-in-children-ages-2-5-in-pediatric-dermatology 2026-03-10 https://biopharmsignal.com/news/FEMY/femasys-advances-fembloc-toward-u-s-approval-with-initiation-of-pivotal-trial-en-156e441c 2026-03-10 https://biopharmsignal.com/news/PRPO/precipio-announces-publication-of-a-joint-study-with-memorial-sloan-kettering-ca-532f6a8d 2026-03-10 https://biopharmsignal.com/news/LGVN/longeveron-announces-private-placement-of-up-to-30-million-17b83701 2026-03-10 https://biopharmsignal.com/news/NXGL/nexgel-signs-definitive-agreement-to-license-and-acquire-transformative-portfolio-of-commercial-stage-regenerative-biomaterial-products 2026-03-10 https://biopharmsignal.com/news/CLOV/updated-moving-from-pledge-to-production-clover-health-is-now-live-on-kno2-participating-in-recently-announced-federal-interoperability-initiatives 2026-03-10 https://biopharmsignal.com/news/DRMA/dermata-announces-appointment-of-kyra-peckaitis-as-vice-president-marketing 2026-03-10 https://biopharmsignal.com/news/OGEN/oragenics-receives-hrec-approval-for-phase-iia-clinical-trial-of-onp-002-as-a-treatment-for-concussion-and-mild-traumatic-brain-injury-in-australia 2026-03-10 https://biopharmsignal.com/news/ICCM/icecure-medical-to-report-2025-full-year-financial-and-operating-results-on-march-17-2026 2026-03-10 https://biopharmsignal.com/news/APVO/mipletamig-delivers-compelling-86-clinical-benefit-rate-and-no-crs-as-evaluable-aml-patient-data-increases-by-nearly-50 2026-03-10 https://biopharmsignal.com/news/ECOR/electrocore-to-participate-at-the-38th-annual-roth-conference-da42a9a3 2026-03-10 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-announces-submission-of-marketing-authorization-application-to-european-medicines-agency-for-vizzr-for-the-treatment-of-presbyopia 2026-03-10 https://biopharmsignal.com/news/LPCN/lipocine-announces-financial-results-for-the-full-year-ended-december-31-2025 2026-03-10 https://biopharmsignal.com/news/TARA/protara-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update 2026-03-10 https://biopharmsignal.com/news/XGN/exagen-inc-reports-strong-fourth-quarter-and-full-year-2025-results 2026-03-10 https://biopharmsignal.com/news/ERAS/erasca-exercises-option-to-secure-worldwide-rights-for-eras-0015-pan-ras-molecular-glue-to-include-china-hong-kong-and-macau 2026-03-10 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypathr-lung-cancer-diagnostic 2026-03-10 https://biopharmsignal.com/news/SABS/sab-bio-announces-additional-phase-1-data-for-sab-142-in-adult-patients-with-established-autoimmune-type-1-diabetes 2026-03-10 https://biopharmsignal.com/news/XAIR/beyond-air-announces-termination-of-agreement-to-sell-its-neuronos-subsidiary-to-92765e52 2026-03-10 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-and-open-hearts-for-orphans-announce-community-partnership-to-strengthen-families-and-support-vulnerable-children 2026-03-10 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-full-year-2025-financial-results-and-provides-program-outlook-for-2026 2026-03-10 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-announces-orphan-drug-designation-granted-to-tegoprubart--03b9004b 2026-03-10 https://biopharmsignal.com/news/TENX/tenax-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-a-98490282 2026-03-10 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-reports-fourth-quarter-and-full-year-2025-financial-res-346b24eb 2026-03-10 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-f-23091110 2026-03-10 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-late-breaking-oral-presentation-of-kt-621-phase-1b-b0905fa0 2026-03-10 https://biopharmsignal.com/news/LEGN/legend-biotech-reports-fourth-quarter-and-full-year-2025-results-and-recent-high-0e5399b6 2026-03-10 https://biopharmsignal.com/news/BNTC/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progress-for-bb-301-the-only-clinical-stage-therapeutic-in-development-for-oculopharyngeal-muscular-dystrophy-opmd 2026-03-10 https://biopharmsignal.com/news/BEAT/heartbeam-and-mount-sinai-announce-strategic-ai-collaboration-to-bring-clinical-grade-heart-monitoring-into-the-home 2026-03-10 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-announces-proposed-convertible-senior-notes-offering 2026-03-10 https://biopharmsignal.com/news/GSK/gsk-tops-antimicrobial-resistance-amr-benchmark-report 2026-03-10 https://biopharmsignal.com/news/BNTX/biontech-ver-ffentlicht-ergebnisse-f-r-das-vierte-quartal-und-das-gesch-ftsjahr--96e2f59e 2026-03-10 https://biopharmsignal.com/news/BNTX/biontech-announces-fourth-quarter-and-full-year-2025-financial-results-and-corpo-fd54f272 2026-03-10 https://biopharmsignal.com/news/ESPR/esperion-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-10 https://biopharmsignal.com/news/INKT/mink-therapeutics-announces-collaboration-with-c-further-to-advance-prame-target-62ce272a 2026-03-10 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-upgrades-from-otc-pink-to-otcqb-venture-market 2026-03-10 https://biopharmsignal.com/news/FMS/fresenius-medical-care-marks-world-kidney-day-and-national-kidney-month 2026-03-09 https://biopharmsignal.com/news/CELC/celcuity-announces-publication-of-results-from-pik3ca-wild-type-cohort-of-phase--c30e0bbc 2026-03-09 https://biopharmsignal.com/news/BFRI/biofrontera-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-an-ef87fde0 2026-03-09 https://biopharmsignal.com/news/SABS/sab-bio-reports-full-year-2025-financial-results-and-business-highlights 2026-03-09 https://biopharmsignal.com/news/HUM/humana-completes-aggregate-1-0-billion-fixed-to-fixed-rate-junior-subordinated-notes-offering 2026-03-09 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-present-at-the-leerink-partners-global-healthcare-conference 2026-03-09 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-fda-acceptance-of-nda-for-lorundrostat-for-treatment-of-adults-with-hypertension-and-topline-explore-osa-trial-results 2026-03-09 https://biopharmsignal.com/news/CHRS/coherus-oncology-reports-full-year-and-fourth-quarter-2025-financial-results-and-provides-business-update 2026-03-09 https://biopharmsignal.com/news/ZVRA/zevra-reports-fourth-quarter-and-full-year-2025-financial-results-12577790 2026-03-09 https://biopharmsignal.com/news/ARDX/ardelyx-announces-publication-of-a-review-article-demonstrating-rapid-and-meanin-8d7f1b23 2026-03-09 https://biopharmsignal.com/news/BNGO/bionano-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-a-conference-call-webcast-on-march-23-2026 2026-03-09 https://biopharmsignal.com/news/DRTS/alpha-tau-announces-full-year-2025-financial-results-and-provides-corporate-upda-17a1c2fd 2026-03-09 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-grant-of-inducement-award-pursuant-to-nasdaq-listing-rule-5635-c-4 2026-03-09 https://biopharmsignal.com/news/DSGN/design-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-updates 2026-03-09 https://biopharmsignal.com/news/STXS/stereotaxis-reports-2025-full-year-financial-results-06b96163 2026-03-09 https://biopharmsignal.com/news/VYGR/voyager-reports-fourth-quarter-and-full-year-2025-financial-and-operating-result-dc8e2ed1 2026-03-09 https://biopharmsignal.com/news/XENE/xenon-pharmaceuticals-announces-proposed-public-offering 2026-03-09 https://biopharmsignal.com/news/MGNX/macrogenics-reports-2025-financial-results-and-highlights-upcoming-planned-data-disclosures 2026-03-09 https://biopharmsignal.com/news/GNFT/genfit-receives-fda-orphan-drug-designation-for-ntz-for-the-treatment-of-aclf 2026-03-09 https://biopharmsignal.com/news/BFRI/biofrontera-inc-reports-positive-phase-2b-results-supporting-further-development-930fe699 2026-03-09 https://biopharmsignal.com/news/MNKD/mannkind-to-present-new-data-from-pediatric-and-adult-studies-of-afrezzar-at-attd-2026 2026-03-09 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-presents-preclinical-data-at-mda-2026-highlighting-tn-301-s-potential-to-correct-skeletal-and-cardiac-muscle-decline-in-duchenne-muscular-dystrophy 2026-03-09 https://biopharmsignal.com/news/BDRX/biodexa-announces-support-for-life-s-a-polyp-foundation-first-u-s-patient-advoca-f1734776 2026-03-09 https://biopharmsignal.com/news/XRAY/first-ever-dental-dedicated-mri-validated-in-clinical-trial-and-cleared-by-fda-f-162e3f15 2026-03-09 https://biopharmsignal.com/news/VERU/veru-enrolls-first-patient-in-phase-2b-plateau-clinical-trial-of-enobosarm-and-semaglutide-combination-for-high-quality-weight-loss 2026-03-09 https://biopharmsignal.com/news/ICCM/american-society-of-breast-surgeons-asbrs-resource-guide-update-recommends-cryoablation-for-low-risk-breast-cancer 2026-03-09 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-update-on-march-12 2026-03-09 https://biopharmsignal.com/news/CADL/candel-therapeutics-to-present-new-data-after-extended-follow-up-from-randomized-phase-3-trial-of-aglatimagene-besadenovec-in-localized-prostate-cancer-at-the-american-urological-association-2026-annual-meeting 2026-03-09 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-advances-rolling-submission-of-bla-to-u-s-fda-for-st-920-in-f44ebdf7 2026-03-09 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-closing-of-additional-50-million-tranche-of-equity-private-placement-and-appointment-of-smital-shah-as-chief-financial-and-business-officer 2026-03-09 https://biopharmsignal.com/news/CUE/cue-biopharma-to-present-new-in-vitro-data-for-cue-401-at-the-20th-world-immune--416a4eef 2026-03-09 https://biopharmsignal.com/news/COCP/first-subjects-dosed-in-cocrystal-pharma-s-phase-1b-study-evaluating-cdi-988-for-7f11a93c 2026-03-09 https://biopharmsignal.com/news/ECOR/electrocore-to-announce-fourth-quarter-and-full-year-ended-december-31-2025-fina-c6f97ade 2026-03-09 https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-collaboration-with-sean-m-healey-amg-center-for-als-d15ac672 2026-03-09 https://biopharmsignal.com/news/KROS/keros-therapeutics-presents-additional-clinical-data-from-its-rinvatercept-progr-c434ac4c 2026-03-09 https://biopharmsignal.com/news/TCMD/tactile-medical-strengthens-board-of-directors-with-appointment-of-andrea-pearson 2026-03-09 https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-on-thursday-march-12-2026 2026-03-09 https://biopharmsignal.com/news/GSK/gsk-and-alfasigma-announce-agreement-on-worldwide-rights-for-linerixibat 2026-03-09 https://biopharmsignal.com/news/TGTX/data-published-in-neurology-and-therapy-demonstrate-significant-reductions-in-relapse-and-mri-activity-with-briumvir-in-people-with-highly-active-relapsing-multiple-sclerosis 2026-03-09 https://biopharmsignal.com/news/IBRX/immunitybio-announces-resubmission-of-supplemental-bla-to-the-fda-for-anktivar-plus-bcg-in-bcg-unresponsive-nmibc-with-papillary-disease-following-agency-review-of-additional-data 2026-03-09 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-provides-business-update-highlighting-building-momentum-in-zevaskynr-commercial-launch 2026-03-09 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-reports-q4-and-2025-financial-results-and-provides-a-corporate-update 2026-03-09 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-to-participate-in-the-bell-potter-healthcare-horizons-summ-5a9dcf39 2026-03-09 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-announces-oversubscribed-160-0-million-private-placement-financing 2026-03-09 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-reports-full-year-2025-financial-results-and-provides-bus-6a3cca66 2026-03-09 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2025-results-and-business-e271cf25 2026-03-09 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-reports-12-month-phase-2-interim-data-for-ndv-01-in-non-muscle-invasive-bladder-cancer 2026-03-09 https://biopharmsignal.com/news/BNTC/benitec-biopharma-announces-positive-interim-phase-1b-2a-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-treatment-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference 2026-03-09 https://biopharmsignal.com/news/IBIO/ibio-reports-preclinical-body-composition-data-from-obese-non-human-primates-treated-with-ibio-610-a-potential-first-in-class-treatment-for-fat-selective-weight-loss 2026-03-09 https://biopharmsignal.com/news/BEAT/heartbeam-to-attend-investor-and-industry-conferences-in-march-focused-on-providing-updates-on-commercial-launch-and-unveiling-12-lead-ecg-extended-wear-patch 2026-03-09 https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-40-million-private-placement-financing 2026-03-09 https://biopharmsignal.com/news/PLSE/pulse-biosciences-announces-clinical-data-from-npulsetm-vybrancetm-system-first-in-human-clinical-durability-study-of-benign-thyroid-nodule-ablation 2026-03-09 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-positive-phase-3-results-from-the-successor-2-study-of-oral-mezigdomide-in-relapsed-or-refractory-multiple-myeloma 2026-03-09 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results--8a193b99 2026-03-09 https://biopharmsignal.com/news/YOU/clear-and-ochsner-health-partner-to-improve-healthcare-experiences-across-locations-in-louisiana-mississippi-and-alabama 2026-03-09 https://biopharmsignal.com/news/HCM/hutchmed-announces-update-on-licensed-oncology-product-tazverik-in-china-9044eb13 2026-03-09 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-initiation-of-phase-3-harmonia-trial-of-z-basivarsen-in-myotonic-dystrophy-type-1-dm1 2026-03-08 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-new-positive-cardiopulmonary-results-from-deliver-trial-of-z-rostudirsen-in-duchenne-muscular-dystrophy-dmd 2026-03-08 https://biopharmsignal.com/news/BMY/u-s-fda-approves-bristol-myers-squibb-s-sotyktur-deucravacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis 2026-03-07 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-enters-into-definitive-agreement-to-be-acquired-by-kuva-labs-inc 2026-03-06 https://biopharmsignal.com/news/MGRX/mangoceuticals-inc-announces-pct-patent-filing-for-mgx-0024-antiviral-technology-b8252b74 2026-03-06 https://biopharmsignal.com/news/PGNY/progyny-inc-executives-to-participate-in-upcoming-investor-conferences 2026-03-06 https://biopharmsignal.com/news/GDRX/goodrx-to-expand-employer-sponsored-access-to-zepboundr-kwikpenr 2026-03-06 https://biopharmsignal.com/news/SLDB/solid-biosciences-announces-oversubscribed-240-million-private-placement-2862c1f7 2026-03-06 https://biopharmsignal.com/news/DAWN/servier-and-day-one-biopharmaceuticals-announce-acquisition-to-expand-servier-s-rare-oncology-portfolio 2026-03-06 https://biopharmsignal.com/news/SLDB/solid-biosciences-to-present-at-the-2026-muscular-dystrophy-association-mda-clin-e478715c 2026-03-06 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and-corporate-highlights 2026-03-06 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-closes-20-million-financing-to-accelerate-the-advance-of-s-29a7eed1 2026-03-06 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-fourth-quarter-and-full-year-2025-results-march-17-2026 2026-03-06 https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-reverse-stock-split 2026-03-06 https://biopharmsignal.com/news/INTS/intensity-therapeutics-regains-compliance-with-nasdaq-s-minimum-bid-price-requirement 2026-03-06 https://biopharmsignal.com/news/IMRX/immuneering-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates 2026-03-06 https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-schedule-of-data-presentations-for-briumvir-ublituximab-in-multiple-sclerosis-at-the-american-academy-of-neurology-2026-annual-meeting 2026-03-06 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-provides-corporate-update-and-2026-strategic-outlook 2026-03-06 https://biopharmsignal.com/news/HCM/intended-retirement-of-independent-non-executive-director-and-changes-of-composi-09f79993 2026-03-06 https://biopharmsignal.com/news/ARGX/argenx-to-present-new-data-at-2026-aan-annual-meeting-that-continue-to-transform-e336f7a0 2026-03-06 https://biopharmsignal.com/news/HUM/humana-prices-1-0-billion-fixed-to-fixed-rate-junior-subordinated-notes-offering 2026-03-06 https://biopharmsignal.com/news/MDWD/mediwound-files-annual-report-on-form-20-f-eafb2fdf 2026-03-05 https://biopharmsignal.com/news/MNKD/mannkind-announces-settlement-of-convertible-senior-notes 2026-03-05 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-to-present-new-data-from-neuroimmunology-franchise-at-aan-2-6dba1491 2026-03-05 https://biopharmsignal.com/news/COO/coopercompanies-announces-first-quarter-2026-results-c5617842 2026-03-05 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-provides-update-following-type-a-meeting-with-fda-regarding-ons-5010-lytenavatm-bevacizumab-vikg 2026-03-05 https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-05 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-05 https://biopharmsignal.com/news/NXTC/nextcure-provides-business-update-and-reports-full-year-2025-financial-results-d73e1a5a 2026-03-05 https://biopharmsignal.com/news/AMRX/amneal-to-participate-in-upcoming-investor-conference 2026-03-05 https://biopharmsignal.com/news/HYPR/hyperfine-inc-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-18-2026 2026-03-05 https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-05 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026 2026-03-05 https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2025-results-and-provides-corporate-update 2026-03-05 https://biopharmsignal.com/news/INGN/inogen-announces-participation-in-the-keybanc-virtual-life-sciences-and-medtech-investor-forum 2026-03-05 https://biopharmsignal.com/news/ARQT/arcutis-announces-promotion-of-mas-matsuda-to-executive-vice-president-and-chief-legal-officer-to-support-next-phase-of-growth 2026-03-05 https://biopharmsignal.com/news/VERA/vera-therapeutics-appoints-christopher-hite-to-board-of-directors-df1891e8 2026-03-05 https://biopharmsignal.com/news/DRMA/dermata-opens-a-new-chapter-with-the-release-of-tome-skincare 2026-03-05 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-enters-into-research-collaboration-with-alnylam-pharmaceuticals-to-identify-and-validate-novel-genetic-targets-for-cardiovascular-disease-therapeutics 2026-03-05 https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wv-80808d62 2026-03-05 https://biopharmsignal.com/news/PACB/pacbio-announces-the-appointment-of-chris-gibson-to-the-board-of-directors-b93b07ea 2026-03-05 https://biopharmsignal.com/news/SLRX/decoy-therapeutics-announces-1-for-12-reverse-stock-split 2026-03-05 https://biopharmsignal.com/news/ICU/seastar-medical-announces-completion-of-fda-enrollment-requirement-for-save-surv-ef1c429a 2026-03-05 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026 2026-03-05 https://biopharmsignal.com/news/MDXG/mimedx-expands-surgical-product-portfolio-with-the-launch-of-amniofixr-thyroid-shields 2026-03-05 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2025-financial-results 2026-03-05 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-inc-to-participate-in-the-be-well-beauty-and-wellness-s-cc988f68 2026-03-05 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-receives-health-canada-clearance-to-initiate-phase-2-study-of-dm199-in-preeclampsia 2026-03-05 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-appoints-justin-renz-as-chief-financial-officer-f1bde4fd 2026-03-05 https://biopharmsignal.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-pro-3ab86416 2026-03-05 https://biopharmsignal.com/news/CRVO/cervomed-to-participate-in-upcoming-investor-conferences-59aadfc0 2026-03-05 https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-2025-financial-results-and-provides-corporate-updat-e02da3d4 2026-03-05 https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-upcoming-march-conferences-f4c89047 2026-03-05 https://biopharmsignal.com/news/NEPH/nephros-schedules-fourth-quarter-2025-financial-results-conference-call-d964bd22 2026-03-05 https://biopharmsignal.com/news/ERAS/erasca-and-tango-therapeutics-enter-into-clinical-collaboration-to-evaluate-combination-of-eras-0015-and-vopimetostat 2026-03-05 https://biopharmsignal.com/news/IMTX/immatics-announces-full-year-2025-financial-results-and-business-update 2026-03-05 https://biopharmsignal.com/news/GHRS/gh-research-reports-full-year-2025-financial-results-and-provides-business-update 2026-03-05 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-positive-phase-2-topline-results-from-columbia-university-led-study-of-bxcl501-for-treatment-of-opioid-withdrawal 2026-03-05 https://biopharmsignal.com/news/TNGX/tango-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights 2026-03-05 https://biopharmsignal.com/news/MDWD/mediwound-reports-fourth-quarter-and-full-year-2025-financial-results-f2af1ec2 2026-03-05 https://biopharmsignal.com/news/ACIU/ac-immune-announces-upcoming-industry-symposium-on-parkinson-s-disease-and-prese-a50b1ce2 2026-03-05 https://biopharmsignal.com/news/ALT/altimmune-announces-fourth-quarter-and-full-year-2025-financial-results-and-busi-86f63ebd 2026-03-05 https://biopharmsignal.com/news/BEAT/heartbeam-announces-first-patient-enrollments-in-heart-attack-detection-pilot-study 2026-03-05 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-reports-fourth-quarter-2025-financial-results-and-provid-bb33c332 2026-03-05 https://biopharmsignal.com/news/KURA/kura-oncology-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-05 https://biopharmsignal.com/news/ZURA/zura-bio-to-present-phase-2-tibusure-study-design-poster-evaluating-dual-il-17a-and-baff-inhibition-in-systemic-sclerosis-at-9th-systemic-sclerosis-world-congress 2026-03-05 https://biopharmsignal.com/news/LQDA/liquidia-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-05 https://biopharmsignal.com/news/STTK/shattuck-labs-reports-fourth-quarter-and-full-year-2025-financial-results-and-re-09fb026b 2026-03-05 https://biopharmsignal.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-at-coffee-microcaps-conference-66b1c8e8 2026-03-05 https://biopharmsignal.com/news/HCM/hutchmed-reports-2025-full-year-results-and-business-updates-25f73567 2026-03-05 https://biopharmsignal.com/news/SCYX/scynexis-reports-full-year-2025-financial-results-and-provides-corporate-update 2026-03-04 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2025-financial-results 2026-03-04 https://biopharmsignal.com/news/LUNG/pulmonx-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-04 https://biopharmsignal.com/news/LUNG/pulmonx-announces-closing-of-up-to-60-million-credit-facility 2026-03-04 https://biopharmsignal.com/news/SGHT/sight-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-initiates-full-year-2026-financial-guidance 2026-03-04 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-leerink-partners-2026-global-healthcare-602ce959 2026-03-04 https://biopharmsignal.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-year-ended-december-31-20-51542aad 2026-03-04 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-to-participate-in-upcoming-investor-conferences-in-march 2026-03-04 https://biopharmsignal.com/news/PEPG/pepgen-reports-fourth-quarter-and-year-end-2025-financial-results-and-recent-corporate-highlights 2026-03-04 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-participate-in-the-citizens-life-sciences-conference 2026-03-04 https://biopharmsignal.com/news/PEPG/pepgen-announces-regulatory-updates-on-freedom2 2026-03-04 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-04 https://biopharmsignal.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-ful-37a05541 2026-03-04 https://biopharmsignal.com/news/BEAT/heartbeam-to-host-fourth-quarter-full-year-2025-results-conference-call-on-thursday-march-12-2026-at-4-30-p-m-eastern-time 2026-03-04 https://biopharmsignal.com/news/MKT/maia-biotechnology-announces-closing-of-30-million-underwritten-public-offering-of-common-stock 2026-03-04 https://biopharmsignal.com/news/AZTA/azenta-completes-strategic-acquisition-of-uk-biocentre-limited-to-expand-biorepository-capabilities 2026-03-04 https://biopharmsignal.com/news/MNKD/mannkind-to-participate-in-upcoming-investor-conferences 2026-03-04 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-initiates-live-ask-me-anything-ama-session-highlighting-growth-and-future-plans 2026-03-04 https://biopharmsignal.com/news/OCGN/ocugen-provides-business-update-with-fourth-quarter-and-full-year-2025-financial-798f96dd 2026-03-04 https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-fourth-quarter-and-fiscal-year-2025-financial-results-on-march-18-2026 2026-03-04 https://biopharmsignal.com/news/AZYO/elutia-regains-compliance-with-nasdaq-listing-requirements 2026-03-04 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-inc-issues-letter-to-shareholders-highlighting-major-mi-a7db1c1c 2026-03-04 https://biopharmsignal.com/news/ARDX/ardelyx-to-participate-in-upcoming-investor-conferences-15d358d0 2026-03-04 https://biopharmsignal.com/news/VCEL/vericel-announces-fda-approval-of-new-state-of-the-art-advanced-therapy-manufact-f3448bfd 2026-03-04 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-16-2026 2026-03-04 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-presents-data-at-srnt-demonstrating-successful-cessation-in-smokers-with-extensive-prior-treatment-exposure-and-on-participant-experience-in-the-orca-ol-study 2026-03-04 https://biopharmsignal.com/news/NGEN/nervgen-pharma-appoints-shamim-ruff-as-chief-regulatory-affairs-officer-and-chri-03268655 2026-03-04 https://biopharmsignal.com/news/CRVO/cervomed-announces-selection-of-formulation-and-dosing-regimen-for-planned-phase-9cace83b 2026-03-04 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-appoints-daniel-o-claassen-m-d-m-s-as-chief-medical-adviso-05efe00d 2026-03-04 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-clinical-research-collaboration-with-tampa-general-hospital-cancer-institute 2026-03-04 https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-participate-in-the-citizens-life-sciences-conference 2026-03-04 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-leerink-global-healt-0a237ea1 2026-03-04 https://biopharmsignal.com/news/EYPT/eyepoint-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlig-c73a9090 2026-03-04 https://biopharmsignal.com/news/HROW/harrow-to-present-at-leerink-partner-s-2026-global-healthcare-conference-3ffdcb1b 2026-03-04 https://biopharmsignal.com/news/BEAT/heartbeam-announces-first-commercial-customer-as-clearcardio-brings-groundbreaking-12-lead-ecg-technology-to-high-growth-preventive-cardiology-market 2026-03-04 https://biopharmsignal.com/news/HCM/hutchmed-initiates-global-trial-of-pi3k-pikk-egfr-attc-candidate-hmpl-a580-in-pa-e0a35404 2026-03-04 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-resul-bb27988e 2026-03-03 https://biopharmsignal.com/news/PRQR/proqr-announces-webcast-of-presentation-at-the-2026-citizens-life-sciences-confe-b754a217 2026-03-03 https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-ubs-global-consumer-and-retail-conference 2026-03-03 https://biopharmsignal.com/news/ROIV/roivant-announces-genevant-sciences-and-arbutus-biopharma-s-2-25-billion-global-settlement-with-moderna 2026-03-03 https://biopharmsignal.com/news/ABUS/genevant-sciences-and-arbutus-biopharma-announce-2-25-billion-global-settlement-with-moderna 2026-03-03 https://biopharmsignal.com/news/XRAY/dentsply-sirona-to-participate-in-the-leerink-partners-global-healthcare-confere-470b8a17 2026-03-03 https://biopharmsignal.com/news/ANAB/anaptys-provides-update-on-business-separation-and-announces-fourth-quarter-and-full-year-2025-financial-results 2026-03-03 https://biopharmsignal.com/news/AORT/artivion-to-participate-in-the-oppenheimer-36th-annual-healthcare-medtech-and-services-conference 2026-03-03 https://biopharmsignal.com/news/SANA/sana-biotechnology-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-updates 2026-03-03 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update 2026-03-03 https://biopharmsignal.com/news/TDOC/teladoc-health-to-participate-in-upcoming-investor-conference-af0f802c 2026-03-03 https://biopharmsignal.com/news/FATE/fate-therapeutics-to-participate-in-leerink-partners-2026-global-healthcare-conference 2026-03-03 https://biopharmsignal.com/news/VXRT/vaxart-to-host-upcoming-conference-calls-f6082456 2026-03-03 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-three-upcoming-march-investor-conferen-d9c2f3ad 2026-03-03 https://biopharmsignal.com/news/RIGL/rigel-provides-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-03 https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-plans-to-advance-oral-epetraborole-into-phase-2-study-for-polycythemia-vera-pv 2026-03-03 https://biopharmsignal.com/news/EHC/encompass-health-rehabilitation-hospital-of-irmo-now-open-in-south-carolina 2026-03-03 https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-rapt-therapeutics 2026-03-03 https://biopharmsignal.com/news/SNTI/senti-biosciences-to-present-at-leerink-partners-2026-global-healthcare-conferen-876bf671 2026-03-03 https://biopharmsignal.com/news/XGN/exagen-inc-to-participate-in-upcoming-investor-conferences 2026-03-03 https://biopharmsignal.com/news/IMMX/immix-biopharma-to-participate-in-upcoming-investor-conferences-36bea774 2026-03-03 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-participate-in-the-leerink-partners-global-healthcare-co-15e8204a 2026-03-03 https://biopharmsignal.com/news/VCEL/vericel-to-present-at-multiple-upcoming-investor-conferences-eed98e2a 2026-03-03 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-presents-positive-research-findings-for-its-novel-diagnostic-platform-technology-to-identify-optimal-therapies-for-asthma-patients 2026-03-03 https://biopharmsignal.com/news/STIM/neuronetics-to-report-fourth-quarter-2025-financial-and-operating-results-and-host-conference-call 2026-03-03 https://biopharmsignal.com/news/TBPH/theravance-biopharma-reports-phase-3-cypress-study-did-not-meet-primary-endpoint-board-accelerates-strategic-review-and-announces-cost-reduction-actions 2026-03-03 https://biopharmsignal.com/news/ARQT/arcutis-begins-enrolling-phase-1a-1b-study-evaluating-arq-234-a-cd200r-agonist-in-healthy-volunteers-and-adults-with-atopic-dermatitis 2026-03-03 https://biopharmsignal.com/news/PRME/prime-medicine-reports-full-year-2025-financial-results-and-provides-business-updates 2026-03-03 https://biopharmsignal.com/news/CERT/certara-simcypr-simulator-results-replace-ten-human-trials-for-chronic-myeloid-leukemia-cml-therapy-asciminib 2026-03-03 https://biopharmsignal.com/news/ABSI/absci-strengthens-clinical-leadership-with-appointment-of-ransi-somaratne-m-d-facc-mba-as-chief-medical-officer 2026-03-03 https://biopharmsignal.com/news/ANVS/annovis-announces-two-presentations-at-the-ad-pd-2026-international-conference-44e4365d 2026-03-03 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-to-participate-in-upcoming-march-investor-conferences-443439e1 2026-03-03 https://biopharmsignal.com/news/BCDA/biocardia-late-breaking-echocardiography-clinical-results-from-cardiamp-hf-trial-ee891cb9 2026-03-03 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-present-at-the-leerink-partners-2026-global-healthcare-co-7586dcde 2026-03-03 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-showcase-advances-in-alzheimer-s-treatment-at-internat-34906892 2026-03-03 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-announces-first-peer-reviewed-clinical-publication-demonstrating-oral-overdose-protection-with-mpar-r-technology 2026-03-03 https://biopharmsignal.com/news/DCTH/delcath-systems-announces-publication-of-chopin-clinical-trial-results-in-the-lancet-oncology 2026-03-03 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-in-licenses-ctrna-biomarker-assay-to-facilitate-early-dia-5419c60d 2026-03-03 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-df95bb20 2026-03-03 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-date-of-fourth-quarter-full-year-2025-financial-results-and-participation-in-upcoming-2026-leerink-global-healthcare-conference 2026-03-03 https://biopharmsignal.com/news/NTLA/intellia-therapeutics-presents-longer-term-clinical-data-for-lonvoguran-ziclumeran-lonvo-z-hereditary-angioedema-hae-patient-focused-research-at-aaaai-2026 2026-03-03 https://biopharmsignal.com/news/USNA/190-usana-sponsored-athletes-earn-a-record-28-medals-at-2026-winter-olympic-games 2026-03-03 https://biopharmsignal.com/news/ROIV/priovant-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-brepocitinib-in-dermatomyositis 2026-03-03 https://biopharmsignal.com/news/TENX/tenax-therapeutics-to-participate-in-the-2026-leerink-partners-global-healthcare-a185aaea 2026-03-03 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-leerink-partners-2026-global-healthca-68eeb440 2026-03-03 https://biopharmsignal.com/news/HROW/harrow-to-initiate-phase-3-clinical-trial-seeking-to-expand-triesence-label-to-i-aa0f67bb 2026-03-03 https://biopharmsignal.com/news/PASG/passage-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-recent-business-highlights 2026-03-03 https://biopharmsignal.com/news/PEPG/pepgen-to-participate-in-the-leerink-global-healthcare-conference 2026-03-03 https://biopharmsignal.com/news/SRRK/scholar-rock-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights 2026-03-03 https://biopharmsignal.com/news/SRRK/correcting-and-replacing-scholar-rock-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights 2026-03-03 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-at-the-citizens-life-sciences-conference 2026-03-03 https://biopharmsignal.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences 2026-03-03 https://biopharmsignal.com/news/ESPR/esperion-therapeutics-and-corstasis-therapeutics-announce-esperion-s-definitive-agreement-to-acquire-corstasis-expanding-its-cardiovascular-franchise-with-enbumysttm-bumetanide-nasal-spray 2026-03-03 https://biopharmsignal.com/news/ANL/adlai-nortye-to-participate-in-upcoming-investor-conferences 2026-03-03 https://biopharmsignal.com/news/MKT/maia-biotechnology-announces-pricing-of-30-million-underwritten-public-offering-of-common-stock 2026-03-03 https://biopharmsignal.com/news/ALHC/alignment-healthcare-announces-pricing-of-secondary-offering 2026-03-03 https://biopharmsignal.com/news/MKT/maia-biotechnology-announces-proposed-underwritten-public-offering-of-common-stock-and-pre-funded-warrants 2026-03-02 https://biopharmsignal.com/news/ALHC/alignment-healthcare-announces-secondary-offering 2026-03-02 https://biopharmsignal.com/news/USNA/usana-health-sciences-to-participate-in-upcoming-investor-conferences 2026-03-02 https://biopharmsignal.com/news/IMRX/immuneering-to-present-at-the-leerink-global-healthcare-conference 2026-03-02 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-to-participate-in-the-leerink-partners-global-healthcare-conference-2026 2026-03-02 https://biopharmsignal.com/news/HROW/harrow-announces-q4-and-full-year-2025-financial-results-and-2026-financial-guid-a2d18172 2026-03-02 https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-appointment-of-richard-n-kender-as-executive-chair-and-interim-ceo-provides-business-updates 2026-03-02 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences 2026-03-02 https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-reports-fourth-quarter-and-full-year-2025-financial-resu-00aa85f7 2026-03-02 https://biopharmsignal.com/news/INBX/inhibrx-announces-participation-in-upcoming-scientific-conference 2026-03-02 https://biopharmsignal.com/news/CHRS/coherus-oncology-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-9-2026 2026-03-02 https://biopharmsignal.com/news/SABS/sab-bio-to-participate-in-upcoming-investor-conferences 2026-03-02 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-launches-randomized-colorectal-cancer-study-a171785c 2026-03-02 https://biopharmsignal.com/news/ASND/ascendis-pharma-to-participate-in-the-td-cowen-46th-annual-health-care-conference 2026-03-02 https://biopharmsignal.com/news/CVRX/cvrx-announces-late-breaking-data-and-scientific-presentations-highlighting-barostim-outcomes-at-the-tht-2026-annual-meeting 2026-03-02 https://biopharmsignal.com/news/CRMD/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-p-fccea034 2026-03-02 https://biopharmsignal.com/news/AZYO/elutia-selects-pete-ligotti-as-cco-to-lead-the-commercial-launch-of-nxt-41x-and-transform-post-mastectomy-care-in-the-1-5b-u-s-breast-surgery-market 2026-03-02 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-enters-into-agreement-to-acquire-cullgen-to-gain-targeted-prot-8faa2981 2026-03-02 https://biopharmsignal.com/news/HCWB/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-d4325b9b 2026-03-02 https://biopharmsignal.com/news/XLO/xilio-therapeutics-to-present-at-the-leerink-partners-global-healthcare-conferen-8fe4e6c2 2026-03-02 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-appoints-proteomics-commercial-leader-amber-faust-as-vice-998b4438 2026-03-02 https://biopharmsignal.com/news/AMRN/effects-of-icosapent-ethyl-on-risk-and-duration-of-hospitalizations-and-death-in-812cfc56 2026-03-02 https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-the-leerink-global-healthcare-conference-17122ba5 2026-03-02 https://biopharmsignal.com/news/HCAT/health-catalyst-to-announce-fourth-quarter-and-year-end-2025-operating-results-a-9f57d051 2026-03-02 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-enters-into-agreement-to-acquire-cullgen-to-gain-targeted-protein-degradation-platform-and-pipeline 2026-03-02 https://biopharmsignal.com/news/PULM/pulmatrix-announces-termination-of-prior-planned-merger-and-continues-pursuit-of-alternative-merger-opportunities 2026-03-02 https://biopharmsignal.com/news/MNPR/monopar-expands-leadership-team-with-appointment-of-seasoned-biopharma-executive-susan-rodriguez-as-chief-commercial-and-strategy-officer 2026-03-02 https://biopharmsignal.com/news/XTNT/xtant-medical-finalizes-companion-spine-transactions 2026-03-02 https://biopharmsignal.com/news/RLYB/rallybio-corporation-and-candid-therapeutics-announce-merger-agreement 2026-03-02 https://biopharmsignal.com/news/URGN/urogen-announces-zusduritm-launch-is-on-track-and-reports-fourth-quarter-and-full-year-2025-financial-results 2026-03-02 https://biopharmsignal.com/news/REPL/replimune-to-present-at-two-upcoming-investor-conferences 2026-03-02 https://biopharmsignal.com/news/CRL/charles-river-laboratories-to-present-at-td-cowen-and-barclays-conferences 2026-03-02 https://biopharmsignal.com/news/URGN/urogen-announces-refinanced-term-loan-agreement-with-pharmakon-advisors 2026-03-02 https://biopharmsignal.com/news/DYN/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights 2026-03-02 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-announces-details-for-q4-and-full-year-2025-financial-results-7f38c016 2026-03-02 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-advancing-zervimesine-ct1812-for-dementia-with-lewy-bodie-df654b5c 2026-03-02 https://biopharmsignal.com/news/BCAB/bioatla-announces-formal-process-to-evaluate-strategic-options-to-monetize-asset-845454d9 2026-03-02 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-expands-rare-disease-portfolio-through-acquisition-of-u-s-c-7c16ebdb 2026-03-02 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-recognizes-multiple-system-atrophy-msa-awareness-month-in--482ba014 2026-03-02 https://biopharmsignal.com/news/OCGN/ocugen-announces-phase-3-limelight-enrollment-completion-for-ocu400-a-novel-modi-f947a06c 2026-03-02 https://biopharmsignal.com/news/ADMA/adma-biologics-announces-125-million-accelerated-share-repurchase-with-jpmorgan-as-part-of-a-planned-200-million-2026-total-share-repurchase-initiative 2026-03-02 https://biopharmsignal.com/news/APLS/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors 2026-03-02 https://biopharmsignal.com/news/APGE/apogee-therapeutics-provides-pipeline-progress-and-reports-full-year-2025-financ-be766455 2026-03-02 https://biopharmsignal.com/news/AGIO/agios-pyrukynd-mitapivat-approved-for-adults-with-thalassemia-in-the-united-arab-9038d202 2026-03-02 https://biopharmsignal.com/news/EYPT/eyepoint-announces-first-patients-dosed-in-both-global-phase-3-clinical-trials-o-a4cb94e2 2026-03-02 https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-presents-new-data-highlighting-high-patient-satisfaction-and-evolving-treatment-trends-with-ekterlyr-sebetralstat 2026-03-02 https://biopharmsignal.com/news/XERS/xeris-biopharma-reports-record-performance-for-fourth-quarter-and-full-year-2025-and-provides-full-year-2026-guidance 2026-03-02 https://biopharmsignal.com/news/ISRG/intuitive-expands-investment-and-footprint-in-europe 2026-03-02 https://biopharmsignal.com/news/PHVS/deucrictibant-data-supporting-potentially-differentiated-profile-for-the-on-dema-56f7575f 2026-03-02 https://biopharmsignal.com/news/ZURA/zura-bio-to-participate-in-upcoming-investor-conferences 2026-03-02 https://biopharmsignal.com/news/BLTE/belite-bio-reports-preliminary-unaudited-fourth-quarter-and-full-year-2025-finan-9113175c 2026-03-02 https://biopharmsignal.com/news/YOU/introducing-the-reimagined-clear-app-win-the-day-of-travel-from-home-to-gate 2026-03-02 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-additional-positive-data-from-phase-3-transcend-c41021cc 2026-03-01 https://biopharmsignal.com/news/CLDX/celldex-presents-positive-data-demonstrating-barzolvolimab-retreatment-achieves--ce386bd8 2026-03-01 https://biopharmsignal.com/news/COGT/cogent-biosciences-highlights-additional-data-with-six-bezuclastinib-posters-from-summit-trial-at-2026-aaaai-annual-meeting 2026-02-28 https://biopharmsignal.com/news/ASND/fda-approves-once-weekly-yuviwelr-navepegritide-for-children-with-achondroplasia-aged-2-years-and-older 2026-02-27 https://biopharmsignal.com/news/AVCO/avalon-globocare-announces-closing-of-up-to-9-75-million-private-placement-priced-at-the-market-under-nasdaq-rules 2026-02-27 https://biopharmsignal.com/news/FEMY/femasys-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-d5cce916 2026-02-27 https://biopharmsignal.com/news/CCEL/cryo-cell-reports-financial-results-for-fiscal-year-ended-november-30-2025 2026-02-27 https://biopharmsignal.com/news/ARQT/arcutis-management-to-present-at-td-cowen-s-46th-annual-health-care-conference 2026-02-27 https://biopharmsignal.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-march-ac4bd5c3 2026-02-27 https://biopharmsignal.com/news/CLDX/celldex-presents-additional-positive-data-from-phase-2-chronic-spontaneous-urtic-b5a671c9 2026-02-27 https://biopharmsignal.com/news/RNA/novartis-successfully-completes-acquisition-of-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy 2026-02-27 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-call-for-applications-for-the-9th-annual-route-79-the-duchenne-scholarship-program 2026-02-27 https://biopharmsignal.com/news/CGON/cg-oncology-reports-2025-year-end-financial-results-and-provides-business-update-2de4be66 2026-02-27 https://biopharmsignal.com/news/URGN/zusduritm-achieves-durable-complete-responses-across-eortc-risk-groups-in-patients-with-recurrent-lg-ir-nmibc 2026-02-27 https://biopharmsignal.com/news/NKTX/nkarta-to-participate-in-march-investor-conferences 2026-02-27 https://biopharmsignal.com/news/ALXO/alx-oncology-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update 2026-02-27 https://biopharmsignal.com/news/BNGO/bionano-symposium-2026-concluded-with-9-speakers-describing-the-breadth-of-bionano-solutions-and-their-potential-for-use-on-a-large-scale 2026-02-27 https://biopharmsignal.com/news/OPKO/opko-health-to-participate-in-the-jefferies-biotech-on-the-beach-summit 2026-02-27 https://biopharmsignal.com/news/TMCI/treace-medical-concepts-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-27 https://biopharmsignal.com/news/FLGT/fulgent-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-27 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2025-financial-r-91cdcacd 2026-02-27 https://biopharmsignal.com/news/ZURA/zura-bio-announces-closing-of-its-144-million-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares 2026-02-27 https://biopharmsignal.com/news/AMRX/amneal-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-27 https://biopharmsignal.com/news/GNTA/genenta-advances-transformation-into-saentra-forge-strengthens-atc-governance-and-expands-strategic-industrial-consolidation-platform 2026-02-27 https://biopharmsignal.com/news/AVCO/avalon-globocare-announces-up-to-9-75-million-private-placement-priced-at-the-market-under-nasdaq-rules 2026-02-27 https://biopharmsignal.com/news/XERS/xeris-biopharma-subsidiaries-file-recorlevr-patent-infringement-lawsuit 2026-02-26 https://biopharmsignal.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences 2026-02-26 https://biopharmsignal.com/news/EHC/encompass-health-to-participate-in-barclays-global-healthcare-conference 2026-02-26 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-present-at-td-cowen-46th-annual-health-care-conference 2026-02-26 https://biopharmsignal.com/news/MOH/molina-healthcare-announces-first-quarter-2026-earnings-release-and-conferences-call-dates-and-investor-day-meeting 2026-02-26 https://biopharmsignal.com/news/HUM/humana-inc-to-present-at-the-2026-leerink-partners-global-healthcare-conference 2026-02-26 https://biopharmsignal.com/news/SEER/seer-adopts-limited-duration-tax-benefit-preservation-plan-to-protect-its-valuable-tax-assets 2026-02-26 https://biopharmsignal.com/news/CLOV/clover-health-reports-fourth-quarter-and-full-year-2025-results-provides-full-year-2026-guidance 2026-02-26 https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-2025-financial-results-posts-record-revenue 2026-02-26 https://biopharmsignal.com/news/SEER/seer-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-2026-outlook 2026-02-26 https://biopharmsignal.com/news/GALT/galectin-therapeutics-to-host-virtual-kol-event-to-discuss-belapectin-developmen-cb223373 2026-02-26 https://biopharmsignal.com/news/RLAY/relay-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-a-d04b6dd6 2026-02-26 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-re-93fdd9f1 2026-02-26 https://biopharmsignal.com/news/OPKO/opko-health-reports-fourth-quarter-2025-business-highlights-and-financial-results 2026-02-26 https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-highlights 2026-02-26 https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-multiple-upcoming-presentations-at-2026-muscular-dystrophy-association-mda-clinical-and-scientific-conference 2026-02-26 https://biopharmsignal.com/news/PGNY/progyny-inc-announces-fourth-quarter-2025-results 2026-02-26 https://biopharmsignal.com/news/ALHC/alignment-healthcare-reports-fourth-quarter-and-full-year-2025-results-beats-high-end-of-guidance-across-all-key-metrics 2026-02-26 https://biopharmsignal.com/news/BDSX/biodesix-announces-fourth-quarter-and-fiscal-year-2025-results-and-highlights-61037511 2026-02-26 https://biopharmsignal.com/news/KROS/keros-therapeutics-appoints-charles-newton-to-its-board-of-directors-b5c92425 2026-02-26 https://biopharmsignal.com/news/DNLI/denali-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results--a252ad9d 2026-02-26 https://biopharmsignal.com/news/XRAY/dentsply-sirona-reports-fourth-quarter-and-full-year-2025-results-provides-full--e5f22c25 2026-02-26 https://biopharmsignal.com/news/PSNL/personalis-reports-fourth-quarter-and-full-year-2025-results-and-recent-highlights 2026-02-26 https://biopharmsignal.com/news/SNDX/syndax-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-02-26 https://biopharmsignal.com/news/MDXH/mdxhealth-announces-fourth-quarter-and-full-year-2025-financial-results-726f9e49 2026-02-26 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-progress 2026-02-26 https://biopharmsignal.com/news/GNFT/genfit-reports-fourth-quarter-2025-financial-information-and-provides-a-corporate-update 2026-02-26 https://biopharmsignal.com/news/AMN/amn-healthcare-survey-reveals-sharp-divide-between-leaders-organizational-confid-69477fad 2026-02-26 https://biopharmsignal.com/news/BFRI/u-s-patent-office-issues-final-written-decision-finding-all-challenged-claims-of-154d4ae9 2026-02-26 https://biopharmsignal.com/news/FEMY/femasys-announces-fembloc-permanent-birth-control-has-achieved-mdsap-certificati-116fbb03 2026-02-26 https://biopharmsignal.com/news/FATE/fate-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-updates 2026-02-26 https://biopharmsignal.com/news/IRON/disc-medicine-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-02-26 https://biopharmsignal.com/news/QNRX/netherton-now-recognizes-rare-disease-day-and-highlights-growing-global-awarenes-e7e3546b 2026-02-26 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-report-fourth-quarter-2025-financial-results-on-march-de11cce2 2026-02-26 https://biopharmsignal.com/news/AVCO/avalon-globocare-s-subsidiary-accepted-into-amd-ai-developer-program-to-advance-next-generation-media-infrastructure 2026-02-26 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-present-new-long-term-and-safety-data-across-gene-therapy-and-exon-skipping-programs-at-2026-muscular-dystrophy-association-clinical-and-scientific-congress 2026-02-26 https://biopharmsignal.com/news/SCYX/scynexis-announces-first-participants-dosed-in-a-phase-1-single-ascending-dose-and-multiple-ascending-dose-trial-of-intravenous-scy-247 2026-02-26 https://biopharmsignal.com/news/PULM/pulmatrix-announces-year-end-and-fourth-quarter-2025-financial-results 2026-02-26 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-to-announce-4th-quarter-2025-financial-results-on-march-5-2026 2026-02-26 https://biopharmsignal.com/news/PMVP/new-england-journal-of-medicine-publishes-first-in-human-rezatapopt-data-showing-selective-reactivation-of-mutant-p53-in-advanced-solid-tumors 2026-02-26 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-retirement-of-james-mackaness-and-appointment-of-j-e189fa61 2026-02-26 https://biopharmsignal.com/news/HRTX/heron-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-0c27bf55 2026-02-26 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-reports-fourth-quarter-and-fiscal-year-2025-financial-res-2144be1c 2026-02-26 https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-5-2026 2026-02-26 https://biopharmsignal.com/news/MIST/milestoner-pharmaceuticals-to-present-at-the-td-cowen-46th-annual-health-care-conference 2026-02-26 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences 2026-02-26 https://biopharmsignal.com/news/DCTH/delcath-systems-reports-fourth-quarter-and-full-year-2025-results 2026-02-26 https://biopharmsignal.com/news/BNGO/10-presentations-on-day-3-of-bionano-symposium-2026-showcase-ogm-s-utility-in-unraveling-the-complex-puzzles-of-constitutional-genetic-disorders 2026-02-26 https://biopharmsignal.com/news/MNKD/mannkind-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-02-26 https://biopharmsignal.com/news/PRCT/procept-biorobotics-hosts-2026-investor-day-to-detail-multi-year-financial-outlo-50d3341a 2026-02-26 https://biopharmsignal.com/news/VCEL/vericel-reports-fourth-quarter-and-full-year-2025-financial-results-f88e4ca3 2026-02-26 https://biopharmsignal.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-full-year-2025-financial--1801b811 2026-02-26 https://biopharmsignal.com/news/IFRX/inflarx-announces-participation-in-the-leerink-partners-global-healthcare-confer-480871ef 2026-02-26 https://biopharmsignal.com/news/ALT/altimmune-to-report-fourth-quarter-and-full-year-2025-financial-results-and-prov-eb3e2d4d 2026-02-26 https://biopharmsignal.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-a-d381fa27 2026-02-26 https://biopharmsignal.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2025-financial-results 2026-02-26 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-financial-guidance-corrected 2026-02-26 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-host-fourth-quarter-and-full-year-2025-financial-results-and-business-update-conference-call-on-march-5-2026 2026-02-26 https://biopharmsignal.com/news/TGTX/tg-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-raises-briumvi-revenue-guidance 2026-02-26 https://biopharmsignal.com/news/BCRX/biocryst-reports-full-year-2025-financial-results-and-provides-business-update 2026-02-26 https://biopharmsignal.com/news/INDV/indivior-reports-fourth-quarter-and-full-year-2025-financial-results-35beae03 2026-02-26 https://biopharmsignal.com/news/CCCC/c4-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and--e518ea37 2026-02-26 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results--c9ef8ab4 2026-02-26 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-26cef31b 2026-02-26 https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-resul-c1ec1533 2026-02-26 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-result-2f9bb61f 2026-02-26 https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-report-full-year-2025-financial-results-on-march-5-2026 2026-02-26 https://biopharmsignal.com/news/GSK/bepirovirsen-accepted-for-regulatory-review-in-japan-as-a-potential-first-in-class-treatment-for-chronic-hepatitis-b 2026-02-26 https://biopharmsignal.com/news/BMY/systimmune-and-bristol-myers-squibb-highlight-positive-phase-iii-interim-topline-results-for-izalontamab-brengitecan-iza-bren-in-previously-treated-unresectable-locally-advanced-or-metastatic-triple-negative-breast-cancer 2026-02-26 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-7985dbeb 2026-02-26 https://biopharmsignal.com/news/AVAH/aveanna-announces-fourth-quarter-and-full-year-2025-earnings-release-date-and-conference-call 2026-02-26 https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-secures-second-1-million-strategic-placement-total-2-million-raised-in-february 2026-02-26 https://biopharmsignal.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-financial-guidance 2026-02-26 https://biopharmsignal.com/news/PRVA/privia-health-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-26 https://biopharmsignal.com/news/CERT/certara-reports-fourth-quarter-2025-financial-results-provides-full-year-2026-guidance 2026-02-26 https://biopharmsignal.com/news/GSK/linerixibat-accepted-for-priority-review-in-china-for-cholestatic-pruritus-in-patients-with-primary-biliary-cholangitis 2026-02-26 https://biopharmsignal.com/news/MOLN/molecular-partners-signs-development-agreement-with-eckert-ziegler-for-targeted--1c15284f 2026-02-26 https://biopharmsignal.com/news/MOLN/molecular-partners-announces-participation-in-march-investor-conferences-and-upc-b23eb140 2026-02-26 https://biopharmsignal.com/news/ARGX/argenx-reports-full-year-2025-financial-results-and-provides-fourth-quarter-busi-0b5f7071 2026-02-26 https://biopharmsignal.com/news/ARGX/argenx-announces-positive-topline-results-from-phase-3-adapt-oculus-trial-of-vyv-8f94d2b8 2026-02-26 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-pricing-of-upsized-100-million-underwritten-public-offering 2026-02-26 https://biopharmsignal.com/news/LNSR/lensar-provides-update-on-pending-acquisition-by-alcon-a1a49edc 2026-02-25 https://biopharmsignal.com/news/PNTG/pennant-reports-fourth-quarter-and-fiscal-year-2025-results 2026-02-25 https://biopharmsignal.com/news/PPBT/purple-biotech-announces-plan-to-implement-ads-ratio-change-9113c2cd 2026-02-25 https://biopharmsignal.com/news/AZYO/elutia-to-report-fourth-quarter-2025-financial-results-on-wednesday-march-11-2026 2026-02-25 https://biopharmsignal.com/news/ADMA/adma-biologics-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-02-25 https://biopharmsignal.com/news/TERN/terns-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences 2026-02-25 https://biopharmsignal.com/news/OSUR/orasure-announces-fourth-quarter-2025-financial-results 2026-02-25 https://biopharmsignal.com/news/RXST/rxsight-inc-reports-fourth-quarter-and-2025-results-issues-2026-guidance 2026-02-25 https://biopharmsignal.com/news/ALEC/alector-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-71948925 2026-02-25 https://biopharmsignal.com/news/LMAT/lemaitre-q4-2025-financial-results-db49c9f7 2026-02-25 https://biopharmsignal.com/news/TDOC/teladoc-health-reports-fourth-quarter-and-full-year-2025-results-59b9d2df 2026-02-25 https://biopharmsignal.com/news/BTMD/biote-schedules-fourth-quarter-and-full-year-2025-financial-results-release-and-conference-call 2026-02-25 https://biopharmsignal.com/news/INVA/innoviva-reports-fourth-quarter-and-full-year-2025-financial-results-highlights-recent-company-progress 2026-02-25 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference 2026-02-25 https://biopharmsignal.com/news/GDRX/goodrx-reports-fourth-quarter-and-full-year-2025-results 2026-02-25 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-developments 2026-02-25 https://biopharmsignal.com/news/PRCT/procept-biorobotics-reports-fourth-quarter-2025-financial-results-and-updates-20-8d74ce44 2026-02-25 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-td-cowen-46th-annual-health-care-conference 2026-02-25 https://biopharmsignal.com/news/MDXG/mimedx-announces-record-fourth-quarter-and-full-year-2025-operating-and-financial-results 2026-02-25 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results--3aca491a 2026-02-25 https://biopharmsignal.com/news/CLDX/celldex-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides--9b245429 2026-02-25 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-proposed-75-million-underwritten-public-offering 2026-02-25 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-announces-u-s-fda-approval-for-desmoda-desmopressin-acetate-568a5e35 2026-02-25 https://biopharmsignal.com/news/LGVN/longeveron-results-of-phase-2b-clinical-trial-demonstrating-stem-cell-therapy-im-2392db11 2026-02-25 https://biopharmsignal.com/news/PRPO/precipio-2025-unaudited-revenues-grew-to-24-0m-a-30-increase-year-over-year-75a56918 2026-02-25 https://biopharmsignal.com/news/IXHL/incannex-announces-reverse-stock-split-b5b67342 2026-02-25 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-release-fourth-quarter-of-fiscal-year-2025-financial-fc2bc127 2026-02-25 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-successfully-manufactures-and-ships-first-readers-with-0f5a9231 2026-02-25 https://biopharmsignal.com/news/PYPD/polypid-announces-participation-in-upcoming-investor-conferences 2026-02-25 https://biopharmsignal.com/news/EQ/equillium-to-participate-in-the-leerink-partners-2026-global-healthcare-conferen-4efb81a7 2026-02-25 https://biopharmsignal.com/news/STRO/sutro-biopharma-to-participate-in-upcoming-investor-conferences-5470cd63 2026-02-25 https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-announces-validation-study-with-brooke-army-medical-center-to-expand-sample-collection-options-for-the-cypathr-lung-noninvasive-early-detection-lung-cancer-test 2026-02-25 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march 2026-02-25 https://biopharmsignal.com/news/PRME/prime-medicine-to-participate-in-upcoming-investor-conferences 2026-02-25 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conferenc-810c3329 2026-02-25 https://biopharmsignal.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-march-investor-conferences-4976b1f0 2026-02-25 https://biopharmsignal.com/news/IPSC/century-therapeutics-to-participate-in-upcoming-investor-conferences-in-march-7a741c07 2026-02-25 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-initiates-review-of-strategic-alternatives-to-enhance-shareholder-value 2026-02-25 https://biopharmsignal.com/news/ACST/grace-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference 2026-02-25 https://biopharmsignal.com/news/XTNT/xtant-medical-to-participate-in-the-canaccord-genuity-2026-musculoskeletal-conference 2026-02-25 https://biopharmsignal.com/news/BNGO/11-presentations-on-day-2-of-bionano-symposium-2026-showcase-expanding-impact-of-optical-genome-mapping-across-oncology-and-cell-and-gene-therapy 2026-02-25 https://biopharmsignal.com/news/TPST/tempest-announces-interim-results-from-ongoing-redeem-1-trial-of-tpst-2003-preparing-for-potential-u-s-registrational-study-in-2026 2026-02-25 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-to-present-at-the-citizens-life-sciences-conference-8424b818 2026-02-25 https://biopharmsignal.com/news/DYN/dyne-therapeutics-to-participate-in-upcoming-investor-conferences 2026-02-25 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-achieves-2025-financial-guidance-and-reiterates-strong-2026-outlook 2026-02-25 https://biopharmsignal.com/news/CLDX/celldex-completes-enrollment-in-global-phase-3-studies-embarq-csu1-and-embarq-cs-8defef5b 2026-02-25 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-participate-in-upcoming-march-investor-conferences 2026-02-25 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-new-biomarker-data-showing-nasal-foralumab-downr-4cca495a 2026-02-25 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-participation-in-three-upcoming-investor-conferenc-6fc28cec 2026-02-25 https://biopharmsignal.com/news/EYPT/eyepoint-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march--750a01be 2026-02-25 https://biopharmsignal.com/news/AMRN/amarin-reports-fourth-quarter-and-full-year-2025-financial-results-8a12ecb5 2026-02-25 https://biopharmsignal.com/news/GERN/geron-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-an-0d1adf90 2026-02-25 https://biopharmsignal.com/news/ACHC/acadia-healthcare-announces-fourth-quarter-and-2025-results 2026-02-25 https://biopharmsignal.com/news/ALKS/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec-31-2025-and-provides-financial-expectations-for-2026 2026-02-25 https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-to-present-at-upcoming-investor-conferences 2026-02-25 https://biopharmsignal.com/news/IMCR/immunocore-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update 2026-02-25 https://biopharmsignal.com/news/CRL/charles-river-laboratories-provides-update-on-planned-divestitures 2026-02-25 https://biopharmsignal.com/news/BRKR/bruker-accelerates-the-future-of-diagnostic-and-prognostic-spatial-proteomics-with-the-launch-of-cellscape-xr 2026-02-25 https://biopharmsignal.com/news/GSK/viiv-healthcare-presents-pipeline-data-for-two-investigational-hiv-treatment-therapies-with-potential-for-twice-yearly-dosing 2026-02-25 https://biopharmsignal.com/news/GSK/viiv-healthcare-reports-positive-12-month-data-showing-investigational-bnab-lotivibart-n6ls-maintains-high-levels-of-viral-suppression-in-long-acting-hiv-treatment-regimen 2026-02-25 https://biopharmsignal.com/news/GSK/gsk-enters-agreement-to-acquire-35pharma-inc 2026-02-25 https://biopharmsignal.com/news/ALKS/alkermes-plc-announces-ceo-succession-plan 2026-02-25 https://biopharmsignal.com/news/RXRX/recursion-reports-fourth-quarter-and-full-year-2025-financial-results-and-provid-8d9b4ffb 2026-02-25 https://biopharmsignal.com/news/ZURA/zura-bio-announces-pricing-of-125-million-public-offering-of-class-a-ordinary-shares-and-pre-funded-warrants 2026-02-25 https://biopharmsignal.com/news/LFST/lifestance-reports-fourth-quarter-and-full-year-2025-results 2026-02-25 https://biopharmsignal.com/news/IMRN/immuron-reports-hy26-results-and-strategic-reset-55184b59 2026-02-25 https://biopharmsignal.com/news/YOU/clear-announces-fourth-quarter-and-full-year-2025-financial-results 2026-02-25 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-to-present-at-46th-annual-td-cowen-healthcare-conference-d48b74e6 2026-02-24 https://biopharmsignal.com/news/XRAY/dentsply-sirona-appoints-james-forbes-and-brian-mckeon-to-board-of-directors-1c9910f5 2026-02-24 https://biopharmsignal.com/news/EHC/encompass-health-recognized-for-corporate-excellence-on-fortune-and-forbes-2026-lists 2026-02-24 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026 2026-02-24 https://biopharmsignal.com/news/GMED/globus-medical-reports-fourth-quarter-and-full-year-2025-results-7696e824 2026-02-24 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-announces-plan-to-explore-strategic-alternatives-9654d674 2026-02-24 https://biopharmsignal.com/news/PCVX/vaxcyte-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-02-24 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-to-participate-in-upcoming-march-investor-conferences-e76d8459 2026-02-24 https://biopharmsignal.com/news/MMSI/merit-medical-reports-fourth-quarter-and-full-year-2025-results-and-issues-fisca-41c027df 2026-02-24 https://biopharmsignal.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2025-audited-financial-results-provides-corporate-update 2026-02-24 https://biopharmsignal.com/news/SUPN/supernus-announces-record-fourth-quarter-and-full-year-2025-financial-results 2026-02-24 https://biopharmsignal.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-financial-outlook 2026-02-24 https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-the-td-cowen-46th-annual-health-care-conference 2026-02-24 https://biopharmsignal.com/news/AZTA/azenta-to-participate-in-raymond-james-47th-annual-institutional-investor-conference 2026-02-24 https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-march 2026-02-24 https://biopharmsignal.com/news/ZURA/zura-bio-announces-proposed-public-offering-of-class-a-ordinary-shares-and-pre-funded-warrants 2026-02-24 https://biopharmsignal.com/news/AXON/axon-reports-q4-2025-revenue-of-797-million-up-39-year-over-year 2026-02-24 https://biopharmsignal.com/news/DAWN/day-one-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026-outlook-and-revenue-guidance 2026-02-24 https://biopharmsignal.com/news/ALKS/alkermes-to-present-at-the-td-cowen-46th-annual-health-care-conference 2026-02-24 https://biopharmsignal.com/news/INGN/inogen-announces-30-million-share-repurchase-program 2026-02-24 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-participate-in-upcoming-march-investor-conferences 2026-02-24 https://biopharmsignal.com/news/SNTI/senti-biosciences-to-present-at-td-cowen-46th-annual-health-care-conference-2d72c6e7 2026-02-24 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-commercial-launch-of-elevidys-in-japan 2026-02-24 https://biopharmsignal.com/news/PACB/pacbio-and-dnastack-launch-first-global-federated-hifi-whole-genome-dataset-to-a-4767e31c 2026-02-24 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-to-prioritize-registration-focused-programs-in-anal-and-color-88555fbe 2026-02-24 https://biopharmsignal.com/news/XRAY/dentsply-sirona-and-burkhart-dental-supply-announce-expanded-distribution-partne-5c2ba082 2026-02-24 https://biopharmsignal.com/news/XGN/exagen-inc-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-10-2026 2026-02-24 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-late-breaking-presentation-at-2026-mda-clinical-and-scientific-conference 2026-02-24 https://biopharmsignal.com/news/GDRX/goodrx-expands-into-employer-market-with-launch-of-goodrx-employer-direct 2026-02-24 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-partners-with-bouygues-uk-part-of-multi-billion-dollar-b3724a63 2026-02-24 https://biopharmsignal.com/news/MKT/maia-biotechnology-s-phase-3-momentum-demonstrates-potential-breakthrough-anticancer-opportunity-in-50-billion-immunotherapy-market 2026-02-24 https://biopharmsignal.com/news/BRTX/biorestorative-expands-global-protection-for-thermostem-a-potentially-longer-las-7f787bd2 2026-02-24 https://biopharmsignal.com/news/MXCT/maxcyte-unveils-expert-dtxtm-a-96-well-electroporation-platform-to-accelerate-discovery 2026-02-24 https://biopharmsignal.com/news/CADL/candel-therapeutics-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston 2026-02-24 https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-update 2026-02-24 https://biopharmsignal.com/news/ESPR/esperion-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-10 2026-02-24 https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference 2026-02-24 https://biopharmsignal.com/news/ABSI/absci-to-report-business-updates-and-fourth-quarter-and-full-year-2025-financial-and-operating-results-on-march-24-2026 2026-02-24 https://biopharmsignal.com/news/INAB/in8bio-to-present-at-td-cowen-46th-annual-health-care-conference 2026-02-24 https://biopharmsignal.com/news/ANNX/annexon-biosciences-to-present-at-the-td-cowen-46th-annual-health-care-conference 2026-02-24 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-appoints-biotech-leaders-sravan-emany-and-andrew-miller-to--59a11913 2026-02-24 https://biopharmsignal.com/news/VERA/vera-therapeutics-to-participate-at-upcoming-investor-conferences-57dcbdf1 2026-02-24 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-d58ae5f3 2026-02-24 https://biopharmsignal.com/news/CLNN/clene-issues-stockholder-letter-highlighting-upcoming-cnm-au8-2026-catalysts-4c72a23c 2026-02-24 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-unveils-voyager-platform-enabling-single-molecule-iterati-69bd7062 2026-02-24 https://biopharmsignal.com/news/ALEC/alector-to-participate-in-the-td-cowen-46th-annual-health-care-conference-37db60ef 2026-02-24 https://biopharmsignal.com/news/ARDX/ardelyx-and-the-lpga-announce-multi-year-partnership-to-break-stigma-around-dige-7e62e592 2026-02-24 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-td-cowen-46th-annual-health-care-conference-0d2a0cc2 2026-02-24 https://biopharmsignal.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-fourth-quarter-and-full-year--7e132942 2026-02-24 https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-td-cowen-46th-annual-health-care--f3b44a24 2026-02-24 https://biopharmsignal.com/news/ARTL/artelo-biosciences-provides-business-update-highlighting-clinical-progress-and-reports-fiscal-2025-year-end-financial-results 2026-02-24 https://biopharmsignal.com/news/BNGO/9-presentations-kick-off-day-1-of-the-bionano-symposium-2026-covering-advances-in-optical-genome-mapping-for-hematologic-malignancies 2026-02-24 https://biopharmsignal.com/news/CABA/cabaletta-bio-to-participate-in-the-td-cowen-46th-annual-health-care-conference 2026-02-24 https://biopharmsignal.com/news/ERAS/erasca-announces-issuance-of-a-u-s-patent-covering-pan-kras-inhibitor-eras-4001 2026-02-24 https://biopharmsignal.com/news/ATRC/atricure-to-participate-in-the-citizens-life-sciences-conference 2026-02-24 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-portfolio-execution 2026-02-24 https://biopharmsignal.com/news/APGE/apogee-therapeutics-to-participate-in-upcoming-march-conferences-bd23f4f5 2026-02-24 https://biopharmsignal.com/news/RGEN/repligen-reports-fourth-quarter-and-full-year-2025-financial-results-and-provide-f6eac616 2026-02-24 https://biopharmsignal.com/news/HRMY/harmony-biosciences-reports-strong-2025-financial-results-and-reiterates-2026-net-revenue-guidance-of-over-1-billion 2026-02-24 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-participate-in-upcoming-march-2026-events 2026-02-24 https://biopharmsignal.com/news/TMCI/treace-highlights-new-product-innovations-and-updated-positive-clinical-study-data-at-the-2026-acfas-annual-scientific-conference 2026-02-24 https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-24 https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-announces-new-liver-targeted-genetic-disease-program-in-phenylketonuria-pku 2026-02-24 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results--b5de230f 2026-02-24 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-two-upcoming-investor-conferences 2026-02-24 https://biopharmsignal.com/news/ARVN/arvinas-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update 2026-02-24 https://biopharmsignal.com/news/SHC/sotera-health-delivers-20th-consecutive-year-of-revenue-growth-and-provides-2026-outlook 2026-02-24 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-report-fourth-quarter-2025-financial-results-and-recent-business-highlights-on-march-4-and-host-conference-call-on-march-5-at-8-00-a-m-et 2026-02-24 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-presents-preclinical-results-supporting-first-in-class-potential-of-at-587-for-treatment-of-hepatitis-e-virus-at-croi-2026 2026-02-24 https://biopharmsignal.com/news/BEAM/beam-therapeutics-announces-500-million-strategic-financing-facility-with-sixth-street 2026-02-24 https://biopharmsignal.com/news/ACIU/ac-immune-initiates-phase-1-clinical-trial-of-nlrp3-inhibitor-acf953bf 2026-02-24 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-5795c240 2026-02-24 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-initiates-phase-1b-proof-of-concept-trial-in-patients-with--08fdcccb 2026-02-24 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-presents-updated-clinical-data-from-phase-1-2-study-of-m-b2b15935 2026-02-24 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-positive-12-week-results-from-the-20-mg-dose-coho-6a645dcd 2026-02-24 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-participate-in-march-investor-conferences-f694285e 2026-02-24 https://biopharmsignal.com/news/AXSM/axsome-therapeutics-initiates-clarity-phase-3-trial-of-solriamfetol-in-adults-wi-ce208c8b 2026-02-24 https://biopharmsignal.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences-0a48e13d 2026-02-24 https://biopharmsignal.com/news/APTO/aptose-biosciences-announces-amendment-to-arrangement-agreement-and-details-of-postponed-special-meeting-of-shareholders 2026-02-24 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-highlights-strong-fourth-quarter-and-full-year-2025-results-business-achievements-and-corporate-updates 2026-02-24 https://biopharmsignal.com/news/IOVA/iovance-announces-positive-results-from-the-first-clinical-trial-for-til-cell-therapy-in-soft-tissue-sarcomas 2026-02-24 https://biopharmsignal.com/news/IBIO/ibio-to-participate-in-upcoming-investor-conferences 2026-02-24 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-upcoming-investor-conferences 2026-02-24 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-fda-breakthrough-therapy-designation-for-nomlabofusp-in-fa-and-reiterates-planned-bla-submission-in-june-2026 2026-02-24 https://biopharmsignal.com/news/AXGN/axogen-inc-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-24 https://biopharmsignal.com/news/OPCH/option-care-health-announces-financial-results-for-fourth-quarter-and-full-year-2025 2026-02-24 https://biopharmsignal.com/news/TECH/bio-techne-to-present-at-upcoming-investor-conferences 2026-02-24 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-present-at-upcoming-investor-conferences-ca5a2f12 2026-02-24 https://biopharmsignal.com/news/YOU/clear-and-mount-sinai-announce-collaboration-to-bring-simple-and-secure-healthcare-experiences-to-new-yorkers 2026-02-24 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-announces-positive-results-for-nuzyrar-therapeutic-efficacy-studies-in-inhalation-anthrax-triggering-additional-procurement-under-barda-project-bioshield-contract 2026-02-24 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-march-investor-conferences 2026-02-23 https://biopharmsignal.com/news/MGNX/macrogenics-announces-pausing-of-enrollment-of-new-study-participants-in-linnet-trial 2026-02-23 https://biopharmsignal.com/news/FMS/fresenius-medical-care-published-report-on-form-20-f-for-fiscal-year-2025 2026-02-23 https://biopharmsignal.com/news/FMS/fresenius-medical-care-delivers-27-earnings-growth-in-2025-and-reaches-upper-end-of-its-financial-outlook-margin-within-2025-mid-term-target-band 2026-02-23 https://biopharmsignal.com/news/TARA/tara-002-demonstrates-68-complete-response-rate-at-six-months-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer 2026-02-23 https://biopharmsignal.com/news/RARE/ultragenyx-to-participate-at-investor-conferences-in-march-9f90d60b 2026-02-23 https://biopharmsignal.com/news/ANGO/angiodynamics-to-present-at-the-leerink-partners-global-healthcare-conference 2026-02-23 https://biopharmsignal.com/news/HSTM/healthstream-announces-fourth-quarter-and-full-year-2025-results 2026-02-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-the-td-cowen-46th-annual-health-care-conference 2026-02-23 https://biopharmsignal.com/news/RCEL/avita-medical-to-participate-at-the-td-cowen-46th-annual-health-care-conference-f9e85222 2026-02-23 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-to-attend-the-truist-securities-virtual-human-capital-conference-and-the-oppenheimer-36th-annual-healthcare-medtech-and-services-conference 2026-02-23 https://biopharmsignal.com/news/SIBN/si-bone-inc-reports-record-financial-results-for-the-fourth-quarter-2025-and-issues-2026-guidance 2026-02-23 https://biopharmsignal.com/news/TARS/tarsus-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-achievements 2026-02-23 https://biopharmsignal.com/news/MXCT/maxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-24-2026 2026-02-23 https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-updates 2026-02-23 https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-march-2026-investor-conferences 2026-02-23 https://biopharmsignal.com/news/MGRX/mangoceuticals-patented-mgx-0024-achieves-zero-respiratory-related-mortality-in--cf53e7e2 2026-02-23 https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-march-3be43fa7 2026-02-23 https://biopharmsignal.com/news/PRCT/procept-biorobotics-announces-updated-dates-for-4q25-earnings-conference-call-an-c455f75a 2026-02-23 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-23 https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-host-investor-webcast-for-fourth-quarter-and-year-end-2025-financial-results-and-new-liver-targeted-genetic-disease-program 2026-02-23 https://biopharmsignal.com/news/OKYO/okyo-abstract-selected-for-presentation-at-premier-global-ophthalmology-congress-f0a01c51 2026-02-23 https://biopharmsignal.com/news/CHRS/coherus-oncology-to-participate-in-upcoming-investor-conferences 2026-02-23 https://biopharmsignal.com/news/INMB/inmune-bio-to-detail-xpro1595-registrational-strategy-in-upcoming-alzheimer-s-we-9acc1ea1 2026-02-23 https://biopharmsignal.com/news/FBIO/update-fortress-biotech-s-subsidiary-cyprium-therapeutics-enters-into-agreement-to-sell-rare-pediatric-disease-priority-review-voucher-for-205-million 2026-02-23 https://biopharmsignal.com/news/FEMY/femasys-receives-ama-cpt-editorial-panel-approval-for-new-category-iii-cpt-code--fc6f247a 2026-02-23 https://biopharmsignal.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conferences-28a7ddcd 2026-02-23 https://biopharmsignal.com/news/RARE/ultragenyx-announces-u-s-fda-acceptance-and-priority-review-of-the-biologics-lic-9c65457e 2026-02-23 https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-oppenheimer-36th-annual-healthcare-life-science-ae1cc913 2026-02-23 https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-participation-at-the-16th-world-adc-london-summit-c229d910 2026-02-23 https://biopharmsignal.com/news/ICUI/icu-medical-to-participate-in-upcoming-investor-conferences-7eb475f2 2026-02-23 https://biopharmsignal.com/news/ACRV/key-opinion-leader-kol-panel-to-discuss-acrivon-s-acr-368-endometrial-cancer-ec-trial-during-the-2026-european-society-of-gynecological-oncology-esgo-congress 2026-02-23 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-to-participate-in-the-oppenheimer-healthcare-life-science-conference 2026-02-23 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-march-investor-conferences 2026-02-23 https://biopharmsignal.com/news/ALHC/alignment-healthcare-to-present-at-the-leerink-partners-global-healthcare-conference 2026-02-23 https://biopharmsignal.com/news/CLDX/celldex-announces-multiple-upcoming-presentations-at-aaaai-2026-supporting-barzo-8f2e2e2d 2026-02-23 https://biopharmsignal.com/news/AEMD/aethlon-medical-to-present-on-the-emerging-growth-conference-on-february-25th-2026 2026-02-23 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-presents-positive-data-at-the-conference-on-retroviruses-and-opportunistic-infections-croi 2026-02-23 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-td-cowen-46th-annual-health-care-conference 2026-02-23 https://biopharmsignal.com/news/CGON/cg-oncology-to-present-at-the-td-cowen-46th-annual-health-care-conference-1340b3f4 2026-02-23 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcast-for-its-fourth-quarter-43275237 2026-02-23 https://biopharmsignal.com/news/BIVI/join-biovie-s-exclusive-live-investor-webinar-and-q-a-session-on-march-4-2d2139ac 2026-02-23 https://biopharmsignal.com/news/AMRN/this-american-heart-month-amarin-spotlights-the-need-to-prioritize-proven-widely-88e21670 2026-02-23 https://biopharmsignal.com/news/BLTE/belite-bio-to-host-webcast-on-march-2-2026-to-discuss-preliminary-unaudited-four-e03bf63d 2026-02-23 https://biopharmsignal.com/news/VOR/vor-bio-to-participate-in-the-46th-annual-td-cowen-health-care-conference-b1c840cb 2026-02-23 https://biopharmsignal.com/news/RXRX/recursion-to-be-featured-in-highres-lightning-talk-at-nvidia-gtc-14ec0a8f 2026-02-23 https://biopharmsignal.com/news/ATXI/avenue-therapeutics-enters-into-exclusive-worldwide-license-agreement-for-atx-04-a4f2b121 2026-02-23 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-to-present-at-upcoming-investor-conferences 2026-02-23 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences 2026-02-23 https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-provides-a-business-update 2026-02-23 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-invited-to-participate-in-upcoming-scientific-and-industry-events 2026-02-23 https://biopharmsignal.com/news/FBIO/avenue-therapeutics-enters-into-exclusive-worldwide-license-agreement-for-atx-04-for-the-treatment-of-pompe-disease 2026-02-23 https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-intention-to-adjourn-and-reconvene-special-meeting-of-stockholders 2026-02-23 https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-host-conference-call-on-fourth-quarter-and-full-year-2025-financial-results-and-business-update 2026-02-23 https://biopharmsignal.com/news/CCCC/c4-therapeutics-to-participate-in-upcoming-march-conferences-00d8920b 2026-02-23 https://biopharmsignal.com/news/HLF/herbalife-plans-to-refinance-senior-secured-debt 2026-02-23 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-participate-in-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-23 https://biopharmsignal.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences 2026-02-23 https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-td-cowen-46th-annual-health-care-conference 2026-02-23 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-strengthens-financial-leadership-with-appointment-of-ryan-maynard-as-chief-financial-officer 2026-02-23 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-to-participate-in-upcoming-investor-conferences-af98a770 2026-02-23 https://biopharmsignal.com/news/CCCC/c4-therapeutics-announces-first-patient-dosed-in-phase-2-momentum-trial-of-cemsi-95ab536d 2026-02-23 https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-present-detailed-sol-1-data-at-the-49th-macula-society-ann-5a06b8cb 2026-02-23 https://biopharmsignal.com/news/BNTC/benitec-biopharma-announces-acceptance-of-late-breaking-abstract-for-the-bb-301-phase-1b-2a-clinical-treatment-study-at-the-muscular-dystrophy-association-clinical-and-scientific-conference 2026-02-23 https://biopharmsignal.com/news/SNDX/syndax-announces-participation-in-march-investor-conferences 2026-02-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-positive-top-line-results-from-registrational-phase-2-study-of-luspatercept-in-adults-with-alpha-thalassemia 2026-02-23 https://biopharmsignal.com/news/ZURA/zura-bio-welcomes-accomplished-drug-development-leaders-mark-eisner-m-d-m-p-h-and-ajay-nirula-m-d-ph-d-to-board-of-directors 2026-02-23 https://biopharmsignal.com/news/MD/pediatrix-medical-group-announces-47th-annual-neo-the-conference-for-neonatology 2026-02-23 https://biopharmsignal.com/news/ARGX/argenx-to-present-at-td-cowen-46th-annual-healthcare-conference-238a7584 2026-02-23 https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-upcoming-presentations-across-neuromuscular-pipeline-at-2026-mda-clinical-and-scientific-conference 2026-02-22 https://biopharmsignal.com/news/MLTX/moonlake-announces-positive-topline-results-from-its-phase-2-clinical-trial-of-sonelokimab-in-axial-spondyloarthritis-and-reports-2025-financial-results 2026-02-22 https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-02-20 https://biopharmsignal.com/news/ACHC/acadia-healthcare-to-participate-in-march-investor-conferences 2026-02-20 https://biopharmsignal.com/news/SNTI/senti-bio-participates-in-cell-gene-live-event-highlighting-cutting-edge-technol-8ad935a8 2026-02-20 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-tri-2b4ef20c 2026-02-20 https://biopharmsignal.com/news/LUNG/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026 2026-02-20 https://biopharmsignal.com/news/XAIR/beyond-air-comments-on-landmark-independent-review-article-highlighting-the-anti-2dbf80a5 2026-02-20 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-presents-real-world-data-supporting-the-integration-and-clinical-use-of-pedmarkr-in-treating-adults-with-head-and-neck-cancers 2026-02-20 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-present-new-clinical-data-on-anaphylmtm-dibutepinephrine-sublingual-film-at-the-2026-aaaai-annual-meeting 2026-02-20 https://biopharmsignal.com/news/BSEM/biostem-technologies-to-present-at-the-46th-annual-td-cowen-healthcare-conferenc-0e14055f 2026-02-20 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-participate-at-leerink-partners-global-healthcare-confer-a534ba16 2026-02-20 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-all-prefunded-warrants-now-exercised 2026-02-20 https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-1-million-strategic-financing-at-premium-to-market 2026-02-20 https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-pricing-of-public-offering 2026-02-20 https://biopharmsignal.com/news/AMN/update-amn-healthcare-announces-fourth-quarter-and-full-year-2025-results-02c1711a 2026-02-20 https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-announce-fourth-quarter-and-full-year-2025-financial-resul-8af61e65 2026-02-19 https://biopharmsignal.com/news/OLMA/olema-oncology-to-present-at-the-td-cowen-46th-annual-health-care-conference 2026-02-19 https://biopharmsignal.com/news/AMN/amn-healthcare-announces-fourth-quarter-and-full-year-2025-results-d23726bc 2026-02-19 https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2025-financial-results-on-february-26-2026 2026-02-19 https://biopharmsignal.com/news/MGRX/mangorx-experiences-initial-success-with-newly-launched-99-month-all-inclusive-i-48b1c67f 2026-02-19 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-confirms-nasdaq-delisting-5731a467 2026-02-19 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-td-cowen-46th-annual-health-care-co-b3035888 2026-02-19 https://biopharmsignal.com/news/IRTC/irhythm-holdings-announces-fourth-quarter-and-full-year-2025-financial-results-935fd849 2026-02-19 https://biopharmsignal.com/news/ICUI/icu-medical-announces-fourth-quarter-2025-results-and-provides-fiscal-year-2026--0e1ae898 2026-02-19 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-a-83108945 2026-02-19 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-24-2026 2026-02-19 https://biopharmsignal.com/news/ARDX/ardelyx-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-511231c0 2026-02-19 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-19 https://biopharmsignal.com/news/CORT/corcept-provides-update-on-patent-dispute-with-teva-pharmaceuticals 2026-02-19 https://biopharmsignal.com/news/INMB/inmune-bio-announces-upcoming-webinar-to-present-new-clinical-data-on-cordstrom--c606a14a 2026-02-19 https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-proposed-100-million-public-offering 2026-02-19 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-expands-european-footprint-with-exclusive-commercial-distribution-agreement-with-mediconsult-ag-for-lytenavatm-bevacizumab-gamma-in-switzerland 2026-02-19 https://biopharmsignal.com/news/MNKD/mannkind-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-19 https://biopharmsignal.com/news/MBRX/moleculin-announces-exercise-of-warrants-for-8-3-million-gross-proceeds-459845a8 2026-02-19 https://biopharmsignal.com/news/ALXO/alx-oncology-to-present-at-upcoming-investor-conferences-in-q1-2026 2026-02-19 https://biopharmsignal.com/news/ALXO/alx-oncology-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-27-2026 2026-02-19 https://biopharmsignal.com/news/CLNN/clene-to-present-at-the-emerging-growth-conference-b5bc20f6 2026-02-19 https://biopharmsignal.com/news/WVE/wave-life-sciences-fourth-quarter-and-full-year-2025-financial-results-scheduled-21af143e 2026-02-19 https://biopharmsignal.com/news/VERU/veru-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-19 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-to-present-at-oppenheimer-s-36th-annual-healthcare-life-sciences-conference 2026-02-19 https://biopharmsignal.com/news/ANGO/angiodynamics-expands-indications-for-the-nanoknife-system-across-europe-strengthening-multi-organ-tumor-ablation-platform 2026-02-19 https://biopharmsignal.com/news/MDWD/mediwound-to-report-fourth-quarter-and-full-year-2025-financial-results-929ef613 2026-02-19 https://biopharmsignal.com/news/COCP/cocrystal-pharma-s-first-oral-norovirus-protease-inhibitor-cdi-988-to-be-feature-7ef8cf89 2026-02-19 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-result-86ae0b14 2026-02-19 https://biopharmsignal.com/news/SENS/sequel-med-tech-and-senseonics-launch-transformative-combination-of-twiist-and-e-606115a0 2026-02-19 https://biopharmsignal.com/news/TARA/protara-therapeutics-to-participate-in-upcoming-investor-conferences 2026-02-19 https://biopharmsignal.com/news/INVA/innoviva-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-19 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-19 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-to-host-virtual-roundtable-featuring-leading-medical-experts-addressing-latest-developments-in-treatment-of-acute-agitation-in-alzheimer-s-dementia 2026-02-19 https://biopharmsignal.com/news/APLS/apellis-announces-eight-oral-presentations-at-the-49th-macula-society-annual-meeting 2026-02-19 https://biopharmsignal.com/news/SEER/leading-scientists-demonstrate-how-seer-s-proteograph-product-suite-advances-cardiovascular-and-neurodegenerative-research-at-us-hupo-2026 2026-02-19 https://biopharmsignal.com/news/GANX/gain-therapeutics-to-present-at-oppenheimer-36th-annual-healthcare-life-sciences-c75dd1f0 2026-02-19 https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-res-c7262eb5 2026-02-19 https://biopharmsignal.com/news/PASG/passage-bio-to-participate-in-upcoming-investor-conferences 2026-02-19 https://biopharmsignal.com/news/SNDX/syndax-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-and-webcast-on-february-26-2026 2026-02-19 https://biopharmsignal.com/news/MD/pediatrix-medical-group-reports-fourth-quarter-results 2026-02-19 https://biopharmsignal.com/news/ARGX/argenx-to-report-full-year-2025-financial-results-and-fourth-quarter-business-up-c80c7a90 2026-02-19 https://biopharmsignal.com/news/RNA/the-new-england-journal-of-medicine-publishes-results-from-phase-1-2-marinar-trial-of-delpacibart-etedesiran-del-desiran-for-treatment-of-myotonic-dystrophy-type-1 2026-02-18 https://biopharmsignal.com/news/AMWL/amwell-makes-grant-to-new-employee-under-inducement-plan-0750ee5a 2026-02-18 https://biopharmsignal.com/news/TDOC/teladoc-health-appoints-michael-smith-experienced-insurance-and-financial-servic-26c0dc06 2026-02-18 https://biopharmsignal.com/news/XOMA/xoma-royalty-to-present-at-investor-conferences-in-march 2026-02-18 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2025-investor-update-call 2026-02-18 https://biopharmsignal.com/news/HLF/herbalife-delivers-fourth-quarter-and-full-year-net-sales-growth-net-sales-and-adjusted-ebitda-exceed-guidance 2026-02-18 https://biopharmsignal.com/news/HLF/herbalife-announces-cristiano-ronaldo-invests-7-5-million-in-pro2coltm-technology-acquires-10-equity-stake 2026-02-18 https://biopharmsignal.com/news/SEER/seer-to-participate-in-the-td-cowen-46th-annual-health-care-conference 2026-02-18 https://biopharmsignal.com/news/IMRX/immuneering-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-18 https://biopharmsignal.com/news/SGHT/sight-sciences-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026 2026-02-18 https://biopharmsignal.com/news/PACB/pacbio-to-participate-in-the-td-cowen-46th-annual-health-care-conference-2d5f19f7 2026-02-18 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4 2026-02-18 https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-participation-at-upcoming-healthcare-conferences-3e4a8e3b 2026-02-18 https://biopharmsignal.com/news/MNKD/mannkind-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026 2026-02-18 https://biopharmsignal.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-and-year-ended--cf3bd63e 2026-02-18 https://biopharmsignal.com/news/TARS/tarsus-pharmaceuticals-appoints-renowned-biopharmaceutical-leader-and-former-allergan-ceo-david-pyott-to-its-board-of-directors 2026-02-18 https://biopharmsignal.com/news/RXRX/recursion-to-report-fourth-quarter-and-full-year-2025-business-updates-and-finan-06e17201 2026-02-18 https://biopharmsignal.com/news/MBRX/moleculin-miracle-trial-delivers-40-preliminary-blinded-crc-rate-n-30-889b4585 2026-02-18 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-doses-first-patients-in-va-funded-phase-2-trial-focused-on-f7fb9ad0 2026-02-18 https://biopharmsignal.com/news/SSKN/johns-hopkins-dermatology-expands-advanced-care-for-inflammatory-and-autoimmune--33c1b6e0 2026-02-18 https://biopharmsignal.com/news/AZYO/where-purpose-meets-performance-elutia-earns-2026-great-place-to-work-certificationtm 2026-02-18 https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-strengthens-its-precision-medicine-therapeutics-capabilities-with-launch-of-internal-clia-certified-laboratory 2026-02-18 https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-additional-positive-clinical-activity-for-wee1-inhibitor-apr-1051-including-second-partial-response-in-ongoing-acesot-1051-trial 2026-02-18 https://biopharmsignal.com/news/DSGN/design-therapeutics-to-participate-in-upcoming-investor-conferences 2026-02-18 https://biopharmsignal.com/news/SYRE/spyre-therapeutics-announces-presentations-at-the-21st-ecco-congress-supporting--d5e3ffb6 2026-02-18 https://biopharmsignal.com/news/MRKR/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sc-ffe3e690 2026-02-18 https://biopharmsignal.com/news/VXRT/vaxart-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-confer-ebeb787b 2026-02-18 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-participate-in-the-citizens-life-sciences-conference-4483bb44 2026-02-18 https://biopharmsignal.com/news/GNLX/genelux-corporation-to-participate-in-upcoming-conferences-2aef90ae 2026-02-18 https://biopharmsignal.com/news/LPCN/lipocine-announces-last-patient-last-visit-in-pivotal-phase-3-trial-of-lpcn-1154-for-postpartum-depression-ppd 2026-02-18 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-appoints-sidney-braun-as-ceo-of-its-liora-technologies-europe-ltd-subsidiary 2026-02-18 https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-announces-acquisition-of-faeth-therapeutics-and-200-million-concurrent-private-placement 2026-02-18 https://biopharmsignal.com/news/AVCO/avalon-globocare-s-subsidiary-files-third-u-s-provisional-patent-for-its-catch-up-generative-ai-video-platform 2026-02-18 https://biopharmsignal.com/news/ATYR/atyr-pharma-to-present-at-the-leerink-partners-global-healthcare-conference 2026-02-18 https://biopharmsignal.com/news/SRRK/scholar-rock-to-present-at-upcoming-investor-conferences 2026-02-18 https://biopharmsignal.com/news/TWST/twist-bioscience-to-present-at-upcoming-investor-conferences 2026-02-18 https://biopharmsignal.com/news/NGEN/nervgen-pharma-to-participate-at-upcoming-investor-conferences-84dd73a0 2026-02-18 https://biopharmsignal.com/news/MDNA/medicenna-therapeutics-announces-participation-in-upcoming-conferences 2026-02-18 https://biopharmsignal.com/news/OCGN/ocugen-to-host-conference-call-on-wednesday-march-4-2026-at-8-30-a-m-et-to-discu-e2d5cc77 2026-02-18 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-full-year-2025-financial-results-and-provides-corporate-update 2026-02-18 https://biopharmsignal.com/news/CRL/charles-river-laboratories-announces-executive-appointments 2026-02-18 https://biopharmsignal.com/news/AQST/aquestive-therapeutics-appoints-internationally-recognized-allergist-dr-matthew-greenhawt-as-chief-medical-officer 2026-02-18 https://biopharmsignal.com/news/ADMA/adma-biologics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026 2026-02-18 https://biopharmsignal.com/news/TNGX/tango-therapeutics-to-report-fourth-quarter-2025-financial-results-and-participate-in-three-upcoming-investor-conferences 2026-02-18 https://biopharmsignal.com/news/EYPT/eyepoint-appoints-michael-campbell-as-chief-commercial-officer-1bbbf91c 2026-02-18 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-participate-in-fireside-chat-at-the-citi-2026-virtual-o-fa58ccae 2026-02-18 https://biopharmsignal.com/news/HROW/harrow-to-report-fourth-quarter-and-year-end-2025-financial-results-after-market-6a9b3ddf 2026-02-18 https://biopharmsignal.com/news/IMCR/immunocore-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-call-on-february-25-2026 2026-02-18 https://biopharmsignal.com/news/CRL/charles-river-laboratories-announces-fourth-quarter-and-full-year-2025-results-and-provides-2026-guidance 2026-02-18 https://biopharmsignal.com/news/GSK/viiv-healthcare-s-long-acting-cabenuva-cabotegravir-rilpivirine-for-hiv-demonstrates-superior-efficacy-compared-to-daily-oral-therapy-for-people-with-adherence-challenges-results-published-in-nejm 2026-02-18 https://biopharmsignal.com/news/CRVO/cervomed-s-neflamapimod-elected-for-inclusion-in-uk-experts-als-platform-designe-774b7189 2026-02-18 https://biopharmsignal.com/news/HCWB/hcw-biologics-announces-pricing-of-1-5-million-follow-on-offering-priced-at-the--cdb73ab1 2026-02-18 https://biopharmsignal.com/news/TARS/tarsus-to-report-fourth-quarter-and-full-year-2025-financial-results-on-monday-february-23-2026 2026-02-17 https://biopharmsignal.com/news/SIBN/si-bone-to-present-at-td-cowen-46th-annual-health-care-conference-on-march-2-2026 2026-02-17 https://biopharmsignal.com/news/CHRS/coherus-oncology-inc-announces-closing-of-public-offering-of-common-stock 2026-02-17 https://biopharmsignal.com/news/CLOV/clover-health-to-participate-in-upcoming-leerink-2026-global-healthcare-conference 2026-02-17 https://biopharmsignal.com/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-17 https://biopharmsignal.com/news/TCMD/tactile-medical-acquires-lymphatech-expanding-breadth-and-depth-of-its-lymphedema-solutions-portfolio 2026-02-17 https://biopharmsignal.com/news/PSNL/personalis-to-participate-in-the-td-cowen-46th-annual-healthcare-conference 2026-02-17 https://biopharmsignal.com/news/MDRX/veradigm-provides-business-and-strategy-update 2026-02-17 https://biopharmsignal.com/news/ATRC/atricure-reports-fourth-quarter-2025-and-full-year-2025-financial-results 2026-02-17 https://biopharmsignal.com/news/BFRI/biofrontera-inc-announces-database-lock-of-phase-1-pharmacokinetics-study-of-ame-d2f93b3b 2026-02-17 https://biopharmsignal.com/news/SANA/sana-biotechnology-appoints-brian-piper-as-executive-vice-president-chief-financial-officer 2026-02-17 https://biopharmsignal.com/news/MBRX/moleculin-announces-notice-of-allowance-for-japanese-patent-covering-annamycin-f508613e 2026-02-17 https://biopharmsignal.com/news/IART/integra-lifesciences-announces-key-executive-leadership-appointments 2026-02-17 https://biopharmsignal.com/news/HRTX/heron-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-d8466c48 2026-02-17 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-highlights-meta-analysis-confirming-clinical-efficacy-of-30-46b0403b 2026-02-17 https://biopharmsignal.com/news/SERA/sera-prognostics-to-present-at-td-cowen-46th-annual-health-care-conference 2026-02-17 https://biopharmsignal.com/news/HRMY/harmony-biosciences-receives-u-s-food-and-drug-administration-approval-for-wakixr-pitolisant-for-the-treatment-of-cataplexy-in-pediatric-narcolepsy 2026-02-17 https://biopharmsignal.com/news/APRE/aprea-therapeutics-to-present-at-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-17 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-thursday-february-26-2026 2026-02-17 https://biopharmsignal.com/news/ANNX/annexon-to-host-in-person-and-virtual-kol-event-to-discuss-vonaprument-for-the-treatment-of-geographic-atrophy 2026-02-17 https://biopharmsignal.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-fourth-quarter-and-full-year-2025-financial-results 2026-02-17 https://biopharmsignal.com/news/MDXG/mimedx-to-host-fourth-quarter-and-full-year-2025-operating-and-financial-results-conference-call-on-february-25 2026-02-17 https://biopharmsignal.com/news/MDWD/mediwound-to-present-at-upcoming-investor-conferences-253b2d00 2026-02-17 https://biopharmsignal.com/news/CUE/cue-biopharma-announces-preclinical-safety-and-tolerability-data-for-cue-401-for-ed6f8465 2026-02-17 https://biopharmsignal.com/news/CING/cingulate-announces-the-closing-of-a-12-million-private-placement-priced-at-the--a79698dc 2026-02-17 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-present-12-week-data-from-the-20-mg-dose-cohort-of-the-p-8443da5a 2026-02-17 https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-to-participate-in-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-17 https://biopharmsignal.com/news/RLYB/rallybio-announces-positive-data-for-rlyb116-phase-1-study-demonstrating-complete-and-sustained-inhibition-of-terminal-complement 2026-02-17 https://biopharmsignal.com/news/TGTX/long-term-data-published-in-jama-neurology-demonstrate-sustained-efficacy-and-consistent-safety-of-briumvi-in-relapsing-multiple-sclerosis 2026-02-17 https://biopharmsignal.com/news/SHC/sotera-health-announces-fourth-quarter-and-full-year-2025-earnings-release-date 2026-02-17 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-to-participate-in-the-td-cowen-46th-annual-health-care-confer-3dda8e6f 2026-02-17 https://biopharmsignal.com/news/XERS/xeris-biopharma-to-report-full-year-2025-financial-results-and-provide-full-year-2026-guidance-on-march-2-2026 2026-02-17 https://biopharmsignal.com/news/NTRB/nutriband-signs-exclusive-distribution-agreement-with-innomedica-for-aversa-fent-1914d982 2026-02-17 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-17 https://biopharmsignal.com/news/ARVN/arvinas-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-24-2026 2026-02-17 https://biopharmsignal.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conference 2026-02-17 https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-provide-business-highlights-and-report-full-year-202-fa8cd9c9 2026-02-17 https://biopharmsignal.com/news/TRDA/independent-data-monitoring-committee-recommends-initiation-of-cohort-2-at-the-i-eb107124 2026-02-17 https://biopharmsignal.com/news/HROW/harrow-announces-cash-pay-direct-to-prescriber-pharmapack-kits-f7d44be9 2026-02-17 https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-fourth-quarter-and-full-year-2025-financial-and-operat-e586cf83 2026-02-17 https://biopharmsignal.com/news/CYCN/cyclerion-therapeutics-announces-progress-toward-cyc-126-phase-2-proof-of-concept-study-with-fda-feedback-and-formation-of-clinical-advisory-board 2026-02-17 https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-participate-in-fireside-chat-at-leerink-global-healthcare-conference 2026-02-17 https://biopharmsignal.com/news/AXGN/axogen-inc-to-participate-in-multiple-upcoming-investor-conferences 2026-02-17 https://biopharmsignal.com/news/TWST/twist-bioscience-expands-antibody-discovery-offering-with-bispecific-licensing-agreement 2026-02-17 https://biopharmsignal.com/news/GSK/gsk-s-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows 2026-02-17 https://biopharmsignal.com/news/GSK/exdensur-depemokimab-approved-by-the-european-commission-for-severe-asthma-with-type-2-inflammation-and-chronic-rhinosinusitis-with-nasal-polyps 2026-02-17 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-drug-application-for-iberdomide-in-patients-with-relapsed-or-refractory-multiple-myeloma 2026-02-17 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-successfully-enrolls-545-patients-in-symontm-ii-study-and-advances-manufacturing-readiness-into-2026 2026-02-17 https://biopharmsignal.com/news/GRI/gri-bio-ceo-marc-hertz-featured-in-virtual-investor-what-this-means-segment 2026-02-17 https://biopharmsignal.com/news/TECH/bio-techne-s-ella-platform-achieves-ce-ivd-marking-expanding-access-to-rapid-cartridge-based-immunoassays-for-european-clinical-laboratories 2026-02-16 https://biopharmsignal.com/news/BRTX/biorestorative-announces-closing-of-5-0-million-public-offering-5f1a0781 2026-02-14 https://biopharmsignal.com/news/LGVN/longeveron-appoints-stephen-h-willard-as-chief-executive-officer-845df2be 2026-02-13 https://biopharmsignal.com/news/IRON/disc-medicine-receives-complete-response-letter-from-fda-for-bitopertin-for-the-treatment-of-epp 2026-02-13 https://biopharmsignal.com/news/INTS/intensity-therapeutics-announces-reverse-stock-split 2026-02-13 https://biopharmsignal.com/news/HCWB/hcw-biologics-and-wy-biotech-announce-closing-of-first-round-of-financing-for-ne-ca515e4d 2026-02-13 https://biopharmsignal.com/news/NEPH/nephros-expands-into-puerto-rico-to-deliver-differentiated-water-filtration-solu-798de5c5 2026-02-13 https://biopharmsignal.com/news/MDNA/medicenna-therapeutics-reports-third-quarter-fiscal-2026-financial-results-and-provides-a-corporate-update 2026-02-13 https://biopharmsignal.com/news/MDRX/veradigm-brings-patient-voice-to-healthcare-research-with-new-real-world-data-survey-solution 2026-02-13 https://biopharmsignal.com/news/XAIR/beyond-air-reports-fiscal-third-quarter-2026-financial-results-and-provides-corp-594e96a0 2026-02-13 https://biopharmsignal.com/news/MDNA/medicenna-announces-changes-to-board-composition 2026-02-13 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2025-financial-resul-b7d8e0a4 2026-02-13 https://biopharmsignal.com/news/CHRS/coherus-oncology-inc-announces-pricing-of-public-offering-of-common-stock 2026-02-13 https://biopharmsignal.com/news/TMCI/treace-updates-date-of-fourth-quarter-and-full-year-2025-financial-results-release-to-february-27-2026 2026-02-12 https://biopharmsignal.com/news/MDXH/mdxhealth-to-present-fourth-quarter-and-full-year-2025-financial-results-and-cor-ee7072dc 2026-02-12 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-provides-regulatory-update-on-translarnatm 2026-02-12 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-on-february-24-2026 2026-02-12 https://biopharmsignal.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2025-earnings-release-and--1487cd77 2026-02-12 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-12 https://biopharmsignal.com/news/NGEN/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams-0320b587 2026-02-12 https://biopharmsignal.com/news/AEMD/aethlon-medical-announces-fiscal-q3-2026-financial-results-and-corporate-update 2026-02-12 https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-reports-second-quarter-fiscal-year-2026-financial-results-and-recent-updates 2026-02-12 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-to-hold-fourth-quarter-and-full-year-2025-earnings-conference-call-on-wednesday-march-4-2026 2026-02-12 https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-upcoming-investor-conferences 2026-02-12 https://biopharmsignal.com/news/CVRX/cvrx-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results 2026-02-12 https://biopharmsignal.com/news/CELC/celcuity-appoints-charles-romp-to-its-board-of-directors-7cb35cea 2026-02-12 https://biopharmsignal.com/news/AMWL/amwell-announces-results-for-fourth-quarter-and-full-year-2025-bef0d25f 2026-02-12 https://biopharmsignal.com/news/PACB/pacbio-announces-fourth-quarter-and-full-year-2025-financial-results-fa35b490 2026-02-12 https://biopharmsignal.com/news/AORT/artivion-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-12 https://biopharmsignal.com/news/CHRS/coherus-oncology-inc-announces-proposed-public-offering-of-common-stock 2026-02-12 https://biopharmsignal.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2025-financial-results-and-corpo-545cbbce 2026-02-12 https://biopharmsignal.com/news/RCEL/avita-medical-reports-fourth-quarter-and-full-year-2025-financial-results-98d4584d 2026-02-12 https://biopharmsignal.com/news/PSNL/personalis-to-announce-fourth-quarter-and-full-year-2025-financial-results 2026-02-12 https://biopharmsignal.com/news/PGNY/progyny-inc-announces-details-for-its-fourth-quarter-and-full-year-2025-results-report 2026-02-12 https://biopharmsignal.com/news/PNTG/pennant-announces-fourth-quarter-and-year-end-2025-earnings-release-and-call 2026-02-12 https://biopharmsignal.com/news/GNFT/genfit-to-receive-us-20m-milestone-after-ipsen-s-iqirvor-exceeds-the-us-200m-threshold-in-its-first-full-year-of-net-sales 2026-02-12 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-be-inaugural-partner-for-life-science-cares-national-campaign-to-advance-health-equity-and-fight-food-insecurity 2026-02-12 https://biopharmsignal.com/news/PRI/primerica-household-budget-indextm-data-purchasing-power-for-middle-income-americans-held-steady-in-december 2026-02-12 https://biopharmsignal.com/news/HSTM/healthstream-to-host-fourth-quarter-and-full-year-2025-earnings-conference-call 2026-02-12 https://biopharmsignal.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2025-financial-results-on-mar-1eb63baa 2026-02-12 https://biopharmsignal.com/news/APRE/aprea-therapeutics-strengthens-global-patent-portfolio-in-dna-damage-response-ddr-cancer-therapeutics-paving-way-for-pipeline-growth 2026-02-12 https://biopharmsignal.com/news/CRMD/cormedix-to-participate-in-upcoming-investor-conferences-722a4b0c 2026-02-12 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-reports-record-fiscal-second-quarter-revenue-growth-of-cd576ea8 2026-02-12 https://biopharmsignal.com/news/VCEL/vericel-to-report-fourth-quarter-and-full-year-2025-financial-results-on-februar-b0e9dfd8 2026-02-12 https://biopharmsignal.com/news/BNTC/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update 2026-02-12 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-appoints-chris-chapman-as-chief-commercial-officer 2026-02-12 https://biopharmsignal.com/news/ANVS/annovis-secures-dsmb-approval-to-advance-pivotal-phase-3-trial-of-buntanetap-in--9daaeb1e 2026-02-12 https://biopharmsignal.com/news/CUE/cue-biopharma-appoints-industry-veteran-lucinda-warren-as-chief-financial-and-bu-c173f226 2026-02-12 https://biopharmsignal.com/news/BIVI/biovie-announces-abstracts-accepted-for-presentation-at-the-2026-american-colleg-1e6efb30 2026-02-12 https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-third-quarter-2026-financial-results-provides-business-update 2026-02-12 https://biopharmsignal.com/news/DCTH/delcath-systems-to-host-fourth-quarter-and-full-year-2025-earnings-call 2026-02-12 https://biopharmsignal.com/news/OPKO/opko-health-to-report-fourth-quarter-2025-financial-results-on-february-26 2026-02-12 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-to-present-at-the-36th-annual-oppenheimer-healthcare-life-sciences-conference 2026-02-12 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-initiation-of-patient-dosing-in-first-of-its-kind-phase-3-head-to-head-car-t-cell-clinical-trial-in-aggressive-large-b-cell-lymphoma 2026-02-12 https://biopharmsignal.com/news/FLGT/fulgent-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-friday-february-27-2026 2026-02-12 https://biopharmsignal.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-company-progress 2026-02-12 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-completes-market-opportunity-assessment-and-advances-commercialization-plans-for-igalmir-in-the-at-home-setting 2026-02-12 https://biopharmsignal.com/news/ARVN/arvinas-announces-appointment-of-randy-teel-ph-d-as-president-chief-executive-officer-and-director 2026-02-12 https://biopharmsignal.com/news/INMB/inmune-bio-announces-fda-alignment-on-integrated-phase-2b-3-registration-pathway-d3d37a95 2026-02-12 https://biopharmsignal.com/news/PACB/pacbio-joins-ihope-initiative-as-first-long-read-genomic-sequencing-partner-259d70fd 2026-02-12 https://biopharmsignal.com/news/MCRB/seres-provides-program-and-corporate-updates-and-prioritizes-emerging-programs-in-inflammatory-and-immune-diseases 2026-02-12 https://biopharmsignal.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-b-14f4294f 2026-02-12 https://biopharmsignal.com/news/BDSX/biodesix-to-report-fourth-quarter-and-full-year-2025-financial-results-on-februa-dee64371 2026-02-12 https://biopharmsignal.com/news/ANL/adlai-nortye-announces-first-patient-enrolled-in-global-phase-1-trial-of-pan-ras-on-inhibitor-an9025-for-solid-tumors-harboring-ras-mutations 2026-02-12 https://biopharmsignal.com/news/BRTX/biorestorative-announces-pricing-of-5-0-million-public-offering-380d51e4 2026-02-12 https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-pricing-of-underwritten-offering-850c5421 2026-02-12 https://biopharmsignal.com/news/PRI/primerica-reports-fourth-quarter-2025-results 2026-02-11 https://biopharmsignal.com/news/RXST/rxsight-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026 2026-02-11 https://biopharmsignal.com/news/EMBC/embecta-names-new-chairman-of-the-board-and-lead-independent-director 2026-02-11 https://biopharmsignal.com/news/PCVX/vaxcyte-doses-first-participants-in-opus-3-phase-3-trial-evaluating-vax-31-in-adults-previously-vaccinated-with-lower-valency-pneumococcal-vaccines 2026-02-11 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-corporate-updates-on-tuesday-february-24-2026 2026-02-11 https://biopharmsignal.com/news/OM/outset-medical-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-11 https://biopharmsignal.com/news/LMAT/lemaitre-will-announce-fourth-quarter-2025-earnings-results-february-25-2026-95215f65 2026-02-11 https://biopharmsignal.com/news/BFRI/biofrontera-announces-fda-filing-acceptance-of-supplemental-new-drug-application-4b5dc0c7 2026-02-11 https://biopharmsignal.com/news/SLRX/decoy-therapeutics-joins-webull-corporate-connect-service-platform 2026-02-11 https://biopharmsignal.com/news/TECH/bio-techne-announces-changes-to-its-leadership-team 2026-02-11 https://biopharmsignal.com/news/SNTI/senti-biosciences-completes-enrollment-in-phase-1-clinical-trial-of-senti-202-fo-e05b55c7 2026-02-11 https://biopharmsignal.com/news/AVAH/aveanna-s-heartways-program-receives-chap-disease-program-certification 2026-02-11 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-result-f5b4af5a 2026-02-11 https://biopharmsignal.com/news/AMRN/amarin-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-co-fcf4cb2a 2026-02-11 https://biopharmsignal.com/news/BRTX/biorestorative-announces-positive-outcome-from-type-b-meeting-with-fda-4c6ac847 2026-02-11 https://biopharmsignal.com/news/PYPD/polypid-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-11 https://biopharmsignal.com/news/NGEN/nervgen-pharma-to-present-at-unite2fight-paralysis-20th-annual-science-and-advoc-add15779 2026-02-11 https://biopharmsignal.com/news/TPST/tempest-lays-out-strategic-plan-to-advance-recently-acquired-dual-targeting-car-t-assets 2026-02-11 https://biopharmsignal.com/news/VERU/veru-reports-fiscal-2026-first-quarter-financial-results-and-clinical-program-progress 2026-02-11 https://biopharmsignal.com/news/YOU/clear-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026 2026-02-11 https://biopharmsignal.com/news/HUM/humana-reports-fourth-quarter-2025-financial-results-provides-full-year-2026-financial-guidance 2026-02-11 https://biopharmsignal.com/news/STIM/neuronetics-announces-selected-preliminary-unaudited-fourth-quarter-and-full-year-2025-financial-results 2026-02-10 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-reports-third-fiscal-quarter-2026-financial-results 2026-02-10 https://biopharmsignal.com/news/PCVX/vaxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-february-24-2026 2026-02-10 https://biopharmsignal.com/news/IBIO/ibio-reports-q2-fiscal-year-2026-financial-results-and-provides-corporate-update 2026-02-10 https://biopharmsignal.com/news/EXEL/exelixis-announces-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides-corporate-update 2026-02-10 https://biopharmsignal.com/news/MDRX/veradigm-to-release-business-update-february-17th-and-host-investor-call-february-18th 2026-02-10 https://biopharmsignal.com/news/AXON/axon-to-release-fourth-quarter-2025-earnings-on-february-24-2026 2026-02-10 https://biopharmsignal.com/news/BCDA/biocardia-files-pre-submission-for-fda-approval-of-helix-transendocardial-delive-c9531cd3 2026-02-10 https://biopharmsignal.com/news/DAWN/day-one-to-report-fourth-quarter-and-full-year-2025-financial-results-tuesday-february-24-2026 2026-02-10 https://biopharmsignal.com/news/OSUR/orasure-to-launch-oraquicktm-hiv-self-test-in-canada 2026-02-10 https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-24-2026 2026-02-10 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-multiple-summit-posters-at-the-2026-aaaai-annual-meeting 2026-02-10 https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-new-listing-of-the-rain-token-on-kraken-the-se-e195e669 2026-02-10 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-to-showcase-scientific-innovation-and-robust-clinical-data-o-229cfbdc 2026-02-10 https://biopharmsignal.com/news/BRTX/biorestorative-completes-patient-enrollment-in-landmark-phase-2-trial-of-brtx-10-e3b0cae0 2026-02-10 https://biopharmsignal.com/news/IRMD/iradimed-corporation-reports-record-fourth-quarter-and-full-year-of-2025-financi-2c24018d 2026-02-10 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-report-fourth-quarter-and-full-year-2025-financial-results-on-b86cdf96 2026-02-10 https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-appoints-david-sandoval-as-general-counsel-and-chief-compliance-officer 2026-02-10 https://biopharmsignal.com/news/SRRK/scholar-rock-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-3-2026 2026-02-10 https://biopharmsignal.com/news/TWST/twist-bioscience-launches-next-generation-library-preparation-kits-powered-by-proprietary-enzymes 2026-02-10 https://biopharmsignal.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2025-financial-results-b379f7e1 2026-02-10 https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-february-24-2026-to-discuss-fourth-quarter-and-full-year-2025-financial-results 2026-02-10 https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-pricing-of-110-0-million-underwritten-offering-d4dab582 2026-02-10 https://biopharmsignal.com/news/AXGN/axogen-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-24-2026 2026-02-10 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting 2026-02-10 https://biopharmsignal.com/news/PHVS/pharvaris-to-present-clinical-data-at-the-aaaai-2026-annual-meeting-2bd74dbf 2026-02-10 https://biopharmsignal.com/news/PSNL/personalis-receives-medicare-coverage-for-next-personalr-in-lung-cancer-surveillance 2026-02-10 https://biopharmsignal.com/news/GSK/gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-in-china-for-adults-aged-60-years-and-older 2026-02-10 https://biopharmsignal.com/news/OSUR/orasure-to-announce-fourth-quarter-2025-financial-results-and-host-earnings-call-on-february-25th 2026-02-09 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-reports-fourth-quarter-and-full-year-2025-results 2026-02-09 https://biopharmsignal.com/news/LFST/lifestance-to-host-fourth-quarter-and-full-year-2025-earnings-conference-call-on-february-25-2026 2026-02-09 https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-february-19-2026-and-participate-in-upcoming-investor-conferences 2026-02-09 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-december-31-2025 2026-02-09 https://biopharmsignal.com/news/XOMA/xoma-royalty-announces-closing-of-tender-offer-and-completed-acquisition-of-generation-bio-inc 2026-02-09 https://biopharmsignal.com/news/BFRI/biofrontera-announces-positive-results-in-phase-3-study-of-ameluz-pdt-for-actini-8fd57dae 2026-02-09 https://biopharmsignal.com/news/OGEN/oragenics-targets-projected-9-billion-market-by-advancing-first-and-only-clinical-stage-concussion-and-mild-traumatic-brain-injury-therapy 2026-02-09 https://biopharmsignal.com/news/ICU/seastar-medical-announces-publication-in-pediatric-nephrology-of-positive-real-w-dd08e72f 2026-02-09 https://biopharmsignal.com/news/STXS/klinikum-f-rth-establishes-leading-robotic-heart-arrhythmia-program-d73a5c1f 2026-02-09 https://biopharmsignal.com/news/CLDX/celldex-to-present-at-upcoming-investor-conferences-b2c5a1cd 2026-02-09 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-announces-launch-of-ycanthr-for-the-treatment-of-molluscum-contagiosum-in-japan-by-partner-torii-pharmaceutical 2026-02-09 https://biopharmsignal.com/news/INAB/in8bio-promotes-kate-rochlin-ph-d-to-president-and-chief-operating-officer 2026-02-09 https://biopharmsignal.com/news/SLDB/solid-biosciences-announces-positive-feedback-from-type-c-meeting-with-fda-for-s-d32a39f1 2026-02-09 https://biopharmsignal.com/news/PRQR/proqr-announces-planned-changes-to-board-composition-7bf99866 2026-02-09 https://biopharmsignal.com/news/VYGR/voyager-to-present-at-upcoming-investor-conferences-a9ba72db 2026-02-09 https://biopharmsignal.com/news/FDMT/4dmt-completes-enrollment-for-4front-1-phase-3-clinical-trial-of-4d-150-in-wet-a-e6c90f99 2026-02-09 https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-rmat-designation-granted-by-fda-to-kb707-for-the-treat-d4d220d6 2026-02-09 https://biopharmsignal.com/news/CNTX/context-therapeutics-to-participate-in-upcoming-investor-conferences 2026-02-09 https://biopharmsignal.com/news/BYSI/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference-22ca5854 2026-02-09 https://biopharmsignal.com/news/OCGN/ocugen-appoints-rita-johnson-greene-to-chief-financial-officer-0883dbd7 2026-02-09 https://biopharmsignal.com/news/NGEN/nervgen-pharma-appoints-adam-rogers-as-chief-executive-officer-to-continue-leadi-189eb7a6 2026-02-09 https://biopharmsignal.com/news/MD/pediatrix-medical-group-2025-fourth-quarter-conference-call-webcast-scheduled-for-thursday-february-19-2026 2026-02-09 https://biopharmsignal.com/news/IART/integra-lifesciences-to-host-fourth-quarter-and-full-year-2025-financial-results-conference-call-on-february-26-2026 2026-02-09 https://biopharmsignal.com/news/MNKD/mannkind-announces-first-patient-enrolled-in-inhale-1st-pediatric-study-evaluating-afrezzar-for-youth-with-newly-diagnosed-type-1-diabetes-t1d 2026-02-09 https://biopharmsignal.com/news/LXRX/lexicon-announces-closing-of-approximately-94-6-million-public-offering-and-conc-a514ae02 2026-02-06 https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-announces-intention-to-voluntarily-delist-from-nasdaq-and-deregister-with-sec 2026-02-06 https://biopharmsignal.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-piper-sandler-virtual-novel-ta-89ce62e0 2026-02-06 https://biopharmsignal.com/news/IMMP/immutep-achieves-50-enrolment-in-global-tacti-004-keynote-f91-phase-iii-trial-in-222e3755 2026-02-06 https://biopharmsignal.com/news/SLDB/solid-biosciences-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2-81abcb22 2026-02-06 https://biopharmsignal.com/news/ROIV/roivant-announces-positive-phase-2-results-for-brepocitinib-in-cutaneous-sarcoidosis-cs-and-reports-financial-results-for-the-third-quarter-ended-december-31-2025 2026-02-06 https://biopharmsignal.com/news/ROIV/priovant-announces-positive-phase-2-results-for-brepocitinib-in-cutaneous-sarcoidosis-cs 2026-02-06 https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-third-quarter-ended-december-31-2025 2026-02-06 https://biopharmsignal.com/news/GSK/nucala-mepolizumab-approved-by-the-european-commission-for-the-treatment-of-chronic-obstructive-pulmonary-disease-copd 2026-02-06 https://biopharmsignal.com/news/HCM/hutchmed-to-announce-2025-final-results-75c308ae 2026-02-06 https://biopharmsignal.com/news/HIMS/hims-glp-1-weight-loss-what-consumers-should-know-about-the-reported-49-compound-4d7ec809 2026-02-06 https://biopharmsignal.com/news/GDRX/goodrx-powers-pricing-for-leading-brand-medications-on-trumprx 2026-02-06 https://biopharmsignal.com/news/IOVA/best-in-class-real-world-data-support-early-amtagvir-treatment-in-advanced-melanoma 2026-02-05 https://biopharmsignal.com/news/IRTC/irhythm-holdings-to-report-fourth-quarter-and-full-year-2025-financial-results-o-6fe033e5 2026-02-05 https://biopharmsignal.com/news/TDOC/teladoc-health-to-announce-fourth-quarter-2025-financial-results-d888d71b 2026-02-05 https://biopharmsignal.com/news/COO/coopercompanies-announces-release-date-for-first-quarter-2026-6843a4fc 2026-02-05 https://biopharmsignal.com/news/XRAY/dentsply-sirona-to-host-fourth-quarter-and-full-year-conference-call-on-february-6105bc82 2026-02-05 https://biopharmsignal.com/news/ANAB/anaptys-announces-participation-at-upcoming-investor-conferences 2026-02-05 https://biopharmsignal.com/news/MOH/molina-healthcare-reports-fourth-quarter-and-year-end-2025-financial-results 2026-02-05 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-the-guggenheim-emerging-outlook-biotech-5675db97 2026-02-05 https://biopharmsignal.com/news/PCVX/vaxcyte-to-present-at-the-guggenheim-emerging-outlook-biotech-summit 2026-02-05 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-05 https://biopharmsignal.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2025-financi-a0c816a2 2026-02-05 https://biopharmsignal.com/news/AMWL/amwell-to-report-fourth-quarter-and-full-year-2025-operating-results-f4ff4125 2026-02-05 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-in-1eafd2ef 2026-02-05 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-fiscal-2026-first-quarter-results 2026-02-05 https://biopharmsignal.com/news/DNLI/denali-therapeutics-presents-enzyme-transportvehicle-progress-across-three-clini-f5279cc4 2026-02-05 https://biopharmsignal.com/news/LGVN/longeveron-applauds-passage-of-the-mikaela-naylon-give-kids-a-chance-act-and-rea-057190bf 2026-02-05 https://biopharmsignal.com/news/SLRX/decoy-therapeutics-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial 2026-02-05 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-and-soundhealth-announce-collaboration-to-expand-access-to-so-e650cf48 2026-02-05 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-expects-to-report-fiscal-second-quarter-2026-revenue-g-f4e8dd06 2026-02-05 https://biopharmsignal.com/news/HSCS/university-of-west-england-adopts-heartsciences-myovista-insights-platform-and-m-f878d98f 2026-02-05 https://biopharmsignal.com/news/ICUI/icu-medical-announces-time-of-fourth-quarter-2025-earnings-conference-call-eb99507c 2026-02-05 https://biopharmsignal.com/news/IMNN/imunon-sharpens-focus-on-its-promising-pivotal-phase-3-ovarian-cancer-study-e9f9b5fc 2026-02-05 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026 2026-02-05 https://biopharmsignal.com/news/ALHC/alignment-healthcare-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-thursday-feb-26-2026 2026-02-05 https://biopharmsignal.com/news/APGE/apogee-therapeutics-to-participate-at-the-guggenheim-emerging-outlook-biotech-su-a5ae9a93 2026-02-05 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-announce-fourth-quarter-and-full-year-2025-financial-r-1b8238b0 2026-02-05 https://biopharmsignal.com/news/ARDX/ardelyx-to-report-full-year-and-fourth-quarter-2025-financial-results-on-februar-ea353ecd 2026-02-05 https://biopharmsignal.com/news/CABA/cabaletta-bio-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026 2026-02-05 https://biopharmsignal.com/news/ANGO/angiodynamics-and-the-pert-consortiumr-launch-investigator-led-research-fund-to-advance-pulmonary-embolism-care 2026-02-05 https://biopharmsignal.com/news/ERAS/erasca-to-present-at-upcoming-conferences-in-february 2026-02-05 https://biopharmsignal.com/news/SHC/sotera-health-appoints-richard-kyle-to-the-board-of-directors 2026-02-05 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-extends-expanded-access-program-for-zervimesine-ct1812-in-1ca7b1aa 2026-02-05 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-participation-in-two-upcoming-investor-conferences-91ab1d3e 2026-02-05 https://biopharmsignal.com/news/XCUR/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-ce-28575f3b 2026-02-05 https://biopharmsignal.com/news/EYPT/eyepoint-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026-9a1f8f97 2026-02-05 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-participate-in-fireside-chat-at-the-guggenheim-emerging-f8467e60 2026-02-05 https://biopharmsignal.com/news/SNDX/syndax-announces-participation-at-the-2026-guggenheim-emerging-outlook-biotech-summit 2026-02-05 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2025 2026-02-05 https://biopharmsignal.com/news/EMBC/embecta-corp-reports-first-quarter-fiscal-2026-financial-results 2026-02-05 https://biopharmsignal.com/news/GRI/gri-bio-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial 2026-02-05 https://biopharmsignal.com/news/TPST/tempest-announces-closing-of-strategic-acquisition-of-dual-targeting-car-t-assets 2026-02-04 https://biopharmsignal.com/news/ENSG/the-ensign-group-reports-fiscal-year-and-fourth-quarter-2025-results-issues-2026-afa0a9e9 2026-02-04 https://biopharmsignal.com/news/PMN/promis-neurosciences-to-participate-in-the-guggenheim-emerging-outlook-biotech-s-dedb2c22 2026-02-04 https://biopharmsignal.com/news/IRMD/iradimed-corporation-to-hold-fourth-quarter-and-full-year-2025-financial-results-fcd8fc24 2026-02-04 https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit--f7ef49bf 2026-02-04 https://biopharmsignal.com/news/LFVN/lifevantage-announces-planned-retirement-of-steve-fife-and-ceo-succession-plan 2026-02-04 https://biopharmsignal.com/news/LFVN/lifevantage-announces-financial-results-for-the-second-quarter-of-fiscal-2026 2026-02-04 https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-attend-the-td-cowen-46th-annual-health-care-conference-an-e92ee5ef 2026-02-04 https://biopharmsignal.com/news/MDXG/mimedx-enters-into-exclusive-distribution-agreement-with-summit-products-group-for-multiple-innovative-surgical-and-wound-products 2026-02-04 https://biopharmsignal.com/news/ACHC/acadia-healthcare-announces-date-for-fourth-quarter-and-year-end-2025-earnings-release 2026-02-04 https://biopharmsignal.com/news/SLRX/decoy-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recently-announced-global-access-commitment-agreement 2026-02-04 https://biopharmsignal.com/news/CHRS/coherus-oncology-announces-clinical-supply-agreement-to-evaluate-tagmokitug-in-combination-with-pasritamig 2026-02-04 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-receives-fda-fast-track-designation-for-pelareorep-in-2l-kras-09e05c04 2026-02-04 https://biopharmsignal.com/news/GRI/gri-bio-reiterates-full-year-2025-financial-results-strengthens-balance-sheet-an-7611ed6b 2026-02-04 https://biopharmsignal.com/news/APRE/aprea-therapeutics-appoints-industry-veteran-eugene-kennedy-md-as-chief-medical-advisor 2026-02-04 https://biopharmsignal.com/news/BDRX/biodexa-announces-exclusive-license-of-otsuka-s-opb-171775-a-potent-phase-1-read-ccd62631 2026-02-04 https://biopharmsignal.com/news/VERU/veru-to-report-fiscal-2026-first-quarter-financial-results-on-february-11th 2026-02-04 https://biopharmsignal.com/news/AEMD/aethlon-medical-to-release-fiscal-third-quarter-financial-results-and-host-conference-call-on-february-12-2026 2026-02-04 https://biopharmsignal.com/news/CRBU/caribou-biosciences-announces-late-breaking-presentations-at-the-2026-tandem-meetings-of-astctr-and-cibmtrr 2026-02-04 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit 2026-02-04 https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-3625d3e2 2026-02-04 https://biopharmsignal.com/news/XAIR/beyond-cancer-abstract-featuring-phase-1-data-on-intratumoral-ultra-high-concent-d059cadf 2026-02-04 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-february-conferences 2026-02-04 https://biopharmsignal.com/news/OPKO/opko-health-and-entera-bio-expand-partnership-to-advance-first-in-class-oral-long-acting-pth-tablet-for-patients-with-hypoparathyroidism 2026-02-04 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-presents-positive-new-real-world-data-on-miplyffa-in-patients-b6b1b207 2026-02-04 https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-unveil-new-precision-ai-capability 2026-02-04 https://biopharmsignal.com/news/CELC/celcuity-to-present-at-upcoming-guggenheim-emerging-outlook-biotech-summit-2026-44c89a77 2026-02-04 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheim-s-emerging-outlook-biotech-summit 2026-02-04 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summi-2e7e7c05 2026-02-04 https://biopharmsignal.com/news/TENX/tenax-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-sum-f2529a33 2026-02-04 https://biopharmsignal.com/news/CCCC/c4-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-fa3526ac 2026-02-04 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-to-present-at-upcoming-investor-conferences-14ce009b 2026-02-04 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-two-february-healthcare-conferences-29d11194 2026-02-04 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-teams-up-with-kasey-keller-to-share-his-lymphoma-journey-with-breyanzi 2026-02-04 https://biopharmsignal.com/news/ZURA/zura-bio-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit 2026-02-04 https://biopharmsignal.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2026-results 2026-02-04 https://biopharmsignal.com/news/INKT/mink-therapeutics-presents-new-data-of-allo-inkt-cell-therapy-as-a-potential-dis-7c298e9b 2026-02-04 https://biopharmsignal.com/news/GSK/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks 2026-02-04 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-presents-detailed-data-from-registrational-staar-study-in-f-7551dc26 2026-02-03 https://biopharmsignal.com/news/BSEM/biostem-technologies-highlights-alignment-with-fda-s-openness-to-bayesian-statis-d1aa307a 2026-02-03 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conference-74f862ff 2026-02-03 https://biopharmsignal.com/news/RLYB/rallybio-announces-reverse-stock-split-of-common-stock 2026-02-03 https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-fourth-quarter-and-fiscal-year-2025-financial-results-on-february-17-2026 2026-02-03 https://biopharmsignal.com/news/FEMY/femasys-expands-european-commercial-footprint-with-swiss-partner-for-fembloc-fem-4ffbf58a 2026-02-03 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-announces-pricing-of-25-0-million-underwritten-offering-9de561df 2026-02-03 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-ind-for-prt12396-a-mutant-selective-jak2v617f-inhibitor 2026-02-03 https://biopharmsignal.com/news/SNTI/senti-biosciences-selected-for-on-stage-presentation-at-healthcare-conference-ta-0f2c8eed 2026-02-03 https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-sale-of-oncology-assets-to-neotrail-therapeutics-03f4fec9 2026-02-03 https://biopharmsignal.com/news/OGEN/oragenics-partners-with-duck-flats-pharma-to-support-fda-ind-readiness-and-clinical-trial-design-for-concussion-program 2026-02-03 https://biopharmsignal.com/news/ARDX/ardelyx-receives-new-patent-for-tenapanor-0f1a8768 2026-02-03 https://biopharmsignal.com/news/APVO/aptevo-announces-executive-leadership-transitions-to-support-next-phase-of-growth 2026-02-03 https://biopharmsignal.com/news/RIGL/rigel-appoints-michael-p-miller-to-the-board-of-directors 2026-02-03 https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences 2026-02-03 https://biopharmsignal.com/news/INAB/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february 2026-02-03 https://biopharmsignal.com/news/RARE/ultragenyx-announces-positive-longer-term-data-demonstrating-treatment-with-ux11-bc619ecd 2026-02-03 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-appoints-mayo-pujols-as-chief-technology-officer-e624ad85 2026-02-03 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-announces-that-its-collaborative-phase-2-trial-with-the-un-6386e311 2026-02-03 https://biopharmsignal.com/news/BCDA/biocardia-announces-late-breaking-echocardiography-results-from-the-cardiamp-hf--d546c836 2026-02-03 https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-scheduling-of-fda-type-c-meeting-to-discuss-efzofitimod-program-in-pulmonary-sarcoidosis 2026-02-03 https://biopharmsignal.com/news/ANGO/angiodynamics-to-convene-cardiovascular-leaders-at-scientific-forum-as-pipeline-continues-to-advance 2026-02-03 https://biopharmsignal.com/news/REPL/replimune-reports-fiscal-third-quarter-2026-financial-results-and-provides-corporate-update 2026-02-03 https://biopharmsignal.com/news/TNGX/tango-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026 2026-02-03 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit 2026-02-03 https://biopharmsignal.com/news/ANL/adlai-nortye-announces-140-0-million-private-placement-equity-financing 2026-02-03 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-participate-in-guggenheim-s-emerging-outlook-biotech-summi-7fce9300 2026-02-03 https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-zovegalisib-granted-breakthrough-therapy-designatio-b6a544a1 2026-02-03 https://biopharmsignal.com/news/PRPH/prophase-labs-initiates-potential-sale-or-strategic-partnership-of-be-smarttm-and-advances-crown-medical-collections-initiative 2026-02-03 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-introduces-change-the-target-change-what-s-possible-to-highlight-unmet-needs-in-cardiovascular-and-thromboembolic-care 2026-02-03 https://biopharmsignal.com/news/PYXS/pyxis-oncology-announces-interim-ceo-appointment-and-leadership-transition-to-su-b2552efb 2026-02-03 https://biopharmsignal.com/news/ENSG/the-ensign-group-adds-real-estate-and-operations-in-texas-7bcee660 2026-02-03 https://biopharmsignal.com/news/ENSG/the-ensign-group-acquires-real-estate-and-operations-in-texas-274f149c 2026-02-03 https://biopharmsignal.com/news/ENSG/the-ensign-group-buys-real-estate-and-operations-in-wisconsin-58c824bf 2026-02-03 https://biopharmsignal.com/news/ENSG/the-ensign-group-obtains-real-estate-and-operations-in-texas-4f1f3b75 2026-02-03 https://biopharmsignal.com/news/ENSG/the-ensign-group-grows-operations-in-arizona-e75989cd 2026-02-03 https://biopharmsignal.com/news/ADXN/addex-announces-publication-of-preclinical-data-supporting-potential-of-mglu7-ne-84cccc22 2026-02-03 https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-expected-record-date-for-spin-off 2026-02-03 https://biopharmsignal.com/news/ENSG/the-ensign-group-schedules-year-end-2025-earnings-call-for-thursday-february-5-2-a7a82f8d 2026-02-02 https://biopharmsignal.com/news/SIBN/si-bone-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-23-2026 2026-02-02 https://biopharmsignal.com/news/PCVX/vaxcyte-announces-closing-of-632-5-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares 2026-02-02 https://biopharmsignal.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-02-02 https://biopharmsignal.com/news/MDRX/veradigm-extends-stockholder-rights-plan 2026-02-02 https://biopharmsignal.com/news/PACB/pacbio-completes-sale-of-short-read-sequencing-assets-72ae5914 2026-02-02 https://biopharmsignal.com/news/AVCO/avalon-globocare-eliminates-majority-of-debentures-through-2-6-million-conversion-strengthening-balance-sheet-reduces-overhang 2026-02-02 https://biopharmsignal.com/news/GDRX/goodrx-earns-hitrust-i1-certification-for-the-second-consecutive-year-reinforcing-its-commitment-to-protecting-healthcare-data-at-scale 2026-02-02 https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-pricing-of-175-million-underwritten-offering--01927356 2026-02-02 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-announces-share-repurchase-program-76e2bfb1 2026-02-02 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-50-enrollment-in-ongoing-halneuronr-phase-2b-trial-top-line-results-anticipated-in-q3-2026 2026-02-02 https://biopharmsignal.com/news/OGEN/oragenics-to-participate-in-scope-summit-2026-focused-on-advancing-clinical-research-and-patient-care 2026-02-02 https://biopharmsignal.com/news/MDXG/mimedx-celebrates-15-year-anniversary-of-epifixr-and-amniofixr 2026-02-02 https://biopharmsignal.com/news/MLTX/moonlake-announces-fda-fast-track-designation-for-sonelokimab-palmoplantar-pustulosis-ppp-and-provides-details-on-upcoming-investor-day 2026-02-02 https://biopharmsignal.com/news/SPRY/eurneffy-1-mg-adrenaline-nasal-spray-recommended-for-approval-in-the-eu-for-emer-0a6cea76 2026-02-02 https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-host-webcast-highlighting-presentations-on-enzyme-transpo-bec4b7df 2026-02-02 https://biopharmsignal.com/news/PRPH/join-prophase-labs-exclusive-live-investor-webinar-and-qanda-session-on-february-3rd 2026-02-02 https://biopharmsignal.com/news/AORT/artivion-announces-presentation-of-positive-new-clinical-data-from-nexus-triomphe-and-amds-persevere-trials-at-the-62nd-society-of-thoracic-surgery-annual-meeting 2026-02-02 https://biopharmsignal.com/news/EXEL/exelixis-announces-u-s-fda-accepted-the-new-drug-application-for-zanzalintinib-in-combination-with-an-immune-checkpoint-inhibitor-for-patients-with-metastatic-colorectal-cancer 2026-02-02 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-to-ring-nasdaq-stock-market-opening-bell-on-monday-february-9-132752ed 2026-02-02 https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-plans-to-accelerate-regulatory-engagement-with-full-0bfd88c8 2026-02-02 https://biopharmsignal.com/news/TWST/twist-bioscience-announces-fiscal-2026-first-quarter-financial-results 2026-02-02 https://biopharmsignal.com/news/SGMT/sagimet-announces-positive-52-week-data-from-license-partner-ascletis-open-label-bef68b7f 2026-02-02 https://biopharmsignal.com/news/HROW/harrow-reaffirms-2025-full-year-revenue-guidance-of-270-280-million-marking-anot-c05959c6 2026-02-02 https://biopharmsignal.com/news/IRIX/iridex-announces-plans-to-relocate-headquarters 2026-02-02 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-announces-licensing-of-rare-disease-product-candidate-9bf5ad15 2026-02-02 https://biopharmsignal.com/news/TECH/bio-techne-expands-3d-stem-cell-and-organoid-culture-portfolio-with-a-fully-defined-synthetic-alternative 2026-02-02 https://biopharmsignal.com/news/MOLN/molecular-partners-announces-presentation-of-first-imaging-and-dosimetry-data-of-d2e10347 2026-02-02 https://biopharmsignal.com/news/ALXO/alx-oncology-announces-pricing-of-underwritten-offering 2026-01-30 https://biopharmsignal.com/news/RARE/ultragenyx-resubmits-biologics-license-application-for-ux111-aav-gene-therapy-to-a78aa523 2026-01-30 https://biopharmsignal.com/news/ALXO/new-data-demonstrate-cd47-expression-level-helps-predict-response-to-alx-oncology-s-evorpacept-in-combination-with-ziihera-zanidatamab-hrii-in-advanced-her2-positive-breast-cancer 2026-01-30 https://biopharmsignal.com/news/PMN/promis-neurosciences-announces-up-to-175-million-private-placement-financing-976caaa3 2026-01-30 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-appendix-4c-q2-fy26-quarterly-cash-flow-report-corporate-u-a8a6f87d 2026-01-30 https://biopharmsignal.com/news/NTRB/nutriband-inc-provides-summary-of-annual-shareholder-meeting-key-discussion-poin-9b18961f 2026-01-30 https://biopharmsignal.com/news/IMCR/immunocore-announces-randd-leadership-evolution 2026-01-30 https://biopharmsignal.com/news/LXRX/lexicon-announces-pricing-of-approximately-94-6-million-public-offering-and-conc-1eab0ac0 2026-01-30 https://biopharmsignal.com/news/PCVX/vaxcyte-announces-pricing-of-550-million-public-offering 2026-01-30 https://biopharmsignal.com/news/MNOV/medicinova-announces-100-patients-enrolled-in-seanobi-study-expanded-access-program-eap-evaluating-mn-166-ibudilast-in-als-patients 2026-01-29 https://biopharmsignal.com/news/ALT/altimmune-announces-closing-of-75-million-registered-direct-offering-of-common-s-f2d21283 2026-01-29 https://biopharmsignal.com/news/LXRX/lexicon-announces-proposed-public-offering-of-common-stock-a73be6cf 2026-01-29 https://biopharmsignal.com/news/CVRX/cvrx-to-report-fourth-quarter-2025-financial-and-operating-results-and-host-conference-call-on-february-12-2026 2026-01-29 https://biopharmsignal.com/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offering-of-common-stock-and-pre-funded-warrants 2026-01-29 https://biopharmsignal.com/news/CLOV/clover-health-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026 2026-01-29 https://biopharmsignal.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-fourth-quarter-2025-financial-results 2026-01-29 https://biopharmsignal.com/news/OPCH/option-care-health-to-participate-in-the-td-cowen-healthcare-conference 2026-01-29 https://biopharmsignal.com/news/SYK/stryker-reports-2025-operating-results-and-2026-outlook 2026-01-29 https://biopharmsignal.com/news/SENS/senseonics-receives-european-approval-for-eversense-365-world-s-longest-lasting--ea8d2485 2026-01-29 https://biopharmsignal.com/news/DNLI/denali-therapeutics-announces-data-presentations-on-enzyme-transportvehicle-prog-bb09041f 2026-01-29 https://biopharmsignal.com/news/LGVN/longeveron-granted-japan-patent-for-potency-assay-methods-for-assessing-human-me-fbbdd4be 2026-01-29 https://biopharmsignal.com/news/UNCY/update-unicycive-therapeutics-announces-fda-acceptance-of-oxylanthanum-carbonate-olc-new-drug-application-nda-resubmission 2026-01-29 https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-announces-final-results-of-tender-offer 2026-01-29 https://biopharmsignal.com/news/CERT/certara-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26th-2026 2026-01-29 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-to-host-in-person-and-virtual-analyst-day-in-new-york-on-f-53c72395 2026-01-29 https://biopharmsignal.com/news/HSCS/cibolo-health-designates-heartsciences-myovista-insights-as-endorsed-ecg-managem-58191825 2026-01-29 https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-early-clinical-proof-of-concept-in-the-ongoing-acesot-1051-dose-escalation-trial-evaluating-wee1-inhibitor-apr-1051-including-partial-response-observed-on-first-scan 2026-01-29 https://biopharmsignal.com/news/ICU/seastar-medical-to-present-at-upcoming-noble-capital-markets-emerging-growth-vir-7bccc30e 2026-01-29 https://biopharmsignal.com/news/IXHL/incannex-healthcare-announces-additional-appointments-to-clinical-advisory-board-5f484bdc 2026-01-29 https://biopharmsignal.com/news/IMMP/immutep-quarterly-activities-report-q2-fy26-44615488 2026-01-29 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-to-participate-in-upcoming-conferences-47ed2b8d 2026-01-29 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-participate-at-the-btig-13th-annual-medtech-digital--422a7636 2026-01-29 https://biopharmsignal.com/news/BLTE/belite-bio-announces-participation-at-the-41st-asia-pacific-academy-of-ophthalmo-39effde4 2026-01-29 https://biopharmsignal.com/news/IFRX/inflarx-announces-participation-in-february-investor-conferences-35349363 2026-01-29 https://biopharmsignal.com/news/VANI/vivani-subsidiary-cortigent-presents-promising-6-year-early-feasibility-study-results-for-the-orion-system-at-nans-2026 2026-01-29 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-announces-fda-acceptance-of-oxylanthanum-carbonate-olc-new-drug-application-nda-resubmission 2026-01-29 https://biopharmsignal.com/news/PRI/national-survey-middle-income-families-settling-into-a-new-reality-with-ongoing-cost-of-living-pressure 2026-01-29 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-welcomes-new-member-of-its-board-of-directors-and-new-senior-vice-president-of-regulatory-quality-and-product-development 2026-01-28 https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-to-participate-at-the-btig-13th-annual-medtech-digital-h-67c8b6e2 2026-01-28 https://biopharmsignal.com/news/AMRX/amneal-pharmaceuticals-added-to-sandp-smallcap-600r-index 2026-01-28 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides-a-corporate-update 2026-01-28 https://biopharmsignal.com/news/MDRX/veradigm-launches-new-ai-application-for-powerful-revenue-cycle-insights-for-independent-practices 2026-01-28 https://biopharmsignal.com/news/IMMX/immix-biopharma-receives-u-s-fda-breakthrough-therapy-designation-for-nxc-201-59d7d798 2026-01-28 https://biopharmsignal.com/news/GRI/gri-bio-delivers-compelling-new-phase-2a-gene-expression-data-demonstrating-impr-aadb2188 2026-01-28 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-presentation-of-preliminary-results-from-phase-2-study-of--7bda06d4 2026-01-28 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-initiates-additional-clinical-studies-for-fda-510-k-su-17439110 2026-01-28 https://biopharmsignal.com/news/ARDX/first-patient-dosed-in-accel-phase-3-chronic-idiopathic-constipation-study-of-ib-2cfe8c39 2026-01-28 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-and-weill-cornell-medicine-qatar-collaborate-with-the-mic-2fa58ee6 2026-01-28 https://biopharmsignal.com/news/PYPD/polypid-to-report-fourth-quarter-2025-financial-results-and-operational-highlights-on-february-11-2026 2026-01-28 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-provides-enrollment-update-on-pivotal-phase-3-trial-of-pf614-its-next-generation-opioid-for-severe-acute-pain 2026-01-28 https://biopharmsignal.com/news/SCYX/scynexis-announces-presentations-highlighting-the-potent-antifungal-activity-of-its-second-generation-fungerp-scy-247-against-drug-resistant-fungi-at-the-inaugural-interdisciplinary-meeting-on-antimicrobial-resistance-and-innovation-imari 2026-01-28 https://biopharmsignal.com/news/VERA/vera-therapeutics-announces-appointment-of-matt-skelton-to-chief-commercial-offi-553eaa84 2026-01-28 https://biopharmsignal.com/news/RANI/rani-therapeutics-announces-the-promotion-of-alireza-javadi-ph-d-to-chief-technical-officer 2026-01-28 https://biopharmsignal.com/news/INDV/indivior-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host--92748f31 2026-01-28 https://biopharmsignal.com/news/TECH/bio-techne-launches-simple-plex-ultra-sensitive-assays-on-ella-platform-to-enable-femtogram-level-detection-of-neurological-biomarkers 2026-01-28 https://biopharmsignal.com/news/ALT/altimmune-announces-pricing-of-75-million-registered-direct-offering-of-common-s-c10544fa 2026-01-28 https://biopharmsignal.com/news/PACB/pacbio-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-28fb3da6 2026-01-27 https://biopharmsignal.com/news/XAIR/beyond-air-to-participate-in-two-upcoming-healthcare-investor-conferences-c4d89124 2026-01-27 https://biopharmsignal.com/news/VANI/vivani-medical-inc-announces-closing-of-common-stock-offering 2026-01-27 https://biopharmsignal.com/news/EXEL/exelixis-to-release-fourth-quarter-and-fiscal-year-2025-financial-results-on-tuesday-february-10-2026 2026-01-27 https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-announces-preliminary-results-of-tender-offer 2026-01-27 https://biopharmsignal.com/news/OM/next-generation-tablo-hemodialysis-system-receives-fda-clearance-second-quarter-launch-planned 2026-01-27 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-announces-submission-to-japanese-mhlw-for-orphan-drug-desi-c6ae6103 2026-01-27 https://biopharmsignal.com/news/LQDA/liquidia-to-present-clinical-data-across-its-portfolio-at-the-pulmonary-vascular-research-institute-2026-annual-congress 2026-01-27 https://biopharmsignal.com/news/HYPR/hyperfine-announces-publication-of-breakthrough-clinical-data-demonstrating-the-swoopr-system-s-enhanced-stroke-detection-capabilities 2026-01-27 https://biopharmsignal.com/news/DCTH/delcath-systems-to-participate-at-the-btig-13th-annual-medtech-digital-health-life-science-and-diagnostic-tools-conference 2026-01-27 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-announces-mutual-termination-of-license-agreement-with-qilu-pharmaceutical-for-certepetide 2026-01-27 https://biopharmsignal.com/news/BLTE/belite-bio-completes-enrollment-in-the-dragon-ii-clinical-trial-of-tinlarebant-f-6cc1dd4a 2026-01-27 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-1-for-4-reverse-stock-split 2026-01-27 https://biopharmsignal.com/news/ATRC/atricure-to-announce-fourth-quarter-and-full-year-2025-financial-results 2026-01-27 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-completes-type-c-meeting-with-fda-for-zervimesine-ct1812--f39fee84 2026-01-27 https://biopharmsignal.com/news/BFRG/bullfrog-ai-on-data-harmonization-the-hidden-prerequisite-for-reliable-ai-ml-in-life-sciences 2026-01-27 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-initiates-phase-1-2a-study-of-aro-dimer-pa-the-first-dual-functional-rnai-therapeutic-for-the-treatment-of-mixed-hyperlipidemia 2026-01-27 https://biopharmsignal.com/news/KPRX/retinal-disease-expert-dr-taiji-sakamoto-joins-kiora-pharmaceuticals-scientific-advisory-board 2026-01-27 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-novel-itk-jak3-inhibitor-ati-2138-demonstrates-rapid-and-su-c79922be 2026-01-27 https://biopharmsignal.com/news/GNTA/genenta-announces-strategic-transformation-into-a-biotech-defense-aerospace-and-national-security-industrial-consolidator 2026-01-27 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial--50ac9976 2026-01-26 https://biopharmsignal.com/news/XAIR/beyond-air-schedules-third-fiscal-quarter-2026-financial-results-conference-call-88a6d58d 2026-01-26 https://biopharmsignal.com/news/OM/outset-medical-to-report-fourth-quarter-2025-financial-results-on-wednesday-february-11-2026 2026-01-26 https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-host-4q25-earnings-conference-call-on-february-24-2026-an-9d2e2bc4 2026-01-26 https://biopharmsignal.com/news/ISRG/da-vinci-5-cleared-for-cardiac-procedures 2026-01-26 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-breakthrough-therapy-designation-for-bezuclastinib-in-combination-with-sunitinib-for-patients-with-gastrointestinal-stromal-tumors-gist 2026-01-26 https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-listing-of-the-rain-token-on-whitebit-a-leadin-d3cfb8a8 2026-01-26 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-to-present-multiple-analyses-on-miplyffa-at-the-22nd-annual-w-222b908d 2026-01-26 https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-host-virtual-kol-event-to-discuss-roluperidone-from-unmet-need-to-reality-potentially-the-first-treatment-for-patients-with-negative-symptoms-of-schizophrenia-on-february-3-2026 2026-01-26 https://biopharmsignal.com/news/INDV/indivior-announces-completion-of-redomiciliation-to-the-united-states-100f03bd 2026-01-26 https://biopharmsignal.com/news/MRKR/good-morning-america-features-baylor-college-of-medicine-pancreatic-cancer-study-4374218f 2026-01-26 https://biopharmsignal.com/news/AGIO/agios-to-host-fourth-quarter-and-full-year-2025-financial-results-conference-cal-a5e226a9 2026-01-26 https://biopharmsignal.com/news/PRPH/prophase-labs-provides-crown-medical-collections-update-250-insurance-payors-engaged-approximately-50-matters-in-advanced-settlement-posture 2026-01-26 https://biopharmsignal.com/news/MNKD/mannkind-announces-fda-approval-of-updated-afrezzar-label-providing-starting-dose-guidance-when-switching-from-multiple-daily-injections-mdi-or-insulin-pump-mealtime-therapy 2026-01-26 https://biopharmsignal.com/news/GRI/gri-bio-secures-new-u-s-composition-of-matter-patent-covering-novel-compound-structures 2026-01-26 https://biopharmsignal.com/news/GSK/gsk-s-rsv-vaccine-arexvy-receives-european-approval-for-expanded-use-in-all-adults-18-years-and-older 2026-01-26 https://biopharmsignal.com/news/VANI/vivani-medical-inc-announces-pricing-of-common-stock-offering 2026-01-26 https://biopharmsignal.com/news/RCEL/data-at-2026-boswick-burn-wound-symposium-highlight-first-integrated-use-of-avit-6cf82abd 2026-01-25 https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-third-quarter-ended-december-31-2025-and-provide-business-update-on-friday-february-6-2026 2026-01-23 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-announces-closing-of-upsized-public-offering-of-common-stock-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-generating-gross-proceeds-of-approximately-201m 2026-01-23 https://biopharmsignal.com/news/ROIV/roivant-to-report-financial-results-for-the-third-quarter-ended-december-31-2025-and-provide-business-update-on-friday-february-6-2026 2026-01-23 https://biopharmsignal.com/news/ISRG/20-million-patients-benefit-from-da-vinci-surgery-globally 2026-01-23 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-ring-the-nasdaq-closing-bell-on-january-27-2026-to-ce-9dac7952 2026-01-23 https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-announces-late-breaking-oral-presentation-at-upcoming-european-society-of-gynecological-oncology-esgo-annual-international-congress 2026-01-23 https://biopharmsignal.com/news/ENLV/enlivex-therapeutics-shares-to-trade-exclusively-on-nasdaq-51059a68 2026-01-23 https://biopharmsignal.com/news/OCGN/ocugen-inc-announces-closing-of-22-5-million-underwritten-registered-direct-offe-f48ae623 2026-01-23 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-reports-unaudited-preliminary-financial-results-for-the-fourt-8d4f3b0a 2026-01-23 https://biopharmsignal.com/news/AMN/amn-healthcare-to-hold-fourth-quarter-and-full-year-2025-earnings-conference-cal-904c3bd0 2026-01-23 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-presents-long-term-phase-1b-data-for-tegoprubart-in-kidne-01b28da9 2026-01-23 https://biopharmsignal.com/news/NXTC/nextcure-provides-business-update-b488bcaf 2026-01-23 https://biopharmsignal.com/news/GSK/trelegy-ellipta-approved-in-china-for-use-in-adults-with-uncontrolled-asthma 2026-01-23 https://biopharmsignal.com/news/FMS/statement-from-fresenius-medical-care-on-upcoming-winter-storm 2026-01-23 https://biopharmsignal.com/news/EMBC/embecta-to-report-fiscal-first-quarter-financial-results 2026-01-22 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-announces-eu-mdr-certification-for-clearpoint-navigation-software-version-3-0-2-expanding-access-to-the-latest-operating-room-navigation-platform-in-europe 2026-01-22 https://biopharmsignal.com/news/CVRX/cvrx-announces-initiation-of-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population 2026-01-22 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-5-2026 2026-01-22 https://biopharmsignal.com/news/CRNX/crinetics-initiates-phase-2-3-pediatric-trial-evaluating-atumelnant-in-congenita-084dd4f8 2026-01-22 https://biopharmsignal.com/news/ISRG/intuitive-announces-fourth-quarter-earnings 2026-01-22 https://biopharmsignal.com/news/PRVA/privia-health-to-report-fourth-quarter-2025-results-on-thursday-february-26 2026-01-22 https://biopharmsignal.com/news/AVCO/avalon-globocare-s-subsidiary-files-ai-patent-targeting-compliance-ready-automated-video-commentary 2026-01-22 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-new-u-s-patent-covering-technology-underlying-pds0101-9ec7b3b2 2026-01-22 https://biopharmsignal.com/news/IXHL/incannex-healthcare-announces-formation-of-clinical-advisory-board-for-psx-001-p-3e552127 2026-01-22 https://biopharmsignal.com/news/TARA/protara-therapeutics-to-present-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-unresponsive-nmibc-patients-at-the-asco-genitourinary-cancers-symposium 2026-01-22 https://biopharmsignal.com/news/VANI/vivani-subsidiary-cortigent-to-present-orion-system-s-advanced-brain-implant-technology-in-poster-session-at-nans-2026 2026-01-22 https://biopharmsignal.com/news/PRPH/prophase-labs-uplists-from-pink-sheets-to-otc-market 2026-01-22 https://biopharmsignal.com/news/AXGN/axogen-announces-pricing-of-upsized-124-million-public-offering-of-common-stock 2026-01-22 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-announces-pricing-of-upsized-public-offering-of-common-stock 2026-01-22 https://biopharmsignal.com/news/BSEM/biostem-technologies-advances-entry-into-the-acute-wound-care-market-with-acquis-38c7eb3f 2026-01-21 https://biopharmsignal.com/news/CRL/charles-river-laboratories-schedules-fourth-quarter-2025-earnings-and-2026-guidance-release-and-conference-call 2026-01-21 https://biopharmsignal.com/news/PRI/primerica-schedules-fourth-quarter-2025-financial-results-webcast 2026-01-21 https://biopharmsignal.com/news/AXGN/axogen-announces-proposed-public-offering-of-common-stock 2026-01-21 https://biopharmsignal.com/news/OPCH/option-care-health-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call 2026-01-21 https://biopharmsignal.com/news/GRI/gri-bio-announces-reverse-stock-split-66be78bf 2026-01-21 https://biopharmsignal.com/news/ALHC/alignment-healthcare-named-to-the-2026-fortune-world-s-most-admired-companiestm-list-for-first-time 2026-01-21 https://biopharmsignal.com/news/ZURA/zura-bio-appoints-immunology-industry-leader-sandeep-kulkarni-m-d-as-chief-executive-officer 2026-01-21 https://biopharmsignal.com/news/OCGN/ocugen-inc-announces-pricing-of-22-5-million-offering-of-common-stock-bcb1577e 2026-01-21 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-announces-successful-end-of-phase-2-meeting-with-fda-for-efcfda83 2026-01-21 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-provides-phase-2-b-supreme-study-progress-updates 2026-01-21 https://biopharmsignal.com/news/SPRY/california-k-12-schools-now-eligible-for-neffyinschools-program-offering-needle--c29bb8cf 2026-01-21 https://biopharmsignal.com/news/ECOR/acacia-clinics-and-vagus-nerve-society-conduct-study-using-electrocore-s-gammaco-adea8ddb 2026-01-21 https://biopharmsignal.com/news/LEGN/legend-biotech-to-present-carvykti-data-at-2026-tandem-meetings-reinforcing-grow-ac1eef31 2026-01-21 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-expands-global-opioid-patent-portfolio 2026-01-21 https://biopharmsignal.com/news/LIXT/de-la-soul-led-good-health-summit-launches-february-19-at-morehouse-college 2026-01-21 https://biopharmsignal.com/news/SCYX/scynexis-receives-fda-qualified-infectious-disease-product-qidp-and-fast-track-designations-for-scy-247 2026-01-21 https://biopharmsignal.com/news/CRL/charles-river-enters-manufacturing-collaboration-with-gazi-university 2026-01-21 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-issues-shareholder-letter-highlighting-2025-progress-and-k-278096d3 2026-01-21 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-enters-into-term-sheet-to-be-acquired-by-kuva-labs-for-4-00-per-share-in-an-all-cash-tender-offer 2026-01-21 https://biopharmsignal.com/news/XCUR/exicure-to-present-data-from-burixafor-phase-2-trial-at-the-2026-tandem-meetings-877b2cad 2026-01-21 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-closing-of-exercise-of-warrants-for-4-64-million-gr-c08c745d 2026-01-20 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-webcast-fiscal-2026-first-quarter-results 2026-01-20 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants 2026-01-20 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-the-peer-reviewed-publication-of-clinical-study--3987c500 2026-01-20 https://biopharmsignal.com/news/MKT/maia-biotechnology-advances-ateganosine-cancer-treatment-program-outlines-targeted-2026-clinical-milestones-and-growth-momentum 2026-01-20 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-provides-regulatory-update-on-deramiocel-bla-following-fda-review-of-hope-3-topline-data 2026-01-20 https://biopharmsignal.com/news/AVCO/avalon-globocare-announces-fda-registration-renewal-for-ketoairtm-and-planned-b2b-and-b2c-launch-through-catch-uptm-its-automated-generative-ai-powered-short-form-video-saas-platform 2026-01-20 https://biopharmsignal.com/news/HYPR/hyperfine-announces-neuro-pmr-study-results-showing-high-diagnostic-value-and-superior-patient-experience-in-neurology-clinics 2026-01-20 https://biopharmsignal.com/news/DRMA/dermata-receives-notice-of-grant-of-patent-for-next-generation-acne-treatment-by-australian-patent-office 2026-01-20 https://biopharmsignal.com/news/COGT/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor 2026-01-20 https://biopharmsignal.com/news/ALHC/alignment-health-appoints-adnan-mansour-as-chief-digital-officer-to-accelerate-ai-driven-growth-and-technology-leadership 2026-01-20 https://biopharmsignal.com/news/ACHC/acadia-healthcare-appoints-debbie-osteen-as-chief-executive-officer 2026-01-20 https://biopharmsignal.com/news/LPCN/lipocine-announces-completion-of-enrollment-and-dosing-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd 2026-01-20 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-attending-the-dealflow-discovery-conference-january-28-29 2026-01-20 https://biopharmsignal.com/news/DYN/dyne-therapeutics-receives-orphan-drug-designation-in-japan-for-zeleciment-basivarsen-dyne-101-for-myotonic-dystrophy-type-1 2026-01-20 https://biopharmsignal.com/news/CELC/celcuity-announces-fda-acceptance-of-new-drug-application-for-gedatolisib-in-hr--72567459 2026-01-20 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-submits-supplemental-new-drug-application-to-u-s-food-and-drug-administration-for-igalmir-label-expansion-in-the-at-home-setting 2026-01-20 https://biopharmsignal.com/news/NGEN/nervgen-pharma-to-ring-the-nasdaq-closing-bell-on-january-22-2026-celebrating-it-6f8dde30 2026-01-20 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-announces-positive-data-from-cohort-4-confirming-results-for-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis 2026-01-20 https://biopharmsignal.com/news/TECH/bio-techne-to-host-conference-call-on-february-4-2026-to-announce-second-quarter-fiscal-2026-financial-results 2026-01-20 https://biopharmsignal.com/news/GSK/gsk-enters-agreement-to-acquire-rapt-therapeutics 2026-01-20 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-collaboration-with-microsoft-to-advance-ai-driven-early-detection-of-lung-cancer 2026-01-20 https://biopharmsignal.com/news/GSK/gsk-pfizer-and-shionogi-agree-on-changes-to-viiv-healthcare-shareholding 2026-01-20 https://biopharmsignal.com/news/IMRN/immuron-reports-continued-sales-growth-7c1ec9be 2026-01-19 https://biopharmsignal.com/news/RPTX/repare-shareholders-approve-acquisition-by-xenotherapeutics-inc 2026-01-16 https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-01-16 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-announce-results-from-cohort-4-of-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis 2026-01-16 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-closing-of-oversubscribed-8-8-million-registered-33be1831 2026-01-16 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-exercise-of-warrants-for-4-64-million-gross-proceed-64ecdaa3 2026-01-16 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-registered-direct-offering-of-up-to-approximatel-6af4a026 2026-01-16 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders-508804b7 2026-01-15 https://biopharmsignal.com/news/MDRX/veradigm-and-meperia-launch-industry-first-8-way-match-edi-platform-to-strengthen-healthcare-supply-chain-integrity 2026-01-15 https://biopharmsignal.com/news/OSUR/orasure-technologies-confirms-receipt-of-director-nominations-from-altai-capital 2026-01-15 https://biopharmsignal.com/news/PRPO/precipio-takes-major-steps-toward-a-clean-balance-sheet-e3d181cd 2026-01-15 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-foundation-launches-national-program-to-bolster-mental-health-diversion-initiatives 2026-01-15 https://biopharmsignal.com/news/OCGN/ocugen-announces-positive-preliminary-phase-2-data-from-ocu410-modifier-gene-the-5e7d0bd3 2026-01-15 https://biopharmsignal.com/news/HYPR/hyperfine-announces-enrollment-of-first-patient-in-study-to-expand-intended-use-of-the-swoopr-system-with-contrast-agents 2026-01-15 https://biopharmsignal.com/news/IXHL/incannex-healthcare-wins-research-and-development-award-for-obstructive-sleep-ap-4b793cbd 2026-01-15 https://biopharmsignal.com/news/VXRT/vaxart-publishes-positive-data-for-its-oral-bivalent-norovirus-candidate-in-lact-4d77b17e 2026-01-15 https://biopharmsignal.com/news/MDNA/medicenna-therapeutics-announces-key-program-updates-and-2026-outlook 2026-01-15 https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-poster-presentation-of-new-preclinical-data-supporting-expansion-of-orexin-receptor-2-ox2r-agonist-pipeline-into-neuropsychiatric-indications-at-the-64th-acnp-annual-meeting 2026-01-14 https://biopharmsignal.com/news/EGRX/eagle-pharmaceuticals-announces-divestiture-of-barhemsys 2026-01-14 https://biopharmsignal.com/news/SNTI/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discus-adb3d1c5 2026-01-14 https://biopharmsignal.com/news/ISRG/intuitive-announces-preliminary-fourth-quarter-and-full-year-2025-results 2026-01-14 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-appoints-john-mcadory-as-evp-of-strategy-and-operations-and-y-03a3bea3 2026-01-14 https://biopharmsignal.com/news/FEMY/femasys-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bi-dd789e9b 2026-01-14 https://biopharmsignal.com/news/CLOV/clover-health-announces-53-growth-in-medicare-advantage-membership-during-aep-increasing-to-153-000-members-as-of-january-1-2026-expects-first-ever-full-year-gaap-net-income-profitability-in-2026 2026-01-14 https://biopharmsignal.com/news/AVAH/aveanna-healthcare-holdings-announces-updated-full-year-2025-and-initial-full-year-2026-guidance 2026-01-14 https://biopharmsignal.com/news/XAIR/beyond-air-announces-5-0-million-private-placement-priced-at-the-market-under-na-3ed0208c 2026-01-14 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-and-sarah-jessica-parker-announce-the-launch-of-make-it-vizzable-the-vizz-consumer-campaign 2026-01-14 https://biopharmsignal.com/news/SLS/sellas-life-sciences-enters-agreement-with-impact-aml-to-expand-sls009-clinical-program-into-europe 2026-01-14 https://biopharmsignal.com/news/OGEN/oragenics-to-present-at-the-2026-sequire-investor-summit-in-puerto-rico 2026-01-14 https://biopharmsignal.com/news/IXHL/incannex-healthcare-delivers-transformational-2025-progress-and-outlines-well-fu-1ea2a0f3 2026-01-14 https://biopharmsignal.com/news/XRAY/patterson-dental-and-dentsply-sirona-renew-u-s-dental-technology-distribution-pa-6d153585 2026-01-14 https://biopharmsignal.com/news/CCCC/c4-therapeutics-outlines-strategic-milestones-to-advance-cemsidomide-as-a-potent-12c7d678 2026-01-14 https://biopharmsignal.com/news/HCM/hutchmed-highlights-publication-of-phase-iii-sachi-results-in-the-lancet-b8f40457 2026-01-14 https://biopharmsignal.com/news/XRAY/dentsply-sirona-and-benco-dental-announce-expanded-partnership-to-include-dental-0be4d5a3 2026-01-13 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-announces-record-preliminary-unaudited-fourth-quarter-and-full-year-2025-revenue 2026-01-13 https://biopharmsignal.com/news/SLDB/solid-biosciences-provides-2026-outlook-underscoring-neuromuscular-and-cardiac-p-4671c2fa 2026-01-13 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-announces-closing-of-50-million-registered-direct-financing-at-a-30-premium 2026-01-13 https://biopharmsignal.com/news/FEMY/femasys-announces-partnership-with-refuah-health-center-to-expand-first-line-acc-9b2af7f7 2026-01-13 https://biopharmsignal.com/news/VCEL/vericel-announces-preliminary-2025-financial-results-and-business-updates-7f2b8e33 2026-01-13 https://biopharmsignal.com/news/BFRI/biofrontera-inc-announces-record-preliminary-fourth-quarter-2025-revenues-betwee-e00b5001 2026-01-13 https://biopharmsignal.com/news/RCEL/avita-medical-pre-j-p-morgan-update-highlights-2025-revenue-growth-new-debt-faci-e5ef65f0 2026-01-13 https://biopharmsignal.com/news/SLRX/decoy-therapeutics-reaches-global-access-commitment-agreement-to-focus-on-development-of-a-globally-accessible-scalable-peptide-conjugate-manufacturing-platform 2026-01-13 https://biopharmsignal.com/news/ALGS/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer 2026-01-13 https://biopharmsignal.com/news/XRAY/dentsply-sirona-appoints-donald-zurbay-to-board-of-directors-13cf687d 2026-01-13 https://biopharmsignal.com/news/INTS/intensity-therapeutics-highlights-2025-milestones-and-outlines-2026-strategic-priorities 2026-01-13 https://biopharmsignal.com/news/FBIO/fortress-biotech-and-cyprium-therapeutics-announce-u-s-fda-approval-of-zycubor-copper-histidinate-the-first-and-only-approved-treatment-for-menkes-disease-in-the-united-states 2026-01-13 https://biopharmsignal.com/news/XAIR/xtl-biopharmaceuticals-acquires-85-of-beyond-air-s-subsidiary-neuronos-entering--91b63ed0 2026-01-13 https://biopharmsignal.com/news/SGHT/sight-sciences-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-financial-highlights 2026-01-13 https://biopharmsignal.com/news/TMCI/treace-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-revenue 2026-01-13 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-provides-outlook-on-pas-004-clinical-programs-and-data-release-timelines 2026-01-13 https://biopharmsignal.com/news/ARGX/argenx-announces-fda-acceptance-of-supplemental-biologics-license-application-wi-fe8a99f7 2026-01-13 https://biopharmsignal.com/news/OPCH/option-care-health-announces-preliminary-fourth-quarter-and-full-year-2025-financial-results-and-preliminary-financial-guidance-for-full-year-2026 2026-01-12 https://biopharmsignal.com/news/IRON/disc-medicine-appoints-lisa-amaya-price-mba-as-chief-human-resources-officer 2026-01-12 https://biopharmsignal.com/news/SLDB/solid-biosciences-receives-fda-orphan-drug-designation-for-sgt-212-dual-route-ge-cf5c35f9 2026-01-12 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-announces-january-2026-inducement-grants-under-nasdaq--b5dd9bbd 2026-01-12 https://biopharmsignal.com/news/GNLX/genelux-corporation-announces-upcoming-virtual-fireside-chat-hosted-by-titan-par-a0681614 2026-01-12 https://biopharmsignal.com/news/ATRC/atricure-reports-preliminary-results-for-fourth-quarter-and-full-year-2025-provides-financial-outlook-for-2026 2026-01-12 https://biopharmsignal.com/news/PACB/pacbio-announces-plans-for-collaboration-with-n-lorem-foundation-and-esperare-to-a9c96cdc 2026-01-12 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-to-attend-44th-annual-j-p-morgan-healthcare-conference 2026-01-12 https://biopharmsignal.com/news/PACB/pacbio-announces-preliminary-fourth-quarter-and-full-year-2025-revenue-daabe5c7 2026-01-12 https://biopharmsignal.com/news/PACB/pacbio-hifi-adopted-as-first-line-sequencing-approach-to-investigate-sudden-unex-08bcbe96 2026-01-12 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-updated-clinical-data-from-goblet-cohort-4-demonstr-ee812a13 2026-01-12 https://biopharmsignal.com/news/XRAY/dentsply-sirona-appoints-mark-r-bezjak-as-group-vice-president-americas-regional-ef563fef 2026-01-12 https://biopharmsignal.com/news/AVCO/avalon-globocare-regains-compliance-with-nasdaq-stockholders-equity-requirement-launches-marketing-for-automated-generative-ai-video-platform 2026-01-12 https://biopharmsignal.com/news/SIBN/si-bone-announces-preliminary-revenue-for-the-fourth-quarter-and-full-year-2025 2026-01-12 https://biopharmsignal.com/news/ACHV/achieve-life-sciences-confirms-promotion-of-dr-mark-rubinstein-to-chief-medical-officer 2026-01-12 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-highlights-strategic-priorities-and-anticipated-2026-milestones 2026-01-12 https://biopharmsignal.com/news/IRON/disc-medicine-highlights-recent-achievements-and-key-business-objectives-and-milestones-for-2026 2026-01-12 https://biopharmsignal.com/news/CLOV/counterpart-health-2025-results-how-better-clinical-decisions-at-scale-improve-outcomes-quality-and-cost 2026-01-12 https://biopharmsignal.com/news/CLNN/clene-announces-additional-cnm-au8-biomarker-data-supporting-potential-nda-filin-4229b82e 2026-01-12 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-inc-announces-financing-of-up-to-26-8-million-to-progress-halneuronr-through-phase-2b-development 2026-01-12 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-revenue 2026-01-12 https://biopharmsignal.com/news/INGN/inogen-announces-preliminary-revenue-results-for-fourth-quarter-and-full-year-2025 2026-01-12 https://biopharmsignal.com/news/OM/outset-medical-reports-unaudited-fourth-quarter-and-2025-results 2026-01-12 https://biopharmsignal.com/news/HYPR/hyperfine-reports-preliminary-unaudited-fourth-quarter-and-full-year-2025-financial-results 2026-01-12 https://biopharmsignal.com/news/MXCT/maxcyte-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-financial-results 2026-01-12 https://biopharmsignal.com/news/SLDB/solid-biosciences-doses-first-participant-in-first-in-class-phase-1b-falcon-tria-f3f8e3f9 2026-01-12 https://biopharmsignal.com/news/RIGL/rigel-provides-business-update-and-2026-outlook 2026-01-12 https://biopharmsignal.com/news/HRMY/harmony-biosciences-guides-to-over-1-billion-in-wakixr-revenue-in-2026-advancing-robust-late-stage-pipeline-with-potential-for-long-term-value-creation 2026-01-12 https://biopharmsignal.com/news/BMEA/biomea-fusion-enters-2026-focused-on-executing-key-icovamenib-and-bmf-650-milestones 2026-01-12 https://biopharmsignal.com/news/AZYO/elutia-reports-preliminary-fourth-quarter-2025-results-strengthened-financial-position-and-upcoming-nxt-41x-milestones 2026-01-12 https://biopharmsignal.com/news/PGNY/progyny-to-discuss-updated-financial-expectations-at-upcoming-jp-morgan-healthcare-conference 2026-01-12 https://biopharmsignal.com/news/ADMA/adma-biologics-announces-preliminary-full-year-2025-unaudited-total-revenue-and-provides-business-update 2026-01-12 https://biopharmsignal.com/news/INAB/in8bio-presents-updated-phase-i-ii-data-demonstrating-meaningful-and-durable-survival-improvements-in-newly-diagnosed-glioblastoma 2026-01-12 https://biopharmsignal.com/news/CVRX/cvrx-reports-preliminary-fourth-quarter-and-fiscal-year-2025-financial-results-and-issues-fiscal-2026-guidance 2026-01-12 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-provides-corporate-update-and-outlines-2026-strategic-prior-0331b4a5 2026-01-12 https://biopharmsignal.com/news/MDXH/mdxhealth-reports-preliminary-fourth-quarter-and-full-year-2025-revenues-issues--eb75eeee 2026-01-12 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-reports-preliminary-unaudited-fourth-quarter-and-full-y-ecfeaf36 2026-01-12 https://biopharmsignal.com/news/MREO/mereo-biopharma-provides-corporate-update-bfa2a60d 2026-01-12 https://biopharmsignal.com/news/SENS/senseonics-announces-preliminary-unaudited-revenue-for-fourth-quarter-2025-and-p-353d8be1 2026-01-12 https://biopharmsignal.com/news/LEGN/legend-biotech-highlights-recent-business-updates-at-44th-annual-j-p-morgan-heal-aa180882 2026-01-12 https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-provides-regulatory-and-business-update-on-ebvallotm-tabelecleucel 2026-01-12 https://biopharmsignal.com/news/LPCN/lipocine-reports-encouraging-progress-post-second-interim-safety-review-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd 2026-01-12 https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-2026-strategic-priorities 2026-01-12 https://biopharmsignal.com/news/TWST/twist-bioscience-announces-preliminary-first-quarter-fiscal-2026-revenue 2026-01-12 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-announces-preliminary-fourth-quarter-and-full-year-2025-results 2026-01-12 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-provides-corporate-update 2026-01-12 https://biopharmsignal.com/news/WVE/wave-life-sciences-highlights-strategic-priorities-for-2026-at-the-44th-annual-j-06f812c3 2026-01-12 https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-provides-a-business-and-pipeline-update-at-the-44th-annu-0089a802 2026-01-12 https://biopharmsignal.com/news/IRTC/irhythm-technologies-inc-shares-preliminary-fourth-quarter-2025-highlights-and-b-9de37d49 2026-01-12 https://biopharmsignal.com/news/XOMA/xoma-royalty-announces-cfo-transition 2026-01-12 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-provides-corporate-update 2026-01-12 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-outlines-2026-goals-and-objectives-for-advancing-bexobrutideg-and-its-pipeline-of-novel-degrader-based-medicines-in-cancer-and-autoimmune-diseases 2026-01-12 https://biopharmsignal.com/news/ANNX/annexon-accelerating-next-generation-targeted-immunotherapy-platform-for-treatment-of-neuroinflammatory-diseases-with-multiple-registrational-milestones-in-2026 2026-01-12 https://biopharmsignal.com/news/SHC/sotera-health-to-showcase-continued-revenue-growth-and-strategic-value-creation-at-44th-annual-j-p-morgan-healthcare-conference 2026-01-12 https://biopharmsignal.com/news/APLS/apellis-highlights-commercial-execution-and-strategic-priorities-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-12 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-announces-preliminary-unaudited-fourth-quarter-and-full-yea-6e0b0020 2026-01-12 https://biopharmsignal.com/news/MDWD/mediwound-provides-corporate-update-and-financial-outlook-ahead-of-the-j-p-morga-b7f53f89 2026-01-12 https://biopharmsignal.com/news/CATX/perspective-therapeutics-provides-business-updates-and-strategic-priorities-ahea-7a908835 2026-01-12 https://biopharmsignal.com/news/AGIO/agios-outlines-2026-strategic-priorities-and-key-milestones-to-accelerate-rare-d-9d09b45d 2026-01-12 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-select-preliminary-fourth-quarter-and-full-year-20-b38ae0a1 2026-01-12 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-provides-regulatory-update-confirming-fda-alignment-on-registrational-studies-design-for-ndv-01-for-two-separate-indications 2026-01-12 https://biopharmsignal.com/news/TARA/protara-therapeutics-highlights-recent-updates-and-anticipated-2026-milestones 2026-01-12 https://biopharmsignal.com/news/IRIX/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025 2026-01-12 https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-fda-clearance-to-proceed-with-90-patient-investigator-initiated-trial-iit-of-epetraborole-in-patients-with-m-abscessus-lung-disease 2026-01-12 https://biopharmsignal.com/news/AXGN/axogen-inc-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2025 2026-01-12 https://biopharmsignal.com/news/SNDX/syndax-reports-preliminary-2025-financial-highlights-and-provides-business-updates-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-12 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-positive-topline-results-from-phase-3-scout-hcm-trial-evaluating-camzyos-mavacamten-in-adolescents-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-ohcm 2026-01-12 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-initiates-phase-1b-proof-of-concept-trial-in-atopic-dermati-53cb2c66 2026-01-12 https://biopharmsignal.com/news/PHVS/pharvaris-outlines-2026-strategic-priorities-b5b637db 2026-01-12 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-highlights-significant-growth-in-2025-provides-2026-financia-51752c4f 2026-01-12 https://biopharmsignal.com/news/BDSX/biodesix-announces-preliminary-fourth-quarter-and-full-year-2025-results-unaudit-e30147ed 2026-01-12 https://biopharmsignal.com/news/TDOC/teladoc-health-launches-enhanced-24-7-care-service-7533f844 2026-01-12 https://biopharmsignal.com/news/DAWN/day-one-announces-preliminary-2025-ojemdatm-net-product-revenue-and-provides-2026-net-product-revenue-guidance 2026-01-11 https://biopharmsignal.com/news/BEAM/beam-therapeutics-sets-strategic-priorities-for-its-genetic-disease-and-hematology-franchises-to-drive-execution-of-late-stage-clinical-programs-and-extends-its-operating-runway-through-commercial-transition 2026-01-11 https://biopharmsignal.com/news/EXEL/exelixis-announces-preliminary-fiscal-year-2025-financial-results-provides-2026-financial-guidance-and-outlines-key-priorities-and-milestones-for-2026 2026-01-11 https://biopharmsignal.com/news/MOLN/molecular-partners-highlights-clinical-development-progress-and-anticipated-mile-ccb9126a 2026-01-11 https://biopharmsignal.com/news/XGN/exagen-inc-announces-select-preliminary-2025-financial-results 2026-01-11 https://biopharmsignal.com/news/KRYS/krystal-biotech-provides-business-update-at-44th-annual-j-p-morgan-healthcare-co-ebd48c88 2026-01-11 https://biopharmsignal.com/news/RXST/rxsight-inc-announces-preliminary-q4-and-2025-financial-results-new-chief-financial-officer 2026-01-11 https://biopharmsignal.com/news/BNTC/benitec-biopharma-provides-positive-long-term-clinical-study-results-for-bb-301-phase-1b-2a-clinical-trial-demonstrating-robust-efficacy-and-continued-durability-of-response 2026-01-11 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-highlights-january-equity-financing-program-progress-and-strategic-objectives-for-2026 2026-01-10 https://biopharmsignal.com/news/HRTX/heron-therapeutics-announces-preliminary-unaudited-q4-and-full-year-2025-net-rev-63d8051f 2026-01-09 https://biopharmsignal.com/news/ONCY/oncolytics-biotech-outlines-strategic-rationale-for-proposal-to-change-jurisdict-cad77bc3 2026-01-09 https://biopharmsignal.com/news/SNTI/senti-bio-to-participate-in-panel-presentation-at-biotech-showcase-alongside-the-92709dac 2026-01-09 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-fda-alignment-on-use-of-progression-free-survival-pfs-as-p-6bdc0adf 2026-01-09 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-announces-2026-strategic-priorities-and-anticipated-milestones 2026-01-09 https://biopharmsignal.com/news/CGON/cg-oncology-provides-updated-timeline-for-pivot-006-phase-3-topline-data-in-inte-900d3a03 2026-01-09 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-confer-68db04ba 2026-01-09 https://biopharmsignal.com/news/CLNN/clene-announces-registered-direct-offering-of-over-28-million-3b0eedac 2026-01-09 https://biopharmsignal.com/news/APVO/aptevo-therapeutics-secures-60-million-equity-line-of-credit-to-support-multispecific-portfolio-advancement-increase-strategic-optionality 2026-01-09 https://biopharmsignal.com/news/DCTH/delcath-systems-announces-preliminary-fourth-quarter-and-full-year-2025-financial-results 2026-01-09 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-highlights-recent-progress-and-outlines-2026-outlook-9a21a7d3 2026-01-09 https://biopharmsignal.com/news/AZYO/elutia-to-present-at-global-bioinnovation-forum-on-nxt-41x-biomatrix-program-for-plastic-and-reconstructive-surgery 2026-01-09 https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-highlights-2025-achievements-and-outlines-2026-strategic-priorities 2026-01-09 https://biopharmsignal.com/news/CRIS/curis-announces-closing-of-private-placement-totaling-up-to-80-8-million-in-gross-proceeds 2026-01-09 https://biopharmsignal.com/news/CATX/perspective-therapeutics-presents-updated-interim-data-of-212pb-vmt-net-in-its-o-08a87158 2026-01-09 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-to-present-at-the-9th-annual-neuroscience-innovation-forum-7c468942 2026-01-09 https://biopharmsignal.com/news/AMRN/amarin-applauds-breakthroughs-in-therapies-for-patients-with-elevated-triglyceri-3f78627a 2026-01-09 https://biopharmsignal.com/news/IBIO/ibio-announces-26-million-private-placement 2026-01-09 https://biopharmsignal.com/news/IMCR/immunocore-announces-2026-strategic-priorities-at-44th-annual-j-p-morgan-healthcare-conference 2026-01-09 https://biopharmsignal.com/news/LQDA/liquidia-corporation-announces-preliminary-full-year-2025-yutrepia-net-sales-and-corporate-update 2026-01-09 https://biopharmsignal.com/news/HUM/humana-inc-to-release-fourth-quarter-2025-results-on-february-11-2026 2026-01-09 https://biopharmsignal.com/news/FMS/fresenius-medical-care-accelerates-the-second-tranche-of-its-eur-1-billion-share-buyback-program-with-around-eur-415-million-repurchase-planned 2026-01-09 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-pricing-of-300-million-underwritten-public-off-ccdd4d59 2026-01-09 https://biopharmsignal.com/news/ANAB/anaptys-files-motion-to-dismiss-tesaro-s-claim-of-anticipatory-breach-of-contract-in-ongoing-litigation-against-tesaro-a-gsk-subsidiary 2026-01-08 https://biopharmsignal.com/news/CLLS/cellectis-announces-2026-strategy-and-catalysts 2026-01-08 https://biopharmsignal.com/news/TMCI/treace-announces-first-surgical-case-utilizing-lapiplastyr-lightningtm-technology 2026-01-08 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-highlights-recent-business-milestones-and-provides-2026-o-d6659e47 2026-01-08 https://biopharmsignal.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q4-and-full-year-of-2-9536cfe0 2026-01-08 https://biopharmsignal.com/news/MMSI/merit-medical-appoints-f-ann-millner-as-chair-of-the-board-and-announces-project-6c5ffd5e 2026-01-08 https://biopharmsignal.com/news/SENS/senseonics-announces-first-commercial-patients-using-eversense-365-continuous-gl-4501fc0d 2026-01-08 https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-positive-interim-clinical-update-from-kb407-phase-1-co-5ec99bc5 2026-01-08 https://biopharmsignal.com/news/INKT/mink-therapeutics-and-university-of-wisconsin-madison-announce-phase-1-clinical--8ce3a11d 2026-01-08 https://biopharmsignal.com/news/ALXO/alx-oncology-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-08 https://biopharmsignal.com/news/GNLX/genelux-corporation-announces-pricing-of-20-0-million-underwritten-public-offeri-e438a210 2026-01-08 https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-ceo-transition-barbara-weber-to-retire-malte-peters-appointed-successor 2026-01-08 https://biopharmsignal.com/news/PACB/pacbio-and-uc-davis-researchers-introduce-cifi-a-new-long-read-3c-method-that-en-3ae5a720 2026-01-08 https://biopharmsignal.com/news/ELVN/enliven-reports-positive-initial-phase-1b-data-for-elvn-001-in-cml-and-outlines-2026-clinical-milestones 2026-01-08 https://biopharmsignal.com/news/BFRI/biofrontera-inc-announces-data-base-locks-for-two-clinical-studies-supporting-ke-28728447 2026-01-08 https://biopharmsignal.com/news/ALXO/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004 2026-01-08 https://biopharmsignal.com/news/XLO/xilio-therapeutics-highlights-upcoming-milestones-and-recent-corporate-updates-ab7260d5 2026-01-08 https://biopharmsignal.com/news/ARDX/ardelyx-reports-preliminary-2025-revenue-and-provides-2026-strategic-outlook-a3c05cb8 2026-01-08 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-announces-leadership-and-board-updates-62c07416 2026-01-08 https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-announces-positive-outcome-from-type-b-meeting-with-u-s-fda-and-announces-investor-day 2026-01-08 https://biopharmsignal.com/news/ANNX/annexon-submits-tanruprubart-marketing-authorization-application-to-the-european-medicines-agency-for-guillain-barre-syndrome 2026-01-08 https://biopharmsignal.com/news/GRI/gri-bio-announces-additional-positive-data-from-phase-2a-study-in-idiopathic-pul-09999498 2026-01-08 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-announces-preliminary-fourth-quarter-and-full-year-2025-re-719fb15e 2026-01-08 https://biopharmsignal.com/news/BIVI/biovie-completes-enrollment-in-phase-2-sunrise-pd-trial-in-early-parkinson-s-dis-6c6efa37 2026-01-08 https://biopharmsignal.com/news/BBLG/bone-biologics-highlights-2025-key-operational-scientific-and-corporate-mileston-598b77cc 2026-01-08 https://biopharmsignal.com/news/PRQR/proqr-announces-encouraging-ax-0810-phase-1-safety-and-pk-data-development-candi-ec3860bb 2026-01-08 https://biopharmsignal.com/news/RVPH/reviva-announces-publication-on-clinical-vocal-biomarker-data-from-the-recover-p-e52340ba 2026-01-08 https://biopharmsignal.com/news/IPSC/century-therapeutics-secures-oversubscribed-135-million-private-placement-financ-eec4bd5e 2026-01-08 https://biopharmsignal.com/news/IFRX/inflarx-announces-strategy-focused-on-capital-efficient-execution-with-izicopan--c5b723b2 2026-01-08 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-launches-early-access-program-for-novel-single-molecule-p-3cc54ace 2026-01-08 https://biopharmsignal.com/news/ENSC/ensysce-biosciences-receives-eu-patent-expanding-its-first-in-class-adhd-therapy-with-built-in-abuse-and-overdose-protection 2026-01-08 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-business-update-and-company-milestones-for-2026 2026-01-08 https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-announces-positive-acr-368-phase-2b-endometrial-cancer-clinical-data-with-eu-expansion-to-accelerate-enrollment-initial-acr-2316-clinical-data-and-acr-6840-its-next-ap3-enabled-development-candidate-targeting-cdk11 2026-01-08 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conferenc-f39d511a 2026-01-08 https://biopharmsignal.com/news/VERA/vera-therapeutics-to-participate-in-the-44th-annual-j-p-morgan-healthcare-confer-20d5e037 2026-01-08 https://biopharmsignal.com/news/RANI/rani-therapeutics-initiates-phase-1-study-of-rt-114-ranipillr-for-the-treatment-of-obesity-in-collaboration-with-progen 2026-01-08 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-highlight-2026-strategic-priorities-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-08 https://biopharmsignal.com/news/INDV/indivior-provides-full-year-2026-financial-guidance-and-business-update-97c51012 2026-01-08 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-poster-presentation-at-the-10th-annual-mash-tag-20-831598bc 2026-01-08 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-positive-updated-data-from-briquilimab-studies-in-ch-d3ba5057 2026-01-08 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-highlights-anticipated-2026--a3f8806c 2026-01-08 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-highlights-progress-across-its-portfolio-of-rna-based-thera-2a772511 2026-01-08 https://biopharmsignal.com/news/AMRN/amarin-announces-preliminary-2025-financial-highlights-and-operational-accomplis-46bea157 2026-01-08 https://biopharmsignal.com/news/XERS/xeris-expects-to-deliver-record-fourth-quarter-and-full-year-2025-total-revenue 2026-01-08 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-provides-update-on-its-research-and-development-programs-and-2026-outlook 2026-01-08 https://biopharmsignal.com/news/NGEN/nervgen-pharma-begins-trading-on-nasdaq-today-22ae3903 2026-01-08 https://biopharmsignal.com/news/TFX/teleflex-announces-leadership-transition-d572754c 2026-01-08 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-announces-pricing-of-130-million-public-offering-of-common-stock-and-pre-funded-warrants 2026-01-08 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-reports-fourth-quarter-2025-preliminary-unaudited-financial-results-and-recent-corporate-updates 2026-01-07 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-appoints-jeet-mahal-as-chief-executive-officer-to-lead-next--6b03c50a 2026-01-07 https://biopharmsignal.com/news/GMED/globus-medical-reports-preliminary-record-fourth-quarter-and-full-year-sales-res-f17f9e7c 2026-01-07 https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/TERN/terns-pharmaceuticals-to-highlight-2026-priorities-and-program-milestones-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/ANNX/annexon-biosciences-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants 2026-01-07 https://biopharmsignal.com/news/BSEM/biostem-technologies-comments-on-withdrawal-of-cms-cy-2026-final-medicare-reimbu-86f0947e 2026-01-07 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-receives-innovative-technology-contract-from-vizient-for-bias-56b1499d 2026-01-07 https://biopharmsignal.com/news/STRO/sutro-biopharma-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-70f1b4d0 2026-01-07 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-announce-interim-clinical-update-from-highest-dose-cohort-of--a44be477 2026-01-07 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/GNLX/genelux-corporation-announces-proposed-public-offering-of-common-stock-8e6243fa 2026-01-07 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-proposed-public-offering-of-common-stock-and-p-d21761e6 2026-01-07 https://biopharmsignal.com/news/IMRX/immuneering-announces-exceptional-64-overall-survival-at-12-months-in-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp 2026-01-07 https://biopharmsignal.com/news/GNFT/genfit-announces-2026-financial-calendar 2026-01-07 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-present-at-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-bolsters-board-to-prepare-for-next-phase-of-development 2026-01-07 https://biopharmsignal.com/news/CRIS/curis-announces-pricing-of-private-placement-totaling-up-to-80-8-million-in-gross-proceeds 2026-01-07 https://biopharmsignal.com/news/IRON/disc-medicine-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/SERA/landmark-study-finds-pretrmr-blood-test-reduces-earliest-preterm-births-and-newborn-complications 2026-01-07 https://biopharmsignal.com/news/INGN/inogen-announces-the-launch-of-aurora-cpap-masks-for-obstructive-sleep-apnea-in-the-united-states 2026-01-07 https://biopharmsignal.com/news/ICU/seastar-medical-announces-2026-milestones-dc6d6f08 2026-01-07 https://biopharmsignal.com/news/ICCC/immucell-to-conduct-conference-call-with-investors-to-discuss-strategic-change-i-e356cc0c 2026-01-07 https://biopharmsignal.com/news/RIGL/rigel-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/PRME/prime-medicine-to-present-at-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-announces-first-patient-dosed-in-phase-3-program-evaluating-ycanthr-vp-102-for-the-treatment-of-common-warts 2026-01-07 https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-listing-of-the-rain-token-on-kucoin-a-leading--470d3b97 2026-01-07 https://biopharmsignal.com/news/PPBT/purple-biotech-achieves-toxicology-milestone-demonstrating-an-expanded-therapeut-30dad56e 2026-01-07 https://biopharmsignal.com/news/FDMT/4dmt-provides-company-update-and-anticipated-development-milestones-for-2026-6293e849 2026-01-07 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-participate-in-the-44th-annual-j-p-morgan-healthcare-con-533f0621 2026-01-07 https://biopharmsignal.com/news/TARA/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/TARA/protara-therapeutics-announces-dosing-of-first-patient-in-phase-3-registrational-thrive-3-trial-of-iv-choline-chloride-in-patients-on-long-term-parenteral-support 2026-01-07 https://biopharmsignal.com/news/EXEL/exelixis-and-natera-to-collaborate-on-stellar-316-a-phase-3-pivotal-trial-of-zanzalintinib-for-patients-with-colorectal-cancer 2026-01-07 https://biopharmsignal.com/news/DYN/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/SHC/sotera-health-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/VERA/vera-therapeutics-announces-u-s-fda-granted-priority-review-to-biologics-license-1a9a4f2c 2026-01-07 https://biopharmsignal.com/news/GANX/gain-therapeutics-announces-announces-conference-participation-during-j-p-morgan-a5eca80b 2026-01-07 https://biopharmsignal.com/news/EYPT/eyepoint-reports-corporate-update-and-anticipated-pivotal-milestones-for-2026-6b5b2566 2026-01-07 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-positive-interim-phase-1-data-of-mrt-8102-demo-12224893 2026-01-07 https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-present-at-44th-annual-j-p-morgan-healthcare-conference 2026-01-07 https://biopharmsignal.com/news/SNDX/syndax-and-world-orphan-drug-alliance-to-launch-a-multi-regional-managed-access-program-expanding-access-to-revuforjr-revumenib-outside-the-u-s 2026-01-07 https://biopharmsignal.com/news/GSK/gsk-s-shingrix-recombinant-zoster-vaccine-prefilled-syringe-presentation-approved-by-the-european-commission 2026-01-07 https://biopharmsignal.com/news/GSK/gsk-announces-positive-results-from-b-well-1-and-b-well-2-phase-iii-trials-for-bepirovirsen-a-potential-first-in-class-treatment-for-chronic-hepatitis-b 2026-01-07 https://biopharmsignal.com/news/ADXN/addex-spin-out-neurosterix-has-started-a-phase-1-clinical-study-with-m4-pam-ntx--5191fa38 2026-01-07 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-6f48172f 2026-01-07 https://biopharmsignal.com/news/HCM/hutchmed-announces-positive-topline-results-of-phase-iii-part-of-eslim-02-trial--405f3aec 2026-01-07 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-present-at-the-44th-annual-j-p-morgan-healthcare-conferen-3a1a51bc 2026-01-06 https://biopharmsignal.com/news/ANAB/anaptys-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-06 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-to-present-interim-mrt-8102-phase-1-study-results-ae13a1e6 2026-01-06 https://biopharmsignal.com/news/EXEL/exelixis-to-present-at-the-j-p-morgan-2026-healthcare-conference-on-january-12-2026 2026-01-06 https://biopharmsignal.com/news/GNFT/genfit-favorable-phase-1-safety-profile-and-strong-anti-inflammatory-activity-for-aclf-lead-asset-g1090n 2026-01-06 https://biopharmsignal.com/news/ACHC/acadia-healthcare-to-participate-in-44th-annual-j-p-morgan-healthcare-conference 2026-01-06 https://biopharmsignal.com/news/CHRS/coherus-management-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-06 https://biopharmsignal.com/news/DAWN/day-one-completes-acquisition-of-mersana-therapeutics 2026-01-06 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-evaluate-automated-manufacturing-of-aucatzyl-obe-cel-on--e87432d3 2026-01-06 https://biopharmsignal.com/news/MNOV/2026-new-year-s-greetings-from-the-ceo 2026-01-06 https://biopharmsignal.com/news/ICU/seastar-medical-to-present-at-upcoming-biotech-showcase-2026-investor-conference-f689a914 2026-01-06 https://biopharmsignal.com/news/CVRX/cvrx-announces-implementation-of-new-category-i-cpt-codes-for-barostim-therapy 2026-01-06 https://biopharmsignal.com/news/VCEL/vericel-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-wednes-8f4fa5e8 2026-01-06 https://biopharmsignal.com/news/HYPR/hyperfine-announces-first-peer-reviewed-publication-demonstrating-significant-economic-benefits-of-using-the-swoopr-ai-powered-portable-mri-system-in-acute-hospital-care 2026-01-06 https://biopharmsignal.com/news/STXS/stereotaxis-receives-fda-approval-for-magic-ablation-catheter-2125a5e1 2026-01-06 https://biopharmsignal.com/news/NCNA/nucana-appoints-theresa-bruce-as-chief-operating-officer 2026-01-06 https://biopharmsignal.com/news/CGON/cg-oncology-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-41fa5717 2026-01-06 https://biopharmsignal.com/news/SLDB/solid-biosciences-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-601b3d00 2026-01-06 https://biopharmsignal.com/news/MDXH/mdxhealth-and-university-of-oxford-to-validate-gps-test-in-largest-randomized-tr-66d2b944 2026-01-06 https://biopharmsignal.com/news/CMPX/compass-therapeutics-provides-corporate-update-c6899b71 2026-01-06 https://biopharmsignal.com/news/VOR/vor-bio-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference-0193d813 2026-01-06 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-provides-corporate-update-and-highlights-key-milestones-5ac45fa6 2026-01-06 https://biopharmsignal.com/news/DNLI/denali-therapeutics-announces-key-anticipated-milestones-and-priorities-for-2026-3dc74caf 2026-01-06 https://biopharmsignal.com/news/LCTX/lineage-takes-delivery-of-gene-edited-hypoimmune-cell-line-under-partnership-with-factor-bioscience 2026-01-06 https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal-gene-therapy-program-in-rett-syndrome 2026-01-06 https://biopharmsignal.com/news/RXRX/recursion-to-present-at-44th-annual-j-p-morgan-healthcare-conference-a211ee4a 2026-01-06 https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-to-announce-clinical-update-on-its-ongoing-phase-2b-studies-and-planned-confirmatory-phase-3-trial-for-acr-368-initial-clinical-data-on-acr-2316-and-other-ap3-pipeline-updates-via-webcast 2026-01-06 https://biopharmsignal.com/news/PROK/prokidney-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-06 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-publishes-phase-2-clinical-results-showing-zervimesine-s--c6a412d6 2026-01-06 https://biopharmsignal.com/news/RGEN/repligen-executive-chair-tony-hunt-to-retire-dr-martin-d-madaus-elected-chair-bb108359 2026-01-06 https://biopharmsignal.com/news/BFRG/bullfrog-ai-driven-precision-oncology-analytics-identifies-3x-increase-in-overall-survivability-in-patient-subgroups-through-key-biomarkers-in-pancreatic-cancer 2026-01-06 https://biopharmsignal.com/news/TIL/instil-bio-s-subsidiary-discontinues-clinical-development-of-axn-2510-and-terminates-license-and-collaboration-agreement-with-immuneonco 2026-01-06 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-06 https://biopharmsignal.com/news/GANX/gain-therapeutics-highlights-biomarker-evidence-supporting-disease-modifying-pot-f9804883 2026-01-06 https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-publications-in-nature-medicine-and-journal-of-infectious-diseases-highlighting-vowsttm-mechanism-of-action-and-supporting-broader-live-biotherapeutic-strategy 2026-01-06 https://biopharmsignal.com/news/GSK/exdensur-depemokimab-approved-in-japan-for-severe-asthma-and-chronic-rhinosinusitis-with-nasal-polyps 2026-01-06 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-announces-positive-interim-results-of-phase-1a-trial-of-ant-dfc6b1f6 2026-01-06 https://biopharmsignal.com/news/APGE/apogee-therapeutics-announces-positive-interim-results-from-phase-1b-trial-of-zu-4f02075e 2026-01-06 https://biopharmsignal.com/news/ANGO/angiodynamics-reports-fiscal-year-2026-second-quarter-financial-results-continued-double-digit-med-tech-growth-drives-increased-profitability 2026-01-06 https://biopharmsignal.com/news/IART/integra-lifesciences-leadership-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-05 https://biopharmsignal.com/news/CMPX/compass-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-e1032059 2026-01-05 https://biopharmsignal.com/news/RCEL/avita-medical-announces-changes-to-its-board-of-directors-1dff779b 2026-01-05 https://biopharmsignal.com/news/OM/outset-medical-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-05 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2025-financial-results-on-february-9-2026 2026-01-05 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-announces-proposed-public-offering-of-common-stock-b68d3ead 2026-01-05 https://biopharmsignal.com/news/APGE/apogee-therapeutics-to-host-conference-call-to-report-interim-results-from-the-p-3a713b58 2026-01-05 https://biopharmsignal.com/news/CYCN/cyclerion-therapeutics-announces-strategic-agreement-with-medsteer-and-progress-toward-initiating-phase-2-proof-of-concept-study-for-cyc-126-in-treatment-resistant-depression 2026-01-05 https://biopharmsignal.com/news/CHRS/coherus-oncology-announces-publication-in-molecular-cancer-therapeutics-highlighting-the-strong-pharmacology-of-investigational-ccr8-antibody-tagmokitug-chs-114 2026-01-05 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-completes-enrollment-of-20th-patient-for-formal-interim-analysis-in-phase-2-ngc-cap-breast-cancer-study 2026-01-05 https://biopharmsignal.com/news/BDRX/appointment-of-fiona-sharp-to-the-board-as-chief-financial-officer-and-company-s-3ea29b0b 2026-01-05 https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-44th-annual-j-p-morgan-healthcare-conference-4a7d4ca1 2026-01-05 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-05 https://biopharmsignal.com/news/OSUR/orasure-submits-ct-ng-molecular-self-test-and-colli-peetm-urine-collection-device-for-fda-review 2026-01-05 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference-a00e82c1 2026-01-05 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-publication-of-results-from-pivotal-study-of-vykat-3bf6f741 2026-01-05 https://biopharmsignal.com/news/CMPX/compass-therapeutics-announces-key-leadership-appointments-e83eceaa 2026-01-05 https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-encouraging-interim-data-of-systemic-administration--1b92538f 2026-01-05 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-44th-annual-j-p-morgan-healthcare-conference-fd564c34 2026-01-05 https://biopharmsignal.com/news/CRNX/crinetics-announces-strong-palsonify-launch-execution-and-positive-results-for-c-6ec94f9e 2026-01-05 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-and-lunatus-announce-exclusive-commercialization-partnership-for-vizztm-in-the-middle-east 2026-01-05 https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-issues-letter-to-stockholders 2026-01-05 https://biopharmsignal.com/news/TARA/protara-therapeutics-receives-both-fda-breakthrough-therapy-and-fast-track-designations-for-tara-002-in-pediatric-patients-with-lymphatic-malformations 2026-01-05 https://biopharmsignal.com/news/SYK/stryker-to-announce-financial-results-for-its-fourth-quarter-and-full-year-2025 2026-01-05 https://biopharmsignal.com/news/ALT/altimmune-receives-fda-breakthrough-therapy-designation-for-pemvidutide-in-mash-1049af72 2026-01-05 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-05 https://biopharmsignal.com/news/HLF/herbalife-to-announce-fourth-quarter-and-full-year-2025-results-on-february-18 2026-01-05 https://biopharmsignal.com/news/GSK/nucala-mepolizumab-approved-in-china-for-use-in-adults-with-chronic-obstructive-pulmonary-disease-copd 2026-01-05 https://biopharmsignal.com/news/GHRS/gh-research-announces-fda-lifts-clinical-hold-on-gh001-clearing-path-for-global-phase-3-initiation-in-2026 2026-01-05 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-05 https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-05 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-announces-alignment-with-china-s-cde-on-conditional-approval-p-dc492683 2026-01-05 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-alignment-with-china-s-cde-on-conditional-approval-pathway-and-priority-review-eligibility-for-hydronidone-following-pre-nda-meeting 2026-01-05 https://biopharmsignal.com/news/ADMA/adma-biologics-to-present-at-the-j-p-morgan-healthcare-conference-on-january-12-2026 2026-01-05 https://biopharmsignal.com/news/TNGX/tango-therapeutics-appoints-sung-lee-to-board-of-directors 2026-01-05 https://biopharmsignal.com/news/MRKR/baylor-college-of-medicine-publishes-promising-safety-and-efficacy-results-of-mu-9304cbc5 2026-01-05 https://biopharmsignal.com/news/AGIO/agios-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-january--3331e93d 2026-01-05 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-05 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-05 https://biopharmsignal.com/news/SNDX/syndax-announces-presentation-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-05 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-highlights-2026-pipeline-strategy-and-anticipated-upcoming--b64e9aa5 2026-01-05 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-announces-positive-results-from-nmra-511-phase-1b-signal-se-b5148c48 2026-01-05 https://biopharmsignal.com/news/PRPH/prophase-labs-provides-update-on-convertible-debt-conversions-capital-structure-and-underlying-asset-value 2026-01-05 https://biopharmsignal.com/news/HCM/hutchmed-initiates-phase-iii-stage-of-the-ongoing-trial-of-the-combination-of-su-8bf2f8f5 2026-01-05 https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topl-ffb55916 2026-01-04 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-announces-closing-of-10-0-million-private-placement-pr-d575c3cc 2026-01-02 https://biopharmsignal.com/news/XERS/xeris-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-01-02 https://biopharmsignal.com/news/PRI/primerica-achieves-new-milestones-kicking-off-2026-with-its-largest-senior-leadership-meeting-ever 2026-01-02 https://biopharmsignal.com/news/RXST/rxsight-inc-to-present-at-the-j-p-morgan-healthcare-conference 2026-01-02 https://biopharmsignal.com/news/GHRS/gh-research-to-announce-ind-status-for-gh001 2026-01-02 https://biopharmsignal.com/news/GNLX/genelux-corporation-announces-appointment-of-jason-litten-m-d-as-chief-medical-o-b92c8d08 2026-01-02 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-maintains-fy-2025-financial-guidance-and-announces-fy-2026-financial-guidance 2026-01-02 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-at-j-p-morgan-s-44th-annual-healthcare-conference 2026-01-02 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-announces-10-0-million-private-placement-priced-at-the-44eaa087 2025-12-31 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-announces-new-manufacturing-partnership-to-strengthen--0d76b477 2025-12-31 https://biopharmsignal.com/news/ICUI/icu-medical-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-4c26b720 2025-12-31 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-issues-2025-end-of-year-ceo-letter-to-shareholders-838b142c 2025-12-31 https://biopharmsignal.com/news/DCTH/delcath-systems-announces-publication-of-subgroup-analyses-of-the-phase-3-focus-study-of-melphalan-hepatic-delivery-system-in-patients-with-unresectable-metastatic-uveal-melanoma 2025-12-31 https://biopharmsignal.com/news/NTRB/nutriband-ceo-publishes-letter-to-shareholders-f2ecf8a4 2025-12-31 https://biopharmsignal.com/news/BCAB/bioatla-and-gatc-health-announce-a-40-million-special-purpose-vehicle-spv-transa-3cc03299 2025-12-31 https://biopharmsignal.com/news/MOH/molina-healthcare-announces-fourth-quarter-and-year-end-2025-earnings-release-and-conference-call-dates 2025-12-30 https://biopharmsignal.com/news/TMCI/treace-to-present-at-44th-annual-j-p-morgan-healthcare-conference 2025-12-30 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2025-12-30 https://biopharmsignal.com/news/IMNN/imunon-announces-pricing-of-7-0-million-registered-direct-offering-priced-at-the-71132803 2025-12-30 https://biopharmsignal.com/news/DNLI/the-new-england-journal-of-medicine-publishes-phase-1-2-study-of-denali-therapeu-337ba2b4 2025-12-30 https://biopharmsignal.com/news/BFRG/bullfrog-ai-publishes-annual-letter-to-shareholders 2025-12-30 https://biopharmsignal.com/news/IFRX/inflarx-provides-update-on-phase-3-data-analyses-for-vilobelimab-in-pyoderma-gan-e56aa987 2025-12-30 https://biopharmsignal.com/news/XAIR/beyond-air-appoints-dan-moorhead-as-chief-financial-officer-67539ffc 2025-12-30 https://biopharmsignal.com/news/XOMA/xoma-royalty-and-takeda-execute-strategic-royalty-sharing-transaction-and-amend-existing-agreement-for-mezagitamab 2025-12-30 https://biopharmsignal.com/news/HCM/hutchmed-announces-nda-acceptance-in-china-with-priority-review-status-for-savol-f359eca3 2025-12-30 https://biopharmsignal.com/news/IRTC/irhythm-technologies-to-present-at-the-44th-annual-j-p-morgan-healthcare-confere-8aa5675a 2025-12-29 https://biopharmsignal.com/news/COO/coopercompanies-to-present-at-the-j-p-morgan-healthcare-conference-8fe3bf3e 2025-12-29 https://biopharmsignal.com/news/DRMA/dermata-therapeutics-announces-closing-of-up-to-12-4-million-private-placement-priced-at-the-market-under-nasdaq-rules 2025-12-29 https://biopharmsignal.com/news/IMNN/imunon-2025-a-transformative-year-of-significant-clinical-advances-looking-ahead-e546447f 2025-12-29 https://biopharmsignal.com/news/NTRB/nutriband-inc-signs-agreement-to-sell-majority-stake-of-subsidiary-pocono-pharma-4012de03 2025-12-29 https://biopharmsignal.com/news/SLS/sellas-life-sciences-provides-update-on-pivotal-phase-3-regal-trial-of-galinpepimut-s-gps-in-acute-myeloid-leukemia-aml 2025-12-29 https://biopharmsignal.com/news/MREO/mereo-biopharma-announces-phase-3-orbit-and-cosmic-results-for-setrusumab-ux143--6a206b71 2025-12-29 https://biopharmsignal.com/news/SPRY/neffy-epinephrine-nasal-spray-approved-in-china-as-the-first-and-only-community--787d43bb 2025-12-29 https://biopharmsignal.com/news/TLSA/tiziana-files-annual-safety-report-for-intranasal-foralumab-with-fda-7af39ab2 2025-12-29 https://biopharmsignal.com/news/RVPH/reviva-to-present-at-the-sachs-9th-annual-neuroscience-innovation-forum-83d6ca38 2025-12-29 https://biopharmsignal.com/news/ZVRA/zevra-therapeutics-executes-distribution-agreement-to-broaden-access-to-miplyffa-41851f3e 2025-12-29 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-announces-resubmission-of-new-drug-application-nda-for-oxylanthanum-carbonate-olc 2025-12-29 https://biopharmsignal.com/news/INDP/indaptus-enters-into-6-million-securities-purchase-agreement-with-investor-david-bcf9b890 2025-12-29 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-completion-of-commercial-scale-il-6-antibody-production 2025-12-29 https://biopharmsignal.com/news/ANL/adlai-nortye-enters-exclusive-license-agreement-with-ask-pharm-for-pan-ras-on-inhibitor-an9025-in-greater-china 2025-12-29 https://biopharmsignal.com/news/HCM/hutchmed-announces-nda-acceptance-in-china-with-priority-review-status-for-fanre-dc58785f 2025-12-29 https://biopharmsignal.com/news/FENC/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc 2025-12-26 https://biopharmsignal.com/news/APVO/aptevo-therapeutics-announces-1-for-18-reverse-stock-split 2025-12-26 https://biopharmsignal.com/news/ICCC/immucell-announces-strategic-focus-on-first-defense-after-receiving-an-fda-incom-9a1ec1cd 2025-12-24 https://biopharmsignal.com/news/MKT/maia-biotechnology-board-members-continue-to-participate-in-private-placement-financings 2025-12-24 https://biopharmsignal.com/news/DRMA/dermata-therapeutics-announces-up-to-12-4-million-private-placement-priced-at-the-market-under-nasdaq-rules 2025-12-24 https://biopharmsignal.com/news/RPTX/repare-therapeutics-announces-acquisition-of-pol-atpase-inhibitor-rp-3467-by-gilead-sciences-for-up-to-30-million-in-total-consideration 2025-12-24 https://biopharmsignal.com/news/AGIO/u-s-fda-approves-agios-aqvesme-mitapivat-for-the-treatment-of-anemia-in-adults-w-1dfbe039 2025-12-24 https://biopharmsignal.com/news/ICU/seastar-medical-announces-1-for-10-reverse-split-011110a6 2025-12-23 https://biopharmsignal.com/news/ORGO/organogenesis-announces-initiation-of-biologics-license-application-for-renur 2025-12-23 https://biopharmsignal.com/news/VOR/vor-bio-appoints-ra-capital-s-andrew-levin-m-d-ph-d-and-forbion-s-wouter-joustra-b55fc1d7 2025-12-23 https://biopharmsignal.com/news/MMSI/merit-medical-to-participate-at-the-j-p-morgan-healthcare-conference-9daaf106 2025-12-23 https://biopharmsignal.com/news/ARTL/artelo-bioscience-commends-presidential-executive-order-expanding-cbd-research-and-access-highlights-art12-11-as-a-leading-pharmaceutical-grade-cannabidiol-candidate 2025-12-23 https://biopharmsignal.com/news/VCNX/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease 2025-12-23 https://biopharmsignal.com/news/IMRX/immuneering-to-announce-12-month-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-january-7-2026 2025-12-23 https://biopharmsignal.com/news/BBLG/bone-biologics-improves-extension-of-rhnell-1-product-shelf-life-to-24-months-bde63f6d 2025-12-23 https://biopharmsignal.com/news/RVPH/reviva-announces-regulatory-update-regarding-the-development-of-brilaroxazine-fo-3a56096b 2025-12-23 https://biopharmsignal.com/news/COO/coopercompanies-appoints-walter-m-rosebrough-jr-to-its-board-of-directors-c90e6439 2025-12-23 https://biopharmsignal.com/news/LIXT/lixte-and-its-collaborators-expand-clear-cell-ovarian-cancer-trial 2025-12-23 https://biopharmsignal.com/news/ANGO/angiodynamics-to-report-fiscal-2026-second-quarter-results-on-january-6-2026 2025-12-23 https://biopharmsignal.com/news/TECH/bio-techne-to-present-at-the-2026-j-p-morgan-healthcare-conference 2025-12-23 https://biopharmsignal.com/news/RXST/rxsight-inc-announces-chief-financial-officer-transition 2025-12-22 https://biopharmsignal.com/news/FLGT/fulgent-genetics-agrees-to-acquire-bako-diagnostics-and-stratadx 2025-12-22 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-positive-interim-phase-2b-clinical-trial-results-in-chemotherapy-induced-neuropathic-pain 2025-12-22 https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-announces-its-intent-to-commence-a-self-tender-offer 2025-12-22 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-provides-broad-update-on-zugocaptagene-geleucel-zugo-cel-formerly-ctx112tm-in-autoimmune-diseases-and-hematologic-malignancies 2025-12-22 https://biopharmsignal.com/news/IMMP/immutep-announces-positive-update-on-imp761-a-first-in-class-lag-3-agonist-antib-fc943a34 2025-12-22 https://biopharmsignal.com/news/ASMB/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes 2025-12-22 https://biopharmsignal.com/news/SCYX/scynexis-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-requirement 2025-12-22 https://biopharmsignal.com/news/ANGO/angiodynamics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2025-12-22 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-completes-patient-enrollment-in-north-american-phase-3-trial-evaluating-regimen-of-bemnifosbuvir-and-ruzasvir-for-treatment-of-hepatitis-c-virus 2025-12-22 https://biopharmsignal.com/news/APTO/aptose-biosciences-announces-rescheduling-of-special-meeting-of-shareholders-to-approve-the-acquisition-by-hanmi-pending-final-clearance-from-sec 2025-12-19 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi-fa92867d 2025-12-19 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-agreement-with-u-s-government-to-improve-affordability-and-access-to-critical-medicines-for-americans 2025-12-19 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-announces-acquisition-of-shares-by-executive-chairman-0919bf6c 2025-12-19 https://biopharmsignal.com/news/MGRX/mangoceuticals-inc-announces-closing-of-2-5-million-registered-direct-and-privat-4148f6b7 2025-12-19 https://biopharmsignal.com/news/INAB/in8bio-announces-pricing-of-private-placement-of-up-to-40-2-million-to-advance-novel-gamma-delta-t-cell-engager 2025-12-19 https://biopharmsignal.com/news/CUE/cue-biopharma-announces-pricing-of-10-million-public-offering-e3d90ba2 2025-12-19 https://biopharmsignal.com/news/GALT/galectin-therapeutics-provides-regulatory-update-following-fda-written-response--70b6c6ee 2025-12-19 https://biopharmsignal.com/news/MGRX/mangoceuticals-inc-announces-partnership-with-the-cube-group-to-launch-up-to-100-eb41f91d 2025-12-19 https://biopharmsignal.com/news/PRPH/prophase-labs-signs-non-binding-loi-for-proposed-reverse-merger-with-advanced-biological-laboratories 2025-12-19 https://biopharmsignal.com/news/GSK/gsk-enters-agreement-with-u-s-government-to-lower-drug-prices-and-expand-access-to-respiratory-medicines-for-millions-of-americans 2025-12-19 https://biopharmsignal.com/news/ALT/altimmune-announces-that-pemvidutide-achieved-key-measures-of-success-at-48-week-28f9c9bb 2025-12-19 https://biopharmsignal.com/news/ENSG/the-ensign-group-inc-increases-quarterly-dividend-to-0-0650-per-share-c3debdc1 2025-12-19 https://biopharmsignal.com/news/SPRO/spero-announces-nda-resubmission-of-tebipenem-hbr-by-gsk-to-the-fda-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis 2025-12-19 https://biopharmsignal.com/news/GNTA/genenta-science-provides-update-on-ceo-ownership 2025-12-19 https://biopharmsignal.com/news/SNTI/senti-biosciences-announces-new-employment-inducement-grants-119e04ef 2025-12-18 https://biopharmsignal.com/news/EMBC/embecta-to-participate-at-the-j-p-morgan-2026-healthcare-conference 2025-12-18 https://biopharmsignal.com/news/ANVS/annovis-announces-open-label-extension-study-for-parkinson-s-disease-patients-c74efc5f 2025-12-18 https://biopharmsignal.com/news/RCEL/avita-medical-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-7f45670e 2025-12-18 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-announces-the-appointment-of-adrian-bot-to-board-of-direc-21fce344 2025-12-18 https://biopharmsignal.com/news/GANX/gain-therapeutics-to-host-virtual-kol-event-on-gt-02287-for-parkinson-s-disease-f12576e2 2025-12-18 https://biopharmsignal.com/news/CUE/cue-biopharma-announces-proposed-public-offering-bd6ef7ae 2025-12-18 https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference 2025-12-18 https://biopharmsignal.com/news/FEMY/femasys-secures-u-s-fda-clearance-for-next-generation-femvue-diagnostic-device-8a3c1673 2025-12-18 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-4-3-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2025-12-18 https://biopharmsignal.com/news/BFRI/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-assoc-fa58de94 2025-12-18 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-provides-dm199-preeclampsia-program-update-following-pre-ind-meeting-with-fda 2025-12-18 https://biopharmsignal.com/news/TMCI/treace-medical-secures-up-to-175-million-in-debt-financing 2025-12-18 https://biopharmsignal.com/news/BDRX/biodexa-announces-pricing-of-10-million-public-offering-823dd701 2025-12-18 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-announces-strategic-partnership-with-vlepis-provider-o-07604d8f 2025-12-18 https://biopharmsignal.com/news/MGRX/mangoceuticals-inc-announces-2-5-million-registered-direct-and-private-placement-67a0ffe7 2025-12-18 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-initiates-rolling-submission-of-bla-to-u-s-fda-for-st-920-i-30ef2e43 2025-12-18 https://biopharmsignal.com/news/PULM/pulmatrix-and-cullgen-continue-to-pursue-merger-while-granting-each-other-waivers-to-explore-alternatives 2025-12-18 https://biopharmsignal.com/news/CGON/suo-ctc-and-cg-oncology-announce-the-second-annual-non-muscle-invasive-bladder-c-adf2bbbb 2025-12-18 https://biopharmsignal.com/news/OVID/ovid-therapeutics-reports-phase-1-results-for-the-first-ever-direct-activator-of-cc560731 2025-12-18 https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-announces-positive-data-from-ongoing-real-world-evidence-s-2b05db6b 2025-12-18 https://biopharmsignal.com/news/NTRB/nutriband-inc-signs-letter-of-intent-with-qvanta-group-of-companies-to-explore-a-669596d5 2025-12-18 https://biopharmsignal.com/news/COCP/cocrystal-pharma-receives-irb-approval-from-emory-university-school-of-medicine--911a0827 2025-12-18 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-announces-pipeline-and-business-updates-0185d190 2025-12-18 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2025-12-18 https://biopharmsignal.com/news/REPL/replimune-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2025-12-18 https://biopharmsignal.com/news/PMN/promis-neurosciences-exceeds-target-enrollment-in-precise-ad-phase-1b-clinical-t-947d174a 2025-12-18 https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-j-p-morgan-2026-healthcare-conference-053249e7 2025-12-18 https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-con-3baf9eed 2025-12-18 https://biopharmsignal.com/news/BSEM/biostem-technologies-products-placed-on-12-month-status-quo-period-list-in-updat-6ef9d286 2025-12-18 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-positive-results-from-the-phase-1-pk-clinical-tria-83327268 2025-12-18 https://biopharmsignal.com/news/NTRB/nutriband-differentiates-prescription-fentanyl-from-illicit-fentanyl-in-response-65848123 2025-12-18 https://biopharmsignal.com/news/GANX/gain-therapeutics-announces-positive-results-in-key-exploratory-endpoint-from-it-171f4a85 2025-12-18 https://biopharmsignal.com/news/PYXS/pyxis-oncology-announces-positive-preliminary-phase-1-data-for-micvotabart-pelid-1dab341d 2025-12-18 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-fourth-quarter-2025-on-february-5-2026 2025-12-18 https://biopharmsignal.com/news/MNOV/medicinova-announces-completion-of-patient-enrollment-evaluating-mn-166-ibudilast-in-the-prevention-of-chemotherapy-induced-peripheral-neuropathy 2025-12-18 https://biopharmsignal.com/news/MOLN/molecular-partners-to-present-at-44th-annual-j-p-morgan-healthcare-conference-acbd73be 2025-12-18 https://biopharmsignal.com/news/AVAH/aveanna-to-participate-at-the-44th-annual-j-p-morgan-healthcare-conference 2025-12-17 https://biopharmsignal.com/news/IMRX/immuneering-advances-towards-dosing-first-patient-in-phase-3-atebimetinib-trial-for-first-line-metastatic-pancreatic-cancer-patients-securing-alignment-with-fda-and-ema 2025-12-17 https://biopharmsignal.com/news/STRO/sutro-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement-9ec047b3 2025-12-17 https://biopharmsignal.com/news/OSUR/orasure-technologies-issues-statement-regarding-altai-capital-s-intent-to-nominate-director-candidates 2025-12-17 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-to-ring-the-closing-bell-at-nasdaq-e97bcd00 2025-12-17 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-announces-pricing-of-100-million-public-offering-of-common--fc19e175 2025-12-17 https://biopharmsignal.com/news/TENX/tenax-therapeutics-announces-result-of-prespecifed-blinded-sample-size-assessmen-5243912d 2025-12-17 https://biopharmsignal.com/news/TLSA/tiziana-life-sciences-doses-first-patient-in-phase-2-alzheimer-s-clinical-trial-44c3bfcf 2025-12-17 https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-initiation-of-phase-1-clinical-study-of-oral-small-molecule-amylin-receptor-agonist-accg-2671-for-the-treatment-of-obesity 2025-12-17 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-and-yarrow-bioscience-announce-merger-agreement-cb196680 2025-12-17 https://biopharmsignal.com/news/LEGN/legend-biotech-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-66027e2e 2025-12-17 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-provides-clinical-update-on-phase-2-study-in-metastatic-breast-cancer 2025-12-17 https://biopharmsignal.com/news/ATRC/atricure-to-participate-in-the-j-p-morgan-44th-annual-healthcare-conference 2025-12-17 https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-the-j-p-morgan-2026-healthcare-conference-4309d9d2 2025-12-17 https://biopharmsignal.com/news/XAIR/beyond-air-signs-new-international-lungfit-ph-distribution-agreements-most-notab-8e5d340d 2025-12-17 https://biopharmsignal.com/news/BMEA/biomea-fusion-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2025-12-17 https://biopharmsignal.com/news/TNGX/tango-therapeutics-to-participate-in-44th-annual-j-p-morgan-healthcare-conference 2025-12-17 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-and-tapi-announce-global-license-agreement-for-innovative-fo-1089c28b 2025-12-17 https://biopharmsignal.com/news/EYPT/eyepoint-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-fb04e020 2025-12-17 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-confere-a71724e6 2025-12-17 https://biopharmsignal.com/news/FDMT/4dmt-announces-positive-interim-clinical-data-from-4d-710-aerow-phase-1-clinical-6f0ba1f7 2025-12-17 https://biopharmsignal.com/news/AXGN/axogen-inc-to-participate-in-the-j-p-morgan-2026-healthcare-conference 2025-12-17 https://biopharmsignal.com/news/VERU/veru-reports-fiscal-year-2025-financial-results-and-clinical-program-progress 2025-12-17 https://biopharmsignal.com/news/HCM/hutchmed-initiates-global-clinical-development-of-attc-candidate-hmpl-a251-in-pa-cab845ad 2025-12-17 https://biopharmsignal.com/news/INBX/inhibrx-biosciences-provides-progress-updates-on-the-inbrx-106-program-and-the-expansion-cohorts-of-the-ozekibart-inbrx-109-program 2025-12-16 https://biopharmsignal.com/news/MKT/maia-biotechnology-announces-1-51-million-private-placement 2025-12-16 https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-139b1198 2025-12-16 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-and-parent-project-muscular-dystrophy-to-host-webinar-highlighting-positive-phase-3-hope-3-topline-results-in-duchenne-muscular-dystrophy 2025-12-16 https://biopharmsignal.com/news/ORTX/orchard-therapeutics-celebrates-addition-of-metachromatic-leukodystrophy-to-the-u-s-recommended-uniform-screening-panel 2025-12-16 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-grand-opening-of-affiliated-sleep-center-near-detro-f300ea43 2025-12-16 https://biopharmsignal.com/news/DAWN/day-one-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2025-12-16 https://biopharmsignal.com/news/PYPD/polypid-appoints-veteran-medtech-leader-brooke-story-as-chairman-of-the-board-of-directors 2025-12-16 https://biopharmsignal.com/news/ABSI/absci-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference 2025-12-16 https://biopharmsignal.com/news/ANVS/annovis-to-host-corporate-update-webinar-on-january-28-2026-0511a3fd 2025-12-16 https://biopharmsignal.com/news/IMMP/immutep-announces-strong-operational-progress-in-global-tacti-004-keynote-f91-ph-725b5709 2025-12-16 https://biopharmsignal.com/news/BCDA/biocardia-cell-therapy-for-ischemic-heart-failure-to-progress-to-formal-clinical-44d5771e 2025-12-16 https://biopharmsignal.com/news/RGEN/repligen-introduces-next-generation-chromatography-resins-to-advance-new-modalit-d7fdc176 2025-12-16 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-compelling-clinical-activity-of-mrt-2359-in-co-f3d2f28d 2025-12-16 https://biopharmsignal.com/news/GSK/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-asthma 2025-12-16 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-to-participate-in-online-fireside-chat-with-water-tower-resea-dfa8b634 2025-12-15 https://biopharmsignal.com/news/XOMA/xoma-royalty-enters-into-agreement-to-acquire-generation-bio 2025-12-15 https://biopharmsignal.com/news/CLLS/cellectis-announces-arbitral-decision-in-dispute-with-servier 2025-12-15 https://biopharmsignal.com/news/ORGO/organogenesis-announces-successful-fda-meeting-and-plan-to-file-bla-for-renur-for-knee-osteoarthritis-pain 2025-12-15 https://biopharmsignal.com/news/HSCS/heartsciences-reports-fiscal-second-quarter-2026-financial-results-and-provides--4ab6bfe5 2025-12-15 https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-21a40f6e 2025-12-15 https://biopharmsignal.com/news/HSTM/healthstream-acquires-missioncare-collective-adding-the-nation-s-largest-caregiver-network-with-mycnajobs-com-which-becomes-the-company-s-third-career-network 2025-12-15 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-announces-proposed-public-offering-of-common-stock-a03666c2 2025-12-15 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results-4ea446da 2025-12-15 https://biopharmsignal.com/news/GSK/exdensur-depemokimab-approved-in-the-uk-for-treatment-of-asthma-with-type-2-inflammation-and-chronic-rhinosinusitis-with-nasal-polyps 2025-12-15 https://biopharmsignal.com/news/HSCS/heartsciences-announces-fda-510-k-submission-for-myovista-wavecg-device-7575a4ed 2025-12-15 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-announces-ceo-transition 2025-12-15 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-announces-two-immune-receptor-licensing-agreements-with-pfizer 2025-12-15 https://biopharmsignal.com/news/VOR/vor-bio-announces-150-million-private-placement-46597442 2025-12-15 https://biopharmsignal.com/news/FBIO/fortress-biotech-and-cyprium-therapeutics-announce-fda-acceptance-of-cutx-101-nda-resubmission 2025-12-15 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-appointment-of-mohamad-tabrizi-as-chief-business-officer 2025-12-15 https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-announces-positive-topline-data-from-registrational-kysa-8--b6d3a807 2025-12-15 https://biopharmsignal.com/news/INVA/u-s-fda-approves-nuzolvencer-zoliflodacin-a-first-in-class-single-dose-oral-antibiotic-for-the-treatment-of-uncomplicated-urogenital-gonorrhea-in-adults-and-adolescents 2025-12-12 https://biopharmsignal.com/news/GRI/gri-bio-announces-closing-of-8-0-million-public-offering-9ad04fc6 2025-12-12 https://biopharmsignal.com/news/ALEC/alector-appoints-neil-berkley-as-chief-financial-officer-and-chief-business-offi-a31ca2cf 2025-12-12 https://biopharmsignal.com/news/INBS/intelligent-bio-solutions-inc-announces-reverse-stock-split-8c4fbf35 2025-12-12 https://biopharmsignal.com/news/GSK/nucala-mepolizumab-receives-positive-chmp-opinion-for-treatment-of-chronic-obstructive-pulmonary-disease-copd 2025-12-12 https://biopharmsignal.com/news/GSK/depemokimab-receives-positive-chmp-opinion-for-severe-asthma-with-type-2-inflammation-and-chronic-rhinosinusitis-with-nasal-polyps 2025-12-12 https://biopharmsignal.com/news/BYSI/beyondspring-announces-esmo-asia-presentation-on-plinabulin-docetaxel-improving--bb928d08 2025-12-12 https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-efficacy-subset-analysis-of-zovegalisib-rly-2608-fu-ef19d6e8 2025-12-12 https://biopharmsignal.com/news/SNDX/revuforjr-revumenib-named-best-new-drug-at-the-scrip-awards-2025 2025-12-12 https://biopharmsignal.com/news/OPCH/option-care-health-to-participate-in-the-j-p-morgan-healthcare-conference 2025-12-12 https://biopharmsignal.com/news/GSK/gsk-s-rsv-vaccine-arexvy-receives-positive-chmp-opinion-for-all-adults-18-years-and-older 2025-12-12 https://biopharmsignal.com/news/MRUS/genmab-announces-completion-of-tender-offer-for-outstanding-common-shares-of-merus-n-v-and-commencement-of-subsequent-offering-period 2025-12-12 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-announces-pricing-of-public-offering 2025-12-12 https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-announces-publication-in-the-lancet-of-positive-zoliflodacin-phase-3-data-for-the-treatment-of-uncomplicated-urogenital-gonorrhea 2025-12-11 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-adjournment-of-2025-annual-meeting 2025-12-11 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules 2025-12-11 https://biopharmsignal.com/news/TERN/terns-announces-closing-of-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares 2025-12-11 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-announces-proposed-public-offering 2025-12-11 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-announces-rapid-resolution-and-lifting-of-clinical-hold-for-mypeak-1tm-phase-1b-2a-clinical-trial-of-tn-201-gene-therapy 2025-12-11 https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-reports-positive-interim-data-from-cohort-1-of-ridgetm-1-phase-1b-2-clinical-trial-of-tn-401-gene-therapy-for-adults-with-pkp2-associated-arvc 2025-12-11 https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-closing-of-upsized-747-5-million-public-offering-of-adss-and-pre-funded-warrants-and-full-exercise-of-the-underwriters-option-to-purchase-additional-adss 2025-12-11 https://biopharmsignal.com/news/CELC/celcuity-presents-updated-results-from-the-pik3ca-wild-type-cohort-of-the-phase--d961bcdb 2025-12-11 https://biopharmsignal.com/news/GRI/gri-bio-announces-pricing-of-8-000-000-public-offering-3eead79a 2025-12-11 https://biopharmsignal.com/news/NEPH/nephros-launches-the-nephros-water-institute-to-lead-national-water-safety-educa-6859055c 2025-12-11 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-new-ceo-to-drive-next-phase-of-development 2025-12-11 https://biopharmsignal.com/news/HSCS/heartsciences-announces-major-upgrade-to-user-features-of-myovista-insights-plat-1446ecd8 2025-12-11 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-reports-antigen-spreading-to-patient-specific-neoantigens-be-2afc616d 2025-12-11 https://biopharmsignal.com/news/XTNT/xtant-medical-announces-commercial-launch-of-its-next-generation-nanoss-stratatm-synthetic-bone-graft 2025-12-11 https://biopharmsignal.com/news/ATRC/atricure-announces-the-first-patients-treated-with-novel-dual-energy-platform 2025-12-11 https://biopharmsignal.com/news/INTS/intensity-therapeutics-inc-to-present-two-posters-at-the-2025-san-antonio-breast-cancer-symposium 2025-12-11 https://biopharmsignal.com/news/ROIV/roivant-highlights-continued-pipeline-progress-and-outlook-for-company-s-next-phase-of-growth-at-2025-investor-day 2025-12-11 https://biopharmsignal.com/news/IFRX/inflarx-announces-international-nonproprietary-name-of-izicopan-for-inf904-19ffa63d 2025-12-11 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-new-qualified-treatment-center-for-zevaskynr-in-texas 2025-12-11 https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-ceo-transition-as-company-advances-strategy-to-extend-orexin-leadership-into-multiple-neuroscience-indications 2025-12-11 https://biopharmsignal.com/news/IMTX/immatics-presents-ima203cd8-prame-cell-therapy-data-from-ongoing-dose-escalation-and-shows-promising-initial-anti-tumor-activity-in-prame-positive-tumors-at-esmo-io-2025-congress 2025-12-11 https://biopharmsignal.com/news/PPBT/purple-biotech-reports-positive-new-preclinical-data-demonstrating-multi-arm-ant-6e44ce8e 2025-12-11 https://biopharmsignal.com/news/BYSI/beyondspring-announces-new-analyses-of-dublin-3-phase-3-study-showing-survival-b-016d174e 2025-12-11 https://biopharmsignal.com/news/ACIU/ac-immune-positive-interim-phase-2-data-on-aci-7104-056-support-potential-slowin-ca30a27d 2025-12-11 https://biopharmsignal.com/news/IRIX/iridex-announces-the-publication-of-an-independent-study-demonstrating-safe-and-effective-retreatment-with-transscleral-laser-treatment-using-micropulser-technology-in-glaucoma-management 2025-12-11 https://biopharmsignal.com/news/GSK/blujepa-gepotidacin-approved-by-us-fda-as-oral-option-for-treatment-of-uncomplicated-urogenital-gonorrhoea-ugc 2025-12-11 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-reports-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913-for-the-treatment-for-obesity-demonstrating-favorable-safety-profile-and-emerging-evidence-of-weight-loss 2025-12-11 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-fda-grants-priority-review-to-bristol-myers-squibb-s-application-for-opdivor-nivolumab-plus-chemotherapy-combination-for-classical-hodgkin-lymphoma 2025-12-11 https://biopharmsignal.com/news/TECH/bio-techne-partners-with-the-wyss-center-geneva-to-advance-automated-3d-multiomics-technology-and-accelerate-spatial-biology 2025-12-11 https://biopharmsignal.com/news/CERT/certara-appoints-jon-resnick-as-chief-executive-officer 2025-12-11 https://biopharmsignal.com/news/IMVT/immunovant-announces-pricing-of-550-million-common-stock-financing 2025-12-11 https://biopharmsignal.com/news/ADXN/addex-amends-its-at-the-market-offering-agreement-with-h-c-wainwright-co-1a80f167 2025-12-11 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-dividend-increase 2025-12-10 https://biopharmsignal.com/news/ISRG/intuitive-announces-expanded-indications-for-da-vinci-sp 2025-12-10 https://biopharmsignal.com/news/GRI/gri-bio-announces-positive-topline-data-from-its-phase-2a-study-in-idiopathic-pu-66db2eed 2025-12-10 https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-to-report-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913-for-the-treatment-for-obesity-on-thursday-december-11-2025 2025-12-10 https://biopharmsignal.com/news/GNFT/genfit-gns561-shows-promising-antitumor-activity-in-combination-therapy 2025-12-10 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-and-biomimetic-innovations-provide-update-on-osstic-111d1d56 2025-12-10 https://biopharmsignal.com/news/DERM/journey-medical-corporation-announces-publication-of-clinical-trial-results-assessing-the-impact-of-emrositm-dfd-29-on-microbial-flora-of-healthy-adults-in-the-journal-of-drugs-in-dermatology 2025-12-10 https://biopharmsignal.com/news/VERU/veru-to-report-fiscal-year-2025-financial-results-on-december-17th 2025-12-10 https://biopharmsignal.com/news/BRNS/barinthus-bio-announces-update-on-phase-1-avalon-clinical-trial-of-vtp-1000-for-the-treatment-of-celiac-disease 2025-12-10 https://biopharmsignal.com/news/NCNA/nucana-presents-latest-data-demonstrating-clinical-activity-and-favorable-safety-for-nuc-7738-in-patients-with-pd-1-resistant-melanoma 2025-12-10 https://biopharmsignal.com/news/FMS/fresenius-medical-care-appoints-charles-hugh-jones-as-global-chief-medical-officer-and-member-of-the-management-board 2025-12-10 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-pricing-of-upsized-175-0-million-public-offering--8f75dd51 2025-12-10 https://biopharmsignal.com/news/PMN/promis-neurosciences-announces-new-peer-reviewed-publication-highlighting-select-765ed950 2025-12-10 https://biopharmsignal.com/news/MDNA/medicenna-updates-mdna11-clinical-trial-results-at-the-esmo-io-congress-2025-further-bolstering-its-anti-tumor-activity-in-advanced-solid-tumors 2025-12-10 https://biopharmsignal.com/news/SGMT/sagimet-s-license-partner-ascletis-announced-acceptance-of-new-drug-application--99cc80b2 2025-12-10 https://biopharmsignal.com/news/MDWD/mediwound-reports-new-clinical-data-demonstrating-nexobrid-s-effectiveness-in-pr-8d378d27 2025-12-10 https://biopharmsignal.com/news/BSEM/biostem-technologies-to-debut-american-amnion-at-the-2025-desert-foot-multi-disc-e28dff8a 2025-12-10 https://biopharmsignal.com/news/GSK/gsk-227-a-b7-h3-targeted-antibody-drug-conjugate-granted-orphan-drug-designation-in-small-cell-lung-cancer-by-the-us-fda 2025-12-10 https://biopharmsignal.com/news/DNLI/denali-therapeutics-announces-pricing-of-public-offering-of-common-stock-and-pre-4cf2b9d2 2025-12-10 https://biopharmsignal.com/news/TERN/terns-announces-pricing-of-upsized-650-million-public-offering 2025-12-10 https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-pricing-of-upsized-650-million-public-offering-of-adss-and-pre-funded-warrants 2025-12-10 https://biopharmsignal.com/news/WVE/wave-life-sciences-prices-upsized-350-million-public-offering-of-ordinary-shares-223e1cbf 2025-12-10 https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-kol-presentation-and-interview-on-menin-and-icovamenib-at-wcirdc-2025 2025-12-09 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-closing-of-upsized-100-million-underwritten-offering-o-a692323f 2025-12-09 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-to-participate-in-jefferies-fireside-chat-series-on-minimal-residual-disease 2025-12-09 https://biopharmsignal.com/news/HSTM/healthstream-ceo-rewards-employees-with-contribution-of-personally-owned-shares-of-company-stock 2025-12-09 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-315b923d 2025-12-09 https://biopharmsignal.com/news/DNLI/denali-therapeutics-announces-proposed-offering-of-common-stock-and-pre-funded-w-7c296469 2025-12-09 https://biopharmsignal.com/news/TFX/teleflex-announces-sale-of-acute-care-interventional-urology-and-oem-businesses--da92348c 2025-12-09 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-showcases-xtrac-and-theraclearx-at-teracilad-2025-reports-e-b8d287bc 2025-12-09 https://biopharmsignal.com/news/APVO/aptevo-therapeutics-highlights-compelling-safety-and-strong-remission-rates-for-mipletamig-in-frontline-aml-at-ash-2025 2025-12-09 https://biopharmsignal.com/news/CLDX/celldex-initiates-global-registrational-phase-3-program-of-barzolvolimab-in-cold-cda596a3 2025-12-09 https://biopharmsignal.com/news/IPSC/century-therapeutics-appoints-accomplished-biotechnology-leaders-dr-han-lee-and--e9ba40d1 2025-12-09 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-new-composition-of-matter-patent-for-pds0101-in-japan-ec4588e0 2025-12-09 https://biopharmsignal.com/news/SNTI/senti-bio-announces-updated-senti-202-clinical-data-from-ongoing-phase-1-trial-i-721ec012 2025-12-09 https://biopharmsignal.com/news/SNTI/senti-bio-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-f-75b1107b 2025-12-09 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-investigator-sponsored-trial-to-be-conducted-by-city-of-hope-in-metastatic-testicular-germ-cell-tumors 2025-12-09 https://biopharmsignal.com/news/PEPG/pepgen-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-to-newly-appointed-chief-business-and-legal-officer 2025-12-09 https://biopharmsignal.com/news/BMY/biontech-and-bristol-myers-squibb-present-first-global-phase-2-data-for-pd-l1xvegf-a-bispecific-antibody-pumitamig-showing-encouraging-efficacy-in-advanced-triple-negative-breast-cancer 2025-12-09 https://biopharmsignal.com/news/TECH/bio-techne-launches-the-enhanced-leotm-system-delivering-advanced-multiplexing-and-high-throughput-protein-analysis 2025-12-09 https://biopharmsignal.com/news/TERN/terns-announces-proposed-public-offering 2025-12-09 https://biopharmsignal.com/news/PTIX/results-from-phase-1-multiple-dose-study-of-pt00114 2025-12-09 https://biopharmsignal.com/news/XCUR/exicure-presents-positive-topline-phase-2-data-for-burixafor-in-multiple-myeloma-af8fc1be 2025-12-08 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-advances-lymphoma-research-with-new-targeted-protein-degradation-and-cell-therapy-data-at-ash-2025 2025-12-08 https://biopharmsignal.com/news/ASMB/assembly-biosciences-reports-positive-interim-results-from-phase-1b-clinical-studies-of-long-acting-helicase-primase-inhibitor-candidates-abi-1179-and-abi-5366-showing-reductions-in-viral-shedding-rate-and-virologically-confirmed-genital-lesion-rate-in-recurrent-genital-herpes 2025-12-08 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-presents-updated-clinical-data-from-the-carlysle-trial-in-p-6913e12d 2025-12-08 https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-proposed-500-million-public-offering-of-american-depositary-shares-and-pre-funded-warrants 2025-12-08 https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-sh-3fc933bb 2025-12-08 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-proposed-150-0-million-public-offering-of-common--7cd8f9df 2025-12-08 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-showcases-compelling-clinical-data-in-aml-for-cln-049-nove-7648e4d4 2025-12-08 https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-publication-in-nature-biotechnology-of-in-vivo-gene-editing-of-human-hematopoietic-stem-cells-in-preclinical-models-using-the-fusogen-platform 2025-12-08 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-presents-initial-clinical-data-in-pediatric-r-r-b-all-patie-e7ce5f2d 2025-12-08 https://biopharmsignal.com/news/IRMD/iradimed-announces-special-cash-dividend-of-0-50-per-share-e0e4d7d1 2025-12-08 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-presents-new-data-from-the-phase-1-trial-of-bexobrutideg-nx-5948-in-waldenstroem-macroglobulinemia-at-the-67th-american-society-of-hematology-ash-annual-meeting-and-exposition 2025-12-08 https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-positive-topline-data-from-access-program-for-its-once-daily-oral-small-molecule-glp-1-receptor-agonist-aleniglipron 2025-12-08 https://biopharmsignal.com/news/IMMP/immutep-and-dr-reddy-s-enters-into-strategic-collaboration-for-commercialisation-6d1ca962 2025-12-08 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-first-patient-treatment-with-zevaskynr-gene-therapy 2025-12-08 https://biopharmsignal.com/news/AGIO/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia-ee629bc6 2025-12-08 https://biopharmsignal.com/news/IRIX/iridex-announces-new-thermal-dynamics-study-that-strengthens-clinical-foundation-and-market-potential-of-micropulser-technology-and-continuous-wave-laser-for-glaucoma-treatment 2025-12-08 https://biopharmsignal.com/news/PEPG/pepgen-appoints-joseph-vittiglio-esq-as-chief-business-and-legal-officer 2025-12-08 https://biopharmsignal.com/news/MNOV/medicinova-announces-update-and-basic-characteristic-randomized-patients-of-phase-2-3-clinical-trial-of-mn-166-ibudilast-in-als-combat-als-clinical-trial-presented-at-the-36th-international-symposium-on-als-mnd 2025-12-08 https://biopharmsignal.com/news/CLLS/ash-2025-cellectis-presents-development-plan-to-further-enhance-high-response-rate-observed-for-eti-cel-in-r-r-nhl 2025-12-08 https://biopharmsignal.com/news/GPCR/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025 2025-12-07 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-pricing-of-upsized-100-million-underwritten-offering-o-0475aa41 2025-12-07 https://biopharmsignal.com/news/IMMX/at-ash-2025-oral-presentation-immix-biopharma-reports-positive-phase-2-nxc-201-r-65ed4456 2025-12-07 https://biopharmsignal.com/news/SLS/sellas-life-sciences-presents-positive-phase-2-data-of-sls009-in-combination-with-aza-ven-in-relapsed-refractory-aml-mr-at-ash-2025 2025-12-07 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-presents-new-clinical-data-from-ongoing-trial-of-ronde-cel-showing-high-rates-of-durable-complete-responses-in-patients-with-large-b-cell-lymphoma-at-the-67th-ash-annual-meeting-and-exposition 2025-12-07 https://biopharmsignal.com/news/RIGL/rigel-presents-updated-data-from-the-ongoing-phase-1b-study-evaluating-r289-in-patients-with-lower-risk-mds-at-the-67th-ash-annual-meeting-and-exposition 2025-12-07 https://biopharmsignal.com/news/PRME/prime-medicine-announces-the-new-england-journal-of-medicine-publication-of-pm359-clinical-data-for-the-treatment-of-chronic-granulomatous-disease 2025-12-07 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-positive-initial-results-from-the-20-mg-dose-coho-7738c422 2025-12-06 https://biopharmsignal.com/news/LEGN/legend-biotech-highlights-new-carvykti-data-in-multiple-myeloma-and-first-in-hum-dda9101a 2025-12-06 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-presents-data-at-the-2025-ash-annual-meeting-from-its-myeloproliferative-neoplasm-mpn-programs 2025-12-06 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-presents-new-data-demonstrating-durable-deepening-responses-in-phase-1-trial-of-bexobrutideg-nx-5948-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-at-the-67th-american-society-of-hematology-ash-annual-meeting-and-exposition 2025-12-06 https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-showcases-leadership-in-hematology-oncology-mrd-with-new-clonoseqr-data-driving-treatment-interventions-at-2025-ash-annual-meeting 2025-12-06 https://biopharmsignal.com/news/ARVN/arvinas-presents-preclinical-data-supporting-mechanistic-synergies-and-enhanced-antitumor-activity-with-the-combination-of-arv-393-and-glofitamab-at-the-2025-american-society-of-hematology-annual-meeting-and-exposition 2025-12-06 https://biopharmsignal.com/news/IRON/disc-medicine-presents-positive-initial-data-from-rally-mf-phase-2-trial-in-patients-with-myelofibrosis-mf-and-anemia-at-the-67th-american-society-of-hematology-ash-annual-meeting 2025-12-06 https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-updated-data-from-beacon-phase-1-2-trial-of-ristoglogene-autogetemcel-risto-cel-highlighting-durable-differentiated-profile-in-sickle-cell-disease-scd-at-american-society-of-hematology-ash-annual-meeting 2025-12-06 https://biopharmsignal.com/news/APTO/aptose-s-tuspetinib-triple-drug-therapy-featured-at-the-2025-ash-annual-meeting-high-rate-of-frontline-clinical-responses-continues-across-aml-populations 2025-12-06 https://biopharmsignal.com/news/CARM/carisma-announces-delisting-from-nasdaq-and-sec-deregistration 2025-12-05 https://biopharmsignal.com/news/PRPO/precipio-to-showcase-its-bcr-abl1-panel-at-2025-ash-american-society-of-hematolo-079a3f9d 2025-12-05 https://biopharmsignal.com/news/AEMD/aethlon-medical-announces-pricing-of-a-private-placement-and-warrant-inducement-priced-at-the-market-for-aggregate-gross-proceeds-of-3-3-million 2025-12-05 https://biopharmsignal.com/news/CGON/new-cretostimogene-grenadenorepvec-data-highlight-its-potential-to-become-the-ba-0943255a 2025-12-05 https://biopharmsignal.com/news/INTS/intensity-therapeutics-granted-180-day-extension-to-regain-compliance-with-nasdaq-s-minimum-bid-price-requirement 2025-12-05 https://biopharmsignal.com/news/BMEA/biomea-fusion-presents-covalent-111-study-results-at-the-23rd-world-congress-on-insulin-resistance-diabetes-and-cardiovascular-disease-wcirdc 2025-12-05 https://biopharmsignal.com/news/IRIX/iridex-to-present-at-the-sidoti-year-end-virtual-investor-conference 2025-12-05 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-pricing-of-150-million-public-offering-of-common-stock 2025-12-05 https://biopharmsignal.com/news/IMTX/immatics-announces-125-million-underwritten-offering 2025-12-05 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-s-breyanzi-approved-by-the-u-s-fda-as-the-first-and-only-car-t-cell-therapy-for-adults-with-relapsed-or-refractory-marginal-zone-lymphoma-mzl 2025-12-05 https://biopharmsignal.com/news/AVAH/aveanna-to-participate-at-the-bofa-securities-home-care-conference 2025-12-04 https://biopharmsignal.com/news/CRVO/cervomed-announces-late-breaking-data-at-the-18th-ctad-conference-demonstrating--081898b3 2025-12-04 https://biopharmsignal.com/news/COO/coopercompanies-announces-new-chair-of-the-board-and-strategic-review-3d2e2ebe 2025-12-04 https://biopharmsignal.com/news/COO/coopercompanies-announces-fourth-quarter-and-full-year-2025-results-3a321bcd 2025-12-04 https://biopharmsignal.com/news/VRAX/virax-biolabs-group-limited-announces-closing-of-5-million-private-placement 2025-12-04 https://biopharmsignal.com/news/BFRI/last-patient-completes-biofrontera-s-phase-1-pharmacokinetics-study-of-ameluz-fo-12e41843 2025-12-04 https://biopharmsignal.com/news/SNTI/senti-bio-to-host-conference-call-and-webcast-to-discuss-senti-202-clinical-data-53746b0e 2025-12-04 https://biopharmsignal.com/news/VERU/veru-to-present-at-the-society-on-sarcopenia-cachexia-and-wasting-disorders-18th-international-conference-and-regulatory-and-clinical-trials-update-regulatory-workshop 2025-12-04 https://biopharmsignal.com/news/HRTX/heron-therapeutics-announces-inclusion-of-aponvie-aprepitant-injectable-emulsion-d30e00d8 2025-12-04 https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-fireside-chat-on-december-11-to-discuss-rain-token-st-22a8f3f3 2025-12-04 https://biopharmsignal.com/news/PRPO/precipio-identifies-unauthorized-access-to-isolated-storage-no-operational-impac-664039be 2025-12-04 https://biopharmsignal.com/news/DRMA/a-new-realm-of-skincare-is-coming-dermata-teases-new-otc-brand-identity 2025-12-04 https://biopharmsignal.com/news/INTS/intensity-therapeutics-announces-two-presentations-at-the-upcoming-2025-san-antonio-breast-cancer-symposium 2025-12-04 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-interim-data-from-pln-101095-in-patients-with-immune-checkpoint-inhibitor-refractory-advanced-solid-tumors 2025-12-04 https://biopharmsignal.com/news/PPBT/purple-biotech-to-present-new-preclinical-data-from-its-captn-3-tri-specific-ant-4c30ed05 2025-12-04 https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-acceptance-of-vmt-net-data-for-presentation-a-073e9401 2025-12-04 https://biopharmsignal.com/news/DNLI/denali-therapeutics-and-royalty-pharma-announce-275-million-royalty-funding-agre-827a5e25 2025-12-04 https://biopharmsignal.com/news/ADXN/addex-therapeutics-reports-2025-third-quarter-financial-results-and-provides-cor-9c737f8d 2025-12-04 https://biopharmsignal.com/news/APLS/the-new-england-journal-of-medicine-publishes-positive-phase-3-valiant-results-of-empavelir-pegcetacoplan-for-c3g-and-primary-ic-mpgn 2025-12-03 https://biopharmsignal.com/news/LUNG/pulmonx-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2025-12-03 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-the-passing-of-board-member-william-g-harris-e3d97377 2025-12-03 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-the-bank-of-america-securities-2025-cns-therapeutics-virtual-conference 2025-12-03 https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-virtual-2025-research-and-development-randd-day-on-wednesday-december-10-2025 2025-12-03 https://biopharmsignal.com/news/VRAX/virax-biolabs-group-limited-announces-5-million-private-placement 2025-12-03 https://biopharmsignal.com/news/PYPD/polypid-announces-positive-fda-pre-nda-meeting-minutes-for-d-plex-supporting-nda-submission 2025-12-03 https://biopharmsignal.com/news/BDSX/biodesix-to-present-new-data-at-two-major-upcoming-scientific-meetings-7b58ae02 2025-12-03 https://biopharmsignal.com/news/IXHL/incannex-granted-fda-fast-track-designation-for-ihl-42x-in-obstructive-sleep-apn-55bb137d 2025-12-03 https://biopharmsignal.com/news/BCDA/biocardia-announces-election-of-new-board-director-marvin-slosman-and-completion-864ecafe 2025-12-03 https://biopharmsignal.com/news/CLNN/clene-announces-statistically-significant-als-biomarker-results-supporting-accel-531c35e2 2025-12-03 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-announces-approval-and-commercial-launch-of-apyx-one-co-14529e99 2025-12-03 https://biopharmsignal.com/news/ANVS/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group-25bf6caf 2025-12-03 https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-first-cohort-of-patients-dosed-in-phase-1-trial-of-str-ed797a3d 2025-12-03 https://biopharmsignal.com/news/VRAX/virax-biolabs-ceo-james-foster-outlines-clinical-progress-and-2026-priorities-in-latest-annual-letter-to-shareholders 2025-12-03 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-reaches-full-enrollment-in-expanded-access-program-for-ze-b7ab9f4b 2025-12-03 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-announces-presentation-of-ndv-01-phase-2-data-at-the-society-for-urologic-oncology 2025-12-03 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-preliminary-phase-2-data-for-silevertinib-in-1l-nsclc-and-plans-for-a-phase-2-trial-of-silevertinib-in-gbm 2025-12-03 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-continuation-of-adept-2-phase-3-study-in-psychosis-associated-with-alzheimer-s-disease 2025-12-03 https://biopharmsignal.com/news/PHVS/pharvaris-announces-positive-topline-data-from-rapide-3-pivotal-study-confirming-77f9ccda 2025-12-03 https://biopharmsignal.com/news/IMRN/immuron-new-u-s-department-of-defense-award-clinical-trial-update-cb3a50ba 2025-12-03 https://biopharmsignal.com/news/CLNN/clene-to-provide-cnm-au8-als-program-update-8c6e17c6 2025-12-02 https://biopharmsignal.com/news/ACHC/acadia-healthcare-updates-plgl-reserves-following-annual-actuarial-review-lowers-2025-guidance 2025-12-02 https://biopharmsignal.com/news/PIII/p3-expands-footprint-through-joint-venture-with-commonwealth-primary-care-aco 2025-12-02 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update 2025-12-02 https://biopharmsignal.com/news/BFRI/biofrontera-inc-announces-filing-of-supplemental-new-drug-application-snda-for-t-eee77c8b 2025-12-02 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-scheduling-of-type-c-meeting-with-u-s-food-and-drug-admini-667d97d3 2025-12-02 https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-host-investor-event-to-review-new-clinical-data-from-the-3b7eb9c0 2025-12-02 https://biopharmsignal.com/news/ICU/seastar-medical-announces-fda-approval-of-reduction-in-mandatory-enrollment-for--b71ae82e 2025-12-02 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-receives-u-s-fda-fast-track-designation-for-st-503-for-the--08966e8c 2025-12-02 https://biopharmsignal.com/news/AEMD/aethlon-medical-announces-publication-of-preclinical-data-showing-that-the-gna-affinity-resin-in-the-hemopurifierr-binds-to-extracellular-vesicles-in-long-covid-patient-samples-and-decreases-inflammatory-micrornas 2025-12-02 https://biopharmsignal.com/news/IMMP/immutep-to-present-new-data-from-aipac-003-phase-ii-at-the-2025-san-antonio-brea-300b1e60 2025-12-02 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-technology-for-oligome-842f124f 2025-12-02 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-files-new-synthetic-halneuron-r-intellectual-property-protection-projected-to-extend-exclusivity-period-up-to-2045 2025-12-02 https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-nebokitug-phase-2-spring-trial-results-in-primary-sclerosing-cholangitis-published-in-the-american-journal-of-gastroenterology 2025-12-02 https://biopharmsignal.com/news/NKTX/nkarta-to-participate-in-evercore-healthcare-conference 2025-12-02 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-positive-topline-results-from-investigator-initiated-clinical-study-of-pedmarkr-in-japan-to-reduce-cisplatin-induced-hearing-loss 2025-12-02 https://biopharmsignal.com/news/OVID/ovid-therapeutics-appoints-dr-petra-kaufmann-as-chief-medical-officer-7aacd98b 2025-12-02 https://biopharmsignal.com/news/CRVO/cervomed-presents-new-plasma-biomarker-data-that-indicates-neflamapimod-broadly--68c24fb8 2025-12-02 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-positive-preliminary-data-from-etesian-study-of-briq-35eb59a2 2025-12-02 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-closing-of-60-million-public-offering-of-common-stock 2025-12-02 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-formation-of-futurevision-advisory-council-to-help-96f94c8c 2025-12-02 https://biopharmsignal.com/news/BLTE/belite-bio-announces-pricing-of-350-0-million-underwritten-public-offering-of-am-ac4cc593 2025-12-02 https://biopharmsignal.com/news/MNOV/message-from-the-ceo-to-medicinova-shareholders 2025-12-01 https://biopharmsignal.com/news/IART/integra-lifesciences-leadership-to-present-at-the-citi-2025-global-healthcare-conference 2025-12-01 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-to-host-an-investor-webinar-on-december-2nd-to-present-preli-189d4cea 2025-12-01 https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-host-in-person-and-virtual-kol-event-at-ash-2025 2025-12-01 https://biopharmsignal.com/news/ALEC/alector-to-participate-in-the-bank-of-america-cns-therapeutics-conference-a70f9878 2025-12-01 https://biopharmsignal.com/news/XTNT/xtant-medical-completes-sale-of-its-coflexr-assets-and-paradigm-ous-businesses-to-companion-spine 2025-12-01 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-to-participate-in-the-piper-sandler-healthcare-conference 2025-12-01 https://biopharmsignal.com/news/BDRX/biodexa-announces-enrolment-of-first-european-patients-into-pivotal-phase-3-sere-70399e35 2025-12-01 https://biopharmsignal.com/news/RXRX/recursion-announces-webinar-for-upcoming-clinical-data-readout-on-the-tupelo-pha-078eee75 2025-12-01 https://biopharmsignal.com/news/LENZ/lenz-therapeutics-announces-mfds-submission-of-new-drug-application-for-lnz100-vizztm-in-south-korea-for-the-treatment-of-presbyopia 2025-12-01 https://biopharmsignal.com/news/COCP/cocrystal-pharma-to-present-at-the-noble-capital-markets-21st-emerging-growth-eq-705adce5 2025-12-01 https://biopharmsignal.com/news/PRQR/proqr-to-participate-in-8th-annual-evercore-healthcare-conference-8fd3adf3 2025-12-01 https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-1-for-10-reverse-stock-split-506ed8b5 2025-12-01 https://biopharmsignal.com/news/PMN/promis-neurosciences-announces-new-peer-reviewed-publication-showing-plasma-ptau-50ebc7d5 2025-12-01 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-presents-phase-3-plan-for-zervimesine-ct1812-in-alzheimer-f82d9614 2025-12-01 https://biopharmsignal.com/news/ALT/altimmune-announces-ceo-transition-and-succession-plan-22f23576 2025-12-01 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-webcast-to-review-new-and-updated-data-from-the-phase-1-clinical-trial-of-btk-degrader-bexobrutideg-nx-5948-to-be-presented-at-the-67th-american-society-of-hematology-ash-annual-meeting-and-exposition 2025-12-01 https://biopharmsignal.com/news/PMN/promis-neurosciences-to-participate-in-the-8th-annual-evercore-healthcare-confer-1cc8a7f7 2025-12-01 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-the-37th-annual-piper-sandler-healthcar-4510b546 2025-12-01 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-receives-fda-fast-track-designation-for-cln-049-a-novel-fl-17acb520 2025-12-01 https://biopharmsignal.com/news/AUTL/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors-c5ad4695 2025-12-01 https://biopharmsignal.com/news/XERS/xeris-announces-notice-of-allowance-from-u-s-patent-and-trademark-office-for-xp-8121-patent-application 2025-12-01 https://biopharmsignal.com/news/GSK/gsk-data-at-ash-show-potential-to-redefine-outcomes-for-people-living-with-blood-cancers 2025-12-01 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-data-at-ash-2025-showcase-potential-of-hematology-pipeline-and-build-momentum-for-next-generation-portfolio 2025-12-01 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-announces-board-transition-cf3475b5 2025-12-01 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-granted-u-s-patent-covering-additional-formulations-for-the-kio-100-family-of-anti-inflammatory-compounds 2025-12-01 https://biopharmsignal.com/news/ADXN/addex-therapeutics-to-report-2025-third-quarter-financial-results-and-host-confe-48097b1c 2025-12-01 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-pricing-of-60-million-public-offering-of-common-stock 2025-11-28 https://biopharmsignal.com/news/LEGN/legend-biotech-awarded-2025-fiba-foreign-investor-of-the-year-by-flanders-invest-1cca3105 2025-11-27 https://biopharmsignal.com/news/CELC/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-57ae9938 2025-11-26 https://biopharmsignal.com/news/RIGL/rigel-to-present-at-the-piper-sandler-37th-annual-healthcare-conference 2025-11-26 https://biopharmsignal.com/news/ENLV/enlivex-announces-closing-of-previously-announced-212-000-000-private-placement-5a128931 2025-11-26 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-to-participate-in-piper-sandler-37th-annual-healthcare-confe-bd9a2767 2025-11-26 https://biopharmsignal.com/news/GNLX/genelux-corporation-to-participate-in-a-fireside-chat-at-piper-sandler-37th-annu-51b34384 2025-11-26 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-8th-annual-evercore-healthcare-conference-05824d31 2025-11-26 https://biopharmsignal.com/news/PRPH/join-prophase-labs-exclusive-live-investor-webinar-and-qanda-session-on-december-1 2025-11-26 https://biopharmsignal.com/news/ALT/altimmune-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference-fc2f17f6 2025-11-26 https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-evercore-healthcare-conference-26d99430 2025-11-26 https://biopharmsignal.com/news/CELC/celcuity-to-present-at-upcoming-8th-annual-evercore-healthcare-conference-b46d6251 2025-11-26 https://biopharmsignal.com/news/TNGX/tango-therapeutics-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference 2025-11-26 https://biopharmsignal.com/news/ARVN/arvinas-to-present-at-piper-sandler-37th-annual-healthcare-conference 2025-11-26 https://biopharmsignal.com/news/CGON/cg-oncology-announces-new-board-member-and-board-transition-05cdc2c3 2025-11-26 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-citi-s-2025-global-healthcare-conference 2025-11-26 https://biopharmsignal.com/news/CGON/cg-oncology-to-present-results-on-cretostimogene-grenadenorepvec-at-the-society--275b1cf0 2025-11-25 https://biopharmsignal.com/news/MGNX/macrogenics-to-participate-in-the-8th-annual-evercore-healthcare-conference 2025-11-25 https://biopharmsignal.com/news/IPSC/century-therapeutics-to-participate-in-piper-sandler-37th-annual-healthcare-conf-4361fd95 2025-11-25 https://biopharmsignal.com/news/PMCB/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment 2025-11-25 https://biopharmsignal.com/news/IART/integra-lifesciences-welcomes-policy-advancements-supporting-medicare-beneficiary-access 2025-11-25 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-acquires-liora-technologies-proprietary-proton-therapy-platform-for-cancer-treatment 2025-11-25 https://biopharmsignal.com/news/PRME/prime-medicine-to-present-at-8th-annual-evercore-healthcare-conference 2025-11-25 https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-december-investor-events-0fdc5c96 2025-11-25 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-piper-sandler-37th-annual-healthcare--8ec6e82f 2025-11-25 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-december-investor-conferences 2025-11-25 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-to-participate-in-upcoming-investor-events-in-december 2025-11-25 https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-to-participate-in-upcoming-investor-conferences 2025-11-25 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-8th-annual-evercore-healthcare-conference 2025-11-25 https://biopharmsignal.com/news/TENX/tenax-therapeutics-to-participate-in-upcoming-investor-conferences-2811537b 2025-11-25 https://biopharmsignal.com/news/CCCC/c4-therapeutics-to-participate-in-the-8th-annual-evercore-healthcare-conference-409f1b8d 2025-11-25 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-to-participate-in-the-8th-annual-evercore-healthcare-conference 2025-11-25 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-1-million-award-by-als-association-to-study-the-efficacy-safety-and-tolerability-of-pas-004-for-treatment-of-als 2025-11-25 https://biopharmsignal.com/news/INVA/innoviva-to-participate-in-the-37th-annual-piper-sandler-healthcare-conference 2025-11-25 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-present-at-the-piper-sandler-37th-annual-healthcare-confe-af00c677 2025-11-25 https://biopharmsignal.com/news/EMBC/embecta-corp-reports-fiscal-2025-fourth-quarter-and-full-year-financial-results-provides-initial-fiscal-year-2026-financial-guidance 2025-11-25 https://biopharmsignal.com/news/AUTL/nice-recommends-aucatzyl-obecabtagene-autoleucel-as-a-treatment-option-for-adult-ba440e10 2025-11-25 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-approval-from-the-european-commission-to-expand-use-of-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-mantle-cell-lymphoma 2025-11-24 https://biopharmsignal.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conference 2025-11-24 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-present-at-piper-sandler-37th-annual-healthcare-conferen-6d4ff210 2025-11-24 https://biopharmsignal.com/news/RCEL/avita-medical-to-present-at-the-piper-sandler-37-annual-healthcare-conference-aef4ebe0 2025-11-24 https://biopharmsignal.com/news/IBIO/ibio-to-participate-in-the-8th-annual-evercore-healthcare-conference 2025-11-24 https://biopharmsignal.com/news/RANI/rani-therapeutics-to-participate-in-the-evercore-healthcare-conference 2025-11-24 https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-december-2025-investor-conferences 2025-11-24 https://biopharmsignal.com/news/PIII/p3-health-partners-to-present-at-the-noble-capital-markets-21st-annual-emerging-growth-equity-conference 2025-11-24 https://biopharmsignal.com/news/LCTX/lineage-achieves-first-milestone-under-worldwide-collaboration-agreement-with-genentech 2025-11-24 https://biopharmsignal.com/news/ENLV/enlivex-appoints-former-italy-prime-minister-matteo-renzi-to-board-of-directors-80bd7a9f 2025-11-24 https://biopharmsignal.com/news/STXS/stereotaxis-to-participate-in-piper-sandler-37th-annual-healthcare-conference-c318e86f 2025-11-24 https://biopharmsignal.com/news/BDRX/biodexa-activates-first-european-site-for-registrational-phase-3-serenta-trial-i-f57160d2 2025-11-24 https://biopharmsignal.com/news/DAWN/day-one-announces-three-year-follow-up-data-from-ojemdatm-tovorafenib-phase-2-firefly-1-trial-at-the-2025-society-for-neuro-oncology-sno-annual-meeting 2025-11-24 https://biopharmsignal.com/news/PMN/promis-neurosciences-announces-reverse-stock-split-93e27e88 2025-11-24 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-to-present-at-the-piper-sandler-37th-annual-healthcare-confe-501707bc 2025-11-24 https://biopharmsignal.com/news/ANVS/annovis-announces-two-presentations-at-the-ctad-2025-conference-db6e55f7 2025-11-24 https://biopharmsignal.com/news/CMMB/chemomab-to-participate-in-oppenheimer-s-movers-in-rare-disease-summit 2025-11-24 https://biopharmsignal.com/news/ENLV/enlivex-announces-212-000-000-private-placement-to-initiate-world-s-first-predic-cff41ea8 2025-11-24 https://biopharmsignal.com/news/CLSD/clearside-biomedical-to-pursue-strategic-sale-of-its-business-through-voluntary-chapter-11-process 2025-11-24 https://biopharmsignal.com/news/CRVO/cervomed-to-share-new-data-on-neflamapimod-as-a-treatment-for-dementia-with-lewy-c99c0f3f 2025-11-24 https://biopharmsignal.com/news/HROW/harrow-to-present-at-two-investor-conferences-in-december-c6ad2c86 2025-11-24 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-completion-of-cohort-7-in-ongoing-phase-1-trial-of-pas-004-in-advanced-cancer-patients-with-positive-safety-pharmacokinetic-pk-and-pharmacodynamic-pd-data 2025-11-24 https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-participate-in-piper-sandler-healthcare-conference 2025-11-24 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-host-hematology-focused-investor-event 2025-11-24 https://biopharmsignal.com/news/ENLV/enlivex-announces-positive-6-month-topline-data-demonstrating-durable-and-persis-5eb2c0d4 2025-11-24 https://biopharmsignal.com/news/GNTA/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial 2025-11-24 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference 2025-11-21 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-positive-pas-004-tablet-pharmacokinetic-pk-data-in-ongoing-phase-1-1b-trial-in-adult-nf1-patients 2025-11-21 https://biopharmsignal.com/news/IRTC/18-aphrs2025-irhythm-zio-c7866645 2025-11-21 https://biopharmsignal.com/news/IRTC/new-data-at-the-asia-pacific-heart-rhythm-society-aphrs-2025-highlight-the-perfo-ff33482d 2025-11-21 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-announces-fda-acceptance-of-bla-rolling-submission-request--03716dc2 2025-11-21 https://biopharmsignal.com/news/BCAB/bioatla-enters-into-agreements-for-up-to-22-5-million-flexible-financing-33b8bcad 2025-11-21 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-pricing-of-100-million-public-offering-of-common-stock-and-pre-funded-warrants 2025-11-21 https://biopharmsignal.com/news/RPTX/repare-therapeutics-enters-into-support-and-voting-agreements-with-significant-shareholders-for-proposed-transaction-with-xenotherapeutics-inc 2025-11-20 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-completes-acquisition-of-irras 2025-11-20 https://biopharmsignal.com/news/EQ/equillium-to-participate-in-upcoming-investor-conferences-33acedb9 2025-11-20 https://biopharmsignal.com/news/MOH/molina-healthcare-announces-closing-of-offering-of-850-million-of-6-500-senior-notes-due-2031 2025-11-20 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants 2025-11-20 https://biopharmsignal.com/news/RXST/rxsight-inc-to-present-at-the-piper-sandler-healthcare-conference 2025-11-20 https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-present-at-upcoming-37th-annual-piper-sandler-healthcare--5cca8284 2025-11-20 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-to-participate-in-37th-annual-piper-sandler-healthcare-co-791274b7 2025-11-20 https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-final-results-of-tender-offer-0b2f30d3 2025-11-20 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-advancing-ikt-001-to-global-phase-3-study-in-pulmonary-arterial-hypertension 2025-11-20 https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-20 https://biopharmsignal.com/news/INKT/mink-therapeutics-announces-new-data-showing-mink-215-drives-potent-anti-tumor-a-87294060 2025-11-20 https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-host-virtual-kol-investor-event-to-review-ampreloxetine-phase-3-clinical-development-program-ahead-of-topline-data-in-q1-2026-on-december-8-2025 2025-11-20 https://biopharmsignal.com/news/ICU/seastar-medical-to-present-at-upcoming-noblecon21-investor-conference-e524cd6e 2025-11-20 https://biopharmsignal.com/news/PGNY/new-men-s-health-research-from-progyny-challenges-conventional-beliefs-about-fertility-knowledge-and-action 2025-11-20 https://biopharmsignal.com/news/ICUI/icu-medical-to-participate-at-the-piper-sandler-37th-annual-healthcare-conferenc-340c7525 2025-11-20 https://biopharmsignal.com/news/NXTC/nextcure-to-present-at-the-piper-sandler-37th-annual-healthcare-conference-93ce567d 2025-11-20 https://biopharmsignal.com/news/CLNN/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor--111e7723 2025-11-20 https://biopharmsignal.com/news/STTK/shattuck-labs-to-participate-in-upcoming-december-investor-conferences-429bf68f 2025-11-20 https://biopharmsignal.com/news/MDWD/mediwound-reports-third-quarter-2025-financial-results-and-provides-corporate-up-cd1bbabd 2025-11-20 https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-participate-in-upcoming-december-conferences-c7adeabb 2025-11-20 https://biopharmsignal.com/news/SGMT/sagimet-biosciences-to-participate-in-the-8th-annual-evercore-isi-healthcare-con-bb1c3933 2025-11-20 https://biopharmsignal.com/news/GANX/gain-therapeutics-presents-preclinical-gt-02287-data-at-neuroscience-2025-22ef9c5f 2025-11-20 https://biopharmsignal.com/news/GSK/tesaro-a-gsk-subsidiary-initiates-litigation-against-anaptysbio-inc 2025-11-20 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-reports-significant-revenue-growth-during-the-third-quarter-2-f7901a12 2025-11-19 https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-u-s-managed-access-program-map-for-investigational-therapy-del-zota-in-dmd44 2025-11-19 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-extends-research-and-development-collaboration-with-institute-investigator-at-scripps-research-to-advance-dnase-platform 2025-11-19 https://biopharmsignal.com/news/NERV/minerva-neurosciences-appoints-dr-inderjit-kaul-to-the-company-s-board-of-directors 2025-11-19 https://biopharmsignal.com/news/TELA/tela-bio-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference 2025-11-19 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-schedules-release-of-third-quarter-2025-financial-results-and-8cde1e52 2025-11-19 https://biopharmsignal.com/news/HCWB/hcw-biologics-enters-into-4-0-million-warrant-inducement-priced-at-the-market-un-c6bbc5a8 2025-11-19 https://biopharmsignal.com/news/PRPH/prophase-labs-reported-results-for-the-third-quarter-ended-september-30-2025-and-will-hold-a-virtual-conference-call-today-at-2pm-et 2025-11-19 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-appoints-veteran-cmc-and-technical-operations-executive-marc-26068f90 2025-11-19 https://biopharmsignal.com/news/BIVI/join-biovie-s-exclusive-live-investor-webinar-and-q-a-session-on-december-9-d7bad1d7 2025-11-19 https://biopharmsignal.com/news/ALZN/alzamend-neuro-announces-completion-of-clinical-portion-of-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-conducted-at-massachusetts-general-hospital 2025-11-19 https://biopharmsignal.com/news/SMTI/sanara-medtech-to-participate-in-the-piper-sandler-37th-annual-healthcare-confer-4f872b74 2025-11-19 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-8th-annual-evercore-healthcare-conference 2025-11-19 https://biopharmsignal.com/news/AGIO/agios-announces-topline-results-from-rise-up-phase-3-trial-of-mitapivat-in-sickl-25755a60 2025-11-19 https://biopharmsignal.com/news/SCYX/scynexis-completes-transfer-of-brexafemmer-new-drug-application-to-gsk 2025-11-19 https://biopharmsignal.com/news/GSK/gsk-and-ltz-announce-strategic-collaboration-to-advance-novel-myeloid-cell-engagers-in-oncology 2025-11-19 https://biopharmsignal.com/news/CLLS/cellectis-publishes-nature-communications-article-on-a-non-viral-gene-editing-process-enabling-efficient-gene-insertion-in-hematopoietic-stem-cells 2025-11-19 https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-preliminary-results-of-tender-offer-679d2528 2025-11-19 https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-participate-in-upcoming-investor-conferences 2025-11-19 https://biopharmsignal.com/news/APTO/aptose-biosciences-announces-arrangement-agreement-for-acquisition-by-hanmi-pharmaceutical 2025-11-19 https://biopharmsignal.com/news/SIBN/si-bone-to-present-at-piper-sandler-37th-annual-healthcare-conference-on-december-2-2025 2025-11-18 https://biopharmsignal.com/news/ELDN/eledon-reports-preliminary-data-from-first-six-patients-with-type-1-diabetes-tre-46653d7e 2025-11-18 https://biopharmsignal.com/news/TCMD/tactile-medical-to-present-at-the-piper-sandler-37th-annual-healthcare-conference 2025-11-18 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-accepted-amounts-and-pricing-terms-of-its-tender-offers 2025-11-18 https://biopharmsignal.com/news/DAWN/day-one-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference 2025-11-18 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-present-on-recruitment-strategies-for-phase-2-altitude-1e713b3a 2025-11-18 https://biopharmsignal.com/news/ATRC/atricure-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference 2025-11-18 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-announces-pricing-of-10-million-public-offering-of-comm-9d84e088 2025-11-18 https://biopharmsignal.com/news/HCWB/hcw-biologics-announces-initiation-of-first-in-human-clinical-trial-to-evaluate--779080b5 2025-11-18 https://biopharmsignal.com/news/HROW/harrow-announces-closing-of-acquisition-of-melt-pharmaceuticals-2b30a869 2025-11-18 https://biopharmsignal.com/news/TECH/bio-techne-licenses-ai-designed-novobodytm-duo-molecules-from-monod-bio-to-expand-recombinant-protein-portfolio 2025-11-18 https://biopharmsignal.com/news/MNOV/medicinova-appoints-dr-christopher-breder-md-phd-as-clinical-and-regulatory-advisor 2025-11-18 https://biopharmsignal.com/news/GSK/gsk-and-fleming-initiative-scientists-unite-to-target-amr-with-advanced-ai 2025-11-18 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-early-participation-results-amendment-and-early-settlement-of-tender-offers 2025-11-18 https://biopharmsignal.com/news/MOH/molina-healthcare-announces-pricing-of-850-million-of-6-500-senior-notes-due-2031 2025-11-17 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-appoints-mike-doyle-as-non-executive-chairman-of-the-boar-c0e452a5 2025-11-17 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-announces-proposed-public-offering-of-common-stock-d44eb6d5 2025-11-17 https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-ended-september-30-2025 2025-11-17 https://biopharmsignal.com/news/SCYX/scynexis-announces-federal-funding-of-collaboration-between-hackensack-meridian-cdi-and-johns-hopkins-researchers-to-develop-new-therapeutics-including-novel-fungerps-for-resistant-fungal-infections 2025-11-17 https://biopharmsignal.com/news/ICU/seastar-medical-announces-appointment-of-michael-messinger-as-cfo-9b717991 2025-11-17 https://biopharmsignal.com/news/MOH/molina-healthcare-announces-proposed-offering-of-750-million-of-senior-notes-due-2031 2025-11-17 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-chief-scientific-officer-dr-michael-newman-to-present-at-t-834c2934 2025-11-17 https://biopharmsignal.com/news/NXTC/nextcure-announces-closing-of-21-5-million-pipe-financing-in-advance-of-first-ha-84d4773e 2025-11-17 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-announces-first-participant-dosed-in-phase-2-open-label-e-c224fec6 2025-11-17 https://biopharmsignal.com/news/ACST/grace-therapeutics-to-participate-in-16th-annual-craig-hallum-alpha-select-conference 2025-11-17 https://biopharmsignal.com/news/OSUR/orasure-to-participate-in-upcoming-investor-conference 2025-11-17 https://biopharmsignal.com/news/ADAP/adaptimmune-announces-changes-to-board-and-executive-leadership-team 2025-11-17 https://biopharmsignal.com/news/MRUS/merus-and-halozyme-enter-global-collaboration-and-license-agreement-to-develop-subcutaneous-formulation-of-petosemtamab 2025-11-17 https://biopharmsignal.com/news/IMTX/immatics-announces-third-quarter-2025-financial-results-and-business-update 2025-11-17 https://biopharmsignal.com/news/BRTX/biorestorative-granted-type-b-meeting-with-fda-to-discuss-accelerated-bla-approv-07cf4c15 2025-11-17 https://biopharmsignal.com/news/FMS/fresenius-medical-care-places-bond-with-a-volume-of-500-million-euros 2025-11-16 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-announces-recent-business-highlights-and-third-quarter-20-fe84f151 2025-11-14 https://biopharmsignal.com/news/BNTC/benitec-biopharma-releases-first-quarter-2026-financial-results-and-provides-operational-update 2025-11-14 https://biopharmsignal.com/news/HCWB/hcw-biologics-reports-third-quarter-2025-business-highlights-and-financial-resul-b5576ce6 2025-11-14 https://biopharmsignal.com/news/RPTX/repare-therapeutics-enters-into-definitive-agreement-to-be-acquired-by-xenotherapeutics-inc 2025-11-14 https://biopharmsignal.com/news/PRPO/precipio-announces-its-q3-2025-financial-results-bb439b46 2025-11-14 https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-14 https://biopharmsignal.com/news/HCAT/health-catalyst-to-participate-in-upcoming-investor-conferences-8907e462 2025-11-14 https://biopharmsignal.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-third-quarter-2025-financial-results 2025-11-14 https://biopharmsignal.com/news/FEMY/femasys-announces-third-quarter-financial-results-for-2025-e5279fcf 2025-11-14 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-third-quarter-2025-financial-results-and-highlights-recent-activity 2025-11-14 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-provides-third-quarter-2025-financial-results-and-provides-31d93d97 2025-11-14 https://biopharmsignal.com/news/MOH/molina-healthcare-awarded-new-florida-medicaid-contract 2025-11-14 https://biopharmsignal.com/news/VCEL/vericel-to-present-at-the-stephens-annual-investment-conference-on-thursday-nove-50cdf2a9 2025-11-14 https://biopharmsignal.com/news/CGON/cg-oncology-reports-third-quarter-2025-financial-results-and-provides-business-u-59efad5d 2025-11-14 https://biopharmsignal.com/news/PPBT/purple-biotech-reports-third-quarter-2025-financial-results-and-provides-busines-9885fee6 2025-11-14 https://biopharmsignal.com/news/COCP/cocrystal-pharma-reports-third-quarter-2025-financial-results-and-provides-updat-0e2a89f0 2025-11-14 https://biopharmsignal.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-september--05dbe7c2 2025-11-14 https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-third-quarter-2025-financial-results 2025-11-14 https://biopharmsignal.com/news/INKT/mink-therapeutics-reports-q3-2025-results-and-accelerates-inkt-platform-toward-p-26e73d6c 2025-11-14 https://biopharmsignal.com/news/MRKR/marker-therapeutics-reports-third-quarter-2025-financial-results-and-provides-bu-ede25e6b 2025-11-14 https://biopharmsignal.com/news/BMY/update-on-phase-3-librexia-acs-trial 2025-11-14 https://biopharmsignal.com/news/TFX/teleflex-to-present-at-the-jefferies-global-healthcare-conference-in-london-78b44fb9 2025-11-14 https://biopharmsignal.com/news/MGRX/mangoceuticals-provides-clarification-on-launch-of-branded-glp-1-weight-manageme-9f8245ed 2025-11-14 https://biopharmsignal.com/news/FMS/fresenius-medical-care-marks-world-diabetes-day-2025-living-well-with-diabetes-and-beyond 2025-11-13 https://biopharmsignal.com/news/PIII/p3-health-partners-announces-third-quarter-2025-results 2025-11-13 https://biopharmsignal.com/news/APTO/aptose-reports-third-quarter-2025-results 2025-11-13 https://biopharmsignal.com/news/SNTI/senti-bio-reports-third-quarter-2025-financial-results-and-confirms-next-clinica-68d94b2f 2025-11-13 https://biopharmsignal.com/news/TELA/tela-bio-announces-pricing-of-13-0-million-underwritten-registered-direct-offering-of-common-stock-and-pre-funded-warrants 2025-11-13 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-third-quarter-2025-operating-results-and-provides-a-4e1ffa1e 2025-11-13 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-announces-strong-efficacy-signal-in-phase-2-trial-of-desc-ceebe7e4 2025-11-13 https://biopharmsignal.com/news/EQ/equillium-reports-third-quarter-2025-financial-results-and-provides-operational--c009d18b 2025-11-13 https://biopharmsignal.com/news/ICU/seastar-medical-reports-third-quarter-2025-financial-results-and-provides-busine-ad781857 2025-11-13 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-reports-third-quarter-2025-financial-results-and-provides-a-d23b0614 2025-11-13 https://biopharmsignal.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-september-3-e338815f 2025-11-13 https://biopharmsignal.com/news/BCAB/bioatla-reports-third-quarter-2025-financial-results-and-highlights-recent-progr-f5e6e50a 2025-11-13 https://biopharmsignal.com/news/RVPH/reviva-reports-third-quarter-2025-financial-results-and-recent-business-highligh-c9ef9de5 2025-11-13 https://biopharmsignal.com/news/MMSI/merit-medical-provides-update-on-u-s-reimbursement-and-commercial-strategies-for-77c019bf 2025-11-13 https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-reports-first-quarter-fiscal-year-2026-financial-results-and-recent-updates 2025-11-13 https://biopharmsignal.com/news/NCNA/nucana-reports-third-quarter-2025-financial-results-and-provides-business-update 2025-11-13 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-reports-third-quarter-2025-financial-results-and-provides-co-f64cfcce 2025-11-13 https://biopharmsignal.com/news/VOR/vor-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-upda-3e2e52e8 2025-11-13 https://biopharmsignal.com/news/RLMD/relmada-therapeutics-reports-third-quarter-2025-financial-results-and-provides-key-clinical-regulatory-and-corporate-updates 2025-11-13 https://biopharmsignal.com/news/PGNY/progyny-inc-to-present-at-jefferies-global-healthcare-conference 2025-11-13 https://biopharmsignal.com/news/LEGN/legend-biotech-celebrates-official-opening-of-new-state-of-the-art-cell-therapy--69bd04a0 2025-11-13 https://biopharmsignal.com/news/BTMD/nearly-40-of-women-say-they-were-misdiagnosed-during-perimenopause-national-survey-reveals 2025-11-13 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-reports-third-quarter-2025-financial-results 2025-11-13 https://biopharmsignal.com/news/SNOA/national-rosacea-society-awards-seal-of-acceptance-to-sonoma-pharmaceuticals-for-reliefacyn-advanced 2025-11-13 https://biopharmsignal.com/news/BFRI/biofrontera-inc-reports-third-quarter-2025-financial-results-and-provides-a-busi-c8150a09 2025-11-13 https://biopharmsignal.com/news/MGTX/meiragtx-reports-third-quarter-2025-financial-and-operational-results 2025-11-13 https://biopharmsignal.com/news/IMMP/translational-data-and-significant-pathologic-response-rates-from-eftisarc-neo-p-efbdb2b9 2025-11-13 https://biopharmsignal.com/news/CING/cingulate-inc-reports-third-quarter-2025-financial-results-and-provides-corporat-25e316a0 2025-11-13 https://biopharmsignal.com/news/CLNN/clene-reports-third-quarter-2025-financial-results-and-recent-operating-highligh-23fbddc2 2025-11-13 https://biopharmsignal.com/news/MNPR/monopar-therapeutics-reports-third-quarter-2025-financial-results-and-recent-developments 2025-11-13 https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-second-quarter-2026-financial-results-provides-business-update 2025-11-13 https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-present-at-the-jefferies-london-healthcare-conference 2025-11-13 https://biopharmsignal.com/news/IMNN/imunon-reports-third-quarter-2025-financial-results-and-provides-business-update-61e718db 2025-11-13 https://biopharmsignal.com/news/VANI/vivani-medical-provides-business-update-and-reports-third-quarter-2025-financial-results 2025-11-13 https://biopharmsignal.com/news/CGTX/cognition-therapeutics-completes-enrollment-in-phase-2-study-of-zervimesine-ct18-3fa8b4bd 2025-11-13 https://biopharmsignal.com/news/ABUS/arbutus-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-13 https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-third-quarter-202-393a925d 2025-11-13 https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-third-quarter-2025-financial-results-and-provides-b-c78cf5a6 2025-11-13 https://biopharmsignal.com/news/PDSB/pds-biotech-reports-third-quarter-2025-financial-results-and-provides-clinical-p-3313cfa0 2025-11-13 https://biopharmsignal.com/news/TIL/instil-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-13 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-reports-third-quarter-2025-financial-results-af8642ac 2025-11-13 https://biopharmsignal.com/news/MGRX/mangoceuticals-partners-with-eli-lilly-and-novo-nordisk-to-deliver-affordable-ac-65906891 2025-11-13 https://biopharmsignal.com/news/IPSC/century-therapeutics-announces-new-beta-islet-program-for-type-1-diabetes-a98a9765 2025-11-13 https://biopharmsignal.com/news/GOCO/gohealth-prioritizes-retention-quality-and-strategic-flexibility-as-medicare-adv-16f7a495 2025-11-13 https://biopharmsignal.com/news/DAWN/day-one-to-acquire-mersana-therapeutics-to-advance-mission-to-bring-new-medicines-to-people-of-all-ages-with-life-threatening-diseases 2025-11-13 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-announces-completion-of-enrollment-and-dosing-in-phase-1-mad-study 2025-11-13 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-participate-at-16th-annual-craig-hallum-alpha-select-con-9e0f1047 2025-11-12 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-highlights 2025-11-12 https://biopharmsignal.com/news/AEMD/aethlon-medical-announces-fiscal-q2-2025-financial-results-and-corporate-update 2025-11-12 https://biopharmsignal.com/news/LMAT/lemaitre-to-participate-in-upcoming-investor-conferences-68d11590 2025-11-12 https://biopharmsignal.com/news/LGMK/logicmark-inc-announces-third-quarter-2025-results-b345e00e 2025-11-12 https://biopharmsignal.com/news/MXCT/maxcyte-announces-planned-cfo-transition-in-2026 2025-11-12 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-third-quarter-2025 2025-11-12 https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-third-quarter-2025-financial-results-and-provides-business-update 2025-11-12 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-business-update 2025-11-12 https://biopharmsignal.com/news/LUNG/pulmonx-reports-third-quarter-2025-financial-results 2025-11-12 https://biopharmsignal.com/news/MXCT/maxcyte-reports-third-quarter-2025-financial-results-and-reiterates-full-year-2025-revenue-guidance 2025-11-12 https://biopharmsignal.com/news/TENX/tenax-therapeutics-reports-third-quarter-2025-financial-results-and-provides-cor-d040f5a9 2025-11-12 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-reports-third-quarter-2025-financial-results-and-provid-f68f789e 2025-11-12 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-third-quarter-2025-financial-results-and-provides-b-237a81ff 2025-11-12 https://biopharmsignal.com/news/SUPN/supernus-to-participate-in-the-2025-jefferies-global-healthcare-conference-in-london 2025-11-12 https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-12 https://biopharmsignal.com/news/TXMD/therapeuticsmd-announces-third-quarter-2025-financial-results 2025-11-12 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-third-quarter-financial-results-and-provides-a-business-update 2025-11-12 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-jefferies-global-healthcare-conference-in-london 2025-11-12 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-12 https://biopharmsignal.com/news/MDXH/mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-sept-0b06a333 2025-11-12 https://biopharmsignal.com/news/DERM/journey-medical-corporation-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights 2025-11-12 https://biopharmsignal.com/news/IBIO/ibio-reports-q1-fiscal-year-2026-financial-results-and-provides-corporate-update 2025-11-12 https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-and-scientific-highlights 2025-11-12 https://biopharmsignal.com/news/MGNX/macrogenics-reports-third-quarter-2025-financial-results-and-provides-update-on-corporate-progress 2025-11-12 https://biopharmsignal.com/news/STRO/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-r-d-day-fee86334 2025-11-12 https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-financial-results-and-operational-progress 2025-11-12 https://biopharmsignal.com/news/BMY/sarah-cannon-research-institute-and-bristol-myers-squibb-expand-strategic-collaboration-to-accelerate-patient-enrollment-and-broaden-access-to-innovative-cancer-research 2025-11-12 https://biopharmsignal.com/news/IMMX/immix-biopharma-appoints-chief-commercial-officer-to-drive-nxc-201-launch-521d103a 2025-11-12 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-reports-third-quarter-2025-financial-results-and-provides--c94ae201 2025-11-12 https://biopharmsignal.com/news/OGEN/oragenics-q3-2025-shareholder-update 2025-11-12 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-third-quarter-2025-financial-results-and-corporate-highlights 2025-11-12 https://biopharmsignal.com/news/NXTC/nextcure-announces-21-5-million-private-placement-of-common-stock-priced-at-the--446a01b4 2025-11-12 https://biopharmsignal.com/news/RVPH/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-fr-5d105696 2025-11-12 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-announces-pricing-of-50-million-underwritten-public-offer-0ab5acaf 2025-11-12 https://biopharmsignal.com/news/CRMD/cormedix-inc-reports-third-quarter-2025-financial-results-and-updates-fy-2025-gu-6d2295ad 2025-11-12 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-reports-third-quarter-2025-financial-results-and-corporate-updates 2025-11-12 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-to-present-at-the-bell-potter-healthcare-virtual-conferenc-c3ecdbc4 2025-11-12 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-announces-third-quarter-2025-financial-results-and-provides-business-update 2025-11-12 https://biopharmsignal.com/news/PEPG/pepgen-announces-issuance-of-u-s-patent-for-proprietary-pgn-edodm1-molecule 2025-11-12 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-12 https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-participate-in-2025-jefferies-london-healthcare-conference 2025-11-12 https://biopharmsignal.com/news/IMTX/immatics-achieves-clinical-proof-of-concept-of-its-next-generation-tcr-bispecific-tcerr-pipeline-with-data-on-ima402-prame-and-ima401-magea4-8-and-announces-next-development-steps 2025-11-12 https://biopharmsignal.com/news/OVID/ovid-therapeutics-announces-planned-leadership-succession-and-reports-business-u-6a0a8f39 2025-11-12 https://biopharmsignal.com/news/PMN/promis-neurosciences-announces-third-quarter-2025-financial-results-corporate-hi-91611cca 2025-11-12 https://biopharmsignal.com/news/BYSI/beyondspring-reports-third-quarter-2025-financial-results-and-provides-corporate-744a0444 2025-11-12 https://biopharmsignal.com/news/GANX/gain-therapeutics-reports-financial-results-for-third-quarter-2025-and-provides--a6cea32f 2025-11-12 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-reports-third-quarter-2025-financial-results-unaudited-7780a31e 2025-11-12 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-reports-third-quarter-2025-financial-results-and-business-e685ba4f 2025-11-12 https://biopharmsignal.com/news/PEPG/pepgen-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights 2025-11-12 https://biopharmsignal.com/news/PHVS/pharvaris-reports-third-quarter-2025-financial-results-and-provides-business-upd-a6c02612 2025-11-12 https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-pricing-of-250-000-000-public-offering-of-american-depositary-shares 2025-11-12 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-announces-proposed-underwritten-public-offering-of-common-28c7f470 2025-11-11 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-announces-strategic-realignment-to-focus-on-surgical-business-ce0a5e8e 2025-11-11 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference-lon-033e0567 2025-11-11 https://biopharmsignal.com/news/IRIX/iridex-reports-third-quarter-2025-financial-results 2025-11-11 https://biopharmsignal.com/news/STXS/stereotaxis-reports-2025-third-quarter-financial-results-ff60ac76 2025-11-11 https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-proposed-public-offering-of-american-depositary-shares 2025-11-11 https://biopharmsignal.com/news/PDSB/pds-biotechnology-announces-up-to-11-1-million-registered-direct-offering-56402bf6 2025-11-11 https://biopharmsignal.com/news/GOCO/gohealth-to-announce-third-quarter-2025-results-on-november-13-2025-67798cda 2025-11-11 https://biopharmsignal.com/news/XGN/exagen-inc-to-participate-in-fourth-quarter-investor-conferences 2025-11-11 https://biopharmsignal.com/news/ALT/altimmune-announces-publication-of-impact-phase-2b-trial-data-in-the-lancet-and--9b712b3d 2025-11-11 https://biopharmsignal.com/news/VIRI/dogwood-announces-enrollment-of-first-100-patients-in-ongoing-halneuron-r-phase-2b-trial-interim-sample-size-analysis-on-track-for-december-2025 2025-11-11 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-announces-achievement-of-topical-rapamycin-target-loadings-f6d0ca0f 2025-11-11 https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-abstract-accepted-for-presentation-at-society-of-vascular-and-interventional-neurology-annual-meeting 2025-11-11 https://biopharmsignal.com/news/IRTC/irhythm-technologies-announces-publication-of-large-scale-study-in-heart-rhythm--eac73517 2025-11-11 https://biopharmsignal.com/news/SGHT/new-peer-reviewed-publications-highlight-effectiveness-of-omnir-surgical-system-with-trusynctm-technology-in-reducing-iop-and-medication-usage-in-cataract-combination-procedures-standalone-procedures-and-in-african-americans 2025-11-11 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-entry-into-100-million-accelerated-share-repurchas-9745faee 2025-11-11 https://biopharmsignal.com/news/ACIU/ac-immune-to-present-at-the-jefferies-2025-london-healthcare-conference-a3e7244f 2025-11-11 https://biopharmsignal.com/news/VOR/vor-bio-announces-pricing-of-public-offering-of-100-million-of-common-stock-f0163f70 2025-11-11 https://biopharmsignal.com/news/XTNT/xtant-medical-reports-third-quarter-2025-financial-results 2025-11-10 https://biopharmsignal.com/news/PROK/prokidney-reports-third-quarter-2025-financial-results-and-provides-regulatory-and-clinical-updates 2025-11-10 https://biopharmsignal.com/news/PASG/passage-bio-reports-third-quarter-2025-financial-results-and-provides-recent-business-highlights 2025-11-10 https://biopharmsignal.com/news/ASMB/assembly-biosciences-reports-third-quarter-2025-financial-results-and-recent-updates 2025-11-10 https://biopharmsignal.com/news/NKTX/nkarta-reports-third-quarter-2025-financial-results-and-corporate-highlights 2025-11-10 https://biopharmsignal.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-third-quarter-2025-and-raises-2025-guidance 2025-11-10 https://biopharmsignal.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-3q-2025-33883709 2025-11-10 https://biopharmsignal.com/news/STXS/genesisx-robotic-magnetic-navigation-system-receives-u-s-fda-clearance-15c4e9bf 2025-11-10 https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-reports-third-quarter-2025-financial-results-and-operat-deea8fd0 2025-11-10 https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-10 https://biopharmsignal.com/news/RNA/avidity-biosciences-reports-third-quarter-2025-financial-results-and-recent-highlights 2025-11-10 https://biopharmsignal.com/news/OM/outset-medical-reports-third-quarter-results 2025-11-10 https://biopharmsignal.com/news/HCAT/health-catalyst-reports-third-quarter-2025-results-c9c53cf9 2025-11-10 https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-third-quarter-2025-financial-results-and-provides-corpor-8da8f309 2025-11-10 https://biopharmsignal.com/news/CLDX/celldex-reports-third-quarter-2025-financial-results-and-provides-corporate-upda-58ca59e4 2025-11-10 https://biopharmsignal.com/news/IMNN/imunon-public-webcast-highlights-resilience-and-innovation-in-pursuit-of-the-fir-87b46878 2025-11-10 https://biopharmsignal.com/news/FEMY/femasys-advances-global-growth-with-second-partner-order-for-fembloc-in-europe-0451345b 2025-11-10 https://biopharmsignal.com/news/IRMD/iradimed-corporation-named-to-time-s-list-of-america-s-growth-leaders-for-2026-9be21818 2025-11-10 https://biopharmsignal.com/news/PDSB/pds-biotechnology-announces-translational-data-showing-strong-immunological-and--7eb6442e 2025-11-10 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-in-london 2025-11-10 https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-to-participate-in-the-stifel-2025-healthcare-conference-629bd038 2025-11-10 https://biopharmsignal.com/news/APVO/aptevo-debuts-first-trispecific-antibody-candidate-apvo451-with-preclinical-data-demonstrating-immune-activation-in-hard-to-treat-solid-tumors 2025-11-10 https://biopharmsignal.com/news/VYGR/voyager-reports-third-quarter-2025-financial-and-operating-results-9a811074 2025-11-10 https://biopharmsignal.com/news/VYGR/transition-bio-and-voyager-announce-collaboration-to-advance-small-molecules-tar-9ad52912 2025-11-10 https://biopharmsignal.com/news/CLDX/celldex-announces-appointment-of-teri-lawver-as-chief-commercial-officer-9b536dd8 2025-11-10 https://biopharmsignal.com/news/CING/cingulate-names-industry-veteran-bryan-downey-chief-commercial-officer-to-lead-l-7a9b4cac 2025-11-10 https://biopharmsignal.com/news/GALT/galectin-therapeutics-presented-navigate-trial-results-at-the-american-associati-615ed26f 2025-11-10 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-third-quarter-2025-financial-results-and-provides-co-a3014eb3 2025-11-10 https://biopharmsignal.com/news/RVPH/reviva-announces-grant-of-european-patent-covering-use-of-brilaroxazine-for-the--e01af84c 2025-11-10 https://biopharmsignal.com/news/SENS/senseonics-announces-transfer-to-nasdaq-stock-exchange-55b174bc 2025-11-10 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-appoints-george-golumbeski-ph-d-as-chairman-of-its-board--6052a822 2025-11-10 https://biopharmsignal.com/news/ATYR/atyr-pharma-to-present-at-piper-sandler-37th-annual-healthcare-conference 2025-11-10 https://biopharmsignal.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial-results 2025-11-10 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-acquires-exclusive-global-rights-to-a-next-generation-car-t-cell-product-candidate-in-clinical-development-for-metastatic-colorectal-cancer 2025-11-10 https://biopharmsignal.com/news/IMNN/imunon-r-d-day-showcases-clinical-progress-of-its-novel-immunotherapy-phase-3-tr-f604a0ec 2025-11-10 https://biopharmsignal.com/news/IFRX/inflarx-reports-positive-phase-2a-data-for-inf904-in-hidradenitis-suppurative-hs-7834825e 2025-11-10 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-corporate-update-advancing-clinical-milestones-and-strategic-partnerships 2025-11-10 https://biopharmsignal.com/news/CABA/cabaletta-bio-reports-third-quarter-2025-financial-results-and-provides-business-update 2025-11-10 https://biopharmsignal.com/news/ATHE/alterity-therapeutics-presents-promising-impact-of-ath434-on-orthostatic-hypoten-aff298b9 2025-11-10 https://biopharmsignal.com/news/APGE/apogee-therapeutics-provides-pipeline-progress-and-reports-third-quarter-2025-fi-76077537 2025-11-10 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-strong-third-quarter-2025-results-raises-full-year-2025-financial-guidance 2025-11-10 https://biopharmsignal.com/news/ROIV/roivant-reports-financial-results-for-the-second-quarter-ended-september-30-2025-and-provides-business-update 2025-11-10 https://biopharmsignal.com/news/DAWN/day-one-announces-new-ojemdatm-tovorafenib-data-to-be-presented-in-oral-session-at-the-2025-society-for-neuro-oncology-sno-annual-meeting 2025-11-10 https://biopharmsignal.com/news/MGTX/meiragtx-enters-into-strategic-collaboration-with-eli-lilly-and-company-to-develop-and-commercialize-genetic-medicines-in-ophthalmology 2025-11-10 https://biopharmsignal.com/news/APGE/apogee-therapeutics-announces-positive-interim-phase-1-results-from-healthy-volu-99855942 2025-11-10 https://biopharmsignal.com/news/CRVO/cervomed-reports-third-quarter-2025-financial-results-and-provides-corporate-upd-8f5b91dc 2025-11-10 https://biopharmsignal.com/news/HCWB/hcw-biologics-shares-the-latest-data-for-its-second-generation-immune-checkpoint-f64b740d 2025-11-10 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-and-host-a-99ee04a2 2025-11-10 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-third-quarter-2025-results-and-business-updates-0f433bdc 2025-11-10 https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-research-collaboration-with-gsk-to-advance-boron-based-leurs-inhibitors-targeting-tuberculosis-tb 2025-11-10 https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-second-quarter-ended-september-30-2025 2025-11-10 https://biopharmsignal.com/news/PHVS/data-supporting-the-potentially-differentiated-pharvaris-portfolio-presented-at--294e63b7 2025-11-10 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights--0a2d138e 2025-11-10 https://biopharmsignal.com/news/AMRN/new-reduce-it-aspirin-analysis-presented-at-aha-scientific-sessions-2025-reinfor-e2db5ba1 2025-11-09 https://biopharmsignal.com/news/MNPR/monopar-presents-new-data-and-analyses-on-rapidly-improved-copper-balance-in-wilson-disease-patients-on-tiomolybdate-choline-at-aasld-the-liver-meetingr-2025 2025-11-09 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-aha-scientific-sessions-202-3f3b9b88 2025-11-08 https://biopharmsignal.com/news/REPL/replimune-presents-late-breaking-abstract-and-additional-posters-on-rp1-at-40th-annual-meeting-of-the-society-for-the-immunotherapy-of-cancer-sitc-2025 2025-11-07 https://biopharmsignal.com/news/CLLS/cellectis-reports-third-quarter-2025-financial-results-and-provides-business-update 2025-11-07 https://biopharmsignal.com/news/ARDX/real-world-evidence-studies-of-xphozah-tenapanor-demonstrate-patient-satisfactio-1d6772be 2025-11-07 https://biopharmsignal.com/news/FLGT/fulgent-to-participate-in-upcoming-conferences 2025-11-07 https://biopharmsignal.com/news/XCUR/exicure-inc-reports-third-quarter-2025-financial-results-fa014eba 2025-11-07 https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-late-breaking-phase-2-data-for-vilastobart-in-patie-5a59f778 2025-11-07 https://biopharmsignal.com/news/XLO/xilio-therapeutics-highlights-portfolio-of-differentiated-masked-immunotherapies-2489f3a2 2025-11-07 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-reports-robust-cytolytic-mkras-specific-t-cell-responses-acr-d85095e7 2025-11-07 https://biopharmsignal.com/news/INKT/mink-therapeutics-reports-durable-responses-and-immune-reactivation-with-allo-in-31934d1d 2025-11-07 https://biopharmsignal.com/news/BCAB/bioatla-s-mecbotamab-vedotin-mec-v-an-axl-targeting-adc-demonstrates-a-median-ov-ff6fb560 2025-11-07 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-presents-data-expanding-its-predator-platform-at-the-socie-3c7338de 2025-11-07 https://biopharmsignal.com/news/TMCI/treace-announces-participation-in-two-upcoming-investor-conferences 2025-11-07 https://biopharmsignal.com/news/IMNN/imunon-r-d-day-opportunity-to-hear-clinical-trial-investigators-discuss-signific-053db62c 2025-11-07 https://biopharmsignal.com/news/AEMD/aethlon-medical-to-release-fiscal-second-quarter-financial-results-and-host-conference-call-on-november-12-2025 2025-11-07 https://biopharmsignal.com/news/ASMB/assembly-biosciences-presents-positive-phase-1b-data-for-next-generation-capsid-assembly-modulator-abi-4334-at-aasld-the-liver-meetingr 2025-11-07 https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-presents-new-data-supporting-the-fixed-dose-combination-of-bemnifosbuvir-and-ruzasvir-as-a-potential-best-in-class-regimen-for-treatment-of-hepatitis-c-virus-infection-at-the-liver-meetingr-2025 2025-11-07 https://biopharmsignal.com/news/BFRI/biofrontera-inc-announces-sale-of-license-to-xepi-antibiotic-cream-to-pelthos-th-d8cd7081 2025-11-07 https://biopharmsignal.com/news/GSK/gsk-presents-data-from-its-advancing-liver-pipeline-at-aasld-2025 2025-11-07 https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-third-quarter-2025-financial-results-and-updates-on-corporate-developments 2025-11-07 https://biopharmsignal.com/news/CNTX/context-therapeutics-highlights-ct-95-and-ct-202-programs-at-2025-sitc-annual-meeting 2025-11-07 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-date-of-third-quarter-financial-results-and-upcoming-investor-conference-participation 2025-11-07 https://biopharmsignal.com/news/FLGT/fulgent-reports-third-quarter-2025-financial-results 2025-11-07 https://biopharmsignal.com/news/PRME/prime-medicine-reports-third-quarter-2025-financial-results-and-provides-business-updates 2025-11-07 https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-reports-record-third-quarter-2025-financial-results-and-rais-249b97a3 2025-11-07 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-reports-third-quarter-2025-financial-results-announces-record-multi-system-customer-order-and-raises-full-year-revenue-and-system-placement-guidance 2025-11-07 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-reports-third-quarter-2025-and-year-to-date-financial-results--971af5d5 2025-11-07 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-third-quarter-2025-and-year-to-date-financial-results-and-provides-business-update 2025-11-07 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-reports-third-quarter-fiscal-2025-results-161558b4 2025-11-07 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-third-quarter-2025-results-company-advances-pipeline-with-two-actively-enrolling-phase-2-clinical-trials-for-retinal-diseases 2025-11-07 https://biopharmsignal.com/news/ELDN/eledon-presents-phase-2-bestow-trial-results-for-tegoprubart-for-the-prevention--e399dfc2 2025-11-06 https://biopharmsignal.com/news/MNOV/medicinova-wins-contract-research-and-development-innovation-award-at-2025-biotech-breakthrough-awards 2025-11-06 https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-participate-in-fireside-chat-at-evercore-healthconx-conference 2025-11-06 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-reports-third-quarter-2025-results 2025-11-06 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-announces-agreement-to-acquire-irras 2025-11-06 https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-third-quarter-2025-financial-results-provides-corporate-update 2025-11-06 https://biopharmsignal.com/news/STTK/shattuck-labs-reports-third-quarter-2025-financial-results-and-recent-business-h-bdcd3e52 2025-11-06 https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-third-quarter-2025-financial-results-and-business-highli-595bd4b8 2025-11-06 https://biopharmsignal.com/news/MGNX/macrogenics-to-participate-in-the-stifel-2025-healthcare-conference 2025-11-06 https://biopharmsignal.com/news/CERT/certara-reports-third-quarter-2025-financial-results 2025-11-06 https://biopharmsignal.com/news/AMN/amn-healthcare-announces-third-quarter-2025-results-8b5e7ec7 2025-11-06 https://biopharmsignal.com/news/GMED/globus-medical-reports-third-quarter-2025-results-7d19bc72 2025-11-06 https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-a-business-update-november-13-2025 2025-11-06 https://biopharmsignal.com/news/NEPH/nephros-announces-strong-third-quarter-financial-results-achieving-highest-level-504b4261 2025-11-06 https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-2025-financial-results-posts-record-revenue-and-raises-2025-guidance 2025-11-06 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update 2025-11-06 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-third-quarter-2025-financial-results 2025-11-06 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-reports-third-quarter-2025-financial-results-530d7184 2025-11-06 https://biopharmsignal.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-september-9d1b3d35 2025-11-06 https://biopharmsignal.com/news/ALEC/alector-reports-third-quarter-2025-financial-results-and-provides-business-updat-da8e2e5f 2025-11-06 https://biopharmsignal.com/news/LMAT/lemaitre-q3-2025-financial-results-ce8bf412 2025-11-06 https://biopharmsignal.com/news/RLAY/relay-therapeutics-reports-third-quarter-2025-financial-results-and-corporate-up-ae0fdd0c 2025-11-06 https://biopharmsignal.com/news/ICUI/icu-medical-announces-third-quarter-2025-results-and-updates-its-fiscal-year-202-66e18417 2025-11-06 https://biopharmsignal.com/news/AORT/artivion-reports-third-quarter-2025-financial-results 2025-11-06 https://biopharmsignal.com/news/PGNY/progyny-inc-announces-third-quarter-2025-results 2025-11-06 https://biopharmsignal.com/news/BFRI/biofrontera-inc-to-report-third-quarter-2025-financial-results-on-november-12-20-27320f17 2025-11-06 https://biopharmsignal.com/news/DNLI/denali-therapeutics-reports-third-quarter-2025-financial-results-and-business-hi-9d11115a 2025-11-06 https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update 2025-11-06 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-to-exhibit-at-medica-2025-in-duesseldorf 2025-11-06 https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-third-quarter-2025-results-and-provides-corporate-update 2025-11-06 https://biopharmsignal.com/news/INAB/in8bio-reports-third-quarter-2025-financial-results-and-recent-business-highlights 2025-11-06 https://biopharmsignal.com/news/DNLI/denali-therapeutics-announces-board-and-executive-leadership-updates-e9bbebb4 2025-11-06 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights-recent-progress 2025-11-06 https://biopharmsignal.com/news/PROK/prokidney-presents-full-results-from-the-phase-2-regen-007-trial-of-rilparencel-at-the-american-society-of-nephrology-kidney-week-2025 2025-11-06 https://biopharmsignal.com/news/PNTG/pennant-group-to-participate-in-the-2025-stephens-annual-investment-conference 2025-11-06 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-reports-third-quarter-2025-financial-results 2025-11-06 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-announces-corporate-update-and-third-quarter-2025-financia-fbf7b921 2025-11-06 https://biopharmsignal.com/news/IMNN/imunon-to-hold-third-quarter-2025-financial-results-and-business-update-conferen-883229c2 2025-11-06 https://biopharmsignal.com/news/APVO/aptevo-therapeutics-reports-3q25-financial-results-and-provides-a-business-update 2025-11-06 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-reports-recent-business-highlights-and-third-quarter-2025-f-f70ce43a 2025-11-06 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-wins-2025-biotech-breakthrough-award-for-overall-biopharma-solution-of-the-year 2025-11-06 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-reports-2025-third-quarter-financial-results-and-provides-busi-83d99919 2025-11-06 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-announces-cms-recognition-of-expanded-cpt-codes-for-inflamm-3e447f0e 2025-11-06 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-conference-call-and-webcast-for-third-quarter-2025-financi-0887c143 2025-11-06 https://biopharmsignal.com/news/RLYB/rallybio-reports-third-quarter-2025-financial-results-and-provides-business-updates 2025-11-06 https://biopharmsignal.com/news/AORT/artivion-announces-treatment-of-first-patient-with-arcevo-lsa-in-artizen-pivotal-trial 2025-11-06 https://biopharmsignal.com/news/REPL/replimune-reports-fiscal-second-quarter-2026-financial-results-and-provides-corporate-update 2025-11-06 https://biopharmsignal.com/news/VCEL/vericel-reports-third-quarter-2025-financial-results-d1d66e56 2025-11-06 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-06 https://biopharmsignal.com/news/GHRS/gh-research-reports-third-quarter-2025-financial-results-and-provides-business-updates 2025-11-06 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-reports-third-quarter-2025-financial-results-and-provides-b-8b6509b3 2025-11-06 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-reports-third-quarter-2025-financial-results-and-provides-f2d8b257 2025-11-06 https://biopharmsignal.com/news/TENX/tenax-therapeutics-to-host-virtual-kol-call-to-discuss-tnx-103-oral-levosimendan-c637b8d3 2025-11-06 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-third-quarter-financial-results-conf-04c66d19 2025-11-06 https://biopharmsignal.com/news/LNSR/lensar-reports-third-quarter-2025-results-and-provides-business-update-1edc548d 2025-11-06 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-reports-third-quarter-2025-financial-results-6c515c5d 2025-11-06 https://biopharmsignal.com/news/CCCC/c4-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-2cd5bc14 2025-11-06 https://biopharmsignal.com/news/PRQR/proqr-announces-third-quarter-2025-operating-and-financial-results-1b7da3f0 2025-11-06 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-third-quarter-2025-f-e3ead7d8 2025-11-06 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-reports-third-quarter-2025-financial-results-335e7780 2025-11-06 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-third-quarter-2025-financial-results-and-busin-41536b5d 2025-11-06 https://biopharmsignal.com/news/ATXI/avenue-therapeutics-announces-acquisition-of-subsidiary-baergic-bio-by-axsome-therapeutics 2025-11-06 https://biopharmsignal.com/news/AVTX/avalo-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-updates 2025-11-06 https://biopharmsignal.com/news/XERS/xeris-biopharma-posts-record-financial-results-for-the-third-quarter-2025 2025-11-06 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2025-financial-results-and-provides-c-71fb40c6 2025-11-06 https://biopharmsignal.com/news/TFX/teleflex-announces-quarterly-dividend-b49b5009 2025-11-06 https://biopharmsignal.com/news/TFX/teleflex-reports-third-quarter-financial-results-and-full-year-2025-outlook-7e2975be 2025-11-06 https://biopharmsignal.com/news/PRVA/privia-health-reports-third-quarter-2025-financial-results 2025-11-06 https://biopharmsignal.com/news/LFST/lifestance-reports-third-quarter-2025-results 2025-11-06 https://biopharmsignal.com/news/BNTC/benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering 2025-11-06 https://biopharmsignal.com/news/BNTC/benitec-biopharma-inc-announces-proposed-public-offering 2025-11-05 https://biopharmsignal.com/news/BRTX/biorestorative-therapies-to-report-third-quarter-2025-financial-results-and-host-7c380565 2025-11-05 https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-third-quarter-2025-financial-results-and-provides-ge-d399e2a3 2025-11-05 https://biopharmsignal.com/news/SCYX/scynexis-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-05 https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-third-quarter-2025-operating-and-financial-results 2025-11-05 https://biopharmsignal.com/news/PNTG/the-pennant-group-announces-expansion-of-credit-facility 2025-11-05 https://biopharmsignal.com/news/ADMA/adma-biologics-announces-third-quarter-2025-financial-results-and-provides-business-update 2025-11-05 https://biopharmsignal.com/news/NXTC/nextcure-provides-business-update-and-reports-third-quarter-2025-financial-resul-901d5716 2025-11-05 https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-reports-third-quarter-financial-results-4b227433 2025-11-05 https://biopharmsignal.com/news/STRO/sutro-biopharma-to-host-virtual-research-development-day-on-november-12-2025-87c2b6ba 2025-11-05 https://biopharmsignal.com/news/PNTG/pennant-reports-third-quarter-2025-results 2025-11-05 https://biopharmsignal.com/news/BTMD/biote-reports-third-quarter-2025-financial-results 2025-11-05 https://biopharmsignal.com/news/INVA/innoviva-reports-third-quarter-2025-financial-results-highlights-recent-company-progress 2025-11-05 https://biopharmsignal.com/news/OM/new-research-demonstrates-the-advantages-of-an-insourced-dialysis-service-line-for-acute-care-facilities-using-outset-medical-s-tablor-hemodialysis-system 2025-11-05 https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-plans-to-initiate-patient-dosing-of-dt-818-in-myotonic-dystrophy-type-1-dm1-in-the-first-half-of-2026-and-reports-third-quarter-2025-financial-results 2025-11-05 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-participate-in-guggenheim-s-second-annual-healthcare-innov-b6f2155c 2025-11-05 https://biopharmsignal.com/news/KROS/keros-therapeutics-reports-third-quarter-2025-financial-results-c63c6027 2025-11-05 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-report-third-quarter-2025-financial-results-on-novembe-ee1135bf 2025-11-05 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-prices-5-billion-of-senior-unsecured-notes 2025-11-05 https://biopharmsignal.com/news/ICU/seastar-medical-to-report-third-quarter-financial-results-on-november-13-2025-78d44451 2025-11-05 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-announces-poster-presentation-of-adaptive-phase-2-3-pcs499-study-in-fsgs-at-asn-kidney-week-2025 2025-11-05 https://biopharmsignal.com/news/INKT/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-c-e8adcc84 2025-11-05 https://biopharmsignal.com/news/MMSI/merit-medical-releases-24-month-efficacy-results-from-the-randomized-arterioveno-acf4d50f 2025-11-05 https://biopharmsignal.com/news/LFST/nearly-7-in-10-americans-feel-pressure-to-appear-happier-than-they-are-this-holiday-season 2025-11-05 https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-third-quarter-2025-financial-results-on-november-12-2025 2025-11-05 https://biopharmsignal.com/news/MXCT/maxcyte-reports-preliminary-third-quarter-2025-financial-results-and-reiterates-full-year-2025-revenue-guidance 2025-11-05 https://biopharmsignal.com/news/NCNA/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-china 2025-11-05 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-to-report-third-quarter-2025-financial-results-on-november--9e6b9d59 2025-11-05 https://biopharmsignal.com/news/BCAB/bioatla-to-announce-third-quarter-2025-financial-results-and-provide-business-hi-38d23269 2025-11-05 https://biopharmsignal.com/news/ARDX/ardelyx-to-participate-at-the-jefferies-global-healthcare-conference-in-london-449325ff 2025-11-05 https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-and-snbl-announce-publication-of-impression-of-use-and-satisfaction-with-sts101-dihydroergotamine-nasal-powder-atzumitm-in-headache 2025-11-05 https://biopharmsignal.com/news/NERV/minerva-neurosciences-reports-third-quarter-2025-financial-results-and-business-updates 2025-11-05 https://biopharmsignal.com/news/MDWD/mediwound-to-report-third-quarter-2025-financial-results-19bafe7a 2025-11-05 https://biopharmsignal.com/news/MRKR/marker-therapeutics-appoints-kathryn-penkus-corzo-to-board-of-directors-3ff88c81 2025-11-05 https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-third-quarter-2025-financial-results-and-provides-c-fd271092 2025-11-05 https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-announces-pricing-of-75-million-underwritten-offering 2025-11-05 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-third-quarter-2025-financial-and-corporate-update 2025-11-05 https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-for-the-third-quarter-of-2025-and-provides-update-on-potential-best-in-class-orexin-receptor-2-ox2r-agonist-program 2025-11-05 https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-reports-third-quarter-2025-financial-results-and-announces-new-data-from-clinical-trials-of-its-nanobodyr-sonelokimab 2025-11-05 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-to-present-at-guggenheim-second-annual-healthcare-innovat-4514f199 2025-11-05 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-cor-fc4b799e 2025-11-05 https://biopharmsignal.com/news/PASG/passage-bio-to-present-at-guggenheim-securities-2nd-annual-healthcare-innovation-conference 2025-11-05 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-third-quarter-2025-financial-results 2025-11-05 https://biopharmsignal.com/news/RXRX/recursion-reports-third-quarter-2025-financial-results-and-provides-business-upd-56adb7f6 2025-11-05 https://biopharmsignal.com/news/RXRX/recursion-announces-ceo-transition-plan-to-drive-next-phase-of-growth-fc19c1ea 2025-11-05 https://biopharmsignal.com/news/IMRN/immuron-imm-529-ind-approved-by-fda-dfc792f4 2025-11-05 https://biopharmsignal.com/news/PRPO/precipio-announces-q3-2025-shareholder-update-call-11bdc97d 2025-11-04 https://biopharmsignal.com/news/IRTC/irhythm-technologies-to-participate-in-upcoming-investor-conferences-f9cb1c44 2025-11-04 https://biopharmsignal.com/news/COO/coopercompanies-announces-release-date-for-fourth-quarter-and-full-year-2025-7517ae1b 2025-11-04 https://biopharmsignal.com/news/TARS/tarsus-reports-third-quarter-2025-financial-results-and-recent-business-achievements 2025-11-04 https://biopharmsignal.com/news/ICCC/immucell-announces-onboarding-of-new-ceo-and-related-management-changes-a3175de4 2025-11-04 https://biopharmsignal.com/news/AMWL/amwell-announces-results-for-third-quarter-2025-77292b6d 2025-11-04 https://biopharmsignal.com/news/PRCT/procept-biorobotics-reports-third-quarter-2025-financial-results-and-issues-2026-2db3cbe3 2025-11-04 https://biopharmsignal.com/news/AXON/axon-to-acquire-carbyne-uniting-cloud-infrastructure-and-ai-to-redefine-the-911-experience 2025-11-04 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-reports-third-quarter-2025-financial-results-and-provides-up-3e74756f 2025-11-04 https://biopharmsignal.com/news/SUPN/supernus-announces-third-quarter-2025-financial-results 2025-11-04 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent 2025-11-04 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-stifel-healthcare-conference-4773aab0 2025-11-04 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-13-2025 2025-11-04 https://biopharmsignal.com/news/CMPX/compass-therapeutics-presents-preclinical-data-on-ctx-10726-a-differentiated-pd--ca25a5d8 2025-11-04 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-reports-second-fiscal-quarter-2026-financial-results 2025-11-04 https://biopharmsignal.com/news/IMNN/imunon-announces-webcast-of-in-person-r-d-day-highlighting-progress-on-ovation-3-6b787fa3 2025-11-04 https://biopharmsignal.com/news/CERT/certara-automates-scientific-workflows-with-phoenixr-cloud 2025-11-04 https://biopharmsignal.com/news/SPRY/ars-pharma-launches-get-neffy-on-us-for-patients-with-severe-allergic-reactions--5aae1af3 2025-11-04 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-to-present-at-upcoming-investor-conferences-9185f5af 2025-11-04 https://biopharmsignal.com/news/HRTX/heron-therapeutics-announces-q3-2025-financial-results-and-highlights-commercial-360e3c5a 2025-11-04 https://biopharmsignal.com/news/XGN/exagen-inc-reports-strong-q3-2025-results 2025-11-04 https://biopharmsignal.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-investor-conferences-in-november-and-december 2025-11-04 https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-upcoming-november-conferences-35920013 2025-11-04 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-strategic-business-update 2025-11-04 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-exclusive-option-agreement-with-incyte-to-advance-mutant-selective-jak2v617f-jh2-inhibitors 2025-11-04 https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-updates 2025-11-04 https://biopharmsignal.com/news/CRVO/cervomed-announces-alignment-with-fda-on-registration-path-for-neflamapimod-in-d-84fea2d1 2025-11-04 https://biopharmsignal.com/news/ACIU/ac-immune-reports-third-quarter-2025-financial-results-and-provides-a-corporate--95b49a36 2025-11-04 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-reports-third-quarter-2025-financial-results-and-provides--a7bda575 2025-11-04 https://biopharmsignal.com/news/MNOV/medicinova-announces-completion-of-patient-enrollment-in-mn-001-natg-202-clinical-trial-of-mn-001-tipelukast 2025-11-04 https://biopharmsignal.com/news/FMS/fresenius-medical-care-further-accelerates-organic-revenue-development-and-achieves-an-inflection-in-earnings-growth-delivering-28-operating-income-growth-in-the-third-quarter-of-2025 2025-11-04 https://biopharmsignal.com/news/HSTM/healthstream-announces-third-quarter-2025-results 2025-11-03 https://biopharmsignal.com/news/PMN/promis-neurosciences-to-participate-in-the-guggenheim-2nd-annual-healthcare-inno-2cc5cd4f 2025-11-03 https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-novemb-38b18b6a 2025-11-03 https://biopharmsignal.com/news/TCMD/tactile-systems-technology-inc-reports-third-quarter-2025-financial-results 2025-11-03 https://biopharmsignal.com/news/OPCH/option-care-health-to-participate-in-upcoming-investor-conferences 2025-11-03 https://biopharmsignal.com/news/MDXH/mdxhealth-to-release-third-quarter-2025-financial-results-on-november-12-290a5b28 2025-11-03 https://biopharmsignal.com/news/BDSX/biodesix-announces-third-quarter-2025-results-and-highlights-f59f4e70 2025-11-03 https://biopharmsignal.com/news/SPRY/update-ars-pharma-to-present-real-world-data-on-intranasal-epinephrine-at-2025-a-ef8cffa4 2025-11-03 https://biopharmsignal.com/news/ORGO/organogenesis-applauds-cms-s-significant-step-in-payment-reform 2025-11-03 https://biopharmsignal.com/news/IMMX/immix-biopharma-s-nxc-201-nexicart-2-clinical-trial-results-selected-for-oral-pr-11aa97e3 2025-11-03 https://biopharmsignal.com/news/MMSI/merit-medical-releases-24-month-efficacy-results-from-the-single-arm-arterioveno-a86fe989 2025-11-03 https://biopharmsignal.com/news/MRKR/marker-therapeutics-announces-upcoming-presentations-on-mt-601-in-relapsed-non-h-63e9d864 2025-11-03 https://biopharmsignal.com/news/CLLS/cellectis-to-present-a-development-update-for-eti-cel-at-ash-2025 2025-11-03 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-showcase-new-data-demonstrating-compelling-clinical-act-1e9c42a7 2025-11-03 https://biopharmsignal.com/news/SNTI/senti-bio-to-present-updated-clinical-results-of-first-in-class-logic-gated-cd33-948f4fe1 2025-11-03 https://biopharmsignal.com/news/LYEL/lyell-announces-two-oral-presentations-from-the-phase-1-2-clinical-trial-of-ronde-cel-for-the-treatment-of-aggressive-large-b-cell-lymphoma-at-the-67th-ash-annual-meeting-and-exposition 2025-11-03 https://biopharmsignal.com/news/XCUR/new-burixafor-clinical-data-to-be-presented-as-an-oral-presentation-at-the-2025--b5324291 2025-11-03 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-edit-401-poster-presentation-at-the-american-heart-ass-ac9f8eb6 2025-11-03 https://biopharmsignal.com/news/SLS/sellas-life-sciences-announces-presentation-of-phase-2-data-of-sls009-in-combination-with-azacitidine-and-venetoclax-in-relapsed-refractory-aml-with-mds-related-changes-aml-mr-at-the-2025-american-society-of-hematology-ash-annual-meeting 2025-11-03 https://biopharmsignal.com/news/APTO/aptose-tuspetinib-clinical-data-from-ongoing-tuscany-trial-in-newly-diagnosed-aml-selected-for-presentation-at-the-2025-ash-annual-meeting 2025-11-03 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-clinical-data-in-cml-patients-with-atypical-fusion-transcripts-at-ash-2025-annual-meeting 2025-11-03 https://biopharmsignal.com/news/BDRX/biodexa-announces-approval-of-cta-in-europe-for-phase-3-serenta-trial-in-fap-fir-fd14a11b 2025-11-03 https://biopharmsignal.com/news/FEMY/femasys-secures-fda-approval-to-advance-final-fembloc-trial-phase-and-12-million-20f174f9 2025-11-03 https://biopharmsignal.com/news/AMRN/amarin-to-present-new-analyses-affirming-robustness-of-data-from-reduce-it-and-a-37e7f712 2025-11-03 https://biopharmsignal.com/news/IRMD/iradimed-corporation-reports-record-third-quarter-2025-financial-results-2c2e7646 2025-11-03 https://biopharmsignal.com/news/VRAX/virax-biolabs-completes-uk-clinical-recruitment-and-reports-constructive-fda-feedback-for-viraximmunetm-study-evaluating-t-cell-dysfunction-in-post-acute-infection-syndromes 2025-11-03 https://biopharmsignal.com/news/PRME/prime-medicine-appoints-matthew-hawryluk-ph-d-m-b-a-as-chief-business-officer 2025-11-03 https://biopharmsignal.com/news/MDWD/mediwound-successfully-completes-commissioning-of-expanded-gmp-manufacturing-fac-407f0267 2025-11-03 https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcast-for-its-third-quarter--b7925eb5 2025-11-03 https://biopharmsignal.com/news/ELTX/elicio-therapeutics-to-present-clinical-and-preclinical-data-at-the-sitc-2025-an-3626157b 2025-11-03 https://biopharmsignal.com/news/IMMP/immutep-receives-a-4-6-million-r-d-tax-incentive-from-french-government-b5bb7638 2025-11-03 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-reports-successful-installation-and-testing-of-its-first--e4a0eb91 2025-11-03 https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-november-investor-events-91e49377 2025-11-03 https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference-48faf31a 2025-11-03 https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-present-at-upcoming-healthcare-investment-conferences 2025-11-03 https://biopharmsignal.com/news/SPRY/ars-pharma-to-present-real-world-data-on-intranasal-epinephrine-at-2025-american-a8a9d9f5 2025-11-03 https://biopharmsignal.com/news/APGE/apogee-therapeutics-to-participate-in-upcoming-conferences-f3cc75ed 2025-11-03 https://biopharmsignal.com/news/BNTC/benitec-biopharma-provides-positive-interim-clinical-study-results-for-bb-301-phase-1b-2a-clinical-trial-and-receives-fda-fast-track-designation-for-bb-301 2025-11-03 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-the-guggenheim-2nd-annual-healthcare-innovation-conference 2025-11-03 https://biopharmsignal.com/news/CRBU/caribou-biosciences-announces-positive-data-from-antler-phase-1-trial-demonstrating-efficacy-and-durability-of-vispa-cel-cb-010-an-allogeneic-car-t-cell-therapy-on-par-with-autologous-car-t-cell-therapies 2025-11-03 https://biopharmsignal.com/news/CRBU/caribou-biosciences-announces-positive-data-from-cammouflage-phase-1-trial-of-cb-011-in-multiple-myeloma 2025-11-03 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-to-participate-in-upcoming-conferences-in-november-28df1a31 2025-11-03 https://biopharmsignal.com/news/TENX/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innova-f0334c16 2025-11-03 https://biopharmsignal.com/news/PYXS/pyxis-oncology-provides-business-update-and-reports-third-quarter-2025-financial-d3f24eda 2025-11-03 https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-third-quarter-2025-financial-and-operating-results-3e67defe 2025-11-03 https://biopharmsignal.com/news/PEPG/pepgen-to-participate-in-upcoming-investor-conferences 2025-11-03 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-showcases-new-long-term-and-real-world-data-from-cardiovascular-portfolio-at-the-american-heart-association-scientific-sessions-2025 2025-11-03 https://biopharmsignal.com/news/LQDA/liquidia-corporation-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-03 https://biopharmsignal.com/news/MD/pediatrix-medical-group-reports-third-quarter-results 2025-11-03 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-cash-tender-offers-to-purchase-certain-notes 2025-11-03 https://biopharmsignal.com/news/CLLS/cellectis-to-report-third-quarter-financial-results-on-november-7-2025 2025-10-31 https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2025-10-31 https://biopharmsignal.com/news/CRMD/cormedix-inc-to-report-third-quarter-2025-financial-results-and-provide-a-corpor-ba0c5a1c 2025-10-31 https://biopharmsignal.com/news/VERU/veru-to-present-two-abstracts-at-obesityweek-2025 2025-10-31 https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-completion-of-sale-of-hbv-and-hiv-assets-to-gilead-204a9211 2025-10-31 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-announces-third-quarter-fiscal-2025-earnings-release-date-de84785e 2025-10-31 https://biopharmsignal.com/news/IMRN/immuron-announces-clinical-trial-update-b374a8ae 2025-10-31 https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-the-stifel-2025-healthcare-conference 2025-10-30 https://biopharmsignal.com/news/LGMK/logicmark-inc-to-announce-third-quarter-2025-financial-results-on-november-12-20-5fb9e08e 2025-10-30 https://biopharmsignal.com/news/IRTC/irhythm-technologies-announces-third-quarter-2025-financial-results-959e2948 2025-10-30 https://biopharmsignal.com/news/MMSI/merit-medical-reports-third-quarter-2025-results-and-updates-full-year-guidance-302f4618 2025-10-30 https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-announce-third-quarter-2025-financial-results-and-corporat-47d030ee 2025-10-30 https://biopharmsignal.com/news/PRME/prime-medicine-to-host-virtual-kol-event-to-showcase-wilson-s-disease-strategy 2025-10-30 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-announces-third-quarter-2025-earnings-call-0c012464 2025-10-30 https://biopharmsignal.com/news/NEPH/nephros-schedules-third-quarter-2025-financial-results-conference-call-4dc4571d 2025-10-30 https://biopharmsignal.com/news/FORA/forian-inc-to-announce-third-quarter-2025-results-on-november-14-2025 2025-10-30 https://biopharmsignal.com/news/NKTX/nkarta-to-participate-in-november-investor-conferences 2025-10-30 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-permanent-j-code-for-zevaskynr-prademagene-zamikeracel 2025-10-30 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-to-report-third-quarter-2025-financial-results-on-thursday-november-6-2025 2025-10-30 https://biopharmsignal.com/news/XLO/xilio-therapeutics-to-present-phase-2-data-for-vilastobart-highlighting-response-b67f1b12 2025-10-30 https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-announces-initiation-of-strategic-review-to-maximize-shareholder-value 2025-10-30 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-joins-rare-x-vision-consortium-promoting-collaboration-and-development-of-new-treatments-for-rare-ocular-disorders 2025-10-30 https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-to-provide-corporate-update-and-announce-third-quarter-202-5aff1632 2025-10-30 https://biopharmsignal.com/news/RANI/rani-therapeutics-to-present-preclinical-data-on-oral-delivery-of-semaglutide-via-the-ranipillr-capsule-at-obesityweekr-2025 2025-10-30 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-a-business-update-on-thursday-november-6-2025 2025-10-30 https://biopharmsignal.com/news/IXHL/incannex-provides-shareholder-update-highlighting-clinical-progress-capital-disc-1c7f7aba 2025-10-30 https://biopharmsignal.com/news/IMNN/imunon-to-present-phase-3-ovation-3-study-of-imnn-001-in-advanced-ovarian-cancer-ab3961b2 2025-10-30 https://biopharmsignal.com/news/COCP/cocrystal-pharma-insiders-purchase-1-03-million-in-private-placement-priced-at-t-d02a5fd4 2025-10-30 https://biopharmsignal.com/news/PDSB/new-clinical-and-translational-data-on-pds-biotechnology-s-novel-investigational-e5c7df7a 2025-10-30 https://biopharmsignal.com/news/VERU/veru-announces-pricing-of-25-million-public-offering 2025-10-30 https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-announces-upcoming-presentation-of-new-data-reinforcing-the-potential-of-oxylanthanum-carbonate-for-the-treatment-of-hyperphosphatemia-at-the-american-society-of-nephrology-kidney-week-2025-conference 2025-10-30 https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-announces-carsten-brunn-ph-d-named-as-chairman-of-the-com-01175966 2025-10-30 https://biopharmsignal.com/news/GANX/gain-therapeutics-to-present-at-neuroscience-2025-544af22e 2025-10-30 https://biopharmsignal.com/news/IBIO/ibio-unveils-new-non-human-primate-data-on-ibio-610-an-activin-e-antibody-with-strong-therapeutic-potential-for-fat-selective-weight-loss-and-weight-maintenance 2025-10-30 https://biopharmsignal.com/news/OPCH/option-care-health-announces-financial-results-for-the-third-quarter-ended-september-30-2025 2025-10-30 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-third-quarter-financial-results-for-2025 2025-10-30 https://biopharmsignal.com/news/EGRX/eagle-pharmaceuticals-board-extends-limited-duration-stockholder-rights-plan 2025-10-30 https://biopharmsignal.com/news/BDSX/biodesix-to-share-its-r-d-roadmap-during-its-corporate-day-presentation-at-amp-a-0b19efb4 2025-10-30 https://biopharmsignal.com/news/FMS/fresenius-medical-care-highlights-real-world-advances-in-hemodiafiltration-and-ai-at-asn-kidney-week-2025 2025-10-30 https://biopharmsignal.com/news/HRTX/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors-deec40f7 2025-10-29 https://biopharmsignal.com/news/AORT/artivion-to-participate-in-the-stifel-2025-healthcare-conference 2025-10-29 https://biopharmsignal.com/news/TDOC/teladoc-health-reports-third-quarter-2025-results-bb024679 2025-10-29 https://biopharmsignal.com/news/ATRC/atricure-reports-third-quarter-2025-financial-results-raises-financial-outlook-for-2025 2025-10-29 https://biopharmsignal.com/news/PDSB/pds-biotech-to-seek-expedited-approval-pathway-for-pds0101-in-hpv16-positive-hea-85f2b047 2025-10-29 https://biopharmsignal.com/news/INAB/in8bio-expands-inb-100-phase-1-clinical-trial-with-addition-of-the-ohio-state-university-as-new-site 2025-10-29 https://biopharmsignal.com/news/IMMP/immutep-quarterly-activities-report-q1-fy26-2e35cde6 2025-10-29 https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-the-spartan-capital-securities-second-annual-investor-c-f2618ceb 2025-10-29 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-holdings-to-present-at-the-spartan-capital-investor-conference-2025-november-3 2025-10-29 https://biopharmsignal.com/news/PPBT/purple-biotech-achieves-manufacturing-milestone-for-im1240-a-tri-specific-antibo-21fd3a64 2025-10-29 https://biopharmsignal.com/news/PROK/prokidney-to-participate-in-two-upcoming-conferences-guggenheim-healthcare-innovation-conference-and-the-jefferies-global-healthcare-conference 2025-10-29 https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-three-november-healthcare-conferences-8bc1f0bb 2025-10-29 https://biopharmsignal.com/news/AMRN/amarin-reports-third-quarter-2025-financial-results-2cca0a85 2025-10-29 https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-present-data-on-ampreloxetine-at-the-36th-international-symposium-on-the-autonomic-nervous-system 2025-10-29 https://biopharmsignal.com/news/ADXN/addex-increases-issued-share-capital-to-create-treasury-shares-590808eb 2025-10-29 https://biopharmsignal.com/news/GSK/gsk-delivers-strong-q3-performance-and-upgrades-2025-guidance 2025-10-29 https://biopharmsignal.com/news/LFST/lifestance-to-present-at-the-ubs-global-healthcare-conference 2025-10-28 https://biopharmsignal.com/news/TCMD/landmark-study-demonstrates-sustained-clinical-benefits-of-flexitouchr-plus-as-first-line-therapy-in-treating-head-and-neck-cancer-related-lymphedema 2025-10-28 https://biopharmsignal.com/news/NTRB/repeat-nutriband-announces-successful-meeting-completed-with-united-states-fda-f-eac71585 2025-10-28 https://biopharmsignal.com/news/ENLV/enlivex-therapeutics-to-present-phase-iia-3-month-data-of-allocetra-in-patients--68c84470 2025-10-28 https://biopharmsignal.com/news/ASRT/assertio-announces-leadership-transition-13208d9d 2025-10-28 https://biopharmsignal.com/news/LFST/calm-health-partners-with-lifestance-health-to-help-users-access-high-quality-mental-health-care 2025-10-28 https://biopharmsignal.com/news/CRVO/cervomed-strengthens-board-with-appointment-of-life-sciences-business-strategy-l-3ac8d05f 2025-10-28 https://biopharmsignal.com/news/CING/cingulate-presents-positive-phase-3-results-for-ctx-1301-demonstrating-statistic-a95708d1 2025-10-28 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-to-participate-in-upcoming-november-conferences-07e3f36f 2025-10-28 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-fi-fc71667d 2025-10-28 https://biopharmsignal.com/news/RVPH/reviva-to-present-negative-symptom-data-for-brilaroxazine-in-schizophrenia-from--bbf99183 2025-10-28 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-reports-third-quarter-2025-financial-results-d7f9b1d3 2025-10-28 https://biopharmsignal.com/news/RXRX/recursion-to-report-third-quarter-2025-business-updates-and-financial-results-on-3282ea8d 2025-10-28 https://biopharmsignal.com/news/AQB/aquabounty-technologies-announces-third-quarter-2025-financial-results 2025-10-28 https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-reports-third-quarter-2025-financial-results-and-recent-portfolio-execution 2025-10-28 https://biopharmsignal.com/news/RGEN/repligen-reports-third-quarter-2025-financial-results-and-updates-full-year-2025-00910463 2025-10-28 https://biopharmsignal.com/news/NTRB/nutriband-announces-successful-meeting-completed-with-united-states-fda-for-its--610e4509 2025-10-28 https://biopharmsignal.com/news/ACIU/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-a-8f5624be 2025-10-28 https://biopharmsignal.com/news/GSK/gsk-and-empirico-enter-license-agreement-for-clinical-stage-first-in-class-oligonucleotide-candidate-to-treat-respiratory-diseases 2025-10-28 https://biopharmsignal.com/news/GSK/gsk-s-b7-h3-targeted-antibody-drug-conjugate-gsk-227-receives-orphan-drug-designation-in-the-eu 2025-10-28 https://biopharmsignal.com/news/ORTX/kyowa-kirin-and-orchard-therapeutics-announce-otl-200-granted-orphan-regenerative-medicine-product-designation-for-early-onset-mld-in-japan 2025-10-28 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-closing-of-public-offering-and-full-exercise-of-the-abde75d3 2025-10-27 https://biopharmsignal.com/news/FMS/fresenius-medical-care-again-named-to-top-100-women-led-businesses-in-massachusetts 2025-10-27 https://biopharmsignal.com/news/AMWL/amwell-to-report-third-quarter-2025-operating-results-company-leaders-to-attend--00244871 2025-10-27 https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025 2025-10-27 https://biopharmsignal.com/news/LUNG/pulmonx-announces-management-transition-and-preliminary-third-quarter-2025-revenue-reschedules-third-quarter-2025-earnings-call-to-november-12-2025 2025-10-27 https://biopharmsignal.com/news/IRMD/iradimed-corporation-to-hold-third-quarter-of-2025-financial-results-conference--b147b470 2025-10-27 https://biopharmsignal.com/news/SLS/sellas-life-sciences-group-announces-exercise-of-existing-warrants-held-by-a-current-institutional-investor-for-31-million-in-gross-proceeds 2025-10-27 https://biopharmsignal.com/news/COCP/cocrystal-pharma-receives-nih-sbir-award-to-advance-its-influenza-inhibitor-prog-7e65052c 2025-10-27 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-participate-in-upcoming-november-investor-conference-66d31e56 2025-10-27 https://biopharmsignal.com/news/AMRN/amarin-issues-statement-supporting-fda-s-action-to-revise-labeling-for-fenofibra-bca52c41 2025-10-27 https://biopharmsignal.com/news/IMTX/immatics-appoints-amie-krause-as-chief-people-officer 2025-10-27 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-announces-initiation-of-phase-1-clinical-study-of-m4-positi-ebb8b823 2025-10-27 https://biopharmsignal.com/news/NTRB/nutriband-co-founder-gareth-sheridan-returns-as-ceo-2bd309dc 2025-10-27 https://biopharmsignal.com/news/CABA/cabaletta-bio-presents-positive-clinical-data-and-development-updates-for-rese-cel-at-acr-convergence-2025 2025-10-27 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-two-late-breaking-presentations-demonstrating-sotyktu-deucravacitinib-efficacy-in-psoriatic-arthritis-and-systemic-lupus-erythematosus 2025-10-27 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-announces-class-leading-weight-loss-demonstrated-with-nmra--41b9aec9 2025-10-27 https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025 2025-10-27 https://biopharmsignal.com/news/GSK/gsk-acquires-exclusive-rights-from-syndivia-for-antibody-drug-conjugate-adc-in-prostate-cancer 2025-10-27 https://biopharmsignal.com/news/GNTA/genenta-announces-pricing-of-15-0-million-registered-direct-offering-of-american-depositary-shares 2025-10-27 https://biopharmsignal.com/news/RNA/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis-ag 2025-10-26 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-shares-additional-preclinical-b-cell-depletion-data-for-cl-1983f826 2025-10-25 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-encouraging-data-from-phase-1-breakfree-1-study-of-cd19-nex-ttm-car-t-cell-therapy-in-three-chronic-autoimmune-diseases-at-acr-convergence-2025 2025-10-25 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-announces-updated-rezatapopt-monotherapy-interim-data-from-ongoing-pynnacle-phase-2-trial-across-multiple-solid-tumors-with-a-tp53-y220c-mutation 2025-10-24 https://biopharmsignal.com/news/MRUS/merus-interim-data-on-petosemtamab-in-metastatic-colorectal-cancer-demonstrates-monotherapy-activity-and-robust-response-rate-in-combination-with-folfox-folfiri-with-well-tolerated-safety 2025-10-24 https://biopharmsignal.com/news/ACIU/first-characterization-of-a-tdp-43-pet-tracer-published-in-nature-communications-af576eb3 2025-10-24 https://biopharmsignal.com/news/DERM/journey-medical-corporation-reports-combined-emrositm-dfd-29-phase-3-clinical-trial-efficacy-data-analysis-presented-at-the-2025-fall-clinical-dermatology-conference 2025-10-24 https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-acr-convergence-2025-on-the-bd525604 2025-10-24 https://biopharmsignal.com/news/GNTA/genenta-and-anemocyte-announce-strategic-partnership-to-advance-off-the-shelf-lvv-plasmid-dna-production 2025-10-24 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-pricing-of-135-million-underwritten-public-offering-3f98d251 2025-10-24 https://biopharmsignal.com/news/CING/cingulate-s-lead-adhd-candidate-ctx-1301-selected-for-podium-presentation-at-aac-1418da66 2025-10-23 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-report-third-quarter-2025-financial-results-on-thursday--bf665f64 2025-10-23 https://biopharmsignal.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-third-quarter-2025-financial-results 2025-10-23 https://biopharmsignal.com/news/RANI/rani-therapeutics-announces-the-appointments-of-abe-bassan-and-vasudev-bailey-ph-d-to-board-of-directors 2025-10-23 https://biopharmsignal.com/news/TDOC/teladoc-health-announces-chief-financial-officer-transition-e15eb455 2025-10-23 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-proposed-underwritten-public-offering-83b47b3a 2025-10-23 https://biopharmsignal.com/news/XGN/exagen-announces-acceptance-of-six-abstracts-at-2025-american-college-of-rheumatology-convergence 2025-10-23 https://biopharmsignal.com/news/BFRI/biofrontera-inc-closes-purchase-of-all-ameluz-and-rhodoled-us-assets-from-biofro-2f452f35 2025-10-23 https://biopharmsignal.com/news/CRMD/cormedix-inc-receives-innovative-technology-designation-from-vizient-for-defenca-1b38ad83 2025-10-23 https://biopharmsignal.com/news/VCEL/vericel-to-report-third-quarter-2025-financial-results-on-november-6-2025-73c8d6f2 2025-10-23 https://biopharmsignal.com/news/ICUI/icu-medical-announces-time-of-third-quarter-2025-earnings-conference-call-4d9a7b03 2025-10-23 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-release-third-quarter-of-fiscal-year-2025-financial--e95eb4ea 2025-10-23 https://biopharmsignal.com/news/BCAB/bioatla-presents-compelling-mechanistic-rationale-for-targeting-ror2-with-ozurif-6ba1ce8b 2025-10-23 https://biopharmsignal.com/news/ACST/grace-therapeutics-secures-approximately-4-0-million-through-common-warrant-exercises-following-acceptance-of-new-drug-application-for-gtx-104-for-formal-fda-review 2025-10-23 https://biopharmsignal.com/news/GSK/blenrep-approved-by-us-fda-for-use-in-treatment-of-relapsed-refractory-multiple-myeloma 2025-10-23 https://biopharmsignal.com/news/XERS/xeris-biopharma-to-report-third-quarter-2025-financial-results-on-november-6-2025 2025-10-23 https://biopharmsignal.com/news/IBIO/ibio-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference 2025-10-23 https://biopharmsignal.com/news/PHVS/pharvaris-to-present-clinical-data-at-the-acaai-2025-annual-scientific-meeting-25859746 2025-10-23 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-reports-third-quarter-2025-results 2025-10-22 https://biopharmsignal.com/news/MOH/molina-healthcare-reports-third-quarter-2025-financial-results 2025-10-22 https://biopharmsignal.com/news/BTMD/biote-schedules-third-quarter-2025-financial-results-release-and-conference-call 2025-10-22 https://biopharmsignal.com/news/NKTX/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting 2025-10-22 https://biopharmsignal.com/news/SLS/sellas-life-sciences-to-participate-in-the-j-p-morgan-u-s-opportunities-forum 2025-10-22 https://biopharmsignal.com/news/VANI/vivani-medical-to-present-at-the-thinkequity-conference-on-october-30-2025 2025-10-22 https://biopharmsignal.com/news/EQ/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025-642f114f 2025-10-22 https://biopharmsignal.com/news/PMN/promis-neurosciences-strengthens-board-with-appointment-of-slanix-paul-alex-phar-e47dc69f 2025-10-22 https://biopharmsignal.com/news/GRTX/galera-therapeutics-announces-acquisition-of-dismutase-mimetics-portfolio-by-tor-3af0371d 2025-10-22 https://biopharmsignal.com/news/BDSX/biodesix-announces-expanded-bio-rad-laboratories-partnership-agreement-to-develo-7611f176 2025-10-22 https://biopharmsignal.com/news/GSK/gsk-announces-positive-pivotal-phase-iii-data-for-next-generation-low-carbon-version-of-ventolin-salbutamol-metered-dose-inhaler 2025-10-22 https://biopharmsignal.com/news/ANL/adlai-nortye-to-present-short-talk-on-an4035-preclinical-results-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics 2025-10-22 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-third-quarter-2025-financial-results-and-host-conference-call-on-november-4-2025 2025-10-21 https://biopharmsignal.com/news/HRTX/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-nov-23265eb1 2025-10-21 https://biopharmsignal.com/news/EGRX/eagle-pharmaceuticals-announces-results-of-2025-annual-meeting-of-stockholders 2025-10-21 https://biopharmsignal.com/news/ALEC/alector-announces-topline-results-from-latozinemab-phase-3-trial-in-individuals--4739640a 2025-10-21 https://biopharmsignal.com/news/XGN/exagen-inc-to-announce-third-quarter-2025-financial-results-on-november-4-2025 2025-10-21 https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-third-quarter-2025-earnings-release-and-conference-call 2025-10-21 https://biopharmsignal.com/news/ISRG/intuitive-announces-third-quarter-earnings 2025-10-21 https://biopharmsignal.com/news/STXS/stereotaxis-to-report-third-quarter-2025-financial-results-on-november-11-2025-60b76106 2025-10-21 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-to-report-third-quarter-2025-financial-results-on-november-4-e2658e21 2025-10-21 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-report-third-quarter-2025-financial-results-on-november-3-202-dd51c7e6 2025-10-21 https://biopharmsignal.com/news/OGEN/oragenics-regains-full-nyse-american-compliance-company-resolves-stockholder-equity-deficiency 2025-10-21 https://biopharmsignal.com/news/MD/pediatrix-medical-group-2025-third-quarter-conference-call-webcast-scheduled-for-monday-november-3-2025 2025-10-21 https://biopharmsignal.com/news/GSK/gsk-s-shingrix-new-prefilled-syringe-presentation-receives-positive-chmp-opinion 2025-10-21 https://biopharmsignal.com/news/SPRO/pivot-po-phase-3-data-show-tebipenem-hbr-s-potential-as-the-first-oral-carbapene-4765cba6 2025-10-21 https://biopharmsignal.com/news/GSK/positive-pivot-po-phase-iii-data-show-tebipenem-hbr-s-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis 2025-10-21 https://biopharmsignal.com/news/GSK/global-fund-welcomes-renewed-commitment-from-gsk-and-viiv-healthcare-to-expand-community-led-health-solutions-with-6-million-joint-pledge-ahead-of-8th-replenishment 2025-10-20 https://biopharmsignal.com/news/HCAT/health-catalyst-to-announce-third-quarter-2025-operating-results-and-host-confer-5e00a6a5 2025-10-20 https://biopharmsignal.com/news/SIBN/si-bone-to-report-third-quarter-2025-financial-results-on-november-10-2025 2025-10-20 https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-third-quarter-of-fiscal-year-2025-financial-results-on-november-3-2025 2025-10-20 https://biopharmsignal.com/news/PPBT/purple-biotech-announces-receipt-of-nasdaq-minimum-bid-price-notification-b3a4a32e 2025-10-20 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-appoints-james-a-gow-md-mba-ms-mhcm-as-senior-vice-president-head-of-clinical-development-and-medical-affairs 2025-10-20 https://biopharmsignal.com/news/CRVO/cervomed-to-present-at-the-emerging-growth-conference-1388fa76 2025-10-20 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-reinforces-market-leadership-following-key-litigation-miles-6cb3137d 2025-10-20 https://biopharmsignal.com/news/GALT/galectin-therapeutics-to-present-at-the-h-c-wainwright-9th-annual-mash-investor--0f3c9d8b 2025-10-20 https://biopharmsignal.com/news/BCAB/bioatla-presents-promising-interim-data-from-its-phase-1-trial-with-ba3182-in-pa-cd8a8986 2025-10-20 https://biopharmsignal.com/news/PRQR/proqr-receives-cta-authorization-for-ax-0810-and-announces-virtual-investor-and--ee5e4b27 2025-10-20 https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-announces-oral-presentation-featuring-new-analyses-from-the-zoliflodacin-pivotal-phase-3-trial-at-idweek-2025 2025-10-20 https://biopharmsignal.com/news/ADAP/adaptimmune-announces-delisting-from-nasdaq 2025-10-20 https://biopharmsignal.com/news/PROK/prokidney-announces-two-abstracts-selected-for-presentation-at-the-american-society-of-nephrology-s-kidney-week-2025 2025-10-20 https://biopharmsignal.com/news/CRMD/cormedix-inc-announces-preliminary-third-quarter-2025-results-and-raises-2025-ne-3c1e1353 2025-10-20 https://biopharmsignal.com/news/REPL/replimune-announces-fda-acceptance-of-bla-resubmission-of-rp1-for-the-treatment-of-advanced-melanoma 2025-10-20 https://biopharmsignal.com/news/BDSX/biodesix-to-report-third-quarter-2025-financial-results-on-november-3-2025-d447945a 2025-10-20 https://biopharmsignal.com/news/KROS/keros-therapeutics-commences-issuer-tender-offer-to-repurchase-up-to-194-4-milli-bb1e31fd 2025-10-20 https://biopharmsignal.com/news/FLGT/fulgent-shares-preliminary-data-from-poster-presentation-at-esmo-2025-conference 2025-10-20 https://biopharmsignal.com/news/REPL/replimune-highlights-acral-melanoma-data-for-rp1-plus-nivolumab-at-the-esmo-congress-2025 2025-10-19 https://biopharmsignal.com/news/NCNA/nucana-presents-encouraging-data-on-nuc-7738-in-combination-with-pd-1-inhibitors-using-primary-patient-derived-organoids-and-autologous-tumor-infiltrating-lymphocytes-at-the-esmo-congress-2025 2025-10-18 https://biopharmsignal.com/news/BMY/systimmune-inc-and-bristol-myers-squibb-announce-first-global-phase-i-results-of-iza-bren-an-egfr-x-her3-bispecific-antibody-drug-conjugate-in-patients-with-advanced-solid-tumors-at-esmo-2025 2025-10-17 https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-new-clinical-results-highlighting-durable-progression-free-survival-data-for-solnerstotug-in-pd-l-1-resistant-tumors-at-the-esmo-congress-2025 2025-10-17 https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-to-present-results-from-phase-2-bestow-trial-of-tegopruba-dc21e67b 2025-10-17 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-present-new-data-on-nuzyrar-omadacycline-at-idweek-2025-and-chest-2025 2025-10-17 https://biopharmsignal.com/news/IRTC/irhythm-technologies-to-report-third-quarter-2025-financial-results-on-october-3-40fec07a 2025-10-16 https://biopharmsignal.com/news/GMED/globus-medical-schedules-third-quarter-earnings-release-and-conference-call-9fd30d3d 2025-10-16 https://biopharmsignal.com/news/TFX/teleflex-announces-third-quarter-2025-earnings-conference-call-information-and-v-910c02b8 2025-10-16 https://biopharmsignal.com/news/CLLS/cellectis-randd-day-highlights-lasme-cel-s-potential-to-address-significant-unmet-need-for-patients-with-r-r-b-all 2025-10-16 https://biopharmsignal.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference 2025-10-16 https://biopharmsignal.com/news/NXTC/nextcure-and-simcere-zaiming-announce-expansion-of-ongoing-phase-1-trial-of-sim0-c0b6a07f 2025-10-16 https://biopharmsignal.com/news/TBPH/theravance-biopharma-launches-disease-education-campaign-to-advance-scientific-understanding-of-neurogenic-orthostatic-hypotension-due-to-multiple-system-atrophy 2025-10-16 https://biopharmsignal.com/news/LIXT/lixte-biotechnology-holdings-highlights-q4-2025-priorities-including-ongoing-advancement-of-lead-candidate-lb-100-strategic-oncology-business-development-and-acquisition-plans 2025-10-16 https://biopharmsignal.com/news/CCCC/c4-therapeutics-announces-pricing-of-125-million-underwritten-offering-79c484a2 2025-10-16 https://biopharmsignal.com/news/GANX/gain-therapeutics-to-attend-the-2025-maxim-growth-summit-2aba082f 2025-10-16 https://biopharmsignal.com/news/CLLS/cellectis-hosts-randd-day-today-showcasing-pipeline-progress-and-long-term-value-drivers 2025-10-16 https://biopharmsignal.com/news/CCEL/cord-blood-banking-leader-cryo-cell-reports-fiscal-third-quarter-2025-financial-results 2025-10-15 https://biopharmsignal.com/news/EGRX/eagle-pharmaceuticals-announces-availability-of-unaudited-second-quarter-2025-financial-statements 2025-10-15 https://biopharmsignal.com/news/TDOC/teladoc-health-to-announce-third-quarter-2025-financial-results-5590486b 2025-10-15 https://biopharmsignal.com/news/MMSI/merit-medical-signs-asset-purchase-agreement-with-pentax-medical-to-acquire-c2-c-172fcd91 2025-10-15 https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-report-third-quarter-2025-financial-results-on-november-4-fb88edc9 2025-10-15 https://biopharmsignal.com/news/CLNN/clene-to-participate-in-a-panel-discussion-at-the-maxim-growth-summit-8ff9e3a5 2025-10-15 https://biopharmsignal.com/news/AMRN/amarin-to-report-third-quarter-2025-financial-results-and-host-conference-call-o-f3c61d95 2025-10-15 https://biopharmsignal.com/news/MNPR/monopar-announces-abstract-accepted-for-oral-presentation-at-aasld-the-liver-meetingr-2025 2025-10-15 https://biopharmsignal.com/news/GSK/viiv-healthcare-s-clarity-study-shows-long-acting-cabotegravir-more-acceptable-than-lenacapavir-injections-after-a-single-dose-with-90-preferring-cabotegravir 2025-10-15 https://biopharmsignal.com/news/STXS/stereotaxis-announces-eu-launch-and-510-k-submission-for-synchrony-system-to-mod-97ab40f3 2025-10-15 https://biopharmsignal.com/news/RGEN/repligen-to-report-third-quarter-2025-financial-results-a08f5946 2025-10-15 https://biopharmsignal.com/news/GYRE/gyre-therapeutics-announces-completion-of-patient-enrollment-in-phase-3-clinical-f639c730 2025-10-15 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-completion-of-patient-enrollment-in-phase-3-clinical-trial-of-pirfenidone-capsules-for-the-treatment-of-pneumoconiosis 2025-10-15 https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-to-participate-in-the-2025-maxim-growth-summit-and-eyecelerator-at-aao-2025 2025-10-15 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-foundation-announces-1-million-donation-to-patient-advocate-foundation 2025-10-15 https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-plan-for-return-of-375-million-in-excess-capital-1eebb644 2025-10-15 https://biopharmsignal.com/news/BDSX/biodesix-announces-presentations-and-events-at-the-chest-2025-annual-meeting-331a6577 2025-10-15 https://biopharmsignal.com/news/GMED/globus-medical-launches-anthem-elbow-fracture-system-a-comprehensive-plating-por-ac3f006f 2025-10-14 https://biopharmsignal.com/news/IPSC/century-therapeutics-to-present-at-chardan-s-9th-annual-genetic-medicines-confer-df234297 2025-10-14 https://biopharmsignal.com/news/GOCO/gohealth-helps-medicare-consumers-navigate-another-disruptive-annual-enrollment--9b94228d 2025-10-14 https://biopharmsignal.com/news/IMMX/immix-biopharma-to-present-at-the-guggenheim-2nd-annual-healthcare-innovation-co-18c04a4b 2025-10-14 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-presentations-on-tebipenem-hbr-at-idweek-eefe5ceb 2025-10-14 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-and-medline-industries-launch-new-hocl-wound-cleanser-for-u-s-hospitals 2025-10-14 https://biopharmsignal.com/news/SSKN/excimer-laser-demonstrates-promising-results-in-treating-rare-variant-of-cutaneo-c1fd7868 2025-10-14 https://biopharmsignal.com/news/NCNA/nucana-announces-encouraging-data-for-nuc-3373-in-combination-with-anti-pd-1-therapy 2025-10-14 https://biopharmsignal.com/news/CING/fda-accepts-cingulate-s-new-drug-application-for-ctx-1301-in-attention-deficit-h-a6a75750 2025-10-14 https://biopharmsignal.com/news/AMRN/amarin-and-hls-therapeutics-collaborate-on-presenting-reduce-it-and-epa-mechanis-ce93678e 2025-10-14 https://biopharmsignal.com/news/KRYS/krystal-biotech-receives-fda-platform-technology-designation-for-hsv-1-viral-vec-b58e7670 2025-10-14 https://biopharmsignal.com/news/MRUS/merus-announces-publication-of-an-abstract-on-petosemtamab-in-metastatic-colorectal-cancer-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics 2025-10-14 https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-upcoming-investor-conference-participation 2025-10-14 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-to-present-results-from-positive-phase-3-clinical-trial-evaluating-hydronidone-for-the-treatment-of-liver-fibrosis-in-chronic-hepatitis-b-at-aasld-the-liver-meetingr-2025 2025-10-14 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-fda-acceptance-of-bla-resubmission-of-kresladitm-for-the-treatment-of-severe-leukocyte-adhesion-deficiency-i-lad-i 2025-10-14 https://biopharmsignal.com/news/PASG/passage-bio-to-participate-in-chardan-s-9th-annual-genetic-medicines-conference 2025-10-14 https://biopharmsignal.com/news/TDOC/teladoc-health-adds-workplace-safety-capability-to-its-ai-enabled-clarity-monito-943f45e3 2025-10-14 https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-present-new-analyses-highlighting-yupelrir-revefenacin-outcomes-in-copd-at-the-2025-chest-annual-meeting 2025-10-14 https://biopharmsignal.com/news/GSK/gsk-s-shingrix-approved-in-china-for-prevention-of-shingles-in-adults-aged-18-and-over-who-are-at-increased-risk-due-to-immunodeficiency-or-immunosuppression 2025-10-14 https://biopharmsignal.com/news/ANL/adlai-nortye-to-present-short-talk-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics 2025-10-14 https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-present-translational-data-and-key-biology-findings-elucidatin-2cd6c6aa 2025-10-13 https://biopharmsignal.com/news/RPTX/repare-therapeutics-to-present-initial-data-from-phase-1-lions-clinical-trial-at-37th-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics 2025-10-13 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-to-present-rezatapopt-pivotal-phase-2-initial-analysis-and-natural-history-study-results-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics 2025-10-13 https://biopharmsignal.com/news/DNLI/denali-therapeutics-announces-fda-review-extension-of-bla-for-tividenofusp-alfa--40db04cb 2025-10-13 https://biopharmsignal.com/news/MRUS/merus-announces-petosemtamab-in-metastatic-colorectal-cancer-abstract-selected-for-plenary-session-oral-presentation-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics 2025-10-13 https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-positive-pre-bla-meeting-with-u-s-fda-for-del-zota-in-dmd44-with-a-submission-planned-for-q1-2026 2025-10-13 https://biopharmsignal.com/news/PRQR/proqr-to-participate-in-upcoming-investor-conferences-in-october-2025-704b6bbf 2025-10-13 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-appoints-biopharmaceutical-executive-mark-w-hahn-to-its-boar-e5f0f875 2025-10-13 https://biopharmsignal.com/news/APYX/apyx-medical-corporation-submits-fda-510-k-for-device-label-expansion-of-ayon-bo-8105d73f 2025-10-13 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-to-present-at-ld-micro-main-event-xix 2025-10-13 https://biopharmsignal.com/news/STXS/stereotaxis-cardiofocus-collaborate-to-advance-robotic-pulsed-field-ablation-for-60e622ee 2025-10-13 https://biopharmsignal.com/news/ABEO/abeona-therapeuticsr-announces-abo-503-gene-therapy-for-x-linked-retinoschisis-xlrs-selected-by-fda-for-rare-disease-endpoint-advancement-rdea-pilot-program 2025-10-13 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-data-at-esmor-2025-showcasing-progress-of-oncology-portfolio-across-diverse-tumor-types 2025-10-13 https://biopharmsignal.com/news/IMRN/immuron-q1-fy26-yoy-growth-698794a6 2025-10-13 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-closing-of-4-5-million-private-placement-priced-at-the-market-under-nasdaq-rules 2025-10-10 https://biopharmsignal.com/news/APGE/apogee-therapeutics-inc-announces-closing-of-public-offering-and-full-exercise-o-b82c6dd4 2025-10-10 https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2025-10-10 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-pricing-of-4-5-million-underwritten-offering-of-common-stock 2025-10-10 https://biopharmsignal.com/news/ASMB/assembly-biosciences-presents-interim-phase-1b-data-for-hsv-helicase-primase-inhibitor-candidate-abi-5366-at-the-38th-congress-of-the-international-union-against-sexually-transmitted-infections-iusti-europe 2025-10-10 https://biopharmsignal.com/news/NTRB/nutriband-signs-agreement-with-brand-institute-to-develop-the-commercial-brand-n-90e4e807 2025-10-10 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-strengthens-and-diversifies-cell-therapy-portfolio-with-acquisition-of-orbital-therapeutics 2025-10-10 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-and-tv-host-gail-simmons-tackle-stigma-in-schizophrenia-with-new-initiative-spotlighting-the-power-of-support-and-connection 2025-10-10 https://biopharmsignal.com/news/LMAT/lemaitre-will-announce-third-quarter-2025-earnings-results-on-november-6-2025-f931d019 2025-10-09 https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-4-5-million-private-placement-priced-at-the-market-under-nasdaq-rules 2025-10-09 https://biopharmsignal.com/news/EDIT/editas-medicine-reports-in-vivo-proof-of-concept-data-for-edit-401-at-the-europe-323d1aae 2025-10-09 https://biopharmsignal.com/news/PYXS/pyxis-oncology-appoints-alex-kane-as-senior-vice-president-investor-relations-ca-2e9365d0 2025-10-09 https://biopharmsignal.com/news/GHRS/gh-research-announces-novel-therapies-symposium-presentation-and-posters-at-the-2025-ecnp-congress 2025-10-09 https://biopharmsignal.com/news/APGE/apogee-therapeutics-inc-announces-pricing-of-300-million-underwritten-public-off-5a8aefca 2025-10-09 https://biopharmsignal.com/news/NAVB/navidea-biopharmaceuticals-inc-files-for-bankruptcy 2025-10-08 https://biopharmsignal.com/news/AMN/amn-healthcare-to-hold-third-quarter-2025-earnings-conference-call-on-thursday-n-71c493bd 2025-10-08 https://biopharmsignal.com/news/ISRG/intuitive-expands-ai-and-advanced-imaging-integration-in-ion-endoluminal-system 2025-10-08 https://biopharmsignal.com/news/NEPH/nephros-launches-new-pfas-filter-for-point-of-use-protection-of-potable-water-1b863160 2025-10-08 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-and-catalent-announce-global-antibody-drug-conjugate-adc-license-agreement 2025-10-08 https://biopharmsignal.com/news/NTRB/nutriband-files-provisional-patent-application-for-enhanced-transdermal-abuse-de-3a4a8a91 2025-10-08 https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-participate-in-october-2025-investor-conferences 2025-10-08 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-receives-fast-track-designation-from-the-u-s-fda-for-wtx-1-9031109f 2025-10-08 https://biopharmsignal.com/news/CRVO/cervomed-announces-new-data-from-phase-2b-trial-demonstrating-neflamapimod-s-pot-a28628d8 2025-10-08 https://biopharmsignal.com/news/NTRB/nutriband-to-present-at-the-noble-capital-markets-emerging-growth-virtual-equity-97306bad 2025-10-08 https://biopharmsignal.com/news/IMRN/immuron-submits-imm-529-ind-to-fda-4630f035 2025-10-08 https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-key-opinion-leader-webinar-hosted-by-alliance-global-pa-41d26f60 2025-10-07 https://biopharmsignal.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q3-of-2025-3a7edbdd 2025-10-07 https://biopharmsignal.com/news/PRVA/privia-health-to-report-third-quarter-2025-results-on-thursday-november-6 2025-10-07 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-expands-market-reach-with-fda-cosmetic-product-facility-registration-and-microcyn-based-cosmetic-product-listing-under-mocra 2025-10-07 https://biopharmsignal.com/news/OGEN/oragenics-announces-strategic-partnership-with-receptor-ai-to-accelerate-pipeline-development 2025-10-07 https://biopharmsignal.com/news/MGTX/meiragtx-announces-two-posters-at-the-european-society-of-gene-and-cell-therapy-esgct-2025-annual-congress 2025-10-07 https://biopharmsignal.com/news/ABUS/arbutus-announces-four-abstracts-accepted-for-presentation-at-aasld-the-liver-meetingr-2025 2025-10-07 https://biopharmsignal.com/news/AEMD/aethlon-medical-s-hemopurifierr-shows-changes-in-extracellular-vesicles-extracellular-micrornas-and-t-cell-numbers-in-australian-oncology-clinical-trial 2025-10-07 https://biopharmsignal.com/news/CRVO/cervomed-appoints-matthew-winton-ph-d-as-chief-commercial-and-business-officer-b2ca4975 2025-10-07 https://biopharmsignal.com/news/GALT/galectin-therapeutics-to-present-at-the-american-association-for-the-study-of-li-b029526f 2025-10-07 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-announce-third-quarter-2025-financial-results-on-octob-e450a832 2025-10-07 https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-to-deliver-six-presentations-from-its-infectious-diseases-and-critical-care-portfolio-at-idweek-2025 2025-10-07 https://biopharmsignal.com/news/CLLS/cellectis-to-present-data-on-non-viral-gene-therapy-and-tale-base-editors-at-the-esgct-annual-congress 2025-10-07 https://biopharmsignal.com/news/EGRX/eagle-pharmaceuticals-announces-availability-of-unaudited-first-quarter-2025-financial-statements 2025-10-06 https://biopharmsignal.com/news/IMMX/immix-biopharma-to-present-abstract-at-the-upcoming-ash-2025-annual-meeting-f8fd4f0c 2025-10-06 https://biopharmsignal.com/news/EQ/equillium-announces-leadership-and-corporate-updates-d2e29f67 2025-10-06 https://biopharmsignal.com/news/BDSX/biodesix-unveils-october-lung-health-events-in-colorado-with-the-association-of--ab1f3427 2025-10-06 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-edit-401-oral-presentation-at-the-european-society-of--31fa9f7c 2025-10-06 https://biopharmsignal.com/news/BDRX/biodexa-to-host-breakfast-symposium-on-fap-mechanisms-and-chemoprevention-trial--f373adc7 2025-10-06 https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-poster-presentations-at-the-society-for-immunotherapy-of-cancer-s-sitc-40th-annual-meeting 2025-10-06 https://biopharmsignal.com/news/MRKR/marker-therapeutics-announces-first-patient-treated-in-off-the-shelf-program-b73f1784 2025-10-06 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-announces-clinical-plan-for-lyr-210-and-late-breaking-oral-presentation-of-phase-3-enlighten-2-study 2025-10-06 https://biopharmsignal.com/news/XCUR/exicure-highlights-recent-achievements-and-near-term-strategic-priorities-a7b1c11e 2025-10-06 https://biopharmsignal.com/news/SSKN/marking-eczema-awareness-month-clinical-research-validates-strata-skin-sciences--d9f7a44f 2025-10-03 https://biopharmsignal.com/news/MMSI/merit-medical-systems-to-announce-third-quarter-2025-results-on-october-30-2025-7ce48064 2025-10-03 https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-upcoming-presentations-at-the-society-for-immunothe-ace2dfad 2025-10-03 https://biopharmsignal.com/news/BCAB/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sa-ace2359b 2025-10-03 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-can-0ca5727a 2025-10-03 https://biopharmsignal.com/news/VANI/vivani-medical-withdraws-record-date-for-cortigent-neuromodulation-subsidiary-spin-off 2025-10-03 https://biopharmsignal.com/news/OVID/ovid-therapeutics-announces-pricing-of-private-placement-totaling-up-to-175-mill-be382fbd 2025-10-03 https://biopharmsignal.com/news/OVID/ovid-announces-positive-topline-results-for-the-next-generation-gaba-aminotransf-82bbdfda 2025-10-03 https://biopharmsignal.com/news/CRVO/cervomed-to-participate-in-the-4th-annual-roth-healthcare-opportunities-conferen-1d7789e3 2025-10-02 https://biopharmsignal.com/news/COCP/cocrystal-pharma-to-present-at-noble-capital-markets-emerging-growth-virtual-equ-544d5aac 2025-10-02 https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-the-4th-annual-roth-healthcare-opportunities-conference-525cf456 2025-10-02 https://biopharmsignal.com/news/DRMA/dermata-announces-acceptance-of-patent-application-for-next-generation-acne-treatment-by-australian-patent-office 2025-10-02 https://biopharmsignal.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-wedbush-securities-key-opinion-2cd196e6 2025-10-02 https://biopharmsignal.com/news/PEPG/pepgen-announces-oral-presentations-at-the-30th-annual-international-congress-of-the-world-muscle-society 2025-10-02 https://biopharmsignal.com/news/IMRN/immuron-letter-to-shareholders-projects-update-b362ecad 2025-10-02 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-provides-update-on-bdc-4182-and-extends-cash-runway-into-20-8bbaa910 2025-10-01 https://biopharmsignal.com/news/IMMX/immix-biopharma-to-present-at-the-37th-annual-piper-sandler-healthcare-conferenc-fcc142dd 2025-10-01 https://biopharmsignal.com/news/MMSI/merit-medical-announces-scout-milestone-750-000-patients-treated-with-wire-free--d2158f0b 2025-10-01 https://biopharmsignal.com/news/SMTI/sanara-medtech-to-report-third-quarter-2025-financial-results-on-november-12-202-d7a9759f 2025-10-01 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-to-host-virtual-r-d-day-on-october-27-aa5adfe1 2025-10-01 https://biopharmsignal.com/news/CCCC/c4-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-3e38d233 2025-10-01 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-s-anti-mtbr-tau-targeting-antibody-bms-986446-granted-fast-track-designation-by-u-s-fda-for-the-treatment-of-alzheimer-s-disease 2025-10-01 https://biopharmsignal.com/news/FMS/fresenius-medical-care-appoints-joseph-turk-as-new-management-board-member-for-care-enablement 2025-10-01 https://biopharmsignal.com/news/PYXS/pyxis-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-65cdcb26 2025-09-30 https://biopharmsignal.com/news/VVOS/vivos-therapeutics-releases-additional-clinical-data-showing-marked-improvement--0b23c68a 2025-09-30 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-receives-continued-validation-for-its-personalized-approach-c1090e39 2025-09-30 https://biopharmsignal.com/news/BRNS/barinthus-biotherapeutics-to-combine-with-clywedog-therapeutics-to-target-metabolic-and-autoimmune-diseases 2025-09-30 https://biopharmsignal.com/news/ATYR/atyr-pharma-presents-additional-findings-from-phase-3-efzo-fittm-study-in-late-breaking-oral-abstract-at-the-european-respiratory-society-ers-congress-2025 2025-09-30 https://biopharmsignal.com/news/ADXN/addex-therapeutics-reports-2025-half-year-and-second-quarter-financial-results-a-2f0d1abc 2025-09-30 https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-operational-restructuring-intended-to-extend-cash-runw-0ec3de64 2025-09-29 https://biopharmsignal.com/news/ICCC/immucell-announces-selection-of-its-next-president-and-ceo-1b852365 2025-09-29 https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-recent-updates 2025-09-29 https://biopharmsignal.com/news/ENLV/d-boral-capital-to-host-kol-webinar-with-world-leading-experts-featuring-insight-d3e1c185 2025-09-29 https://biopharmsignal.com/news/MDWD/mediwound-announces-30-million-registered-direct-offering-of-ordinary-shares-7a15f3f7 2025-09-29 https://biopharmsignal.com/news/ICU/seastar-medical-reports-positive-early-results-for-quelimmune-therapy-in-pediatr-03c55a68 2025-09-29 https://biopharmsignal.com/news/CRMD/cormedix-announces-completion-of-enrollment-in-phase-iii-respect-clinical-trial--fd67ecf1 2025-09-29 https://biopharmsignal.com/news/LSTA/lisata-therapeutics-announces-encouraging-preliminary-results-from-the-pancreatic-cancer-cohort-of-the-cendifox-trial 2025-09-29 https://biopharmsignal.com/news/APYX/apyx-medical-to-host-virtual-key-opinion-leader-event-to-discuss-the-commercial--69bd2e95 2025-09-29 https://biopharmsignal.com/news/GSK/luke-miels-appointed-ceo-designate-for-gsk 2025-09-29 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-positive-data-from-ongoing-long-term-open-label-study-and-updates-to-nomlabofusp-program-for-friedreich-s-ataxia 2025-09-29 https://biopharmsignal.com/news/MRUS/genmab-to-acquire-merus-expanding-late-stage-pipeline-and-accelerating-into-a-wholly-owned-model 2025-09-29 https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-conference-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreich-s-ataxia 2025-09-28 https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-reports-on-week-16-results-of-the-vela-phase-3-hidradenitis-suppurativa-program-with-the-nanobodyr-sonelokimab 2025-09-28 https://biopharmsignal.com/news/BIVI/biovie-to-host-live-investor-webinar-and-q-a-on-oct-8-aa890057 2025-09-26 https://biopharmsignal.com/news/ADXN/addex-therapeutics-to-report-2025-half-year-and-second-quarter-financial-results-abcf72f9 2025-09-26 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025 2025-09-25 https://biopharmsignal.com/news/CLNN/clene-presents-new-clinical-data-at-ectrims-2025-meeting-demonstrating-cnm-au8-i-3d2c9101 2025-09-25 https://biopharmsignal.com/news/RLYB/rallybio-completes-dosing-of-first-cohort-in-rlyb116-phase-1-confirmatory-pharmacokinetic-pharmacodynamic-study 2025-09-25 https://biopharmsignal.com/news/MDWD/mediwound-expands-global-reach-with-marketing-approval-of-nexobrid-in-australia-2ce37f8b 2025-09-25 https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-announces-first-patients-dosed-in-phase-1-single-ascending-dose-study-of-intravenous-selonabant-under-development-for-acute-cannabis-induced-toxicity 2025-09-25 https://biopharmsignal.com/news/ACIU/peer-reviewed-results-from-phase-1b-2a-trial-of-anti-ptau-active-immunotherapy-f-b178e5d0 2025-09-25 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-builds-on-eliquisr-apixaban-direct-to-patient-program-announces-new-bms-patient-connect-platform-offering-sotyktur-deucravacitinib 2025-09-25 https://biopharmsignal.com/news/NTRB/nutriband-inc-to-present-at-the-microcap-rodeo-conference-1d32dd6a 2025-09-24 https://biopharmsignal.com/news/MNPR/monopar-therapeutics-inc-announces-pricing-of-135-million-underwritten-offering-of-common-stock-and-pre-funded-warrants 2025-09-24 https://biopharmsignal.com/news/MNPR/monopar-announces-journal-of-hepatology-publishes-physicians-letter-to-the-editor-demonstrating-alxn1840-rapidly-improved-copper-balance-in-wilson-disease-patients 2025-09-24 https://biopharmsignal.com/news/PRVA/privia-health-expands-value-based-care-footprint-with-acquisition-of-accountable-care-organization-business-from-evolent-health 2025-09-23 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-to-report-third-quarter-2025-financial-results-on-october-22-2025 2025-09-23 https://biopharmsignal.com/news/CYCN/cyclerion-announces-transformational-relaunch-as-a-neuropsychiatric-company 2025-09-23 https://biopharmsignal.com/news/LGMK/logicmark-launches-predictive-activity-metrics-in-freedom-alert-max-device-1ca35941 2025-09-23 https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-the-lytham-partners-fall-2025-investor-conference-d78de3d1 2025-09-23 https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-to-host-virtual-kol-event-to-discuss-full-dose-expansion-data-for-solnerstotug-in-pd-l-1-resistant-tumors-on-october-20-2025 2025-09-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-phase-3-excaliber-rrmm-study-evaluating-iberdomide-in-combination-with-standard-therapies-demonstrated-a-significant-improvement-in-minimal-residual-disease-negativity-rates-in-relapsed-or-refractory-multiple-myeloma 2025-09-23 https://biopharmsignal.com/news/ADXN/addex-appoints-bank-of-new-york-mellon-as-depositary-bank-454393ff 2025-09-23 https://biopharmsignal.com/news/AMN/amn-healthcare-announces-pricing-of-senior-notes-offering-b63ff827 2025-09-22 https://biopharmsignal.com/news/SSKN/new-peer-reviewed-publication-of-combination-therapy-in-vitiligo-with-strata-ski-09c885cb 2025-09-22 https://biopharmsignal.com/news/AMN/amn-healthcare-launches-400-0-million-offering-of-senior-notes-ab272e92 2025-09-22 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-presents-new-phase-2-clinical-data-for-stenoparib-2x-121-s-3c678436 2025-09-22 https://biopharmsignal.com/news/ACST/grace-therapeutics-pivotal-phase-3-strive-on-safety-trial-presented-at-2025-neurocritical-care-annual-meeting 2025-09-22 https://biopharmsignal.com/news/GSK/gsk-to-submit-label-update-for-wellcovorin-leucovorin-at-us-fda-s-request 2025-09-22 https://biopharmsignal.com/news/STXS/erasmus-medical-center-advances-cardiovascular-care-with-genesis-robotic-system-99449be9 2025-09-22 https://biopharmsignal.com/news/CCCC/c4-therapeutics-presents-cemsidomide-phase-1-multiple-myeloma-data-supporting-po-1133d0eb 2025-09-20 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-third-quarter-2025-on-october-30-2025 2025-09-19 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-pricing-of-30-million-public-offering-of-common-st-25ef0eea 2025-09-19 https://biopharmsignal.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-announces-pricing-of-9-million-public-offeri-1bf9960b 2025-09-19 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-proposed-public-offering-of-common-stock-pre-funde-8b4f120f 2025-09-18 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-50-enrollment-milestone-surpassed-in-its-ongoing-relap-111efe26 2025-09-18 https://biopharmsignal.com/news/REPL/replimune-provides-update-following-type-a-meeting-with-fda 2025-09-18 https://biopharmsignal.com/news/PDSB/pds-biotech-sets-significant-benchmark-in-head-and-neck-cancer-by-achieving-exte-ec41cbc8 2025-09-18 https://biopharmsignal.com/news/FMS/fresenius-medical-care-advances-its-fme-reignite-strategy-by-increasing-ownership-in-its-value-based-care-asset-and-appointing-a-new-leader-for-the-operating-segment 2025-09-18 https://biopharmsignal.com/news/ETNB/89bio-inc-announces-agreement-to-be-acquired-by-roche 2025-09-18 https://biopharmsignal.com/news/EGRX/eagle-pharmaceuticals-announces-availability-of-proxy-materials-and-audited-financial-statements-for-the-2023-and-2024-fiscal-years 2025-09-17 https://biopharmsignal.com/news/COO/coopercompanies-announces-expanded-share-repurchase-program-d90cc558 2025-09-17 https://biopharmsignal.com/news/PIII/p3-health-partners-to-participate-in-the-jefferies-healthcare-services-conference 2025-09-17 https://biopharmsignal.com/news/CING/cingulate-secures-exclusive-manufacturing-partnership-with-bend-bio-sciences-to--856e0a78 2025-09-17 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-ceo-to-present-at-biomarkers-precision-medicine-2025-1f9e2990 2025-09-17 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-appoints-core-ir-for-investor-relations-shareholder-communic-7dbf6e27 2025-09-17 https://biopharmsignal.com/news/GSK/gsk-to-invest-30-billion-in-randd-and-manufacturing-in-the-united-states-over-next-5-years 2025-09-17 https://biopharmsignal.com/news/CRVO/cervomed-highlights-neflamapimod-s-potential-benefits-in-session-on-dementia-wit-ceeaf50e 2025-09-17 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-restructuring-of-business-operations-designed-to-dr-605b8cc3 2025-09-17 https://biopharmsignal.com/news/YMAB/serb-pharmaceuticals-completes-acquisition-of-y-mabs-therapeutics 2025-09-16 https://biopharmsignal.com/news/ALEC/alector-to-host-virtual-research-and-development-event-highlighting-pgrn-franchi-775438de 2025-09-16 https://biopharmsignal.com/news/TENX/tenax-therapeutics-announces-european-patent-office-intention-to-grant-patent-co-f9184166 2025-09-16 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-the-bernstein-insights-healthcare-leaders-and-disruptors-2nd-annual-healthcare-forum 2025-09-16 https://biopharmsignal.com/news/MDXH/mdxhealth-announces-closing-of-exosome-diagnostics-acquisition-from-bio-techne-305cb76b 2025-09-15 https://biopharmsignal.com/news/COCP/cocrystal-pharma-inc-announces-closing-of-up-to-13-million-registered-direct-off-ff62a889 2025-09-15 https://biopharmsignal.com/news/GSK/gsk-to-showcase-new-research-from-its-broad-respiratory-portfolio-at-the-european-respiratory-society-ers-congress-2025 2025-09-15 https://biopharmsignal.com/news/ASRT/assertio-presents-first-ever-real-world-study-showing-patient-experience-with-sy-14523696 2025-09-15 https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-fda-approval-of-updated-vyjuvek-label-61631978 2025-09-15 https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-topline-results-from-phase-3-efzo-fittm-study-of-efzofitimod-in-pulmonary-sarcoidosis 2025-09-15 https://biopharmsignal.com/news/FMS/fresenius-medical-care-celebrates-nephrology-nurses-week-with-the-care-award 2025-09-15 https://biopharmsignal.com/news/MNPR/monopar-to-present-new-long-term-neurological-efficacy-and-safety-data-for-alxn1840-in-wilson-disease-at-the-150th-american-neurological-association-annual-meeting 2025-09-14 https://biopharmsignal.com/news/MMSI/merit-medical-embosphere-microspheres-achieve-ce-mark-for-genicular-artery-embol-adad39eb 2025-09-12 https://biopharmsignal.com/news/COCP/cocrystal-pharma-inc-announces-up-to-13-million-registered-direct-offering-price-22a97c57 2025-09-12 https://biopharmsignal.com/news/ISRG/intuitive-introduces-real-time-surgical-insights-for-da-vinci-5 2025-09-12 https://biopharmsignal.com/news/BDRX/interim-results-for-the-six-months-ended-june-30-2025-933a70a9 2025-09-12 https://biopharmsignal.com/news/COCP/cocrystal-pharma-showcases-cdi-988-the-first-oral-antiviral-in-development-for-n-70eaa426 2025-09-12 https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-announces-update-on-going-private-transaction-and-strategic-alternatives 2025-09-12 https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-participate-in-fireside-chat-at-the-stifel-2025-virtual-49c0bb84 2025-09-12 https://biopharmsignal.com/news/HSCS/heartsciences-provides-business-update-and-reports-first-quarter-of-fiscal-2026--149a62b7 2025-09-11 https://biopharmsignal.com/news/IMMX/nancy-t-chang-proven-biotechnology-leader-joins-immix-biopharma-board-of-directo-3f38f57b 2025-09-11 https://biopharmsignal.com/news/GRI/gri-bio-reports-6-week-interim-lung-function-data-in-ongoing-phase-2a-study-in-i-f1201615 2025-09-11 https://biopharmsignal.com/news/BDSX/biodesix-announces-one-for-twenty-reverse-stock-split-1b8f5040 2025-09-11 https://biopharmsignal.com/news/TFX/first-patient-enrolled-in-dubstent-diabetes-trial-targeting-improved-pci-outcome-7f894c3d 2025-09-11 https://biopharmsignal.com/news/ENLV/enlivex-ceo-issues-letter-to-shareholders-outlining-strategic-roadmap-following-positive-phase-iia-allocetratm-results 2025-09-11 https://biopharmsignal.com/news/DSGN/design-therapeutics-appoints-justin-gover-to-board-of-directors 2025-09-10 https://biopharmsignal.com/news/NTRB/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yo-9c68f056 2025-09-10 https://biopharmsignal.com/news/PPBT/purple-biotech-receives-intention-to-grant-a-european-patent-covering-nt219-comb-470de183 2025-09-10 https://biopharmsignal.com/news/ASRT/assertio-to-present-new-data-from-real-world-evidence-study-of-sympazan-at-upcom-a319cbba 2025-09-10 https://biopharmsignal.com/news/TIL/instil-bio-announces-immuneonco-s-presentation-of-2510-monotherapy-data-in-patients-with-2l-squamous-nsclc-at-the-2025-world-conference-on-lung-cancer-wclc 2025-09-10 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-announces-promising-rezatapopt-monotherapy-interim-data-from-pynnacle-phase-2-trial-across-multiple-solid-tumors-with-a-tp53-y220c-mutation 2025-09-10 https://biopharmsignal.com/news/ENLV/enlivex-announces-issuance-of-new-patent-application-covering-the-use-of-allocet-eb62be7d 2025-09-09 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-strategic-investment-by-houston-based-goose-capital-le-cc792695 2025-09-08 https://biopharmsignal.com/news/NMTC/neuroone-to-participate-in-sidoti-small-cap-conference-on-september-17th-and-18t-d0cb5764 2025-09-08 https://biopharmsignal.com/news/ENTX/entera-bio-presents-positive-effects-of-eb613-on-both-trabecular-and-cortical-bo-b7325c0a 2025-09-08 https://biopharmsignal.com/news/COCP/cocrystal-pharma-receives-fda-ind-clearance-for-challenge-study-of-oral-broad-sp-9e965826 2025-09-08 https://biopharmsignal.com/news/BCAB/bioatla-announces-regulatory-update-on-clinical-development-plan-for-ozuriftamab-b294b1b8 2025-09-08 https://biopharmsignal.com/news/KROS/keros-therapeutics-presents-additional-clinical-data-from-its-ker-065-program-at-eeb9222c 2025-09-08 https://biopharmsignal.com/news/BMY/first-disclosure-of-global-interim-phase-2-data-for-biontech-and-bristol-myers-squibb-pd-l1xvegf-a-bispecific-antibody-pumitamig-bnt327-bms986545-in-patients-with-extensive-stage-small-cell-lung-cancer-shows-encouraging-antitumor-activity 2025-09-08 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference 2025-09-05 https://biopharmsignal.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2025-09-05 https://biopharmsignal.com/news/PPBT/purple-biotech-announces-closing-of-up-to-18-million-public-offering-6-million-u-861a3b84 2025-09-05 https://biopharmsignal.com/news/NCNA/nucana-compliant-with-all-nasdaq-continued-listing-criteria 2025-09-05 https://biopharmsignal.com/news/CGON/cg-oncology-continues-to-demonstrate-best-in-disease-durability-and-tolerability-ea511643 2025-09-05 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-announces-recipients-of-third-annual-dreams-grant-program-c623d830 2025-09-05 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-announces-closing-of-2-42-million-registered-direct-offerin-367e811a 2025-09-04 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-provides-clinical-update-cc3b1325 2025-09-04 https://biopharmsignal.com/news/PPBT/purple-biotech-announces-pricing-of-up-to-18-million-public-offering-0eb5b6f1 2025-09-04 https://biopharmsignal.com/news/LGMK/logicmark-becomes-first-to-integrate-medication-reminders-into-medical-alert-tec-89d6c801 2025-09-04 https://biopharmsignal.com/news/CLNN/clene-presents-preclinical-data-supporting-cnm-au8-for-the-treatment-of-parkinso-b2b2f06e 2025-09-04 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-elevate-360-consulting-offering-drives-growth-in-partner-cl-a7f44627 2025-09-04 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-presents-detailed-data-from-registrational-staar-study-in-f-29a789dd 2025-09-04 https://biopharmsignal.com/news/PPBT/purple-biotech-announces-new-data-supporting-the-unique-design-of-captn-3-tri-sp-8d9febf1 2025-09-04 https://biopharmsignal.com/news/NXTC/nextcure-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conferen-7289ab95 2025-09-04 https://biopharmsignal.com/news/CCCC/c4-therapeutics-highlights-recent-achievement-in-biogen-collaboration-20b891a3 2025-09-04 https://biopharmsignal.com/news/ACIU/ac-immune-sharpens-pipeline-focus-with-operational-efficiencies-extending-cash-r-21af8f7d 2025-09-04 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-participate-at-the-h-c-wainwright-27th-annual-global-investment-conference 2025-09-04 https://biopharmsignal.com/news/NTRB/nutriband-inc-announces-exercise-of-warrants-at-6-43-for-gross-proceeds-of-5-306-7aafa3ce 2025-09-03 https://biopharmsignal.com/news/IMVT/immunovant-unveils-durability-and-treatment-free-six-month-remission-data-with-potential-to-change-treatment-paradigm-for-uncontrolled-graves-disease-patients 2025-09-03 https://biopharmsignal.com/news/MOH/molina-healthcare-announces-third-quarter-2025-earnings-release-and-conference-call-dates 2025-09-03 https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-participate-in-september-2025-investor-conferences 2025-09-03 https://biopharmsignal.com/news/ASRT/assertio-to-participate-in-the-hc-wainwright-and-lake-street-conferences-in-sept-8cca2126 2025-09-03 https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-the-initiation-of-a-phase-3-head-to-head-car-t-cell-therapy-clinical-trial-in-aggressive-large-b-cell-lymphoma-and-formation-of-expert-steering-committee 2025-09-03 https://biopharmsignal.com/news/NCNA/nucana-to-present-data-on-nuc-7738-s-synergy-with-pd-1-inhibitors-at-the-esmo-congress-2025 2025-09-03 https://biopharmsignal.com/news/CGON/cg-oncology-completes-enrollment-in-pivot-006-24113900 2025-09-03 https://biopharmsignal.com/news/COCP/cocrystal-pharma-to-participate-at-the-h-c-wainwright-global-investment-conferen-d638d5e7 2025-09-03 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-announces-pricing-of-2-42-million-registered-direct-offerin-7720a02d 2025-09-03 https://biopharmsignal.com/news/MNPR/monopar-announces-abstract-accepted-with-distinction-for-oral-and-poster-presentations-at-the-upcoming-american-neurological-association-2025-annual-meeting 2025-09-03 https://biopharmsignal.com/news/RLYB/rallybio-receives-12-5-million-equity-milestone-payment-from-recursion-for-advancement-of-rev102-program 2025-09-03 https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference 2025-09-03 https://biopharmsignal.com/news/PPBT/purple-biotech-expands-captn-3-portfolio-with-im1305-a-novel-tri-specific-antibo-b6ae0949 2025-09-03 https://biopharmsignal.com/news/PMN/promis-neurosciences-receives-dsmb-approval-to-advance-to-final-dose-escalation--32a75106 2025-09-03 https://biopharmsignal.com/news/GRI/gri-bio-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference 2025-09-03 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-announces-chief-executive-officer-transition-26cdac25 2025-09-02 https://biopharmsignal.com/news/MGNX/macrogenics-to-present-at-h-c-wainwright-27th-annual-global-investment-conference 2025-09-02 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-to-present-at-the-h-c-wainwright-27-annual-global-investme-73501cfc 2025-09-02 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-to-present-at-the-h-c-wainwright-27th-annual-global-investm-99a79ac9 2025-09-02 https://biopharmsignal.com/news/LNSR/lensar-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-b7643c2c 2025-09-02 https://biopharmsignal.com/news/GNLX/genelux-corporation-to-participate-in-a-fireside-chat-at-h-c-wainwright-global-i-a0f98e2b 2025-09-02 https://biopharmsignal.com/news/PRPO/precipio-terminates-its-atm-1cfb69b9 2025-09-02 https://biopharmsignal.com/news/PMCB/pharmacyte-biotech-inc-increases-stake-in-tnf-pharmaceuticals-around-recent-license-for-breakthrough-light-speed-computing-platform-for-use-in-cryptocurrency-applications 2025-09-02 https://biopharmsignal.com/news/STXS/first-us-commercial-robotic-hd-mapping-procedures-successfully-completed-with-ma-9b6ebd27 2025-09-02 https://biopharmsignal.com/news/SSKN/strata-skin-sciences-ip-portfolio-holds-exclusivity-in-combination-therapies-of--4363b0cf 2025-09-02 https://biopharmsignal.com/news/NKTX/nkarta-to-participate-in-a-september-investor-conference 2025-09-02 https://biopharmsignal.com/news/CLNN/clene-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-d45d32a2 2025-09-02 https://biopharmsignal.com/news/GALT/galectin-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-invest-69241907 2025-09-02 https://biopharmsignal.com/news/IRMD/iradimed-corporation-announces-board-transition-anthony-vuoto-retires-joe-kiani--f2b1e782 2025-09-02 https://biopharmsignal.com/news/PDSB/pds-biotech-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-c-1561dd76 2025-09-02 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-to-participate-in-the-upcoming-h-c-wainwright-27th-annual--2262fc70 2025-09-02 https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-cantor-global-healthcare-conference-2025-497461c5 2025-09-02 https://biopharmsignal.com/news/MDWD/mediwound-s-nexobrid-to-be-highlighted-in-36-scientific-presentations-at-the-21s-a364bc2c 2025-09-02 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-to-participate-in-upcoming-conferences-in-september-132befb0 2025-09-02 https://biopharmsignal.com/news/EDIT/editas-medicine-nominates-edit-401-an-ldlr-targeted-medicine-as-lead-in-vivo-dev-cb17fa4d 2025-09-02 https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference 2025-09-02 https://biopharmsignal.com/news/CGON/cg-oncology-s-executive-leadership-to-participate-in-upcoming-investor-conferenc-a477a31b 2025-08-29 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-real-world-outcomes-of-camzyos-mavacamten-across-four-continents-at-the-european-society-of-cardiology-esc-congress-2025 2025-08-29 https://biopharmsignal.com/news/IRTC/amalfi-randomized-clinical-trial-results-demonstrate-increased-atrial-fibrillati-757df478 2025-08-29 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference 2025-08-29 https://biopharmsignal.com/news/EGRX/eagle-pharmaceuticals-to-appoint-abhinav-jain-to-its-board-of-directors 2025-08-28 https://biopharmsignal.com/news/PRVA/privia-health-acos-delivered-233-million-in-total-savings-in-the-2024-performance-year-of-medicare-shared-savings-program-a-32-year-over-year-increase 2025-08-28 https://biopharmsignal.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-september-7d9b69b3 2025-08-28 https://biopharmsignal.com/news/GMED/globus-medical-inc-secures-jury-verdict-in-delaware-patent-litigation-against-li-cf530ac0 2025-08-28 https://biopharmsignal.com/news/ETNB/89bio-to-participate-in-upcoming-investor-conferences 2025-08-28 https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-septem-192a6967 2025-08-28 https://biopharmsignal.com/news/EDIT/editas-medicine-to-host-webinar-announcing-lead-in-vivo-development-candidate-0648a3c5 2025-08-28 https://biopharmsignal.com/news/VCEL/vericel-to-present-at-the-wells-fargo-healthcare-conference-on-thursday-septembe-024dd811 2025-08-28 https://biopharmsignal.com/news/MRKR/marker-therapeutics-to-participate-in-a-fireside-chat-at-the-h-c-wainwright-27th-91015497 2025-08-28 https://biopharmsignal.com/news/ENTX/entera-bio-to-unveil-clinical-and-non-clinical-data-across-3-oral-peptide-progra-03fec212 2025-08-28 https://biopharmsignal.com/news/ALEC/alector-to-participate-in-upcoming-healthcare-conferences-3feb4b00 2025-08-28 https://biopharmsignal.com/news/MRUS/merus-to-present-at-the-2025-wells-fargo-healthcare-conference 2025-08-28 https://biopharmsignal.com/news/TENX/tenax-therapeutics-to-participate-in-the-cantor-global-healthcare-conference-202-205c7e53 2025-08-28 https://biopharmsignal.com/news/PASG/passage-bio-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference 2025-08-28 https://biopharmsignal.com/news/COO/coopercompanies-announces-third-quarter-2025-results-f116ef58 2025-08-27 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-to-present-at-the-cantor-global-healthcare-conference-on-sept-7e70fc0c 2025-08-27 https://biopharmsignal.com/news/DSGN/design-therapeutics-to-participate-in-the-2025-cantor-global-healthcare-conference 2025-08-27 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-to-participate-in-upcoming-september-conferences-e122390e 2025-08-27 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-participate-in-upcoming-september-investor-conferences-8ef6522e 2025-08-27 https://biopharmsignal.com/news/PROK/prokidney-to-participate-in-two-upcoming-conferences-the-citi-biopharma-back-to-school-conference-and-the-morgan-stanley-global-healthcare-conference 2025-08-27 https://biopharmsignal.com/news/IMRN/immuron-partners-with-investorhub-a28026a9 2025-08-27 https://biopharmsignal.com/news/LUNG/pulmonx-to-participate-in-september-investor-conferences 2025-08-26 https://biopharmsignal.com/news/IRMD/iradimed-corporation-to-participate-in-the-2025-wells-fargo-healthcare-conferenc-db1c37d0 2025-08-26 https://biopharmsignal.com/news/SIBN/si-bone-to-present-at-morgan-stanley-23rd-global-healthcare-conference-on-september-9-2025 2025-08-26 https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-upcoming-investor-conferences-b12659cb 2025-08-26 https://biopharmsignal.com/news/SNOA/national-psoriasis-foundation-awards-seal-of-recognition-to-sonoma-pharmaceuticals-for-reliefacyn-advanced 2025-08-26 https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-multiple-presentations-on-suprachoroidal-delivery-to-be-featured-at-the-25th-euretina-congress 2025-08-26 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-granted-fda-fast-track-designation-for-stenoparib-for-the--1710cc4a 2025-08-26 https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-september-investor-events-c0df44b7 2025-08-26 https://biopharmsignal.com/news/VRAX/virax-biolabs-partners-with-emory-university-on-viraximmunetm-clinical-studies-readies-for-fda-pre-submission-meeting-in-early-september 2025-08-26 https://biopharmsignal.com/news/MRKR/marker-therapeutics-provides-update-on-phase-1-apollo-study-highlighting-encoura-e67f51e0 2025-08-26 https://biopharmsignal.com/news/STTK/shattuck-labs-announces-closing-of-up-to-103-million-private-placement-and-appoi-3db08827 2025-08-26 https://biopharmsignal.com/news/TFX/teleflex-to-present-at-the-morgan-stanley-23rd-annual-global-healthcare-conferen-72d657b9 2025-08-26 https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-oral-and-poster-presentations-at-the-society-of-hematologic-oncology-soho-2025-annual-meeting 2025-08-25 https://biopharmsignal.com/news/IMMX/immix-biopharma-to-present-at-the-stifel-2025-healthcare-conference-0101f21d 2025-08-25 https://biopharmsignal.com/news/FORA/forian-receives-unsolicited-proposal-from-ceo-to-be-taken-private 2025-08-25 https://biopharmsignal.com/news/PDSB/pds-biotech-announces-final-topline-survival-data-from-versatile-002-phase-2-tri-fd04503f 2025-08-25 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-new-clinical-and-real-world-data-at-the-european-society-of-cardiology-congress-2025 2025-08-25 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-provides-update-on-form-10-q-filing-timeline-and-nasdaq-compliance 2025-08-22 https://biopharmsignal.com/news/IPSC/century-therapeutics-to-present-at-h-c-wainwright-27th-annual-global-investment--701c5f6d 2025-08-22 https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-upcoming-september-conferences-a5825b08 2025-08-22 https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-the-appointment-of-dan-weng-m-d-to-board-of-directors 2025-08-22 https://biopharmsignal.com/news/STTK/shattuck-labs-announces-ind-for-sl-325-is-in-effect-for-the-treatment-of-inflamm-a2c500d8 2025-08-21 https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences-fe5842da 2025-08-21 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-advances-pt00114-into-multiple-dose-phase-1-trial-positioning-for-phase-2-in-stress-and-mood-disorders 2025-08-21 https://biopharmsignal.com/news/NCNA/nucana-reports-second-quarter-2025-financial-results-and-provides-business-update 2025-08-20 https://biopharmsignal.com/news/KROS/keros-announces-u-s-fda-orphan-drug-designation-granted-to-ker-065-for-the-treat-0320d129 2025-08-20 https://biopharmsignal.com/news/PMCB/pharmacyte-biotech-inc-announces-closing-of-7-million-financing 2025-08-20 https://biopharmsignal.com/news/MDWD/mediwound-to-present-at-the-h-c-wainwright-27th-annual-global-investment-confere-e062250c 2025-08-20 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-participate-at-2025-wells-fargo-healthcare-conference-290de2d7 2025-08-20 https://biopharmsignal.com/news/CING/cingulate-inc-reports-second-quarter-2025-financial-results-and-provides-recent--eae118a3 2025-08-19 https://biopharmsignal.com/news/LGMK/walking-alone-at-night-is-the-greatest-safety-fear-of-women-nationwide-almost-ha-ac062bd4 2025-08-19 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-strengthens-leadership-team-with-appointment-of-timothy-pigot-as-chief-commercial-and-strategy-officer 2025-08-19 https://biopharmsignal.com/news/TFX/teleflex-announces-the-launch-of-barrigel-rectal-spacer-in-japan-as-a-proven-saf-a4c5771b 2025-08-19 https://biopharmsignal.com/news/EGRX/eagle-pharmaceuticals-announces-2025-annual-meeting-date 2025-08-18 https://biopharmsignal.com/news/MD/pediatrix-medical-group-announces-250-million-share-repurchase-program 2025-08-18 https://biopharmsignal.com/news/MMSI/first-patient-enrolled-in-merit-medical-s-wrapsody-wrap-north-america-registry-d6881496 2025-08-18 https://biopharmsignal.com/news/PMCB/pharmacyte-biotech-inc-announces-7-million-capital-raise-led-by-existing-investors 2025-08-18 https://biopharmsignal.com/news/ENLV/enlivex-announces-positive-topline-data-from-multi-country-randomized-controlled-49e3ab85 2025-08-18 https://biopharmsignal.com/news/BDRX/biodexa-announces-enrolment-of-first-patients-into-pivotal-phase-3-serenta-trial-bac11d8b 2025-08-18 https://biopharmsignal.com/news/NMTC/neuroone-receives-fda-510-k-clearance-for-onerf-trigeminal-nerve-ablation-system-b8800223 2025-08-18 https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-present-at-the-emerging-growth-conference 2025-08-18 https://biopharmsignal.com/news/BMY/izalontamab-brengitecan-egfrxher3-adc-granted-breakthrough-therapy-designation-by-u-s-fda-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer 2025-08-18 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-provides-second-quarter-2025-update-highlighting-clinical--a9401a04 2025-08-15 https://biopharmsignal.com/news/HSCS/heartsciences-announces-conference-participation-and-investor-webinar-e4e518ce 2025-08-15 https://biopharmsignal.com/news/CING/cingulate-provides-management-team-update-f7837b08 2025-08-15 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-second-quarter-2025-financial-results-and-highlights-recent-activity 2025-08-14 https://biopharmsignal.com/news/COO/coopercompanies-to-participate-in-the-wells-fargo-healthcare-conference-88cb0ed3 2025-08-14 https://biopharmsignal.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-june-30-202-10105bef 2025-08-14 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-second-quarter-2025-financial-results-and-provides--307e5422 2025-08-14 https://biopharmsignal.com/news/PYXS/pyxis-oncology-reports-second-quarter-2025-financial-results-and-provides-busine-2fdf37d5 2025-08-14 https://biopharmsignal.com/news/PIII/p3-health-partners-announces-second-quarter-2025-results 2025-08-14 https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-second-quarter-2025-financial-results-and-provides--e09e5ee6 2025-08-14 https://biopharmsignal.com/news/MGNX/macrogenics-reports-second-quarter-2025-financial-results-and-highlights-key-strategic-priorities 2025-08-14 https://biopharmsignal.com/news/GRI/gri-bio-to-present-at-the-webull-financial-corporate-connect-webinar-series-biot-12075e90 2025-08-14 https://biopharmsignal.com/news/ENLV/enlivex-to-present-3-month-topline-data-from-phase-iia-moderate-severe-knee-oste-65534899 2025-08-14 https://biopharmsignal.com/news/CCEL/cryo-cell-international-inc-provides-dividend-update 2025-08-14 https://biopharmsignal.com/news/MGTX/meiragtx-reports-second-quarter-2025-financial-and-operational-results 2025-08-14 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-reports-2025-second-quarter-financial-results-and-provides-bus-e849c9da 2025-08-14 https://biopharmsignal.com/news/COCP/cocrystal-pharma-reports-second-quarter-2025-financial-results-and-provides-upda-d33a3e26 2025-08-14 https://biopharmsignal.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-june-30-20-0afd8431 2025-08-14 https://biopharmsignal.com/news/NMTC/neuroone-reports-third-quarter-fiscal-year-2025-financial-results-revenue-increa-2aa62a86 2025-08-14 https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-second-quarter-2025-financial-results-and-provides-corporate-update 2025-08-14 https://biopharmsignal.com/news/MDWD/mediwound-reports-second-quarter-2025-financial-results-and-provides-corporate-u-aadcb152 2025-08-14 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-reports-second-quarter-2025-financial-results-and-provides-affa4bc3 2025-08-14 https://biopharmsignal.com/news/STTK/shattuck-labs-reports-second-quarter-2025-financial-results-and-recent-business--f6f2bc3b 2025-08-14 https://biopharmsignal.com/news/PRPO/precipio-announces-its-q2-2025-financial-results-d05d2a64 2025-08-13 https://biopharmsignal.com/news/BIVI/biovie-highlighted-address-lc-phase-2-trial-design-exploring-bezisterim-for-the--627908a5 2025-08-13 https://biopharmsignal.com/news/TENX/tenax-therapeutics-reports-second-quarter-2025-financial-results-and-provides-co-c9e6808a 2025-08-13 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-second-quarter-2025-financial-results-and-provides-c-93f0ee04 2025-08-13 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-announces-launch-of-diaper-rash-product-in-walmart-and-other-u-s-chains 2025-08-13 https://biopharmsignal.com/news/MDWD/mediwound-announces-new-escharex-phase-ii-data-demonstrating-strong-link-between-b884eb3e 2025-08-13 https://biopharmsignal.com/news/OVID/ovid-therapeutics-reports-business-updates-and-second-quarter-2025-financial-res-7ed09fa4 2025-08-13 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-reports-second-quarter-2025-financial-results-and-provides-29a6e1a4 2025-08-13 https://biopharmsignal.com/news/BYSI/beyondspring-reports-second-quarter-2025-financial-results-and-provides-corporat-4dbd9f67 2025-08-13 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-reports-second-quarter-2025-financial-results 2025-08-13 https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-antimicrobial-therapies-zevterar-and-xacduror-nominated-for-the-2025-prix-galien-usa-best-pharmaceutical-product-award 2025-08-13 https://biopharmsignal.com/news/ADAP/adaptimmune-reports-q2-financial-results-and-provides-business-update 2025-08-13 https://biopharmsignal.com/news/PMN/promis-neurosciences-announces-second-quarter-2025-financial-results-corporate-h-e070c023 2025-08-13 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-reports-second-quarter-2025-financial-results-c1bba5ca 2025-08-13 https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-closing-of-upsized-85-million-private-placement-6d132027 2025-08-13 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-reports-second-quarter-2025-financial-results-unaudited-1c5ec0d8 2025-08-13 https://biopharmsignal.com/news/TIL/instil-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update 2025-08-13 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-announces-participation-in-sidoti-micro-cap-conference-316af744 2025-08-13 https://biopharmsignal.com/news/CMPX/compass-therapeutics-announces-pricing-of-upsized-120-million-public-offering-5606c6d1 2025-08-13 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-second-quarter-2025-operating-results-and-provides--a07dadae 2025-08-12 https://biopharmsignal.com/news/LGMK/logicmark-inc-reports-second-quarter-2025-results-highlighted-by-22-sales-growth-e0b7cb8a 2025-08-12 https://biopharmsignal.com/news/ICCC/immucell-announces-bank-debt-refinancing-8de50e56 2025-08-12 https://biopharmsignal.com/news/PHVS/pharvaris-reports-second-quarter-2025-financial-results-and-provides-business-up-b3058363 2025-08-12 https://biopharmsignal.com/news/TXMD/therapeuticsmd-announces-second-quarter-2025-financial-results 2025-08-12 https://biopharmsignal.com/news/PROK/prokidney-reports-second-quarter-2025-financial-results-and-provides-regulatory-and-clinical-updates 2025-08-12 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update 2025-08-12 https://biopharmsignal.com/news/NKTX/nkarta-reports-second-quarter-2025-financial-results-and-corporate-highlights 2025-08-12 https://biopharmsignal.com/news/CMPX/compass-therapeutics-announces-proposed-public-offering-941c4e99 2025-08-12 https://biopharmsignal.com/news/EDIT/editas-medicine-announces-second-quarter-2025-results-and-business-updates-364fb035 2025-08-12 https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-and-scientific-highlights 2025-08-12 https://biopharmsignal.com/news/MNPR/monopar-therapeutics-reports-second-quarter-2025-financial-results-and-recent-developments 2025-08-12 https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-second-quarter-2025-financial-results-and-provides-corpo-57cf7c54 2025-08-12 https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-highlights-for-the-second-quarter-of-2025 2025-08-12 https://biopharmsignal.com/news/PASG/passage-bio-reports-second-quarter-2025-financial-results-and-provides-recent-business-highlights 2025-08-12 https://biopharmsignal.com/news/BIVI/biovie-inc-announces-closing-of-12-million-public-offering-e0164038 2025-08-11 https://biopharmsignal.com/news/ASRT/assertio-reports-second-quarter-2025-financial-results-d87a0872 2025-08-11 https://biopharmsignal.com/news/DNLI/denali-therapeutics-reports-second-quarter-2025-financial-results-and-business-h-eda68238 2025-08-11 https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-financial-results-and-operational-progress 2025-08-11 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-the-initiation-of-the-phase-1b-program-for-nxp900 2025-08-11 https://biopharmsignal.com/news/OGEN/oragenics-q2-2025-shareholder-update 2025-08-11 https://biopharmsignal.com/news/GSK/gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhoea 2025-08-11 https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-2025-second-quarter-financial-results-and-provides--b39ccaa6 2025-08-11 https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-quarter-ended-june-30-2025 2025-08-11 https://biopharmsignal.com/news/FMS/fresenius-medical-care-announces-first-tranche-of-its-share-buyback-program-of-up-to-eur-600-million-as-part-of-its-new-capital-allocation-framework 2025-08-11 https://biopharmsignal.com/news/ENTX/entera-bio-announces-second-quarter-2025-financial-results-and-business-updates-bac62f69 2025-08-08 https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-pricing-of-175-million-in-equity-financings 2025-08-08 https://biopharmsignal.com/news/ASMB/assembly-biosciences-reports-positive-interim-results-from-phase-1b-clinical-study-of-long-acting-helicase-primase-inhibitor-candidate-abi-5366-showing-reductions-in-viral-shedding-rate-and-genital-lesion-rate-in-recurrent-genital-herpes 2025-08-08 https://biopharmsignal.com/news/CGON/cg-oncology-reports-second-quarter-2025-financial-results-and-provides-business--f5022707 2025-08-08 https://biopharmsignal.com/news/GSK/gsk-provides-update-on-us-settlement-of-curevac-biontech-mrna-patent-litigation 2025-08-08 https://biopharmsignal.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-second-quarter-2025-financial-results 2025-08-08 https://biopharmsignal.com/news/YMAB/y-mabs-reports-second-quarter-2025-financial-results-and-recent-corporate-developments 2025-08-08 https://biopharmsignal.com/news/BIVI/biovie-inc-announces-pricing-of-12-million-public-offering-0e4120a6 2025-08-08 https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-second-quarter-2025-financial-results-and-business-highl-ff72619c 2025-08-07 https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-second-quarter-2025-financial-results-and-provides-g-426f2985 2025-08-07 https://biopharmsignal.com/news/AMN/amn-healthcare-announces-second-quarter-2025-results-04c1c535 2025-08-07 https://biopharmsignal.com/news/GMED/globus-medical-reports-second-quarter-2025-results-291b68de 2025-08-07 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-reports-first-fiscal-quarter-2026-financial-results 2025-08-07 https://biopharmsignal.com/news/ETNB/89bio-reports-second-quarter-2025-financial-results-and-corporate-updates 2025-08-07 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial-results 2025-08-07 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-reports-second-quarter-2025-financial-results-6278e25d 2025-08-07 https://biopharmsignal.com/news/NXTC/nextcure-provides-business-update-and-reports-second-quarter-2025-financial-resu-428d319e 2025-08-07 https://biopharmsignal.com/news/BCAB/bioatla-reports-second-quarter-2025-financial-results-and-highlights-recent-prog-7622fef7 2025-08-07 https://biopharmsignal.com/news/ALEC/alector-reports-second-quarter-2025-financial-results-and-provides-business-upda-7c326efe 2025-08-07 https://biopharmsignal.com/news/RLAY/relay-therapeutics-reports-second-quarter-2025-financial-results-and-corporate-u-00118a47 2025-08-07 https://biopharmsignal.com/news/ICUI/icu-medical-announces-second-quarter-2025-results-and-updates-its-fiscal-year-20-787aa9ba 2025-08-07 https://biopharmsignal.com/news/HCAT/health-catalyst-reports-second-quarter-2025-results-07163e22 2025-08-07 https://biopharmsignal.com/news/DSGN/design-therapeutics-highlights-progress-across-lead-genetacr-programs-and-reports-second-quarter-2025-financial-results 2025-08-07 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-reports-recent-business-highlights-and-second-quarter-2025--104f4f3f 2025-08-07 https://biopharmsignal.com/news/NEPH/nephros-announces-strong-second-quarter-financial-results-0297946b 2025-08-07 https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-second-quarter-2025-results-and-provides-corporate-update 2025-08-07 https://biopharmsignal.com/news/MMSI/merit-medical-launches-the-prelude-wave-hydrophilic-sheath-introducer-with-snapf-a96e2637 2025-08-07 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-second-quarter-2025-financial-results-and-corporate-highlights 2025-08-07 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-secures-strategic-investment-and-evaluates-corporate-crypto-treasury-strategies 2025-08-07 https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-second-quarter-2025-financial-results-and-updates-on-corporate-developments 2025-08-07 https://biopharmsignal.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-june-30-2-8ce633f8 2025-08-07 https://biopharmsignal.com/news/RLYB/rallybio-reports-second-quarter-2025-financial-results-and-provides-business-updates 2025-08-07 https://biopharmsignal.com/news/YMAB/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025 2025-08-07 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update 2025-08-07 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-second-quarter-2025-results-maintains-full-year-2025-financial-guidance 2025-08-07 https://biopharmsignal.com/news/GHRS/gh-research-reports-second-quarter-2025-financial-results-and-provides-business-updates 2025-08-07 https://biopharmsignal.com/news/LNSR/lensar-reports-second-quarter-2025-results-and-provides-business-update-25fe1b59 2025-08-07 https://biopharmsignal.com/news/PRQR/proqr-announces-second-quarter-2025-operating-and-financial-results-9fc14cd4 2025-08-07 https://biopharmsignal.com/news/GOCO/gohealth-announces-strategic-capital-and-governance-actions-to-support-long-term-691f3421 2025-08-07 https://biopharmsignal.com/news/PRVA/privia-health-reports-second-quarter-2025-financial-results 2025-08-07 https://biopharmsignal.com/news/GOCO/gohealth-to-announce-strategic-capital-and-governance-actions-to-support-long-te-6cf66f2c 2025-08-06 https://biopharmsignal.com/news/KROS/keros-to-exclusively-prioritize-the-clinical-advancement-of-ker-065-9bce2d9c 2025-08-06 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-reports-second-quarter-2025-financial-results-and-provides--fd6a7741 2025-08-06 https://biopharmsignal.com/news/XGN/exagen-inc-to-participate-in-third-quarter-investor-conferences 2025-08-06 https://biopharmsignal.com/news/BTMD/biote-reports-second-quarter-2025-financial-results 2025-08-06 https://biopharmsignal.com/news/PRCT/procept-biorobotics-reports-second-quarter-2025-financial-results-and-increases--d0a8472f 2025-08-06 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-provides-update-on-u-s-launch-of-vykat-tm-xr-and-reports-sec-6961615b 2025-08-06 https://biopharmsignal.com/news/VYGR/voyager-reports-second-quarter-2025-financial-and-operating-results-9c018d47 2025-08-06 https://biopharmsignal.com/news/KROS/keros-therapeutics-reports-second-quarter-2025-financial-results-aa8ac5d1 2025-08-06 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-other-serious-diseases-strategy-4930ec71 2025-08-06 https://biopharmsignal.com/news/CING/cingulate-submits-new-drug-application-to-fda-for-lead-adhd-asset-ctx-1301-3e08560d 2025-08-06 https://biopharmsignal.com/news/MRUS/merus-to-present-at-the-canaccord-genuity-45th-annual-growth-conference 2025-08-06 https://biopharmsignal.com/news/ABUS/arbutus-reports-second-quarter-2025-financial-results-and-provides-corporate-update 2025-08-06 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-second-quarter-financial-results-con-129c005b 2025-08-06 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-reports-second-quarter-2025-financial-results-6809d79a 2025-08-06 https://biopharmsignal.com/news/MRUS/merus-announces-financial-results-for-the-second-quarter-2025-and-provides-business-update 2025-08-05 https://biopharmsignal.com/news/AMWL/amwell-announces-results-for-second-quarter-2025-57a70b92 2025-08-05 https://biopharmsignal.com/news/LMAT/lemaitre-q2-2025-financial-results-addd2772 2025-08-05 https://biopharmsignal.com/news/MDXH/mdxhealth-reports-preliminary-second-quarter-2025-results-reaches-positive-adjus-64a3bd6f 2025-08-05 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-second-quarter-2025-financial-results-and-provide-business-update-on-tuesday-august-12-2025 2025-08-05 https://biopharmsignal.com/news/AMN/report-the-average-starting-salary-for-physicians-exceeds-400-000-9761901d 2025-08-05 https://biopharmsignal.com/news/YMAB/serb-pharmaceuticals-agrees-to-acquire-y-mabs-therapeutics 2025-08-05 https://biopharmsignal.com/news/ASRT/assertio-holdings-inc-to-report-second-quarter-2025-financial-results-on-august--ddf76665 2025-08-05 https://biopharmsignal.com/news/AMWL/amwell-set-to-continue-to-enable-u-s-defense-health-agency-healthcare-teams-to-d-690c41c2 2025-08-05 https://biopharmsignal.com/news/AQB/aquabounty-technologies-announces-second-quarter-2025-financial-results 2025-08-05 https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-reports-second-quarter-2025-financial-results-and-provides-a-business-update 2025-08-05 https://biopharmsignal.com/news/ACIU/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-4d7c7e53 2025-08-05 https://biopharmsignal.com/news/STTK/shattuck-labs-announces-oversubscribed-private-placement-of-up-to-approximately--50e85530 2025-08-05 https://biopharmsignal.com/news/RXRX/recursion-reports-second-quarter-2025-financial-results-and-provides-business-up-33f67b63 2025-08-05 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2025-financial-results-and-business-highlights 2025-08-05 https://biopharmsignal.com/news/FMS/fresenius-medical-care-delivers-strong-organic-revenue-growth-and-double-digit-operating-income-growth-in-the-second-quarter-of-2025 2025-08-05 https://biopharmsignal.com/news/CLLS/cellectis-reports-second-quarter-2025-financial-results-and-business-updates 2025-08-04 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-s-application-for-breyanzi-lisocabtagene-maraleucel-accepted-for-priority-review-by-u-s-food-and-drug-administration-fda-in-fifth-cancer-type-for-relapsed-or-refractory-marginal-zone-lymphoma-mzl 2025-08-04 https://biopharmsignal.com/news/MRUS/merus-n-v-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2025-08-04 https://biopharmsignal.com/news/BCAB/bioatla-to-announce-second-quarter-2025-financial-results-and-provide-business-h-f0f645d9 2025-08-04 https://biopharmsignal.com/news/IRMD/iradimed-corporation-reports-record-second-quarter-2025-financial-results-fddcf38b 2025-08-01 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-reports-second-quarter-fiscal-2025-results-9b323386 2025-08-01 https://biopharmsignal.com/news/PRPO/precipio-announces-q2-2025-shareholder-update-call-5556b032 2025-07-31 https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-announces-second-quarter-2025-earnings-call-2308a5bb 2025-07-31 https://biopharmsignal.com/news/ALEC/alector-to-host-second-quarter-and-mid-year-2025-earnings-conference-call-d290f194 2025-07-31 https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2025-earnings-release-and-conference-call 2025-07-31 https://biopharmsignal.com/news/NEPH/nephros-schedules-second-quarter-2025-financial-results-conference-call-60d10a39 2025-07-31 https://biopharmsignal.com/news/NMTC/neuroone-to-report-third-quarter-fiscal-year-2025-financial-results-on-thursday--da73b95a 2025-07-31 https://biopharmsignal.com/news/GRI/gri-bio-reports-6-week-interim-biomarker-data-in-ongoing-phase-2a-study-in-idiop-a54b3652 2025-07-31 https://biopharmsignal.com/news/GRI/gri-bio-ceo-marc-hertz-participates-in-virtual-investor-what-this-means-segment 2025-07-31 https://biopharmsignal.com/news/BDRX/adr-ratio-change-effective-dd770a4e 2025-07-31 https://biopharmsignal.com/news/NMTC/neuroone-to-report-third-quarter-fiscal-year-2025-financial-results-on-thursday--4c1f9af8 2025-07-31 https://biopharmsignal.com/news/OGEN/oragenics-selects-southern-star-research-as-clinical-research-organization-for-onp-002-phase-iia-trial 2025-07-31 https://biopharmsignal.com/news/VCEL/vericel-reports-second-quarter-2025-financial-results-c0ae0c14 2025-07-31 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-reports-second-quarter-2025-financial-results-b353ed9b 2025-07-31 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-second-quarter-financial-results-for-2025 2025-07-31 https://biopharmsignal.com/news/TFX/teleflex-reports-second-quarter-financial-results-and-full-year-2025-outlook-db891440 2025-07-31 https://biopharmsignal.com/news/TIL/immuneonco-announced-preliminary-safety-and-efficacy-data-from-the-clinical-trial-studying-imm2510-axn-2510-a-pd-l1xvegf-bispecific-antibody-in-combination-with-chemotherapy-in-front-line-nsclc-in-china 2025-07-31 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-provides-final-clinical-data-update-from-the-nxp800-phase-1b-study-in-ovarian-cancer-and-reports-completion-of-the-nxp900-phase-1a-dose-escalation-study 2025-07-31 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-entry-by-collaboration-partner-into-clinical-study-agreement-to-advance-development-of-dnase-platform-for-the-treatment-of-large-b-cell-lymphoma 2025-07-30 https://biopharmsignal.com/news/MRKR/marker-therapeutics-to-participate-in-a-fireside-chat-at-the-canaccord-genuity-4-31824567 2025-07-30 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-announces-topline-results-from-phase-2b-trial-with-repibresib--c28b44af 2025-07-30 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-announces-agreement-with-the-allen-institute-further-vali-2f60b4aa 2025-07-30 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-announces-grant-of-new-patent-in-japan-for-its-modified-stilbenoid-program-drug-candidates 2025-07-30 https://biopharmsignal.com/news/GSK/gsk-delivers-continued-strong-performance 2025-07-30 https://biopharmsignal.com/news/ATRC/atricure-reports-second-quarter-2025-financial-results-raises-financial-outlook-for-2025 2025-07-29 https://biopharmsignal.com/news/LGMK/logicmark-inc-to-announce-second-quarter-2025-financial-results-on-august-12-202-cb271c6f 2025-07-29 https://biopharmsignal.com/news/CING/cingulate-receives-4-3m-waiver-from-fda-ahead-of-imminent-filing-for-marketing-a-77782e0b 2025-07-29 https://biopharmsignal.com/news/GSK/gsk-highlights-new-findings-on-dementia-and-alzheimer-s-disease-at-aaic-2025-building-on-leadership-in-immunology-and-inflammation 2025-07-29 https://biopharmsignal.com/news/VRAX/virax-biolabs-appoints-iain-miller-phd-as-independent-director-to-accelerate-commercial-strategy 2025-07-29 https://biopharmsignal.com/news/CLLS/cellectis-to-report-second-quarter-2025-financial-results-on-august-4-2025 2025-07-28 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-and-bain-capital-create-new-company-dedicated-to-developing-innovative-immunology-therapies-that-address-the-unmet-medical-needs-of-patients 2025-07-28 https://biopharmsignal.com/news/ENLV/enlivex-reaffirms-august-18-2025-as-target-date-for-announcement-of-phase-ii-top-93c28c07 2025-07-28 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-to-report-second-quarter-2025-financial-results-on-august-6--a4797b3b 2025-07-28 https://biopharmsignal.com/news/PRQR/proqr-announces-upcoming-presentation-at-rna-editing-summit-986c02ab 2025-07-28 https://biopharmsignal.com/news/ALZN/alzamend-neuro-to-present-at-the-2025-military-health-system-research-symposium 2025-07-28 https://biopharmsignal.com/news/GSK/gsk-and-hengrui-pharma-enter-agreements-to-develop-up-to-12-innovative-medicines-across-respiratory-immunology-and-inflammation-and-oncology 2025-07-28 https://biopharmsignal.com/news/ENTX/entera-bio-receives-fda-agreement-on-bmd-as-primary-endpoint-for-eb613-registrat-72c80cc5 2025-07-28 https://biopharmsignal.com/news/ADAP/adaptimmune-announces-entry-into-definitive-agreement-for-sale-of-tecelra-lete-cel-afami-cel-and-uza-cel-cell-therapies-to-us-worldmeds 2025-07-28 https://biopharmsignal.com/news/ETON/eton-pharmaceuticals-to-report-second-quarter-2025-financial-results-on-thursday-b3b19282 2025-07-28 https://biopharmsignal.com/news/IRMD/iradimed-corporation-to-hold-second-quarter-of-2025-financial-results-conference-8beaa94e 2025-07-25 https://biopharmsignal.com/news/BMY/cristian-massacesi-m-d-joins-bristol-myers-squibb-as-executive-vice-president-chief-medical-officer-and-head-of-development 2025-07-25 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-announces-second-quarter-fiscal-2025-earnings-release-dat-57fc63db 2025-07-25 https://biopharmsignal.com/news/PRCT/procept-biorobotics-president-and-ceo-dr-reza-zadno-to-retire-company-appoints-l-147ff7b8 2025-07-24 https://biopharmsignal.com/news/HSCS/heartsciences-provides-business-update-and-reports-fiscal-2025-financial-results-f6a483c0 2025-07-24 https://biopharmsignal.com/news/COO/coopercompanies-announces-release-date-for-third-quarter-2025-6adf5344 2025-07-24 https://biopharmsignal.com/news/NXTC/preclinical-data-demonstrate-anti-siglec-15-treatment-improves-bone-microarchite-d87dc2e2 2025-07-24 https://biopharmsignal.com/news/ICUI/icu-medical-announces-time-of-second-quarter-2025-earnings-conference-call-38f2654f 2025-07-24 https://biopharmsignal.com/news/BIVI/biovie-presented-data-highlighting-that-patients-treated-with-bezisterim-potenti-78140676 2025-07-24 https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-u-s-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-tabelecleucel-tab-celr-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2025-07-24 https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsed-refractory-multiple-myeloma 2025-07-24 https://biopharmsignal.com/news/BTMD/biote-schedules-second-quarter-2025-financial-results-release-and-conference-call 2025-07-23 https://biopharmsignal.com/news/OVID/ovid-therapeutics-to-participate-in-the-btig-virtual-biotech-conference-7f5b58a8 2025-07-23 https://biopharmsignal.com/news/NMTC/neuroone-receives-notice-of-allowance-for-key-patent-from-u-s-patent-trademark-o-8a72db67 2025-07-23 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-expands-research-and-development-collaboration-with-the-scripps-research-institute-to-advance-dnase-platform 2025-07-23 https://biopharmsignal.com/news/GHRS/gh-research-announces-global-pivotal-program-plans-and-further-development-updates 2025-07-23 https://biopharmsignal.com/news/PRCT/ambulatory-surgery-center-completes-water-iv-trial-procedures-for-prostate-cance-79150e7a 2025-07-23 https://biopharmsignal.com/news/ALZN/alzamend-neuro-reports-annual-2025-financial-results-and-provides-update-on-clinical-programs 2025-07-23 https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-approves-plan-to-terminate-registration-of-its-common-stock 2025-07-23 https://biopharmsignal.com/news/GSK/gsk-announces-extension-of-us-food-and-drug-administration-review-period-for-blenrep-belantamab-mafodotin-blmf-in-relapsed-refractory-multiple-myeloma 2025-07-23 https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-approval-of-xiperer-suprachoroidal-treatment-for-uveitic-macular-edema-in-canada 2025-07-23 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-to-report-second-quarter-2025-financial-results-on-wednesda-0717bf8e 2025-07-23 https://biopharmsignal.com/news/AMWL/amwell-to-report-second-quarter-2025-operating-results-company-leaders-to-attend-77bee78a 2025-07-22 https://biopharmsignal.com/news/BIVI/biovie-appoints-industry-veterans-amy-chappell-md-faan-and-kameel-farag-to-board-2fd418e9 2025-07-22 https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-research-collaboration-with-the-fda-to-advance-regulat-a777ef4a 2025-07-22 https://biopharmsignal.com/news/GRI/gri-bio-participates-in-the-virtual-investor-what-s-your-story-summer-spotlight-on-demand-conference 2025-07-22 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-reports-second-quarter-2025-results 2025-07-21 https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2025-financial-results-on-august-6--7a3af3bc 2025-07-21 https://biopharmsignal.com/news/GMED/globus-medical-announces-leadership-transitions-and-preliminary-second-quarter-2-b93f33aa 2025-07-21 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-s-supplemental-new-drug-application-snda-for-sotyktu-deucravacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis-accepted-for-review-across-four-regions-globally 2025-07-21 https://biopharmsignal.com/news/VRAX/virax-biolabs-announces-receipt-of-nasdaq-notification-letter-regarding-minimum-bid-price-deficiency 2025-07-18 https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-intention-to-voluntarily-delist-and-deregister-its-comm-9406013c 2025-07-18 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-topline-results-from-phase-3-independence-trial-for-reblozylr-luspatercept-aamt-in-adult-patients-with-myelofibrosis-associated-anemia 2025-07-18 https://biopharmsignal.com/news/HCAT/health-catalyst-to-announce-second-quarter-2025-operating-results-and-host-confe-a9e43871 2025-07-17 https://biopharmsignal.com/news/VCEL/vericel-to-report-second-quarter-2025-financial-results-on-july-31-2025-7452edd2 2025-07-17 https://biopharmsignal.com/news/BCAB/bioatla-announces-upcoming-oral-presentation-at-the-2025-european-society-for-me-a65f9cd9 2025-07-17 https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-the-first-patient-dosing-in-the-phase-3-renew-clini-52288ce0 2025-07-17 https://biopharmsignal.com/news/GSK/gsk-provides-update-on-us-fda-advisory-committee-review-of-blenrep-belantamab-mafodotin-blmf-combinations-for-patients-with-relapsed-refractory-multiple-myeloma 2025-07-17 https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-plan-to-explore-strategic-alternatives-to-advance-its-proprietary-suprachoroidal-space-scsr-delivery-platform-and-promising-ophthalmology-pipeline 2025-07-17 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-and-pfizer-announce-direct-to-patient-eliquisr-apixaban-option 2025-07-17 https://biopharmsignal.com/news/TFX/teleflex-announces-second-quarter-2025-earnings-conference-call-information-31740172 2025-07-17 https://biopharmsignal.com/news/IMRN/immuron-fy25-global-sales-exceed-projection-up-49-on-prior-year-806fa699 2025-07-17 https://biopharmsignal.com/news/GSK/us-fda-approves-gsk-s-shingrix-in-a-prefilled-syringe-presentation 2025-07-17 https://biopharmsignal.com/news/OGEN/oragenics-inc-announces-u-s-based-drug-manufacturing-agreement-to-support-onp-002-clinical-development 2025-07-16 https://biopharmsignal.com/news/VYGR/voyager-adds-fourth-wholly-owned-alzheimer-s-disease-program-to-pipeline-complem-80b6486d 2025-07-16 https://biopharmsignal.com/news/CCEL/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results 2025-07-15 https://biopharmsignal.com/news/GMED/globus-medical-introduces-durapro-with-navigation-a-next-generation-oscillating--872e8ba4 2025-07-15 https://biopharmsignal.com/news/SMTI/sanara-medtech-to-report-second-quarter-2025-financial-results-on-august-13-2025-fdea7415 2025-07-15 https://biopharmsignal.com/news/RPTX/repare-therapeutics-enters-exclusive-worldwide-licensing-agreement-with-debiopharm-for-lunresertib 2025-07-15 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-announces-new-licensing-and-laboratory-services-agreement--67ecece0 2025-07-15 https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-2025-financial-results-on-july-b443a8a8 2025-07-15 https://biopharmsignal.com/news/PROK/prokidney-announces-alignment-with-the-fda-on-the-accelerated-approval-pathway-for-rilparencel 2025-07-15 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-announces-launch-of-tissue-health-plus-wound-care-provider-pi-0010a6fd 2025-07-14 https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-provides-regulatory-and-business-updates-on-tabelecleucel-tab-celr 2025-07-14 https://biopharmsignal.com/news/GSK/viiv-healthcare-extends-voluntary-licensing-agreement-with-medicines-patent-pool-to-enable-access-to-innovative-long-acting-injectable-hiv-treatment 2025-07-14 https://biopharmsignal.com/news/GSK/viiv-healthcare-data-show-89-of-treatment-naive-people-with-hiv-choose-to-switch-to-long-acting-injectable-vocabria-rekambys-from-daily-pills-after-achieving-rapid-viral-suppression 2025-07-14 https://biopharmsignal.com/news/GSK/us-fda-accepts-application-to-review-expanded-use-of-gsk-s-rsv-vaccine-arexvy-for-adults-18-49-at-increased-risk 2025-07-14 https://biopharmsignal.com/news/PRPO/precipio-enters-into-agreement-with-warrant-holder-to-exercise-majority-of-warra-4c68a36b 2025-07-11 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-class-leading-safety-profile-allowing-potential-future-517f84e8 2025-07-11 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-pricing-of-200-million-public-offering-of-common-s-9325583e 2025-07-10 https://biopharmsignal.com/news/PRVA/privia-health-to-report-second-quarter-2025-results-on-thursday-august-7 2025-07-10 https://biopharmsignal.com/news/AMN/amn-healthcare-to-hold-second-quarter-2025-earnings-conference-call-on-thursday--cf1a8762 2025-07-10 https://biopharmsignal.com/news/PASG/passage-bio-announces-1-for-20-reverse-stock-split 2025-07-10 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-proposed-200-million-public-offering-of-common-sto-8f9efa4e 2025-07-10 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-preliminary-financial-and-operational-results-for--121f1037 2025-07-10 https://biopharmsignal.com/news/BIVI/biovie-announces-data-highlighting-bezisterim-s-potential-to-slow-or-reverse-bio-e19642fb 2025-07-09 https://biopharmsignal.com/news/CING/cingulate-appoints-nilay-patel-as-chief-legal-officer-to-support-growth-ahead-of-78e827c0 2025-07-09 https://biopharmsignal.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q2-of-2025-92a5a041 2025-07-09 https://biopharmsignal.com/news/GALT/galectin-therapeutics-announces-new-10-million-credit-line-from-richard-e-uihlei-6b450c42 2025-07-09 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-corporate-reorganization-and-other-cost-cutting-me-1db3cdd5 2025-07-09 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-to-participate-in-the-kidneycan-7th-annual-kidney-cancer-r-69fe7fd3 2025-07-09 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-announces-initiation-of-phase-1-clinical-study-of-m4-positi-45474388 2025-07-09 https://biopharmsignal.com/news/LMAT/lemaitre-will-announce-second-quarter-2025-earnings-results-august-5-2025-4959f0cb 2025-07-08 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-update-from-collaboration-partner-of-first-patient-dosed-in-exploratory-clinical-study-of-dnase-i-in-combination-with-folfirinox-for-the-first-line-treatment-of-unresectable-locally-advanced-or-metastatic-pancreatic-cancer 2025-07-08 https://biopharmsignal.com/news/ENTX/opko-health-and-entera-bio-announce-abstract-on-pk-pd-of-oral-glp-2-tablet-for-t-8ba25ddf 2025-07-08 https://biopharmsignal.com/news/RLYB/rallybio-sells-interest-in-rev102-program-to-recursion-pharmaceuticals 2025-07-08 https://biopharmsignal.com/news/GSK/viiv-healthcare-presents-new-data-demonstrating-positive-real-world-impact-of-its-innovative-long-acting-injectables-for-hiv-at-ias-2025 2025-07-08 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-successful-completion-of-a-drug-drug-interaction-study-in-healthy-volunteers-supporting-nxp900-s-potential-as-a-combination-partner-with-leading-therapies 2025-07-08 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-accelerated-nexicart-2-clinical-trial-progress-in-rela-ad738e65 2025-07-07 https://biopharmsignal.com/news/MBIO/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-101-il13ra2-targeted-car-t-cells-to-treat-astrocytomas-and-glioblastoma 2025-07-07 https://biopharmsignal.com/news/ALLR/allarity-therapeutics-announces-appointment-of-jeff-ervin-as-chief-financial-off-25aa7343 2025-07-07 https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-efimosfermin-a-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-sld 2025-07-07 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-clinical-data-update-from-briquilimab-studies-in-chr-e5b51207 2025-07-07 https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-last-patient-treated-in-registrational-trial-of-otl-203-for-mps-i-hurler-syndrome 2025-07-07 https://biopharmsignal.com/news/BYSI/beyondspring-publishes-human-clinical-study-in-med-cell-press-showing-plinabulin-a137ac2b 2025-07-07 https://biopharmsignal.com/news/GNLX/genelux-corporation-announces-appointment-of-eric-groen-as-general-counsel-corpo-0825e68e 2025-07-07 https://biopharmsignal.com/news/MDXH/mdxhealth-appoints-michael-holder-to-board-of-directors-and-announces-management-e54a8b6d 2025-07-03 https://biopharmsignal.com/news/BCAB/bioatla-presents-data-from-ongoing-dose-escalation-of-ba3182-dual-conditionally--f3840536 2025-07-03 https://biopharmsignal.com/news/FMS/fresenius-medical-care-collaborates-with-coordination-of-national-institutes-of-health-and-specialty-hospital-to-extend-access-to-innovative-dialysis-therapy-in-mexico 2025-07-03 https://biopharmsignal.com/news/OGEN/oragenics-completes-approximately-16-5-million-offering 2025-07-02 https://biopharmsignal.com/news/AMN/amn-healthcare-sells-smart-square-scheduling-technology-to-symplr-creates-commer-5ee87b08 2025-07-02 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-provides-program-update-on-oral-bet-inhibitor-vyn202-1c6c4e61 2025-07-02 https://biopharmsignal.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-leerink-partners-therapeutics--c690932e 2025-07-02 https://biopharmsignal.com/news/TIL/instil-bio-announces-u-s-f-d-a-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsed-refractory-solid-tumors 2025-07-02 https://biopharmsignal.com/news/GRI/gri-bio-completes-enrollment-in-phase-2a-study-of-gri-0621-for-the-treatment-of--5808f140 2025-07-01 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-provides-portfolio-and-business-update 2025-07-01 https://biopharmsignal.com/news/OGEN/oragenics-inc-announces-pricing-of-public-offering-of-up-to-20-million-of-preferred-stock-and-warrants 2025-07-01 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-inc-announces-additional-sale-of-3-4-million-in-private-pl-077f36f5 2025-07-01 https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-two-presentations-featuring-vykat-tm-xr-in-prader--eff9a9c8 2025-07-01 https://biopharmsignal.com/news/TFX/teleflex-completes-acquisition-of-biotronik-s-vascular-intervention-business-95f20bc8 2025-07-01 https://biopharmsignal.com/news/GOCO/gohealth-secures-amended-credit-agreement-highlighting-broad-based-support-from--060e1ca8 2025-06-30 https://biopharmsignal.com/news/ADXN/addex-leads-chf-2-million-investment-in-stalicla-to-advance-precision-medicine-i-504c0d36 2025-06-30 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-announces-up-to-approximately-15-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules 2025-06-27 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-approves-streamlined-patient-monitoring-requirements-and-removal-of-rems-programs-within-bristol-myers-squibb-s-cell-therapy-labels 2025-06-27 https://biopharmsignal.com/news/PRQR/proqr-announces-cta-submission-for-phase-1-study-of-ax-0810-targeting-ntcp-31ce7522 2025-06-26 https://biopharmsignal.com/news/CLLS/cellectis-reports-results-from-shareholders-meeting-held-on-june-26-2025 2025-06-26 https://biopharmsignal.com/news/GRI/gri-bio-s-gri-0621-demonstrates-encouraging-safety-results-at-planned-interim-6--cbe9b66b 2025-06-26 https://biopharmsignal.com/news/ENTX/entera-bio-data-for-eb613-effects-on-trabecular-and-cortical-bone-in-post-menopa-f09d93f7 2025-06-26 https://biopharmsignal.com/news/BIVI/biovie-highlights-patient-centric-design-of-sunrise-pd-trial-at-advanced-therape-343cb588 2025-06-26 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-successfully-completes-application-to-the-otcqb-9ba83e8c 2025-06-25 https://biopharmsignal.com/news/OVID/ovid-therapeutics-enters-agreement-with-immedica-pharma-ab-for-sale-of-future-ga-190c02d5 2025-06-25 https://biopharmsignal.com/news/ENTX/opko-health-and-entera-bio-abstract-for-first-in-class-dual-glp-1-glucagon-table-9b1ad8ef 2025-06-25 https://biopharmsignal.com/news/ABUS/arbutus-reacquires-greater-china-rights-to-imdusiran-and-announces-scientific-advisory-board-with-late-stage-clinical-focus 2025-06-25 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-announces-reverse-stock-split-9d726f0f 2025-06-25 https://biopharmsignal.com/news/GSK/price-of-world-s-first-malaria-vaccine-rts-s-for-children-in-endemic-countries-to-be-reduced-by-more-than-half-to-less-than-5 2025-06-25 https://biopharmsignal.com/news/BIVI/biovie-to-present-overview-of-phase-2-sunrise-pd-trial-at-the-advanced-therapeut-5e38f301 2025-06-24 https://biopharmsignal.com/news/AMN/celia-huber-joins-amn-healthcare-board-of-directors-11aaf3fb 2025-06-24 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-to-report-second-quarter-2025-financial-results-on-july-21-2025 2025-06-23 https://biopharmsignal.com/news/SHCR/sharecare-wins-21-digital-health-awards-in-spring-2025-competition 2025-06-23 https://biopharmsignal.com/news/NMTC/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treat-ab1a7b32 2025-06-23 https://biopharmsignal.com/news/GSK/linerixibat-accepted-for-review-by-the-european-medicines-agency-for-cholestatic-pruritus-in-patients-with-primary-biliary-cholangitis-pbc 2025-06-23 https://biopharmsignal.com/news/PASG/passage-bio-reports-updated-interim-data-from-uplift-d-study-and-provides-program-update 2025-06-23 https://biopharmsignal.com/news/GSK/japan-s-ministry-of-health-labour-and-welfare-accepts-regulatory-application-to-expand-use-of-gsk-s-rsv-vaccine-arexvy-in-adults-aged-18-49-at-increased-risk-of-severe-rsv-disease 2025-06-20 https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-and-snbl-announce-four-abstracts-to-be-presented-at-the-american-headache-society-s-67th-annual-scientific-meeting 2025-06-19 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2025-financial-results 2025-06-17 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-announces-pricing-of-7-million-public-offering 2025-06-17 https://biopharmsignal.com/news/LGMK/logicmark-inc-appoints-jeffrey-durkin-as-senior-vice-president-of-sales-to-drive-bd7beccb 2025-06-17 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-signs-binding-term-sheet-granting-intact-therapeutics-exclusive-option-to-license-phase-2-gastroparesis-drug-candidate 2025-06-17 https://biopharmsignal.com/news/MRKR/marker-therapeutics-and-cellipont-bioservices-announce-collaboration-to-advance--7b3c301d 2025-06-17 https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-multiple-presentations-to-be-featured-at-the-clinical-trials-at-the-summit-meeting 2025-06-17 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-dr-kaouthar-lbiati-as-interim-chief-executive-o-a94f00a0 2025-06-16 https://biopharmsignal.com/news/ALZN/alzamend-neuro-announces-final-closing-of-5-million-private-placement-months-ahead-of-schedule 2025-06-16 https://biopharmsignal.com/news/NXTC/nextcure-and-simcere-zaiming-announce-strategic-partnership-for-a-novel-antibody-572f0c8b 2025-06-16 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-first-data-from-the-marginal-zone-lymphoma-cohort-of-the-transcend-fl-trial-demonstrating-deep-and-durable-responses-with-breyanzi-lisocabtagene-maraleucel 2025-06-16 https://biopharmsignal.com/news/AIRS/airsculpt-strengthens-balance-sheet-with-10-0-million-debt-paydown-dc2985d8 2025-06-16 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-positive-data-from-180mg-cohort-in-spotlight-study-o-f8f285bd 2025-06-14 https://biopharmsignal.com/news/ALEC/alector-provides-executive-leadership-update-f2300948 2025-06-13 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-inc-announces-sale-of-2-3-million-in-private-placement-of--5cfc623b 2025-06-13 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-to-engage-potential-partners-and-investors-at-bio-international-convention-2025 2025-06-13 https://biopharmsignal.com/news/GSK/gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-european-medicines-agency-to-expand-use-in-adults-18-years-and-older 2025-06-13 https://biopharmsignal.com/news/SHCR/sharecare-introduces-new-interactive-solutions-to-elevate-health-literacy-and-increase-condition-specific-treatment-adherence 2025-06-12 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-to-participate-in-the-bio-international-convention-afa41029 2025-06-12 https://biopharmsignal.com/news/RLYB/rallybio-initiates-dosing-in-rlyb116-phase-1-confirmatory-pharmacokinetic-pharmacodynamic-study 2025-06-12 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-data-across-targeted-protein-degradation-research-including-celmodtm-agents-and-bcl6-ligand-directed-degrader-at-eha-2025 2025-06-12 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-second-quarter-2025-on-july-31-2025 2025-06-12 https://biopharmsignal.com/news/TFX/new-prospective-cohort-study-reporting-the-efficacy-of-arrow-chlorhexidine-impre-be78eeb8 2025-06-12 https://biopharmsignal.com/news/GSK/gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech-for-continued-development 2025-06-12 https://biopharmsignal.com/news/EDIT/editas-medicine-reports-proprietary-targeted-lipid-nanoparticle-delivery-in-non--1075bb9a 2025-06-12 https://biopharmsignal.com/news/AIRS/airsculpt-announces-closing-of-offering-of-common-stock-and-underwriters-full-ex-9ae1f3c2 2025-06-11 https://biopharmsignal.com/news/TCBP/tc-biopharm-announces-complete-response-in-minimal-residual-disease-mrd-patient 2025-06-11 https://biopharmsignal.com/news/TIL/instil-bio-names-john-maraganore-ph-d-to-board-role-supporting-the-advancement-of-pd-l1xvegf-bispecific-antibody-program 2025-06-11 https://biopharmsignal.com/news/MNPR/monopar-and-ednoc-announce-expanded-access-program-for-mnpr-101-zr-and-mnpr-101-lu-in-advanced-cancers 2025-06-11 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-late-breaking-data-from-pivotal-phase-3-poetyk-psa-1-trial-demonstrating-superiority-of-sotyktu-deucravacitinib-compared-with-placebo-in-adults-with-psoriatic-arthritis 2025-06-11 https://biopharmsignal.com/news/TFX/teleflex-highlights-prostate-health-and-quality-of-life-awareness-through-two-ke-8a5102ff 2025-06-11 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-advances-toward-phase-3-development-for-ad04 2025-06-11 https://biopharmsignal.com/news/ENLV/enlivex-therapeutics-to-present-clinical-data-of-allocetra-in-osteoarthritis-at--7d85645f 2025-06-10 https://biopharmsignal.com/news/GALT/galectin-therapeutics-to-host-virtual-kol-event-to-discuss-belapectin-for-treatm-56e46215 2025-06-10 https://biopharmsignal.com/news/VCEL/vericel-to-present-at-the-truist-securities-medtech-conference-on-tuesday-june-1-7f7ec20b 2025-06-10 https://biopharmsignal.com/news/VYGR/voyager-to-present-at-h-c-wainwright-6th-annual-neuro-perspectives-hybrid-confer-ce3a2b58 2025-06-10 https://biopharmsignal.com/news/AIRS/airsculpt-announces-pricing-of-offering-of-common-stock-cd6c26ab 2025-06-10 https://biopharmsignal.com/news/AIRS/airsculpt-announces-public-offering-of-common-stock-e125e9dd 2025-06-09 https://biopharmsignal.com/news/BTMD/biote-names-rich-barrera-to-board-of-directors 2025-06-09 https://biopharmsignal.com/news/BPTH/bio-path-holdings-to-present-at-life-sciences-virtual-investor-forum-6c80073e 2025-06-09 https://biopharmsignal.com/news/KROS/keros-announces-return-of-375-million-in-excess-capital-to-stockholders-305c1f45 2025-06-09 https://biopharmsignal.com/news/IMMX/immix-biopharma-attends-fda-ceo-forum-in-washington-dc-fcb28905 2025-06-06 https://biopharmsignal.com/news/OVID/ovid-therapeutics-to-host-investor-and-media-event-thursday-june-12-2025-9409a8c5 2025-06-05 https://biopharmsignal.com/news/ETNB/89bio-to-participate-in-goldman-sachs-46th-annual-global-healthcare-conference 2025-06-04 https://biopharmsignal.com/news/HSCS/heartsciences-receives-fda-breakthrough-device-designation-for-myovista-insights-566d1bd8 2025-06-04 https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-start-of-friedreich-ataxia-patient-dosing-ex-u-s-in-its-restore-fa-phase-1-2-multiple-ascending-dose-trial-of-dt-216p2 2025-06-04 https://biopharmsignal.com/news/FMS/fresenius-medical-care-begins-broader-u-s-commercialization-of-5008xtm-caresystem-achieves-key-milestones-in-efforts-to-introduce-high-volume-hemodiafiltration-dialysis-therapy-to-individuals-with-kidney-disease-in-the-u-s 2025-06-04 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-primary-endpoint-met-in-positive-nxc-201-interim-resul-629ebdaf 2025-06-03 https://biopharmsignal.com/news/HSCS/foundational-us-patent-granted-for-ecg-assessment-of-heart-function-further-expa-d09723b6 2025-06-03 https://biopharmsignal.com/news/NMTC/neuroone-strengthens-leadership-team-with-appointment-of-emily-johns-as-general--604ec968 2025-06-03 https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-briquilimab-presentations-at-the-european-academy--eec0a864 2025-06-03 https://biopharmsignal.com/news/ALEC/alector-to-participate-in-the-goldman-sachs-46th-annual-global-healthcare-confer-5d98df60 2025-06-03 https://biopharmsignal.com/news/BPTH/bio-path-holdings-provides-clinical-and-operational-update-945f6be3 2025-06-03 https://biopharmsignal.com/news/BYSI/beyondspring-presents-efficacy-safety-data-from-a-phase-2-study-of-pembrolizumab-9a0a00d3 2025-06-03 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-appoints-maha-radhakrishnan-m-d-to-its-board-of-directors-102bff77 2025-06-03 https://biopharmsignal.com/news/MNPR/monopar-therapeutics-announces-inclusion-in-the-russell-3000r-and-russell-2000r-indexes 2025-06-03 https://biopharmsignal.com/news/LGMK/logicmark-inc-common-stock-to-commence-trading-on-otc-markets-as-the-company-con-ef2d521e 2025-06-02 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-doses-first-patient-in-phase-1b-2-combination-study-of-dec-310df3b8 2025-06-02 https://biopharmsignal.com/news/BCAB/bioatla-presents-phase-2-ozuriftamab-vedotin-oz-v-clinical-trial-data-demonstrat-adcc5693 2025-06-02 https://biopharmsignal.com/news/STRO/sutro-biopharma-appoints-greg-chow-as-chief-financial-officer-7eab54bf 2025-06-02 https://biopharmsignal.com/news/TIL/instil-bio-announces-appointment-of-jamie-freedman-m-d-ph-d-as-chief-medical-officer 2025-06-02 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-reports-positive-results-from-the-enlighten-2-phase-3-trial-of-lyr-210-achieving-statistically-significant-results-for-primary-and-key-secondary-endpoints-in-the-treatment-of-chronic-rhinosinusitis-crs 2025-06-02 https://biopharmsignal.com/news/NGEN/nervgen-pharma-reports-positive-topline-data-from-the-chronic-cohort-of-its-phas-80ea1c11 2025-06-02 https://biopharmsignal.com/news/BMY/biontech-and-bristol-myers-squibb-announce-global-strategic-partnership-to-co-develop-and-co-commercialize-next-generation-bispecific-antibody-candidate-bnt327-broadly-for-multiple-solid-tumor-types 2025-06-02 https://biopharmsignal.com/news/GSK/linerixibat-new-drug-application-nda-accepted-for-review-by-the-us-fda-for-cholestatic-pruritus-in-patients-with-primary-biliary-cholangitis-pbc 2025-06-02 https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-announces-presentation-and-publication-of-three-abstracts-at-2025-asco-annual-meeting 2025-05-30 https://biopharmsignal.com/news/TIL/instil-bio-to-participate-in-the-2025-jefferies-global-healthcare-conference 2025-05-30 https://biopharmsignal.com/news/ANL/adlai-nortye-announces-topline-results-of-phase-iii-buran-trial-evaluating-buparlisib-an2025-in-combination-with-paclitaxel-for-recurrent-or-metastatic-hnscc 2025-05-30 https://biopharmsignal.com/news/COO/coopercompanies-announces-second-quarter-2025-results-e0561039 2025-05-29 https://biopharmsignal.com/news/NXTC/nextcure-and-ligachembio-to-present-trial-in-progress-poster-for-lncb74-a-b7-h4--1ce8cc1e 2025-05-29 https://biopharmsignal.com/news/NMTC/neuroone-to-attend-medinvest-s-medtech-ai-digital-health-conference-on-june-3-4--55cc4dc5 2025-05-29 https://biopharmsignal.com/news/GSK/gsk-data-at-asco-and-eha-showcase-latest-research-and-innovation-across-the-oncology-portfolio 2025-05-29 https://biopharmsignal.com/news/HSCS/heartsciences-signs-first-myovista-insights-platform-customer-marking-major-comm-f0ad79b4 2025-05-29 https://biopharmsignal.com/news/IRMD/iradimed-corporation-announces-fda-510-k-clearance-for-mridium-3870-infusion-pum-282e6747 2025-05-29 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-to-participate-in-the-upcoming-jefferies-global-healthcare-f4a504a2 2025-05-29 https://biopharmsignal.com/news/ALZN/alzamend-neuro-announces-dosing-of-first-patient-in-its-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-taking-place-at-massachusetts-general-hospital 2025-05-29 https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2025 2025-05-29 https://biopharmsignal.com/news/IPSC/century-therapeutics-announces-two-upcoming-presentations-at-the-eular-2025-cong-b69c4e9b 2025-05-28 https://biopharmsignal.com/news/DSGN/design-therapeutics-to-participate-in-2025-jefferies-global-healthcare-conference 2025-05-28 https://biopharmsignal.com/news/SPRO/spero-therapeutics-and-gsk-announce-pivot-po-phase-3-study-for-tebipenem-hbr-sto-5b19429f 2025-05-28 https://biopharmsignal.com/news/BYSI/beyondspring-announces-poster-presentation-at-2025-asco-annual-meeting-b676b0a1 2025-05-28 https://biopharmsignal.com/news/TRDA/entrada-therapeutics-receives-authorization-in-the-european-union-to-initiate-el-10ed8da0 2025-05-28 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-the-goldman-sachs-46th-annual-global-healthcare-conference 2025-05-28 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-european-commission-approval-for-the-subcutaneous-formulation-of-opdivor-nivolumab-across-multiple-solid-tumor-indications 2025-05-28 https://biopharmsignal.com/news/YMAB/y-mabs-hosts-virtual-radiopharmaceutical-randd-update-highlighting-clinical-progress-and-expanded-pipeline 2025-05-28 https://biopharmsignal.com/news/GSK/pivot-po-phase-iii-study-for-tebipenem-hbr-stopped-early-for-efficacy-following-review-by-independent-data-monitoring-committee 2025-05-28 https://biopharmsignal.com/news/AMN/new-survey-shows-physician-appointment-wait-times-surge-19-since-2022-48-since-2-a1dd4339 2025-05-27 https://biopharmsignal.com/news/MGRX/mangoceuticals-patented-mgx-0024-delivers-100-respiratory-survival-in-poultry-st-c2bd811b 2025-05-27 https://biopharmsignal.com/news/VCNX/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting 2025-05-27 https://biopharmsignal.com/news/YMAB/y-mabs-presents-gd2-sada-prit-trial-in-progress-poster-at-the-advances-in-neuroblastoma-research-meeting 2025-05-26 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-to-participate-at-upcoming-investor-conferences 2025-05-23 https://biopharmsignal.com/news/AEON/aeon-biopharma-reports-inducement-grants-under-nyse-american-llc-company-guide-s-24111f7c 2025-05-23 https://biopharmsignal.com/news/IMMX/immix-biopharma-further-expands-u-s-clinical-sites-for-relapsed-refractory-al-am-27e64b8e 2025-05-23 https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-combinations-receive-positive-chmp-opinion-in-relapsed-refractory-multiple-myeloma 2025-05-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-data-at-ascor-2025-highlighting-differentiated-research-platform-of-oncology-treatments-and-innovative-research-pipeline 2025-05-22 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-positive-results-for-nxc-201-at-asco-oral-presentation-5512d085 2025-05-22 https://biopharmsignal.com/news/BPTH/bio-path-holdings-to-host-corporate-update-conference-call-on-may-29-2025-7d0815d0 2025-05-22 https://biopharmsignal.com/news/GSK/nucala-mepolizumab-approved-by-us-fda-for-use-in-adults-with-chronic-obstructive-pulmonary-disease-copd 2025-05-22 https://biopharmsignal.com/news/GRI/gri-bio-presents-positive-pre-clinical-data-demonstrating-gri-0621-resolves-infl-fb7b502f 2025-05-22 https://biopharmsignal.com/news/FMS/fresenius-medical-care-annual-general-meeting-strong-performance-against-its-strategic-plan-results-in-highest-dividend-per-share-in-its-history 2025-05-21 https://biopharmsignal.com/news/IMMX/immix-biopharma-to-host-kol-event-to-discuss-nxc-201-clinical-data-presented-at--cee47ded 2025-05-21 https://biopharmsignal.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-26-2025 2025-05-21 https://biopharmsignal.com/news/NAVB/navidea-biopharmaceuticals-inc-announces-extension-of-authority-to-implement-a-reverse-stock-split 2025-05-21 https://biopharmsignal.com/news/GRI/gri-bio-to-participate-in-the-virtual-investor-closing-bell-series-2f8d38ac 2025-05-21 https://biopharmsignal.com/news/CLSD/clearside-biomedical-to-participate-in-a-fireside-chat-at-the-stifel-2025-virtual-ophthalmology-forum 2025-05-21 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-the-bernstein-41st-annual-strategic-decisions-conference 2025-05-21 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-receives-3-1-million-from-recent-warrant-activity 2025-05-21 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-completes-acquisition-of-optinose-creating-an-expanded-portfolio-of-specialty-therapies 2025-05-21 https://biopharmsignal.com/news/COO/coopercompanies-2024-sustainability-report-showcases-efforts-that-benefit-people-cdc2457b 2025-05-20 https://biopharmsignal.com/news/HOWL/honorhealth-research-institute-patient-with-advanced-skin-cancer-in-remission-fo-d4a2553a 2025-05-20 https://biopharmsignal.com/news/ENLV/enlivex-selected-to-present-at-israeli-biomed-2025-conference-dd2d6126 2025-05-20 https://biopharmsignal.com/news/MRKR/marker-therapeutics-reports-that-lymphodepletion-improves-the-expansion-and-pers-d76fde88 2025-05-20 https://biopharmsignal.com/news/CING/efficacy-results-announced-from-cingulate-s-phase-3-pediatric-study-of-ctx-1301--243d621e 2025-05-20 https://biopharmsignal.com/news/ASRT/assertio-to-participate-in-the-alliance-global-partners-healthcare-company-showc-501adae1 2025-05-19 https://biopharmsignal.com/news/AEON/aeon-biopharma-to-present-at-the-aegis-capital-corp-virtual-conference-2025-e6c5b5d1 2025-05-19 https://biopharmsignal.com/news/MRKR/marker-therapeutics-to-spotlight-multi-antigen-recognizing-mar-t-cells-in-high-p-5d8e377a 2025-05-19 https://biopharmsignal.com/news/ALZN/alzamend-neuro-enrolls-first-patient-in-its-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-taking-place-at-massachusetts-general-hospital 2025-05-19 https://biopharmsignal.com/news/TFX/teleflex-publishes-2024-global-impact-report-5d2861ec 2025-05-19 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-and-phytanix-announce-business-combination-to-form-neuroactive-biopharmaceutical-company-with-six-drug-candidates-in-development-including-treatments-for-obesity-and-metabolic-disorders 2025-05-19 https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-combinations-approved-in-japan-for-treatment-of-relapsed-refractory-multiple-myeloma 2025-05-19 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference 2025-05-16 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-european-commission-approval-for-perioperative-regimen-of-neoadjuvant-opdivor-nivolumab-and-chemotherapy-followed-by-adjuvant-opdivo-for-resectable-high-risk-non-small-cell-lung-cancer-with-pd-l1-expression-1 2025-05-16 https://biopharmsignal.com/news/GRI/gri-bio-to-present-at-a-g-p-s-annual-healthcare-company-showcase 2025-05-16 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-present-clinical-data-on-nuzyrar-omadacycline-at-the-american-thoracic-society-ats-2025-international-conference 2025-05-16 https://biopharmsignal.com/news/GMED/globus-medical-announces-500-million-share-repurchase-program-dc8cc360 2025-05-15 https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-first-quarter-2025-financial-results-and-provides-b-14d51db2 2025-05-15 https://biopharmsignal.com/news/AQB/aquabounty-technologies-announces-first-quarter-2025-financial-results 2025-05-15 https://biopharmsignal.com/news/GRI/gri-bio-reports-first-quarter-2025-financial-results-and-confirms-gri-0621-phase-f7ea1c1f 2025-05-15 https://biopharmsignal.com/news/BIVI/biovie-enrolls-first-patient-in-address-lc-clinical-trial-assessing-novel-anti-i-32ee476d 2025-05-15 https://biopharmsignal.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-march-31-2-ac82dc9f 2025-05-15 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-reports-first-quarter-2025-financial-results-e798d07c 2025-05-15 https://biopharmsignal.com/news/PYXS/pyxis-oncology-reports-first-quarter-2025-financial-results-and-provides-busines-912adaa3 2025-05-15 https://biopharmsignal.com/news/VYGR/voyager-demonstrates-alpl-receptor-mediated-blood-brain-barrier-transport-of-nov-bfa88bec 2025-05-15 https://biopharmsignal.com/news/TFX/teleflex-showcases-new-clinical-data-presented-at-the-2025-american-urological-a-22b15f2b 2025-05-15 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-update 2025-05-15 https://biopharmsignal.com/news/PRPO/precipio-announces-its-q1-2025-financial-results-0789c89b 2025-05-14 https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-first-quarter-2025-financial-results-and-provides-corporate-update 2025-05-14 https://biopharmsignal.com/news/AEON/aeon-biopharma-reports-first-quarter-2025-financial-results-and-provides-corpora-0ada1efe 2025-05-14 https://biopharmsignal.com/news/TENX/tenax-therapeutics-reports-first-quarter-2025-financial-results-and-provides-cor-b19c85af 2025-05-14 https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-first-quarter-2025-financial-results-and-highlights-recent-activity 2025-05-14 https://biopharmsignal.com/news/MDXH/mdxhealth-reports-q1-2025-results-1119b69c 2025-05-14 https://biopharmsignal.com/news/EDIT/editas-medicine-to-present-in-vivo-hsc-delivery-editing-and-biodistribution-data-05463a27 2025-05-14 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-reports-first-quarter-2025-financial-results-and-provides-business-update 2025-05-14 https://biopharmsignal.com/news/CING/fda-and-cingulate-aligned-with-filing-requirements-for-new-drug-application-for--700eaa00 2025-05-14 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-reports-first-quarter-2025-financial-results-and-provides--7cf05e24 2025-05-14 https://biopharmsignal.com/news/ABUS/arbutus-reports-first-quarter-2025-financial-results-and-provides-corporate-update 2025-05-14 https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-participate-in-two-upcoming-investor-conferences-4b135b2b 2025-05-14 https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-reports-first-quarter-2025-financial-results-unaudited-90d13891 2025-05-14 https://biopharmsignal.com/news/GSK/gsk-to-acquire-efimosfermin-a-phase-iii-ready-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-sld 2025-05-14 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-first-quarter-2025-operating-results-and-provides-a-cc354a84 2025-05-13 https://biopharmsignal.com/news/MGTX/meiragtx-announces-the-presentation-of-four-posters-at-the-american-society-of-gene-and-cell-therapy-asgct-2025-annual-meeting 2025-05-13 https://biopharmsignal.com/news/RPTX/repare-therapeutics-provides-business-and-clinical-update-and-reports-first-quarter-2025-financial-results 2025-05-13 https://biopharmsignal.com/news/TXMD/therapeuticsmd-announces-first-quarter-2025-financial-results 2025-05-13 https://biopharmsignal.com/news/GSK/gsk-provides-update-on-belrestotug-development-programme 2025-05-13 https://biopharmsignal.com/news/OVID/ovid-therapeutics-reports-business-updates-and-first-quarter-2025-financial-resu-80a659a0 2025-05-13 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-to-participate-in-hanson-wade-s-6th-annual-cytokine-based--fc00d8db 2025-05-13 https://biopharmsignal.com/news/MNPR/monopar-therapeutics-reports-first-quarter-2025-financial-results-and-recent-developments 2025-05-13 https://biopharmsignal.com/news/ALZN/alzamend-neuro-initiates-first-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-taking-place-at-massachusetts-general-hospital 2025-05-13 https://biopharmsignal.com/news/NMTC/neuroone-reports-second-quarter-fiscal-year-2025-financial-results-gross-margin--a07c4c09 2025-05-13 https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-first-quarter-2025-financial-results-and-provides-corpor-e983b57d 2025-05-13 https://biopharmsignal.com/news/ADAP/adaptimmune-reports-q1-financial-results-and-provides-business-update 2025-05-13 https://biopharmsignal.com/news/YMAB/y-mabs-to-host-virtual-radiopharmaceutical-randd-update-on-may-28-2025 2025-05-13 https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-new-england-journal-of-medicine-publication-of-long-term-clinical-outcomes-from-its-hsc-gene-therapy-for-mld-and-multiple-presentations-at-asgct-2025 2025-05-13 https://biopharmsignal.com/news/GOCO/gohealth-reports-first-quarter-2025-results-6ea76f6a 2025-05-13 https://biopharmsignal.com/news/YMAB/y-mabs-reports-first-quarter-2025-financial-results-and-recent-corporate-developments 2025-05-13 https://biopharmsignal.com/news/TFX/new-retrospective-study-reports-significantly-reduced-post-operative-gerd-rates--112f9d75 2025-05-13 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-receives-milestone-payment-from-adovate-following-initiation-of-phase-1-study 2025-05-13 https://biopharmsignal.com/news/BYSI/beyondspring-reports-first-quarter-2025-financial-results-and-provides-corporate-9e08ef46 2025-05-12 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-receipt-of-delisting-notification-from-nasdaq-b29aaf82 2025-05-12 https://biopharmsignal.com/news/CLLS/cellectis-reports-financial-results-for-the-first-quarter-2025 2025-05-12 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-update 2025-05-12 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-first-quarter-2025-financial-results-and-provides-b-f6833a1d 2025-05-12 https://biopharmsignal.com/news/NMRA/neumora-therapeutics-reports-first-quarter-2025-financial-results-and-provides-b-933c4979 2025-05-12 https://biopharmsignal.com/news/ASRT/assertio-reports-first-quarter-2025-financial-results-e0a89e65 2025-05-12 https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-reports-first-quarter-2025-financial-results-and-provides-a-business-update 2025-05-12 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-first-quarter-financial-results-conf-c82b3509 2025-05-12 https://biopharmsignal.com/news/AMN/nurses-speak-out-on-burnout-balance-and-the-future-of-the-profession-in-new-surv-381c4675 2025-05-12 https://biopharmsignal.com/news/NMTC/neuroone-appoints-renowned-neurosurgeon-dr-parag-patil-as-chief-medical-advisor-a4f82352 2025-05-12 https://biopharmsignal.com/news/GALT/galectin-therapeutics-presented-navigate-trial-results-at-the-european-associati-5f61f3c3 2025-05-12 https://biopharmsignal.com/news/ENTX/entera-bio-announces-first-quarter-2025-financial-results-and-business-updates-557c05c1 2025-05-09 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2025-financial-results-and-corporate-highlights 2025-05-09 https://biopharmsignal.com/news/CLSD/clearside-biomedical-data-featured-in-six-presentations-at-association-for-research-in-vision-and-ophthalmology-arvo-2025-meeting 2025-05-09 https://biopharmsignal.com/news/CCEL/cord-blood-banking-leader-cryo-cell-announces-cash-dividend 2025-05-08 https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-first-quarter-2025-financial-results-and-business-highli-d6cb9d36 2025-05-08 https://biopharmsignal.com/news/CING/cingulate-inc-reports-first-quarter-2025-financial-results-and-provides-an-updat-b0644464 2025-05-08 https://biopharmsignal.com/news/AMN/amn-healthcare-announces-first-quarter-2025-results-a9ce2427 2025-05-08 https://biopharmsignal.com/news/GMED/globus-medical-reports-first-quarter-2025-results-261fcde1 2025-05-08 https://biopharmsignal.com/news/COO/coopercompanies-to-participate-in-the-william-blair-growth-stock-conference-0c5e0e0f 2025-05-08 https://biopharmsignal.com/news/ALEC/alector-reports-first-quarter-2025-financial-results-and-provides-business-updat-e623d886 2025-05-08 https://biopharmsignal.com/news/ICUI/icu-medical-announces-first-quarter-2025-results-89cf76fd 2025-05-08 https://biopharmsignal.com/news/GRI/gri-bio-s-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibroti-4e5fc230 2025-05-08 https://biopharmsignal.com/news/AXDX/accelerate-diagnostics-files-for-chapter-11-protection-and-agrees-to-terms-to-sell-substantially-all-assets 2025-05-08 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-reports-2025-first-quarter-financial-results-and-provides-busi-b66cb6d1 2025-05-08 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-founder-and-chief-scientific-officer-dr-michael-newman-nam-d4fe06b3 2025-05-08 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-to-host-kol-conference-call-and-webcast-to-discuss-bdc-3042-3e5b86a7 2025-05-08 https://biopharmsignal.com/news/RLYB/rallybio-reports-first-quarter-2025-financial-results-and-provides-business-updates 2025-05-08 https://biopharmsignal.com/news/VCEL/vericel-reports-first-quarter-2025-financial-results-and-raises-full-year-profit-e848c168 2025-05-08 https://biopharmsignal.com/news/CLSD/clearside-biomedical-to-report-first-quarter-2025-financial-results-on-wednesday-may-14-2025 2025-05-08 https://biopharmsignal.com/news/LNSR/lensar-reports-first-quarter-2025-results-and-provides-business-update-ba85570c 2025-05-08 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-reports-first-quarter-2025-financial-results-and-provides--9c51acff 2025-05-08 https://biopharmsignal.com/news/GSK/glisten-phase-iii-trial-results-show-linerixibat-significantly-improves-cholestatic-pruritus-relentless-itch-in-primary-biliary-cholangitis-pbc 2025-05-08 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration 2025-05-08 https://biopharmsignal.com/news/BTMD/biote-reports-first-quarter-2025-financial-results 2025-05-07 https://biopharmsignal.com/news/HCAT/health-catalyst-reports-first-quarter-2025-results-19cc960f 2025-05-07 https://biopharmsignal.com/news/ADAP/adaptimmune-to-report-q1-2025-financial-and-business-updates-on-tuesday-may-13-2025 2025-05-07 https://biopharmsignal.com/news/GRI/gri-bio-continues-to-drive-enrollment-in-ongoing-phase-2a-study-of-gri-0621-in-i-61d7aeb9 2025-05-07 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-executes-binding-letter-of-intent-with-new-day-diagnostic-4fed3351 2025-05-07 https://biopharmsignal.com/news/VCEL/vericel-to-present-at-the-bank-of-america-securities-2025-healthcare-conference--42b638c1 2025-05-07 https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-first-quarter-2025-financial-results-and-updates-on-corporate-developments 2025-05-07 https://biopharmsignal.com/news/GOCO/gohealth-s-statement-on-recent-allegations-in-the-united-states-false-claims-act-c153a3d7 2025-05-07 https://biopharmsignal.com/news/YMAB/y-mabs-announces-update-to-national-comprehensive-cancer-networkr-nccnr-clinical-practice-guidelines-in-oncology-for-neuroblastoma-to-include-naxitamab-gqgk-danyelzar 2025-05-07 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-first-quarter-2025-results 2025-05-07 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-to-present-52-week-extension-stage-results-for-enlighten-1-phase-3-study-for-lyr-210-for-the-treatment-of-chronic-rhinosinusitis-at-cosm-2025 2025-05-07 https://biopharmsignal.com/news/MNPR/monopar-presents-alxn1840-late-breaker-data-at-easl-2025 2025-05-07 https://biopharmsignal.com/news/ABUS/arbutus-presents-clinical-trial-data-from-its-two-hbv-assets-imdusiran-and-ab-101-at-the-european-association-for-the-study-of-the-liver-easl-congress-2025 2025-05-07 https://biopharmsignal.com/news/CLLS/cellectis-to-report-first-quarter-financial-results-on-may-12-2025 2025-05-06 https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-first-quarter-2025-financial-results-and-provides-ge-9b3326e4 2025-05-06 https://biopharmsignal.com/news/BCAB/bioatla-reports-first-quarter-2025-financial-results-and-highlights-recent-progr-b117fc6e 2025-05-06 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-update 2025-05-06 https://biopharmsignal.com/news/VYGR/voyager-reports-first-quarter-2025-financial-and-operating-results-01312eef 2025-05-06 https://biopharmsignal.com/news/FORA/forian-inc-to-announce-first-quarter-2025-results-on-may-14-2025 2025-05-06 https://biopharmsignal.com/news/YMAB/y-mabs-to-announce-first-quarter-2025-financial-and-operating-results-on-may-13-2025 2025-05-06 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-appoints-cari-gallman-as-executive-vice-president-general-counsel-and-chief-policy-officer 2025-05-06 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-first-quarter-2025-financial-results-and-business-highlights 2025-05-06 https://biopharmsignal.com/news/FMS/fresenius-medical-care-starts-2025-with-strong-organic-revenue-and-income-growth 2025-05-05 https://biopharmsignal.com/news/LMAT/lemaitre-to-present-at-the-bank-of-america-securities-2025-healthcare-conference-ef29ec0d 2025-05-05 https://biopharmsignal.com/news/GOCO/gohealth-to-announce-first-quarter-2025-results-on-may-13-2025-eb425013 2025-05-05 https://biopharmsignal.com/news/ASRT/assertio-holdings-inc-to-report-first-quarter-2025-financial-results-on-may-12-2-3a76608e 2025-05-05 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-presents-new-preclinical-data-further-characterizing-its-i-8704c828 2025-05-05 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-to-participate-in-upcoming-investor-conferences-338d593d 2025-05-05 https://biopharmsignal.com/news/IRMD/iradimed-corporation-announces-first-quarter-2025-financial-results-04bdf41d 2025-05-05 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update-on-tuesday-may-13-2025 2025-05-05 https://biopharmsignal.com/news/GSK/gsk-continues-to-advance-the-future-of-respiratory-medicine-and-patient-care-with-new-data-at-ats 2025-05-02 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-announces-a-warrant-inducement-transaction-for-2-75-million-in-gross-proceeds 2025-05-02 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-reports-first-quarter-fiscal-2025-results-and-full-year-g-6df29aa4 2025-05-02 https://biopharmsignal.com/news/FMS/fresenius-medical-care-celebrates-40-of-dialysis-center-in-sokolov-czech-republic 2025-05-01 https://biopharmsignal.com/news/PRPO/precipio-announces-q1-2025-shareholder-update-call-691d68ac 2025-05-01 https://biopharmsignal.com/news/STTK/shattuck-labs-reports-first-quarter-2025-financial-results-and-recent-business-h-4177f507 2025-05-01 https://biopharmsignal.com/news/AMWL/amwell-announces-results-for-first-quarter-2025-56879a81 2025-05-01 https://biopharmsignal.com/news/GNLX/genelux-corporation-to-participate-in-a-fireside-chat-at-the-citizens-life-scien-169e6c37 2025-05-01 https://biopharmsignal.com/news/LMAT/lemaitre-q1-2025-financial-results-5e944b07 2025-05-01 https://biopharmsignal.com/news/NMTC/neuroone-to-report-second-quarter-fiscal-year-2025-financial-results-on-tuesday--797351db 2025-05-01 https://biopharmsignal.com/news/CLSD/clearside-biomedical-to-participate-in-a-fireside-chat-at-the-citizens-life-sciences-conference 2025-05-01 https://biopharmsignal.com/news/BPTH/bio-path-holdings-achieves-third-pre-clinical-milestone-confirming-potential-of--a70a6183 2025-05-01 https://biopharmsignal.com/news/RPTX/repare-therapeutics-announces-out-licensing-of-its-discovery-platforms-to-dcx-biotherapeutics 2025-05-01 https://biopharmsignal.com/news/TFX/teleflex-reports-first-quarter-financial-results-and-full-year-2025-outlook-20fe8cfa 2025-05-01 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-expands-intellectual-property-portfolio-with-new-u-s-patent-granted-for-genetic-based-treatment-of-alcohol-and-opioid-use-disorders 2025-05-01 https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-announces-u-s-fda-approval-for-atzumitm-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine 2025-05-01 https://biopharmsignal.com/news/COO/coopercompanies-appoints-barbara-carbone-to-board-of-directors-b01d74ee 2025-04-30 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-presents-preclinical-results-for-next-generation-boltbody-i-7dd04668 2025-04-30 https://biopharmsignal.com/news/MDXH/mdxhealth-to-release-first-quarter-2025-financial-results-on-may-14-88886d62 2025-04-30 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-issuance-of-u-s-patent-no-12-281-056-including-58--540af8e3 2025-04-30 https://biopharmsignal.com/news/BCAB/bioatla-to-participate-in-the-citizens-life-sciences-conference-ecd25cad 2025-04-30 https://biopharmsignal.com/news/ANL/adlai-nortye-reports-full-year-2024-financial-results-and-business-updates 2025-04-30 https://biopharmsignal.com/news/GSK/nucala-mepolizumab-delivers-clinically-meaningful-and-statistically-significant-reduction-in-copd-exacerbations-with-positive-matinee-trial-results-published-in-new-england-journal-of-medicine 2025-04-30 https://biopharmsignal.com/news/GSK/gsk-makes-strong-start-to-2025-with-growth-in-sales-profits-and-earnings 2025-04-30 https://biopharmsignal.com/news/COO/coopercompanies-announces-release-date-for-second-quarter-2025-7b212118 2025-04-29 https://biopharmsignal.com/news/ATRC/atricure-reports-first-quarter-2025-financial-results 2025-04-29 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-provides-poster-presentation-highlights-for-nxp900-from-the-2025-aacr-meeting 2025-04-29 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-to-effect-1-for-14-reverse-stock-split 2025-04-29 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-proposes-potentially-groundbreaking-study-aimed-at-reducing--15eb7318 2025-04-29 https://biopharmsignal.com/news/BCAB/bioatla-to-announce-first-quarter-2025-financial-results-and-provide-business-hi-defd6041 2025-04-29 https://biopharmsignal.com/news/MNPR/monopar-announces-alxn1840-data-selected-for-late-breaker-presentation-at-easl-congress-2025 2025-04-29 https://biopharmsignal.com/news/IPSC/century-therapeutics-announces-two-upcoming-presentations-at-the-asgct-28th-annu-ab029f50 2025-04-28 https://biopharmsignal.com/news/VYGR/voyager-next-generation-cns-capsids-featured-at-asgct-28th-annual-meeting-7edf22b6 2025-04-28 https://biopharmsignal.com/news/CLLS/cellectis-presents-non-viral-gene-editing-and-base-editing-innovation-at-the-asgct-annual-meeting 2025-04-28 https://biopharmsignal.com/news/SPRO/spero-therapeutics-appoints-esther-rajavelu-as-president-and-chief-executive-officer 2025-04-28 https://biopharmsignal.com/news/IRMD/correction-iradimed-corporation-to-hold-first-quarter-of-2025-financial-results--8023eca5 2025-04-28 https://biopharmsignal.com/news/LGMK/logicmark-inc-unveils-new-board-committee-leadership-structure-to-align-with-str-6c5fb429 2025-04-28 https://biopharmsignal.com/news/IRMD/iradimed-corporation-to-hold-first-quarter-of-2025-financial-results-conference--eabfc710 2025-04-28 https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-to-host-a-capital-markets-day-on-tuesday-april-29 2025-04-25 https://biopharmsignal.com/news/AEON/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-comp-3d1e3467 2025-04-25 https://biopharmsignal.com/news/PYXS/pyxis-oncology-presents-promising-preclinical-results-providing-proof-of-mechani-115b84b9 2025-04-25 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-presents-results-from-the-phase-1-dose-escalation-clinical--3f6d8a98 2025-04-25 https://biopharmsignal.com/news/RPTX/repare-therapeutics-announces-six-abstracts-accepted-for-presentation-at-aacr-annual-meeting-2025 2025-04-25 https://biopharmsignal.com/news/MGRX/mangoceuticals-announces-strategic-entry-into-high-growth-pouch-industry-through-03023e73 2025-04-25 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-provides-update-on-vyn202-program-a6ccad8e 2025-04-25 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reiterates-full-year-2025-linzess-u-s-net-sales-guidance-and-raises-adjusted-ebitda-guidance 2025-04-25 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-announces-first-quarter-fiscal-2025-earnings-release-date-4b4510e1 2025-04-25 https://biopharmsignal.com/news/ICUI/icu-medical-announces-time-of-first-quarter-2025-earnings-conference-call-696b2234 2025-04-24 https://biopharmsignal.com/news/AMWL/amwell-to-participate-in-upcoming-investor-conferences-1b88c8ce 2025-04-24 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-first-quarter-financial-results-for-2025 2025-04-24 https://biopharmsignal.com/news/IMMX/immix-biopharma-s-nxc-201-nexicart-2-clinical-trial-data-selected-for-oral-prese-09170597 2025-04-23 https://biopharmsignal.com/news/ENLV/enlivex-therapeutics-to-showcase-allocetra-s-potential-in-osteoarthritis-at-oars-d3b9b130 2025-04-23 https://biopharmsignal.com/news/NMTC/neuroone-completes-fda-submission-for-the-onerf-trigeminal-nerve-ablation-system-ff234a8f 2025-04-23 https://biopharmsignal.com/news/SMTI/sanara-medtech-to-report-first-quarter-2025-financial-results-on-may-14-2025-a804a743 2025-04-23 https://biopharmsignal.com/news/ABUS/arbutus-to-present-imdusiran-and-ab-101-data-at-easl-congress-2025 2025-04-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-topline-results-from-phase-3-arise-trial-evaluating-cobenfy-xanomeline-and-trospium-chloride-as-an-adjunctive-treatment-to-atypical-antipsychotics-in-adults-with-schizophrenia 2025-04-22 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-present-real-world-data-at-digestive-disease-weekr-2025-on-adoption-of-new-diagnosis-codes-among-short-bowel-syndrome-patients-who-are-dependent-on-parenteral-support 2025-04-22 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-announces-registration-of-acne-products-in-the-united-kingdom-and-launch-of-the-products-in-leading-u-k-pharmacy-chain 2025-04-22 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-issuance-of-u-s-patent-no-12-275-684-further-stren-7031edc2 2025-04-22 https://biopharmsignal.com/news/OCEA/ocean-biomedical-expands-into-energy-and-digital-asset-sectors-to-accelerate-gro-87c6ee7c 2025-04-22 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-reports-first-quarter-2025-results 2025-04-21 https://biopharmsignal.com/news/AEON/aeon-biopharma-appoints-industry-veteran-rob-bancroft-as-chief-executive-officer-deed6b7a 2025-04-21 https://biopharmsignal.com/news/ENLV/enlivex-announces-completion-of-enrollment-in-the-phase-ii-stage-of-its-phase-i--8d828bec 2025-04-21 https://biopharmsignal.com/news/VCNX/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemab-s-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr 2025-04-21 https://biopharmsignal.com/news/IMVT/immunovant-announces-next-phase-of-growth-with-roivant-including-changes-to-its-leadership-team-and-additional-indications-sjoegren-s-disease-sjd-and-cutaneous-lupus-erythematosus-cle-for-imvt-1402 2025-04-21 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-updates-camzyosr-mavacamten-label-to-reduce-echocardiography-monitoring-requirements-and-contraindications 2025-04-18 https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsed-refractory-multiple-myeloma 2025-04-17 https://biopharmsignal.com/news/ALEC/alector-announces-completion-of-enrollment-in-the-progress-ad-phase-2-clinical-t-2126a3fe 2025-04-17 https://biopharmsignal.com/news/HCAT/health-catalyst-to-announce-first-quarter-2025-operating-results-and-host-confer-5d783f97 2025-04-17 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer-b2264dc5 2025-04-17 https://biopharmsignal.com/news/AMWL/amwell-to-report-first-quarter-2025-operating-results-1f355427 2025-04-17 https://biopharmsignal.com/news/GSK/gsk-s-5-in-1-meningococcal-vaccine-penmenvy-receives-positive-recommendation-from-us-advisory-committee-on-immunization-practices 2025-04-16 https://biopharmsignal.com/news/GSK/arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-rsv-disease-by-us-advisory-committee-on-immunization-practices 2025-04-16 https://biopharmsignal.com/news/NMTC/neuroone-issues-letter-to-shareholders-a5e78624 2025-04-16 https://biopharmsignal.com/news/GRI/gri-bio-announces-abstract-selected-for-poster-discussion-session-at-the-2025-american-thoracic-society-ats-international-conference 2025-04-16 https://biopharmsignal.com/news/IPSC/century-therapeutics-to-host-live-fireside-chat-focused-on-newly-prioritized-pre-fc650775 2025-04-15 https://biopharmsignal.com/news/ENTX/entera-bio-s-eb613-demonstrates-early-impact-on-both-trabecular-and-cortical-bon-59bc26ff 2025-04-15 https://biopharmsignal.com/news/CCEL/cord-blood-banking-leader-cryo-cell-reports-fiscal-first-quarter-2025-financial-results 2025-04-15 https://biopharmsignal.com/news/GALT/galectin-therapeutics-to-present-at-the-european-association-for-the-study-of-th-44dd1516 2025-04-15 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-provides-update-on-phase-3-odyssey-hcm-trial 2025-04-14 https://biopharmsignal.com/news/NMTC/neuroone-onerf-technology-success-story-featured-on-fox-news-2fe7bd3f 2025-04-14 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-provides-clinical-and-regulatory-update-on-apraglutide 2025-04-14 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-approves-opdivor-nivolumab-plus-yervoyr-ipilimumab-as-a-first-line-treatment-for-unresectable-or-metastatic-hepatocellular-carcinoma 2025-04-11 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-annual-shareholder-meeting-to-be-hel-7d6455cf 2025-04-11 https://biopharmsignal.com/news/IMRN/immuron-travelan-highest-sales-in-history-3187b5d7 2025-04-10 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-present-new-data-on-nuzyrar-omadacycline-at-escmid-global-2025 2025-04-10 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-releases-virtual-investor-what-this-means-segment 2025-04-09 https://biopharmsignal.com/news/TCBP/tcbp-announces-grant-of-european-patent-for-targeting-of-microbial-oncological-and-viral-indications-using-modified-gamma-delta-t-cells 2025-04-09 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-to-present-at-the-planet-microcap-showcase-veg-1dd1a6bc 2025-04-09 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-approves-opdivor-nivolumab-plus-yervoyr-ipilimumab-as-a-treatment-for-patients-with-previously-untreated-microsatellite-instability-high-or-mismatch-repair-deficient-unresectable-or-metastatic-colorectal-cancer 2025-04-08 https://biopharmsignal.com/news/LMAT/lemaitre-will-announce-first-quarter-2025-earnings-results-may-1-2025-3a1886d0 2025-04-07 https://biopharmsignal.com/news/SHCR/sharecare-names-industry-veteran-elizabeth-delahoussaye-as-chief-privacy-officer-of-health-data-solutions 2025-04-07 https://biopharmsignal.com/news/NMTC/neuroone-medical-technologies-corporation-announces-pricing-of-8-0-million-publi-cc88e708 2025-04-04 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-strong-full-year-20-760ba9f0 2025-04-04 https://biopharmsignal.com/news/NMTC/neuroone-medical-technologies-corporation-announces-proposed-public-offering-of--0d815163 2025-04-03 https://biopharmsignal.com/news/ENLV/enlivex-announces-the-dosing-of-the-first-patient-in-a-phase-i-trial-evaluating--021c5909 2025-04-03 https://biopharmsignal.com/news/GMED/globus-medical-completes-acquisition-of-nevro-corp-441e0e2d 2025-04-03 https://biopharmsignal.com/news/GRI/gri-bio-announces-closing-of-5-0-million-public-offering-9908ae6b 2025-04-02 https://biopharmsignal.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-24th-annual-needham-virtual-he-34813046 2025-04-02 https://biopharmsignal.com/news/OVID/ovid-therapeutics-to-present-at-the-24th-annual-needham-virtual-healthcare-confe-40b596bb 2025-04-02 https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum-de4b2983 2025-04-02 https://biopharmsignal.com/news/LMAT/lemaitre-to-present-at-the-24th-annual-needham-virtual-healthcare-conference-92b25998 2025-04-01 https://biopharmsignal.com/news/GRI/gri-bio-announces-pricing-of-5-0-million-public-offering-15678970 2025-04-01 https://biopharmsignal.com/news/GRI/gri-bio-reports-encouraging-interim-2-week-safety-results-from-ongoing-phase-2a--b0b45a00 2025-04-01 https://biopharmsignal.com/news/LGMK/logicmark-secures-approval-to-deliver-new-medical-alert-with-cell-phone-tech-to--70b9516b 2025-04-01 https://biopharmsignal.com/news/MRKR/marker-therapeutics-to-present-at-canaccord-genuity-s-horizons-in-oncology-confe-a3054789 2025-04-01 https://biopharmsignal.com/news/NAVB/navidea-biopharmaceuticals-announces-the-extension-of-plan-designed-to-protect-nols-and-other-tax-assets 2025-03-31 https://biopharmsignal.com/news/FMS/fresenius-medical-care-places-bonds-with-a-volume-of-1-1-billion-euros 2025-03-31 https://biopharmsignal.com/news/CARM/carisma-therapeutics-provides-corporate-updates 2025-03-31 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-fourth-quarter-and-full-year-2024-ea-67b41124 2025-03-31 https://biopharmsignal.com/news/EGRX/eagle-pharmaceuticals-announces-69-million-agreement-to-monetize-bendekar-royalties 2025-03-31 https://biopharmsignal.com/news/GRI/gri-bio-bolsters-intellectual-property-portfolio-with-granting-of-two-global-pat-ff4b01b0 2025-03-31 https://biopharmsignal.com/news/MRKR/marker-therapeutics-reports-year-end-2024-corporate-and-financial-results-a5525882 2025-03-31 https://biopharmsignal.com/news/TENX/tenax-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare--2a657af0 2025-03-31 https://biopharmsignal.com/news/GALT/galectin-therapeutics-reports-2024-financial-results-and-provides-business-updat-14facc6d 2025-03-31 https://biopharmsignal.com/news/HOWL/werewolf-therapeutics-to-present-at-the-24th-annual-needham-virtual-healthcare-c-4784e125 2025-03-31 https://biopharmsignal.com/news/MNPR/monopar-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-developments 2025-03-31 https://biopharmsignal.com/news/VYGR/voyager-presents-robust-preclinical-data-from-tau-targeting-gene-therapy-and-ant-692be8d6 2025-03-31 https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-fourth-quarter-and-full-year-2024-financial-results--f159bf9b 2025-03-28 https://biopharmsignal.com/news/ENTX/entera-bio-announces-full-year-2024-financial-results-and-provides-business-upda-0106b51e 2025-03-28 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-positive-chmp-opinion-for-perioperative-regimen-of-neoadjuvant-opdivor-nivolumab-and-chemotherapy-followed-by-surgery-and-adjuvant-opdivo-for-resectable-non-small-cell-lung-cancer-in-patients-with-tumor-cell-pd-l1 2025-03-28 https://biopharmsignal.com/news/OCEA/ocean-biomedical-announces-grant-on-patent-right-for-bispecific-antibodies-targe-03e78d2e 2025-03-28 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-positive-chmp-opinion-for-the-subcutaneous-formulation-of-opdivor-nivolumab-across-multiple-solid-tumor-indications 2025-03-28 https://biopharmsignal.com/news/BPTH/bio-path-holdings-reports-full-year-2024-financial-results-d19bcd3b 2025-03-28 https://biopharmsignal.com/news/FMS/fresenius-medical-care-expands-production-of-bibagr-dry-bicarbonate-concentrate-bags-for-hemodialysis-in-the-state-of-sao-paulo-in-brazil 2025-03-27 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2024-operating-results-065e6a4b 2025-03-27 https://biopharmsignal.com/news/AEON/aeon-biopharma-announces-ceo-transition-38f011b3 2025-03-27 https://biopharmsignal.com/news/TXMD/therapeuticsmd-announces-full-year-2024-financial-results 2025-03-27 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-announces-receipt-of-nasdaq-non-compliance-notification-regarding-late-2024-form-10-k-filing 2025-03-27 https://biopharmsignal.com/news/AQB/aquabounty-technologies-announces-full-year-2024-financial-results 2025-03-27 https://biopharmsignal.com/news/BYSI/beyondspring-files-2024-annual-report-on-form-10-k-a9dab0d8 2025-03-27 https://biopharmsignal.com/news/BYSI/beyondspring-reports-2024-year-end-financial-results-and-highlights-key-clinical-b9fa9087 2025-03-27 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-entry-by-collaboration-partner-into-a-clinical-study-agreement-to-advance-development-of-dnase-platform-for-the-treatment-of-relapsed-refractory-osteosarcoma-and-ewing-sarcoma 2025-03-26 https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-full-year-2024-financial-results-and-provides-corporate--bc66946e 2025-03-26 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-upcoming-presentations-for-nxp900-at-the-2025-american-association-for-cancer-research-meeting 2025-03-26 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-to-present-data-from-phase-1-dose-escalation-clinical-study-8deb2673 2025-03-25 https://biopharmsignal.com/news/TENX/tenax-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-a-6d7d73b3 2025-03-25 https://biopharmsignal.com/news/GSK/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections-uutis-in-female-adults-and-paediatric-patients-12-years-of-age-and-older 2025-03-25 https://biopharmsignal.com/news/GSK/gsk-uk-dementia-research-institute-uk-dri-and-health-data-research-uk-hdr-uk-to-collaborate-on-first-of-its-kind-dementia-research-initiative 2025-03-25 https://biopharmsignal.com/news/MGRX/mangoceuticals-expands-into-33-billion-addressable-diabetes-market-through-its-e-bb922abe 2025-03-25 https://biopharmsignal.com/news/GNLX/genelux-corporation-announces-pricing-of-10-5-million-underwritten-offering-of-c-042e3504 2025-03-25 https://biopharmsignal.com/news/NGEN/nervgen-pharma-to-host-virtual-investor-event-2aa6efc0 2025-03-25 https://biopharmsignal.com/news/GNLX/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-64f29b7e 2025-03-25 https://biopharmsignal.com/news/GNLX/genelux-and-newsoara-announce-positive-preliminary-phase-1b-2-data-of-olvi-vec-i-6248b7b1 2025-03-25 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-chief-medical-officer-roger-waltzman-m-d-m-b-a-to-moderate-8b205a51 2025-03-25 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-full-year-2024-financial-results-and-provides-corp-d35fa88f 2025-03-25 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-02430f36 2025-03-24 https://biopharmsignal.com/news/AEON/aeon-biopharma-reports-fourth-quarter-and-full-year-2024-financial-results-and-p-8caaf904 2025-03-24 https://biopharmsignal.com/news/ICUI/icu-medical-to-present-at-the-24th-annual-needham-virtual-healthcare-conference-0005ff72 2025-03-24 https://biopharmsignal.com/news/LNSR/alcon-agrees-to-acquire-lensar-inc-e893c338 2025-03-24 https://biopharmsignal.com/news/GSK/gsk-s-application-to-expand-use-of-nucala-mepolizumab-for-the-treatment-of-copd-accepted-for-review-by-the-european-medicines-agency 2025-03-24 https://biopharmsignal.com/news/EGRX/eagle-pharmaceuticals-announces-amendment-to-limited-duration-stockholder-rights-plan 2025-03-21 https://biopharmsignal.com/news/AXDX/accelerate-diagnostics-submits-wave-system-and-gram-negative-positive-blood-culture-menu-to-the-fda-for-510-k-clearance 2025-03-21 https://biopharmsignal.com/news/TCBP/tcbp-announces-transition-from-nasdaq-to-otc-markets 2025-03-21 https://biopharmsignal.com/news/AXDX/accelerate-diagnostics-reports-fourth-quarter-and-full-year-2024-financial-results 2025-03-21 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-result-51da956e 2025-03-20 https://biopharmsignal.com/news/ASRT/assertio-to-participate-in-the-iaccess-alpha-virtual-best-ideas-conference-on-ma-1267d747 2025-03-20 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inf-cbcef987 2025-03-20 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-reports-new-data-demonstrating-successful-broad-immune-sys-d719ba50 2025-03-20 https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-full-year-2024-financial-results-and-updates-on-corporate-developments 2025-03-20 https://biopharmsignal.com/news/ADAP/adaptimmune-provides-q4-and-full-year-2024-business-update 2025-03-20 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-acquire-optinose-creating-significant-commercial-expansion-opportunities-for-xhancer-in-chronic-rhinosinusitis-crs 2025-03-19 https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-full-year-2024-financial-results-and-provides-busin-0a02f5f5 2025-03-19 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-reports-full-year-2024-financial-results 2025-03-19 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-to-report-first-quarter-2025-financial-results-on-april-21-2025 2025-03-18 https://biopharmsignal.com/news/NMTC/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-today-s-marke-f518f294 2025-03-18 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-6e0d94e3 2025-03-18 https://biopharmsignal.com/news/NMTC/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-today-s-marke-95d95048 2025-03-18 https://biopharmsignal.com/news/TCBP/tcbp-announces-outsourcing-initiatives-reducing-burn-rate-and-overhead 2025-03-18 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-initiates-phase-1-combination-study-of-decoy20-with-pd-1-c-ecba8e74 2025-03-18 https://biopharmsignal.com/news/VRAX/virax-biolabs-enrolls-first-patients-in-clinical-study-assessing-t-cell-dysfunction-in-post-acute-infection-syndromes 2025-03-18 https://biopharmsignal.com/news/BPTH/bio-path-holdings-announces-pre-clinical-results-signaling-increased-potential-f-da00b5ac 2025-03-18 https://biopharmsignal.com/news/GRI/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment 2025-03-18 https://biopharmsignal.com/news/GRI/gri-bio-reports-full-year-2024-financial-results-and-reiterates-expected-clinica-0307f763 2025-03-17 https://biopharmsignal.com/news/ENLV/enlivex-receives-notice-of-allowance-for-chinese-patent-application-covering-the-244630ba 2025-03-17 https://biopharmsignal.com/news/ENTX/opko-health-and-entera-bio-enter-into-collaboration-agreement-to-advance-oral-gl-6ada1c08 2025-03-17 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-reverse-stock-split-74cab717 2025-03-14 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-approval-from-the-european-commission-to-expand-use-of-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-follicular-lymphoma 2025-03-14 https://biopharmsignal.com/news/AIRS/airsculpt-technologies-reports-fourth-quarter-and-full-year-fiscal-2024-results-a7759dcb 2025-03-14 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-participate-in-the-37th-annual-roth-conference 2025-03-14 https://biopharmsignal.com/news/CLLS/cellectis-reports-financial-results-for-the-fourth-quarter-and-full-year-2024-and-provides-a-business-update 2025-03-13 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update 2025-03-13 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-presents-positive-preclinical-data-underscoring-the-potential-of-dnase-i-as-an-adjunctive-treatment-to-enhance-immunotherapeutic-responses 2025-03-13 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-9cf7b81e 2025-03-13 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-first-quarter-2025-on-april-24-2025 2025-03-13 https://biopharmsignal.com/news/FMS/fresenius-medical-care-publishes-its-joint-annual-report-and-sustainability-statement-for-2024-building-the-momentum 2025-03-12 https://biopharmsignal.com/news/ADAP/adaptimmune-to-report-full-year-and-q4-2024-financial-and-business-updates-on-thursday-march-20-2025 2025-03-12 https://biopharmsignal.com/news/INDP/registration-is-now-open-for-tribe-public-s-webinar-event-keys-to-the-kingdom-un-93127792 2025-03-12 https://biopharmsignal.com/news/ASRT/assertio-reports-fourth-quarter-and-full-year-2024-financial-results-f55937ab 2025-03-12 https://biopharmsignal.com/news/GSK/viiv-healthcare-s-investigational-broadly-neutralising-antibody-n6ls-successfully-maintains-viral-suppression-in-long-acting-treatment-of-hiv 2025-03-12 https://biopharmsignal.com/news/GSK/viiv-healthcare-announces-new-implementation-study-data-showing-zero-cases-of-hiv-with-apretude-the-only-long-acting-injectable-approved-for-hiv-prep 2025-03-12 https://biopharmsignal.com/news/GMED/globus-medical-extends-versatility-of-advanced-materials-science-anterior-interb-c5473c95 2025-03-11 https://biopharmsignal.com/news/VYGR/voyager-reports-fourth-quarter-and-full-year-2024-financial-and-operating-result-5cd90b01 2025-03-11 https://biopharmsignal.com/news/GSK/viiv-healthcare-showcases-leadership-in-long-acting-injectables-innovation-at-croi-2025-with-data-on-third-generation-integrase-inhibitor-insti-and-highly-potent-capsid-inhibitor-against-hiv-1 2025-03-11 https://biopharmsignal.com/news/NMTC/neuroone-accelerates-timeline-of-510-k-submission-to-fda-for-the-onerf-trigemina-5a38b0ac 2025-03-11 https://biopharmsignal.com/news/GRI/gri-bio-regains-compliance-with-nasdaq-s-minimum-bid-price-rule-beab0726 2025-03-11 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-plans-to-pursue-metastatic-breast-cancer-indicatio-caa1ea49 2025-03-11 https://biopharmsignal.com/news/OVID/ovid-therapeutics-reports-business-updates-and-fourth-quarter-and-full-year-2024-834cd9e7 2025-03-11 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-secures-extensive-u-k-regulatory-clearances-of-key-wound-care-and-dermatology-products-by-the-medicines-and-healthcare-products-regulatory-agency-mhra 2025-03-10 https://biopharmsignal.com/news/GSK/viiv-healthcare-continues-to-deliver-long-acting-injectable-hiv-innovation-with-late-breaking-data-and-real-world-insights-across-pipeline-and-portfolio-at-croi-2025 2025-03-09 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-late-breaking-data-from-phase-3-poetyk-psa-2-trial-demonstrating-superiority-of-sotyktu-deucravacitinib-compared-with-placebo-in-adults-with-psoriatic-arthritis 2025-03-08 https://biopharmsignal.com/news/VCNX/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market 2025-03-07 https://biopharmsignal.com/news/ICUI/icu-medical-to-participate-at-the-keybanc-healthcare-forum-917bca90 2025-03-07 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-european-commission-approval-for-opdivor-nivolumab-plus-yervoyr-ipilimumab-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-advanced-hepatocellular-carcinoma 2025-03-07 https://biopharmsignal.com/news/CLLS/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025 2025-03-07 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-reports-2024-fourth-quarter-and-year-end-financial-results-and-e8800d80 2025-03-06 https://biopharmsignal.com/news/GSK/gsk-to-showcase-latest-research-at-the-international-rsv-symposium-to-advance-rsv-prevention-in-adults 2025-03-06 https://biopharmsignal.com/news/MBIO/mustang-bio-regains-compliance-with-nasdaq-capital-market-requirement 2025-03-05 https://biopharmsignal.com/news/ASRT/assertio-holdings-inc-to-report-fourth-quarter-and-full-year-2024-financial-resu-80a34a36 2025-03-05 https://biopharmsignal.com/news/TCBP/tcbp-announces-non-binding-letter-of-intent-to-acquire-commercial-stage-ophthalmic-pharmaceutical-company 2025-03-05 https://biopharmsignal.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-leerink-partners-global-h-d901f259 2025-03-05 https://biopharmsignal.com/news/IMRN/immuron-and-calmino-join-up-to-treat-irritable-bowel-syndrome-ibs-440ab77e 2025-03-05 https://biopharmsignal.com/news/ENLV/enlivex-therapeutics-announces-investor-webinar-to-discuss-positive-interim-data-08c721d9 2025-03-04 https://biopharmsignal.com/news/ENLV/enlivex-therapeutics-announces-investor-webinar-to-discuss-positive-interim-data-from-phase-i-ii-allocetratm-trial-in-knee-osteoarthritis 2025-03-04 https://biopharmsignal.com/news/AEON/aeon-biopharma-inc-to-participate-in-the-leerink-global-healthcare-conference-44ee1713 2025-03-04 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-expands-patent-portfolio-in-china-japan-and-israel-strengt-f914e5a6 2025-03-04 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-reports-2024-fiscal-year-financial-results-and-provides-business-update 2025-03-04 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-a-new-publication-of-a-research-study-demonstrating-that-the-combination-of-nxp900-and-egfr-inhibitors-improves-the-efficacy-of-the-egfr-inhibitors-in-preclinical-models-of-egfr-mutated-nsclc 2025-03-04 https://biopharmsignal.com/news/AMWL/amwell-makes-inducement-grant-95591ec5 2025-03-03 https://biopharmsignal.com/news/ENLV/enlivex-announces-positive-interim-data-statistically-significant-47-0-durable-a-679766f9 2025-03-03 https://biopharmsignal.com/news/GSK/depemokimab-applications-accepted-for-review-by-the-us-fda-for-asthma-with-type-2-inflammation-and-for-chronic-rhinosinusitis-with-nasal-polyps-crswnp 2025-03-03 https://biopharmsignal.com/news/GSK/depemokimab-delivers-clinically-meaningful-and-statistically-significant-improvements-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp 2025-03-01 https://biopharmsignal.com/news/CCEL/cryo-cell-reports-financial-results-for-fiscal-year-ended-november-30-2024 2025-02-28 https://biopharmsignal.com/news/ICUI/icu-medical-announces-fourth-quarter-2024-results-and-provides-fiscal-year-2025--5f4b2a01 2025-02-27 https://biopharmsignal.com/news/MBIO/mustang-bio-announces-sale-of-fixed-assets-and-exit-of-facility 2025-02-27 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-abstract-accepted-for-poster-presentation-at-the-society-for-immunotherapy-of-cancer-sitc-spring-scientific-2025-cell-therapy-meeting 2025-02-27 https://biopharmsignal.com/news/LNSR/lensar-reports-fourth-quarter-and-full-year-2024-results-and-provides-business-u-d57161aa 2025-02-27 https://biopharmsignal.com/news/GOCO/gohealth-reports-strong-fourth-quarter-and-fiscal-year-2024-results-driven-by-a--e7a7c491 2025-02-27 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-results-achieves-2024-financial-guidance 2025-02-27 https://biopharmsignal.com/news/ALEC/alector-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-2a99d10a 2025-02-26 https://biopharmsignal.com/news/HCAT/health-catalyst-reports-fourth-quarter-and-year-end-2024-results-4e70fa2c 2025-02-26 https://biopharmsignal.com/news/MDXH/mdxhealth-announces-fourth-quarter-and-full-year-2024-financial-results-794075f5 2025-02-26 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-to-exhibit-at-2025-american-academy-of-dermatology-annual-meeting-in-orlando 2025-02-25 https://biopharmsignal.com/news/INDP/indaptus-therapeutics-chief-scientific-officer-dr-michael-newman-to-present-at-t-cdacd4e3 2025-02-25 https://biopharmsignal.com/news/MRKR/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-vir-a0e51615 2025-02-25 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-upcoming-investor-conferences 2025-02-25 https://biopharmsignal.com/news/SPRO/update-spero-therapeutics-to-present-at-td-cowen-45th-annual-health-care-conference 2025-02-25 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-receives-positive-response-from-fda-meeting-regarding-proposed-in-vitro-bridging-strategy-for-ad04 2025-02-25 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-2024-financial-results-and-business-highlights 2025-02-25 https://biopharmsignal.com/news/FMS/fresenius-medical-care-published-form-20-f-for-the-fiscal-year-2024 2025-02-24 https://biopharmsignal.com/news/FMS/fresenius-medical-care-delivers-18-earnings-growth-in-2024-and-continues-the-acceleration-momentum-into-2025 2025-02-24 https://biopharmsignal.com/news/AEON/aeon-biopharma-inc-announces-reverse-stock-split-e7ec4b00 2025-02-24 https://biopharmsignal.com/news/ENTX/entera-bio-to-participate-in-upcoming-events-5e441b54 2025-02-24 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-supplemental-biologics-license-application-for-opdivor-plus-yervoyr-for-patients-with-unresectable-or-metastatic-microsatellite-instability-high-or-mismatch-repair-deficient 2025-02-24 https://biopharmsignal.com/news/NGM/ngm-bio-announces-first-participant-dosed-in-emerald-phase-2-clinical-study-of-ngm120-for-the-treatment-of-hyperemesis-gravidarum-hg-in-pregnant-patients 2025-02-24 https://biopharmsignal.com/news/GSK/gsk-plc-commences-share-buyback-programme 2025-02-24 https://biopharmsignal.com/news/CLLS/cellectis-presents-smart-car-t-strategy-to-enhance-efficacy-against-solid-tumors-at-aacr-io-2025 2025-02-24 https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-idrx-inc 2025-02-24 https://biopharmsignal.com/news/FMS/fresenius-medical-care-announces-divestment-of-select-laboratory-assets-to-quest-diagnostics 2025-02-23 https://biopharmsignal.com/news/GSK/gsk-announces-dr-gavin-screaton-to-join-the-board-as-non-executive-director 2025-02-21 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2024-investor-update-call 2025-02-20 https://biopharmsignal.com/news/HOOK/hookipa-pharma-inc-hookipa-statement-regarding-potential-combination-for-poolbeg-5cecd13c 2025-02-20 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-to-participate-in-march-investor-conferences-dbad2e9b 2025-02-20 https://biopharmsignal.com/news/TCBP/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum 2025-02-20 https://biopharmsignal.com/news/MGRX/mangoceuticals-announces-the-launch-of-peachesrx-a-women-s-telehealth-brand-focu-05985ad2 2025-02-20 https://biopharmsignal.com/news/GSK/nucala-mepolizumab-application-for-copd-accepted-for-review-in-china 2025-02-20 https://biopharmsignal.com/news/LNSR/lensar-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursday-af0b7b4a 2025-02-19 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-initiates-phase-1b-trial-of-vyn202-a-novel-bd2-selective-oral--4225a5f5 2025-02-19 https://biopharmsignal.com/news/CARM/carisma-therapeutics-to-participate-in-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference 2025-02-19 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-opdivor-plus-chemotherapy-as-the-first-and-only-neoadjuvant-only-immuno-oncology-therapy-to-demonstrate-statistically-significant-and-clinically-meaningful-overall-survival-in-resectable-non-small-cell-lung-cancer 2025-02-19 https://biopharmsignal.com/news/GRI/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference 2025-02-19 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-granted-new-u-s-patent-expanding-coverage-of-its-genetic-based-approach-to-treating-and-diagnosing-alcohol-use-disorder-and-other-drug-dependencies 2025-02-19 https://biopharmsignal.com/news/LGMK/logicmark-inc-announces-closing-of-14-4-million-public-offering-59a2c9cb 2025-02-18 https://biopharmsignal.com/news/LGMK/logicmark-inc-announces-pricing-of-14-4-million-public-offering-and-plan-to-hold-11a05290 2025-02-18 https://biopharmsignal.com/news/ENLV/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination-598e2009 2025-02-18 https://biopharmsignal.com/news/BMY/new-five-year-sotyktu-deucravacitinib-data-show-consistent-safety-and-durable-response-rates-in-moderate-to-severe-plaque-psoriasis 2025-02-16 https://biopharmsignal.com/news/GSK/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy 2025-02-15 https://biopharmsignal.com/news/GOCO/gohealth-to-announce-fourth-quarter-2024-results-on-february-27-2025-9369b561 2025-02-13 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-provides-update-on-phase-3-relativity-098-trial 2025-02-13 https://biopharmsignal.com/news/ICUI/icu-medical-to-present-at-the-raymond-james-46th-annual-institutional-investors--79e49e5a 2025-02-13 https://biopharmsignal.com/news/ICUI/icu-medical-announces-time-of-fourth-quarter-2024-earnings-conference-call-4e5c0890 2025-02-13 https://biopharmsignal.com/news/BPTH/bio-path-holdings-expands-global-patent-portfolio-956fc89c 2025-02-13 https://biopharmsignal.com/news/TCBP/tcbp-announces-successful-completion-of-cohort-a-in-the-achieve-clinical-trial 2025-02-13 https://biopharmsignal.com/news/BPTH/bio-path-holdings-provides-key-clinical-updates-1e6bd961 2025-02-13 https://biopharmsignal.com/news/BPTH/bio-path-holdings-provides-update-from-phase-1-1b-clinical-trial-of-bp1002-for-t-e29b360a 2025-02-12 https://biopharmsignal.com/news/ATRC/atricure-reports-fourth-quarter-2024-and-full-year-2024-financial-results 2025-02-12 https://biopharmsignal.com/news/MDXH/mdxhealth-to-present-fourth-quarter-and-full-year-2024-financial-results-and-cor-21e53bef 2025-02-12 https://biopharmsignal.com/news/MGRX/mangoceuticals-advances-antiviral-research-on-its-patented-respiratory-illness-p-a0bdbc78 2025-02-12 https://biopharmsignal.com/news/ORTX/orchard-therapeutics-appoints-robin-kenselaar-to-chief-commercial-officer-and-announces-multiple-business-updates-pertaining-to-its-approved-hsc-gene-therapy-for-mld 2025-02-12 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-awarded-new-u-s-patent-covering-genotype-specific-treatment-of-opioid-related-disorders 2025-02-12 https://biopharmsignal.com/news/MBIO/mustang-bio-regains-compliance-with-nasdaq-minimum-bid-price-requirement 2025-02-11 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-inc-provides-update-on-global-cancer-immunotherapy-co-devel-c991a803 2025-02-11 https://biopharmsignal.com/news/LGMK/logicmark-launches-next-generation-of-guardian-alert-911-plus-technology-1a3d3cb4 2025-02-11 https://biopharmsignal.com/news/TCBP/tcbp-announces-successful-completion-of-initial-cohort-b-patient-dosing-in-the-achieve-clinical-trial 2025-02-10 https://biopharmsignal.com/news/IMMX/immix-biopharma-receives-fda-regenerative-medicine-advanced-therapy-rmat-designa-df65bb43 2025-02-10 https://biopharmsignal.com/news/OCEA/ocean-biomedical-announces-breakthrough-findings-in-egfr-mutant-lung-cancer-and--9958e53d 2025-02-10 https://biopharmsignal.com/news/MBIO/mustang-bio-announces-closing-of-8-million-public-offering 2025-02-10 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-positive-topline-results-for-breyanzir-lisocabtagene-maraleucel-in-adult-patients-with-relapsed-or-refractory-marginal-zone-lymphoma 2025-02-10 https://biopharmsignal.com/news/AEON/aeon-biopharma-inc-receives-notice-of-non-compliance-with-nyse-american-continue-d0db9420 2025-02-07 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-closing-of-15-5-million-public-offering-of-common-stock-and-full-exercise-of-underwriter-s-over-allotment-option 2025-02-07 https://biopharmsignal.com/news/MGRX/mangoceuticals-advances-h1n1-efficacy-study-noting-significant-reduction-in-vira-579fda10 2025-02-06 https://biopharmsignal.com/news/MBIO/mustang-bio-announces-pricing-of-8-million-public-offering 2025-02-06 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2024 2025-02-06 https://biopharmsignal.com/news/VIRX/viracta-therapeutics-announces-wind-down-of-operations 2025-02-05 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-reports-third-fiscal-quarter-2025-financial-results 2025-02-05 https://biopharmsignal.com/news/TCBP/tcbp-to-implement-ads-ratio-change 2025-02-05 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-congratulates-board-director-dr-tessa-cigler-and-weill-corne-c3c6afdc 2025-02-05 https://biopharmsignal.com/news/HCAT/health-catalyst-to-announce-fourth-quarter-and-full-year-2024-operating-results--3e3c8685 2025-02-05 https://biopharmsignal.com/news/CARM/carisma-therapeutics-to-participate-in-oppenheimer-35th-annual-healthcare-life-sciences-conference 2025-02-05 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-pricing-of-13-5-million-public-offering-of-common-stock 2025-02-05 https://biopharmsignal.com/news/GSK/gsk-delivers-strong-2024-performance-with-further-improvement-to-long-term-growth-outlook 2025-02-05 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-proposed-public-offering-of-common-stock 2025-02-04 https://biopharmsignal.com/news/NGM/ngm-bio-announces-appointment-of-wendy-yeh-m-d-as-chief-medical-officer 2025-02-04 https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-multiple-data-presentations-and-receives-2025-new-treatment-award-at-the-21st-annual-worldsymposiumtm 2025-02-03 https://biopharmsignal.com/news/MGRX/mangoceuticals-inc-executes-exclusive-distribution-agreement-with-propre-energie-a266803a 2025-02-03 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-positive-chmp-opinion-for-opdivor-nivolumab-plus-yervoyr-ipilimumab-as-a-first-line-treatment-option-for-adult-patients-with-unresectable-or-advanced-hepatocellular-carcinoma 2025-01-31 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-positive-chmp-opinion-for-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-follicular-lymphoma 2025-01-31 https://biopharmsignal.com/news/GSK/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-rekambys-for-hiv-treatment-in-adolescents 2025-01-31 https://biopharmsignal.com/news/ADAP/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025 2025-01-30 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-responds-to-ptab-ruling-on-u-s-patent-no-11-572-334-and-anno-dd9dbd98 2025-01-30 https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-enrollment-completion-of-phase-1b-clinical-trial-evalua-f79692e4 2025-01-30 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-initiates-apraglutide-nda-submission-highlights-compelling-new-data-and-updates-corporate-structure-to-position-for-the-future 2025-01-29 https://biopharmsignal.com/news/OCEA/ocean-biomedical-advances-malaria-vaccine-research-with-new-nih-funding-and-expe-19f4d018 2025-01-29 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-announces-positive-clinical-study-results-from-the-ad04-103-pharmacokinetics-study-of-ad04-for-the-treatment-of-alcohol-use-disorder 2025-01-29 https://biopharmsignal.com/news/BYSI/beyondspring-announces-35-4-million-sale-of-a-portion-of-equity-interest-in-seed-c74236cd 2025-01-28 https://biopharmsignal.com/news/GSK/depemokimab-accepted-for-review-by-the-european-medicines-agency-for-use-in-asthma-with-type-2-inflammation-and-crswnp 2025-01-28 https://biopharmsignal.com/news/GSK/depemokimab-applications-accepted-for-review-in-china-and-japan-for-asthma-with-type-2-inflammation-and-crswnp 2025-01-28 https://biopharmsignal.com/news/GSK/gsk-and-oxford-establish-the-gsk-oxford-cancer-immuno-prevention-programme-to-advance-novel-cancer-research 2025-01-27 https://biopharmsignal.com/news/GSK/gsk-s-shingrix-new-prefilled-syringe-presentation-accepted-for-review-by-european-medicines-agency 2025-01-27 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-results-from-checkmate-8hw-analysis-evaluating-opdivor-nivolumab-plus-yervoyr-ipilimumab-compared-to-opdivo-monotherapy 2025-01-25 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-issues-letter-to-shareholders-highlighting-2024-accomplishme-bec1276c 2025-01-23 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-9-0-million-public-offering-06c77e87 2025-01-22 https://biopharmsignal.com/news/IPSC/century-therapeutics-announces-investigator-initiated-phase-1-2-trial-of-its-ips-a4f54ce1 2025-01-21 https://biopharmsignal.com/news/GSK/european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2025-01-20 https://biopharmsignal.com/news/IMRN/immuron-travelan-continued-strong-sales-growth-c45170b5 2025-01-17 https://biopharmsignal.com/news/ISPC/ispecimen-secures-suppliers-for-covid-style-hmpv-outbreak 2025-01-16 https://biopharmsignal.com/news/TCBP/tcbp-announces-h5n1-proof-of-concept-studies-intention 2025-01-15 https://biopharmsignal.com/news/IMRN/immuron-announces-new-research-collaboration-targeting-antimicrobial-resistance-5b7feb1b 2025-01-15 https://biopharmsignal.com/news/MBIO/mustang-bio-announces-reverse-stock-split 2025-01-14 https://biopharmsignal.com/news/GRFS/grifols-pioneers-high-tech-analysis-of-plasma-bank-to-detect-early-signs-of-park-b8eefd01 2025-01-14 https://biopharmsignal.com/news/ADAP/adaptimmune-announces-u-s-fda-breakthrough-therapy-designation-granted-to-letetresgene-autoleucel-lete-cel-for-treatment-of-myxoid-round-cell-liposarcoma-mrcls 2025-01-13 https://biopharmsignal.com/news/MDXH/mdxhealth-reports-preliminary-fourth-quarter-and-full-year-2024-revenues-and-iss-85556bdb 2025-01-13 https://biopharmsignal.com/news/GSK/gsk-enters-agreement-to-acquire-idrx-inc 2025-01-13 https://biopharmsignal.com/news/MREO/mereo-biopharma-provides-update-on-lead-clinical-programs-94012df3 2025-01-12 https://biopharmsignal.com/news/AXDX/accelerate-diagnostics-announces-certain-preliminary-fourth-quarter-and-full-year-2024-results 2025-01-10 https://biopharmsignal.com/news/GSK/gsk-s-shingrix-new-prefilled-syringe-presentation-accepted-for-review-by-us-fda 2025-01-10 https://biopharmsignal.com/news/BRNS/barinthus-bio-announces-strategic-focus-in-immunology-and-inflammation-iandi-and-provides-a-financial-update 2025-01-10 https://biopharmsignal.com/news/SPRO/spero-therapeutics-provides-business-update-and-announces-interim-leadership-cha-17dec675 2025-01-10 https://biopharmsignal.com/news/BPTH/bio-path-holdings-provides-2025-clinical-and-operational-update-29fb721b 2025-01-10 https://biopharmsignal.com/news/HOOK/poolbeg-pharma-plc-poolbeg-and-hookipa-pharma-inc-hookipa-update-on-potential-co-78ad9845 2025-01-10 https://biopharmsignal.com/news/FMS/fresenius-medical-care-supports-patients-and-staff-during-the-wildfires-in-southern-california 2025-01-10 https://biopharmsignal.com/news/HOOK/hookipa-pharma-inc-form-8-opd-6683a5ac 2025-01-08 https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-notice-to-shareholders-regarding-u-k-disclosure-require-02ce8779 2025-01-07 https://biopharmsignal.com/news/AEON/aeon-biopharma-inc-announces-closing-of-20-0-million-underwritten-public-offerin-7a66c50f 2025-01-07 https://biopharmsignal.com/news/IMMX/immix-biopharma-accelerates-enrollment-in-u-s-al-amyloidosis-trial-of-nxc-201-ca-aabbf569 2025-01-07 https://biopharmsignal.com/news/TTOO/t2-biosystems-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results 2025-01-07 https://biopharmsignal.com/news/MREO/mereo-biopharma-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-e8e1a332 2025-01-07 https://biopharmsignal.com/news/GSK/gsk-s-b7-h3-targeted-antibody-drug-conjugate-gsk-227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma 2025-01-07 https://biopharmsignal.com/news/AEON/aeon-biopharma-inc-announces-pricing-of-approximately-20-0-million-underwritten--b6984fa1 2025-01-06 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-applauds-u-s-surgeon-general-s-advisory-highlighting-alcohol-c632d758 2025-01-06 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-completes-enrollment-in-phase-2b-trial-evaluating-vyn201-for-t-21165c46 2025-01-06 https://biopharmsignal.com/news/HOOK/hookipa-pharma-inc-hookipa-rule-2-9-announcement-amendment-d6dfdd1f 2025-01-06 https://biopharmsignal.com/news/AEON/aeon-biopharma-inc-announces-launch-of-proposed-public-offering-9e96bcc0 2025-01-04 https://biopharmsignal.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-239d0c8b 2025-01-03 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-at-j-p-morgan-s-43rd-annual-healthcare-conference 2025-01-03 https://biopharmsignal.com/news/GSK/gsk-s-nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic-rhinosinusitis-with-nasal-polyps 2025-01-03 https://biopharmsignal.com/news/HOOK/poolbeg-pharma-plc-poolbeg-or-the-company-combination-of-poolbeg-and-hookipa-pha-4299ae28 2025-01-02 https://biopharmsignal.com/news/GRTX/galera-therapeutics-completes-acquisition-of-nova-pharmaceuticals-e012e8fa 2024-12-31 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-approves-opdivo-qvantigtm-nivolumab-and-hyaluronidase-nvhy-injection-for-subcutaneous-use-in-most-previously-approved-adult-solid-tumor-opdivor-nivolumab-indications 2024-12-27 https://biopharmsignal.com/news/VIRX/viracta-therapeutics-announces-closure-of-naval-1-clinical-trial-and-exploration-of-strategic-alternatives 2024-12-26 https://biopharmsignal.com/news/GRI/gri-bio-announces-european-patent-office-issued-a-decision-to-grant-notice-for-p-73ef6f57 2024-12-23 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-reports-positive-top-line-phase-1a-mad-data-for-vyn202-its-nov-f27773ba 2024-12-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-positive-topline-results-from-two-pivotal-phase-3-trials-evaluating-sotyktu-deucravacitinib-in-adults-with-psoriatic-arthritis 2024-12-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-european-commission-approval-for-opdivor-nivolumab-plus-yervoyr-ipilimumab-for-the-first-line-treatment-of-adult-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-metastatic-colorectal-cancer 2024-12-23 https://biopharmsignal.com/news/MNPR/monopar-therapeutics-inc-announces-pricing-of-40-million-public-offering-of-common-stock-and-concurrent-private-placement-of-pre-funded-warrants 2024-12-20 https://biopharmsignal.com/news/ISPC/ispecimen-will-serve-as-a-preferred-provider-of-cancer-biospecimens 2024-12-20 https://biopharmsignal.com/news/GSK/gsk-announces-first-trial-met-its-primary-endpoint-of-progression-free-survival-in-first-line-advanced-ovarian-cancer 2024-12-20 https://biopharmsignal.com/news/MGRX/mangoceuticals-inc-completes-acquisition-of-mushroom-based-wellness-and-innovati-928c2bab 2024-12-19 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-positive-u-s-clinical-data-from-first-four-patients-in-cc394ffb 2024-12-19 https://biopharmsignal.com/news/ABVC/abvc-biopharma-seeks-to-revolutionize-mental-health-treatment-with-a-safe-prozac-b7b3f3c5 2024-12-19 https://biopharmsignal.com/news/MRKR/marker-therapeutics-announces-16-1-million-private-placement-9f063775 2024-12-19 https://biopharmsignal.com/news/MRKR/marker-therapeutics-provides-a-clinical-update-on-mt-601-in-patients-with-lympho-7a3c07e1 2024-12-19 https://biopharmsignal.com/news/NGM/ngm-bio-and-kdt-ventures-enter-into-worldwide-license-agreement-for-ngm313-a-phase-2-ready-fgfr1c-klotho-agonist-drug-candidate 2024-12-19 https://biopharmsignal.com/news/BPTH/bio-path-holdings-announces-preclinical-testing-of-bp1001-a-as-potential-treatme-33e8be6b 2024-12-19 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-fourth-quarter-2024-on-february-6-2025 2024-12-19 https://biopharmsignal.com/news/TTOO/t2-biosystems-announces-sale-of-four-t2dx-instruments-to-existing-european-distributor 2024-12-18 https://biopharmsignal.com/news/TTOO/t2-biosystems-achieves-key-milestone-with-250-000th-novel-sepsis-test-shipped-globally 2024-12-17 https://biopharmsignal.com/news/VCNX/vaccinex-announces-receipt-of-delisting-notification-from-nasdaq 2024-12-17 https://biopharmsignal.com/news/ASRT/assertio-holdings-inc-appoints-mark-reisenauer-to-its-board-of-directors-a33f2d42 2024-12-17 https://biopharmsignal.com/news/CYCN/cyclerion-s-sgc-stimulator-portfolio-generates-revenues-to-enable-company-growth 2024-12-17 https://biopharmsignal.com/news/MRKR/marker-therapeutics-awarded-9-5-million-grant-from-the-cancer-prevention-researc-00dd58f7 2024-12-17 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-official-notice-of-certificate-of-ne-7c80ef51 2024-12-17 https://biopharmsignal.com/news/GSK/viiv-healthcare-announces-chmp-positive-opinion-for-vocabria-rekambys-the-first-and-only-complete-long-acting-hiv-treatment-for-adolescents-in-europe 2024-12-16 https://biopharmsignal.com/news/IMMX/journal-of-clinical-oncology-publishes-nxc-201-positive-clinical-results-in-rela-c1cc6529 2024-12-16 https://biopharmsignal.com/news/GSK/gsk-s-b7-h3-targeted-antibody-drug-conjugate-gsk-227-receives-ema-priority-medicines-prime-designation-in-relapsed-extensive-stage-small-cell-lung-cancer 2024-12-16 https://biopharmsignal.com/news/TTOO/t2-biosystems-announces-extension-of-multi-year-capital-equipment-supplier-agreement-with-vizient-inc 2024-12-16 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-extends-research-agreement-with-the-university-of-virginia-for-the-advancement-of-its-dnase-based-oncology-platform 2024-12-16 https://biopharmsignal.com/news/FORA/forian-partners-with-databricks-to-expand-access-to-advanced-healthcare-analytics 2024-12-16 https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmr-msi-h-rectal-cancer 2024-12-16 https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-plus-chemotherapy-receives-positive-chmp-opinion-to-expand-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2024-12-16 https://biopharmsignal.com/news/ASRT/assertio-announces-results-of-rolvedon-eflapegrastim-xnst-injection-same-day-dos-b077d5ba 2024-12-13 https://biopharmsignal.com/news/ISPC/ispecimen-reports-positive-results-on-next-day-quote-program-for-researchers-and-providers 2024-12-13 https://biopharmsignal.com/news/ISPC/ispecimen-appoints-robert-lim-as-ceo-and-director 2024-12-12 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-to-present-poster-describing-the-discovery-of-molecules-syne-aeb06cfd 2024-12-12 https://biopharmsignal.com/news/ASRT/assertio-holdings-inc-appoints-paul-schwichtenberg-to-new-cto-role-mary-pietryga-30777910 2024-12-12 https://biopharmsignal.com/news/AQB/aquabounty-announces-plans-to-cease-fish-farming-operations 2024-12-11 https://biopharmsignal.com/news/ENLV/enlivex-receives-regulatory-authorization-for-the-initiation-of-a-phase-i-trial--3b065300 2024-12-11 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-full-results-from-phase-2-karisma-endoxifen-study--ae0500d0 2024-12-11 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-inc-announces-termination-of-merger-agreement-with-pharma-9aaafa18 2024-12-11 https://biopharmsignal.com/news/BPTH/bio-path-holdings-outlines-rationale-for-development-of-bp1001-a-as-potential-tr-81feb925 2024-12-11 https://biopharmsignal.com/news/ABVC/abvc-biopharma-secures-200-000-in-first-cash-licensing-payment-from-oncology-pro-e86c2aff 2024-12-11 https://biopharmsignal.com/news/CLLS/cellectis-announces-the-drawdown-of-the-third-tranche-of-5-million-under-the-credit-facility-agreement-entered-with-the-european-investment-bank-eib 2024-12-10 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-75-complete-response-rate-n-16-31-5-months-best-respon-90547555 2024-12-10 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-to-present-pharmacokinetic-and-tolerability-data-from-phase--ac175bca 2024-12-10 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-present-at-the-2024-ladenburg-virtual-oncology-innovators-and-investors-symposium 2024-12-10 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-highlights-progress-of-cell-therapy-portfolio-at-ash-2024-with-long-term-survival-data-and-results-from-expanding-pipeline 2024-12-09 https://biopharmsignal.com/news/GSK/blenrep-shows-significant-overall-survival-benefit-reducing-the-risk-of-death-by-42-in-multiple-myeloma-at-or-after-first-relapse 2024-12-09 https://biopharmsignal.com/news/IMMX/immix-biopharma-to-host-conference-call-for-investors-analysts-and-members-of-th-b67370ec 2024-12-09 https://biopharmsignal.com/news/GOVX/geovax-receives-notice-of-allowance-for-cancer-vaccine-patent-64188cc4 2024-12-09 https://biopharmsignal.com/news/TTOO/t2-biosystems-announces-plans-to-license-its-proprietary-technology-to-expand-its-leadership-in-direct-from-whole-blood-detection-of-sepsis-causing-pathogens 2024-12-09 https://biopharmsignal.com/news/CARM/carisma-therapeutics-announces-strategic-restructuring-to-re-prioritize-pipeline 2024-12-09 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-presents-data-from-study-investigating-anti-cancer-activity--07e09d27 2024-12-09 https://biopharmsignal.com/news/GSK/us-fda-accepts-gsk-s-submission-for-the-use-of-nucala-mepolizumab-in-copd 2024-12-09 https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-combination-accepted-for-priority-review-in-china-in-relapsed-refractory-multiple-myeloma 2024-12-09 https://biopharmsignal.com/news/MNPR/monopar-announces-first-patient-dosed-with-its-novel-therapeutic-radiopharmaceutical-mnpr-101-lu 2024-12-05 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-enters-into-clinical-trial-services-agreement-with-periness-ltd-to-accelerate-development-of-dnase-i-oncology-program 2024-12-05 https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-successfully-transitions-first-products-to-new-eu-mdr-requirements-for-class-iib-medical-devices 2024-12-05 https://biopharmsignal.com/news/GSK/gsk-and-zhifei-revise-and-extend-strategic-vaccine-collaboration-in-china 2024-12-05 https://biopharmsignal.com/news/NEPH/nephros-to-participate-in-the-benchmark-company-annual-discovery-one-on-one-inve-11af1579 2024-12-04 https://biopharmsignal.com/news/MGRX/mangoceuticals-inc-initiates-investigation-into-potential-stock-manipulation-sch-4704edb0 2024-12-04 https://biopharmsignal.com/news/GSK/first-single-dose-medicine-for-p-vivax-malaria-prequalified-by-who-and-included-in-who-guidelines 2024-12-04 https://biopharmsignal.com/news/MNPR/monopar-to-present-at-the-36th-annual-piper-sandler-healthcare-conference 2024-12-03 https://biopharmsignal.com/news/ENLV/enlivex-announces-positive-interim-efficacy-data-from-allocetra-trial-in-patients-with-moderate-to-severe-knee-osteoarthritis 2024-12-03 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-granted-key-u-s-patent-for-the-treatment-of-alcohol-and-drug-dependence-based-on-expanded-genotype-combinations 2024-12-03 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-80810029 2024-12-02 https://biopharmsignal.com/news/QGEN/qiagen-f-hrt-neuartige-tools-zur-anpassung-von-digitalen-pcr-assays-und-ngs-pane-a242cf6d 2024-11-27 https://biopharmsignal.com/news/QGEN/qiagen-launches-novel-tools-for-customizing-digital-pcr-assays-and-ngs-panels-fo-1dbf1806 2024-11-27 https://biopharmsignal.com/news/GSK/gsk-s-fully-liquid-menveo-meningococcal-vaccine-approved-by-european-commission 2024-11-27 https://biopharmsignal.com/news/CARM/carisma-therapeutics-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference 2024-11-27 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference 2024-11-26 https://biopharmsignal.com/news/GOVX/geovax-to-present-at-the-noble-capital-markets-twentieth-annual-emerging-growth--80440681 2024-11-26 https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-and-snbl-receive-fda-acceptance-of-nda-resubmission-of-sts101-for-the-acute-treatment-of-migraine-with-or-without-aura 2024-11-26 https://biopharmsignal.com/news/LNSR/lensar-to-participate-in-the-btig-4th-annual-ophthalmology-day-f86ea655 2024-11-26 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-citi-s-2024-global-healthcare-conference 2024-11-26 https://biopharmsignal.com/news/ENLV/join-enlivex-therapeutics-exclusive-live-investor-webinar-and-qanda-session-on-december-3 2024-11-26 https://biopharmsignal.com/news/BRNS/barinthus-bio-promotes-snap-ti-co-inventor-geoffrey-lynn-m-d-ph-d-to-chief-scientific-officer 2024-11-25 https://biopharmsignal.com/news/IMMX/immix-biopharma-presents-positive-nxc-201-clinical-data-at-66th-american-society-bf80db88 2024-11-25 https://biopharmsignal.com/news/SHCR/sharecare-wins-17-digital-health-awards-in-fall-2024 2024-11-25 https://biopharmsignal.com/news/GSK/blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsed-refractory-multiple-myeloma 2024-11-25 https://biopharmsignal.com/news/OCEA/ocean-biomedical-inc-announces-receipt-of-notice-from-nasdaq-regarding-late-fili-e07c5a85 2024-11-22 https://biopharmsignal.com/news/GSK/arexvy-approval-expanded-to-adults-aged-50-59-at-increased-risk-of-severe-rsv-disease-in-japan 2024-11-22 https://biopharmsignal.com/news/GRI/gri-bio-showcases-gri-0621-s-potential-to-reduce-inflammation-type-1-cytokines-a-83373aa3 2024-11-21 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-to-present-poster-on-z-endoxifen-at-aacr-special-conference--3615a6ff 2024-11-21 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-five-abstracts-highlighting-z-endoxifen-research-a-ba8f46b0 2024-11-20 https://biopharmsignal.com/news/ENLV/enlivex-adopts-bitcoin-treasury-reserve-strategy 2024-11-20 https://biopharmsignal.com/news/GOVX/geovax-announces-positive-interim-data-review-for-phase-2-clinical-trial-of-covi-efe6dd0a 2024-11-19 https://biopharmsignal.com/news/GSK/statement-gsk-continues-to-show-strong-leadership-in-its-access-to-medicines-index-ranking 2024-11-19 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-s-presentations-at-ash-2024-reinforce-strength-of-hematology-portfolio-and-scientific-advances-in-differentiated-research-platforms 2024-11-19 https://biopharmsignal.com/news/GSK/linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus-relentless-itch-in-primary-biliary-cholangitis-pbc 2024-11-19 https://biopharmsignal.com/news/VCNX/vaccinex-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-18 https://biopharmsignal.com/news/CARM/carisma-therapeutics-presents-promising-new-preclinical-data-on-engineered-macrophages-for-the-treatment-of-liver-fibrosis-at-aasld-the-liver-meetingr-2024 2024-11-17 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-positive-chmp-opinion-for-opdivor-nivolumab-plus-yervoyr-ipilimumab-for-the-first-line-treatment-of-adult-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-metastatic-colorectal-cancer 2024-11-15 https://biopharmsignal.com/news/BPTH/bio-path-holdings-reports-third-quarter-2024-financial-results-0a230ffe 2024-11-15 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-positive-chmp-opinion-for-repotrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer-and-advanced-ntrk-positive-solid-tumors 2024-11-15 https://biopharmsignal.com/news/GRI/gri-bio-reports-third-quarter-2024-financial-results-and-outlines-progress-towar-11896fb0 2024-11-14 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-third-quarter-2024-operating-results-and-provides-a-c9dc081a 2024-11-14 https://biopharmsignal.com/news/HOOK/hookipa-pharma-reports-third-quarter-2024-financial-results-and-provides-recent--7b23a469 2024-11-14 https://biopharmsignal.com/news/TTOO/t2-biosystems-announces-third-quarter-2024-financial-results 2024-11-14 https://biopharmsignal.com/news/ATXI/avenue-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14 https://biopharmsignal.com/news/ABVC/abvc-biopharma-inc-reports-q3-2024-financial-results-and-operational-milestones-36204948 2024-11-14 https://biopharmsignal.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-jefferies-london-healthca-1a09b0d4 2024-11-14 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-announces-completion-of-u-s-onshoring-program-making-nuzyrar-omadacycline-the-only-novel-antibiotic-with-domestic-supply-and-manufacturing-capabilities 2024-11-14 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-announces-positive-topline-results-from-the-ad04-103-pharmacokinetics-study-of-ad04-for-the-treatment-of-alcohol-use-disorder 2024-11-14 https://biopharmsignal.com/news/ENLV/enlivex-announces-the-dosing-of-the-first-patient-in-a-phase-i-clinical-trial-evaluating-allocetra-in-patients-with-psoriatic-arthritis 2024-11-14 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-reports-encouraging-nxp800-interim-data-supporting-ongoing-enrollment-in-phase-1b-study-in-patients-with-platinum-resistant-arid1a-mutated-ovarian-cancer 2024-11-14 https://biopharmsignal.com/news/GSK/blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for-relapsed-refractory-multiple-myeloma 2024-11-14 https://biopharmsignal.com/news/AEON/aeon-biopharma-reports-third-quarter-2024-financial-results-and-provides-corpora-78bc3153 2024-11-13 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-participate-in-the-jefferies-london-healthcare-conference 2024-11-13 https://biopharmsignal.com/news/FORA/forian-inc-announces-third-quarter-2024-financial-results 2024-11-13 https://biopharmsignal.com/news/GSK/gsk-highlights-key-data-from-hepatology-portfolio-at-the-aasld-s-the-liver-meetingr-2024-emphasising-patient-impact-in-areas-of-high-unmet-need 2024-11-13 https://biopharmsignal.com/news/ORGS/orgenesis-provides-third-quarter-2024-business-update-0a0b7433 2024-11-13 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-reports-third-quarter-2024-financial-results-23d50c8f 2024-11-13 https://biopharmsignal.com/news/VIRX/viracta-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-13 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-13 https://biopharmsignal.com/news/SYBX/synlogic-reports-third-quarter-2024-financial-results 2024-11-12 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-third-quarter-2024-financial-results-and-provides-b-36069d92 2024-11-12 https://biopharmsignal.com/news/QGEN/qiagen-und-mcgill-university-starten-partnerschaft-zur-f-rderung-der-mikrobiomfo-d8ea3ab3 2024-11-12 https://biopharmsignal.com/news/QGEN/qiagen-collaborates-with-mcgill-university-to-advance-microbiome-research-98e08ed5 2024-11-12 https://biopharmsignal.com/news/TXMD/therapeuticsmd-announces-third-quarter-2024-financial-results 2024-11-12 https://biopharmsignal.com/news/GOVX/geovax-reports-third-quarter-2024-financial-results-and-provides-business-update-44c641df 2024-11-12 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-third-quarter-2024-financial-results-and-provides--d3545d00 2024-11-12 https://biopharmsignal.com/news/MBIO/mustang-bio-receives-positive-listing-determination-from-nasdaq 2024-11-12 https://biopharmsignal.com/news/GSK/new-gsk-sponsored-survey-reveals-unique-gaps-in-care-and-support-facing-patients-with-gynaecologic-cancers 2024-11-12 https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-third-quarter-2024-financial-results-and-provides-corpor-054cc32f 2024-11-12 https://biopharmsignal.com/news/ENLV/enlivex-announces-the-enrollment-and-dosing-of-the-first-10-patient-in-the-randomized-phase-ii-stage-of-its-allocetra-trial-in-patients-with-moderate-to-severe-knee-osteoarthritis 2024-11-12 https://biopharmsignal.com/news/HOOK/hookipa-pharma-s-eseba-vec-highlighted-in-sitc-late-breaker-6d1411b7 2024-11-11 https://biopharmsignal.com/news/ASRT/assertio-reports-third-quarter-2024-financial-results-321df697 2024-11-11 https://biopharmsignal.com/news/HEPA/pharma-two-b-and-hepion-pharmaceuticals-inc-announce-effectiveness-of-registrati-8e493bec 2024-11-11 https://biopharmsignal.com/news/GOCO/gohealth-honors-veterans-this-medicare-annual-enrollment-period-helping-them-sec-4acc42bc 2024-11-11 https://biopharmsignal.com/news/GOCO/gohealth-to-present-and-host-investor-meetings-at-the-southwest-ideas-conference-78e7d36a 2024-11-11 https://biopharmsignal.com/news/ASRT/assertio-provides-response-to-letter-from-short-seller-c4a23764 2024-11-11 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-showcases-the-continued-strength-of-its-cardiovascular-portfolio-with-new-clinical-and-real-world-data-at-american-heart-association-scientific-sessions-2024 2024-11-11 https://biopharmsignal.com/news/FORA/forian-inc-to-participate-in-the-13th-annual-roth-mkm-technology-event 2024-11-08 https://biopharmsignal.com/news/CARM/carisma-unveils-promising-pre-clinical-data-on-anti-gpc3-in-vivo-car-m-therapy-for-hepatocellular-carcinoma 2024-11-08 https://biopharmsignal.com/news/BPTH/bio-path-holdings-to-announce-third-quarter-2024-financial-results-on-november-1-1eb73fe9 2024-11-08 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-announces-positive-top-line-data-from-phase-2b-study-of-oral-omadacycline-omc-in-nontuberculous-mycobacterial-ntm-abscessus-pulmonary-disease 2024-11-08 https://biopharmsignal.com/news/ISPC/ispecimen-named-top-competitor-in-4-4-billion-usd-market 2024-11-08 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-third-quarter-2024-financial-results-and-provide-bu-117aee83 2024-11-07 https://biopharmsignal.com/news/AXDX/accelerate-diagnostics-reports-third-quarter-2024-financial-results 2024-11-07 https://biopharmsignal.com/news/NEPH/nephros-announces-financial-results-for-quarter-ended-september-30-2024-172dda4a 2024-11-07 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-presents-updated-preclinical-data-for-bdc-4182-and-key-lear-2a0cc2d3 2024-11-07 https://biopharmsignal.com/news/VCNX/vaccinex-provides-update-on-activmabr-platform-multiple-project-deals-and-presentation-at-sitc 2024-11-07 https://biopharmsignal.com/news/MBIO/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-108-hsv-1-oncolytic-virus-to-treat-malignant-glioma 2024-11-07 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-reports-third-quarter-2024-financial-results-and-provides-busi-9f749fe8 2024-11-07 https://biopharmsignal.com/news/CARM/carisma-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights 2024-11-07 https://biopharmsignal.com/news/TRVN/trevena-reports-third-quarter-2024-results-and-provides-business-update 2024-11-07 https://biopharmsignal.com/news/LNSR/lensar-reports-third-quarter-2024-results-and-provides-business-update-f2c46a3c 2024-11-07 https://biopharmsignal.com/news/GOCO/gohealth-reports-third-quarter-2024-results-3b146907 2024-11-07 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-third-quarter-2024-results 2024-11-07 https://biopharmsignal.com/news/ISPC/ispecimen-releases-cancer-biospecimen-offering-orders-anticipated-of-over-9-500-000-annually 2024-11-07 https://biopharmsignal.com/news/ISPC/ispecimen-reports-third-quarter-2024-results 2024-11-07 https://biopharmsignal.com/news/QGEN/qiagen-bertrifft-prognose-f-r-drittes-quartal-2024-mit-solidem-wachstum-und-erh--933db05e 2024-11-06 https://biopharmsignal.com/news/QGEN/qiagen-delivers-solid-q3-2024-growth-ahead-of-outlook-increases-full-year-2024-a-64f03744 2024-11-06 https://biopharmsignal.com/news/VIRX/viracta-therapeutics-announces-reprioritization-of-resources-to-enhance-focus-on-nana-val-development-program-in-patients-with-relapsed-or-refractory-ebv-positive-peripheral-t-cell-lymphoma 2024-11-06 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-third-quarter-2024-earnings-conferen-9e256779 2024-11-06 https://biopharmsignal.com/news/CLLS/cellectis-presents-multiple-strategies-to-enhance-car-t-cell-efficacy-in-solid-tumors-at-the-sitc-annual-meeting 2024-11-05 https://biopharmsignal.com/news/CARM/carisma-therapeutics-to-present-new-data-on-anti-gpc3-in-vivo-car-m-therapy-for-hepatocellular-carcinoma-at-sitc-2024 2024-11-05 https://biopharmsignal.com/news/GOVX/geovax-to-report-third-quarter-2024-financial-results-and-provide-corporate-upda-37cc2e92 2024-11-05 https://biopharmsignal.com/news/FORA/forian-inc-to-announce-third-quarter-2024-results-on-november-13-2024 2024-11-05 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-appoints-claudia-lopez-dvm-msc-as-vice-president-clinical-pr-d51cc401 2024-11-05 https://biopharmsignal.com/news/VCNX/vaccinex-reports-improved-immunity-correlating-with-clinical-benefit-of-pepinemab-combination-treatment-at-society-for-immunotherapy-of-cancer-s-annual-meeting 2024-11-05 https://biopharmsignal.com/news/TTOO/t2-biosystems-to-report-third-quarter-2024-financial-results-and-business-updates-on-november-14-2024 2024-11-05 https://biopharmsignal.com/news/AQB/aquabounty-technologies-announces-third-quarter-2024-financial-results 2024-11-05 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-appoints-vinay-shah-as-chief-financial-officer 2024-11-05 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-announces-closing-of-private-placement-for-aggregate-gross-proceeds-of-1-275-million 2024-11-05 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-third-quarter-2024-financial-results-and-business-highlights 2024-11-05 https://biopharmsignal.com/news/CLLS/cellectis-provides-business-updates-and-financial-results-for-third-quarter-2024 2024-11-04 https://biopharmsignal.com/news/ATOS/atossa-therapeutics-reports-positive-karisma-endoxifen-trial-results-b1c4b16e 2024-11-04 https://biopharmsignal.com/news/QGEN/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-sup-d1a5ac26 2024-11-04 https://biopharmsignal.com/news/QGEN/qiagen-erh-lt-fda-zulassung-f-r-qiastat-dx-meningitis-enzephalitis-panel-zur-unt-37e52c31 2024-11-04 https://biopharmsignal.com/news/FORA/forian-acquires-kyber-data-science-to-enhance-data-analytics-capabilities 2024-11-01 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-new-long-term-data-from-the-emergent-program-evaluating-cobenfytm-xanomeline-and-trospium-chloride-in-adults-with-schizophrenia-at-psych-congress-2024 2024-10-31 https://biopharmsignal.com/news/ISPC/ispecimen-inc-announces-closing-of-5-million-public-offering-of-common-stock-and-pre-funded-warrants 2024-10-31 https://biopharmsignal.com/news/VCNX/vaccinex-reports-new-findings-for-signal-ad-phase-1b-2-trial-of-pepinemab-at-clinical-trials-on-alzheimer-s-disease-ctad-conference-in-madrid-spain 2024-10-31 https://biopharmsignal.com/news/HOOK/hookipa-pharma-to-present-eseba-vec-combo-in-frontline-hnscc-as-a-late-breaker-p-251ba349 2024-10-31 https://biopharmsignal.com/news/SHCR/sharecare-expands-suite-of-interactive-media-solutions-to-engage-educate-and-activate-patients-and-providers 2024-10-31 https://biopharmsignal.com/news/MGRX/mangoceuticals-inc-regains-full-compliance-with-nasdaq-minimum-bid-price-require-5a76d51c 2024-10-31 https://biopharmsignal.com/news/NEPH/nephros-schedules-third-quarter-2024-financial-results-conference-call-843f1d01 2024-10-31 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-third-quarter-financial-results-for-2024 2024-10-31 https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-and-snbl-resubmits-the-new-drug-application-for-sts101-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-with-or-without-aura 2024-10-31 https://biopharmsignal.com/news/CLLS/cellectis-to-report-third-quarter-2024-financial-results-on-november-4-2024 2024-10-30 https://biopharmsignal.com/news/ASRT/assertio-holdings-inc-to-report-third-quarter-2024-financial-results-on-november-a4b07128 2024-10-30 https://biopharmsignal.com/news/HOOK/hookipa-pharma-doses-first-patients-with-eseba-vec-as-adjuvant-therapy-in-phase--3f72346d 2024-10-30 https://biopharmsignal.com/news/ISPC/ispecimen-inc-announces-pricing-of-5-million-public-offering-of-common-stock-and-pre-funded-warrants 2024-10-30 https://biopharmsignal.com/news/ENLV/enlivex-receives-notice-of-allowance-for-japanese-patent-application-covering-the-use-of-allocetratm-in-patients-with-osteoarthritis 2024-10-30 https://biopharmsignal.com/news/GSK/gsk-on-track-to-deliver-2024-outlooks-with-further-good-progress-made-in-randd 2024-10-30 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-spr720-phase-2a-interim-results-and-provides-a-busi-d636b59d 2024-10-29 https://biopharmsignal.com/news/GRFS/grifols-receives-fda-approval-to-treat-surgical-bleeding-in-pediatric-patients-w-83d2c836 2024-10-29 https://biopharmsignal.com/news/GSK/gsk-enters-agreement-to-acquire-cmg1a46-from-chimagen-biosciences-to-expand-immunology-pipeline 2024-10-29 https://biopharmsignal.com/news/QGEN/qiagen-erh-lt-fda-zulassung-f-r-qiastat-dx-mini-panel-f-r-eine-pr-zisere-ambulan-100840b2 2024-10-29 https://biopharmsignal.com/news/QGEN/qiagen-receives-fda-clearance-for-qiastat-dx-mini-panel-to-improve-precision-in--91b9d1c7 2024-10-29 https://biopharmsignal.com/news/IRWD/once-weekly-apraglutide-showed-consistent-treatment-effect-across-baseline-demographics-and-disease-characteristics-in-adults-with-short-bowel-syndrome-with-intestinal-failure-sbs-if-according-to-new-stars-phase-iii-data-from-ironwood-at-acg-2024 2024-10-28 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-new-clinical-and-health-economics-and-outcomes-research-data-at-psych-congress-2024 2024-10-28 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-host-third-quarter-2024-investor-update-call 2024-10-24 https://biopharmsignal.com/news/MBIO/mustang-bio-announces-exercise-of-warrants-for-4-million-gross-proceeds 2024-10-24 https://biopharmsignal.com/news/GRI/gri-bio-raises-a-total-of-13-9-million-in-gross-proceeds-since-the-beginning-of--7a86634c 2024-10-24 https://biopharmsignal.com/news/GSK/new-data-for-arexvy-gsk-s-respiratory-syncytial-virus-vaccine-show-potential-to-help-protect-a-broader-group-of-adults-at-increased-risk-for-rsv-disease 2024-10-24 https://biopharmsignal.com/news/GOCO/gohealth-to-announce-third-quarter-2024-results-on-november-7-2024-1f1a7a10 2024-10-24 https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-multiple-data-presentations-and-publications 2024-10-23 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-2024-thinkequity-conference 2024-10-23 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-upcoming-presentations-for-nxp900-at-the-2024-aacr-nci-eortc-symposium-on-molecular-targets-and-cancer-therapeutics 2024-10-23 https://biopharmsignal.com/news/OCEA/ocean-biomedical-inc-announces-receipt-of-nasdaq-staff-determination-letter-dd6cc7c3 2024-10-22 https://biopharmsignal.com/news/SHCR/altaris-completes-acquisition-of-sharecare 2024-10-22 https://biopharmsignal.com/news/ABVC/abvc-biopharma-receives-50-000-in-incremental-licensing-fees-boosting-total-paym-f7a57177 2024-10-22 https://biopharmsignal.com/news/MGRX/mangorx-announces-formation-of-strategy-and-alternatives-committee-71befd28 2024-10-22 https://biopharmsignal.com/news/GRFS/grifols-partners-with-barda-for-proof-of-concept-testing-of-ocular-immunoglobuli-f977fdfd 2024-10-22 https://biopharmsignal.com/news/CLLS/cellectis-to-present-data-on-tale-base-editors-and-non-viral-gene-therapy-at-the-esgct-31st-annual-congress 2024-10-22 https://biopharmsignal.com/news/GRI/gri-bio-announces-exercise-of-warrants-66e0643d 2024-10-21 https://biopharmsignal.com/news/GSK/gsk-and-cambridge-university-announce-new-five-year-collaboration-in-kidney-and-respiratory-disease 2024-10-21 https://biopharmsignal.com/news/ORGS/orgenesis-commences-trading-on-otcqx-best-market-e1e5be9a 2024-10-21 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-announces-key-management-appointments-a9a2a9d3 2024-10-18 https://biopharmsignal.com/news/HSDT/helius-medical-technologies-inc-to-present-at-the-2024-thinkequity-conference-50f2ae4b 2024-10-18 https://biopharmsignal.com/news/GOCO/gohealth-to-present-and-host-investor-meetings-at-the-ld-micro-main-event-xvii-o-bdc2cde0 2024-10-17 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-receives-notice-of-allowance-for-u-s-patent-covering-expanded-genotype-combinations-identified-using-the-company-s-genetic-diagnostic-for-addiction-treatment 2024-10-17 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-presentation-of-spr719-active-moiety-of-spr720-in-v-5fc3f6da 2024-10-16 https://biopharmsignal.com/news/GRI/gri-bio-presents-positive-preclinical-data-demonstrating-gri-0621-s-ability-to-i-24f0e4d8 2024-10-16 https://biopharmsignal.com/news/GSK/viiv-healthcare-shows-more-than-99-effectiveness-in-real-world-studies-for-apretude-cabotegravir-long-acting-the-only-approved-long-acting-hiv-prep-in-data-presented-at-idweek-2024 2024-10-16 https://biopharmsignal.com/news/GSK/gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections-in-female-adults-and-adolescents 2024-10-16 https://biopharmsignal.com/news/GOCO/gohealth-leveraging-proprietary-technology-to-help-consumers-navigate-an-unprece-4b834ce2 2024-10-15 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-commends-the-national-institute-on-alcohol-abuse-and-alcoholism-s-new-definition-of-recovery 2024-10-15 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-announces-presentation-of-several-new-studies-of-nuzyrar-omadacycline-across-a-range-of-serious-infections-at-idweek-2024 2024-10-14 https://biopharmsignal.com/news/GSK/gsk-announces-positive-phase-iii-results-from-anchor-trials-for-depemokimab-in-chronic-rhinosinusitis-with-nasal-polyps 2024-10-14 https://biopharmsignal.com/news/ASRT/assertio-to-participate-in-the-maxim-group-healthcare-virtual-summit-on-october--506469bc 2024-10-11 https://biopharmsignal.com/news/BPTH/bio-path-holdings-announces-closing-of-4-0-million-private-placement-priced-at-t-17d3caf0 2024-10-10 https://biopharmsignal.com/news/QGEN/qiagen-erweitert-automationsportfolio-f-r-fl-ssigbiopsien-zur-anwendung-in-onkol-ea72cf68 2024-10-10 https://biopharmsignal.com/news/QGEN/qiagen-expands-automated-liquid-biopsy-portfolio-to-enhance-oncology-prenatal-ca-09fd961d 2024-10-10 https://biopharmsignal.com/news/GSK/gsk-and-viiv-healthcare-to-showcase-advances-across-industry-leading-infectious-disease-portfolio-at-idweek-2024 2024-10-10 https://biopharmsignal.com/news/QGEN/qiagen-n-v-to-release-results-for-q3-2024-and-hold-webcast-e6d509a4 2024-10-10 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-settlement-agreements-reached 2024-10-09 https://biopharmsignal.com/news/ATXI/avenue-therapeutics-to-participate-in-maxim-group-s-2024-healthcare-virtual-summit 2024-10-09 https://biopharmsignal.com/news/BPTH/bio-path-holdings-announces-4-0-million-private-placement-priced-at-the-market-u-173be11d 2024-10-09 https://biopharmsignal.com/news/TTOO/t2-biosystems-to-host-business-update-call-on-october-10-2024 2024-10-08 https://biopharmsignal.com/news/GSK/gsk-presents-positive-data-for-arexvy-its-respiratory-syncytial-virus-rsv-vaccine-indicating-protection-over-three-rsv-seasons 2024-10-08 https://biopharmsignal.com/news/TTOO/t2-biosystems-inc-and-prxcision-inc-announce-co-marketing-collaboration-for-rapid-direct-from-blood-diagnostics-and-ai-powered-decision-support-platform 2024-10-08 https://biopharmsignal.com/news/BPTH/bio-path-holdings-initiates-development-of-therapeutic-program-for-treatment-of--f0f6869a 2024-10-08 https://biopharmsignal.com/news/QGEN/global-tb-summit-2024-qiagen-an-vorderster-front-im-kampf-gegen-tuberkulose-eine-fcab3328 2024-10-07 https://biopharmsignal.com/news/QGEN/global-tb-summit-2024-qiagen-leads-the-charge-as-tuberculosis-reemerges-as-a-lea-4d8af56a 2024-10-07 https://biopharmsignal.com/news/GRI/gri-bio-to-present-at-the-22nd-international-colloquium-on-lung-and-airway-fibro-9c671613 2024-10-07 https://biopharmsignal.com/news/TTOO/t2-biosystems-announces-exclusive-u-s-agreement-with-cardinal-health-to-sell-its-fda-cleared-direct-from-blood-diagnostics-for-rapid-detection-of-sepsis-causing-pathogens 2024-10-07 https://biopharmsignal.com/news/ORTX/orchard-therapeutics-and-er-kim-announce-partnership-to-broaden-access-to-libmeldy-to-eligible-patients-in-turkey-and-certain-eurasian-countries 2024-10-07 https://biopharmsignal.com/news/GSK/viiv-healthcare-to-triple-annual-supply-of-long-acting-hiv-prep-for-low-and-middle-income-countries 2024-10-07 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-participate-in-the-3rd-annual-roth-healthcare-opportunities-conference 2024-10-07 https://biopharmsignal.com/news/TRVN/trevena-announces-receipt-of-nasdaq-delisting-notification 2024-10-04 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-approves-perioperative-treatment-of-neoadjuvant-opdivor-nivolumab-and-chemotherapy-followed-by-surgery-and-adjuvant-single-agent-opdivo-for-resectable-non-small-cell-lung-cancer-nsclc 2024-10-03 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-publication-of-spr720-phase-1-lung-exposure-data-in-1d758471 2024-10-02 https://biopharmsignal.com/news/IMMX/immix-biopharma-advances-car-t-nxc-201-to-expansion-cohort-dose-level-in-u-s-al--9e13939d 2024-10-02 https://biopharmsignal.com/news/GOVX/geovax-to-participate-in-the-3rd-annual-roth-healthcare-opportunities-conference-6b5cb622 2024-10-02 https://biopharmsignal.com/news/ADCT/adc-therapeutics-gew-hrt-neuen-mitarbeitern-zuteilungen-im-rahmen-des-anreizplan-4186db9a 2024-10-02 https://biopharmsignal.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-950a18b9 2024-10-01 https://biopharmsignal.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-publication-of-new-data-deepening-und-b24e4caf 2024-10-01 https://biopharmsignal.com/news/ATRC/atricure-receives-ce-mark-for-the-encompassr-clamp 2024-10-01 https://biopharmsignal.com/news/QGEN/qiagen-f-hrt-digitales-pcr-system-qiacuitydx-f-r-klinische-tests-in-der-onkologi-3027052d 2024-09-30 https://biopharmsignal.com/news/QGEN/qiagen-launches-qiacuitydx-digital-pcr-system-for-clinical-testing-in-oncology-21f7aab9 2024-09-30 https://biopharmsignal.com/news/GRI/gri-bio-granted-japan-patent-for-proprietary-natural-killer-t-nkt-cell-modulator-90387044 2024-09-30 https://biopharmsignal.com/news/AEON/aeon-biopharma-announces-positive-outcome-from-fda-biosimilar-advisory-meeting-9e799fe3 2024-09-30 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-new-data-from-two-trials-demonstrating-sotyktu-deucravacitinib-efficacy-in-both-moderate-to-severe-scalp-psoriasis-and-in-a-real-world-setting 2024-09-27 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-approves-bristol-myers-squibb-s-cobenfytm-xanomeline-and-trospium-chloride-a-first-in-class-muscarinic-agonist-for-the-treatment-of-schizophrenia-in-adults 2024-09-27 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-statement-on-oncologic-drugs-advisory-committee-odac-meeting-regarding-class-evaluation-of-pd-l1-expression-levels-for-immune-checkpoint-inhibitors-in-gastric-and-esophageal-cancers 2024-09-27 https://biopharmsignal.com/news/QGEN/qiagen-erh-lt-europ-ische-ivdr-zertifizierung-f-r-syndromisches-testsystem-qiast-400f0f21 2024-09-26 https://biopharmsignal.com/news/QGEN/qiagen-receives-european-ivdr-certification-for-qiastat-dx-syndromic-testing-ins-8c016ce2 2024-09-26 https://biopharmsignal.com/news/GRI/gri-bio-receives-authorization-to-conduct-phase-2a-biomarker-study-evaluating-gr-0b68b0a3 2024-09-26 https://biopharmsignal.com/news/ENLV/enlivex-receives-authorization-from-the-danish-medicines-agency-to-initiate-the-phase-ii-stage-of-its-phase-i-ii-trial-of-allocetra-in-patients-with-moderate-to-severe-knee-osteoarthritis 2024-09-26 https://biopharmsignal.com/news/ISPC/ispecimen-secures-1-million-loan-appoints-three-new-board-members 2024-09-26 https://biopharmsignal.com/news/QGEN/preanalytix-ein-joint-venture-von-qiagen-und-bd-bringt-neuartige-l-sung-f-r-urin-907d3a2f 2024-09-25 https://biopharmsignal.com/news/GRI/gri-bio-nasdaq-gri-to-participate-in-a-virtual-investor-ceo-connect-segment-7ac7c87e 2024-09-25 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-and-2seventy-bio-provide-update-on-karmma-9-trial-of-abecma-in-patients-with-newly-diagnosed-multiple-myeloma 2024-09-25 https://biopharmsignal.com/news/GSK/gsk-s-menveo-meningococcal-vaccine-in-new-single-vial-fully-liquid-presentation-receives-positive-european-chmp-opinion 2024-09-24 https://biopharmsignal.com/news/HOOK/hookipa-pharma-to-present-strong-preclinical-hb-700-dataset-02626ddb 2024-09-24 https://biopharmsignal.com/news/ENLV/enlivex-announces-positive-dsmb-recommendation-to-initiate-the-phase-ii-stage-of-its-phase-i-ii-trial-of-allocetra-in-patients-with-moderate-to-severe-knee-osteoarthritis 2024-09-24 https://biopharmsignal.com/news/SMFL/smart-for-life-reports-significant-balance-sheet-improvement-achieves-over-9-4-m-ee867424 2024-09-23 https://biopharmsignal.com/news/ORGS/orgenesis-announces-reverse-stock-split-ecc39494 2024-09-23 https://biopharmsignal.com/news/SMFL/smart-for-life-provides-update-following-nasdaq-delisting-due-to-audit-delays-re-35ae9593 2024-09-20 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-dr-raymond-comenzo-internationally-recognized-al-amylo-5b188387 2024-09-19 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-announces-database-lock-in-pharmacokinetics-study-of-ad04-for-the-treatment-of-alcohol-use-disorder 2024-09-19 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-russell-and-hughes-cases 2024-09-18 https://biopharmsignal.com/news/GRI/gri-bio-participates-in-virtual-investor-kol-connect-segment-53a31448 2024-09-18 https://biopharmsignal.com/news/BMY/new-long-term-zeposia-ozanimod-data-demonstrate-durable-efficacy-and-consistent-safety-in-relapsing-forms-of-multiple-sclerosis 2024-09-18 https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-combinations-in-relapsed-refractory-multiple-myeloma-accepted-for-regulatory-review-in-japan 2024-09-17 https://biopharmsignal.com/news/BPTH/bio-path-holdings-announces-publication-in-biomedicines-e6656904 2024-09-16 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-landmark-10-year-follow-up-data-from-checkmate-067-which-showed-continued-durable-long-term-survival-benefit-with-opdivor-plus-yervoyr-in-advanced-melanoma 2024-09-15 https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-designation-in-china-for-treatment-of-relapsed-refractory-multiple-myeloma 2024-09-13 https://biopharmsignal.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-2024-cantor-global-health-7f8302ca 2024-09-12 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-announces-positive-phase-1a-sad-data-for-vyn202-a-novel-bd2-se-7ea56036 2024-09-12 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-third-quarter-2024-on-october-31-2024 2024-09-12 https://biopharmsignal.com/news/GSK/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme 2024-09-12 https://biopharmsignal.com/news/ISPC/ispecimen-announces-1-for-20-reverse-stock-split 2024-09-11 https://biopharmsignal.com/news/GSK/gsk-provides-update-on-phase-i-ii-therapeutic-herpes-simplex-virus-hsv-vaccine-trial 2024-09-11 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-dixon-case 2024-09-11 https://biopharmsignal.com/news/SHCR/georgia-s-state-health-benefit-plan-and-sharecare-launch-onmed-carestation-to-enhance-care-access-for-state-employees 2024-09-10 https://biopharmsignal.com/news/GSK/depemokimab-late-breaking-data-presented-at-ers-show-a-54-reduction-in-severe-asthma-exacerbations 2024-09-09 https://biopharmsignal.com/news/SMFL/smart-for-life-announces-participation-at-the-h-c-wainwright-26th-annual-global--5ecdd938 2024-09-09 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-data-at-esmo-demonstrating-ongoing-leadership-in-immuno-oncology-and-progression-of-assets-from-its-differentiated-research-platforms 2024-09-09 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-employees-to-relay-nearly-3-000-miles-cross-country-aspiring-to-raise-over-1-million-for-the-v-foundation-for-cancer-research 2024-09-06 https://biopharmsignal.com/news/GSK/gsk-announces-positive-results-from-phase-iii-trial-of-nucala-mepolizumab-in-copd 2024-09-06 https://biopharmsignal.com/news/VIRX/viracta-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference 2024-09-05 https://biopharmsignal.com/news/GRI/gri-bio-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conferenc-95b4c300 2024-09-05 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference 2024-09-05 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-present-at-upcoming-september-investor-conferences-1e523d80 2024-09-04 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-announces-changes-to-its-board-of-directors-77af1ebb 2024-09-04 https://biopharmsignal.com/news/HEPA/pharma-two-b-and-hepion-pharmaceuticals-inc-announce-filing-of-registration-stat-afa31427 2024-09-04 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference 2024-09-04 https://biopharmsignal.com/news/GRI/gri-bio-to-present-at-the-2024-european-respiratory-congress 2024-09-04 https://biopharmsignal.com/news/CLLS/cellectis-presents-pre-clinical-evidence-of-muc1-car-t-cells-reducing-triple-negative-breast-cancer-while-preserving-safety 2024-09-03 https://biopharmsignal.com/news/GOVX/geovax-to-participate-in-upcoming-investor-conferences-in-september-85812edd 2024-09-03 https://biopharmsignal.com/news/ATXI/avenue-therapeutics-to-participate-in-upcoming-investor-conferences 2024-09-03 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-to-participate-in-september-investor-conferences-a2a2a794 2024-09-03 https://biopharmsignal.com/news/AQB/aquabounty-technologies-provides-update 2024-09-03 https://biopharmsignal.com/news/ADCT/adc-therapeutics-h-lt-vortr-ge-auf-bevorstehenden-investorenkonferenzen-d3528e20 2024-09-03 https://biopharmsignal.com/news/ADCT/adc-therapeutics-to-present-at-upcoming-investor-conferences-f7d93f52 2024-09-03 https://biopharmsignal.com/news/BPTH/bio-path-holdings-to-present-at-h-c-wainwright-26th-annual-global-investment-con-c3cf39bd 2024-09-03 https://biopharmsignal.com/news/GSK/gsk-aims-to-redefine-the-future-of-respiratory-medicine-at-the-european-respiratory-society-international-congress 2024-09-03 https://biopharmsignal.com/news/BMY/long-term-follow-up-data-from-phase-3-study-of-camzyosr-mavacamten-underscores-established-efficacy-and-safety-profile-in-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-ohcm 2024-09-01 https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-board-of-directors-changes-97acc5a1 2024-08-30 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-participate-in-the-2024-wells-fargo-healthcare-conference 2024-08-29 https://biopharmsignal.com/news/ORGS/orgenesis-announces-positive-results-from-a-real-world-study-of-org-101-car-t-th-87fd0475 2024-08-29 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-orphan-drug-designation-granted-by-the-fda-for-nxp800-for-the-treatment-of-arid1a-deficient-ovarian-fallopian-tube-and-primary-peritoneal-cancers 2024-08-29 https://biopharmsignal.com/news/GSK/european-commission-approves-expanded-age-indication-for-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk 2024-08-29 https://biopharmsignal.com/news/GOVX/geovax-to-raise-approximately-5-0-million-of-gross-proceeds-in-offering-priced-a-ad7cff73 2024-08-29 https://biopharmsignal.com/news/SMFL/smart-for-life-to-attend-the-newtopia-now-2024-conference-in-colorado-23bf6b99 2024-08-28 https://biopharmsignal.com/news/IMMX/immix-biopharma-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosi-bc7959c3 2024-08-28 https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-multiple-presentations-from-across-its-late-stage-neurometabolic-portfolio-at-ssiem-2024 2024-08-28 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-to-participate-in-upcoming-september-conferences-ae911c1e 2024-08-28 https://biopharmsignal.com/news/GSK/bepirovirsen-granted-senku-designation-in-japan-for-chronic-hepatitis-b 2024-08-28 https://biopharmsignal.com/news/GSK/gsk-s-nucala-mepolizumab-approved-in-japan-for-treatment-of-adults-with-chronic-rhinosinusitis-with-nasal-polyps 2024-08-28 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-delaware-supreme-court-to-review-superior-court-s-daubert-decision 2024-08-27 https://biopharmsignal.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-patent-issued-for-pfgarp-malaria-anti-0efb90af 2024-08-27 https://biopharmsignal.com/news/SMFL/smart-for-life-provides-update-on-prospective-acquisitions-3f7aa604 2024-08-26 https://biopharmsignal.com/news/CLLS/cellectis-publishes-a-molecular-therapy-article-on-a-smart-dual-car-t-cell-approach-for-treating-recalcitrant-solid-tumors 2024-08-26 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-data-across-cardiovascular-portfolio-at-the-european-society-of-cardiology-congress-2024 2024-08-26 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-statement-on-oncologic-drugs-advisory-committee-odac-meeting-to-discuss-pd-l1-expression-levels-in-gastric-and-esophageal-cancers 2024-08-22 https://biopharmsignal.com/news/SMFL/smart-for-life-announces-engagement-of-amerivest-group-in-expansion-of-its-acqui-be5e549a 2024-08-22 https://biopharmsignal.com/news/GOVX/registration-is-now-open-for-tribe-public-s-webinar-event-now-is-not-the-time-to-c3d82435 2024-08-21 https://biopharmsignal.com/news/SHCR/salinas-becomes-first-certified-blue-zones-communityr-in-monterey-county-california 2024-08-21 https://biopharmsignal.com/news/SMFL/smart-for-life-announces-update-on-prospective-acquisitions-74fee53c 2024-08-21 https://biopharmsignal.com/news/BPTH/bio-path-holdings-reports-solid-tumor-patient-response-supporting-bp1001-a-s-com-632a80a2 2024-08-21 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-u-s-food-and-drug-administration-sbla-acceptance-for-first-line-treatment-of-unresectable-hepatocellular-carcinoma 2024-08-21 https://biopharmsignal.com/news/GOVX/geovax-to-raise-approximately-8-5-million-of-gross-proceeds-in-offering-priced-a-852c82e8 2024-08-20 https://biopharmsignal.com/news/GSK/gsk-receives-us-fda-breakthrough-therapy-designation-for-its-b7-h3-targeted-antibody-drug-conjugate-in-relapsed-or-refractory-extensive-stage-small-cell-lung-cancer 2024-08-20 https://biopharmsignal.com/news/AEON/aeon-biopharma-to-participate-in-the-h-c-wainwright-26th-annual-global-investmen-8047cc61 2024-08-19 https://biopharmsignal.com/news/BMY/european-medicines-agency-validates-bristol-myers-squibb-s-application-for-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-follicular-lymphoma 2024-08-19 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-florida-state-court-daubert-ruling-in-wilson-case 2024-08-15 https://biopharmsignal.com/news/GOVX/geovax-to-present-at-the-emerging-growth-conference-on-august-21-2024-dcf60383 2024-08-15 https://biopharmsignal.com/news/ABVC/abvc-biopharma-inc-reports-strong-q2-2024-financial-results-and-strategic-achiev-5b34ed55 2024-08-15 https://biopharmsignal.com/news/AMS/american-shared-hospital-services-reports-strong-second-quarter-2024-financial-r-f3795955 2024-08-14 https://biopharmsignal.com/news/FORA/forian-inc-announces-second-quarter-2024-financial-results 2024-08-14 https://biopharmsignal.com/news/ORGS/orgenesis-announces-strategic-partnership-with-harley-street-healthcare-group-to-fdf35587 2024-08-14 https://biopharmsignal.com/news/VYNE/vyne-therapeutics-reports-second-quarter-2024-financial-results-and-provides-bus-6d622707 2024-08-14 https://biopharmsignal.com/news/GRTX/galera-announces-board-approval-of-complete-liquidation-and-dissolution-64cc11a7 2024-08-14 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-business-update 2024-08-14 https://biopharmsignal.com/news/GRI/gri-bio-reports-second-quarter-2024-financial-results-and-provides-corporate-update 2024-08-14 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-second-quarter-2024-financial-results-and-provides--d8ca763a 2024-08-13 https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-second-quarter-2024-financial-results-and-provides-corpo-886d099e 2024-08-13 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-signs-agreement-with-boudicca-dx-to-advance-regulatory-strategy-for-companion-diagnostic-genetic-test-for-ad04 2024-08-13 https://biopharmsignal.com/news/AEON/aeon-biopharma-reports-second-quarter-2024-financial-results-and-provides-corpor-d88979d8 2024-08-12 https://biopharmsignal.com/news/TXMD/therapeuticsmd-announces-second-quarter-2024-financial-results 2024-08-12 https://biopharmsignal.com/news/ATXI/avenue-therapeutics-reports-second-quarter-2024-financial-results-and-recent-corporate-highlights 2024-08-09 https://biopharmsignal.com/news/SHCR/sharecare-announces-second-quarter-2024-financial-results-and-operational-highlights 2024-08-09 https://biopharmsignal.com/news/HOOK/hookipa-pharma-reports-second-quarter-2024-financial-results-and-recent-business-8fad6d26 2024-08-08 https://biopharmsignal.com/news/ORGS/orgenesis-provides-second-quarter-2024-business-update-5da2e6dc 2024-08-08 https://biopharmsignal.com/news/TRVN/trevena-announces-reverse-stock-split 2024-08-08 https://biopharmsignal.com/news/GOVX/geovax-appoints-teresa-lambe-acclaimed-professor-of-vaccinology-and-immunology-a-7f8e8bd8 2024-08-08 https://biopharmsignal.com/news/TRVN/trevena-reports-second-quarter-2024-results-and-provides-business-update 2024-08-08 https://biopharmsignal.com/news/SYBX/synlogic-reports-second-quarter-2024-financial-results 2024-08-08 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-second-quarter-2024-results 2024-08-08 https://biopharmsignal.com/news/CYCN/regina-graul-ph-d-promoted-to-chief-executive-officer 2024-08-07 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-announces-last-patient-dosed-in-pharmacokinetics-study-of-ad04-for-the-treatment-of-alcohol-use-disorder 2024-08-07 https://biopharmsignal.com/news/CLLS/cellectis-appoints-dr-adrian-kilcoyne-as-chief-medical-officer 2024-08-07 https://biopharmsignal.com/news/ADCT/adc-therapeutics-berichtet-ber-finanzergebnisse-des-zweiten-quartals-2024-und-gi-360067de 2024-08-06 https://biopharmsignal.com/news/CLLS/cellectis-provides-financial-results-for-the-second-quarter-2024 2024-08-06 https://biopharmsignal.com/news/GOVX/geovax-reports-second-quarter-2024-financial-results-and-provides-business-updat-00f8131a 2024-08-06 https://biopharmsignal.com/news/AQB/aquabounty-technologies-announces-second-quarter-2024-financial-results 2024-08-06 https://biopharmsignal.com/news/ADCT/adc-therapeutics-reports-second-quarter-2024-financial-results-and-provides-oper-249560ad 2024-08-06 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2024-financial-results-and-business-highlights 2024-08-06 https://biopharmsignal.com/news/ISPC/ispecimen-reports-second-quarter-2024-results 2024-08-06 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-joiner-case 2024-08-05 https://biopharmsignal.com/news/FORA/forian-inc-to-announce-second-quarter-2024-results-on-august-14-2024 2024-08-02 https://biopharmsignal.com/news/CLLS/fda-grants-orphan-drug-designation-to-cellectis-clls52-alemtuzumab-for-all-treatment 2024-08-01 https://biopharmsignal.com/news/GSK/us-fda-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer-as-the-first-and-only-immuno-oncology-based-treatment-to-show-an-overall-survival-benefit 2024-08-01 https://biopharmsignal.com/news/GOVX/update-geovax-announces-phase-2-plans-for-gedeptin-cancer-therapy-following-clin-8730d22a 2024-07-31 https://biopharmsignal.com/news/GOVX/geovax-announces-phase-2-plans-for-gedeptin-cancer-therapy-following-clinical-ad-07cc69a7 2024-07-31 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-files-new-patent-application-to-protect-core-assets-and-extend-ip-exclusivity-on-core-technology-to-2044 2024-07-31 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-completes-five-year-microbiologic-surveillance-study-of-nuzyrar-omadacycline-demonstrating-no-change-in-in-vitro-potency-against-indicated-pathogens 2024-07-31 https://biopharmsignal.com/news/GSK/gsk-delivers-continued-strong-performance-and-upgrades-2024-guidance 2024-07-31 https://biopharmsignal.com/news/ADCT/adc-therapeutics-veranstaltet-am-6-august-2024-eine-telefonkonferenz-zu-den-fina-b093df2a 2024-07-30 https://biopharmsignal.com/news/GOVX/geovax-to-report-second-quarter-2024-financial-results-and-provide-corporate-upd-e5ed0974 2024-07-30 https://biopharmsignal.com/news/ADCT/adc-therapeutics-to-host-second-quarter-2024-financial-results-conference-call-o-c956a7a0 2024-07-30 https://biopharmsignal.com/news/GSK/gsk-presents-new-data-at-the-alzheimer-s-association-international-conference-2024 2024-07-30 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-second-quarter-2024-financial-results-and-provide-b-53f3d60c 2024-07-29 https://biopharmsignal.com/news/GSK/arexvy-gsk-s-respiratory-syncytial-virus-rsv-vaccine-receives-positive-european-medicines-agency-chmp-opinion-for-adults-aged-50-59-at-increased-risk-for-rsv-disease 2024-07-29 https://biopharmsignal.com/news/GRFS/grifols-receives-expanded-xembify-immune-globulin-subcutaneous-human-klhw-label--ab81defd 2024-07-29 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-kimbrow-case 2024-07-29 https://biopharmsignal.com/news/GSK/gsk-and-flagship-pioneering-partner-to-discover-novel-medicines-and-vaccines 2024-07-29 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-second-quarter-financial-results-for-2024 2024-07-26 https://biopharmsignal.com/news/IMMX/california-institute-for-regenerative-medicine-awards-funding-for-car-t-nxc-201--d16ae203 2024-07-26 https://biopharmsignal.com/news/CLLS/fda-grants-orphan-drug-and-rare-pediatric-disease-designation-status-to-cellectis-ucart22-product-candidate-for-acute-lymphoblastic-leukemia-all-treatment 2024-07-25 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-host-second-quarter-2024-investor-update-call 2024-07-25 https://biopharmsignal.com/news/ISPC/ispecimen-to-report-second-quarter-2024-results-on-august-6-2024 2024-07-25 https://biopharmsignal.com/news/GSK/viiv-healthcare-premieres-early-data-showing-antiviral-activity-against-integrase-resistance-from-its-investigational-third-generation-integrase-inhibitor 2024-07-23 https://biopharmsignal.com/news/GSK/viiv-healthcare-announces-positive-data-demonstrating-2-drug-regimen-dovato-is-as-effective-as-3-drug-regimen-biktarvy-for-maintenance-therapy-of-hiv-1 2024-07-23 https://biopharmsignal.com/news/GSK/viiv-healthcare-announces-positive-new-data-for-apretude-use-during-pregnancy-at-aids-2024 2024-07-23 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-advances-to-second-cohort-in-pharmacokinetics-study-of-ad04-for-the-treatment-of-alcohol-use-disorder 2024-07-23 https://biopharmsignal.com/news/ENLV/enlivex-receives-regulatory-authorization-for-the-initiation-of-a-phase-i-clinical-trial-to-evaluate-allocetra-in-patients-with-psoriatic-arthritis 2024-07-23 https://biopharmsignal.com/news/HEPA/pharma-two-b-announces-plans-to-go-public-via-merger-with-hepion-pharmaceuticals-a96f6d7f 2024-07-22 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-european-medicines-agency-validation-of-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-first-line-treatment-of-unresectable-or-advanced-hepatocellular-carcinoma 2024-07-19 https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-combinations-in-multiple-myeloma-application-accepted-for-review-by-the-european-medicines-agency 2024-07-19 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reaches-major-milestone-in-environmental-sustainability 2024-07-18 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-announces-positive-top-line-efficacy-and-safety-data-from-post-marketing-study-of-nuzyrar-omadacycline-for-patients-with-moderate-to-severe-community-acquired-bacterial-pneumonia 2024-07-18 https://biopharmsignal.com/news/NGM/ngm-bio-announces-122-million-series-a-financing-to-initiate-registrational-trial-in-primary-sclerosing-cholangitis-and-fund-phase-2-trial-in-hyperemesis-gravidarum 2024-07-17 https://biopharmsignal.com/news/GSK/viiv-healthcare-to-announce-data-from-largest-head-to-head-randomised-clinical-trial-for-2-drug-regimen-dovato-against-3-drug-regimen-biktarvy-at-aids-2024 2024-07-15 https://biopharmsignal.com/news/WGS/genedx-to-report-second-quarter-2024-financial-results-on-tuesday-july-30-2024-4818bc73 2024-07-11 https://biopharmsignal.com/news/SMFL/smart-for-life-announces-appointment-of-jessica-walters-as-chief-marketing-offic-9c36d8dc 2024-07-09 https://biopharmsignal.com/news/AEON/aeon-biopharma-announces-strategic-reprioritization-to-pursue-a-biosimilar-pathw-f6bfc35c 2024-07-09 https://biopharmsignal.com/news/IMMX/immix-biopharma-doses-1st-patient-in-u-s-al-amyloidosis-trial-with-car-t-nxc-201-94d18747 2024-07-08 https://biopharmsignal.com/news/TRVN/trevena-announces-2m-non-dilutive-financing-tranche-and-reduction-in-outstanding-liabilities-in-connection-with-existing-ex-us-royalty-financing 2024-07-08 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-ubs-virtual-targeted-protein-degradation-day 2024-07-08 https://biopharmsignal.com/news/GSK/brazil-and-thailand-become-first-malaria-endemic-countries-to-launch-new-single-dose-radical-cure-medicine-to-prevent-the-relapse-of-plasmodium-vivax-malaria 2024-07-05 https://biopharmsignal.com/news/NAVB/navidea-biopharmaceuticals-inc-announces-results-of-exploratory-analysis-completed-on-july-2-2024 2024-07-03 https://biopharmsignal.com/news/GSK/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement 2024-07-03 https://biopharmsignal.com/news/SMFL/smart-for-life-to-attend-ift-first-annual-event-and-expo-in-chicago-448c73f1 2024-07-02 https://biopharmsignal.com/news/GRFS/grifols-biotest-to-achieve-usd-1-billion-in-us-sales-of-yimmugo-over-next-seven--a949f7c8 2024-07-01 https://biopharmsignal.com/news/CLLS/cellectis-reports-results-from-shareholders-meeting-held-on-june-28-2024 2024-06-28 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-gross-case 2024-06-28 https://biopharmsignal.com/news/ORTX/orchard-therapeutics-celebrates-global-progress-toward-advancing-newborn-screening-for-mld-on-international-neonatal-screening-day 2024-06-28 https://biopharmsignal.com/news/ADCT/adc-therapeutics-tritt-demn-chst-den-indizes-russell-2000-und-russell-3000-bei-fec813c4 2024-06-27 https://biopharmsignal.com/news/ADCT/adc-therapeutics-set-to-join-russell-2000-and-russell-3000-indexes-85c00136 2024-06-27 https://biopharmsignal.com/news/GSK/statement-us-centers-for-disease-control-and-prevention-s-advisory-committee-on-immunisation-practices-updates-recommendations-on-adult-rsv-vaccines-ahead-of-the-next-season 2024-06-26 https://biopharmsignal.com/news/SOPH/sophia-genetics-publishes-results-of-2024-annual-general-meeting-cd3af75f 2024-06-24 https://biopharmsignal.com/news/ENLV/enlivex-announces-the-dosing-of-the-first-patient-in-a-randomized-placebo-controlled-phase-i-ii-trial-evaluating-allocetratm-in-up-to-46-patients-with-thumb-osteoarthritis 2024-06-24 https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-plus-chemotherapy-application-accepted-for-review-by-the-european-medicines-agency-to-expand-use-to-all-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2024-06-24 https://biopharmsignal.com/news/GSK/gsk-s-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis 2024-06-24 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-u-s-fda-accelerated-approval-of-krazatir-adagrasib-in-combination-with-cetuximab-for-adult-patients-with-previously-treated-kras-g12c-mutated-locally-advanced-or-metastatic-colorectal-cancer-crc 2024-06-21 https://biopharmsignal.com/news/SHCR/sharecare-enters-into-definitive-agreement-to-be-acquired-by-altaris 2024-06-21 https://biopharmsignal.com/news/BMY/european-medicines-agency-validates-bristol-myers-squibb-s-application-for-subcutaneous-nivolumab 2024-06-21 https://biopharmsignal.com/news/NAVB/navidea-biopharmaceuticals-inc-announces-special-meeting-of-stockholders-to-be-held-july-8-2024 2024-06-20 https://biopharmsignal.com/news/CLLS/cellectis-publishes-a-scientific-article-unveiling-three-key-factors-for-efficient-tale-base-editing 2024-06-20 https://biopharmsignal.com/news/SMFL/smart-for-life-to-attend-the-international-society-of-sports-nutrition-s-2024-co-cfef68e9 2024-06-20 https://biopharmsignal.com/news/ATXI/avenue-therapeutics-to-present-at-the-h-c-wainwright-5th-annual-neuro-perspectives-virtual-conference 2024-06-20 https://biopharmsignal.com/news/TRVN/trevena-announces-preclinical-trv045-data-providing-insight-into-novel-mechanism-of-analgesic-effect-in-chronic-neuropathic-pain-model-and-demonstrating-statistically-significant-anti-seizure-activity-in-epilepsy-models 2024-06-20 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-second-quarter-2024-on-july-26-2024 2024-06-20 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-announces-publication-in-leading-peer-reviewed-journal-supporting-the-potential-efficacy-of-ad04-as-a-precision-medicine-for-the-treatment-of-alcohol-use-disorder 2024-06-20 https://biopharmsignal.com/news/ENLV/join-enlivex-therapeutics-chief-executive-officer-for-a-live-investor-webinar-and-qanda-session-on-june-25 2024-06-20 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-elects-michael-r-mcmullen-to-board-of-directors 2024-06-18 https://biopharmsignal.com/news/GRFS/grifols-completes-sale-of-a-20-equity-stake-in-sraas-and-forges-strategic-allian-4681e117 2024-06-18 https://biopharmsignal.com/news/IMMX/immix-biopharma-to-present-at-the-stifel-2024-cell-therapy-forum-90dc834b 2024-06-17 https://biopharmsignal.com/news/GRFS/grifols-biotest-receives-fda-approval-for-innovative-yimmugo-immunoglobulin-to-t-0974aedc 2024-06-17 https://biopharmsignal.com/news/ENLV/enlivex-announces-positive-interim-data-readout-from-a-phase-i-ii-trial-evaluating-allocetra-in-end-stage-knee-osteoarthritis 2024-06-17 https://biopharmsignal.com/news/MREO/mereo-biopharma-announces-pricing-of-50-million-underwritten-registered-direct-o-add0dcae 2024-06-14 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-approves-augtyrotm-repotrectinib-a-next-generation-tyrosine-kinase-inhibitor-tki-for-the-treatment-of-patients-with-ntrk-positive-locally-advanced-or-metastatic-solid-tumors 2024-06-13 https://biopharmsignal.com/news/CLLS/cellectis-unveils-a-non-viral-gene-therapy-approach-for-sickle-cell-disease-in-nature-communications 2024-06-12 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-kasza-case 2024-06-10 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-gsk-starts-process-for-appeal-of-recent-delaware-daubert-decision 2024-06-10 https://biopharmsignal.com/news/WGS/genedx-announces-collaboration-with-epic-aura-to-expand-access-to-rapid-whole-ge-740de912 2024-06-10 https://biopharmsignal.com/news/GSK/us-fda-approves-expanded-age-indication-for-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk 2024-06-07 https://biopharmsignal.com/news/AQB/david-f-melbourne-jr-promoted-to-chief-executive-officer-of-aquabounty-sylvia-wulf-to-continue-as-non-executive-board-chair 2024-06-07 https://biopharmsignal.com/news/GSK/gsk-accelerates-oligonucleotide-platform-and-pipeline-medicines-with-acquisition-of-elsie-biotechnologies 2024-06-06 https://biopharmsignal.com/news/OCEA/ocean-biomedical-nasdaq-ocea-congratulates-joint-venture-partner-virion-therapeu-38e8fab9 2024-06-05 https://biopharmsignal.com/news/WGS/genedx-announces-patient-access-program-to-expand-access-to-exome-testing-for-pe-c4b289d2 2024-06-05 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-achieves-important-milestone-of-first-patient-dosed-in-pharmacokinetics-study-of-ad04-for-the-treatment-of-alcohol-use-disorder 2024-06-05 https://biopharmsignal.com/news/CLLS/cellectis-receives-orphan-drug-designation-for-ucart22-its-allogeneic-car-t-product-for-patients-with-acute-lymphoblastic-leukemia 2024-06-04 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-opdivo-nivolumab-plus-yervoy-ipilimumab-significantly-improved-overall-survival-compared-to-lenvatinib-or-sorafenib-as-first-line-treatment-for-patients-with-advanced-hepatocellular-carcinoma-in-checkmate-9dw-trial 2024-06-04 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference 2024-06-04 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-s-breyanzi-demonstrates-clinically-meaningful-outcomes-across-broad-range-of-b-cell-malignancies-in-new-data-presented-at-2024-ascor-annual-meeting 2024-06-03 https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-trial-continues-to-show-unprecedented-results-with-no-evidence-of-disease-in-100-of-patients-with-locally-advanced-mismatch-repair-deficient-dmmr-rectal-cancer 2024-06-03 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-multiple-new-analyses-at-2024-ascor-annual-meeting-highlighting-opdivo-and-opdivo-based-combinations-in-early-and-advanced-stages-of-non-small-cell-lung-cancer 2024-06-03 https://biopharmsignal.com/news/ENLV/enlivex-receives-regulatory-authorization-for-the-initiation-of-a-placebo-controlled-phase-i-ii-trial-evaluating-allocetra-in-up-to-46-patients-with-thumb-osteoarthritis 2024-06-03 https://biopharmsignal.com/news/GSK/blenrep-combination-reduced-the-risk-of-disease-progression-or-death-by-nearly-50-versus-standard-of-care-combination-in-relapsed-refractory-multiple-myeloma 2024-06-02 https://biopharmsignal.com/news/BMY/krazati-adagrasib-demonstrated-statistically-significant-improvement-in-progression-free-survival-in-patients-with-pretreated-locally-advanced-or-metastatic-krasg12c-mutated-non-small-cell-lung-cancer 2024-06-01 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-delaware-state-court-daubert-ruling 2024-06-01 https://biopharmsignal.com/news/SMFL/smart-for-life-to-be-featured-in-whole-foods-magazine-highlighting-product-offer-40ac5bb1 2024-05-31 https://biopharmsignal.com/news/ADCT/adc-therapeutics-nimmt-an-der-jefferies-global-healthcare-conference-teil-ae887bb1 2024-05-30 https://biopharmsignal.com/news/SMFL/smart-for-life-to-attend-ift-first-the-premier-food-science-and-technology-event-96bb107d 2024-05-30 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-approves-bristol-myers-squibb-s-breyanzi-as-a-new-car-t-cell-therapy-for-relapsed-or-refractory-mantle-cell-lymphoma 2024-05-30 https://biopharmsignal.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-jefferies-global-healthca-e847fce5 2024-05-30 https://biopharmsignal.com/news/ADCT/adc-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-d58b7944 2024-05-30 https://biopharmsignal.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-28-2024 2024-05-29 https://biopharmsignal.com/news/ENLV/enlivex-therapeutics-closes-up-to-15-million-registered-direct-offering 2024-05-29 https://biopharmsignal.com/news/AEON/aeon-biopharma-announces-strategic-resource-reprioritization-and-cost-reduction--03965e8a 2024-05-29 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-european-commission-approval-for-opdivor-nivolumab-in-combination-with-cisplatin-and-gemcitabine-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma 2024-05-29 https://biopharmsignal.com/news/ADIL/adial-ceo-to-present-at-the-spring-microcap-rodeo-conference-on-june-6th 2024-05-29 https://biopharmsignal.com/news/SMFL/smart-for-life-announces-updates-on-successful-completion-of-restructuring-progr-5d5fb4b0 2024-05-28 https://biopharmsignal.com/news/CLLS/cellectis-reports-financial-results-for-first-quarter-2024 2024-05-28 https://biopharmsignal.com/news/ENLV/enlivex-therapeutics-announces-up-to-15-million-registered-direct-offering 2024-05-28 https://biopharmsignal.com/news/CLLS/cellectis-to-report-first-quarter-2024-financial-results-on-may-28-2024 2024-05-25 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-data-at-asco-and-eha-from-more-than-130-studies-across-25-diseases-supporting-expansion-into-new-indications-demonstrating-long-term-survival-and-highlighting-novel-modalities-and-research-platforms 2024-05-23 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation-valadez-and-williams-cases 2024-05-23 https://biopharmsignal.com/news/GSK/new-data-at-asco-showcases-the-transformational-potential-of-gsk-s-oncology-portfolio 2024-05-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-data-at-the-2024-american-society-of-clinical-psychopharmacology-annual-meeting 2024-05-23 https://biopharmsignal.com/news/WGS/genedx-to-participate-in-upcoming-investor-conferences-5e6d9364 2024-05-22 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-10-year-strategy-to-reach-more-patients-in-low-and-middle-income-countries 2024-05-22 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-stress-regulating-peptide-demonstrates-exceptional-safety-in-single-dose-portion-of-phase-i-trial-paving-the-way-for-next-steps-toward-potential-breakthrough-treatments-in-stress-related-neuropsychiatric-disorders 2024-05-22 https://biopharmsignal.com/news/SMFL/smart-for-life-to-attend-the-2024-nasc-annual-conference-8a216c0a 2024-05-21 https://biopharmsignal.com/news/PMCB/pharmacyte-biotech-makes-7-million-strategic-investment-in-mymd-a-biopharmaceutical-company-focused-on-inflammatory-disease 2024-05-21 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-taye-diggs-and-schizophrenia-community-partner-to-empower-people-with-schizophrenia-through-live-your-possczible-campaign 2024-05-21 https://biopharmsignal.com/news/ORGS/orgenesis-provides-business-update-for-the-first-quarter-of-2024-ea8659ba 2024-05-21 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-updated-action-date-by-the-u-s-food-and-drug-administration-for-subcutaneous-nivolumab-nivolumab-and-hyaluronidase 2024-05-21 https://biopharmsignal.com/news/IRWD/ironwood-late-breaker-oral-presentation-at-digestive-disease-weekr-reinforces-potential-of-once-weekly-apraglutide-for-adults-with-short-bowel-syndrome-with-intestinal-failure-sbs-if 2024-05-21 https://biopharmsignal.com/news/GSK/gsk-announces-positive-results-from-phase-iii-severe-asthma-trials-of-depemokimab 2024-05-21 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-secures-new-investor-33c094c6 2024-05-17 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-participate-in-h-c-wainwright-annual-bioconnect-investor-c-a6bfcfa3 2024-05-16 https://biopharmsignal.com/news/BMY/new-four-year-sotyktu-deucravacitinib-data-demonstrate-durable-response-rates-and-consistent-safety-in-moderate-to-severe-plaque-psoriasis 2024-05-16 https://biopharmsignal.com/news/ATXI/avenue-therapeutics-announces-last-patient-last-visit-in-phase-1b-2a-clinical-trial-of-aj201-for-the-treatment-of-spinal-and-bulbar-muscular-atrophy-kennedy-s-disease 2024-05-16 https://biopharmsignal.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-patent-allowance-for-malaria-antibodi-bf836b42 2024-05-16 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-presents-this-week-at-the-society-for-investigative-dermato-f740156d 2024-05-16 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference 2024-05-16 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-s-car-t-cell-therapy-breyanzi-approved-by-the-u-s-food-and-drug-administration-for-relapsed-or-refractory-follicular-lymphoma 2024-05-16 https://biopharmsignal.com/news/GSK/gsk-to-become-a-founding-partner-of-fleming-initiative-to-fight-antimicrobial-resistance-amr 2024-05-16 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-first-quarter-2024-operating-results-and-provides-a-0039e64e 2024-05-15 https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-first-quarter-2024-financial-results-and-provides-corpor-1652c264 2024-05-15 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-announces-completion-of-dosing-in-first-patient-cohort-in-p-a91c4fa4 2024-05-15 https://biopharmsignal.com/news/ATXI/avenue-therapeutics-reports-first-quarter-2024-financial-results-and-recent-corporate-highlights 2024-05-15 https://biopharmsignal.com/news/AQB/aquabounty-technologies-announces-first-quarter-2024-financial-results 2024-05-15 https://biopharmsignal.com/news/TRVN/trevena-reports-first-quarter-2024-results-and-provides-business-update 2024-05-15 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-business-update 2024-05-15 https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-first-quarter-2024-results-announces-strategic-pipe-cdd87f85 2024-05-14 https://biopharmsignal.com/news/FORA/forian-inc-announces-first-quarter-2024-financial-results 2024-05-14 https://biopharmsignal.com/news/SYBX/synlogic-reports-first-quarter-2024-financial-results 2024-05-14 https://biopharmsignal.com/news/GRTX/galera-reports-first-quarter-2024-financial-results-and-recent-corporate-updates-6f25c676 2024-05-13 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-provides-update-on-phase-3-checkmate-73l-trial 2024-05-10 https://biopharmsignal.com/news/TXMD/therapeuticsmd-announces-first-quarter-2024-financial-results 2024-05-10 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-positive-nxc-201-relapsed-refractory-al-amyloidosis-cl-abd797b2 2024-05-10 https://biopharmsignal.com/news/SMFL/smart-for-life-to-attend-vitafoods-europe-2024-positioned-to-identify-strategic--d6765331 2024-05-10 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-reports-q1-2024-results-and-provides-business-update-3b4158d7 2024-05-09 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-first-quarter-2024-results 2024-05-09 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-first-quarter-2024-financial-results-and-provide-bu-77896b89 2024-05-08 https://biopharmsignal.com/news/SOPH/sophia-genetics-reports-first-quarter-2024-results-e1a64b37 2024-05-07 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-first-quarter-2024-financial-results-and-business-highlights 2024-05-07 https://biopharmsignal.com/news/ISPC/ispecimen-reports-first-quarter-2024-results 2024-05-07 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-participate-in-the-citizens-jmp-life-sciences-conference 2024-05-06 https://biopharmsignal.com/news/BMY/european-medicines-agency-validates-bristol-myers-squibb-s-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-the-first-line-treatment-of-adult-patients-with-microsatellite 2024-05-06 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-application-for-subcutaneous-nivolumab-nivolumab-and-hyaluronidase 2024-05-06 https://biopharmsignal.com/news/CLLS/cellectis-announces-completion-of-the-additional-equity-investment-by-astrazeneca 2024-05-06 https://biopharmsignal.com/news/GRTX/galera-adopts-limited-duration-stockholder-rights-agreement-3021de3e 2024-05-03 https://biopharmsignal.com/news/CLLS/cellectis-appoints-arthur-stril-as-interim-chief-financial-officer 2024-05-02 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--43e1ef2a 2024-05-01 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-present-new-data-on-once-weekly-apraglutide-in-short-bowel-syndrome-with-intestinal-failure-sbs-if-at-digestive-disease-weekr-2024 2024-05-01 https://biopharmsignal.com/news/FORA/forian-inc-to-announce-first-quarter-2024-results-on-may-14-2024 2024-05-01 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-completes-enrollment-in-single-dose-portion-of-phase-1-of-innovative-stress-disorder-trial 2024-05-01 https://biopharmsignal.com/news/GSK/gsk-makes-a-strong-start-to-2024-with-improving-outlook-for-the-year 2024-05-01 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-announces-upcoming-presentation-at-the-annual-meeting-of-th-d016cf1d 2024-04-30 https://biopharmsignal.com/news/SOPH/sophia-genetics-to-present-at-the-2024-rbc-capital-markets-global-healthcare-con-9aa966bb 2024-04-30 https://biopharmsignal.com/news/WGS/genedx-reports-first-quarter-2024-financial-results-and-business-highlights-6b87f4af 2024-04-29 https://biopharmsignal.com/news/CLLS/cellectis-reports-financial-results-for-the-fourth-quarter-and-full-year-2023 2024-04-29 https://biopharmsignal.com/news/IMMX/immix-biopharma-awarded-european-union-orphan-drug-designation-for-nxc-201-in-mu-f40c9858 2024-04-29 https://biopharmsignal.com/news/SMFL/smart-for-life-to-attend-national-pet-food-forum-on-april-29-to-may-2-c8c67c94 2024-04-29 https://biopharmsignal.com/news/ATXI/avenue-therapeutics-announces-exercise-of-warrants-for-4-4-million-in-gross-proceeds 2024-04-29 https://biopharmsignal.com/news/SMFL/smart-for-life-announces-availability-of-a-white-paper-on-the-nutraceuticals-ind-c5277ba1 2024-04-26 https://biopharmsignal.com/news/TRNR/interactive-strength-inc-nasdaq-trnr-strengthens-balance-sheet-by-partially-conv-ce5a23dc 2024-04-26 https://biopharmsignal.com/news/BMY/chmp-adopts-positive-opinion-recommending-approval-of-bristol-myers-squibb-s-opdivor-nivolumab-in-combination-with-cisplatin-and-gemcitabine-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma 2024-04-26 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-host-first-quarter-2024-investor-update-call 2024-04-25 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-first-quarter-financial-results-for-2024 2024-04-25 https://biopharmsignal.com/news/ISPC/ispecimen-to-report-first-quarter-2024-financial-results-on-may-7-2024 2024-04-25 https://biopharmsignal.com/news/OCEA/ocean-biomedical-inc-announces-receipt-of-notice-from-nasdaq-regarding-late-fili-372211b7 2024-04-24 https://biopharmsignal.com/news/SMFL/smart-for-life-appoints-prominent-industry-executive-david-trosin-to-company-s-a-d60f9fb4 2024-04-24 https://biopharmsignal.com/news/GSK/us-fda-accepts-for-priority-review-gsk-s-application-for-an-expanded-indication-of-jemperli-dostarlimab-plus-chemotherapy-to-include-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2024-04-24 https://biopharmsignal.com/news/SMFL/smart-for-life-announces-the-successful-completion-of-restructuring-program-9b0ffddc 2024-04-23 https://biopharmsignal.com/news/SOPH/sophia-genetics-to-announce-financial-results-for-first-quarter-2024-on-may-7-20-f68ce487 2024-04-23 https://biopharmsignal.com/news/WGS/genedx-announces-partnership-with-komodo-health-to-expand-access-to-world-s-larg-7ef8e99e 2024-04-23 https://biopharmsignal.com/news/PHIO/intratumoral-injection-of-phio-s-ph-762-significantly-inhibits-tumor-growth-in-m-464a8c7c 2024-04-22 https://biopharmsignal.com/news/CLLS/cellectis-presents-novel-talenr-editing-processes-enabling-highly-efficient-gene-correction-and-gene-insertion-in-hspcs 2024-04-22 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-and-cellares-announce-a-380m-worldwide-capacity-reservation-and-supply-agreement-for-the-manufacture-of-car-t-cell-therapies-to-bring-the-promise-of-cell-therapy-to-more-patients-faster 2024-04-22 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-granted-key-patent-from-the-united-states-patent-and-trademark-office 2024-04-22 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-tr-0ccd30d4 2024-04-19 https://biopharmsignal.com/news/SMFL/smart-for-life-announces-the-appointment-of-heather-granato-to-the-company-s-boa-020f06a6 2024-04-18 https://biopharmsignal.com/news/IMMX/immix-biopharma-on-track-to-dose-nxc-201-patients-in-united-states-98f26afe 2024-04-18 https://biopharmsignal.com/news/GRFS/grifols-celebrates-50-years-of-manufacturing-life-changing-plasma-derived-medici-db535bbb 2024-04-18 https://biopharmsignal.com/news/ABVC/aibtl-biopharma-inc-acquired-tt-life-company-valued-at-8-33m-with-1-66m-aibtl-sh-0f954a1d 2024-04-18 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-presenting-new-data-from-nuzyrar-omadacycline-and-investigator-initiated-pre-clinical-studies-at-european-society-of-clinical-microbiology-and-infectious-diseases-global-escmid-global-2024 2024-04-18 https://biopharmsignal.com/news/ABVC/abvc-biopharma-executes-a-global-licensing-definitive-agreement-for-the-treatmen-74856068 2024-04-17 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-innovative-peptide-pt00114-to-be-highlighted-at-boston-summit 2024-04-17 https://biopharmsignal.com/news/GSK/eagle-1-phase-iii-data-show-potential-for-gepotidacin-as-a-new-oral-treatment-option-for-uncomplicated-urogenital-gonorrhoea-gc-amid-growing-resistance-to-existing-treatments 2024-04-17 https://biopharmsignal.com/news/GSK/new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles-in-adults-aged-50-and-over-for-more-than-a-decade 2024-04-17 https://biopharmsignal.com/news/GSK/gsk-s-5-in-1-meningococcal-abcwy-vaccine-candidate-accepted-for-regulatory-review-by-us-fda 2024-04-16 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-announces-upcoming-presentations-at-the-81st-annual-meeting-496b85e2 2024-04-16 https://biopharmsignal.com/news/ORGS/orgenesis-provides-year-end-business-update-7763b8b3 2024-04-15 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-late-breaking-nxc-201-clinical-data-abstract-accepted--f89ec2f5 2024-04-15 https://biopharmsignal.com/news/FORA/forian-inc-announces-the-passing-of-director-martin-j-wygod 2024-04-14 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-announces-upcoming-presentation-at-the-27th-annual-meeting--1518bc1e 2024-04-11 https://biopharmsignal.com/news/ORGS/germfree-and-orgenesis-announce-asset-purchase-and-strategic-partnership-intende-3a51b8cd 2024-04-10 https://biopharmsignal.com/news/CLLS/cellectis-publishes-a-novel-intronic-gene-editing-approach-for-the-treatment-of-inborn-metabolic-diseases-by-edited-hspcs 2024-04-10 https://biopharmsignal.com/news/ABVC/abvc-biopharma-executes-a-global-licensing-term-sheet-for-oncology-hematology-pr-11f7054c 2024-04-10 https://biopharmsignal.com/news/TRNR/interactive-strength-inc-nasdaq-trnr-to-exhibit-clmbr-at-fibo-global-fitness-the-8a0e7453 2024-04-10 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-announces-peer-reviewed-publication-highlighting-promising-safety-data-and-high-patient-compliance-in-a-clinical-trial-of-ad04-as-a-potential-treatment-for-alcohol-use-disorder 2024-04-10 https://biopharmsignal.com/news/BMY/krazati-adagrasib-in-combination-with-cetuximab-demonstrates-clinically-meaningful-activity-as-a-targeted-treatment-option-for-patients-with-previously-treated-kras-g12c-mutated-locally-advanced-or-metastatic-colorectal-cancer-crc 2024-04-08 https://biopharmsignal.com/news/CLLS/cellectis-announces-two-poster-presentations-on-novel-talenr-editing-process-for-gene-correction-and-gene-insertion-in-hspcs-at-the-asgct-annual-meeting 2024-04-08 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-s-nxp900-demonstrates-robust-activity-in-non-small-cell-lung-cancer-cell-lines 2024-04-08 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-new-interim-long-term-efficacy-data-from-the-emergent-4-trial-evaluating-karxt-in-schizophrenia-at-the-2024-annual-congress-of-the-schizophrenia-international-research-society 2024-04-06 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-presents-new-pooled-interim-long-term-safety-and-metabolic-outcomes-data-from-the-emergent-program-evaluating-karxt-in-schizophrenia-at-the-2024-annual-congress-of-the-schizophrenia-international-research-society 2024-04-06 https://biopharmsignal.com/news/NGM/ngm-bio-announces-closing-of-tender-offer 2024-04-05 https://biopharmsignal.com/news/BMY/u-s-fda-approves-bristol-myers-squibb-and-2seventy-bio-s-abecma-for-triple-class-exposed-relapsed-or-refractory-multiple-myeloma-after-two-prior-lines-of-therapy 2024-04-05 https://biopharmsignal.com/news/WGS/genedx-to-report-first-quarter-2024-financial-results-on-monday-april-29-2024-9679878c 2024-04-04 https://biopharmsignal.com/news/GOVX/geovax-presents-data-on-geo-cm04s1-a-next-generation-covid-19-vaccine-ff377d90 2024-04-04 https://biopharmsignal.com/news/GRFS/procleix-arboplex-assay-da-grifols-recebe-a-marca-ce-o-primeiro-e-nico-nat-4-em--6bc3fad5 2024-04-04 https://biopharmsignal.com/news/GRFS/procleix-arboplex-assay-di-grifols-primo-e-unico-test-nat-4-in-1-per-lo-screenin-8f3667cb 2024-04-04 https://biopharmsignal.com/news/GRFS/grifols-procleix-arboplex-assay-erh-lt-die-ce-zertifizierung-der-erste-und-einzi-aef354af 2024-04-04 https://biopharmsignal.com/news/GRFS/le-test-procleix-arboplex-assay-de-grifols-test-de-d-pistage-g-nomique-viral-4-e-c9af22f7 2024-04-04 https://biopharmsignal.com/news/GRFS/grifols-procleix-arboplex-assay-receives-ce-mark-the-first-and-only-4-in-1-nat-f-44b31f9f 2024-04-04 https://biopharmsignal.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-23rd-annual-needham-virtu-6b72fea0 2024-04-03 https://biopharmsignal.com/news/PHIO/national-spotlight-features-phio-s-innovative-rnai-technology-platform-cf0904cd 2024-04-03 https://biopharmsignal.com/news/BMY/european-commission-expands-approval-of-bristol-myers-squibb-s-reblozylr-luspatercept-to-include-first-line-treatment-of-transfusion-dependent-anemia-in-adults-with-lower-risk-myelodysplastic-syndromes-lr-mds 2024-04-03 https://biopharmsignal.com/news/SIEN/sientra-announces-completion-and-winning-bidders-of-its-section-363-sales-auction 2024-04-02 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-reports-2023-year-end-financial-results-and-provides-busine-1779aeb8 2024-04-02 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-releases-2023-environmental-social-and-governance-report-demonstrating-progress-and-setting-new-long-term-goals 2024-04-02 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-reports-2023-fiscal-year-financial-results-and-provides-business-update 2024-04-02 https://biopharmsignal.com/news/TRNR/interactive-strength-inc-nasdaq-trnr-reports-fourth-quarter-2023-results-81fdbc9b 2024-04-02 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-reports-fourth-quarter-and-full-year-2023-results 2024-04-01 https://biopharmsignal.com/news/TRVN/trevena-reports-fourth-quarter-2023-results-and-provides-corporate-update 2024-04-01 https://biopharmsignal.com/news/TXMD/therapeuticsmd-announces-full-year-2023-financial-results 2024-03-29 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-pivotal-krystal-12-confirmatory-trial-evaluating-krazati-adagrasib-meets-primary-endpoint-of-progression-free-survival-for-patients-with-pretreated-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung 2024-03-28 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-provides-update-on-the-first-phase-3-yellowstone-trial-evaluating-oral-zeposia-ozanimod-in-patients-with-moderate-to-severe-active-crohn-s-disease 2024-03-28 https://biopharmsignal.com/news/GOVX/geovax-to-present-data-on-geo-cm04s1-a-next-generation-covid-19-vaccine-at-the-w-6040b0fd 2024-03-28 https://biopharmsignal.com/news/OCEA/ocean-biomedical-nasdaq-ocea-congratulates-jv-partner-virion-therapeutics-on-pro-86799017 2024-03-28 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-announces-positive-results-from-its-phase-ii-exploratory-stargaze-trial-of-apraglutide-in-patients-with-steroid-refractory-gastrointestinal-acute-graft-versus-host-disease-sr-gi-agvhd 2024-03-28 https://biopharmsignal.com/news/GRTX/galera-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-co-9b9b4f55 2024-03-28 https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-full-year-2023-financial-results-and-provides-corporate--94c3d247 2024-03-27 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-successfully-concludes-third-cohort-in-single-dose-portion-of-phase-1-trial-for-stress-related-neuropsychiatric-disorders 2024-03-27 https://biopharmsignal.com/news/ABVC/abvc-biopharma-entered-into-a-global-licensing-deal-of-vitargus-with-licensing-i-907d27c9 2024-03-26 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-expands-health-equity-grant-initiatives-to-improve-health-outcomes 2024-03-26 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-schedules-first-q4-and-fy-2023-earnings-call 2024-03-25 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-present-data-at-the-american-college-of-cardiology-annual-scientific-session-2024-reinforcing-extensive-body-of-evidence-in-clinical-and-real-world-settings-across-cardiovascular-portfolio 2024-03-25 https://biopharmsignal.com/news/ABVC/aibtl-biopharma-inc-completes-7-6m-land-deal-exchanging-stock-for-real-estate-de-e2aa2c75 2024-03-21 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-presenting-data-showing-intasyl-may-result-in-more-effectiv-d57d5c17 2024-03-21 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-announces-resolution-of-nasdaq-deficiency-notice 2024-03-21 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-s-abecma-idecabtagene-vicleucel-becomes-first-car-t-cell-therapy-approved-in-the-european-union-in-earlier-lines-for-triple-class-exposed-relapsed-and-refractory-multiple-myeloma 2024-03-20 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-major-comprehensive-cancer-center-as-lead-site-for-nxc-96a059e2 2024-03-20 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-checkmate-9dw-trial-evaluating-opdivo-nivolumab-plus-yervoy-ipilimumab-meets-primary-endpoint-of-overall-survival-for-the-first-line-treatment-of-advanced-hepatocellular-carcinoma 2024-03-20 https://biopharmsignal.com/news/NGM/ngm-bio-to-present-two-posters-highlighting-clinical-data-from-the-ongoing-phase-1-2-clinical-trial-of-ngm707-a-dual-ilt2-ilt4-antagonist-antibody-product-candidate-at-aacr-2024-annual-meeting 2024-03-19 https://biopharmsignal.com/news/ABVC/abvc-biopharma-inc-ceo-selected-as-2024-top-10-ceo-in-ceo-insights-asia-magazine-ff983382 2024-03-19 https://biopharmsignal.com/news/SYBX/synlogic-reports-fourth-quarter-and-full-year-2023-financial-results 2024-03-19 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-and-ted-danson-empower-those-with-plaque-psoriasis-to-take-action-in-so-have-you-found-it-campaign 2024-03-19 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-upcoming-presentations-at-the-2024-american-association-for-cancer-research-meeting 2024-03-19 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-completes-acquisition-of-karuna-therapeutics-strengthening-neuroscience-portfolio 2024-03-18 https://biopharmsignal.com/news/ORGS/vered-caplan-ceo-of-orgenesis-to-present-at-the-bioprocessing-summit-europe-conf-7142ef99 2024-03-18 https://biopharmsignal.com/news/GSK/positive-ruby-phase-iii-data-show-potential-for-jemperli-dostarlimab-combinations-in-more-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2024-03-16 https://biopharmsignal.com/news/BMY/fda-advisory-committee-votes-in-favor-of-bristol-myers-squibb-s-and-2seventy-bio-s-abecma-for-triple-class-exposed-multiple-myeloma-in-earlier-lines-of-therapy 2024-03-15 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-present-at-the-36th-annual-roth-conference 2024-03-15 https://biopharmsignal.com/news/BMY/u-s-fda-approves-bristol-myers-squibb-s-breyanzi-r-as-the-first-and-only-car-t-cell-therapy-for-adults-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-lymphoma-sll 2024-03-15 https://biopharmsignal.com/news/ABVC/abvc-biopharma-reports-annual-2023-financials-and-provides-fiscal-year-2024-firs-aeae275d 2024-03-14 https://biopharmsignal.com/news/WGS/genedx-to-present-data-at-the-2024-american-college-of-medical-genetics-acmg-ann-06c99589 2024-03-14 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-encouraging-preliminary-data-from-the-nxp800-phase-1b-clinical-trial-in-platinum-resistant-arid1a-mutated-ovarian-cancer 2024-03-14 https://biopharmsignal.com/news/ISPC/ispecimen-reports-full-year-2023-results 2024-03-14 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2023-operating-results-6c417312 2024-03-13 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-announces-addition-of-clinical-trial-sites-at-banner-md-and-a7c46155 2024-03-13 https://biopharmsignal.com/news/ORGS/orgenesis-consortium-awarded-1-5m-eur-grant-from-the-walloon-government-in-belgi-090c593b 2024-03-13 https://biopharmsignal.com/news/ISPC/ispecimen-reschedules-full-year-2023-earnings-release-and-conference-call 2024-03-12 https://biopharmsignal.com/news/GOVX/geovax-to-present-at-the-36th-annual-roth-conference-2eb472bc 2024-03-12 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-first-quarter-2024-on-april-25-2024 2024-03-11 https://biopharmsignal.com/news/NGM/ngm-bio-provides-recent-business-highlights-and-reports-fourth-quarter-and-full-year-2023-financial-results 2024-03-11 https://biopharmsignal.com/news/FORA/forian-inc-to-announce-fourth-quarter-and-full-year-2023-results-on-march-28-2024 2024-03-08 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-approves-opdivo-r-nivolumab-in-combination-with-cisplatin-and-gemcitabine-for-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma 2024-03-07 https://biopharmsignal.com/news/SOPH/sophia-genetics-to-present-at-the-barclays-26th-annual-global-healthcare-confere-76cb280c 2024-03-07 https://biopharmsignal.com/news/GSK/gsk-announces-positive-results-from-dreamm-8-phase-iii-trial-for-blenrep-versus-standard-of-care-combination-in-relapsed-refractory-multiple-myeloma 2024-03-07 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-announces-patent-granted-by-uspto-strengthening-the-company-6265c066 2024-03-06 https://biopharmsignal.com/news/GOVX/geovax-achieves-milestone-in-transition-to-commercially-validated-manufacturing--ff50d031 2024-03-06 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-strengthens-board-of-directors-with-appointment-of-michae-0e261328 2024-03-06 https://biopharmsignal.com/news/GSK/viiv-healthcare-announces-interim-data-at-croi-indicating-superior-efficacy-of-long-acting-injectable-hiv-treatment-cabenuva-cabotegravir-rilpivirine-compared-to-daily-oral-therapy-in-individuals-living-with-hiv-who-have-adherence-challenges 2024-03-06 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-fourth-quarter-and-full-6886a5f8 2024-03-06 https://biopharmsignal.com/news/TRNR/interactive-strength-inc-nasdaq-trnr-to-exhibit-both-clmbr-and-forme-lift-at-ihr-3acbec65 2024-03-06 https://biopharmsignal.com/news/ISPC/ispecimen-to-report-full-year-2023-financial-results-on-march-13-2024 2024-03-05 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-be-proactive-in-al-al-amyloidosis-awareness-initiative-c098de1c 2024-03-05 https://biopharmsignal.com/news/TRNR/interactive-strength-inc-nasdaq-trnr-receives-letter-from-nasdaq-confirming-that-9eac08e1 2024-03-05 https://biopharmsignal.com/news/SOPH/sophia-genetics-reports-fourth-quarter-and-full-year-2023-results-96861e25 2024-03-05 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-fiscal-year-2023-financial-results-and-business-highlights 2024-03-05 https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-announces-positive-efficacy-data-for-nuzyrar-as-post-exposure-prophylaxis-of-inhalational-anthrax-triggering-additional-procurement-under-barda-project-bioshield-contract 2024-03-05 https://biopharmsignal.com/news/ORGS/orgenesis-inc-announces-2-3-million-private-placement-8ef67850 2024-03-04 https://biopharmsignal.com/news/GSK/viiv-healthcare-presents-phase-i-clinical-trial-findings-of-a-cabotegravir-long-acting-injectable-investigational-formulation-allowing-at-least-four-months-between-doses 2024-03-04 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-announces-exercise-of-warrants-for-3-5-million-gross-proceeds 2024-03-01 https://biopharmsignal.com/news/ORGS/orgenesis-consortium-awarded-2-0m-eur-grant-from-walloon-government-in-belgium-f-4d08fc8e 2024-02-29 https://biopharmsignal.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-joint-venture-partner-virion-therapeutics-c6ef2757 2024-02-29 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-new-data-from-the-long-term-daybreak-study-reinforcing-efficacy-and-safety-of-zeposia-ozanimod-in-patients-with-relapsing-forms-of-multiple-sclerosis 2024-02-29 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-announces-positive-topline-results-from-global-phase-iii-trial-of-once-weekly-apraglutide-in-adults-with-short-bowel-syndrome-with-intestinal-failure-sbs-if 2024-02-29 https://biopharmsignal.com/news/GSK/gsk-announces-dr-jeannie-lee-to-join-the-board-as-non-executive-director 2024-02-29 https://biopharmsignal.com/news/GSK/statement-zantac-ranitidine-litigation 2024-02-29 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-clearance-of-ind-for-spr206-to-treat-mdr-gram-negat-2a182dcd 2024-02-28 https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-data-for-its-next-generation-of-ultra-long-acting-treatments-for-hiv 2024-02-28 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-awarded-new-patent-from-the-united-states-patent-and-trademark-office 2024-02-28 https://biopharmsignal.com/news/ABVC/abvc-s-new-horizon-for-oncology-and-hematology-aims-at-cancer-market-of-several--4bd3659b 2024-02-27 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-the-td-cowen-44th-annual-health-care-conference 2024-02-26 https://biopharmsignal.com/news/WGS/genedx-to-participate-in-44th-annual-cowen-health-care-conference-65328beb 2024-02-26 https://biopharmsignal.com/news/NGM/ngm-bio-has-entered-into-a-definitive-agreement-and-plan-of-merger-with-certain-affiliates-of-the-column-group-lp 2024-02-26 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-completes-acquisition-of-rayzebio-adding-differentiated-actinium-based-radiopharmaceutical-platform 2024-02-26 https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-present-at-cowen-s-44th-annual-healthcare-conference-dd6a2313 2024-02-26 https://biopharmsignal.com/news/TRNR/interactive-strength-inc-nasdaq-trnr-enters-into-exclusive-worldwide-distributio-5dee2902 2024-02-26 https://biopharmsignal.com/news/GSK/gsk-announces-positive-headline-results-from-eagle-1-phase-iii-trial-for-gepotidacin-in-uncomplicated-urogenital-gonorrhoea-gc 2024-02-26 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-present-four-abstracts-at-the-aspen-2024-nutrition-science-and-practice-conference 2024-02-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-positive-chmp-opinion-for-reblozyl-r-luspatercept-for-treatment-of-adults-with-transfusion-dependent-anemia-due-to-low-to-intermediate-risk-myelodysplastic-syndromes-mds 2024-02-23 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-expiration-of-rayzebio-tender-offer 2024-02-23 https://biopharmsignal.com/news/SOPH/sophia-genetics-to-participate-in-fireside-chat-at-the-44th-annual-td-cowen-heal-b99a6fcd 2024-02-22 https://biopharmsignal.com/news/GSK/latitude-phase-iii-interim-trial-data-indicates-viiv-healthcare-s-long-acting-injectable-hiv-treatment-cabenuva-cabotegravir-rilpivirine-has-superior-efficacy-compared-to-daily-therapy-in-individuals-living-with-hiv-who-have-adherence-challenges 2024-02-21 https://biopharmsignal.com/news/IMMX/immix-biopharma-12-month-review-progress-update-ce742213 2024-02-21 https://biopharmsignal.com/news/WGS/genedx-reports-fourth-quarter-and-full-year-2023-financial-results-and-issues-gu-b1e81815 2024-02-20 https://biopharmsignal.com/news/NGM/ngm-bio-to-participate-in-the-cowen-44th-annual-health-care-conference 2024-02-20 https://biopharmsignal.com/news/SYBX/synlogic-adopts-limited-duration-stockholders-rights-plan 2024-02-20 https://biopharmsignal.com/news/SOPH/sophia-genetics-to-announce-financial-results-for-the-fourth-quarter-and-full-ye-6069e388 2024-02-20 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-fda-accepts-supplemental-new-drug-application-for-krazatir-adagrasib-in-combination-with-cetuximab-as-a-targeted-treatment-option-for-patients-with-previously-treated-kras-g12c-mutated-locally-advanced-or 2024-02-20 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-exercise-of-warrants-for-approximately-2-0-mill-849c1b82 2024-02-16 https://biopharmsignal.com/news/ABVC/abvc-biopharma-executes-a-definitive-agreement-to-receive-license-fees-of-3m-and-56eda391 2024-02-15 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-results-achieves-2023-financial-guidance 2024-02-15 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-winter-wrap-up-microcap-rodeo-conference-on-february-20 2024-02-15 https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-aiolos-bio 2024-02-15 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-prices-13-billion-of-senior-unsecured-notes 2024-02-15 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-recommends-stockholders-reject-mini-tender-offer-by-tutanota-llc 2024-02-14 https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibb-s-application-for-augtyrotm-repotrectinib-for-the-treatment-of-patients-with-ntrk-positive-locally-advanced-or-metastatic-solid-tumors 2024-02-14 https://biopharmsignal.com/news/GRFS/grifols-announces-positive-topline-phase-3-fibrinogen-clinical-trial-results-50afc2f8 2024-02-14 https://biopharmsignal.com/news/SIEN/sientra-to-pursue-strategic-sale-of-its-business-through-voluntary-chapter-11-process 2024-02-13 https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-awarded-new-patent-notice-of-allowance-from-the-united-states-patent-and-trademark-office 2024-02-13 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-achieves-first-clinical-safety-milestone-with-its-novel-neuropeptide-for-the-potential-treatment-of-stress-related-disorders 2024-02-13 https://biopharmsignal.com/news/ABVC/abvc-biopharma-receives-australian-patent-valid-until-2040-for-its-treatment-of--e5908c06 2024-02-12 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-and-rayzebio-announce-expiration-of-hsr-act-waiting-period 2024-02-12 https://biopharmsignal.com/news/GSK/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b 2024-02-12 https://biopharmsignal.com/news/NVCT/correction-nuvectis-pharma-announces-participation-at-upcoming-investor-conferences 2024-02-09 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-participation-at-upcoming-investor-conferences 2024-02-09 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-closing-of-15-million-public-offering-of-common-stock-5463ceea 2024-02-08 https://biopharmsignal.com/news/SYBX/synlogic-announces-decision-to-discontinue-synpheny-3-study-and-provides-corporate-update 2024-02-08 https://biopharmsignal.com/news/ABVC/abvc-acquires-2-96-million-worth-of-land-in-asia-with-stocks-priced-at-3-50-per--a467870e 2024-02-08 https://biopharmsignal.com/news/IMMX/immix-biopharma-awarded-european-union-orphan-drug-designation-for-nxc-201-in-al-e0981df8 2024-02-07 https://biopharmsignal.com/news/TRNR/interactive-strength-inc-nasdaq-trnr-completes-acquisition-of-clmbr-creating-a-h-f5eb031f 2024-02-07 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-acceptance-of-u-s-and-eu-regulatory-filings-for-neoadjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-surgery-and-adjuvant-opdivo-in-resectable-non-small-cell-lung-cancer 2024-02-07 https://biopharmsignal.com/news/GSK/gsk-s-rsv-vaccine-arexvy-accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk 2024-02-06 https://biopharmsignal.com/news/GSK/gsk-s-regulatory-application-for-shingrix-for-the-prevention-of-shingles-in-at-risk-adults-aged-18-and-over-accepted-for-review-by-china-national-medical-products-administration 2024-02-06 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-pricing-of-15-million-public-offering-of-common-stock-5cfe3dff 2024-02-06 https://biopharmsignal.com/news/GSK/dreamm-7-phase-iii-trial-shows-blenrep-combination-nearly-tripled-median-progression-free-survival-versus-standard-of-care-combination-in-patients-with-relapsed-refractory-multiple-myeloma 2024-02-05 https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-proposed-public-offering-of-common-stock 2024-02-05 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-named-one-of-america-s-most-just-companies-by-just-capital-and-cnbc 2024-02-05 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-and-2seventy-bio-share-update-on-u-s-fda-oncologic-drugs-advisory-committee-meeting-for-abecma-in-triple-class-exposed-multiple-myeloma-based-on-karmma-3-study 2024-02-05 https://biopharmsignal.com/news/SYBX/synlogic-announces-publication-of-preclinical-and-clinical-data-for-synb1353-as-a-potential-treatment-for-classical-homocystinuria 2024-02-02 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2023 2024-02-02 https://biopharmsignal.com/news/WGS/genedx-to-report-fourth-quarter-2023-financial-results-on-tuesday-february-20-20-206af31f 2024-02-01 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2023-investor-update-call 2024-02-01 https://biopharmsignal.com/news/ORGS/orgenesis-acquires-control-of-octomera-with-the-goal-of-progressing-its-decentra-58a25cfe 2024-01-31 https://biopharmsignal.com/news/PHIO/phio-pharmaceuticals-announces-data-showing-intasyl-may-result-in-more-effective-3c523097 2024-01-31 https://biopharmsignal.com/news/GSK/gsk-delivers-strong-2023-performance-and-upgrades-growth-outlooks 2024-01-31 https://biopharmsignal.com/news/BMY/regulatory-applications-accepted-in-the-u-s-and-japan-for-bristol-myers-squibb-s-breyanzi-lisocabtagene-maraleucel-in-relapsed-or-refractory-follicular-lymphoma-fl-and-relapsed-or-refractory-mantle-cell-lymphoma-mcl 2024-01-30 https://biopharmsignal.com/news/GSK/gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-european-medicines-agency-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk 2024-01-29 https://biopharmsignal.com/news/GSK/european-commission-authorises-gsk-s-omjjara-momelotinib 2024-01-29 https://biopharmsignal.com/news/BMY/subcutaneous-nivolumab-nivolumab-and-hyaluronidase-shows-noninferiority-compared-to-intravenous-opdivo-nivolumab-in-advanced-or-metastatic-clear-cell-renal-cell-carcinoma-in-checkmate-67t-trial 2024-01-27 https://biopharmsignal.com/news/NAVB/navidea-biopharmaceuticals-inc-files-form-15-to-voluntarily-deregister-and-suspend-its-sec-reporting-obligations 2024-01-27 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-receives-positive-chmp-opinion-for-car-t-cell-therapy-abecma-idecabtagene-vicleucel-in-earlier-lines-of-therapy-for-triple-class-exposed-relapsed-and-refractory-multiple-myeloma 2024-01-26 https://biopharmsignal.com/news/WGS/genedx-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-a773248e 2024-01-24 https://biopharmsignal.com/news/IMMX/immix-biopharma-statement-on-january-2024-fda-labeling-change-notification-for-approved-car-t-products 2024-01-24 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-completes-acquisition-of-mirati-therapeutics-strengthening-and-diversifying-oncology-portfolio 2024-01-23 https://biopharmsignal.com/news/ISPC/ispecimen-and-trimetis-life-sciences-announce-strategic-partnership-to-help-transform-tissue-based-research 2024-01-23 https://biopharmsignal.com/news/BMY/eight-year-data-for-opdivo-nivolumab-plus-yervoy-ipilimumab-continue-to-demonstrate-longest-survival-benefit-vs-sunitinib-reported-in-patients-with-previously-untreated-advanced-or-metastatic-renal-cell-carcinoma 2024-01-22 https://biopharmsignal.com/news/BMY/opdivor-nivolumab-in-combination-with-cabometyxr-cabozantinib-demonstrates-long-term-survival-benefits-after-four-years-of-follow-up-in-the-checkmate-9er-trial-in-first-line-advanced-renal-cell-carcinoma 2024-01-22 https://biopharmsignal.com/news/BMY/opdivo-nivolumab-plus-yervoy-ipilimumab-reduced-the-risk-of-disease-progression-or-death-by-79-versus-chemotherapy-in-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-metastatic-colorectal-cancer-in-checkmate-8hw-trial 2024-01-20 https://biopharmsignal.com/news/ADIL/adial-announces-appointment-of-tony-goodman-as-chief-operating-officer 2024-01-18 https://biopharmsignal.com/news/ISPC/ispecimen-to-participate-in-maxim-group-healthcare-it-virtual-conference-january-24-and-25-2024 2024-01-18 https://biopharmsignal.com/news/NGM/ngm-bio-to-participate-in-the-b-riley-securities-4th-annual-oncology-conference 2024-01-17 https://biopharmsignal.com/news/BMY/bristol-myers-squibb-data-at-asco-gu-2024-showcase-transformative-research-in-the-treatment-of-genitourinary-cancers 2024-01-17 https://biopharmsignal.com/news/CLLS/cellectis-announces-the-drawdown-of-the-second-tranche-of-15-million-under-the-credit-facility-agreement-entered-with-the-european-investment-bank-eib 2024-01-16 https://biopharmsignal.com/news/GSK/nucala-mepolizumab-approved-in-china-for-use-in-severe-asthma-with-an-eosinophilic-phenotype 2024-01-10 https://biopharmsignal.com/news/GSK/gsk-enters-agreement-to-acquire-aiolos-bio 2024-01-09 https://biopharmsignal.com/news/IRWD/ironwood-announces-publication-in-the-lancet-gastroenterology-and-hepatology-of-new-linaclotide-phase-iii-data-in-children-and-adolescents-aged-6-17-years-with-functional-constipation 2024-01-09 https://biopharmsignal.com/news/WGS/genedx-announces-preliminary-2023-financial-results-c9776c61 2024-01-08 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-maintains-fy-2023-financial-guidance-and-announces-fy-2024-financial-guidance 2024-01-08 https://biopharmsignal.com/news/SPRO/spero-therapeutics-provides-corporate-update-and-2024-outlook-9cf21cb6 2024-01-05 https://biopharmsignal.com/news/SYBX/synlogic-provides-corporate-update-and-outlook-for-2024 2024-01-04 https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-to-present-at-nash-tag-2024-cb4d9511 2024-01-03 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference 2024-01-03 https://biopharmsignal.com/news/ABVC/abvc-biopharma-and-its-subsidiary-receive-460m-from-aibtl-biopharma-as-the-first-fc6848b0 2024-01-03 https://biopharmsignal.com/news/NMRD/important-update-on-listing-status-and-strategic-direction-dbde8592 2024-01-03 https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference 2024-01-03 https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-first-patient-first-visit-for-phase-3-pivot-po-tria-a9509c93 2024-01-02 https://biopharmsignal.com/news/BMY/european-medicines-agency-validates-bristol-myers-squibb-s-application-for-repotrectinib-for-the-treatment-of-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-and-ntrk-positive-solid-tumors 2024-01-02